nct_id,brief_title,official_title,overall_status,study_type,gender,eligibility_text,age_min,age_max,conditions_list
NCT07214935,A TQT Study of Effect of M2951 on Cardiac Repolarization,"A Single-Dose, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Way Crossover Study to Evaluate the Effect of Evobrutinib on the QTc (Corrected QT) Interval in Healthy Adult Participants",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Participants are overtly healthy as determined by medical evaluation, including no clinically significant abnormality identified on physical examination or laboratory evaluation and no active clinically significant disorder, condition, infection, or disease that would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion * Participants have a body weight within 50.0 and 100.0 kilograms (kg) (inclusive) and body mass index (BMI) within the range 19.0 and 30.0 kilograms per square meter (kg/m\^2) (inclusive) * Participants are stable nonsmokers for at least 3 months preceding the first administration of study intervention Exclusion Criteria: * Participants with history or presence of clinically relevant respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, musculoskeletal, genitourinary, immunological, dermatological, connective tissue, psychiatric (due to rare risk of hallucinations, agitation, and activation of psychosis), and other diseases or disorders, and epilepsy, as determined by medical evaluation * Participants with diagnosis of hemochromatosis, Wilson´s disease, alpha 1 antitrypsin deficiency, or any other chronic liver disease including Gilbert's disease will be excluded from the study. Prior history of cholecystectomy or splenectomy, and any clinically relevant surgery within 6 months prior to the first administration of study intervention * Participants with history of any malignancy * Participants with history of seizures * Participants with history of pharmacologically treated psychiatric disease",18.0,55.0,['healthy']
NCT00002135,An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access,An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria Patients must have: * AIDS. * Stable CMV retinitis. * Treatment with IV ganciclovir or IV foscarnet for at least 18 of the past 21 days. * No permanent central IV catheter at present. * Had a permanent central IV catheter removed two or more times within the past 6 months due to catheter infection or thrombosis. * Consent of guardian if less than legal age of consent. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Require continuation of concomitant medications precluded by this protocol. Concurrent Medication: Excluded: * Intravitreal anti-CMV treatment. * Any other concomitant medications precluded by the protocol. Patients with the following prior condition are excluded: History of hypersensitivity to acyclovir or ganciclovir.,13.0,65.0,"['cytomegalovirus retinitis', 'hiv infections']"
NCT02876835,Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND),"A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age: 18 to 99 years of age (inclusive) * CKD stage: Kidney Disease Outcomes Quality Initiative (KDOQI) CKD stages 3, 4, or 5 defined by electronic eGFR using the CKD Epidemiology Collaboration (CKD-EPI) formula. * Erythropoietin-stimulating agents (ESAs)/Hgb: Group 1 (not using ESAs): No ESA use within the 6 weeks prior to screening and no ESA use between screening and randomization (Day 1). Group 2 (ESA users): Use of any approved ESA for the 6 weeks prior to screening and continuing between screening and randomization. * For Group 1 (not using ESAs), Hgb concentration at Week -8 and Week 1 should be 8 to 10 gram per deciliter (g/dL). For Group 2 (ESA users), Hgb concentration at Week -8 should be 8 to 12 g/dL and at Week 1 should be 8 to 11 g/dL. * \>=80% and \ 500 millisecond (msec), or QTcB \>530 msec in subjects with bundle branch block. There is no Q-T Interval Corrected for Heart Rate (QTc) exclusion for subjects with a predominantly ventricular paced rhythm. * Alanine transaminase (ALT): \>2x upper limit of normal (ULN) at screening. * Bilirubin: \>1.5xULN at screening. * Current unstable liver or biliary disease per investigator assessment, generally defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. * Malignancy: History of malignancy within the 2 years prior to screening through to randomization (Day 1) or currently receiving treatment for cancer, or complex kidney cyst (example \[e.g.\] Bosniak Category II F, III or IV) \> 3 centimeter (cm); with the exception of localized squamous cell or basal cell carcinoma of the skin that has been definitively treated \>=4 weeks prior to screening. * Severe allergic reactions: History of severe allergic or anaphylactic reactions or hypersensitivity to excipients in the investigational product, or darbepoetin alfa. * Drugs and supplements: Use of strong inhibitors of Cytochrome P4502C8 (CYP2C8) (e.g., gemfibrozil) or strong inducers of CYP2C8 (e.g., rifampin/rifampicin). * Other study participation: Use of other investigational agent or device prior to screening through to randomization (Day 1). At screening, this exclusion applies to use of the investigational agent within 30 days or within five half lives (whichever is longer). * Prior treatment with daprodustat: Any prior treatment with daprodustat for treatment duration of \>30 days. * Females only: Subject is pregnant \[as confirmed by a positive urine human chorionic gonadotrophin (hCG) test for females of reproductive potential (FRP) only\], subject is breastfeeding, or subject is of reproductive potential and does not agree to follow one of the contraceptive options. * Other Conditions: Any other condition, clinical or laboratory abnormality, or examination finding that the investigator considers would put the subject at unacceptable risk, which may affect study compliance (e.g., intolerance to darbepoetin alfa) or prevent understanding of the aims or investigational procedures or possible consequences of the study.",18.0,99.0,['anaemia']
NCT05168735,Ketamine + Mindfulness for Depression,Ketamine + Mindfulness for Depression,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: All participants will: 1. be between the ages of 18 and 65 years, 2. score ≥ 14 on the Hamilton Depression Rating Scale (modified Ham-D) 3. possess a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an informed consent document Exclusion Criteria: All participants: 1. Presence of lifetime bipolar, psychotic, or autism spectrum; current problematic substance use (e.g., ongoing moderate-to-severe substance use disorder); 2. Acute suicidality or other psychiatric crises requiring treatment escalation. We will use the Columbia Suicide Severity Rating Scale (CSSRS) as both an initial exclusion criteria (CSSRS ""Baseline/Screening"" Version for past 1month period) and as grounds for rescue/removal (CSSRS ""Since Last Visit"" form). The CSSRS will be administered using a paper form by an experienced and thoroughly trained clinical assessor on the study team. Subjects with CSSRS suicide ideation scores scored ""yes"" on items 4 (active suicidal ideation with some intent to act) and/or 5 (active suicidal ideation with specific plan and intent) will be excluded from the study, and if enrolled, will be exited from the study and referred immediately to the nearest emergency mental health facility for additional thorough assessment and appropriate treatment referral. 3. Changes made to treatment regimen within 4 weeks of baseline assessment. 4. Reading level \ 1 hour weekly (on average) for the past 6 months or longer.",18.0,65.0,"['depression, unipolar']"
NCT01920035,Study of Endorectal Cooling During RARP to Minimize Trauma and Promote Earlier Return to Continence,"A Randomized, Controlled Study of the Use of Localized Endorectal Cooling Using the UroCool System During Robotic-Assisted Radical Prostatectomy (RARP) to Minimize Trauma and to Provide Earlier Return to Continence",COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: * Patient is male and a candidate for robotic assisted radical prostatectomy (RARP) for the treatment of prostate cancer * Patient is over eighteen (\>18) years of age * Patient reads, understands and speaks English fluently (U.S. Sites only) * Subject understands and agrees to all pre-operative preparation procedures including a ""self-administered"" fleet enema * Subject understands study procedures, risks of such procedures and is willing to comply with all study procedures * Patient is willing and able to comply with all post-surgical milestones including completing and returning post-surgery follow up questionnaires at specified intervals over a 12 month period * Subject agrees to participate in the study and is willing to sign the written informed consent per the enrolling site's institutional procedure Exclusion Criteria: * Presents with baseline or has a history of urinary incontinence * Rectal or GI pathology deemed unsuitable for placement of the treatment device by the examining physician * Prior extensive pelvic surgery such as low anterior resection, abdominoperineal resection, or proctocolectomy continent stool pouch, or any other extensive abdominopelvic surgery that would render the patient a high-risk for complications as deemed by the surgeon * History of prior treatment of any kind for prostate cancer; e.g. radiation therapy, cryotherapy, high-intensity focused ultrasound (HIFU), hormonal or chemotherapy * Prior intra-operative injuries (for example: rectal injury) * Inadequate hemostasis * Serious concurrent medical condition likely to result in death during the next 12 months. Any other acute or chronic condition which the Investigator believes will unacceptably increase the risk of study participation or interfere with study procedures and assessments. * Active or recent (within 1 month prior to study enrollment) participation in another investigational clinical research study or planned to be enrolled in another study of prostate therapy.",18.0,65.0,['incontinence']
NCT01052935,A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine,A Phase I Extension Study to Assess the Long-Term Persistence of GBS Serotype Ia Antibodies in Women Previously Immunized With a GBS Ia Crm-Glycoconjugate Vaccine,COMPLETED,INTERVENTIONAL,FEMALE,Inclusion Criteria: * Individuals who have given written consent. * Individuals who participated in V98P1 and received the complete schedule of vaccinations. Exclusion Criteria: * Individuals who have not given written consent. * Subjects who did not receive the complete schedule of vaccination in V98P1.,20.0,42.0,['group b streptococcus (gbs) disease']
NCT03144635,A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir,A Prospective Multicenter Observational Study for Characterization of Renal Function G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Subjects aged 20 years or older. 2. Patients positive for HCV RNA for over 6 months and infected with genotype 1b chronic hepatitis C, including compensated cirrhosis. 3. Patients without co-infection of hepatitis B virus. 4. Patients without co-infection of human immunodeficiency virus 5. Patients with moderate chronic kidney disease (CKD stage 3) (eGFR: 30-59 mL/min/1.73m2). A diagnosis of CKD is only confirmed if repeated eGFR tests for at least 90 days. Exclusion Criteria: 1. Patients with decompensated cirrhosis (Child Pugh B and C) 2. Patients with albumin \<3.0 g/dL and platelets \<75,000 /μL 3. Patients with autoimmune hepatitis 4. Constant heavy alcohol drinkers (converted to ethanol ≥60 g/day) 5. Patients who have a history of hypersensitivity to grazoprevir and elbasvir 6. Patients who are pregnant females, or females who may become pregnant, or females who are breastfeeding 7. Patients with heart disease that is hard to control (e.g., very recent cardiac infarction, severe heart failure, unstable arrhythmia) 8. Patients who are under medication with drugs listed as contraindication in a package insert of grazoprevir plus elbasvir treatment 9. Patients judged (by the physician in charge of research) to be inappropriate as subjects for the study for any other reasons.",20.0,65.0,"['hepatitis c viral', 'chronic kidney disease stage3']"
NCT02086708,Ultrasound Method to Measure Fibrosis of the Liver in Children,Sonoelastography: Ultrasound Method to Measure Fibrosis of the Liver in Children,TERMINATED,INTERVENTIONAL,ALL,"Inclusion criteria: * Patients scheduled for random liver biopsy for routine staging of liver fibrosis * Pediatric patients patients (ages 1-21) * Girls or boys * Suspected liver disease * Consent to participate in the study Exclusion criteria: * Pregnancy * Acute illness/cognitive impairment resulting in inability to cooperate with ultrasound * Patients that do not consent to ultrasound guided liver biopsy. * Contraindications to liver biopsy (e.g. low platelets defined as a platelet count of less than 50,000, and hemophilia/coagulopathy as an INR higher than 1.5.)",1.0,21.0,"['chronic liver disease', 'non-alcoholic fatty liver disease', 'hcv coinfection', 'hbv', 'drug-induced liver injury']"
NCT05534308,Effect of Intraoperative Taping on the Control of Edema Resulting From Stripping,Effect of Intraoperative Taping on the Control of Edema Resulting From Stripping,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * young adults, aged from 25 to 59 years old, submitted to stripping and saphenectomy. Exclusion Criteria: * allergies * skin lesions * ulcers.",25.0,59.0,"['edema', 'varices', 'cord']"
NCT02777008,"Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects","A Two-Part Single Center, Randomized, Sequential, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTP-543 in Healthy Volunteers",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Healthy adult males and females between 18 and 50 years of age, inclusive * Body weight ≥ 50 kg and BMI within the range of 18 to 30 kg/m2, inclusive Exclusion Criteria: * History of clinically significant central nervous system (eg, seizures), cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal (GI) conditions * PR interval \> 220 msec or QRS duration \> 120 msec or QTcF interval \> 450 msec obtained at screening visit or prior to the first dose of study drug * History of herpes zoster * Hemoglobin, white blood cell, or platelet levels below the lower reference limit at screening or prior to the first dose of study drug * Liver function tests greater than the upper limit of normal * Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody * Urinalysis positive for protein or glucose * A positive screen for alcohol, drugs of abuse, or tobacco use * Donation of blood, plasma or other blood products prior to screening * A positive tuberculosis test",18.0,50.0,['healthy']
NCT02345408,Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma,An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Histologically or cytologically confirmed non-resectable pancreatic adenocarcinoma with or without metastases * Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2 * Anticipated life expectancy ≥ 12 weeks * Radiographically measurable disease acc. to RECIST 1.1 * Use of adequate contraception (as described in protocol) * Ability to provide written informed consent and comply with study requirements Exclusion Criteria: * Received other cancer treatment or investigational drug within 4 weeks prior to screening * Women who are pregnant or breastfeeding * Had major surgery within 4 weeks of first dose of study drug * Inadequate liver, renal or bone marrow function within 2 weeks of first dose * Serious concurrent illness, altered medical status or any uncontrolled medical condition * Any infection requiring antibiotic or anti-viral treatment within 4 weeks of screening * Known active HIV, HBV or HCV infection * Inability to swallow tablets * History or presence of any medical condition or disease which, in the opinion of the investigator, may place the subject at unacceptable risk for study participation",18.0,65.0,['pancreatic cancer']
NCT06047808,Feasibility Study of the Storytelling Through Music Intervention with Bereaved Parents,A Feasibility Study Evaluating Storytelling Through Music Intervention with Bereaved Parents of Children with Cancer,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * \>18 years old * able to read and speak English * bereaved parent of a child who died from cancer (ages\ 6 months and \<5 years before study initiation * access to the internet and computer. Exclusion Criteria: * do not have the technological requirements for Zoom interviews and REDCap surveys.,18.0,99.0,"['pediatric cancer', 'grief', 'well-being, psychological', 'coping strategies', 'bereavement']"
NCT06519708,Analgesic Efficacy of Erector Spinae Plane Block vs External Oblique Intercostal Plane Block in Subcostal Cancer Surgeries,Analgesic Efficacy of Erector Spinae Plane Block vs External Oblique Intercostal Plane Block in Subcostal Cancer Surgeries: A Randomized Controlled Study,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age (18-65) Years. * Both sexes. * Body mass index (BMI): (20-40) kg/m2. * American Society of Anesthesiology (ASA) physical status II, III. * Type of surgery; unilateral subcostal incision in hepatectomy and nephrectomy. Exclusion Criteria: * Patient refusal. * Subcostal incisions that are crossing the midline or midline incision. * Age \ 65 years * BMI \ 40 kg/m2 * Known sensitivity or contraindication to drugs used in the study * Contraindication to regional anesthesia e.g. local infection at the site of introduction, pre-existing peripheral neuropathies, and coagulopathy. * Pregnancy. * Physical status ASA IV * patients on chronic analgesic therapy (daily morphine ≥30 mg or equivalent dose of other opioids or tramadol or any medication for neuropathic pain) * patients with a history of drug abuse * patients with neuropsychiatric diseases; patients with a history of chronic pain syndromes that may enhance sensitivity to pain, for example, fibromyalgia * All patients who are going to have severe intra- or post-operative bleeding or will require postoperative mechanical ventilation are also excluded from the study.",18.0,65.0,"['analgesia', 'erector spinae plane block', 'external oblique intercostal plane block', 'subcostal cancer surgeries']"
NCT04480008,Resilient Living Program for Patients With Advanced Cancer and Their Caregivers,Resilient Living Program for Patients With Advanced Cancer and Their Caregivers,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria for patients: * Age ≥18 years * English fluency * No diagnosed severe cognitive impairment * Diagnosis of stage IV solid tumor cancer * Expected prognosis \>6 \<18 months * Provide written informed consent * Ability to complete questionnaire(s) by themselves or with assistance * Patient baseline distress score ≥4/10 OR identified as having distress that would benefit from program by care team or provider * Ability to do first Resilient Living session in person Inclusion Criteria for caregivers: * Self-identifies as a caregiver of a patient that meets the above cancer diagnosis criteria, and who also participates in the study * Provide written informed consent * Ability to complete questionnaire(s) by themselves or with assistance * Age ≥18 years * English fluency * No diagnosed severe cognitive impairment * Ability to do first Resilient Living session in person Exclusion Criteria: * As determined through self-report, those diagnosed with a history of a psychotic episode will be excluded. * Other psychological co-morbidities such as untreated schizophrenia, bipolar disease",18.0,65.0,['advanced cancer']
NCT03566108,To Compare Two Commonly Used Soft Tissue Grafting Techniques to Achieve Coronal Flap Advancement and Root Coverage,"A Prospective, Randomized Clinical Trial to Compare Vestibular Incision Supraperiosteal Tunnel Access (VISTA) and Sulcular Tunnel Access Procedures With Coronally Advanced Flap (CAF) and Acellular Dermal Matrix (ADM).",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * English speaking * At least 18 years old * Must be a patient of the UAB Dental School * Able to read and understand informed consent document * One or more adjacent teeth (up to four) with Miller class I or II gingival recession defects and less than or equal to 2mm of KT at each site to be treated. * Presence of periodontally healthy, non-carious neighboring teeth, healthy implants or edentulous ridges on either side of the involved site(s) * No anticipated need for restorative care at the teeth to be treated during the study period. Exclusion Criteria: * Non-English speaking * Less than 18 years old * Smokers/tobacco users (\>10 cigarettes/day) * Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing * Presence of active periodontal disease or radiographic interproximal bone loss or tooth malposition, which would yield a Miller class III or IV categorization for the recession defect. * Presence of frenulae or other soft tissue anomalies at the site(s) to be treated that, in the opinion of the investigators, will interfere with successful access and treatment of the soft tissue defects. * Previous soft tissue grafting at the site(s) to be treated",18.0,99.0,['gingival recession']
NCT03541408,Preventative Delirium Protocol in Elderly Patients,"A Randomized, Controlled Trial Reviewing the Effectiveness of a Preventative Delirium Protocol in Elderly Patients While Analyzing Its Consequential Effects on Awareness, PONV, and/or Pain Control",COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Age \> 65 years * Scheduled for Elective Surgery (outpatient/same-day admit) Exclusion Criteria: * Need emergency surgery * Need intracranial surgery * Dependent on opiate narcotics * Surgeon-specified perioperative procedures that precludes the current study's protocol,65.0,89.0,['delirium']
NCT01951508,"Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study","Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age between 18 and 45 years * Sufficient understanding of the German language * Subjects understand the procedures and the risks associated with the study * Participants must be willing to adhere to the protocol and sign the consent form * Participants must be willing to refrain from taking illicit psychoactive substances including cannabis during the study * Participants must be willing to drink only alcohol-free liquids and no xanthine-containing liquids (such as coffee, black or green tea, red bull, chocolate) after midnight of the evening before the study session, as well as during the study day * Participants must be willing not to drive a traffic vehicle within 24h following MDMA administration * Women of childbearing potential must have a negative pregnancy test at the beginning of the study and must agree to use an effective form of birth control. Pregnancy tests are repeated before each study session. * Body mass index: 18-27kg/m2 Exclusion Criteria: * Chronic or acute medical condition including clinically relevant abnormality in physical exam, laboratory values, or ECG. In particular: Hypertension (\>140/90mmgHg) or Hypotension (SBP\ 10cigarettes / day)",18.0,45.0,"['healthy', 'substance-related disorder', 'mood disorder']"
NCT01253408,Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS),Study of the Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor and Sensory Functions in Patients With Irritable Bowel Syndrome,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age 18-75 years * Positive for IBS symptoms by Rome III criteria * No prior abdominal surgery (except appendectomy or cholecystectomy) * Baseline Geometric Center at 24 hours is greater/equal to 2.0 * Baseline Geometric Center at 48 hours is greater/equal to 3.9 Exclusion Criteria: * Patients with significant depression (score of greater than 10 on Hospital and Anxiety Inventory) * Patients with anxiety (score of greater than 10 on Hospital and Anxiety Inventory) will not be allowed to participate. However, patients on stable doses of selective serotonin re-uptake inhibitors (SSRIs) or low dose of tricyclic antidepressants will be eligible.",18.0,75.0,['irritable bowel syndrome']
NCT03794908,Light Treatment to Improve Symptom Management of Fibromyalgia Syndrome,Bright Light Treatment at Home to Improve Symptom Management of Fibromyalgia Syndrome,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: • Meet criteria for Fibromyalgia syndrome (FMS) Exclusion Criteria: * Significant chronic disease * Severe hearing or memory problems * Pending medical leave applications at workplace * Current pregnancy, breastfeeding, or actively trying to get pregnant * Night work or travel outside the eastern time zone within 1 month of the study * Other research participation * Frequent number of special events during study period (weddings, concerts, exams, etc).",18.0,65.0,"['fibromyalgia', 'fms']"
NCT04798508,EXPRE-SON-REA : Expressive Own Names in Neurophysiologic Assessment of Comatose Patients,EXPRE-SON-REA : Expressive Versus Neutral Own Names in Neurophysiologic Prognosis Assessment of Intensive Care Unit Comatose Patients.,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Age over 18 * Disorder of consciousness defined as : Glasgow coma scale \ 8 but * eyes opening to pain only * No response to basic command * Available neuro-imagery (CT-scan or MRI) * Normal temperature (no fever or hypothermia) * Normal blood pressure during neurophysiologic evaluation * Given consent from relatives Exclusion Criteria: * Brain death * Known deafness * Severe sepsis uncontrolled during neurophysiologic evaluation,18.0,65.0,"['comatose', 'neurophysiologic abnormality']"
NCT04988308,A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa,"A Phase 2a/2b, Multicenter, Randomized, Placebo and Active Comparator-controlled, Double-Blind, Dose-ranging Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Have hidradenitis suppurativa (HS) for at least 1 year (365 days) prior to the baseline visit as determined by the investigator through participant interview and/or review of the medical history * Have Hurley Stage II or Hurley Stage III HS as determined by the investigator at screening and baseline visits * Have HS lesions present in at least 2 distinct anatomic areas (examples include but are not limited to left and right axilla; or left axilla and left inguinocrural fold) at screening and baseline visits * Have a total abscess and inflammatory nodule (AN) count of greater than or equal to (\>=) 5 at the screening and baseline visit * Agree not to receive a live virus or live bacterial vaccination during the study and for 90 days after the last administration of study intervention Exclusion Criteria: * Has a current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances * Has unstable cardiovascular disease, defined as a recent clinical deterioration (that is, unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months * Has or has had herpes zoster within the 2 months before screening * Has a transplanted organ (with exception of a corneal transplant greater than \[\>\] 3 months before the first administration of study intervention) * Has known allergies, hypersensitivity, or intolerance to bermekimab or adalimumab or its excipients",18.0,65.0,['hidradenitis suppurativa']
NCT00509808,Evaluation of an Electro-stimulator for the Treatment of Xerostomia,Safety and Performance Evaluation of an Electro-stimulator Mounted on an Intra-oral Removable Appliance (Saliwell GenNarino) for the Treatment of Xerostomia,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. The patient must be at least 18 years of age. 2. The patient must have clinical symptoms of xerostomia (dry mouth) due to * Primary or secondary Sjögren's syndrome * Medication intake * Head and neck radiation with survival expectancy of more than one year * Chronic graft vs. host disease with survival expectancy of more than one year 3. Patients are requested not to take systemic sialogogues during the first 2 months of the study (when active is tested vs. sham) 4. Female patients of child bearing potential must have a negative pregnancy test within twenty-four hours of enrollment. 5. The patient must understand and consent in writing to the procedure. 6. The patient agrees to undergo all examinations and clinical evaluations planned for the study. Exclusion Criteria: 1. Active HIV or HCV infection 2. Severe systemic disease 3. Known allergy to materials similar to be used in the investigational product 4. Known mental disease 5. Presence of depression, by positive answers to both the following questions: * ""During the past month have you often been bothered by feeling down, depressed or hopeless?"" * ""During the past month have you often been bothered by little interest or pleasure in doing things?"" 6. Patients wearing other active implants like pacemaker or defibrillator 7. Patients with poor oral hygiene 8. Patients whose oral anatomical characteristics precludes the insertion of the device 9. Patients who are unable or unwilling to cooperate with study procedures. 10. Pregnancy 11. Presence of erosive or ulcerative oral lesions, which are chronic or recurrent, such as erosive lichen planus, RAS, eryth. Candidosis, and of suspected pre-malignant or malignant lesions",18.0,65.0,['xerostomia']
NCT02578108,Diagnostic Genicular Nerve Block Prior to Radiofrequency Ablation for Knee Osteoarthritis Pain,A Prospective Trial of Zero Versus One Diagnostic Genicular Nerve Blocks to Determine Clinical Outcomes After Radiofrequency Ablation for the Treatment of Chronic Painful Knee Osteoarthritis,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. All patients ages 30-80 with chronic painful knee osteoarthritis who would undergo treatment by genicular nerve radiofrequency ablation. 2. Knee pain for at least 6 months. 3. Kellgren-Lawrence knee osteoarthritis of 2 or greater. 4. Pain resistant to conventional therapy including NSAIDs, opioids, muscle relaxants, oral steroids, physical therapy, and intra-articular injection therapy. 5. No pain referral beyond the expected distribution for knee osteoarthritis. Exclusion Criteria: 1. NRS pain score of 4 or more 2. Focal neurologic signs or symptoms. 3. Previous radiofrequency ablation treatment for similar symptoms. 4. Intra-articular knee corticosteroid or hyaluronic acid injection in the past 3 months. 5. Concomitant radicular pain. 6. Previous knee surgery. 7. Patient refusal. 8. Lack of consent. 9. Active systemic or local infections at the site of proposed needle and electrode placement. 10. Coagulopathy or other bleeding disorder, current use of anticoagulants or anti-platelet medications. 11. Allergy to medications being used for injection procedures (contrast, local anesthetic). 12. Inability to read English, communicate with staff, or participate in follow-up. 13. Pregnancy. 14. Pacemaker. 15. Cognitive deficit. 16. Unstable medical or psychiatric illness.",30.0,80.0,"['osteoarthritis, knee', 'pain', 'nerve', 'lesion']"
NCT03753308,Mechanism of DCs Dysfunction in Chronic HBV Infection,Mechanism of DCs Dysfunction in Chronic HBV Infection,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria : Group 1a: HBV positive patients / no scheduled biopsy * Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA * Patients who signed a non-opposition * Patient affiliated to social security insurance * HBsAg positive for more than 6 months * known status of HBeAg (positive or negative) * Treated or not with an antiviral Group 1b: HBV positive patients / with scheduled biopsy * Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA * Patients who signed a non-opposition * Patient affiliated to social security insurance * HBsAg positive for more than 6 months * known status of HBeAg (positive or negative) * Treated or not with an antiviral * Patient with a liver biopsy indication as part of the treatment within 3 months. Group 2: NASH patients / with scheduled biopsy * Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA * Patients who signed a non-opposition * Patient affiliated to social security insurance * The existence of at least one element of metabolic syndrome * Steatosis detected by non-invasive tests (echo, CAP, MRI) Group 3: Blood samples from healthy donors * No subject will be included in this group, the samples have been already collected at EFS from healthy donors who had previously given their informed consents for using their blood samples in the research. * The blood samples have been collected in sufficient quantity to carry out the analyzes (20mL from each donor). Exclusion Criteria: For groups 1a, 1b and 2 (HBV or NASH patients): * Positive serology for HCV, HDV, HTLV, HIV * Active autoimmune diseases * Immunosuppressive therapies * Cancer \ 30g / day, female\> 20g / day Group 1a and 1b: * NASH patients Group 2: * Positive HBsAg Group 3: Blood samples from healthy donors * Positive serology for HCV, HTLV, HIV, HBV (in the sense of a positive HBsAg test). * Risk of any infectious disease at the time of sample collection (including fever\> 38 ° C over the past 15 days or recent contact with a person with a contagious disease). * Autoimmune disease or immunosuppressive therapy at the time of sample collection.",18.0,65.0,"['hbv', 'nash - nonalcoholic steatohepatitis']"
NCT03611608,A Study of LY3316531 in Healthy Participants,"A Phase 1 Randomized, Placebo-Controlled Study to Determine the Effect of LY3316531 on Capsaicin-Induced Dermal Blood Flow in Healthy Male Subjects",COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: * Must be healthy males * Must be abstinent or use condoms with spermicide as well as 1 additional highly effective method of contraception or effective method of contraception during the study and for 5 months following dosing of study drug * Must have a body mass index between 18 to 32.0 kilogram per meter square (kg/m²), inclusive, and a minimum body weight of 50 kilogram (kg) * Must have suitable skin characteristics for the dermal capsaicin challenge and have demonstrated at least a 100 percent (%) increase in dermal flow following capsaicin challenge as part of the screening procedures and measured through laser Doppler imaging (LDI) Exclusion Criteria: * Must not have evidence of clinically significant active infection, fever of 100.5 degrees Fahrenheit (°F) (38 degrees Centigrade (°C)) or above, at baseline * Must not show evidence of active or latent tuberculosis (TB) * Must not have received live, attenuated live, or non-live vaccine(s) within 28 days of screening or intend to receive during the study * Must not be immunocompromised * Must not have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing * Must not have significant allergies to humanised monoclonal antibodies * Have a history of multiple or severe allergies or has had an anaphylactic reaction to prescription or nonprescription drugs or food * Must not have had any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin * Must not have eczema, scleroderma, psoriasis, dermatitis, keloids, tumors, ulcers, burns, flaps, or grafts on their forearm or other abnormality of the skin that may interfere with the study assessments * Must avoid excess tanning throughout the study and cannot cover forearms for 24 hours prior to each treatment period * Must not have excessive hair growth on the volar surface of the forearm or currently using lotions, oils, depilatory preparations, or other topical treatments on a regular basis that cannot be discontinued for the duration of the study; participant must not have used any topical treatments within 7 days of the start of the study",18.0,55.0,['healthy']
NCT01211925,Distal Venous Arterialisation of Ischemic Limb,Distal Venous Arterialisation in the Treatment of Critical Ischemia of Lower Limb,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Absence of any possibility for direct revascularisation due to extensive occlusive disease of crural and pedal arteries * Sufficient deep venous system and usable great saphenous vein as a graft for in situ bypass surgery according duplex scanning * localized infective of necrotic process up to the metatarsal level * Satisfactory general patient condition Exclusion Criteria: * advanced lower limb ischemia * venous insufficiency of lower limb,20.0,95.0,['critical limb ischemia']
NCT06811025,Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis,Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis,ENROLLING_BY_INVITATION,INTERVENTIONAL,ALL,"Inclusion Criteria: * (1) Inpatients who have been diagnosed with or clinically diagnosed with tuberculous meningitis within the past 3 months prior to screening; (2) Voluntarily participate in this study and sign the informed consent form; (3) Male and female participants must use effective contraception during the study and for 1 month after the study ends. Exclusion Criteria: * (1) Patients who have been on long-term corticosteroid therapy or taking immunosuppressants within 90 days prior to screening; (2) Pregnant women, patients in the puerperium, and lactating women; (3) Patients with a history of allergy or known hypersensitivity to contezolid or linezolid, or a history of severe adverse reactions; (4) Patients with evidence of resistance to contezolid or linezolid; (5) Patients deemed unsuitable for participation in this study by the investigator's assessment; (6) Patients whom the investigator believes participation in this study would harm their health, or who are deemed unable to comply with the scheduled visits and assessments as outlined in the protocol, and therefore unsuitable for participation in this study.",18.0,65.0,"['tuberculosis', 'meningitis']"
NCT05269225,Organic Diet in Pregnancy and Risk Markers of Health Effects (The OrgDiet Project),Organic Diet in Pregnancy and Risk Markers of Health Effects,RECRUITING,INTERVENTIONAL,FEMALE,Inclusion Criteria: * Nulli- or multipara pregnant in first trimester Exclusion Criteria: * Consuming an organic diet regularly * Using medication regularly that might interfere with study adherence or - outcomes * Diagnosed with a chronic disorder or cancer * Having a food allergy or intolerance,18.0,65.0,['nutrition']
NCT03982225,Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental Fat,"A Multicenter, Randomized, Subject-assessor Blind, Placebo Controlled Phase Ⅱ Study to Determine the Optimal Dose of AYP-101 S.C. Injection for the Reduction of Submental Fat",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Male and female over 19 and under 65 years old. 2. Submental fat graded by the investigator as 2 or 3 using the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and graded by the subject as 2 or 3 using the Patient-Reported Submental Fat Rating Scale (PR-SMFRS) as determined on Visit 1. 3. Dissatisfaction with the submental area expressed by the subject as a rating of 0, 1, or 2 using the Subject Self Rating Scale (SSRS) as determined on Visit 1. 4. Stable weight over the last 6 months (body weight change within +/- 5kg), subject who should refrain from exercise and diet that may affect the study results, and who agreed to remain it for the study period. 5. Signed informed consent obtained before any study-specific procedure is performed. Exclusion Criteria: 1. Allergic to beans or medical devices which used in this clinical trial (sterile oil pan, alcohol swab, grid pad, needle, etc.). 2. Hypersensitivity to the components of the clinical drug, lidocaine or acetaminophen. 3. Central, endocrine, or hereditary obesity (BMI 35kg/m2 or more). 4. Unable to undergo MRI by neurosis or general weakness. 5. History of any treatment (orthognathic surgery, suction lipectomy, Polyene Phosphatidylcholine (PPC) injection) in the neck or chin area. 6. History of any treatment such as massotherapy, carboxy, laser surgery, acupuncture needle, filler, chemical peeling, a botox surgery within 1 year before screening. 7. Inflammation, scars or surgery on the injection area. 8. Judged to be unsuitable subject for the clinical trials; ① Abnormal or sagging skin, ② Noticeable platysma band under the chin area, ③ Less or short chin than normal. 9. Chin or neck disease that are considered to have an impact on the clinical trial such as lymphadenopathy. 10. History of or present symptoms of dysphagia. 11. Heart disease (cardiac insufficiency, angina, cardiac infarction) or stroke within 6 months before screening. 12. Requiring treatment of joint inflammation or a lung disease. 13. Uncontrolled hypertension (systolic blood pressure greater than 180 mmHg or diastolic blood pressure greater than 110 mmHg) or type 2 diabetes mellitus (HbA1c\> 9%). 14. Type 1 diabetes mellitus who needs insulin treatment. 15. Autoimmune disorder as well as those who takes immunodepressant drugs. 16. Hemostatic disorder or those who takes anticoagulant drug such as warfarin and clopidogrel. 17. Thyromegaly, thyrotoxicosis, or HIV-positive. 18. Diagnosed with malignant tumor within the last 5 years. 19. Severe renal dysfunction (serum creatinine \> 2.0 mg/dl) or severe dyshepatia (ALT, aspartate aminotransferase(AST), alkaline phosphatase \> maximum rate of normality x 2.5). 20. History of serious psychiatric disease (Depression, schizophrenia, epilepsy, alcoholism, drug addiction, anorexia, anorexia nervosa, etc.). 21. History of taken a drug that can affect body weight or lipid metabolism such as anorectic agent, steroids, thyroid hormones, amphetamine, cyproheptadine, phenothiazine, or drugs that affect absorption, metabolism, and excretion within 3 months before screening. 22. History of other clinical trial studies within 3 months before screening. 23. Women who are pregnant, breastfeeding, having pregnancy plan, or did not agreed to the contraception (contraceptive pills, contraceptive hormones, intrauterine contraceptive device, spermicide, condoms etc.). 24. Judged to be unsuitable subject for the clinical trials. 25. No or unable to using Smart phone to fill in the e-Pro. 26. Artificial or cavity teeth filled with metallic material (iron, gold, amalgam, cobalt, titanium) which makes misinterpret MRI.",19.0,65.0,['moderate or severe submental fullness']
NCT00884325,Management of Pruritus With Xyzal in Atopic Dermatitis,"Management of Pruritus With Xyzal in Atopic Dermatitis in a Randomized, Double-Blind, Placebo Controlled Study",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Outpatient, male or female subjects of any race, at least 18 years of age. * Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline and practice a reliable method of contraception throughout the study. A female is considered of childbearing potential unless she is: * postmenopausal for at least 12 months prior to study drug administration; * without a uterus and/or both ovaries; or * has been surgically sterile for at least 6 months prior to study drug administration. * Reliable methods of contraception are: * hormonal methods or intrauterine device in use \> 90 days prior to study drug administration; * barrier methods plus spermicide in use at least 14 days prior to study drug administration; or * vasectomized partner. \[Exception: Female subjects of childbearing potential who are not sexually active will not be required to practice a reliable method of contraception. These subjects may be enrolled at the Investigator's discretion if they are counseled to remain sexually inactive during the study and understand the possible risks in getting pregnant during the study.\] * Definitive diagnosis of atopic dermatitis as per Rajka-Hanifin criteria. * Visual Analog Scale (VAS) pruritus score of 6 cm or more (moderate to severe itching) at baseline. * Willing to refrain from other antihistamines and topical steroids and topical immunomodulators for the duration of the study. * Able to understand and comply with the requirements of the study and sign Informed Consent/Health Insurance and Portability Accountability Act (HIPAA) Authorization forms. Exclusion Criteria: * Female subjects who are pregnant (positive urine pregnancy test), breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control. * Requiring oral treatment for their atopic dermatitis apart from oral antihistamines * History of hypersensitivity or idiosyncratic reaction to to any component of the test medication , or to cetirizine. * Atopic Dermatitis triggered by an unavoidable irritant/allergen. * Skin disease/disorder that might interfere with the diagnosis or evaluation of atopic dermatitis (e.g., erythroderma, skin infection on the affected area, etc.) * Non-compliance with the proper wash-out periods for prohibited medications. * Uncontrolled chronic disease such as diabetes * The presence of renal disease with mild, moderate or severe renal impairment * Medical condition that, in the opinion of the Investigator, contraindicates the subject's participation in the clinical study. * Clinically significant alcohol or drug abuse, in the opinion of the Investigator. * History of poor cooperation, non-compliance with medical treatment, or unreliability. * Participation in an investigational drug study within 30 days of the Baseline Visit.",18.0,65.0,"['atopic dermatitis', 'pruritus']"
NCT00400725,Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis,Comparison of the Maintenance Effect of Clobex® Shampoo 0.05% Used Twice Weekly vs. Vehicle on Scalp Psoriasis in Subjects Who Successfully Responded to a 4-week Daily Course of Clobex® Shampoo 0.05%,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Male or female subjects aged 18 years or older. * Subjects with moderate to severe scalp psoriasis Exclusion Criteria: * Subjects who needed systemic treatment for their body psoriasis * Subjects with a washout period for topical treatment(s) on the scalp less than: * Corticosteroids 2 weeks * All other anti-psoriasis medications 2 weeks * Subjects with a washout period for systemic treatment(s) less than: * PUVA therapy 4 weeks * Biological therapies 12 weeks * Treatments other than biologicals with a possible efficacy on psoriasis 4 weeks * Treatment known to worsen psoriasis 2 weeks,18.0,65.0,['scalp psoriasis']
NCT04684225,Telerehabilitation on Hand-Affected Scleroderma,Telerehabilitation Approach on Individuals With Hand-Affected Scleroderma,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Having been diagnosed with scleroderma * Stability of medical treatments * To be able to adapt to the exercises Exclusion Criteria: * The patient has a history of neurological disease or trauma that may affect his symptoms * Systemic involvement that affects the treatment process * Being in the active phase of the disease,18.0,55.0,"['scleroderma', 'scleroderma, systemic', 'scleroderma associated digital ulcer', 'hand rheumatism', 'physiotherapy', 'rehabilitation']"
NCT04849325,IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease,"A Prospective, Multi-Center, Randomized Trial Comparing the IBS Titan™ Sirolimus-Eluting Iron Bioresorbable Peripheral Scaffold System vs. Standard Balloon Angioplasty for Treatment of Below-the-Knee Arteries: GENIUS TRIAL",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Patients must between 18 and 85 years old, without gender limit. 2. Patients who can understand the purpose of the trial, voluntarily participate in and sign the informed consent form, and complete the 1-year follow-up. 3. Subject has lower extremity atherosclerotic occlusive disease with symptomatic Critical Limb Ischemia (CLI). 4. Rutherford Becker Clinical Category 3-5. 5. The target lesion is below the popliteal artery (including bifurcation). 6. The target lesion is located in the proximal 2/3 of native infrapopliteal vessels or tibiofibular trunk. 7. The target lesion stenosis is ≥70% or occlusion of no more than two infrapopliteal arteries (including the anterior and/or posterior tibial and/or peroneal artery and/or tibiofibular trunk). 8. The length of target lesion is ≤200mm, which could be covered by no more than two stents, with vessel diameter of 2.25-4.25 mm. Exclusion Criteria: 1. Severe renal insufficiency, hepatic dysfunction (Cr\>2 times of normal limit or renal dialysis, ALT or AST \> 5 times of normal limit). 2. Surgery in target vessel before treatment. 3. Volume reduction surgery in target vessel before treatment. 4. Thrombosis in target vessel, or acute thrombosis requiring thrombolysis and thrombectomy. 5. Systematic coagulation disorder or hypercoagulability. 6. Lower extremity arteries surgery or thrombolytic therapy in the ipsilateral extremity in the past 6 weeks. 7. Stroke occurs within 3 months before surgery, or stroke occurs with severe hemiplegia aphasia sequelae more than 3 months before treatment. 8. Acute myocardial infarction or angina pectoris within 30 days before treatment. 9. In-stent restenosis. 10. Guide wire cannot pass target lesion. 11. Previously treated with drug eluting balloon within 1 year before treatment. 12. More than two infrapopliteal arteries needed treatment. 13. The inflow tract (including ipsilateral iliac artery, femoral artery, popliteal artery) has lumen stenosis \>30% with or without intervention. 14. The inflow tract (including ipsilateral iliac artery, femoral artery, popliteal artery) has \> 150 mm stenosis or occlusion before treatment. 15. Aneurysm of lower extremity artery. 16. Thromboangiitis obliterans (Buerger's disease). 17. Significant (≥ 50% stenosis) lesion in a distal outflow artery that would be perfused by the target vessel and that requires treatment at the time of the index procedure. 18. Patients known to be allergic to aspirin, heparin, Plavix, contrast agents, Sirolimus, poly lactic acid polymer, iron, zinc and their degradation product, and those who cannot tolerate postoperative dual anti-platelet therapy. 19. Patients who have a history of disease related to iron overload or iron disorder, such as hereditary hemochromatosis, etc. 20. Patients who are participating in another clinical trial that has not yet completed its primary endpoint. 21. Pregnant or those who plan pregnancy during the clinical investigation follow-up period. 22. Angiography suggests intraoperative thromboendarterectomy, percutaneous transluminal rotational atherectomy or laser therapy are needed. 23. Patients have life expectancy ≤ 1 year. 24. Patients who are not suitable for participating the trial judged by investigator.",18.0,85.0,['critical limb ischemia (cli)']
NCT05564325,Real-time Deflectable Guidewire in Neuro-interventions Study,Real-time Deflectable Guidewire in Neuro-interventions Study,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * \>18 years of age * Informed consent signed by patient * Confirmed cerebral unruptured aneurysm treatable via transcatheter approach Exclusion Criteria: * Pregnancy or lactation * Known disorder of vascular fragility with propensity to vascular injury (e.g., Ehlers-Danlos syndrome) * Known prior vascular stenosis or dissection or injury to vessels intended to be catheterized during study procedures * Acute phase myocardial infarction or uncontrolled cardiac arrhythmia * Uncontrolled serum electrolyte imbalance * Bleeding disorder which limits the use of antiplatelet and/or anticoagulant therapy * Known contraindication to intravascular contrast material that cannot be adequately controlled with pre-medication * Known hypersensitivity to Nickel * Subjects currently enrolled in another investigational device or drug study that clinically interferes with the current study endpoints",18.0,65.0,['unruptured cerebral aneurysm']
NCT01707225,Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD),Safety and Efficacy of Octreotide LAR Depot in Left Ventricular Assist Device (LVAD) Associate Gastrointestinal (GI),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * LVAD insertion as bridge to transplant or destination * 18 years of age or older Exclusion Criteria: * Poorly controlled diabetes, A1C greater than 8% * Poorly controlled hypothyroidism, TSH \> upper limit of normal (5.5) * End Stage Renal Disease (ESRD) requiring dialysis * Cirrhosis * Anemia (Hgb \< 8) * Acromegaly * Hx of chronic diarrhea - as determined by history of loose stool lasting longer than 2-4 weeks * Pregnancy or breastfeeding * Inability to provide informed consent * Incarceration or otherwise a ward of the state * Non-English speaking",18.0,65.0,['gastrointestinal bleeding']
NCT03130725,Retention of Bonded Amalgam Sealants Versus Resin-based Sealants,Comparison of Six Months Retention of Bonded Amalgam Sealants Versus Resin-based Sealants: A Randomized Controlled Trial,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Children of aged 12 to 16 years (male and female) who will visit to the study site and fulfilled the eligibility criteria * Teeth should be caries free at the time of sealants placement. As Dental sealant is a preventive treatment it is placed in a caries free surface. Incipient carious lesions will also be included. * Teeth should be completely erupted, as incomplete eruption of teeth is highly correlates to the partial retention of sealants. * Children who will give assent to participate in a study and their parents will give consent. Exclusion Criteria: * Special needs children (because they need special attention of parents) * Children who have blood disorder like (leukemia, lymphoma, and thalassemia) * Persons with impaired vision, speech and hearing (because either they may not be able to respond to questionnaire or conducting baseline dental training will be difficult).",12.0,17.0,"['incipient enamel caries', 'fissure, dental']"
NCT05873725,Retrospective Study of High Dose Follitropin Delta in a Mixed Protocol With Human Chorionic Gonadotropin,Retrospective Study of High Dose Follitropin Delta in a Mixed Protocol With Human Chorionic Gonadotropin,COMPLETED,OBSERVATIONAL,FEMALE,"Inclusion Criteria: * Women 18 to 42 years of age undergoing IVF/ICSI cycle * IVF antagonist protocol * Regular menstrual cycles of 24-35 days * Presence of both ovaries Exclusion Criteria: * Endometriosis stage III/IV * History of recurrent miscarriages, defined as ≥ 3 consecutive losses * Women undergoing ovarian stimulation for oncologic or elective fertility preservation * Women participating in any other research project * Hypersensitivity to follitropin delta and/or human chorionic gonadotropin * Use of Growth Hormone (GH) during the stimulation cycle",18.0,42.0,"['ivf', 'infertility']"
NCT06839625,"The Effect of Emotional FreedomTechnique on Postoperative Pain, Pain Belief and Anxiety in Coronary Artery Bypass Graft Planned Patients","The Effect of Emotional FreedomTechnique on Postoperative Pain, Pain Belief and Anxiety in Coronary Artery Bypass Graft Planned Patients",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Over 18 years old * No infections, sores in the touch areas * No psychiatric medication * No hearing and vision problems * Stable vital parameters Exclusion Criteria: * Patients undergoing re-operation * Postoperative complications (bleeding, delirium, arrhythmia, etc.) * Reintubation after extubation * Drug and stimulant users * Sedated for more than 24 hours * Patients unstable for more than 24 hours",18.0,65.0,"['coronary arterial disease (cad)', 'surgery (cardiac)', 'emotional freedom technique']"
NCT03112525,DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic,DAPHNE Study: Real-Life Observational Study to Evaluate the Impact of the CYP3A4/5/7 and P-gp Pharmacogenetics and Phenotypic Activity on the Pharmacokinetic Profile of the Direct Oral Anticoagulants Rivaroxaban and Apixaban in Hospitalised Patients,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Understanding of French or English language and provide signed and dated informed consent form. * Willing to comply with all study procedures and be available for the duration of the study. * Male or female, aged 18 years or above. * Diagnosed with atrial fibrillation, deep-vein thrombosis or pulmonary embolism and under rivaroxaban or apixaban drug treatment. Exclusion Criteria: * Participation in a clinical study that may interfere with participation in this study. * Under rivaroxaban or apixaban for prophylaxis of deep-vein thrombosis and pulmonary embolism in patients undergoing knee or hip replacement surgery. * Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study. * Known allergy to midazolam or to fexofenadine",18.0,65.0,['anticoagulants and bleeding disorders']
NCT01068925,Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers,"An Open-Label, Single Sequence, Three-Period Drug Interaction Study of GSK1349572 and Tipranavir/Ritonavir in Healthy Adult Subjects (ING113096)",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: A subject will be eligible for inclusion in this study only if all of the following criteria apply: (a single repeat is allowed for assessments to determine eligibility). * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and ECG. * Male or female between 18 and 55 years of age inclusive, at the time of signing the informed consent. * AST, ALT, alkaline phosphatase and bilirubin within normal ranges. A single repeat is allowed to determine eligibility. * A female subject is eligible to participate if she is of: * Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy or bilateral oophorectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \> 40 MlU/ml and estradiol \ 14 drinks/week for men or \>7 drinks/week for women. One drink is equivalent to (12 g alcohol) = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of 80 proof distilled spirits. * History of regular use of tobacco- or nicotine-containing products within 3 months prior to screening. * Consumption of red wine, seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication. * Pregnant females as determined by positive serum or urine human chorionic gonadotrophin (hCG) test at screening or prior to dosing. * Lactating females. * Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs. * Subjects with a history of cholecystectomy, peptic ulceration, inflammatory bowel disease or pancreatitis should be excluded. * Any patient with a history of bleeding diathesis, gastrointestinal bleeding or at increased risk of bleeding such as frequent nose bleeds, high blood pressure, heavy menses, von Willebrand disease, and personal or family history of bleeding disorders * History/evidence of symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PCTA) or any clinically significant cardiac disease. * History/evidence of clinically significant pulmonary disease. * History of significant renal or hepatobiliary diseases. * A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening. * A positive test for HIV antibody. * History of 2nd degree or higher AV block. * Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period. * The subject's systolic blood pressure is outside the range of 90-140mmHg, or diastolic blood pressure is outside the range of 45-90mmHg or heart rate is outside the range of 50-100bpm for female subjects or 45-100 bpm for male subjects. * Exclusion criteria for screening ECG (a single repeat is allowed for eligibility determination):",18.0,55.0,"['infection, human immunodeficiency virus', 'hiv infections']"
NCT06675825,An Innovative Endoscopic Cap for Dilating Benign Esophageal Strictures in Children,"A Novel Endoscopic Attachment Cap for Benign Esophageal Stricture Dilation in Children: a Randomized, Multicentric Pilot Study.",RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * Age under 18 years of age * Indication for endoscopic esophageal dilation * Benign stenosis * Written Informed Consent signed by the subject and/or parent/legal representative (if applicable) Exclusion Criteria: * Stenosis that cannot be treated endoscopically * Malignant esophageal strictures * Contraindications and limitations of the MD as described in the instructions for use,0.0,18.0,"['esophageal stenosis', 'esophageal dilation']"
NCT06089525,Treatment of Complex Pilon Fractures,Treatment of Complex Pilon Fractures: A Pilot Study Comparing Primary Arthrodesis (PA) to Open Reduction and Internal Fixation (ORIF),UNKNOWN,OBSERVATIONAL,ALL,Inclusion Criteria: Individuals receiving ORIF or PA for a multifragmented acute pilon fracture occuring at the joint surface over the age of 18 from 2018 to present at The University of Kansas Medical Center (KUMC) or Emory University Hospital. Exclusion Criteria: Anyone under the age of 18 years. Pregnant women.,18.0,65.0,['pilon fracture']
NCT00873925,Cord Blood Plus Vitamin D and Omega 3s in T1D,Transfusion of Autologous Umbilical Cord Blood Plus Vitamin D and Omega 3 Fatty Acids to Preserve Beta Cell Function in Children With Recent Onset Type 1 Diabetes - A Pilot Study,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * TID diagnosis confirmed by presence of at least 1 diabetes autoantibody Children ≥ 1 years * Stored autologous umbilical cord blood (15 sought) in an AABB and/or FACT accredited cord bank. * Stimulated C-peptide \> 0.2pmol/L on MMTT * Cord blood meets all selection and testing criteria (see below). * Normal screening values for CBC, Renal function and electrolytes (BMP with Ca, Mg, and Phos). * Willing to comply with intensive diabetes management Exclusion Criteria: * Complicating medical issues that would interfere with blood drawing or monitoring. * Chronic use of steroids or other immunosuppressive agents for other conditions. * Positive infectious disease markers from mother's blood or cord at time of -collection (See below for details). * Any evidence of illness on planned infusion date (i.e. fever \>38.5 C, vomiting, diarrhea, wheezing, or crackles). * Allergy to DHA (Omega 3) or Vitamin D * Hypercalcemia",1.0,18.0,['type 1 diabetes']
NCT06233825,Nutritional Intervention to Enhance Recovery After Arthroscopic Knee Surgery in Adults,Nutritional Intervention to Enhance Recovery After Arthroscopic Knee Surgery in Adults: A Randomized Controlled Pilot Trial,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Diagnosed anterior cruciate ligament injury requiring reconstruction surgery * Surgery in Kingston, ON * Patellar tendon graft, quadriceps tendon graft, or hamstring tendon graft reconstruction procedure Exclusion Criteria: * Any muscular, neurological, respiratory, or metabolic disease, subject to investigators' discernment, would negatively affect the subject's ability to comply with the study requirements * Any form of cancer currently or in the last 5 years * Bleeding disorders or antiplatelet / anticoagulation therapy * Currently taking fish oils or within the last 6 months * Regular consumption (≥ 2x week) of fish oil or oily fish in the last 6 months * Allergy or sensitivity to fish, shellfish or safflower oils * Currently taking any form of steroid or within the last 6 months * Medical inability to attain magnetic resonance imaging scans * Known irregular responses to physical activity (e.g., shortness of breath, chest pain, dizziness, etc.) * Surgery scheduled outside of research centre * Scheduled surgery date \< 5 weeks away * Pregnant or plans to become pregnant within the next 6 months * Any current illness that impacts ability to participate in protocols",18.0,65.0,"['anterior cruciate ligament reconstruction', 'muscular atrophy']"
NCT00803725,Spinal Mepivicaine With Fentanyl for Outpatient Knee Arthroscopy,Spinal Mepivicaine With Fentanyl for Outpatient Knee Arthroscopy Surgery,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Patients having unilateral arthroscopic surgery of the knee; 2. ASA I-III status; 3. Age 18-80 years; 4. BMI\< 35. Exclusion Criteria: 1. Patients who have previous history of hypersensitivity to local anesthetics or contraindications for spinal anesthesia (i.e. bleeding diathesis, coagulopathy); 2. Patients with radiating low back pain and neurological deficits in lower extremities; 3. Patients who are incapable of giving an informed consent.",18.0,80.0,['knee arthroscopy']
NCT03553576,Drug Concentration and Volume on Adequate Labor Analgesia With PIEB,The Relationship Between Local Anesthetic Concentration and Volume on Adequate Labor Analgesia With Programmed Intermittent Epidural Bolus,TERMINATED,INTERVENTIONAL,FEMALE,Inclusion Criteria: * 18 years and above * Nulliparous parturients * Present to the labor and delivery unit for an induction of labor or who are in spontaneous labor * Request neuraxial labor analgesia at ≤5 cm cervical dilation Exclusion Criteria: * Patients who are not eligible to receive a combined spinal epidural (CSE) technique with 25 mcg of intrathecal fentanyl * Non-English speaking * Failed initiation of CSE analgesia (VAS pain score \>10 15 minutes after intrathecal dose) * Need to have the epidural catheter replaced during labor * Who deliver within 90 minutes of initiation of labor analgesia * Require re-dose within 90 minutes of initiation of labor analgesia.,18.0,65.0,"['pain', 'anesthesia', 'labor pain']"
NCT02397876,Partially Hydrolyzed Whey Formula in Cow's Milk Allergic Patients,Partially Hydrolyzed Whey Formula in Cow's Milk Allergic Patients,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * age 0.5-18 years old * positive skin prick tests (SPT) or detectable serum milk specific IgE and a history of an allergic reaction to milk within 6 months before study screening; or milk-specific IgE level or SPT highly predictive for clinical reactivity (if ≤ 2 years old, sIgE \>2 kU/L; if \> 2 years old, a level \>5 kU/L; SPT wheal diameter ≥ 3 mm) * a clinical reaction during the cows milk oral food challenge Exclusion Criteria: * negative SPT and undetectable milk-specific sIgE * unstable asthma, allergic rhinitis, or atopic dermatitis * milk-induced eosinophilic gastroenteropathy * recent reaction to partially hydrolyzed whey formula * history of severe anaphylaxis with hypotension to cows milk * participation in any interventional study for the treatment of food allergy in the 6 months prior to screening visit * inhalant allergent immunotherapy that has not yet reached maintenance dosing * inability to discontinue antihistamines for skin testing, OFC * any systemic therapy which in the judgment of the investigator could be immunomodulatory in the 12 months prior to visit 1 (xolair, rituximab, chronic steroids, etc) * investigational drug use 90 days prior to visit 1 or intention to use during study period * the presence of any medical condition that the investigator deems incompatible with participation in the trial. * unable to understand and speak English",6.0,18.0,['food allergy']
NCT01158976,Effect of Omega-3 Supplementation During Pregnancy on Regulation of Stress,Impact of Omega-3 Intake During Pregnancy on Maternal Stress and Infant Outcome,COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * African American race * age between 20 and 34 years * 16-21 weeks gestation * household receipt of public assistance (e.g., Medicaid insurance) due to -low-income * low levels of DHA consumption as defined as less than two fish servings per week. Exclusion Criteria: * known medical complications (e.g., gestational diabetes, pre-eclampsia), -regular use of steroid medications * alcohol use * cigarettes or use of illegal substances (by maternal report) * use of blood thinners or anti-coagulants * use of psychotropic medications * Body Mass Index \>40 * allergy to iodine and/or soy.",20.0,34.0,['healthy pregnant women']
NCT00956176,Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients With Hemorrhagic Cystitis,Intravesical Cidofovir Instillation in HSCT Recipients With Hemorrhagic Cystitis: A Single Dose Pharmacokinetic Study,WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Polyoma BK or adenovirus viruria has been established either by positive urine cytology or by PCR for BK virus or by positive urine and/or blood culture for adenovirus 2. The patient has either gross hematuria and/or passes blood clots 3. Signed informed consent form 4. Hospitalized patients with a Foley catheter 5. Women of childbearing potential must agree to use 2 acceptable methods of birth control (e. g., abstinence, IUD, or barrier method), during the study period and one for a period of 2 months afterward. At least one of the methods must be a barrier method. Males must also agree to use acceptable method of birth control (barrier method) during the study period and for 2 months afterward. Exclusion Criteria: 1. Serum creatinine \>1.5 mg/dl and/or calculated creatinine clearance \ 100 mg/dl (equivalent to \> 2+ proteinuria) 3. Age less than 18 years 4. Prior therapy with formalin or carboprost 1 mg % administered intravesically 5. Hypersensitivity to cidofovir, probenecid or sulfa-containing medications 6. Have received prior cidofovir therapy within 2 weeks. 7. Prior enrollment in the study 8. Women who are pregnant or breast-feeding 9. Evidence of end-organ adenoviral infection",18.0,65.0,"['cystitis', 'bladder diseases']"
NCT06888076,Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Pregnant Women,"An Observational Study to Assess the Safety of Pertagen®, a Recombinant Acellular Pertussis Vaccine in Pregnant Women in Thailand",ACTIVE_NOT_RECRUITING,OBSERVATIONAL,FEMALE,"Inclusion Criteria: 1. Data of pregnant women previously vaccinated with Pertagen® during second or third trimester of pregnancy and have given birth in Thailand from January 2021 to April 2024 and infants born to pregnant women who received Pertagen® during pregnancy. 2. Infant of pregnant women who received Pertagen® during second or third trimester of pregnancy Exclusion Criteria: 1\. pregnant women previously vaccinated with Pertagen®, but maternal and infant data at delivery/birth cannot be obtained.",18.0,65.0,"['pertussis vaccines', 'pertussis (whooping cough)']"
NCT00043576,ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere,"A Phase 2/3 Multicenter, Randomized, Double Blind Study of Docetaxel (Taxotere) Plus DN-101 or Placebo in Androgen Independent Prostate Cancer (AIPC)",UNKNOWN,INTERVENTIONAL,MALE,"* Three rising PSA measurements OR a new metastatic lesion * Adequate liver and kidney function * Ongoing hormonal therapy * No hospitalization for angina, heart attack or congestive heart failure within the last 12 months * No kidney stones in the last 5 years",18.0,65.0,['prostate cancer']
NCT05334576,Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA,Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA Novartis Investigator Initiated Trial: CSEG101AUS12T,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Adult participants age 16 and older 2. Sickle cell disease with confirmation of HbSS, HbSBthal0, HbSC, or HbS thal+ genotype 3. Per patient's sickle cell provider, patient has an increased risk of a silent cerebral infarcts according to one of the following criteria: 1. Silent cerebral infarcts visualized on FLAIR MRI within previous two years 2. Intracranial or extracranial cervical artery vasculopathy 3. History of overt ischemic or hemorrhagic stroke and Intolerance and/or failure of other therapies to prevent cerebral infarction 4. Increased severity of sickle cell disease including having between 2 and 10 sickle cell-related pain crises within the preceding 12 months as determined by medical history or by patient's recall (crises should include the occurrence of appropriate symptoms, a visit to a specific medical facility and/or health care professional, and receipt of pain medication). 5. Increased risk deemed by other objective laboratory and/or imaging results which have been associated with increased risk of cerebral infarction 4. Provide written informed consent. 5. Normal hematologic function defined as: WBC \> 4x10\^9 / L, ANC \>1.5x10\^9 / L and platelets \> 100x10\^9 / L 6. Females of childbearing potential (FCBP) must agree to refrain from becoming pregnant while on crizanlizumb and for 3 months after discontinuation from crizanlizumab, and must agree to use adequate contraception including hormonal contraception, (i.e. birth control pills, etc.), barrier method contraception (i.e. condoms), or abstinence during the time-frame Exclusion Criteria: 1. Current chronic transfusion therapy 2. Planning for hematopoietic stem cell transplant or cerebral revascularization procedure 3. Use of other investigational drug within one year of study participation 4. Other medical/neurological/social/substance abuse history that would alter brain MRI findings prospectively 5. Inability to return for follow-up 6. Contraindication to MRI 7. Acute bacterial, fungal, or viral infection 8. Known HIV, untreated latent tuberculosis (TB), or active hepatitis B or C infection or zoster 9. Pregnant and/or breastfeeding. Negative pregnancy test required prior to starting study treatment. 10. Known hypersensitivity to one or more of the study agents 11. Currently receiving or has received any investigational drugs within the 14 days prior to the first dose of study drug 12. Liver function tests (LFT) higher than 3x the upper limit of normal 13. Treatment with other monoclonal antibody medications within last 30 days 14. Treatment with various forms of anticoagulation within last 30 days, including but not limited to coumadin or direct thrombin inhibitors",16.0,65.0,['sickle cell disease']
NCT06648876,PK and PD of YG1699 in CKD Patients With Diabetes,Pharmacokinetic and Pharmacodynamics of YG1699 in Patients With Diabetes and Kidney Dysfunction,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Ability to provide informed consent 2. Male or female patients ,age between 18 and 70 at screening 3. Meet the diagnostic criteria for diabetic nephropathy, including patients with type 1 or type 2 diabetes; 4. Fasting blood glucose \ 1.2 within 6 months 7. The patient has not used glucocorticoids, calcineurin inhibitors (cyclosporine, tacrolimus), etc. that affect blood sugar within the past month before signing the informed consent form 8. The baseline diabetes management medication regimen has been stable within the past 2 weeks. Exclusion Criteria: 1. Hypoglycemia occurs more than 2 times in one month 2. History of ketoacidosis 3. Patients who are being treated with swiram and digoxin 4. Patients with acute kidney injury (serum creatinine increased by ≥ 50% within 1 week) 5. Abnormal liver function (ALT \> 3 times the upper limit of normal value) 6. Hemoglobin \ 150g/L 7. The blood pressure of patients with recent symptomatic hypotension is lower than 90/60 mmHg 8. There is acute myocardial infarction stroke infection in the past month 9. There is systemic active infection or uncured tumor 10. The dialysis regimen of HD patients included HP treatment 11. Participating in other interventional clinical studies 12. Pregnant or lactating women 13. Other situations that the researcher thinks are not suitable for joining the study",18.0,70.0,"['diabetes', 'renal insufficiency, chronic', 'hemodialysis']"
NCT06144476,Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung,Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung,RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study * Aged 18 years or above * Patient: known or suspected airway disease * Healthy volunteer: considered to be in good health with no significant comorbidity (immune disorder, cancer etc.) Exclusion Criteria: * Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus. * Surgery within the preceding 6 weeks * Participants who are pregnant * History of psychiatric, medical, or surgical disorders that in the opinion of the chief investigator may interfere with sample collection, undergo a bronchoscopy, or may compromise study completion or data collection * Alcohol or recreational drug abuse * Diagnosis of immunodeficiency requiring treatment * Unable to provide written informed consent * Unable to read or write English * Be considered, in the opinion of the investigator, to be an unsuitable candidate for the study",18.0,65.0,"['copd', 'asthma', 'airway disease']"
NCT06929676,Assessment of Tooth Mobility After Non-surgical Periodontal Treatment Followed by Tooth Splinting,Assessment of Tooth Mobility After Non-surgical Periodontal Treatment Followed by Tooth Splinting,ENROLLING_BY_INVITATION,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients diagnosed with Stage III and IV Periodontitis (grades A, B and C). * With periodontal pockets ≥ 4 mm. * Anterior teeth (13-23 and 33-43) with dental mobility (grade 2 or 3). * ≥ 18 years old. Exclusion Criteria: * Crossbite or edge-to-edge * Absence of posterior occlusal contact * Bruxism * Implants adjacent to the tooth with mobility * Extreme mobility * Patients requiring prophylactic antibiotics * Smokers * Diabetics",18.0,65.0,"['periodontal diseases', 'periodontitis']"
NCT07354776,"Effect of Isometric Neck Exercises on Cervicogenic Headache, Cortisol, and BDNF in Adolescents With Smartphone Addiction","A Randomized Controlled Trial Evaluating the Effects of Isometric Neck Exercises and Postural Advice on Cervicogenic Headache Symptoms , Serum Cortisol, and Brain-Derived Neurotrophic Factor Levels in Adolescents With Smartphone Addiction",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Adolescents aged 13 to 19 years. * Smartphone addiction, defined as using a smartphone for ≥4 hours per day. * A confirmed diagnosis of Cervicogenic Headache (CGH), as determined by a positive Cervical Flexion-Rotation Test (CFRT) performed by a physical therapist. Exclusion Criteria: * Diagnosis of other primary headache disorders (e.g., migraine, tension-type headache, cluster headache) or sinusitis. * Presence of fever, cranial tumors, meningitis, or subarachnoid hemorrhage. * Known carotid or vertebral artery dysfunction. * Significant use of other screened devices (e.g., tablets, laptops) that would confound the primary exposure. * History of prior neck injuries or cervical fractures. * Any medical condition that renders the individual unfit to participate in a moderate exercise program. * Presence of photophobia or phonophobia. * Current drug addiction. * Extreme, uncorrectable vision issues (Snellen chart score worse than 20/200 in either eye).",13.0,19.0,"['cervicogenic headache', 'sleep disturbance', 'stress']"
NCT05474976,Compliance With Gluten-Free Diet and Affecting Factors in Adolescents With Celiac Disease,Compliance With Gluten-Free Diet and Affecting Factors in Adolescents With Celiac Disease During the Covid-19 Pandemic,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Being in the 10-19 age group, * Being diagnosed with celiac disease according to the revised ESPGHAN criteria, * Following a gluten-free diet for at least 6 months before the COVID-19 lockdown, * Consenting to participate in the study by the adolescents and their parents. Exclusion Criteria: -Having any cognitive or mental disorders.",10.0,19.0,"['celiac disease in adolescents', 'gluten-free diet in the covid-19 process']"
NCT04661176,"Evaluation of the Sentinel™ PCC4 Assay for Diagnosis, Prognosis and Monitoring of Prostate Cancer in Puerto Rico",Evaluation of the Training Plan and Impact on Acceptance of the Sentinel™ Prostate Cancer Classifier Platform (Sentinel™ PCC4 Assay) and Determination of Assay Performance Characteristics of Clinical Utility in a Puerto Rican Population,UNKNOWN,OBSERVATIONAL,MALE,"Inclusion Criteria: 1. Males with suspicion of prostate cancer including, but not limited to elevated PSA level, suspicious DRE, family history of prostate cancer, and/or germline mutation. 2. Signed informed consent prior to initiation of any study-related procedures. 3. Minorities are included in this protocol. 4. The patient provided a urine sample within 30 days prior to biopsy being performed. 5. Patients who sign the consent form, but after shared decision making discussions with their urologist decide not to undergo a core needle biopsy. Since these may represent up to 5% of patients and represent the current SOC, these patients will be separately categorized as ""Prostate Biopsy Declined"" (PBD). Exclusion Criteria: 1. Persons younger than 22 years of age. Since patients with germline mutations and/or family history may want to be screened before the age of 45 (as recommended by the NCCN) and some men over the age of 75 individuals may request a diagnostic core needle biopsy after shared decision making with their urologist, we have chosen not to include an age range that may exclude these individuals. The lower age limit is designed to exclude children from the study. 2. Persons incapable of providing informed consent. 3. Persons presenting with clinical symptoms of urinary tract infection, including prostatitis at the time of enrollment. 4. Persons with prior history of invasive treatment for benign prostatic hyperplasia within 3- 6 months of study enrollment. 5. Patients treated with finasteride or bicalutamide for BPH or male pattern baldness.",22.0,65.0,['prostate cancer']
NCT01155076,Effects of a Vitality Dietary Supplement on Physical and Mental Function in Middle-aged Adults,"Effects of a Proprietary Ginseng, Cordyceps, and Pomegranate Supplement on Physical and Mental Function in Middle-aged Adults: a Double-blind, Randomized, Placebo-controlled Trial",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Males and females aged 40-70 years * Signed Informed Consent * BMI between 19 and 30 kg/m2 * Normotensive, defined as systolic blood pressure 90-140 mmHg and diastolic blood pressure 50-90 mmHg Exclusion Criteria: * Regular dietary supplement use and unwilling to discontinue use at least 1 month prior to enrollment in the study * Self-reported chronic condition that may affect subject safety (e.g. diabetes, cardiovascular disease) or significantly impact product effectiveness (e.g. chronic fatigue) * Pregnancy/suspected pregnancy, breastfeeding * Antihypertensive medication use * Allergies to any supplement ingredients * Consumption of more than 600mg caffeine from any source per day * Consumption of ""energy drinks"" (e.g. Red Bull, Monster) or any herbal supplement known to affect energy levels * Known iron anemia * Medically treated for insomnia * Medically treated for depression * Taking medications known to affect energy, e.g. thyroid medication * Tobacco user * Planned surgical procedure in next 2 months * Participating in another clinical (medical or nutritional) study or likely to enroll in another medical or nutritional study",40.0,70.0,['health-related quality of life']
NCT00538876,Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML,Phase I Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients must have histologically or cytologically confirmed diagnosis of Acute Myelogenous Leukemia (AML) * Patient is \>18 and ≤ 60 years of age. * AML subgroup is associated with less-than-favorable risk as defined by: * The absence of good risk molecular features: t(8;21), inv(16), t(16;16), or t(15;17) translocations identified by FISH or standard metaphase karyotyping or evidence for the corresponding fusion transcripts, AML1-ETO, CBFβ-SMMHC, or PML-RARα, as identified by RT-PCR or suggested by the FAB M3 phenotype; * A history of an antecedent myelodysplastic syndrome; * A history of an antecedent Philadelphia-chromosome negative myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, primary myelofibrosis); * Treatment-related AML believed secondary to prior cytotoxic chemotherapy for an unrelated disease. * Patient has adequate cardiac function as defined by: * An echocardiogram or MUGA scan demonstrating an ejection fraction within normal limits. * ECOG performance status \> = 2. * Patient has adequate hepatic/renal function as defined by: * Total bilirubin ≤ 2 mg/dL. Patients with documented evidence of Gilbert's Syndrome resulting in elevated total bilirubin levels will be eligible, provided all other eligibility criteria are met. * Aspartate transaminase (AST) and alanine transaminase (ALT) ≤1.5 x the ULN. * Creatinine ≤ 2 mg/dL (or a creatinine clearance \>50 mL/min/1.73 m2, by direct measure). * Patient is not childbearing: * Female subjects must be surgically sterile, postmenopausal, or have a β-HCG indicating that they are not pregnant at the time screening is performed. * Female patients of childbearing potential must agree to take appropriate measures to ensure that they do not become pregnant while enrolled on protocol (i.e., within 2 months of administration of chemotherapy). * Male patients must agree to take appropriate measures to ensure that they do not father a child while enrolled on protocol (i.e., within 2 months following administration of chemotherapy). * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * AML with ""good risk"" molecular features: karyotype demonstrating the presence of t(8;21), inv(16), t(16;16), or t(15;17) translocations identified by FISH or standard metaphase karyotyping or evidence for the corresponding fusion transcripts, AML1-ETO, CBFβ-SMMHC, or PML-RARα, as identified by RT-PCR or suggested by the FAB M3 phenotype. * Patient has a history of chronic myelogenous leukemia or has molecular evidence of the t(9;22) translocation by FISH, metaphase karyotype or RT-PCR for the BCR-ABL fusion transcript. * Patient has received chemotherapy (other than hydroxyurea) or radiation within the 2 weeks prior to planned therapy on this study. * Patient has an active second malignancy. * Patient has a medical condition or illness considered by the Investigator to constitute an unwarranted high risk for investigational drug treatment. * Patient has an uncontrolled serious infection. * Patient is pregnant or nursing an infant. * Patient has a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies. * Patient has an inability or unwillingness, in the opinion of the Investigator, to comply with the protocol requirements. * Patients with central nervous system (CNS) (or leptomeningeal) involvement by their AML may be considered for treatment at the Investigator's discretion and following discussion with the Medical Monitor, in order to allow for appropriate management. * Patient has circulating blast count \> 50,000/μL (patients may be enrolled if circulating blast count is controlled by hydroxyurea and/or, if clinically indicated, by leukopheresis).",18.0,65.0,['acute myeloid leukemia']
NCT01260376,Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise,Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise,COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: \- healthy, untrained males Exclusion Criteria: * medication * history of malignancy, alcohol abuse or drug abuse * participation in isotope trials in the last 6 months",18.0,55.0,"['diabetes', 'obesity']"
NCT00294476,"IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma","A One Arm, Open Label,Multi - Center Phase II Study to Evaluate the Safety and Efficacy of IVIG in the Treatment of Various Metastatic Solid Tumors for Which There is no Better Alternate Treatment",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients older than 18 years of age. * Histological confirmed diagnosis of a prostate adenocarcinoma, melanoma or colon cancer * At least one measurable site of disease as evidenced by CT or MRI, RECIST criteria in soft tissue OR lymph nodes and OR tumor markers as appropriate * Rising PSA in 3 consecutive weeks taken at least one week apart with a value of at least 5 ng/mL * Testosterone that is less than 50 ng/dL in prostate patients * Prostate cancer patients receiving radiation therapy that is less than 30% of pelvic/total bone mass and where acute radiation toxicity is resolved * ECOG Performance status 0- 2 * WBC \> 1,500 cells/mm3, hemoglobin \> 9 g/dL, and platelets \> 100,000 cells/mm3 and \ = 50 ml/min * Life expectancy of at least 3 months * Willing to participate in a 6 month follow-up * Female patients of child-bearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Post menopausal women must be amenorrheic for at least 12 months to be considered of non- childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug. * Patients who have given written informed consent Exclusion Criteria: * Patients suffering from primary or metastatic brain or spinal tumor. * Patients with known sensitivity to any of the components of the IVIG formulation excipients. * IgA levels \<=60mg/dl . * Treatment with IVIG 6 months prior to study start * Patients that are with known seropositivity for HIV or with a known diagnosis of human immunodeficiency virus (HIV) infection. (AIDS) * Patients with significant diseases, active infection or uncontrolled medical condition (e.g., pulmonary, neurological, cardiovascular, gastrointestinal, genitourinary) considered high risk for investigational new drug treatment/ who in the opinion of the investigator would be excluded from the study * Female patients who are pregnant or breast-feeding. * Patient has a severe and/or uncontrolled renal failure. * Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis). * Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent and who in the opinion of investigator, are unlikely to comply with the study protocol * Patients who are currently participating or have participated in another clinical trial in the last 30 days. * Patients who have undergone chemotherapy in the last 4 weeks * Patients who are being treated with antibiotic treatment for an active infection",18.0,65.0,"['cancer of colon', 'malignant melanoma', 'urologic cancer']"
NCT00137176,EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis,EARLY IFNb-1a (Rebif) and Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients with isolated clinical syndrome suggestive of MS * At least three out of four magnetic resonance imaging (MRI) findings on the initial scan: * One Gd-enhancing lesion or nine T2 hyperintense lesions; * At least one infratentorial lesion; * At least one juxtacortical lesion; and * At least three periventricular lesions. * Expanded Disability Status Scale (EDSS) 0-5.5 * 18 to 60 years of age * At least one relapse in previous 12 months Exclusion Criteria: * Patients with a diagnosis of clinically definitive relapsing-remitting (RR) MS, secondary progressive, or primary progressive MS. * Patients who have ever been treated with mitoxantrone, cytoxan, cyclophosphamide, or total lymphoid irradiation (TLI). * Patients treated with IFNb-1a, IFNb-1b, glatiramer acetate, intravenous immunoglobulins (IVIg), plasma exchange, methotrexate, or azathioprine in the previous 3 months. * Patients treated with intravenous or oral steroids within 30 days prior to baseline MRI. * Patients who have been treated with statins in the previous 3 months. * Pregnant or breast-feeding women. * Patients with a history of severe cardiac, hepatic, pulmonary, gastrointestinal, or renal disease. * Abnormal baseline blood tests including alanine transaminase (ALT) or aspartate transaminase (AST) greater than twice the upper limit of normal",18.0,60.0,['multiple sclerosis']
NCT06147076,Social Support Counseling Intervention for Kidney Transplant Candidates,Journey to Transplant: Virtual Coaching for Potential Kidney Transplant Patients and Their Social Support Networks,RECRUITING,INTERVENTIONAL,ALL,Inclusion * Determined by transplant center to be suitable for continuation in evaluation for listing (or a member of that person's social support network) * 18 Years of age or older * English-speaking * Willingness to participate with at least 2 social network members in the session and have calculator results shown to social network members (if a patient) * Able to provide informed consent Exclusion * Prisoners * Individuals with impaired ability to consent * Pregnant females. * Patients who choose to opt out of research. * Non-English speaking,18.0,65.0,['kidney transplant']
NCT02074176,Plasma Orexin A and mRNA Expression Levels of Pre-pro-orexin Gene in Attention-Deficit Hyperactivity Disorder,Plasma Orexin A and mRNA Expression Levels of Pre-pro-orexin Gene in Attention-Deficit Hyperactivity Disorder,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: * For the proband subjects to be eligible to participate in this study, they need to fit the following criteria: (1) subjects have a clinical diagnosis of ADHD, or Hyperkinetic Disorder defined by the DSM-IV and ICD-10, respectively, which was made by a full-time board-certificated child psychiatrist at the first visit and following visits; (2) their ages range from 6 to 18 when we conduct the study; (3) subjects have at least one biological parent; and (4) both parents are Han Chinese. Exclusion Criteria: * The proband subjects will be excluded from the study if they currently meet criteria or have a history of the following condition as defined by DSM-IV: Schizophrenia, Schizoaffective Disorder, Organic Psychosis, or Pervasive Developmental Disorder. Moreover, the subjects will also be excluded from the study if they completely cannot cooperate with blood withdrawal.",6.0,18.0,['attention deficit hyperactivity disorder (adhd)']
NCT04406376,Do We Need to Taper Down Steroid Therapy for Bell's Palsy,Do We Need to Taper Down Steroid Therapy for Bell's Palsy: A Prospective Randomized Controlled Trial,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Adult patients (≥18 years) diagnosed with BP within 72 hour of onset. 2. Adult patients willing to get treatment, attending follow up visits and signing informed consent. Exclusion Criteria: 1. Patients treated with antivirals (i.e acyclovir) for any reason simultaneously, such as Herpes Zoster (Ramsay- Hunt syndrome). 2. Palsy onset \> 72 hours before diagnosis or unknown onset. 3. Previous episodes of BP. 4. Patients suspected for hypothalamic-pituitary-adrenal (HPA) axis suppression who have to be cautiously tapered due to high risk for adrenal insufficiency: steroid treatment in any dosage for more the 3 weeks (due to other indication) or cushingoid appearance. 5. Contraindication for steroid use: uncontrolled diabetes or hypertension, psychosis, peptic ulcer or upper GI bleeding, liver cirrhosis or portal hypertension, known allergy to prednisone, etc. Any case in which steroid treatment was stopped earlier than planned by the patient or the physician. 6. Any conditions suspicious for non-idiopathic facial palsy: chronic otitis media, acute otitis media, mastoiditis, temporal bone/middle ear trauma, other cranial nerve neuropathies (i.e cranial nerve VIII), cerebrovascular disorders, tumor affecting facial nerve (i.e, parotid malignancy, schwannoma) or systemic causes (i.e multiple sclerosis, meningitis, sarcoidosis, HIV infection, etc). 7. Patients with low compliance for treatment according to the physician. 8. Pregnancy or breast-feeding patients.",18.0,80.0,['bell palsy']
NCT05222776,Predictive Values for the Outcome of Genicular Nerve Radiofrequency Ablation for Chronic Knee Pain,Predictive Values for the Outcome of Ultrasound Guided Genicular Nerve Radiofrequency Ablation for Chronic Knee Pain,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Patient's 18 years or older * Patients who recently underwent ultrasound guided genicular nerve radiofrequency (RF) procedure Exclusion Criteria: * lack of documentation of predictive factors to assess outcome * Patients in whom adequate follow-up data was not available * Patients who were prescribed a new analgesic drug or received concurrent treatments for different pain sources during the follow-up period, that could affect interpretation of genicular RF treatment results.",18.0,65.0,"['osteoarthritis, knee']"
NCT01450176,Comparing Patient Satisfaction With Pataday or Bepreve,Comparing Patient Satisfaction Throughout the Day With PATADAY (OLOPATADINE HYDROCHLORIDE) 0.2% QD or BEPREVE (BEPOTASTINE BESILATE OPHTHALMIC SOLUTION) 1.5% BID,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Be male or female subjects of any racial/ethnic group. * Be at least 18 years of age or older. * Have a diagnosis of allergic conjunctivitis with active symptoms, with no concurrent ocular allergy associated conditions and no plans to have ocular surgery during study period. * Willing and able to return for all required visits and follow instructions from investigator and staff. * Able to self-administer test article (TA) or have a caregiver available to instill all doses of TA. * If a woman, capable of becoming pregnant, agrees to have pregnancy testing performed at screening (must be negative) and agrees to use a medically acceptable form of birth control (intrauterine device, birth control pill, patch or subcutaneous implant, condoms, diaphragm, and abstinence) throughout the study duration and for at least one week prior to and one week after completion of the study. Women considered capable of becoming pregnant include all females who have experienced menarche and who have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy). * Sign and date the informed consent form approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC). * Be willing/able to return for all required study visits, to follow instructions from the study investigator and his/her staff, and to complete and return the Screening and Subject Diaries. Exclusion Criteria: * Have known hypersensitivity to BEPREVE or PATADAY or any of their components. * Are actively taking steroids or antihistamines during the study or within 7 days prior to enrolling in the study. * Are pregnant, planning to become pregnant, or nursing/lactating. * Have a known history of alcohol or drug abuse. * Participated in a study of an investigational drug or device within the past 30 days prior to enrolling in the study. * Have a presence of an active ocular infection (bacterial, viral or fungal), positive history of an ocular herpetic infection, or preauricular lymphadenopathy at any visit. * Have any significant illness {eg: any autoimmune disease, or severe cardiovascular disease (including arrhythmias)}that the Investigator feels could be expected to interfere with the subject's safety or study parameters and/or put the subject at anyh unnecessary risk.",18.0,65.0,['eye allergies']
NCT05528276,Does Graft Improves the Outcome TIP Repair for Primary Distal Hypospadias?,Does Preputial Inlay Graft Improves the Outcome of Tubularized Incised Plate Repair for Primary Distal Hypospadias? a Prospective Randomized Controlled Trial.,UNKNOWN,INTERVENTIONAL,MALE,"Inclusion Criteria: 1. Children age more than 12 months to 12 years. 2. De-novo penile hypospadias after degloving of penis intraoperative (fresh, not previously operated) Exclusion Criteria: 1. Circumcised 2. Ventral Penile curvature ≥30° after penile degloving \& artificial erection, (requiring transection of urethral plate). 3. Uretheral plate less than 6mm 4. Megameatus intact prepuce 5. Albumin less than 3.5 g/dL",1.0,12.0,['penile hypospadias']
NCT03315676,Efficacy of Proton Pump Inhibitors in Gastrointestinal Erosions and/or Ulcers,RCT Using Bonopurazan or Esomeprazole in Patients With NSAIDs-induced Erosions and/or Ulcers,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Clinical diagnosis of NSAIDs-induced gastrointestinal Erosions and/or Ulcers who want to take Bonoprazan or Esomeprazole Exclusion Criteria: * Patients allergic to Bonoprazan or Esomeprazole,20.0,99.0,['gastrointestinal erosions and/or ulcers']
NCT04239976,Scrambler Therapy for the Reduction of Chemotherapy-Induced Neuropathic Pain,"Effect of Scramble Therapy on Chemotherapy Induced Peripheral Neuropathic Pain: A Prospective, Pilot Study",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Have a diagnosis of cancer and suffer from CIPN for at least 3 months after the end of their last cancer chemotherapy * Have average pain intensity of at least 4/10 * Be in stable clinical situation (no surgery, radiotherapy, hormone therapy, chemotherapy or other treatment scheduled) in the month following the enrollment) * Can give a written informed consent Exclusion Criteria: * Pre-existence or history of seizure * Pre-existence or history of peripheral neuropathy due to a cause different from neurotoxic chemotherapy (i.e. idiopathic peripheral neuropathy, diabetic neuropathy * Pregnancy * Present with pacemaker or implantable defibrillators * Present or past psychotropic substances and alcohol dependence * Inability to understand patients' information and informed consent * Skin lesion at the electrode placement site",18.0,65.0,"['chemotherapy-induced peripheral neuropathy', 'malignant neoplasm']"
NCT06352476,The Effect of Sleep Hygiene Given to Epilepsy Patients on Seizure Frequency and Sleep Quality,The Effect of Sleep Hygiene Training on Seizure Frequency and Sleep Quality in Epilepsy Patients,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: Diagnosed with epilepsy for at least one year Volunteer to participate in the research Able to read and write Turkish No communication barriers (psychiatric/hereditary problems, ability to speak and understand Turkish) Able to swallow antiepileptic drugs (Gabapentin, valproic acid, phenytoin, phenobarbital, carbamazepine, levetiracetam, etc.), Having had three or more epileptic seizures in the last year Epilepsies who declare that they have sleep problems and whose Pittsburgh Sleep Quality Index (PSQI) is 5 points or above. Exclusion Criteria: Want to leave work who underwent surgery during the study alcohol drinkers Benzodiazepine, sedative, etc. those who swallow tablets Those who do not swallow antiepileptic drug tablets deceased",18.0,80.0,['epilepsy']
NCT01355276,Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia,"A Randomized, Double-blind, Double-dummy, Active Drug Parallel Controlled, Multi-center Clinical Trial on the Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia",COMPLETED,INTERVENTIONAL,ALL,"Inclusion: 1. Aged between 18\~65 years, both males and females; 2. Patients with symptoms of mild to moderate functional dyspepsia; 3. Symptoms related to dyspepsia were developed 6 months ago and early satiety or/and discomfort after meal were developed in the past 3 months; 4. Gastrointestinal malignancy, peptic ulcer, liver, gallbladder and pancreas diseases were excluded through gastroscopy, B-ultrasonography and laboratory examination within 4 weeks prior to administration (endoscopy results considered to be clinically unrelated will not be excluded, such as small hiatal hernia and chronic nonatrophic pangastritis); 5. Patient has signed informed consent form. Exclusion criteria 1. Patients with gastroesophageal reflux and/or irritable bowel syndrome; 2. Acid regurgitation more than once per week; 3. Previously received abdominal surgery (except appendectomy and herniorrhaphy); 4. A history of gastric or duodenal ulcer; 5. Patients with depression and anxiety neurosis; 6. Patients with arrhythmia; 7. QTc more than 0.5s; 8. Hepatic and renal insufficiency: AST or/and ALT equal to or above 1.5 times of the upper normal limit; Cr above the upper normal limit; 9. Pathological lactorrhea; 10. Patients with alcohol abuse (daily alcohol intake more than 40g), drug dependence or neuropsychiatric disorders that are difficult to control, as well as others who are not appropriate to participate in a drug trial; 11. Pregnant or lactating women; 12. Patients who require other therapy to change gastrointestinal mobility; 13. Patients who are participating or participated in other drug clinical trial within 3 months prior to entry; 14. Known to be allergic to cinitapride; Patients who are considered by investigators to be inappropriate to participate.",18.0,65.0,['dyspepsia']
NCT02645617,Safety Evaluation of Advantage Anti-Caries Varnish,Phase 1 Safety Evaluation of Advantage Anti-Caries Varnish,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Healthy Exclusion Criteria: * Weight less than 15 kg or hypersensitivity to iodine,36.0,60.0,['dental caries']
NCT06195917,Robotic-assisted Percutaneous Transhepatic Puncture,"Evaluation of the Safety, Effectiveness and Usability of Robotic-assisted Interventional Percutaneous Transhepatic Puncture: A First-in-human Pilot Study",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. 18 years of age or older, with no gender restrictions. (2) clinically assessed and deemed in need of a liver lesion puncture. (3) with a intrahepatic lesion no less than 1 cm in diameter. (4)with liver function of Child-Pugh Class A or B. (5) agree to participate in this clinical trial and sign an informed consent form. Exclusion Criteria: 1. with severe liver cirrhosis or in a decompensated liver function state within the 3 months prior to screening and who have undergone abdominal paracentesis for the treatment of a large amount of ascites. 2. with severe coagulation disorders during the screening period, characterized by a platelet count \ 6s, and an international normalized ratio (INR) \> 1.5. 3. classified as NYHA heart function Grade III and IV during the screening period. 4. with severe chronic obstructive pulmonary disease (COPD) or severe asthma during the screening period. 5. with renal insufficiency during the screening period, defined by creatinine (Cr) or blood urea nitrogen (BUN/UREA) levels exceeding two times the upper limit of normal. 6. unable to cooperate with surgical positioning and other requirements for surgery. 7. Pregnant or lactating women of childbearing age and other vulnerable groups. 8. have participated in other interventional clinical trials within the month prior to the commencement of this trial. 9. Other individuals who are deemed unsuitable for participation in this trial by the investigator.",18.0,65.0,['liver diseases']
NCT01716117,Safety and Effectiveness of an Intracranial Aneurysm Embolization System for Treating Large or Giant Wide Neck Aneurysms,The Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide Neck Aneurysms (SCENT Trial),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age 19 to 80 years * Subject or legal representative is willing and able to give informed consent * Subject has a single targeted intracranial aneurysm * Subject agrees to return to the treating Investigator for all scheduled follow up visits and is capable of returning to the hospital for follow up Exclusion Criteria: * Known allergy or contraindication to aspirin, clopidogrel/Plavix, heparin, local or general anesthesia * Known history of life threatening allergy to contrast dye * Known allergy to nickel, chromium cobalt, tungsten or platinum * Subject has documented resistance to clopidogrel/Plavix * Major surgery within previous 30 days or planned in the next 120 days after enrollment date * Previous intracranial implant associated with the symptomatic distribution within the past 12 weeks prior to treatment date * Stenting, angioplasty, or endarterectomy of an extracranial (carotid or vertebral artery) or intracranial artery within 30 days prior to treatment date * Any previous stenting of parent artery at or proximal to the aneurysm where it would interfere with the placement and proper apposition of the device * Any previous coiling where it would interfere with the placement and proper apposition of the device * Platelet count less than 100,000 cells/mm3 or known platelet dysfunction * More than one intracranial aneurysm (IA) that requires treatment within 12 months * Asymptomatic extradural aneurysms requiring treatment * Contraindication to CT scan or MRI * Severe neurological deficit that renders the subject incapable of living independently * Unstable neurological deficit (i.e., worsening of clinical condition in the last 30 days) * Evidence of active infection at the time of treatment * Dementia or psychiatric problem that prevents the patient from completing required follow up * Co-morbid conditions that may limit survival to less than 24 months * Serum creatinine greater or equal to 2.5 mg/dL * Female subjects who are pregnant or planning to become pregnant within the study period * Subject with anatomy not appropriate for endovascular treatment due to severe intracranial vessel tortuosity or stenosis * Extra-cranial stenosis or parent vessel with stenosis greater than 50% in the area proximal to the aneurysm * Other known serious concurrent medical conditions * History of intracranial vasospasm not responsive to medical therapy * Subject with an intracranial mass, or is undergoing radiation therapy for carcinoma or sarcoma of the head or neck region * Subject has a history of bleeding diathesis or coagulopathy, international normalized ratio (INR) greater than 1.5, or will refuse blood transfusions * Subject had a subarachnoid hemorrhage within 30 days prior to the enrollment date * Subject has a non-treated arteriovenous malformation (AVM) in the territory of the target aneurysm * Inability to understand the study or a history of non-compliance with medical advice * Current use of illicit substance * Enrollment in another trial involving an investigational product * Subject has a need for long-term use of anticoagulants (i.e., Warfarin, Dabigatran)",19.0,80.0,['brain aneurysm']
NCT03199417,Trial Evaluating multimOdal toPical Cream In CompArison to pLacebo (TOPICAL),Trial Evaluating multimOdal toPical Cream In CompArison to pLacebo (TOPICAL),TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: The inclusion criteria are: 1. adult men or women ages 50-80 years; 2. Diagnosis of symptomatic osteoarthritis of the knee based on clinical and radiographic criteria; 3. provision of informed consent. Exclusion Criteria: The exclusion criteria are: 1. patients with inflammatory osteoarthritis; 2. open wounds or sores over the knee joint; 3. patients that will likely have problems, in the judgment of the investigators, with maintaining follow-up; 4. Cases involving litigation.",50.0,80.0,['knee osteoarthritis']
NCT03732417,Telematic Model Integrated in the Transversal Care of the Secondary Prevention of Patients With Stroke,Effectiveness of a Telematic Model Integrated in the Transversal Care of the Secondary Prevention of Patients With Stroke,WITHDRAWN,OBSERVATIONAL,ALL,"Inclusion Criteria: * Male and female patients ≥18 years old, diagnosed of established ischemic stroke and / or TIA and attended by the HTVC neurology service, on discharge from home and with habitual residence in the Ebro Lands to be able to follow up . * Informed consent of the signed study. Exclusion Criteria: * Patients suffering from other neurological injuries that interfere with the follow-up (established strokes, with or without MCA deviation, glioblastomas, etc.), life expectancy \<6 months, modified Rankin scale score (MRS) ≥3 and present language barrier and / or aphasia.",18.0,65.0,"['stroke', 'risk factor, cardiovascular']"
NCT00765817,Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus,A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Have type 2 diabetes. * Have been taking insulin glargine at a dose of ≥20 units/day for at least 3 months before entering the study. Have been taking insulin glargine alone or in combination with one of the following for at least 3 months before entering the study: 1. metformin (stable dose for 6 weeks) 2. pioglitazone (stable dose for 6 weeks) 3. a combination of metformin and pioglitazone (stable dose for 6 weeks) * Have HbA1C between 7.1% and 10.5%, inclusive. * Have a body mass index (BMI) ≤45 kg/m2. * Have a history of stable body weight (not varying by \>5% for at least 3 months prior to screening). Exclusion Criteria: * Have taken medications to lower blood sugar other than insulin glargine, pioglitazone, or metformin in the 3 months before entering the study for more than a 1-week period, or within 1 week of entering the study. * Have had more than one episode of major (severe) hypoglycemia in the 6 months before entering the study. * Are pregnant or intend to become pregnant during the study or are sexually active women not actively practicing birth control. * Women who are breastfeeding. * Have any significant diseases of the blood, heart, kidney, gastrointestinal system, or other significant diseases such as cancer. * Have had a kidney transplant or are currently on kidney dialysis. * Have a cancer that's never been treated, that's currently being treated, or that was diagnosed within the last 5 years. * Have had a bad reaction to exenatide in the past or have a condition that is not recommended to be exposed to exenatide or any of exenatide's other ingredients. * Have used a drug for weight loss in the 3 months before entering the study for more than a 1-week period, or within 1 month of entering the study. * Are currently on a weight-loss program or have been on one within 3 months of entering the study. * Have had a blood transfusion or severe blood loss within 3 months of entering the study. * Are taking systemic glucocorticoids or have received systemic glucocorticoids within 8 weeks of entering the study. * Have an irregular sleep cycle (for example, sleeping during the day and working during the night). * Have a history of pancreatitis. * Have received treatment with an experimental drug within 30 days of entering the study. * If on metformin, have a condition that is not recommended to be exposed to metformin, or any condition associated with hypoperfusion, hypoxemia, dehydration, or sepsis. * If on metformin, have had a radiologic contrast study performed within 48 hours of entering the study. * If on pioglitazone, have a condition that is not recommended to be exposed to pioglitazone, including congestive heart failure, or are taking pioglitazone at a dose that is not approved for use with insulin.",18.0,65.0,['type 2 diabetes']
NCT05486117,Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema,A Phase 1 Clinical Trial to Evaluate the Pharmacokinetics of Twice-daily Applications of Delgocitinib Cream 20 mg/g for 1 Week in Adult Subjects With Moderate to Severe Chronic Hand Eczema.,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age 18 years or above at screening. * Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months. * Disease severity graded as moderate to severe at screening and baseline according to IGA-CHE (i.e. an IGA-CHE score of 3 or 4). * Subjects who have a documented recent history of inadequate response to treatment with topical corticosteroids (TCS) (at any time within 1 year before the screening visit) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks). * Subjects adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens. Exclusion Criteria: * Concurrent skin diseases on the hands, e.g. tinea manuum. * Active atopic dermatitis (AD) requiring medical treatment in regions other than the hands and feet. * Active psoriasis on any part of the body. * Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body. * Clinically significant infection (e.g. impetiginised hand eczema) on the hands. * Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), immunomodulating drugs, retinoids (e.g. alitretinoin), or corticosteroids within 28 days prior to baseline (steroid eyedrops and inhaled or intranasal steroids corresponding to up to 1 mg prednisolone for allergic conjunctivitis, asthma, or rhinitis are allowed). * Use of tanning beds, phototherapy (e.g. ultraviolet B \[UVB\], ultraviolet A1 \[UVA1\], psoralen ultraviolet A \[PUVA\]), or bleach baths on the hands within 28 days prior to baseline. * Cutaneously applied treatment with immunomodulators (e.g. phosphodiesterase 4 \[PDE-4\] inhibitors, pimecrolimus, tacrolimus) or TCS on the hands within 14 days prior to baseline. * Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline. * Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline.",18.0,65.0,['chronic hand eczema']
NCT00035217,Follow-Up Study for Men Diagnosed With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program,Follow-Up Study for Men Diagnoses With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program,COMPLETED,OBSERVATIONAL,MALE,Men with prostate cancer diagnosed through the PSA screening study,40.0,65.0,['prostate cancer']
NCT06004817,Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis,Evaluation of Severity in Juvenile Dermatomyositis and Adult-onset Dermatomyositis: a National Multicentric Retrospective Study,RECRUITING,OBSERVATIONAL,ALL,Inclusion Criteria: * Patient with dermatomyositis according to 2017 American College of Rheumatology (ACR)/ European Alliance of Associations for Rheumatology (EULAR) classification Exclusion Criteria: * Patient with cancer-associated dermatomyositis (within 3 years before or after diagnosis of dermatomyositis) * Patient with antisynthetase syndrome,18.0,65.0,['dermatomyositis']
NCT03462017,Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus,Study to Assess the Pharmacodynamic Effects of Repeated Oral Doses of SAR247799 on Endothelial Function in Male and Female Patients With Type 2 Diabetes Mellitus,COMPLETED,INTERVENTIONAL,ALL,"Inclusion criteria : * Male and female stable Type 2 diabetes mellitus (T2DM) patients. * Body Mass Index between 18 and 35 kg/m\^2. * Stable T2DM patients, but otherwise healthy as assessed by a clinical and laboratory assessments and detailed medical history. * Diagnosis of T2DM for at least 6 months at the time of the screening visit. * Glycosylated hemoglobin (HbA1c) \ 450 mg/dL. * Any hyperosmolar hyperglycemic episode with severe neurological symptoms (eg, coma, aphasia) in the last 3 months before screening. * Weight change of ≥5 kg during the last 2 months prior to screening. * History or presence of clinically relevant or symptomatic pulmonary disease, such as asthma, chronic obstructive pulmonary disease, pulmonary embolism, pulmonary fibrosis, pulmonary hypertension which as judged by the Investigator, may affect the patient's participation in or the outcome of this study. * Cardiovascular history such as: * History or presence of a clinically relevant or symptomatic cardiovascular disease such as acute coronary syndrome (ACS), stroke, transient ischemic accident (TIA), obstructive or congestive heart failure, or structural heart disease (e.g., valvular disease) which as judged by the Investigator, may affect the patient's participation in or the outcome of this study. * History of elective percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within the past 6 months. * History of clinically relevant or symptomatic cardiac arrhythmia such as sustained ventricular arrhythmia, non-fixed supra-ventricular arrhythmia which as judged by the Investigator, may affect the patient's participation in or the outcome of this study or which occurred within the past 6 months * History of clinically relevant or symptomatic cardiac conduction abnormalities (any type of atrioventricular (AV) block, sick sinus syndrome, sinus node disease). * Patients with a pacemaker or implantable cardioverter defibrillator. * Known history of autoimmune disorders. * Any severe viral, systemic, fungal, bacterial or protozoal infection within the past 6 months or chronic severe infection (hepatitis, HIV infection, tuberculosis). * Presence of macular edema at fundus examination performed within 6 months before the first study drug administration. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",18.0,64.0,['microvascular coronary artery disease']
NCT03022617,A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis,An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * \- Patients older than 18 * Give written informed consent prior to any study procedures being conducted, and candidates will authorize the release and use of protected health information (PHI) * Be willing and consent to having photos taken of their fingernails * Diagnosis of chronic plaque psoriasis that has been present for at least 6 months prior to baseline * Plaque psoriasis involving at least 5% of the patient's body surface area * Nail psoriasis in at least one finger nail with a mNAPSI of 5 or greater * A Nail Pain VAS score of 4 or higher. The Nail Pain VAS will assess the severity of pain linked to the nail disease. * Must have discontinued all systemic therapies for the treatment of psoriasis or psoriatic arthritis at least 4 weeks or 5 half-lives, and biologics 2 months or 5 half-lives (whichever is longer) prior to baseline visit * Must have discontinued all topical therapies for the treatment of psoriasis at least 2 weeks prior to baseline visit * Subjects must have discontinued UV therapy at least 2 weeks prior to baseline and PUVA (psoralen ultraviolet light therapy) at least 4 weeks prior to baseline. * Subjects must be in good general health without significant uncontrolled comorbidities, other than psoriasis, as determined by the investigator based on exam findings, medical history, and clinical laboratories. Patients with stable mild renal insufficiency are eligible for enrolling in this trial. * Females of childbearing potential must use an approved birth control method while receiving treatment and for 28 days following the last dose of apremilast, and there must be a documented negative pregnancy tests prior to initiating treatment. Approved birth control methods include hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring), intrauterine device, partners vasectomy, or male or female condoms that are not made of natural materials plus a diaphragm with spermicide, cervical cap with spermicide, or a contraceptive sponge with spermicide. Females not of child bearing potential are defined as being at least 1 year postmenopausal or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy). * Male subjects, including those who have had a vasectomy, must use condoms not made of natural materials for the duration of the trial and for at least 28 days after the last dose of apremilast if conception is possible. Exclusion Criteria: * \- Unable to comply with the protocol (as defined by the Investigator; i.e. drug or alcohol abuse or history of noncompliance) * Pregnancy or breastfeeding * Female patients of childbearing potential and male patients who engage in activity where contraception is possible who are unable to use the approved methods of contraception throughout the length of the study and 28 days following the last dose * Patients who have or have had thoughts of suicide or hurting themselves. * Patients with prior exposure to apremilast * Subject has been treated with an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to baseline visit. * Patients with severe, progressive, or uncontrolled medical or psychiatric disease. * Concomitant therapy with medications that are strong cytochrome P450 inducers, including rifampin, phenobarbital, carbamazepine, or phenytoin * Any other dermatologic conditions that prohibit or confound the ability of the investigator to interpret skin and/or nail exam findings. * Patients who will be unable to avoid the use of systemic steroids, excluding intranasal or inhaled steroids that will be permitted, for the duration of the trial * Any known hypersensitivity to apremilast * Any subject who, in the opinion of the investigator, will be uncooperative or unable to comply with duty procedures",18.0,65.0,"['psoriatic nail', 'psoriasis vulgaris', 'psoriasis']"
NCT05495217,A Clinical Study for Comparison of the Effects Between Gasless Laparoscopy and Conventional Laparoscopy for Distal Gastric Cancer,"A Single-center, Randomized, Controlled Clinical Study for Comparison of the Effects Between Gasless Laparoscopy-assisted and Conventional Laparoscopy-assisted Gastrectomy With D2 Lymphadenectomy for Distal Gastric Cancer",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Age \>18 and \<75 years old; 2. The gastric primary lesion is diagnosed as gastric adenocarcinoma by endoscopic biopsy histopathologic techniques (papillary adenocarcinoma \[pap\], tubular adenocarcinoma \[tub\], mucinous adenocarcinoma \[muc\], signet ring cell carcinoma \[sig\], and poorly differentiated adenocarcinoma \[por\]); 3. Preoperative clinical staging of T2-4a, N0-3, M0 (see preoperative assessment program; tumor staging is in accordance with AJCC-7th TNM); 4. It is expected that R0 surgical results will be obtained by distal subtotal gastrectomy and D2 lymph node dissection (also applies to multiple primary tumors) 5. Preoperative ECOG status score of 0/1; 6. Preoperative ASA (American society of anesthesiology) class of I -III; 7. Patients signed informed consent. Exclusion Criteria: 1. Pregnant or lactating women; 2. Serious mental illness; 3. History of abdominal surgery (except for laparoscopic cholecystectomy); 4. History of gastric surgery (including ESD/EMR for gastric cancer); 5. Preoperative imaging examination suggests regional integration enlargement of lymph nodes (maximum diameter ≥3 cm) 6. Other malignant disease history within five (5) years; 7. Patients who received or were recommended a new adjuvant therapy; 8. History of unstable angina or myocardial infarction within six (6) months; 9. History of cerebral infarction or cerebral hemorrhage within six (6) months; 10. History of sustained systemic corticosteroid therapy within one (1) month; 11. Patients requiring simultaneous surgical treatment of other diseases; 12. Gastric cancer complications (bleeding, perforation, obstruction) requiring emergency surgery; 13. Pulmonary function test with FEV1 \<50% of the expected value.",18.0,75.0,"['gastrectomy', 'laparoscopy']"
NCT03338517,Helium-Neon Laser Therapy Versus Infrared Laser Therapy in Treating Patients With Diabetic Foot Ulcer,A Randomized Controlled Trial Comparing Helium-Neon Laser Therapy and Infrared Laser Therapy in Patients With Diabetic Foot Ulcer,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * patients with Grade I and II ulcers were selected according to Wagner classification ages ranged between 50 to 60 years of age, BMI of 30 Exclusion Criteria: * nephropathy, cardiomyopathy, recent myocardial infarction and pulmonary problems",18.0,65.0,"['diabetic mellitus', 'laser']"
NCT05921617,A Cohort Study of Musculoskeletal Health in Patients With Breast Cancer During Aromatase Inhibitors Therapy,A Cohort Study of Musculoskeletal Health in Patients With Breast Cancer During Aromatase Inhibitors Therapy,UNKNOWN,OBSERVATIONAL,FEMALE,"Inclusion Criteria: 1. Postoperative early breast cancer； 2. Hormone receptor-positive breast cancer diagnosed by pathology； 3. Aromatase inhibitor therapy (e.g., anastrozole, letrozole, exemestane) was initiated within 3 months; 4. Postmenopausal women, or premenopausal or perimenopausal women taking ovarian function inhibitors; 5. Informed consent and voluntary participation in the study. Exclusion Criteria: 1. Breast cancer recurrence or distant metastasis; 2. With other malignant tumors; 3. With cognitive or psychiatric disorders.",18.0,80.0,['musculoskeletal health']
NCT06606717,Effects of Resistance-band Training and Creatine and Whey Protein,Effects of Resistance-band Training and Nutritional Supplementation in Healthy Older Adults,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Untrained (defined as those performing ≤ 1 resistance training session per week for ≥ 6 weeks prior to the start of the study) Exclusion Criteria: * Taking creatine monohydrate within 30 days prior to the start of the study * Currently ingesting whey protein * Have pre-existing allergies to latex, fruit, dairy, nuts, seafood and mustard",50.0,65.0,['sarcopenia in elderly']
NCT02203617,Using Baby Books to Promote Maternal and Child Health,Using Baby Books to Promote Maternal and Child Health,COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Women who are pregnant with first child and able to read in English at a first grade reading level Exclusion Criteria: * Women with other children, men, those not able to read in English at a first grade level",18.0,50.0,"['condition 1 - educational condition (educational book group)', 'condition 2 - non-educational condition (non-educational book group)', 'condition 3 - control condition (no-book group)']"
NCT04952740,Application of Index of Microcirculatory Resistance to Evaluate Myocardial Protection After Ischemic Adaptation,Application of Index of Microcirculatory Resistance to Evaluate Myocardial Protection After Ischemic Adaptation,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age ≥ 18 years old, no gender limit; * First episode of STEMI (diagnostic criteria: ischemic chest pain lasting ≥30min; ST-segment elevation in two or more adjacent leads on the ECG or new left bundle branch block; with or without elevated myocardial markers), The onset time is within 12 hours, and emergency interventional treatment is planned; * Agree and cooperate to participate in this research. Exclusion Criteria: * Old myocardial infarction; * Killip grade of cardiac function ≥ grade III or cardiogenic shock; * Systolic blood pressure ≤100mmHg; * Bradycardia, HR\<60pbm, or AVB above II degree; * Past history of asthma or severe COPD; * Severe liver and kidney dysfunction.",18.0,65.0,['acute myocardial infarction']
NCT05826340,Getting Kids With Osgood Schlatter Back to Performing Without Pain,"A 3-arm Randomised Parallel Group Superiority Trial to Investigate the Efficacy of Graded Loading and Return to Sport or Pain Guided Activity, Versus Rest or on Symptom and Disease Severity in Patients With Osgood Schlatter",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: \- Children/adolescents (male and female) aged 8-16 years * Diagnosis of OSD based on clinical examination including localised pain at the tibial tuberosity (the insertion of the patellar tendon onto the shin) that increases by palpation, and pain during resisted isometric knee extension. * Ability to understand and the willingness to provide consent Exclusion Criteria: * Any other diagnosable knee pathology, patellar instability, and patellofemoral instability. * Previous knee surgery * Habitual patella subluxation * Clinical suspicion of meniscal lesion * Previous neurologic, musculoskeletal or mental illnesses * Other chronic conditions that may affect the involved musculoloskeletal/connective tissues and treatment (autoimmune, metabolic disorders, diabetes, etc.) * Lack of ability to cooperate",8.0,16.0,['osgood-schlatter disease']
NCT01117740,Pleural Catheters Versus Thoracoscopic Pleurodesis,Comparative Effectiveness of Indwelling Pleural Catheters Versus Thoracoscopic Pleurodesis for Treatment of Malignant Pleural Effusions,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: 1. Patients with MPE who are suitable for either pleural catheter placement or thoracoscopic pleurodesis who subsequently have either procedure performed 2. Sufficient mental capacity to answer SF-6D and Borg score questions 3. Age 18 or older 4. Life expectancy \> 2 months 5. English or Spanish speaking Exclusion Criteria: 1. Patients undergoing pleurodesis for benign disease (e.g., spontaneous pneumothorax) 2. Inability or unwillingness to give informed consent 3. Inability to perform phone call follow-up 4. Pregnancy 5. Previous intrapleural therapy for MPE 6. Prior radiation therapy encompassing the entire hemithorax 7. Chylous effusions associated with malignant disease 8. Bilateral effusions requiring bilateral pleurodesis",18.0,65.0,['lung cancer']
NCT06040840,WALANT Versus Axillary Brachial Plexus Block in Carpal Tunnel Release,WALANT Versus Axillary Brachial Plexus Block in Carpal Tunnel Release: a Non-inferiority Randomized Controlled Trial,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients undergoing endoscopic carpal tunnel release * Consent for participation * Affiliation to a social security system Exclusion Criteria: * Contraindication for regional anesthesia (truncal neuropathy, infection at the puncture site, coagulation disorder, …) * Contraindication to any drugs used in the protocol (paracetamol, ketoprofen, propofol, lidocaine, epinephrine) * Chronic pain syndrome * Preoperative Anxiety * Pregnant or breastfeeding women * Patients under protection of the adults (guardianship, curators or safeguard of justice)",18.0,65.0,['carpal tunnel syndrome']
NCT04812340,Effect of HICT and LIIT on Functional Strength and Weight Efficacy in Overweight and Obese Females,Effect of High-Intensity Circuit Training Versus Low-Intensity Interval Training on Functional Strength and Weight Efficacy in Overweight and Obese Young Females.,COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Females with BMI \>25 kg/m2. * Females not engaged in routine exercise programs in last 6 months Exclusion Criteria: * Females who are using weight loss products. * Females having uncontrolled diabetes, thyroid disease, arthritis, cardiac diseases, asthma, hypertension, and recent trauma would not be included in the study. * Females who are pregnant would not be included in the study.",18.0,35.0,['overweight and obesity']
NCT01102140,The Impact of Pomegranate Extract on Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study,"The Impact of Pomegranate (Punica Granatum) Polyphenol Extract on Oxidative Stress, Ventricular Remodeling and Endothelial Function in Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study",TERMINATED,INTERVENTIONAL,ALL,Inclusion Criteria: * Adult subjects (≥21 years of age) with cardiomyopathy (ejection fraction ≤40%) of at least 1 year duration and CRI (GFR \ 8 ounces daily of pomegranate juice * known hypersensitivity to any fruit in the Punicaceae family * connective tissue or collagen vascular disease,21.0,65.0,"['cardiomyopathy', 'heart failure']"
NCT04034940,"Correlations Between Oxidative Stress Biomarkers, h-FABP and Left Ventricular Dysfunction in Patients With Acute Myocardial Infarction Undergoing Primary PCI","Correlations Between Oxidative Stress Biomarkers, h-FABP and Left Ventricular Dysfunction in Patients With Acute Myocardial Infarction Undergoing Primary PCI",UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Adults with ST elevation Myocardial Infarction (\<12h) diagnostic confirmed; * Included in the Romanian National Programme of Primary Percutaneous Revascularisation (for who the Guidelines recommend primary PCI); Exclusion Criteria: * Patients who do not sign informed consent for primary PCI,18.0,65.0,"['stemi', 'oxidative stress', 'oxidative stress induction', 'primary pci', 'hfabp', 'left ventricular dysfunction', 'bcm']"
NCT03338140,"Outcome of Living Donor Renal Transplantation in Assiut Urology and Nephrology University Hospital ,Initial Experience",Assistant Lecturer of Urology in Assiut University,UNKNOWN,OBSERVATIONAL,ALL,Inclusion Criteria: * All recipients of renal transplantation in Assiut urology and nephrology university Hospital Exclusion Criteria: * All recipients of renal transplantation who were transplanted outside Assiut urology and nephrology university Hospital,18.0,65.0,['renal transplantation']
NCT04974840,Thera-band Resisted Treadmill Training for Chronic Stroke Patients,Effects of Thera-band Resisted Treadmill Training on Walking Ability in Chronic Stroke Patients,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. the diagnosis of first time unilateral stroke more than 6 months before 2. the ability to walk for at least 15 m without person assistance 3. apparent gait deficits upon visual inspection by a trained physical therapist or inability in community ambulation, i.e. walking speed \< 0.8 m/s 4. resting blood pressure lower than 150/90 mmHg. Exclusion Criteria: 1. older than 75 years 2. inability to follow the experimental instructions or procedures 3. any pain, inflammation, or other conditions that could affect walking 4. medically unstable.",20.0,75.0,['chronic stroke']
NCT01459640,Intra-Articular Autologous Bone Marrow Mesenchymal Stem Cells Transplantation to Treat Mild to Moderate Osteoarthritis,Phase 2 Study Assessing the Efficacy of Intra-Articular Autologous Mesenchymal Stem Cells in Patients With Mild to Moderate Osteoarthritis,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Diagnosed with mild to moderate osteoarthritis based on Kellgren-Lawrence radiographic classification * Has a history of joint swelling, pain, stiffness, altered gait and loss of motion due to degenerative cartilage Exclusion Criteria: * Has systemic bone or cartilage disorders * Has significant vascular impairment proximal to implant site * Has substantial joint destabilization including extensive osteophyte formation * Has substantial surface erosion of the weight-bearing articular cartilage * Evidence of infection or fractures in or around the joint * Contraindication to bone marrow aspiration * Any acute or chronic communicable diseases including Hepatitis B, Hepatitis C and HIV * Any past history of neoplasia and primary hematological disease * Renal impairment indicated by serum creatinine greater than 200mM * Liver impairment indicated by serum aspartate transaminase and serum alanine transaminase greater than 120 IU * Any other co-morbidity which the physician deems as a contraindication to stem cell transplantation and bone marrow biopsy",18.0,70.0,['osteoarthritis']
NCT00682240,Morphological and Functional Retinal Changes Following Retinal Photocoagulation,Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Signed informed consent * Age 18 years * Patients with either retinopathy/maculopathy secondary to diabetes mellitus type I or II with medical indication for segmental or panretinal laser coagulation or with necessity for completion of previous incomplete laser photocoagulation. * Patients with proliferative diabetic retinopathy requiring panretinal laser treatment (Group 1, 2 and 3) * Patients with macular edema requiring central focal or grid laser treatment (Group 4). Exclusion criteria: * A condition that would preclude a patient for participation in the study in opinion of investigator, e.g., unstable medical status including glycemic control and blood pressure.",18.0,90.0,"['proliferative diabetic retinopathy', 'macular edema']"
NCT01977040,Optimal Management of Vasa Previa Study - A Retrospective Study,"Optimal Management of Vasa Previa: Screening, Diagnosis and Management - A Retrospective Study.",COMPLETED,OBSERVATIONAL,FEMALE,"Inclusion Criteria: * Patients with the diagnosed of vasa previa made either during the pregnancy via ultrasound or at time of delivery via clinical and/or pathologic investigation. * Patient delivered between January 2000 through December 2012 Exclusion Criteria: * No diagnosis or confirmation of vasa previa * Delivered either before January 1, 2000 or after December 31, 2012",18.0,65.0,['vasa previa']
NCT03318640,Mindfulness and Cognition in Schizophrenia,Effect of Mindfulness (MBSR) on the Parasympathetic System and Cognition in Schizophrenia,TERMINATED,INTERVENTIONAL,MALE,"Inclusion Criteria: * DSM-IV diagnosis of schizophrenia (men only) * aged 18-55 * with no change in antipsychotic medication and clinical status within four weeks prior to the study * affiliates or entitled to a social security scheme * who have given their informed consent before participating in the study. Exclusion Criteria: * History of head trauma, neurological disease or not stabilized serious physical illness * Disorders related to the use of a psychoactive substance, as defined by the DSM-IV (abuse, dependence or withdrawal) within 6 months * Beta blocking and anti-arrhythmic medications.",18.0,55.0,['schizophrenia']
NCT06623240,HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis,"A Randomized, Double-Blind, Phase 2, Efficacy and Safety Cross-Over Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis",WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: The subject will be eligible for inclusion in this clinical trial only if all of the following criteria apply: 1. Male and female subjects who are ≥ 2 years old and \ 10 kg at the screening visit. 6. Subjects without a current established treatment for JIA who are not on treatment because they have failed at least 2 approved medications for their condition, or if being treated, subjects who are on a stable dose of arthritis therapy regimen for ≥3 months prior to screening. 7. Must have an abnormal CRP result and/or abnormal ESR result at screening. Abnormal C-reactive protein (CRP) value defined as \> 1 mg/dL. Abnormal Erythrocyte Sedimentation Rate (ESR) value defined as \>15 mm/hr for males and \>20 mm/hr for females. 8. Female study subjects of childbearing potential should not be pregnant or plan to become pregnant during study participation and for 6 months after the last investigational product administration. Female study subjects of childbearing potential must confirm usage of one of the following contraceptive measures: * Hormonal contraceptives associated with ovulation inhibition (oral, injectable, implantable, patch, or intravaginal). * Intrauterine device (IUD), or intrauterine hormone-releasing system (IUS). * Barrier contraceptive methods (condoms, diaphragm, etc.). 9. Male subjects if their sexual partners can become pregnant should ensure the use one of the following methods of contraception during study participation and for 6 months after the last administration of the investigated product. * Hormonal contraceptives associated with ovulation inhibition (oral, injectable, implantable, patch, or intravaginal). * Intrauterine device (IUD), or intrauterine hormone-releasing system (IUS). * Barrier contraceptive methods (condoms, diaphragm, etc.). 10. Study subject's parent(s)/LAR is/are able and willing to comply with the requirements of this clinical trial. 11. Voluntarily signed informed consent from study subjects' parent(s) or legally authorized representative obtained before any clinical-trial related procedures are performed. Exclusion Criteria: The subject will not be eligible for inclusion in this clinical trial if any of the following criteria apply: 1. Study subject has any of the following laboratory results at the screening visit: 1. WBC: \ 15000 cells/μL (\ 15 K cells/μL) 2. Hemoglobin: \ 150 mEq/L 6. Glucose: \>150 mg/dL 7. Potassium: \ 6 mEq/L 8. BUN: \>25 mg/dL 9. Creatinine: \>2 mg/dL 10. BUN/Creatinine ratio: \>50 11. AST: \>100 U/L 12. ALT: \>100 U/L 2. Study participant has any vital sign abnormalities at the screening visit as determined by the investigator. 3. Study subject has 1 or more significant uncontrolled concurrent medical conditions (verified by medical records), including the following: 1. Diabetes Mellitus 2. Crohn's Disease 3. Lupus 4. Multiple Sclerosis 4. Study subject has any active malignancy, including evidence of cutaneous basal, squamous cell carcinoma or melanoma. 5. Study subject has known alcoholic addiction or dependency or has current substance use or abuse. 6. Study subject has received any stem cell treatment within 1 year before first dose of investigational product other than stem cells produced by Hope Biosciences LLC. 7. Receiving any investigational therapy or any approved therapy for investigational use within 1 year prior first dose of the investigational product other than COVID-19 vaccines. 8. Study subject has any other laboratory abnormality or medical condition which, in the opinion of the investigator, poses a safety risk or will prevent the subject from completing the study. 9. Study subject's parent(s)/LAR unable to understand and provide signed informed consent. 10. Study subject and/or study subject's parent(s)/LAR unlikely to complete the study or adhere to the study procedures. 11. Study subject with known concurrent acute or chronic viral hepatis B or C or human immunodeficiency virus (HIV) infection. 12. Study subject with any systemic infection requiring treatment with antibiotics, antivirals, or antifungals within 30 days prior to first dose of the investigational product.",2.0,16.0,['juvenile idiopathic arthritis (jia)']
NCT07307040,Precision Diabetes Management: Integrated East-West Approach,Construction of a Precision and Individualized Management Model for Diabetes With Integrated Traditional Chinese and Western Medicine,NOT_YET_RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * The age at diabetes diagnosis is ≥18 years but \<40 years. Exclusion Criteria: * The clinical diagnosis was type 1 diabetes, and at the time of enrollment, antibody levels or insulin/C-peptide results still supported the original diagnosis. There were clear secondary factors contributing to hyperglycemia, such as Cushing's syndrome or pheochromocytoma.",18.0,40.0,['early-onset type 2 diabetes']
NCT04492540,Response of Sex Hormones and Different Functions to Exercise and Diet in Elderly Women,Correlation Between Sex Hormones and Different Functions in Response to Aerobic Exercise and MIND Diet in Older Adult Women,COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * • Sixty Postmenopausal women (60-70 y) * Body mass index (BMI) ranged from 30 to 39.9 kg/m2 Exclusion Criteria: * • regular medications(e.g., β-blockers, α-blockers, digoxin, diuretics, aspirin, nitrates, Presently using sex hormones) * having active chronic illness (e.g., rheumatoid arthritis, hyperthyroidism, and inflammatory bowel disease) and diabetes mellitus or other (unstable) endocrine-related diseases * presence of malignant disease * blood donation within the last 30 days * Participation as a subject in any type of study or research during the prior 90 days",60.0,70.0,"['cognitive decline', 'postmenopausal disorder']"
NCT03893240,Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease,"A Multi-Center, Low-Interventional Study With a Retrospective Component in Participants With Late-Onset Pompe Disease",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Provide written informed consent and authorization to use protected health information in accordance with national and local privacy regulations * Male or females ≥18 years of age * Currently on ERT using regular recombinant human GAA infusions for at least 18 months prior to screening * Documented history of clinically moderate late-onset Pompe disease. Exclusion Criteria: * History of HIV infection * Requires any invasive ventilation (other than BiPAP at night) or noninvasive ventilation while awake and upright * Previously received SPK-3006 * Previously dosed with any investigational or approved gene therapy product at any time or treated with an investigational drug within the last 12 weeks (vaccination studies are accepted) * Any concurrent clinically significant condition that would not allow the potential participant to complete the Day 1 examinations, or other condition that, in the opinion of the Investigator and/or Sponsor, makes the subject unsuitable for participation in the study * Unable or unwilling to comply with the schedule of visits and/or study assessments described in the clinical protocol.",18.0,65.0,"['pompe disease', 'pompe disease (late-onset)', 'glycogen storage disease type 2', 'lopd', 'lysosomal storage diseases', 'acid maltase deficiency']"
NCT03365440,Esophageal 3D Mapping System for Cardiac Arrhythmias,Esophageal 3D Mapping System for Cardiac Arrhythmias: Pilot Study to Establish Basis for Improved Arrhythmia Diagnostics Using the esoECG-3D Catheter,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Informed consent as documented by signature * Age \>18 years * Group 1: Patients scheduled for an elective electrophysiological study and/or ablation procedure including a transseptal passage * Group 2: Patients, scheduled for an elective electrophysiological study and/or ablation procedure without transseptal passage * Group 3: Healthy volunteers, without any known cardiac disease Exclusion Criteria: * Contraindications to the class of devices under study, e.g. known hypersensitivity or allergy to class of devices or the investigational device * Status post atrial fibrillation ablation within the last 4 weeks * Unstable angina pectoris or acute coronary syndrome * Hemodynamic instability * Respiratory instability * Disease or malformation of the upper airways or esophagus, making naso-esophageal catheter insertion impossible * Hereditary severe bleeding diathesis * Status post surgical intervention of the esophagus or stomach within the last 4 weeks * Known cancer of the esophagus or stomach * Pregnancy * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.",18.0,65.0,"['arrhythmia', 'atrial fibrillation', 'atrial flutter', 'atrial tachycardia', 'supraventricular tachycardia', 'ventricular ectopic beat(s)', 'cardiac arrythmias']"
NCT06468540,Combination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy,Comparative Study on the Efficacy of the Combination of Micropulse Laser With or Without Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinal Disease,NOT_YET_RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * Age \>18 years old. * The patient diagnosed with chronic central serous chorioretinopathy with a history of more than 6 months. The diagnostic criteria for chronic CSC were as follows: FFA examination showed leakage of strong fluorescent spots with the extension of angiography time, and late fluorescence accumulation, accompanied by decreased central vision, darkening of vision, and deformable microopia. Fundus examination showed superficial detachment of retinal neuroepithelium in macula. * Patients received single micropulse laser therapy or micropulse laser combined with drug-free photodynamic therapy, and had not received other laser or surgical treatment in the six months prior to treatment. * Patients had follow-up data before and after treatment for 1 month and at least 6 months. Exclusion Criteria: * Patients with other fundus diseases or refractive interstitial opacity. * During treatment, other treatments other than micropulse laser or drug-free photodynamic therapy were received. * Various reasons led to incomplete patient data.",18.0,70.0,"['central serous chorioretinopathy', 'micropulse laser', 'photodynamic therapy']"
NCT05227040,Effect of the Nintendo Ring Fit Adventure Exergame on Running Completion Time,Effect of the Nintendo Ring Fit Adventure Exergame on Running Completion Time and Psychological Factors Among University Students Engaging in Distance Learning During the COVID-19 Pandemic: A Randomized Prospective Study,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * students who were over 20 years old and did not have chronic diseases; * students who were able to complete the 1600-meter outdoor run before and after the intervention; * students who understood and agreed with the research purpose and signed the consent form. Exclusion Criteria: * chronic diseases or medications prescribed for over 6 months; * restricted movement or failure to complete the 1600-meter run before and/or after the intervention * wearable devices that were not worn well or inability to calculate the cardiac force index (CFI).,20.0,65.0,"['sleep quality', 'mood disorders']"
NCT07175740,Effect of Macronutrients on Post-Exercise Glycemic Response in Males With Type 2 Diabetes,Influence of the Macronutrient Content of a Standardized Pre-Exercise Meal on the Glycemic Response Following Exercise in Type 2 Diabetics,COMPLETED,INTERVENTIONAL,MALE,Inclusion Criteria: * Type 2 Diabetes * Oral hypoglycemic agents Exclusion Criteria: * Insulin * Other diabetes related medical complications or conditions,18.0,65.0,"['type 2 diabetes', 'glycemic response']"
NCT00556140,The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression,The Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in the Acute Treatment of Psychotic Major Depression: Efficacy and Tolerability,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Men and women aged 18-80 years, inclusive. 2. Drug-free outpatients or inpatients meeting DSM-IV criteria for major depression with psychotic features. 3. Inpatients who undergo a 5-7 day washout period of their medication while concurrently beginning one of the approved SSRI's and abilify. 4. HAM-D-24 score \> 16. Exclusion Criteria: 1. Pregnant women and women of child bearing potential not using a medically accepted means of contraception (oral contraceptives are allowed). 2. Women who are breast-feeding. 3. Patients meeting DSM-IV criteria for major depression without psychotic features, or psychosis without major depression at the screen visit. 4. Patients with serious suicidal risk. 5. Patients with a history of seizure disorder; unstable physical disorders (cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic); or any physical disorder judged to significantly affect central nervous system function. 6. Patients meeting criteria for the following DSM-IV diagnoses: organic mental disorders; substance use disorders, including alcohol, active within the last 6 months; bipolar disorder; schizoaffective disorder; or antisocial personality disorder. 7. Patients who are currently taking an antidepressant, antipsychotic, or mood stabilizing drug and who are responding to one or all of these medications. If patients are not responding to these medications, they may go through a washout period of at least one week under the supervision of a study doctor before entering into this study. 8. Patients who are not able to read and understand the consent form, or who are not capable of understanding or giving informed consent to the procedures of the study",18.0,80.0,['psychotic depression']
NCT05948540,Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant,"A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members and Veterans With PTSD",RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT05422612). Exclusion Criteria: The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT05422612). 1. History of narcolepsy. 2. History of any treatment with daridorexant.,18.0,65.0,['post traumatic stress disorder']
NCT05710289,A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.,A Prospective Blood Collection Study to Assess the Immunogenicity of Homologous Booster Combinations of COVID-19 Vaccines Available Under Emergency Use Authorization Among Adults of 18 Years and Older.,WITHDRAWN,OBSERVATIONAL,ALL,"Inclusion Criteria: * Participant must be 18 years of age and older, at the time of signing the informed consent. * Participants who are healthy or medically stable as determined by medical evaluation including medical history, physical examination, and medical judgement of the investigator. * Participants who are able to attend all scheduled visits and comply with all study procedures. * Participants who received primary vaccination of 1 of 6 different WHO EUA qualified COVID-19 vaccine (mRNA-1273, ChAdOx1 nCOV-19, Ad26.COV2.S, BNT162b2, BBIBP-CorV, CoronaVac) at least 12 weeks of gap prior to first homologous booster vaccination and with no history of other COVID-19 vaccination, including booster doses. * Participants who complete a qualitative test for antibody to SARS-CoV-2 nucleocapsid proteins at screening for assessment of previous SARS-CoV-2 infection. * Female participants with a negative urine or serum pregnancy test at screening. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Exclusion Criteria: * Concurrent or past SARS-CoV-2 infection within 12 weeks prior to the booster study vaccination confirmed by virological or serological testing . * History of congenital, hereditary, acquired immunodeficiency, or autoimmune disease. * History of bleeding disorder or thrombocytopenia which is contraindicating to take blood sample. * History of malignancy within 1 year prior to the screening (with the exception of malignancy with minimal risk of recurrence at the discretion of the investigator). * Significant unstable chronic or acute illness that, in the opinion of the investigator, might pose a health risk to the participant if enrolled, or could interfere with the protocol-specified activities, or interpretation of study results. * Any other conditions which, in the opinion of the investigator, might interfere with the evaluation of the study objectives (e.g., alcohol or drug abuse, neurologic or psychiatric conditions). * Receipt of any medications or vaccinations intended to prevent COVID-19 except for the pre-defined COVID-19 vaccines expected to be given prior to screening (mRNA-1273, ChAdOx1 nCOV-19, Ad26.COV2.S, BNT162b2, BBIBP-CorV, CoronaVac). * Receipt of any vaccine within 4 weeks prior to the booster vaccination or planned receipt of any vaccine from enrollment through 4 weeks after the booster vaccination, except for influenza vaccination, which may be received at least 2 weeks prior to the booster vaccination. * Receipt of immunoglobulins and/or any blood or blood products within 12 weeks prior to the booster vaccination. * Chronic use (more than 2 consecutive weeks) of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy (≥10mg prednisone/day or equivalent for more than 2 consecutive weeks) within 12 weeks prior to the booster vaccination. The use of topical and nasal glucocorticoids will be permitted. * Participation in another clinical study and or concurrent, planned participation in another clinical study with study intervention during the study period. * Investigators, or study staff who are directly involved in the conduct of this study or supervised by the investigator, and their respective family members. * Donation of ≥450mL of blood product within 4 weeks prior to screening, or planned donation of blood product during the study period",18.0,65.0,['covid-19']
NCT03586089,Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome,PHENObarbital for the MANagement of Severe Acute ALcohol Withdrawal Syndrome (PHENOMANAL): a Prospective Randomized Feasibility Study.,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Alcohol withdrawal syndrome (regardless of admitting diagnosis). 2. Severe symptoms, as defined by a 'Clinical Institute for Withdrawal Assessment Adult revised' (CIWA-Ar) score of 16 or more, or delirium severe enough to prohibit assessment with the CIWA-Ar, or observed withdrawal seizures, in each case despite treatment with at least 60 mg of diazepam (or an equivalent dose of another benzodiazepine) in the previous 16 hours, regardless of route of administration.. 3. Early alcohol withdrawal, broadly defined as the first 16 hours after the diagnosis of acute alcohol withdrawal has been made. The time of diagnosis will be taken to be the time of prescription of symptom-triggered benzodiazepine therapy (""CIWA protocol""), or the time of consultation to ICU/Emergency Department, Internal Medicine, or the Addictions Service (Psychiatry) for the management of alcohol withdrawal. 4. Anticipated need for hospitalization (i.e. admission to ICU, medical step-up unit, or wards). Exclusion Criteria: 1. an alternate etiology for delirium thought to be more likely than alcohol withdrawal; 2. age \ 500); liver failure (INR \>2 not otherwise explained); 6. a presenting complaint of neurotrauma, brain mass, or intra-cranial bleed; abnormal cell count or gram stain on lumbar puncture (if performed); 7. strong clinical suspicion of recent co-ingestion of depressant drugs (e.g. opioids, toxic alcohols, gamma-hydroxy-butyrate); 8. hemodynamic instability (systolic blood pressure \[SBP\] \< 90 mmHg); 9. history of barbiturate allergy; 10. history of porphyria; 11. history of myasthenia gravis; 12. inability to obtain IV access; 13. anticipated transfer to another centre; 14. stated intent to leave against medical advice; 15. active outpatient prescription for anti-retroviral therapy for HIV 16. active outpatient prescription for one of the following anti-epileptic drugs: valproic acid, phenytoin, carbamazepine, clobazam, lacosamide, lamotrigine, levetiracetam, topiramate, primidone, or phenobarbital. 17. active outpatient prescription for an anticoagulant medication with a significant metabolic interaction with phenobarbital (i.e. warfarin or apixaban). 18. active outpatient prescription for a monoamine oxidase inhibitor (e.g., phenelzine, selegiline, tranylcypromine, isocarboxazid) 19. renal failure, as defined by a creatinine clearance \<10 mls/minute (as calculated by Cockcroft-Gault equation) and/or active receipt of renal replacement therapy (dialysis). 20. administration of IV or oral phenobarbital during the index admission prior to randomization.",16.0,65.0,"['alcohol withdrawal delirium', 'alcohol withdrawal', 'alcohol withdrawal seizures']"
NCT06963489,Cerebral Large Vessel Occlusion Stroke Multiomics Biosample Cohort,Cerebral Large Vessel Occlusion Stroke Multiomics Biosample Cohort,RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: 1. Age over 18 years. 2. Patients with intracranial and extracranial large vessel occlusion ischemic stroke confirmed by cerebrovascular angiography. 3. Availability of complete clinical and follow-up information required for the study. 4. Availability of blood and/or thrombus biological samples. 5. Voluntary written informed consent signed by the patient or their family (1) For retrospectively enrolled patients, a ""broad informed consent"" was signed at the time of sample collection. Upon enrollment into the cohort, a follow-up phone call was made to confirm the informed consent. (2) For prospectively enrolled patients, informed consent for this study was signed at the time of enrollment by the patient or their family. Exclusion Criteria: 1. Patients for whom biological samples cannot be obtained; 2. Patients or their family members who refuse to sign the informed consent form.",18.0,65.0,"['large vessel occlusion', 'acute ischemic stroke']"
NCT00700089,AID-trial Assertive Intervention After Deliberate Self-harm,AID-trial:A Randomized Clinical Trial Comparing the Effect on Repeated Self-harm of Assertive Intervention and Standard Treatment After Deliberate Self-harm,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Attempted suicide * At least 12 years old Exclusion Criteria: * Psychotic disorder * Severe dementia * Institutionalised or hospitalised for more than 2 weeks at psychiatric department,12.0,65.0,"['suicide, attempted']"
NCT06067789,The ALOFT Pilot Trial,Anesthesia for Lower Limb Revascularization to Optimize Functional ouTcomes,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Age ≥18 years 2. Planned lower limb revascularization surgical procedure (on an elective or urgent basis): infrainguinal arterial bypass, femoral endarterectomy, patch angioplasty 3. Able to access a telephone for postoperative follow-up Exclusion Criteria: 1. Absolute contraindications to neuraxial anesthesia: impaired coagulation state (due to intrinsic, congenital or extrinsic (i.e., anticoagulant not held for guideline recommended period based on the American Society of Regional Anesthesia recommendations) factors), infection at the needle insertion point, increased intracranial pressure or intracranial mass, uncorrected hypovolemia or hypotension (systolic blood pressure \<90 mmHg), severe uncorrected aortic stenosis) 2. Traumatic arterial injuries as an indication for surgery 3. Multiple sclerosis or demyelinating central nervous system conditions 4. Known malignant hyperthermia or who require a malignant hyperthermia trigger-free anesthetic 5. Pregnancy 6. Prior enrollment in this study, or participating in another interventional trial that could interfere with interpretation of data for either study (may be acceptable if unrelated interventions/outcomes and study PIs mutually agree in writing to co-enrollment) 7. Determination by the surgeon, anesthesiologist, or other clinician, that the patient would not be suitable for randomization",18.0,65.0,"['vascular diseases', 'peripheral artery disease', 'surgery']"
NCT04334889,Measurement of Spinal Kinematics During Various Movements,Differences in Spinal Kinematics During Various Activities Between Asymptomatic Subjects and Patients With Chronic Low Back Pain,NOT_YET_RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: \- sufficient French level to understand the instructions for the tests, the information sheet, the consent form. For CLBP patients: \- diagnosis of non-specific low back pain (pain from lower ribs to gluteal folds) for more than 3 months. For asymptomatic participants: * no history of LBP requiring medical attention during the last two years * no other concomitant pain or condition that could compromise the evaluation of lumbar kinematics. Exclusion Criteria: * pregnancy * skin allergy to tape * body mass index (BMI) above 32 For patients with CLBP only: * specific low back pain (such as the presence of infection, rheumatological or neurological diseases, spinal fractures, tumours) * any known important spinal deformities * previous back surgery that limits spinal mobility * high level of pain at the time of experiment that prevents repeated movements (severity and irritability) * other concomitant pain or condition that could compromise the evaluation of spinal kinematics.",18.0,65.0,['low back pain']
NCT06283589,The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis,"The SEAPORT 1 Study: An Open-label Exploratory Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Study Participants With End-Stage Kidney Disease Undergoing Hemodialysis",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: Individuals meeting the following inclusion criteria may participate: 1. Study participants must provide written or electronic consent after the nature of the study has been explained, and prior to any research-related procedures, per International Council for Harmonisation (ICH) Good Clinical Practice (GCP) 2. Have ESKD and are receiving HD treatment 3. Are compliant with receiving 3 treatments of HD per week with a functioning arteriovenous (AV) fistula, AV graft, or central venous catheter 4. PPi level \ 18 years to \ 125 kg 9. Concurrent participation in another interventional clinical study and/or receipt of any other investigational new drug within 5 half-lives of the last dose of the other investigational product or from 4 weeks prior to the first dose of INZ-701, whichever is longer, or use of an investigational device, through completion of participation in the study",18.0,69.0,['calciphylaxis']
NCT01216189,Sexual Function and Wellbeing in Females With Rectal Cancer,Sexual Function and Wellbeing in Females Diagnosed With Rectal Cancer,COMPLETED,OBSERVATIONAL,FEMALE,"Inclusion Criteria: * Females diagnosed with rectal cancer stadium I-III, planned surgery with or without preoperative radiotherapy. Exclusion Criteria: * Rectal cancer stadium IV * Previous radiotherapy to the pelvic region * Inability to provide informed consent. * Life expectancy less than 2 years.",18.0,65.0,['rectal cancer']
NCT02282189,Longitudinal Study of Oscillatory Positive Expiratory Pressure (oPEP) in Stable COPD,Longitudinal Study of Oscillatory Positive Expiratory Pressure (oPEP) in Stable COPD,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Subjects male and female aged 40-85 with a clinical diagnosis of chronic obstructive pulmonary disease (COPD) * Subject understands the study procedures and is willing to participate in the study as indicated by signature on the informed consent * Subject is judged to be in otherwise stable health on the basis of medical history * Subject is ambulatory and can perform the 6MWT * Subject able to perform reproducible pulmonary function testing (i.e., the 3 best acceptable spirograms have FEV1 values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater). * FEV1 \>25% predicted * FVC \> 25% predicted and \>0.5L Exclusion Criteria: * Patient is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained, or cannot read or understand the written material. Capacity to consent will be determined by either Dr. McCormack at the time of the clinic visit or Sandra Blamires, the study coordinator. * Patient is unable to perform spirometry or plethysmography maneuvers * Patient is pregnant",50.0,85.0,['chronic obstructive pulmonary disease']
NCT04827368,Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease,Non-invasive Disease Activity Monitoring in Patients With Inflammatory Bowel Disease (IBD) Using Volatile Organic Compounds,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * Diagnosed as having Crohn's Disease or Ulcerative Colitis * Aged 18-70 years. * Understands the language and signs an informed consent form. * Any disease location, except isolated upper GI Crohn's disease only * Any CD or UC disease activity. * Outpatients and inpatients * Patients will be recruited, and samples obtained at least one day, and no more than one week, prior to out/inpatient colonoscopy preparation to allow objective assessment of disease activity. Exclusion Criteria: * Status post colectomy * Status post diverting loop ileostomy or end ileostomy or colostomy * On antibiotics in the past 3 months or currently * Women (pregnant or breast feeding) * Subjects with concurrent chronic liver, renal, lung or metabolic disorders * Active malignancy * Bowel preparation at day of sample procurement * Isolated upper GI Crohn's disease only * Active disease on colonoscopy, but normal fecal calprotectin at inclusion * C diff. positive at time of inclusion (test to be obtained in routine clinical care).",18.0,70.0,"['ibd', 'crohn disease', 'ulcerative colitis']"
NCT01711268,Sunitinib Drug Levels and Outcomes in Kidney Cancer,Correlating Renal Cell Cancer Treatment Efficacy With Sunitinib Therapeutic Levels and Outcomes,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: * Metastatic renal cell cancer treated with single agent sunitinib * No known primary liver disease and no other severe or uncontrolled concurrent medical conditions * Signed informed consent Exclusion Criteria: * Patients who are unable to sign informed consent * Patients unable to give blood * Patients who are pregnant, nursing or not using an effective contraception method * Patients who had bone-marrow-transplantation prior to sunitinib treatment",18.0,65.0,['renal cell carcinoma']
NCT01898468,Post-Thoracotomy Closure Study,"Post-Thoracotomy Pain Syndrome: A Randomized, Double Blind, Study Comparing Closure Techniques",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients 18-88 years age * Patients undergoing surgery with an open thoracotomy incision Exclusion Criteria: * Patient refusal * Inability to give informed consent * Concurrent drug addiction or methadone use * Present chronic pain syndrome * Significant psychiatric illness excluding depression * Cannot understand English, read or write in English independently",18.0,65.0,['post thoracotomy pain syndrome']
NCT00425568,Transdermal Testosterone Gel/Effect on Erection Quality as Measured by DIR,Phase I Study of Transdermal Testosterone Gel and Its Effect on Erection Quality as Measured by a Digital Inflection Rigidometer (DIR),COMPLETED,OBSERVATIONAL,MALE,"Inclusion Criteria: * Testosterone \<350 ng/dL, * 21-59 years of age, * BMI \<30 Exclusion Criteria: * Those with carcinoma of the breast or known or suspected carcinoma of the prostate or with known hypersensitivity to any of the ingredients in AndroGel. * Men will be excluded if they have unstable angina, hypertension, diabetes, heart failure, or coronary artery disease. * Men will agree to discontinue use of current testosterone replacement, as well as Viagra or any other PDE5 inhibitors for 30 days.",21.0,59.0,['hypogonadism']
NCT01782768,Comparative Effects of Different Noninvasive Ventilation Mode on Neural Respiratory Drive in Recovering AECOPD Patients,Comparative Effects of Noninvasive Proportional Assist and Pressure Support Ventilation on Neural Respiratory Drive in Recovering Acute Exacerbation of Chronic Obstructive Pulmonary Disease(AECOPD) Patients,COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: * Clinical diagnosis of the COPD (Chronic Obstructive Pulmonary Disease) the COPD patients were all in stable condition during recovery from acute exacerbation. Exclusion Criteria: * severe Cardiovascular disease * Pneumonia * neuromuscular and chest wall deformity * Respiratory arrest * Cardiovascular instability (hypotension, arrhythmias, myocardial infarction) * Change in mental status; uncooperative patient * High aspiration risk * Viscous or copious secretions * Recent facial or gastroesophageal surgery * Craniofacial trauma * Fixed nasopharyngeal abnormalities * Burns * Extreme obesity",50.0,75.0,['chronic obstructive pulmonary disease']
NCT05465668,Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics of DWP16001 Drug A and C,A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of DWP16001 Drug A and DWP16001 Drug C in Healthy Adult Volunteers,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: \- Subjects with a body weight of ≥ 50.0 kg to ≤ 90.0 kg with a body mass index (BMI) of ≥ 18.0 kg/m2 and ≤ 30.0 kg/m2 ☞ BMI (kg/m2) = Body weight (kg) / {Height (m)}2 Exclusion Criteria: * musculoskeletal diseases * mental diseases * hemato-oncologic diseases,19.0,65.0,['healthy volunteers']
NCT01459068,Mental Health Assessment Project on the Thailand-Burma Border,Study of Effectiveness of Mental Health Interventions Among Torture Survivors on the Thailand-Burma Border,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Burmese national, 18 or over, living in Thailand outside of refugee camps, meets or exceed the algorithm for the Hopkins Symptoms Checklist 25 (HSCL-25) depression subscale and/or the algorithm for the Harvard Trauma Questionnaire (HTQ) posttraumatic stress scale. Exclusion Criteria: * not Burmese national, under 18, not living in Thailand outside of refugee camps, does not meet meet or exceed the algorithm for the Hopkins Symptoms Checklist 25 (HSCL-25) depression subscale and/or the algorithm for the Harvard Trauma Questionnaire (HTQ) posttraumatic stress scale; active psychosis",18.0,65.0,"['depression', 'anxiety', 'posttraumatic stress']"
NCT06111768,Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study,Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged ≥ 18 and ≤ 85 years-old 4. Diagnosed with heart failure of either preserved or reduced left ventricular function 5. NT-proBNP \> 300 pg/mL 6. Ability to take an oral medication 7. Willing to adhere to the SGLT2i + usual care regimen Exclusion Criteria: 1. Current use of SGLT2 inhibitor or use in the past 72 hours 2. Pregnancy or lactation (a pregnancy test will be performed prior to enrollment in women of child-bearing age) 3. Known allergic reactions to components of an SGLT2 inhibitor 4. Treatment with another investigational drug for heart failure different from or in addition to usual care within the 72 hours preceding AKI 5. Any individual who meets any of the following criteria will be excluded from participation in this study: * Documented history of ileal conduit (neobladder) * No means of collecting urine such as patients with documented incontinence without indwelling or external urinary catheter * Advanced kidney disease at baseline defined as baseline eGFR \< 25 ml/min/1.73m2 * Unexplained hypoglycemia in the past 30 days from enrollment * History of Fournier's gangrene (pelvic necrotizing fasciitis) * History of recurrent urinary tract infection (UTI): defined as documented UTI at least 2x in the past 6 months or 3 x in the past 12 months * End-stage kidney disease with dialysis requirement * Oliguria: defined as less than 30 ml urine output per hour for more than two consecutive hours or less than 500 ml over the preceding 24 hours * Severe acute kidney injury with indications for dialysis * Current dialysis receipt for acute kidney injury * Comfort measures only * Solid organ transplant on immunosuppression",18.0,85.0,['cardiorenal syndrome']
NCT06379568,Risk of Aspergillus Infection in Patients With Chronic Lung Disease,Risk of Aspergillus Infection in Patients With Chronic Structural Lung Disease,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: 1. Age : at least 18 years old ; 2. Imageological examination : Patients who complete high-resolution computed tomography (HRCT) images of the chest; 3. Serological examination : Patients who complete serological test results, including serum aspergillus specific IgG antibody, serum aspergillus IgM antibody and GM antigen detection. Exclusion Criteria: 1. immunodeficiency conditions : Patients diagnosed with HIV infection, hematological malignancies, and autoimmune diseases. 2. Critically ill patients : Those who require mechanical ventilation in the ICU and have established various types of cardiopulmonary bypass. 3. Inadequate Clinical Data: Inability to provide reliable diagnostic measurements or insufficient clinical information.",18.0,65.0,['fungal infection lungs']
NCT03050268,Familial Investigations of Childhood Cancer Predisposition,Familial Investigations of Childhood Cancer Predisposition,RECRUITING,OBSERVATIONAL,ALL,"NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown below, you may enroll regardless of the results of your clinical genetic testing. DEFINITION OF FAMILIAR CANCER FOR THIS PROTOCOL: In this protocol, the definition of ""Familial Cancer"" is met if any of the following is present: * An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR * An individual who has been diagnosed with more than one cancer, at least one of which was diagnosed under 26 years of age; OR * An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome; OR * An individual with a congenital cancer diagnosed before 6 months of age; OR * An individual with a rare pediatric cancer or tumor diagnosed before 26 years of age º Excluding human papilloma virus-associated cervical cancer and non-melanoma skin cancer occurring in adults. INCLUSION CRITERIA: * An individual who meets this protocol's definition of ""Familial Cancer,"" as above. * Biologic relatives of an individual meeting this protocol's definition of ""Familial Cancer,"" who are either affected or unaffected by cancer. EXCLUSION CRITERIA: * An inability or unwillingness of the research participant or his/her legally authorized representative (LAR) to provide written informed consent. * The participant has received allogeneic bone marrow transplantation and has NO pre-transplant germline (cancer-unaffected) DNA available AND is unwilling to provide a skin sample.",18.0,65.0,"['acute leukemia', 'adenomatous polyposis', 'adrenocortical carcinoma', 'aml', 'bap1 tumor predisposition syndrome', 'carney complex', 'choroid plexus carcinoma', 'constitutional mismatch repair deficiency syndrome', 'diamond-blackfan anemia', 'dicer1 syndrome', 'dyskeratosis congenita', 'emberger syndrome', 'familial acute myeloid leukemia', 'familial adenomatous polyposis', 'fanconi anemia', 'familial cancer', 'familial wilms tumor', 'familial neuroblastoma', 'gist', 'hereditary breast and ovarian cancer', 'hereditary paraganglioma-pheochromocytoma syndrome', 'hodgkin lymphoma', 'juvenile polyposis', 'li-fraumeni syndrome', 'lynch syndrome', 'mds', 'melanoma syndrome', 'multiple endocrine neoplasia type 1', 'multiple endocrine neoplasia type 2', 'neuroblastoma', 'neurofibromatosis type 1', 'neurofibromatosis type ii', 'nevoid basal cell carcinoma syndrome', 'non hodgkin lymphoma', 'noonan syndrome and other rasopathy', 'overgrowth syndromes', 'pancreatic cancer', 'peutz-jeghers syndrome', 'pheochromocytoma/paraganglioma', 'pten hamartoma tumor syndrome', 'retinoblastoma', 'rhabdoid tumor predisposition syndrome', 'rhabdomyosarcoma', 'rothmund-thomson syndrome', 'tuberous sclerosis', 'von hippel-lindau disease']"
NCT04632368,Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic,Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: HCPs including physicians, trainee physicians, nurses, nurse practitioners, Physician Assistants, and respiratory therapists providing patient care during the COVID-19 pandemic. * A single-item stress scale will be used as a screen for eligibility; a minimum score of 6 on a 10-point response scale will be needed to meet inclusion criteria * Subjects who have at least a 5% increase from baseline in heart rate after exposure to a personalized stressful script OR at least a 33% increase in skin conductance after exposure to the script * Willingness to address burnout symptoms by non-pharmacological means * All subjects must provide Informed Consent prior to enrollment in the study. * Willingness to wear the provided Apple Watch for the data collection process Exclusion Criteria: * Antipsychotic medications or beta-blockers * Current suicidal or homicidal ideation (suicidal ideation as screened by C-SSRI survey pre-enrollment) * Previous instruction in TM",18.0,65.0,"['burnout, professional', 'stress, psychological']"
NCT00662168,An Investigation of Small Intestinal Carcinoid Carcinoma in Families,An Investigation of Eight Reported Cases of Small Intestinal Carcinoid Carcinoma in Multiple Family Members,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: 1. Over the age of 18 years 2. History of biopsy confirmed small intestinal carcinoid tumor 3. English speaking 4. Mentally and emotionally capable of answering questions 5. Willing and available for study participation 6. At least one first-degree family member with carcinoid tumor Exclusion Criteria: 1. If you are under the age of 18 years, 2. If you have any mental or memory impairments 3. If you are unable to understand the information in the informed consent document.",12.0,65.0,['carcinoid carcinoma']
NCT03827668,A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS,"A PHASE I, OPEN LABEL, FIXED SEQUENCE STUDY TO EVALUATE THE STEADY STATE PHARMACOKINETIC DRUG-DRUG INTERACTION BETWEEN PF-06650833 AND PF-06651600 IN HEALTHY ADULT PARTICIPANTS",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Male and female participants must be 18 to 55 years of age, inclusive, at the time of signing the informed consent document (ICD) * Male and female participants who are healthy as determined by medical evaluation including medical history, physical examination, including blood pressure (BP) and pulse rate measurement, temperature, 12-lead ECG, and laboratory tests. * Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb). * Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in the protocol. Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, dermatological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). * Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy). * Known immunodeficiency disorder, including positive serology for human immunodeficiency virus (HIV) at screening, or a first degree relative with a hereditary immunodeficiency. * Infection with hepatitis B or hepatitis C viruses according to protocol-specific testing algorithm. * Participants with any of the protocol-listed acute or chronic infections or infection history. * History of febrile illness within 5 days prior to the first dose of investigational product (in both Periods). * History of any lymphoproliferative disorder such as Epstein Barr Virus (EBV) related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease. * Participants have a known present or a history of malignancy other than a successfully treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ. * Benign ethnic (cyclic) neutropenia. * Having received any live (attenuated) vaccines within 6 weeks prior to the first dose of investigational product. * Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study. * Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product. * Previous administration of an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives (whichever is longer) preceding the first dose of investigational product used in this study. * Known participation in a clinical trial of PF-06650833 or PF-06651600. * A positive urine drug test at screening or admission. * Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. * Baseline 12-lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results. * Participants with any of the protocol-listed abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary. * Have evidence of untreated or inadequately treated active or latent Mycobacterium tuberculosis (TB) infection. * History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. * Use of tobacco/nicotine containing products in excess of 5 cigarettes/day. * Have a history of major organ transplant or hematopoietic stem cell/marrow transplant. Skin grafts are allowed. * Systemic therapy with any of the medications that are CYP3A4 inhibitors within 7 days or 5 half-lives (whichever is longer) or CYP3A4 inducers within 28 days or 5 half-lives (whichever is longer) prior to the first dose of the trial medication. * Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing. * History of sensitivity to heparin or heparin-induced thrombocytopenia. * Unwilling or unable to comply with the Lifestyle Considerations criteria of the protocol. * Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.",18.0,55.0,['healthy']
NCT05606068,A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy - Expansion Study,A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy - Expansion Study,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age 21- 80 years. * Signed informed consent from patient or legal representative * Scheduled to receive weekly paclitaxel chemotherapy * Patients may receive other chemotherapy drugs alongside taxane e.g. Platinum/Herceptin. Exclusion Criteria: * Open skin wound or ulcers of the limbs * History of Raynaud's phenomenon, peripheral vascular disease, or poorly controlled diabetes * Pregnant woman * A score of more than 5 in Total Neuropathy Score (TNS) at baseline for cancer patients",21.0,80.0,['chemotherapy-induced peripheral neuropathy']
NCT01386268,Kogenate FS Regulatory Post-Marketing Surveillance,"KOGENATE® FS , Local Post Authorization Safety Study",COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Patients with diagnosis of hemophilia A * Treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS * Signed the informed consent form to participate in this study. * For pretreated patients with more than 100 exposure days an inhibitor assessment within three months prior to enrollment should be available * For pretreated patients with less than 100 exposure days an inhibitor assessment at baseline should be available * For patients with no available inhibitor status, it should be checked as per the recommendation of KFDA * Patients are defined as included in the study if there is a documented prescription of KOGENATE FS by the physician. Exclusion Criteria: * Patients with hypersensitivity to any ingredient of KOGENATE FS or to the protein of mouse or hamster will be excluded.",18.0,65.0,['hemophilia a']
NCT06105268,Management of Shoulder Dystocia in Flipped Learning,The Effect of a Flipped Learning Approach on Midwifery Students Learning Shoulder Dystocia Management: A Randomized Controlled Trial.,COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * \- Agreeing to participate in the study, * Being a 4th year student at the Department of Midwifery, Exclusion Criteria: * \- Refusing to participate in the study, * Being a 1st, 2nd and 3rd year student in the midwifery department",18.0,35.0,['shoulder dystocia - delivered']
NCT06592768,"A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma","A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Men and women 18 to 65 years of age; stable, allergic asthma; history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline at least 70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form; positive methacholine challenge at baseline (concentration of methacholine causing 20% decrease in FEV1 \[PC20\] PC20 ≤ 16 mg/mL or PD20 equivalent to ≤400µg); and positive skin-prick test and positive allergen-induced early and late airway bronchoconstriction to common aeroallergens. Exclusion Criteria: * Worsening of asthma or respiratory infection in the preceding 6 weeks; lung disease other than allergic asthma; prior treatment with a c-Kit inhibiting therapy; anaphylaxis to any parenterally administered biologics; use of asthma medications (note: intermittent doses of short-acting β2-agonist are allowed once weekly for relief of symptoms but prophylactic use for exercise is allowed as-needed); pregnant or lactating women; and women actively seeking pregnancy or who are not using adequate contraception.",18.0,65.0,['allergic asthma']
NCT03117868,Mortality of Patients Undergoing Fracture of the Upper Extremity u Femur at the University Hospital of Amiens,Mortality of Patients Undergoing Fracture of the Upper Extremity u Femur at the University Hospital of Amiens,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * All the patients operated from a fracture of traumatic origin of the ESF to the emergency block at the CHU of Amiens * Patients transferred to the CHU after being cared for in another structure will be included. * If a patient successively presents a fracture of each upper extremity of the femur outside of a surgical resumption, two inclusions will be realized Exclusion Criteria: * Do not include non-traumatic fractures of the upper end of the femur (pathological fractures: cancer, for example) * Fractures of the upper end of the femur associated with polytrauma will not be included.",18.0,65.0,"['femur fracture', 'morality']"
NCT00728468,A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients,"A Phase 1 Open Label, Single Arm Trial To Evaluate The Effect Of Pf-00299804 On The Pharmacokinetics Of Dextromethorphan In Patients With Advanced Malignant Solid Tumors",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients with a histologically or cytologically confirmed advanced malignant solid tumor for which there is no currently approved treatment or which is unresponsive to currently approved therapies; * Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Patients with performance status 2 could be eligible upon agreement between sponsors and investigators; * Adequate bone marrow, renal, liver and cardiac functions; Exclusion Criteria: * History of Interstitial Lung Disease (ILD). * Drugs with known CYP2D6 inhibitory effects * Drugs that are highly dependent on CYP2D6 for metabolism. * Women who are pregnant or breastfeeding.",18.0,65.0,['advanced malignant solid tumors']
NCT04952168,Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC,"A Single Arm, Prospective, Open Clinical Study of Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC With EGFR Mutation",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Age ≥18, male or female. 2. Patients must provide written informed consent to participate in the study. 3. Patients must have biopsy proven unresectable stage III NSCLC (AJCC 8th). 4. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R). 5. Patients receiving almonertinib for 3 months and achieved stable disease, partial response or completely response. 6. ECOG score 0-1 7. Demonstrate adequate organ function Patients evaluated as Cr, PR and SD were given concurrent chemoradiotherapy 3 months after targeted therapy Exclusion Criteria: 1. Patients progress in 3 months after almonertinib treatment 2. Patient can't tolerate radiotherapy or targeted therapy 3. Pregnant or nursing women",18.0,65.0,"['nsclc, stage iii']"
NCT05065268,Visual Rehabilitation in Children With Homonymous Hemianopia: a Pilot Study on Virtual-reality Stimulation,Visual Rehabilitation in a Pediatric Population of Patients With Homonymous Hemianopia: a Pilot Study on Virtual-reality Stimulation,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: 1. Homonymous hemianopsia 2. Male and female. 3. \> 8 years old 4. Interpupillary distance \>=56 mm 5. BCVA \> 20/200 6. Ability to follow visual and auditory stimuli and training instructions. 7. Home Wi-Fi access. Exclusion Criteria: 1. Ocular diseases 2. Both eyes with media opacity that impairs microperimetry testing. 3. Inability to perform during testing and training. 4. Consumption of psychoactive drugs. 5. 3 consecutive VRISE scores \< 25 at inclusion. 6. History of vertigo or dizziness 7. Prior vision rehabilitation interventions.,8.0,21.0,"['hemianopia', 'brain tumor', 'children, only']"
NCT03965468,"Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC","A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Histologically confirmed non-small cell lung cancer * Synchronous oligo-metastatic stage IV disease: maximum of three distant metastases, one of which must be extra-cerebral for stereotactic body radiotherapy (SBRT); Initial mediastinal staging is recommended (except for lymph nodes \<1 cm on CT and PET-negative) preferentially by endobronchial ultrasound (EBUS); Neurosurgical resection of one single central nervous system (CNS) metastasis or laparoscopic resection of one adrenal metastasis before study inclusion is allowed (one extra-cerebral metastasis must be available for SBRT) * Able to understand and give written informed consent and comply with study procedures * Age ≥18 years * ECOG Performance Status 0-1 * Availability of tumour tissue for translational research * Adequate haematological, renal and liver function Exclusion Criteria: * Prior chemotherapy, radiotherapy or therapeutic surgery for NSCLC (an exception is the resection of one single CNS or adrenal metastasis, as above) * Activating driver mutation: epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), proto-oncogene receptor tyrosine kinase (ROS1) * More than three distant metastases * Brain metastases not amendable for radiosurgery or neurosurgery * Extracranial metastatic locations such as malignant ascites, pleural or pericardial effusion, diffuse lymphangiomatosis of skin or lung, diffuse bone marrow metastasis, abdominal masses/abdominal organomegaly, identified by physical exam that is not measurable by reproducible imaging techniques. * Primary lung cancer not suitable for radical therapy (pneumonectomy excluded) * History of leptomeningeal carcinomatosis * Major surgery or significant traumatic injury from which the patient has not recovered at least 28 days before enrolment * Any uncontrolled intercurrent illness, including but not limited to: ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease or serious chronic gastrointestinal conditions associated with diarrhea, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol * Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc) at screening. * Known positivity for human immunodeficiency virus (positive HIV 1/2 antibodies) or active tuberculosis infection (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice) * Active autoimmune disease requiring systemic treatment * Severe or uncontrolled cardiac disease requiring treatment * History of active primary immunodeficiency * History of allogeneic organ transplant * Receipt of live attenuated vaccines within 30 days prior to enrolment * Known allergies or hypersensitivity to trial drugs or to any excipient. * Women who are pregnant or in the period of lactation. * Sexually active men and women of childbearing potential who are not willing to use a highly effective contraceptive method during the trial and up to 90 days after last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab and tremelimumab combination therapy",18.0,65.0,"['non-small cell lung cancer', 'stage iv', 'oligometastasis']"
NCT07257068,Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study,Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Eligibility Criteria * Participants on ICI referred to endocrine for new diagnosis of CIADM, will be included provided they are within 12 months of last dose of ICI and if they have: * New onset diabetes≥ 200 mg/dl and/or A1c ≥6.5 OR * Worsening glycemic control: requiring insulin per clinician assessment (fasting glucose or average glucose on CGM\>20% and /or A1c \>0.5% from prior to ICI use ) AND /OR * If Presenting with DKA/HHS: include if within 6 weeks of presentation AND * Must have detectable random c-peptide level 0.2 - 1 ng/mL with blood glucose of 145 mg/dl * Age ≥18 years. Because adverse event data are currently available on the use of infliximab in combination within participants \ 50% * Participants with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. * Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. * Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of infliximab administration. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria * Participants already on insulin for pre-existing type 1 or type 2 diabetes. * Participants with undetectable c-peptide levels i.e. \ 10mg of equivalent at the time of study entry, will be excluded * Participants who have ICI hepatitis and myocarditis will be excluded * Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities ≥ Grade 2) with the exception of alopecia. * Participants who are receiving any other investigational agents for CIADM. * History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to Infliximab or other agents used in study. * Required: any concomitant drugs used as defined in section 5.7 will be excluded. * Participants with uncontrolled intercurrent illness: active infection/ sepsis * Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * Participants with psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant and breastfeeding women are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with infliximab. Breastfeeding should be discontinued if the mother is treated with infliximab. These potential risks may also apply to other agents used in this study",18.0,65.0,"['checkpoint inhibitor', 'pilot study', 'diabetes melletus']"
NCT02645968,Registry for Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases - EXCITING,Registry for Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases - EXCITING,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Signed informed consent * Able to read and understand the scope and nature of data collection * Aged ≥ 18 at time of informed consent * Patients diagnosed with interstitial lung disease (ILD). Patients with suspicion on interstitial lung disease cannot be included into the registry, only after consens diagnosis of an ILD. This is also the case for patients with not classifiable ILDs. Subjects with the following subtypes of ILD will be enrolled: 1. Idiopathic interstitial pneumonia (IIPs) * Idiopathic pulmonary fibrosis (IPF) * Non-specific interstitial pneumonia (NSIP) * Desquamative interstitial pneumonia (DIP) * Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD) * Cryptogenic organizing pneumonia (COP) * Lymphocytic interstitial pneumonia (LIP) * Acute interstitial pneumonia (AIP) * Rare forms of IIPs (e.g. pleuropulmonary fibroelastosis) * Not classifiable IIP 2. Granulomatous lung disease * Sarcoidosis * Berylliosis * Other (e.g. involvement in chronic inflammatory liver and gut diseases, except EAA) 3. Hypersensitivity pneumonitis (exogen allergic alveolitis (EAA)) * Farmer's lung * Bird keepers' lung disease * Origin unknown * Other 4. Rheumatic and connective tissue diseases with pulmonary involvement like: * Connective tissue disease (subtype) * Vasculitis * Rheumatoid arthritis 5. Pneumoconiosis * Asbestosis * Silicosis * Other 6. Other forms * Pulmonary lymphangioleiomyomatosis * Pulmonary Langerhans' cell histiocytosis * Pulmonary alveolar proteinosis * Eosinophilic pneumonia * Post-ARDS Fibrosis 7. Drug-related 8. Radiotherapy associated 9. Fibrosis in emphysema patients without signs of other ILDs (i.e. smoking related interstitial fibrosis or ""emphysemasclerosis"") 10. Others 11. Not classifiable Furthermore for each subtype it will be queried, if a diagnosis of concomitant emphysema in ILD was made. Exclusion Criteria: \- Patients without interstitial lung disease",18.0,65.0,['interstitial lung disease (ild)']
NCT07089368,Photodynamic Therapy With Topical Application of a Zn(II) Phthalocyanine (RLP068/Cl) and Red Light for the Treatment of Moderate-to-severe Acne Vulgaris,Photodynamic Therapy With Topical Application of a Zn(II) Phthalocyanine (RLP068/Cl) and Red Light for the Treatment of Moderate-to-severe Acne Vulgaris,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Male or female participants aged ≥16 years. * Diagnosis of moderate-to-severe acne vulgaris (comedonal, papulopustular, or cystic), with facial lesions symmetrically distributed. * Washout period of at least 6 months from prior oral acne treatments. * Washout period of at least 2 months from prior topical acne treatments. * Ability to understand the study procedures and provide written informed consent. Exclusion Criteria: * Use of systemic or topical photosensitizing medications. * Known photosensitivity disorders. * Pregnancy or breastfeeding. * Participation in another interventional clinical study within the past 3 months. * Any dermatological condition of the face that may interfere with treatment assessment (e.g., eczema, rosacea). * Any serious uncontrolled medical condition deemed by the investigator to pose a risk to the participant or interfere with study results.",16.0,65.0,['acne']
NCT01657968,Procalcitonin-guided Detection of Streptococcal Acute Tonsillitis,Procalcitonin-guided Detection of Streptococcal Acute Tonsillitis,UNKNOWN,OBSERVATIONAL,ALL,Patients with acute tonsillitis: Inclusion Criteria: * Age between 15 and 40 years. * Subjective and objective signs of Acute Tonsillitis + presents of 2-4 Centor Criteria. * participation accept after verbal and written information. Exclusion Criteria: * Antibiotic treatment within the last month. * Other infection within the last month. * Inadequate tonsil swabs due to lack of cooperation. * Suspicion of peritonsillar abscess Control patients: Inclusion criteria: * Age between 15 and 40 years. * Participation accept after verbal and written information. Exclusion Criteria: * Antibiotic treatment within the last month. * Infection within the last month. * Tonsillectomy * More than 2 cases of acute tonsillitis within the last 12 months.,15.0,40.0,['streptococcal acute tonsillitis']
NCT03409068,"C2-C4 Compartment Block Versus Block of Costagliola, in TEAC","The Effectiveness of C2-C4 Compartment Block Versus Block of Costagliola, in the Control of Persistent Postoperative Pain in Patients Undergoing Carotid Thromboendarterectomy",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * patients undergoing to carotid thromboendarterectomy Exclusion Criteria: * ASA status: 4 * pregnancy * BMI \> 39,99 * neurological impairment * neck anatomical abnormalities * status of sepsis * coagulopathy * neck cancer * neck infections",18.0,75.0,"['somatic pain', 'neuropathic pain']"
NCT00474968,Adequacy and Efficacy of the e2TM Cervical Cell Collector Compared to Standard Spatula/CytoBrush Technique.,"Clinical Study Validating the Adequacy, Efficacy, and Safety of the e2TM Cervical Cell Collector Compared to Standard Spatula/CytoBrush Technique In Patients With Recent History of Abnormal Pap Test Returning for Colposcopy/Biopsy.",COMPLETED,OBSERVATIONAL,FEMALE,Inclusion Criteria: * Women ages 18 years old and above * Women scheduled to undergo colposcopy Exclusion Criteria: * Patients who have had a hysterectomy * Patients who are pregnant.,18.0,65.0,"['colposcopy', 'biopsy']"
NCT07140068,GumChucks vs Interdental Brushes in Plaque Removal.,Comparing GumChucks Flossing System and Interdental Brushes in Plaque Removal Efficacy Among Lebanese Adolescents (A Randomized Controlled Trial).,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Healthy adolescents (ASA 1) aged between 10 and 15 years; * Patients who had at least 4 posterior interdental contacts; * Patients who were able to follow verbal and/or written instructions, where they were asked to perform what they understood directly after reading the written instructions and listening to the explanation. Exclusion Criteria: * Patients who had antibiotics within the last 6 months; * Patients who were using antibacterial mouth rinses; * Patients with physical, intellectual, developmental, or emotional disabilities; * Patients with unilateral mastication or a nonfunctional side.",10.0,15.0,"['healthy', 'adolescent', 'dental plaque', 'gingivitis', 'oral hygiene', 'pediatric dentistry']"
NCT05174468,Analysis of Volatile Chemicals in Lung Cancer Screen-Eligible Subjects Using Infrared Spectroscopy,Analysis of Volatile Chemicals in Lung Cancer Screen-Eligible Subjects Using Infrared Spectroscopy,TERMINATED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Being screened for lung cancer on LUCAS; * At high-risk for lung cancer based on USPSTF guidelines: * Asymptomatic adults aged 50-80 years * Tobacco smoking history of at least 20 pack-years (one pack-year = smoking one pack per day for one year; 1 pack = 20 cigarettes) * Current smoker or has quit smoking within the past 15 years. * No history of lung cancer or any other active cancer within 3 years (Note: DCIS, CIN, non-invasive bladder cancer, non-melanomatous skin cancers are an exception); * Ability to provide a breath sample; * Ability to give informed consent. Exclusion Criteria: * Persons who cannot give informed consent or assent (i.e. mentally incompetent persons, or those physically incapacitated) or do not have a legally acceptable representative are not to be recruited into this study; * Persons who require the use of supplemental oxygen; * The breath sampling technology is sensitive to the chemicals produced by tobacco, cannabis, and e-cigarettes as well as alcohol (consumed by the subject or used by the operator around the equipment). So we ask that subjects refrain from Smoking (tobacco, cannabis, or e-cigarettes ) at least 4 hours before and consuming alcohol (including mouthwash) 8 hours before breath sampling",50.0,80.0,['lung cancer']
NCT01085968,Cognitive Rehabilitation in Parkinson's Disease,PC-based Rehabilitation of Motor Planning Deficits in Parkinson Disease,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Clinical diagnosis of PD dominant on the right side with a Hx of response to dopamine replacement. Exclusion Criteria: * Contraindication to MRI * History of stroke or significant head trauma * Significant vision impairment * Hx of brain surgery or claustrophobia * Medication change \<4 weeks * Atypical PD * Severe tremor * Presence of motor fluctuations or dyskinesia * Significantly impaired limb or joint function * Significant memory impairment * Depression or daytime sleepiness,55.0,75.0,"[""parkinson's disease""]"
NCT02268968,Use of Topical Lidocaine to Reduce Pain in Preterm Infants Receiving Nasal CPAP Continuous Positive Airway Pressure,Use of Topical Lidocaine to Reduce Pain in Preterm Infants Receiving Nasal Contiuous Positive Airway Pressure,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Preterm infants \< 37 weeks gestation * Admitted to NICU, Mansoura University Children's Hospital * Respiratory distress requiring use of nasal CPAP * Informed consent obtained Exclusion Criteria: * Serious, life-threatening malformations * Use of sedation, analgesia in the preceding 72 hours * Those who undergo any surgical intervention * Those who undergo any painful procedures as venipuncture, intubation, suctioning, blood sampling, heel-prick, catheterization 30 minutes before assessment * Those with signs of nasal injuries at the time of application of nCPAP * Necrotizing enterocolitis",18.0,28.0,['other preterm infants']
NCT02034968,Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma,Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma,WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patient who was confirmed stage IV esophageal carcinoma by pathologic histology or cytology. * Males or females aged ≥18 years, \< 75 years. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Life expectancy ≥12 weeks. * Adequate bone marrow, renal, and liver function are required. * Able to comply with the required protocol and follow-up procedures, and able to receive oral medications. Exclusion Criteria: * Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease). * Allergy to anti-EGFR antibody. * Female subjects should not be pregnant or breast-feeding. * Adequate hematological function: Absolute neutrophil count (ANC) ≥1.5 x 109/L, and Platelet count ≥100 x 109/L. Adequate renal function: Serum creatinine ≤ 1.5 x ULN, or ≥ 50 ml/min. Adequate liver function: total bilirubin \< 1.5 x upper limit of normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x ULN in the absence of liver metastases, or \< 5 x ULN in case of liver metastases. * Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.",18.0,75.0,['stage iv esophageal squamous cell carcinoma']
NCT04501250,"Comparative Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method","A Double-blinded, Randomized, Comparative, Crossover Pharmacokinetics Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using Method of Euglycemic Hyperinsulinemic Clamp on Healthy Volunteers",COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: * Signed informed consent to participate in the study. * Men of the Caucasian race with a verified diagnosis ""healthy"" according to the data of standard clinical, laboratory and instrumental examination methods. * Age 18-50, inclusive. * Body mass index 18.5 - 27 kg / m2. * Volunteers who have sexual contact with fertile women should agree to use barrier methods of contraception while participating in the study (unless they have undergone surgical sterilization). Study Participants must also not become a sperm donor within the specified period. * Consent to all restrictions imposed during the study. Exclusion Criteria: * Acute inflammatory diseases within 3 weeks from the moment of complete recovery to the stage of screening. * Presence of episodes of hypoglycemia in the history of the volunteer * Presence in the family history of the closest relatives cases of verified diagnosis of diabetes mellitus of any type. * Deviations from the norm of basic vital indicators (heart rate, blood pressure, respiratory rate, body temperature) and ECG from normal values and laboratory values from reference values during screening. * Fasting plasma glucose\> 6.1 mmol / L at screening. * HbA1C\> 6% at the time of screening. * Oral glucose tolerance test - blood glucose level ≥7.8 mmol / L (2 hours after glucose loading) during screening. * Hard-to-reach veins of the upper extremities, vein thrombosis, history of thrombophlebitis or family history of close relatives, ""compromised"" veins due to frequent preceding venipuncture. * Taking medications, phytopreparations, biologically active additives within 14 days before screening. * Significant blood loss 3 months before screening due to, for example, but not limited to the following points: a. donor blood donation; b. extended surgery or trauma leading to significant blood loss. * Incomplete recovery from surgery or surgery scheduled while the volunteer is participating in the study. * Mental, physical and other reasons interferes with adequately assessing behavior and correctly fulfill the conditions of the research protocol (incl. a history of mental illness). * Presence or history (three years before the the study drug) of narcotic, drug and / or substance abuse. * Positive test for the content of narcotic drugs in urine during the screening period. * Anamnestic information about alcoholism or taking more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5 liters of beer, 200 ml of dry wine or 50 ml of spirits). * Positive test for alcohol in breath during screening. * Nicotine addiction (regular use of tobacco less than 6 months before screening). * Any chronic diseases, incl. but not limited to positive test results for hepatitis C or hepatitis B, HIV, syphilis at the time of screening. * Burdened allergological history. * presence of suspicion of an inflammatory disease of the urinary system based on the results of urinalysis during screening. * Presence of oncological diseases within 5 years before the screening. * History of organ transplantation (except of corneal transplant performed more than 3 months before the first injection of the study drug). * Participation in a clinical trial of any drug or experimental medical device within 3 months prior to the first administration of the study drug. * Any other condition that, in the reasonable opinion of the research physician, makes it difficult for the volunteer to participate in the study. * History of hypersensitivity to heparin, insulin or any of the excipients of the investigational drugs.",18.0,50.0,"['pharmacokinetics', 'bioequivalence']"
NCT02767050,Incidence of Caries in Smoking and Smokeless Tobacco,Incidence of Caries in Smoking and Smokeless Tobacco-An Observation Study,COMPLETED,OBSERVATIONAL,ALL,INCLUSION CRITERIA: * Patients who are willing for the study. * A positive history of dental caries in smokers and smokeless tobacco. * Patients with caries not under any treatment of the same. EXCLUSION CRITERIA: * Unwilling patients who do not want to be a part of the study. * Patient with fluorosis.,15.0,100.0,['dental caries']
NCT07339150,MiREA-AC for Reducing Problematic Alcohol and Marijuana Use in College Students,"MiREA, a mHealth Intervention to Reduce Health Disparities by Improving Access to Mandated College Students With Problematic Alcohol and Marijuana Use",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * College student, alcohol consumption in past 90 days Exclusion Criteria: * non-college student, no alcohol use in the past 90 days",18.0,26.0,"['alcohol misuse', 'cannabis misuse']"
NCT02338050,"Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation","A Phase II Study of the Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. ≥ 6 months and \ 60 mL/min/1.73 m2 (updated Schwartz formula or nuclear GFR) must be obtained if serum creatinine is elevated. * Hematologic function: Absolute neutrophil count (ANC) \> 500/μL and platelet count \> 25,000/μL without transfusion * Oxygen saturation at rest or with exercise \> 88% as measured by pulse oximeter or PaO2 \> 55 mm Hg without need for supplemental oxygen at rest or with activity * Serum albumin \> 2 g/dL 8. Performance status: * Subjects ≥ 16 years of age: Karnofsky ≥ 60% (Appendix A) * Subjects \ 18 years of age must have the ability to give informed consent according to applicable regulatory and local institutional requirements. Legal guardian permission must be obtained for patients \ 0.625mg daily as conjugated estrogens or equivalent) within 7 days prior to study enrollment",6.0,24.0,['acute lymphoblastic leukemia (all)']
NCT04288050,"Evaluation of Glycemic Profiles in Diabetic Patients on Dialysis Under Insulin Balsal-bolus Protocol, Using Freestyle Libre","Evaluation of Glycemic Profiles in Diabetic Patients on Dialysis Under Insulin Balsal-bolus Protocol, Using Freestyle Libre. Observational Prospective Study Without Modification of Management.",COMPLETED,OBSERVATIONAL,ALL,Inclusion criteria: * Subjects over 18 years of age * dialysis patients * diabetics (any diabetes) * any anti-diabetic treatment * no objection form Exclusion criteria: * Objection of the subject * Subject under guardianship or tutelage,18.0,65.0,['diabetic']
NCT01970150,The Effect of Repeated Transcranial Magnetic Stimulation on Off-line Resting Electroencephalographic Signal in Alzheimer's Disease,To Investigate the Effect of Application of Repeated Trans-cranial Magnetic Stimulation (rTMS) Applied on the Left Prefrontal Cortex on Electroencephalography Signal Recorded From Brain Regions Involved in Cognitive Function in Patients With Alzheimer's Disease (AD),TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Males and females, * Age 55-85 years old, * Able to consent and agrees to participate (if patient does not have capacity to give a consent then a caregiver will be asked ) * Fluent in English * Diagnosed with probable AD (NINCDS-ADRDA criteria) mild stage as defined by a composite score of 1 or less on clinical dementia rating scale (CDR) Exclusion Criteria: * Other neurological illness that would interfere with cognitive function (significant stroke, seizure d/o, Parkinson, Huntington etc.). * Psychiatric illness known to affect cognition such as schizophrenia/schizo-affective disorder, substance use disorder within 1 year of study, active depression or anxiety disorder or history of recurrent major mood disorder prior to cognitive change. * Medications: benzodiazepines will be exclusionary. Other psychotropic medications including Acetyl Choline Esterase inhibitors will be allowed but the dose needs to be stable for at least one month prior to the start and during the study. Patients taking medications that might increase the risk of seizures should not participate in the study. * Subjects with metal anywhere in the head, excluding the mouth, is generally a contraindication to TMS. This includes shrapnel, and screws and clips from surgical procedures unless the physical properties of the metal object are known and there is a strong reason for using TMS. * Subjects with cardiac pacemakers and implanted medication pumps should not participate in most TMS studies. * TMS also should not be performed in patients with electrodes inside the heart which might provide a low-resistance current path to electrically sensitive tissue. * Persons with serious heart disease are at increased risk in the event of a seizure, * Persons with increased intracranial pressure, as in acute large infarctions or trauma, are also at increased risk in the event of a seizure, and should not receive TMS. * Pregnant women or women in child bearing age that might be pregnant. * Patients who are already enrolled in another study.",55.0,85.0,['alzheimer disease']
NCT00793650,Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study,Combination High Dose Melphalan and Autologous PBSC Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients with multiple myeloma who are eligible for an autologous peripheral blood progenitor transplant * Male and female subjects between the age of 18 and 70 years. * Patient has given informed consent prior to any study related procedures with the knowledge that consent can be withdrawn at anytime without prejudice to future medical care * Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements * Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. * Male subjects agrees to use an acceptable method for contraception for the duration of the study. * Biopsy proven diagnosis of multiple myeloma from bone marrow aspirate and biopsy prior to study initiation * Patient has achieved less than 90% disease reduction from previous treatment prior to transplant (as measured by serum or urine protein electrophoresis) and has more than 5% plasma cells in the bone marrow, or patient has progressed and has more than 5% plasma cells in the bone marrow. * Karnofsky Performance Status score of ≥ 60% * Patient has met the following laboratory requirements prior to Day -4 * Platelet count ≥ 50, 000/mm3 * Absolute Neutrophil Count ≥ 500/mm3 * Hemoglobin ≥ 10 g/dL (transfusion allowed to meet this criterion) * Calculated creatinine clearance ≥ 30mL/min * Toxic effects of previous therapy or surgery resolved to Grade 2 or better Exclusion Criteria: * Unsupportable anemia with \< 10b/dL * Patient has a calculated or measured creatinine clearance of \< 30mL/min within 14 days before enrollment * Patient has ≥ Grade 2 peripheral neuropathy within 14 days before enrollment * Patient has hypersensitivity to bortezomib, boron or mannitol * Patient has had an allergic reaction to melphalan or chlorambucil * Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. * Patient has received other investigational drugs with 14 days before enrollment * Serious medical or psychiatric illness likely to interfere with participation in this clinical study * Cardiac or pulmonary dysfunction such that patients do not meet institutional pre-transplant evaluation criteria * Known central nervous system involvement or suspicion of involvement with Myeloma * Other active malignancies (with the exception of basal and squamous cell skin cancer) within 5 years of study entry. Patients with treated prostate or cervical cancer in situ who are 2 or more years from therapy and remain free of disease may be entered into the study at the investigator's discretion. * Known to be HIV positive, HIV-1 positive",18.0,65.0,"['cancer', 'multiple myeloma']"
NCT02146950,European Active Surveillance Study of LCS12,European Active Surveillance Study of LCS12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,FEMALE,"Inclusion Criteria: * Women aged below 40 years who have a new IUD inserted (LCS12, Kyleena, Mirena, copper IUD, or any other hormonal IUD) * Women who are willing to participate in the active surveillance Exclusion Criteria: * Women aged 40 or older at insertion day * Women who are currently enrolled in an interventional trial on IUD use can not participate",18.0,39.0,['contraception']
NCT05498350,"Randomized Trial Comparing Early ""Trigger"" Versus Delayed ""Trigger"" Timing in Cycles of Controlled Ovarian Stimulation.","Randomized Trial Comparing Early ""Trigger"" Versus Delayed ""Trigger"" Timing in Cycles of Controlled Ovarian Stimulation.",UNKNOWN,INTERVENTIONAL,FEMALE,"Inclusion Criteria: 1. Adult female at least 18 years of age and less than 35 years of age intending to undergo ovarian stimulation for a cycle of IVF with all embryos to be frozen that attain the blastocyst stage. 2. Anticipated at least normal ovarian response evidenced by at least 8 antral follicles observed on ultrasound or a serum level of at least 1.5 ng/ml AMH. 3. Ability read and understand English sufficiently to obtain informed consent. 4. Patients with prior IVF cycles are allowed, but no patient can undergo more than one cycle with oocyte collection under this study. Exclusion Criteria: 1. Any cycle type that would preclude immediate culture to blastocyst stage (e.g. oocyte banking). 2. Any condition that, in the opinion of the physician or principal investigator, would place the patient at undue risk under this protocol or would otherwise make the protocol inappropriate for that subject.",18.0,34.0,"['infertility, female']"
NCT02331550,Observational vs. Ablative Treatment for Low-grade Squamous Intraepithelial Lesions.,Observational vs. Ablative Treatment for Low-grade Squamous Intraepithelial Lesions. Retrospective Paired Cohort Study.,COMPLETED,INTERVENTIONAL,FEMALE,Inclusion Criteria: * Diagnosis of Low-Grade Squamous Intraepithelial Lesion by cervical cytology. * Positive Biopsy for Low-Grade Squamous Intraepithelial Lesion after colposcopy. Exclusion Criteria: * Serological detection of human immunodeficiency virus (HIV).,18.0,65.0,"['lsil, low-grade squamous intraepithelial lesions']"
NCT00092950,Exercise in Women at Risk for Breast Cancer,A Pilot Study of a Three Month Intervention for Increasing Physical Activity in Sedentary Women at Risk for Breast Cancer,COMPLETED,INTERVENTIONAL,FEMALE,"* INCLUSION CRITERIA: This study will enroll 40 breast cancer survivors and 40 women at high risk for breast cancer. All participants must fulfill the following criteria: Age 18 to 75. Sedentary at baseline, as defined by a weekly leisure-time activity score of 15 or less on the Godin Leisure-Time Exercise Questionnaire. This cutoff is equivalent to engaging in moderate activity less than 3 times a week. Ability to complete all study questionnaires, or a willing friend or family member who will assist in questionnaire completion. ECOG performance status 0-1. Ability to successfully perform the level of physical activity prescribed by the protocol, as assessed by the Physical Activity Readiness Questionnaire (PAR-Q). Any participant who answers yes to any of the questions in this screening tool will undergo medical evaluation at the Clinical Center, as appropriate, prior to enrolling on the study. Cardiac risk will be assessed after a complete history and physical exam, and will be determined by the examining physician. Only patients who are felt to be increased cardiac risk will have an EKG performed. This will include patients who answer yes to any of the questions on the PAR-Q that assess cardiac risk (#1,2,3,4,6). Patients with worrisome EKG findings or findings in the history or physical exam that warrant further work-up in the opinion of the health care provider will be referred to the cardiology consult service, or if non-urgent, will be referred back to their source of regular medical care for clearance prior to enrolling on the study. If history of cancer (other than invasive breast cancer, squamous or basal cell skin cancers), subject must have no evidence of disease at time of enrollment AND no history of cancer directed treatment in the 2 years preceding enrollment. Breast cancer survivors: Eligible breast cancer survivors will be women with a documented history of Stage I, II or III invasive breast cancer who are at least two months from the completion of their primary therapy, including surgery, radiation and chemotherapy. Current use of hormonal therapy such as tamoxifen or aromatase inhibitors, will be permitted, however subjects must have completed 2 months of hormonal therapy prior to beginning the study in order to achieve steady state. Women at high risk for breast cancer: Women will be considered at high risk for developing breast cancer if they fulfill one of the following criteria: A Gail model risk of greater than or equal to1.7 percent over 5 years from study entry or a Claus model lifetime risk of greater than 20 percent. Lobular neoplasia. Atypical ductal hyperplasia. Ductal carcinoma in situ (DCIS) that has been previously treated. Patients must be at least 2 months from completion of primary therapy, and if treated with hormonal therapy, they must have completed at least two months of hormonal therapy. Deleterious mutations in BRCA-1 or 2 OR A priori risk assessment of 20 percent chance or greater of carrying a BRCA1/2 gene mutation. The BRCAPRO model (109) will be used to assess this risk. EXCLUSION CRITERIA: Currently pregnant or planning to become pregnant during the study period. Pregnancy will be assessed in women of childbearing potential prior to enrolling in stage II of the study. Postmenopausal women and women who have had a previous hysterectomy, oophorectomy or tubal ligation will not be required to undergo a pregnancy test. Uncontrolled intercurrent illness, including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, recent myocardial infarction or stroke, or psychiatric illness/social situations that would limit compliance with study requirements. Physical conditions that preclude the amount of daily walking prescribed by the protocol (e.g., severe arthritis, use of a walker or cane, wheelchair-bound, etc.). Medical or psychiatric disorder which would, in the opinion of the Principal Investigator, render the subject unable to provide informed consent. Patients with metastatic or recurrent disease will be excluded because of difficulty interpreting results in the context of women with a disease burden and/or on chemotherapy.",18.0,75.0,['breast neoplasms']
NCT07102550,Biliary Anastomosis in Living Donor Liver Transplant With Amniotic Tissue,Biliary Anastomosis in Living Donor Liver Transplant With Amniotic Tissue: A Prospective Non-Randomized Clinical Trial,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Adults \>/= 18 years old * Recipient of LDLT Exclusion Criteria: * Patients who are deemed unsafe for participation for any reason by our multi-disciplinary liver transplant selection committee. * Patients \< 18 years old * Patients who cannot provide informed consent * Patients receiving deceased donor liver transplants, or who are not undergoing Liver transplant (LT) * Patients who do not wish to participate * Children, cognitively-impaired persons, pregnant women, students and house staff under the direct supervision of the investigator are considered vulnerable populations and will, therefore, be excluded from participation.",18.0,65.0,['liver transplant']
NCT03035591,ODM-207 in Patients With Advance Solid Tumours,"Safety and Pharmacokinetics of ODM-207 in Patients With Selected Advanced Solid Tumours: an Open-label, Non-randomised, Uncontrolled, Multicentre, First-in-human Study With Cohort Expansion",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients with histologically or cytologically confirmed locally advanced or metastatic cancer for which no effective standard therapy exists or are refractory or resistant to conventional therapy * Life expectancy \>12 weeks * Patient may have either measurable or non-measurable disease, but must have disease that can be evaluated for improvement of progression * ECOG performance status of 0 to 1 Exclusion Criteria: * History of bleeding disorder or significant bleeding episode within 6 months prior to study treatment * Subjects receiving anticoagulants or medications that durably inhibit platelet function (7-day wash-out prior to study treatment) * History of or current leptomeningeal or brain metastasis or spinal cord compression.",18.0,65.0,['solid tumors']
NCT02817191,Effects of Holy-Comod and Tears Naturale Forte in Patients After Phaco+IOL,Effects of Holy-Comod and Tears Naturale Forte on Ocular Surface and Tear Inflammatory Mediators in Patients After Phaco+IOL,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * 60-72 years old * classification of lens nucleus is LOCS Ⅱ Exclusion Criteria: * patients with previous history of ocular surgery, corneal diseases,uveitis ,ocular hypertension or glaucoma ,systemic diseases.",60.0,72.0,['age-related cataract']
NCT01740791,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection","Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic Hepatitis C Virus Infection",COMPLETED,INTERVENTIONAL,ALL,"Key Inclusion Criteria: * HCV treatment-naive adult participants (18-65 years of age) with chronic HCV infection and plasma HCV RNA ≥ 5 log10 IU/mL at screening * Agree to use protocol defined precautions against pregnancy Key Exclusion Criteria: * Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, α1 antitrypsin deficiency, cholangitis) * Evidence of cirrhosis * Evidence of current drug abuse * Screening laboratory results outside the protocol specified requirements Note: Other protocol defined Inclusion/Exclusion criteria may apply.",18.0,65.0,['chronic hepatitis c virus']
NCT02967991,19 Versus 22-Gauge Needle for EUS-LB,19 Versus 22-Gauge Fine Needle Biopsy (FNB) Needles for Endoscopic Ultrasound Guided Liver Biopsy (EUS-LB): A Prospective Pilot Study,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Patients undergoing EUS-LB 2. Platelet count \> 50,000 3. International normalized ratio (INR) \ 18 years 5. Non-pregnant patients Exclusion Criteria: 1. Age \ 1.5 7. Presence of ascites 8. Known liver cirrhosis",18.0,65.0,"['diagnoses diseases', 'ultrasound therapy', 'complications', 'liver diseases']"
NCT01134991,Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients,"Pilot, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study, to Evaluate the Tolerability and Safety of FXFM244 Antibiotic Foam and to Monitor Its Clinical Effect in Moderate to Severe Rosacea Patients",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Patients with clinical diagnosis of moderate to severe facial rosacea as determined by: * At least 8 but no more than 50 total papules and/or pustules (inflammatory lesions) * Presence of moderate to severe erythema * Presence of telangiectasia. * An Overall Rosacea Severity score ≥2.5 2. Patient is male or female over 18 years of age. 3. No known medical conditions that, in the Investigator's opinion could interfere with study participation 4. Patient is willing and able to comply with all requirement of the protocol 5. Patient is willing and able to give written informed consent prior to participation in the study Exclusion Criteria: 1. Presence of skin diseases at or near the investigational area 2. Immunosuppressed state or other serious systemic disease 3. Signs and/or symptoms of systemic infection 4. Concomitant medication: * Use of oral and/or topical antibiotic treatment within 14 days prior to study entry. * Use of any topical anti-rosacea agent except antibiotics within 14 days prior to study entry. * Use of cyproterone acetate, CPA-containing contraceptives (e.g. Diane) or other corticosteroids (during the last 3 months); * Use of retinoids (during the last 4 weeks) 5. Use of artificial sun bath or having a sun holiday during the last 2 weeks 6. Alcohol or drug abuse, according to assessment by the investigator 7. Known or suspected hypersensitivity to Minocycline or any of the excipients in the Study Medication 8. Use of another investigational drug within 30 days prior to entry into this study 9. Pregnant or lactating women.",18.0,65.0,['rosacea']
NCT03283891,Effects on Nurses' Quality of Working Life of an Educational Intervention to Strengthen Their Humanistic Practice,Effects on Nurses' Quality of Working Life and on Patients' Quality of Life of an Educational Intervention to Strengthen Humanistic Practice Among Haemodialysis Nurses in Switzerland: A Mixed Methods Cluster Randomised Controlled Trial,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Nurses: 1. have at least 6 months' work experience in the department; 2. consent to take part in the study. In addition, nurses who intend to leave the HD unit in the 3 months to come will be excluded * Patients 1. be at least 18 years of age and under active treatment for at least 6 months; 2. understand and read French; 3. able to provide informed consent. Exclusion Criteria: * Nurses: 1\. intention to leave the HD unit in the 3 months after the beginning of the project * Patients 1. being diagnosed with dementia 2. being a new HD patient",18.0,65.0,['patient-centered care']
NCT07027891,The Rule-Out Acute Myocardial Infarction Using Aritifical Intelligence Electrocardiogram (ROMIAE) 2 Trial,ROMIAE 2 Trial: Randomized Controlled Trial for Managing Suspicious Acute Myocardial Infarction in ED Using AI-ECG,RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * chest pain * suspicious of acute myocardial infarction Exclusion Criteria: * STEMI * Revisit of same symptoms within 1 week * traumatic chest pain * Pneumothorax * Transferred from other hospital diagnosed of AMI * Cardiac arrest * Chest pain of clearly non-cardiac etiology * declined to participate in the study,18.0,65.0,"['myocardial infarction (mi)', 'chest pain rule out myocardial infarction']"
NCT01098591,Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE,Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * patient included in one of the registered cell-based cardiac therapy of the participating center Exclusion Criteria: * none,18.0,80.0,['ischemic heart disease']
NCT01062191,Altrazeal Range of Motion Study Comparing With Typical Carboxymethyl,Flexible Hydrogel Nanoparticle Wound Dressing Allows Greater Joint Range of Motion Compared to Typical Sodium Carboxymethylcellulose Dressing,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Male or female patient is at least 2 years of age; 2. Patient is in general good health; 3. Patient has partial thickness burn that crosses at least one peripheral joint axial to the proximal interphalangeal joints; 4. Patient has one unburned contralateral joint without major internal or external joint derangement to be used as control 5. Patient is willing and able to cooperate with the protocol for 30 days 6. Patient is capable of provided informed consent 7. Patient provides authorization for use and disclosure of protected health information Exclusion Criteria: 1. Age less than 2 years; 2. Patient has superficial or full thickness burn wounds; 3. Patient has acutely infected wounds; 4. Patient has wounds with surrounding cellulites; 5. Patient has a history of hypersensitivity to any components of either the nanoparticle or sodium hydrocellulose dressing, or any know sensitivities to other hydrogel bandage treatments 6. Patient has a concurrent clinical condition, which in the judgment of the Investigator cold either pose a health risk to the patient while participating in this study, or could potentially influence the outcome of the study; 7. Patient is wearing any type of orthopedic device that may come in contact with the dressing; 8. Patient has history of poor wound healing, history of smoking, history of drug/alcohol abuse, any other skin/immune system condition that would increase likelihood of wound irritation, infection or increase chance of early termination 9. Patient has wound originating from chronic condition 10. Patients with history of any immunodeficiency syndrome or condition 11. Patients who have applied any dressing or medication (OTC or prescription) to the wound (within 48 hours of study? ) 12. Patient has participated in a clinical research study within the last 30 days prior to enrollment; 13. Patient is unable to communicate or to cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function",2.0,65.0,['burn']
NCT07315191,Finerenone Therapy for Pediatric HSPN With Mild Proteinuria,The Randomized Controlled Trial of Finerenone Therapy for Pediatric Hennoch Scholein Nephritis With Mild Proteinuria,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Children of HSPN meet the following conditions① Age \> 3 years old and \ = 8mg/h/M2 body surface area (or \>= 300mg/d), and \ = IV; 3. Application of glucocorticoids and/or immunosuppressants within 2 weeks; 4. Recent applications involving high-dose glucocorticoids administered for a duration exceeding two weeks.; 5. Liver transaminase \> 2 times the upper limit of normal; 6. Severe cardiac insufficiency; 7. Simultaneous use of CYPA4 inhibitors;-",3.0,18.0,['henoch schönlein purpura nephritis']
NCT06451991,The Effect of Concept Map Use in Nursing Practice,The Effect of Concept Map Use in Nursing Practice on Clinical Decision Making and Reflective Thinking Levels: A Randomized Controlled Study,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * To be taking surgical diseases nursing course * To agree to participate in the study Exclusion Criteria: * To have received training on concept mapping before the study * Not participating in the training given by the researchers before the study,18.0,65.0,"['student', 'educational problems']"
NCT04661891,Real-time Neuromuscular Control of Exoskeletons,Real-time Neuromuscular Control of Exoskeletons,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria for Healthy Participants: * Age from 18 to 80 years * No history of a brain and/or skull lesion * Normal hearing and vision, both can be corrected * Able to understand and give informed consent * No neurological disorders * Absence of pathology that could cause abnormal movements of extremities (e.g., * epilepsy, stroke, marked arthritis, chronic pain, musculoskeletal injuries) * Able to understand and speak English * Height between 3 foot 6 inches (1.1 meters) and 6 foot 9 inches (2.1 meters) Inclusion Criteria for Participants Post-stroke: * Age from 18 to 80 years * History of unilateral, supratentorial, ischemic or hemorrhage stroke greater than 6 months * Ability to walk independently on level ground, allowed to use assistive device or bracing * as needed * Medically stable * No planned surgeries, medical treatments or outpatient therapy during the study period * Normal hearing and vision, both can be corrected * Able to understand and give informed consent * Able to understand and speak English * Height between 3 foot 6 inches (1.1 meters) and 6 foot 9 inches (2.1 meters) Exclusion Criteria for Healthy Participants: * Weight over 220 lbs * Pregnancy (ruled out by pregnancy questionnaire) * Any neurological diagnoses or medications influencing brain function * History of significant head trauma (i.e., extended loss of consciousness, neurological * sequelae) * Known structural brain lesion * Significant other disease (heart disease, malignant tumors, mental disorders) * Non prescribed drug use (as reported by subject) * History of current substance abuse (exception: current nicotine use is allowed) * Recreational marijuana * Dementia; severe depression; or prior neurosurgical procedures * Failure to perform the behavioral or locomotor tasks * Prisoners Exclusion Criteria for Participants Post-Stroke: * Weight over 220 lbs * Pregnancy (ruled out by pregnancy questionnaire) * Botox (botulinum toxin) injection to lower limbs within the prior 3 months, or planned * injection during study period. * History of current substance abuse (exception: current nicotine use is allowed) * Reduced cognitive function * Severe aphasia * Prisoners * Co-existence of other neurological diseases (ex: (Parkinson's disease, traumatic brain * injury, multiple sclerosis, etc.) * Mixed or complex tremors * Severe hip, or knee arthritis * Osteoporosis (as reported by subject) * Medical (cardiac, renal, hepatic, oncological) or psychiatric disease that would * interfere with study procedures for HD-EMG",18.0,80.0,['stroke']
NCT04951791,Lipid Emulsion in Cardiac Valve Replacement Surgery,Effects of Lipid Emulsion on Myocardial Protection and Inflammatory Response in Cardiac Valve Replacement Surgery,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * patients undergoing rheumatic valve replacement surgery * elective surgery * age between 18 and 80 years old * left ventricular ejection fraction \> 0.4 Exclusion Criteria: * Emergency and Re do surgery, * Positive base line CTnI or CK-MB, * Preoperative treatment with intralipid in the last 1 month. * History of allergy to (peanut, eggs, and soya bean) * Implanted pacemaker, * previous myocardial infarction, * Diabetic or other metabolic disorders, * Significant Renal impairment (Cr \> 1.5) or on hemodialysis * Significant hepatic dysfunction (INR\>2) * Drugs interfere as (cyclosporine) * Infection (WBC \>12)",18.0,80.0,['ischemic reperfusion injury']
NCT03732391,Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA),A Phase II Study of Pembrolizumab Plus Carboplatin in BRCA-related Metastatic Breast Cancer,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Be willing and able to provide written informed consent/assent for the trial. 2. Be 18 years of age on day of signing informed consent. 3. Patients must have metastatic confirmed breast cancer 4. Disease progression by radiological techniques within 12 months prior to signing informed consent 5. Documented mutation in BRCA1 or BRCA2 genes that is predicted to be deleterious or suspected deleterious (unknown significance variants) 6. Have measurable disease based on RECIST 1.1. 7. Prior chemotherapy with anthracyclines and taxanes has to be administered in neoadjuvant or adjuvant setting. 8. Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen 9. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. 10. Life expectancy of greater than 3 months 11. Demonstrate adequate organ function. All screening labs should be performed within 10 days of treatment initiation. 12. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 13. Female subjects of childbearing potential must be willing to use an adequate method of contraception as outlined in Section 5.111.2 - Contraception, for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject. 14. Male subjects of childbearing potential must agree to use an adequate method of contraception as outlined in Section 5.11.2- Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject. Exclusion Criteria: 1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment. 2. Has a benign variant of BRCA1/2 genes 3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. 4. Has a known history of active Bacillus Tuberculosis 5. Hypersensitivity to pembrolizumab or any of its excipients. 6. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. 7. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. * Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study. * Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. 8. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. 9. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability. 10. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. 11. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis. 12. Has an active infection requiring systemic therapy. 13. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. 14. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 15. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment. 16. Has received prior therapy with an anti-PD-1 (anti-programmed cell Death-1), anti-PD-L1, or anti-PD-L2 agent. 17. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). 18. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV (Hepatitis C Virus) RNA \[qualitative\] is detected). 19. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed. \-",18.0,65.0,['metastatic breast cancer']
NCT04600791,BATwire Implant Kit,BATwire Implant Kit,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Age at least 21 years and no more than 80 years at the time of enrollment. 2. Appropriate candidate for the surgery as determined by an evaluation from the implanting physician using a carotid duplex ultrasound (CDU) and/or a computed tomography angiography (CTA), and a review of medical history (including existence of infections that may increase implant risk). Evaluation must confirm the following within 45 days of the Barostim implant (60 days allowed if a proctor is required): * Appropriate medical condition and medical history for implantation of the Barostim System AND * Anatomy that enables this implant procedure, with no vascular structures or orientations or neck anomalies that would be obstructive to the implantation path AND * The artery planned for the Barostim implant must have: * A carotid bifurcation below the level of the mandible AND * No ulcerative carotid arterial plaques AND * No carotid atherosclerosis producing a 30% or greater reduction in linear diameter in the internal carotid AND * No carotid atherosclerosis producing a 30% or greater reduction in linear diameter in the distal common carotid AND * Have had no prior surgery, radiation, or endovascular stent placement in the carotid artery or the carotid sinus region AND * Able to discontinue the use of antiplatelet drugs (e.g., aspirin) in advance of the procedure, if required. 3. Six-minute hall walk (6MHW) ≥ 150 m AND ≤ 400 m within 45 days prior to implant (60 days allowed if a proctor is required). 4. Serum estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m\^2 using the CKD-EPI method within 45 days prior to the Barostim implant (60 days allowed if a proctor is required). 5. Body mass index ≤ 40 kg/m\^2 within 45 days prior to the Barostim implant (60 days allowed if a proctor is required). 6. If female and of childbearing potential, must use a medically accepted method of birth control (e.g., barrier method with spermicide, oral contraceptive, or abstinence) and agree to continue use of this method for the duration of the study. Women of childbearing potential must have a negative pregnancy test within 14 days prior to the Barostim implant. 7. Subjects implanted with a cardiac rhythm management device that does not utilize an intracardiac lead, or implanted with a neurostimulation device, must be approved by the CVRx Clinical department. 8. At the end of screening and baseline, the subject still meets the Barostim Indication for Use 9. Signed a CVRx-approved informed consent form for participation in this study. Exclusion Criteria: 1. Received cardiac resynchronization therapy (CRT) within six months of enrollment, or is actively receiving CRT. 2. Any of the following contraindications: * Baroreflex failure or autonomic neuropathy * Uncontrolled, symptomatic cardiac bradyarrhythmias * Known allergy to silicone or titanium 3. Unstable ventricular arrhythmias. 4. Presence of baseline cranial nerve dysfunction at risk from cervical interventions on the carotid bifurcation determined by the Ear, Nose and Throat (ENT) examination. 5. Subjects with any surgery that has occurred, or is planned to occur, within 45 days of the Barostim implant. 6. Recent history (within 6 months of implant) of significant and uncontrolled bleeding. 7. Known and untreated hypercoagulability state. 8. An inappropriate study candidate as evidenced by: * Solid organ or hematologic transplant, or currently being evaluated for an organ transplant. * Has received or is receiving LVAD therapy or chronic dialysis. * Current or planned treatment with intravenous positive inotrope therapy. * Primary pulmonary hypertension. * Severe COPD or severe restrictive lung disease (e.g., requires chronic oral steroid use or home oxygen use). * Heart failure secondary to a reversible cause, such as cardiac structural valvular disease, acute myocarditis and pericardial constriction. * Clinically significant cardiac structural valvular disease. * Unable or unwilling to fulfill the protocol medication compliance and follow-up requirements, for reasons including but not limited to an unresolved history of alcohol or substance abuse or psychiatric disorder. * Active malignancy. * Any other serious medical condition that may adversely affect the safety of the participant or validity of the study, in the opinion of the investigator. * Life expectancy less than one year. 9. Any of the following within 3 months prior to the Barostim implant. * Myocardial infarction * Unstable angina * Percutaneous coronary intervention (e.g., CABG or PTCA) * Cerebral vascular accident or transient ischemic attack * Sudden cardiac death * Surgical cardiac intervention (e.g., cardiac ablation, valve replacement) 10. Enrolled and active in another (e.g., device, pharmaceutical, or biological) clinical study unless approved by the CVRx Clinical department.",21.0,80.0,['heart failure']
NCT05736991,Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma,Deep Learning Signature Based on PET-CT Images for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma,UNKNOWN,OBSERVATIONAL,ALL,Inclusion Criteria: (1) Participants scheduled for surgery for radiological finding of pulmonary lesions from the preoperative thin-section CT scans; (2) The maximum diameter of lesion less than 4 cm on CT scans; (3) The maximum short axis diameter of lymph nodes less than 1 cm on CT scan; (4) The SUVmax of hilar and mediastinal lymph nodes less than 2.5; (5) Pathological confirmation of primary lung adenocarcinoma; (5) Age ranging from 20-75 years; (6) Obtained written informed consent. Exclusion Criteria: (1) Multiple lung lesions; (2) Poor quality of PET-CT images; (3) Participants with incomplete clinical information; (4) Mucinous adenocarcinomas; (5) Participants who have received neoadjuvant therapy.,20.0,75.0,"['lung adenocarcinoma', 'radiomics', 'grading system']"
NCT03264391,Evaluation of Macular Vascular Changes in Behcet's Disease Using Optical Coherence Tomography Angiography,Evaluation of Macular Vascular Changes in Behcet's Disease Using Optical Coherence Tomography Angiography,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * • Patients diagnosed with Behcet's disease Exclusion Criteria: * • Patients less than 18 years old * Hazy media precluding clear fundus view. * Patients with very poor fixation.,18.0,65.0,"['retinal vasculitis', 'behcet syndrome']"
NCT02847091,Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy,"Post-marketing Clinical Study of Ipragliflozin; Multicenter, Open-label Study to Assess the Efficacy of Ipragliflozin Add-on in Reducing Insulin Dose in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * The subject has been receiving insulin therapy for the treatment of diabetes mellitus. * The subject has type 2 diabetes mellitus and has been receiving insulin monotherapy or insulin therapy in combination with one or two oral hypoglycemic agents. * The subject has not modified diet or exercise therapies or dosage regimen of oral hypoglycemic agents, or has not switched to another pharmacotherapy for 12 weeks before Visit 1. * The subject has an HbA1c value between 6.5% and \ 23.0 kg/m2. * If the subject is a female, she must satisfy the following criteria. The subject is not of childbearing potential and satisfies any of the following criteria. * The subject is post-menopausal (absence of menses for at least 1 year). * The subject is surgically sterile. The subject is of childbearing potential but satisfies all of the following criteria: * The subject agrees not to get pregnant to 28 days after the last dose of the study drug. * The subject has a negative pregnancy test. The subject agrees to use two of the established contraceptive methods listed below to 28 days after the last dose of the study drug when having heterosexual intercourse. * If the subject is a female, she must agree not to breastfeed to 28 days after the last dose of the study drug. * If the subject is a female, she must agree not to donate their eggs during the period from the assessment to 28 days after the last dose of the study drug. * In case a male subject's spouse or partner is of childbearing potential, the subject must agree to use two of the established contraceptive methods to 28 days after the last dose of the study drug. * If the subject is a male, he must agree not to donate their sperm to 28 days after the last dose of the study drug. Exclusion Criteria: * The subject has type 1 diabetes mellitus. * The subject has any symptom of dysuria, anuria, oliguria or urinary retention. * The subject has proliferative retinopathy. * The subject has diabetic ketoacidosis. * The subject has a history or complication of medically significant renal disease such as renovascular occlusive disease, nephrectomy and/or renal transplant. * The subject has a history of recurrent urinary tract infection. * The subject has symptomatic urinary tract infection or symptomatic genital infection. * The subject has chronic disease(s) that require the continuous use of corticosteroids, immunosuppressants, etc. * The subject has a history of cerebral vascular attack, unstable angina, myocardial infarction, vascular intervention, and serious heart disease within 1 year (52 weeks) before signing of the informed consent. * The subject has a complication or surgical history of serious gastrointestinal disorder. * The subject has severe hepatic dysfunction. * The subject has uncontrolled blood pressure. * The subject has unstable psychiatric disorder. * The subject has severe infection or serious trauma, or perioperative. * The subject has drug addiction or alcohol abuse. * The subject has a history of malignant tumors. * The subject has a history of an allergy to ipragliflozin and/or similar drugs (drugs possessing SGLT2 inhibitory action). * The subject has used SGLT2 inhibitors, GLP-1 receptor agonists, sulfonylureas (SU), glinide agents, or insulin products other than long-acting insulin within 12 weeks before signing of the informed consent.",20.0,74.0,['type 2 diabetes mellitus']
NCT00492791,Endoscopic Severity Score of Small Bowel Crohn's Disease With Wireless Capsule Endoscopy,Development and Validation of an Endoscopic Severity Score of Small Bowel Crohn's Disease With Wireless Capsule Endoscopy,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Patients older than 18 years. * Crohn's disease diagnosed on clinical, endoscopic, histological criteria. In active or inactive phase of their disease (HBI \> 4; CDAI \> 150). * The patients will belong to the one of the 4 groups defined above according to the examinations carried out during the follow-up of the disease. * Group 1: at least one ileal ulceration at ileocolonoscopy and no radiological abnormality * Group 2: nonsevere attack on radiological examinations with or without endoscopic lesion * Group 3: severe attack on radiological examinations with or without endoscopic lesion. * Group 4: no lesion neither in endoscopy nor on radiologic exams. * Small intestine standard exploration less than 1 year. * Affiliation with the social security or a mode of social protection. * able to understand and sign an informed consent. Exclusion Criteria: * ano-perineal location. * Occlusion or sub-occlusion chronicle or intermittent or if there are frank signs of dilation of small intestine on the morphological examinations. * Martial treatment since less than ten days before the realization of the capsule. * Non steroidal anti-inflammatory treatment since less than three months before the realization of the capsule. * Ileostomy on hail. * Pace-maker or another implantable device. * Swallowing troubles. * Non evacuation of the Patency capsule in the 48 hours. * Occlusion during the passage of the patency capsule. * pregnant woman.",18.0,65.0,"[""crohn's disease""]"
NCT00416091,Neuropsychological Functioning Among Children With Tourret's Disorder and ADHD,"Neuropsychological Functioning, Symptomatology, and Social Adjustment Among Children With Tourret's Disorder, Attention-Deficit/Hyperactivity Disorder, and Comorbid Conditions.",COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * patients aged 8-16 without the diagnosis of ADHD, and/or Tourette's disorder * IQ \> 80 * both children/adolescents and their parents consent to participate and have the ability to complete self-administered measures in this study Exclusion Criteria: * diagnosis of psychotic disorders, bipolar affective disorders, pervasive developmental disorder, seizure, or major physical disorders. * in addition, control subjects will be excluded from the control group if have a history of the following condition as defined by DSM-IV: ADHD, ODD, or CD in addition to the above exclusion criteria.",8.0,16.0,"['tourette disorder', 'attention-deficit/hyperactivity disorder']"
NCT04492891,Cyclosporine For The Treatment Of COVID-19(+),Randomized Phase IIa Clinical Trial Of Cyclosporine For The Treatment Of COVID-19(+) Non-ICU Hospital Inpatients,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 3.1.1 Laboratory-confirmed SARS-CoV-2 infection within the past 10 days. 3.1.2 Patients admitted to non-ICU hospital floors or in an emergency department awaiting admission to a non-ICU hospital bed. 3.1.3 WHO COVID Scale Score 4 (Oxygen by mask or nasal prongs or WHO COVID Scale Score 5 (non-invasive ventilation or high-flow oxygen). 3.1.4 Age 18 to 90 years old. 3.1.5 ECOG (Eastern Cooperative Oncology Group) performance status ≤2 (see Appendix A). 3.1.6 Patients receiving or who have received standard of care therapy for COVID-19 can be included. This includes Remdesivir, Dexamethasone (or other steroids), and convalescent plasma. 3.1.7 Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 3.2.1 Allergy and/or hypersensitivity to CSA. 3.2.2 GFR\ 3X upper limits of normal. 3.2.4 Resistant hypertension (BP\>140/90 mm Hg despite adherence to maximal doses of three antihypertensive agents). 3.2.5 Active bacterial or mycobacterial infection. 3.2.6 Pregnant and/or nursing patients. 3.2.7 Participation in a COVID-19 therapeutic drug trial. 3.2.8 Patients who have received or who are receiving anti-viral medications including hydroxychloroquine will not be excluded. 3.2.9 Patients with psychiatric illness/social situations that would limit compliance with study requirements. 3.2.10 Total cholesterol is \< 100 (increased risk of seizure) 3.2.11 Concomitant dosing with Tacrolimus is a relative contraindication (increases overall immunosuppression and decrease seizure threshold 3.2.12 Concomitant malignancy is a relative contraindication (Neoral can increase susceptibility to development of neoplasia) 3.2.13 Inability to swallow oral medication 3.2.14 Treatment with immunomodulators or immunosuppressant drugs, including but not limited to IL-6 inhibitors, TNF inhibitors, anti-IL-1 agents, and JAK inhibitors. 3.2.15 Investigational Antiviral agents",18.0,90.0,['sars (disease)']
NCT06150391,Evaluation of Amblyopia Protocols Using a Dichoptic Gabor Videogame Program,Randomized Controlled Trial of a Dichoptic Gabor Videogame Program to Improve Visual Function in Children With Amblyopia,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * The sample will be made up of children with amblyopia from 4 to 12 years old (amblyopia will be defined as the best corrected visual acuity less o equal to 0.8 in decimal units or \> 2 lines of difference between both eyes). Strabismus inclusion criteria will be \< 25 prismatic diopters, with a deviation ≥ 2 prismatic diopters. Exclusion Criteria: * Subjects with nystagmus, ocular pathology o cognitive delay will be excluded.",4.0,12.0,['amblyopia']
NCT01169974,Use of Laser Speckle to Study Post Occlusive Reactive Hyperhemia in Healthy Subjects,Evaluation Chez Des Sujets Volontaires Sains de l'ischémie-reperfusion cutanée,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * Healthy volunteers * Affiliation to the French health system Exclusion Criteria: * Any disease or chronic treatment,18.0,65.0,['microcirculation']
NCT02291874,"Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)",Postmarketing Clinical Study of Ipragliflozin - Long-term Study in Combination With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * The subject has a diagnosis of T2DM that was determined at least 12 weeks (84 days) before providing informed consent. * The subject has been receiving the same GLP-1 receptor agonist at a fixed dose and mode of administration for at least 6 weeks (42 days) prior to Visit 1. * If on therapy with a concomitant SU, the subject has been receiving the same SU at a fixed dose and mode of administration for at least 6 weeks (42 days) prior to Visit 1. * The subject has HbA1c levels of ≥7.5% but ≤10.5% at Visit 2, and the difference in HbA1c levels between Visit 1 and Visit 2 is within ±1.0%. * The subject has a BMI of ≥20.0 kg/m2 but ≤45.0 kg/m2 at Visit 2. * If on therapy with a concomitant SU, the subject has fasting plasma glucose levels of ≥126 mg/dL at Visit 2. Exclusion Criteria: * The subject has T1DM. * The subject has symptoms of dysuria, anuria, oliguria, or urinary retention. * The subject has proliferative retinopathy. * The subject has a history of clinically significant renal diseases such as renovascular occlusive disease, nephrectomy, or renal transplant. * The subject has a history of pancreatitis. * The subject has a history of recurrent urinary tract infections (≥3 episodes within 24 weeks before providing informed consent). * The subject has a symptomatic urinary tract infection or symptomatic genital infection. * The subject has a chronic disease that requires the continuous use of adrenocortical steroids and immunosuppressants (oral, injectable, or inhalational medications). * The subject has a history of cerebral vascular attack, unstable angina, myocardial infarction, vascular intervention, or serious heart disease (NYHA Class III-IV) within 1 year (52 weeks) prior to Visit 1, or the subject has heart disease or cerebral vascular disease that, as per the judgment of the investigator or sub-investigator, may interfere with the treatment with ipragliflozin or safety evaluation of this study. * The subject has an unstable psychiatric disorder. * The subject is a female who is currently pregnant or lactating or could be pregnant. * The subject is unable or unwilling to practice an appropriate contraception method during the study. * The subject has severe infection, perioperative or serious trauma. * The subject has drug addiction or abuses alcohol. * The subject has a history of malignant tumors (except when he/she has been free from treatment for at least 5 years before providing informed consent and is not considered to have any recurrence). * The subject has a history of allergy to ipragliflozin or similar drugs that have an SGLT2 inhibitory action. * The subject has participated in a clinical study of an investigational product or medical device or post-marketing study within 12 weeks (84 days) before providing informed consent or is currently participating in any of these studies. * The subject is unable or unwilling, or does not agree, to comply with the study requirements, including the hospital visits, dose instructions, and the subject's responsibilities.",20.0,65.0,['type 2 diabetes mellitus']
NCT04863274,Influence of Additional Physician's Consultations and Short Message Service (SMS) Reminders to Patient Compliance,The Program to Assess the Influence of Routing and In-depth Consultation of Patients With Cardiovascular Risk Factors on the Choice of Medicine and Treatment Compliance,COMPLETED,OBSERVATIONAL,ALL,"Inclusion criteria: Data on the following subjects is planned to be collected in the project: * Aged from 40 to 65 years inclusively * With a high (≥5%) cardiovascular risk measured by SCORE and low density lipoprotein (LDL) levels of ≥2,5 mmol/L, or with a very high (≥10%) cardiovascular risk measured by SCORE and LDL levels ≥1,8 mmol/L or With atherosclerotic stenosis of brachiocephalic arteries of \>50% in the absence of cerebrovascular disease Exclusion criteria: * No contraindications to statin treatment and not taking stating at study entry. * History of the following clinically significant events and conditions: (а) myocardial infarction (б) stroke (в) transient ischemic attack * Presence of the following diseases at the time of a statin administration: (а) ischemic heart disease (б) heart failure (в) peripheral artery atherosclerosis (г) atherosclerotic stenosis of brachiocephalic arteries with cerebrovascular disease . Subjects must give their consent for processing of their personal data for the purposes of this scientific project.",40.0,65.0,['lipid metabolism disorders']
NCT05371574,Clonidine Versus Tranexamic Acid in Reduction of Blood Loss,Premedication With Oral Clonidine Versus Intraoperative Intravenous Tranexamic Acid in Reduction of Blood Loss During Elective Cesarean Section in Abakaliki - a Randomized Control Trial,UNKNOWN,INTERVENTIONAL,FEMALE,"Inclusion Criteria: \- Participants for the study include consenting parturients with singleton pregnancy at 37-42 weeks gestational age,admitted for elective caesarean section. Exclusion Criteria: * Prior history of thromboembolism or bleeding disorder * Renal disease * Liver disease * Antepartum Hemorrhage * Intrauterine Growth restricted fetuses * Patient refusal",18.0,45.0,['blood loss']
NCT03166774,Support of the Sexual Health in Oncology,Support of the Sexual Health in Oncology,WITHDRAWN,OBSERVATIONAL,ALL,Inclusion Criteria: * all patient consulting in oncology service * age \> 18 years * accepting to participate Exclusion Criteria: * Age\< 18 years * Refusing to participate,18.0,65.0,"['oncology', 'sexual health']"
NCT01422174,Clinical Registry on Sudden Death Primary Prevention at Latin America,Clinical Registry on Sudden Death Primary Prevention at Latin America (rEgiStro Clinico en America Latina de Prevencion Primaria en muErte Subita),WITHDRAWN,OBSERVATIONAL,ALL,"Inclusion Criteria: * Patients that had Acute Myocardial Infarction (\>40 days post-AMI) documented with the presence of Q-wave or cardiac-specific enzymatic markers of myocardial necrosis (CK-MB/troponin), occurred within 3 years previous to enrollment / after June 2008. * Left Ventricular Ejection Fraction (LVEF) ≤40% post-revascularization (if no revascularization, measurement performed \ 40 days post-AMI and \>3 months post-revascularization -if applicable-). Exclusion Criteria: * Patient with an implanted ICD * \<18 years old * Pregnant or breast feeding women * Patients that are already participating in other Investigational Study or Registry * Non signed patient informed consent or refusal from patient's reference physician to patient participation * Patient inability to comply with protocol (assist to scheduled follow-ups), due to: residence displacement out of center's activity area; unstable geographical situation or at very long distance from the center; unstable medical and/or psychological condition * Cardiac transplanted (or in transplant waiting list) * Severe Heart Failure (or other co-morbidity: cancer, renal failure, etc.) * Life expectancy lower than 1 year",18.0,65.0,"['myocardial infarction', 'sudden death']"
NCT03749174,Radius Fracture Anesthesia and Rehabilitation (RADAR),Radius Fracture Anesthesia and Rehabilitation (RADAR),COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Understands native language * Cognitive intact * Fracture types AO 23..A and AO 23.C.1 * Operated within 18 days from initial trauma Exclusion Criteria: * Not fulfilling inclusion criterias * High energy trauma * Ligament injury,18.0,65.0,['radial fracture']
NCT01518374,Clinical Evaluation of Florbetapir F 18 (18F-AV-45),Clinical Evaluation of Florbetapir F 18 (18F-AV-45),COMPLETED,INTERVENTIONAL,ALL,"Subjects who meet all of the following criteria are eligible to enroll in this study: 1. Male or female subjects at least 18 years of age; 2. Subjects who sign an IRB approved informed consent prior to any study procedures. Where subjects are deemed incapable of informed consent, a legally authorized representative may provide consent, with the subject's documented assent; and 3. Subjects who in the opinion of the investigator can tolerate the PET scan procedures. Subjects will be excluded from enrollment if they: 1. Have clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances as indicated by history, which in the opinion of the investigator might pose a potential safety risk to the subject; 2. Have current clinically significant cardiovascular disease. Clinically significant cardiovascular disease usually includes one or more of the following: * cardiac surgery or myocardial infarction within the last 4 weeks; * unstable angina; * acute decompensated congestive heart failure or class IV heart failure; * current significant cardiac arrhythmia or conduction disturbance, particularly those resulting in ventricular fibrillation, or causing syncope, or near syncope; * uncontrolled high blood pressure; or * QTc \> 450 msec (by history or for patients with cardiac disease by screening evaluation in companion study) Before enrolling a patient with any of the above conditions, the investigator must have performed a cardiac evaluation and obtain permission from the sponsor. 3. Have a history of drug or alcohol abuse within the last year, or prior prolonged history of abuse; 4. Women of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception. Women of childbearing potential must not be pregnant (negative urine beta-hCG at the time of screening and negative urine beta-hCG on the day of imaging) or breastfeeding at screening. Women must avoid becoming pregnant, and must agree to refrain from sexual activity or to use reliable contraceptive methods for 24 hours following administration of Florbetapir F 18 Injection ( such as oral contraceptives for at least three months or an IUD for at least two months prior to the start of the screening visit, or various barrier methods, e.g., diaphragm or combination condom and spermicide); 5. Have a history of relevant severe drug allergy or hypersensitivity (Relevant severe drug allergies should be determined by the PI, and any questions about a subject's eligibility can be directed to Avid. If a subject has a history of severe drug allergies, it may be dangerous for them to participate in a study); 6. Are patients who have received an investigational medication under an FDA IND protocol within the last 30 days. Additionally, the time between the last dose of the previous experimental medication and enrollment (completion of screening assessments) must be at least equal to 5 times the terminal half-life of the previous experimental medication. Patients who have ever participated in an experimental study with an amyloid targeting therapy (e.g., immunotherapy, secretase inhibitor) may not be enrolled without prior sponsor approval unless it can be demonstrated that the patient received only placebo in the course of the trial; 7. Are patients with current clinically significant unstable medical comorbidities, as indicated by history or physical exam, that pose a potential safety risk to the subject. 8. Are patients who have received a radiopharmaceutical for imaging or therapy within the past 24 hours prior to the imaging session for this study. If another radiotracer is required in the companion protocol, patients may be able to receive a radiopharmaceutical for imaging or therapy within the 24 hours prior to the imaging session with prior sponsor approval and at the discretion of the investigator.; and 9. Are patients who, in the opinion of the investigator, are otherwise unsuitable for a study of this type. If at the time of enrollment subjects do not meet all eligibility criteria, the subjects may still be enrolled if documentation is provided demonstrating that the subject will meet all criteria at the time of the first imaging procedure.",18.0,65.0,"['alzheimer disease', 'mild cognitive impairment', 'neurodegenerative diseases']"
NCT05466474,PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma,"A Single-center, Open-arm, Single-arm Phase II Trial of the PD-1 Antibody Tirelizumab Plus Dacarbazine as First-line Treatment for Advanced Melanoma",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Male or female patients aged 18-72 years (inclusive); 2. patients with unresectable stage III or IV melanoma diagnosed histologically or cytologically; 3. According to the efficacy evaluation criteria for solid tumors (RECIST V1.1), there are lesions that can be used as target lesions for evaluation; 4. Prior adjuvant or neoadjuvant therapy must have been completed for at least 4 weeks prior to study drug administration, and all associated toxic effects (except hair loss) have been recovered (to ≤ class 1 or baseline) prior to study drug administration; 5. ECOG score was 0-1; 6. The expected survival time is more than 3 months; 7. No major surgery (except for baseline tumor biopsy) or severe trauma occurred at least 14 days prior to the first administration of study therapy; 8. Adequate organ and bone marrow function, as defined below: Blood routine (no blood transfusion, no G-CSF, no drug correction within 14 days prior to screening) Neutrophil count (ANC) ≥ 1,500/mm3 (1.5 × 109 /L); Platelet count (PLT) ≥ 100,000/mm3 (100 × 109 /L); Hemoglobin (Hb) ≥ 9 g/dL (90 g/L); Blood biochemical Serum creatinine (Cr) ≤ 1.5× upper limit of normal (ULN) or creatinine clearance Rate (Cockroft-Gault formula) ≥ 60 mL /min; Total bilirubin (TBIL) ≤ 1.5×ULN; Aspartate aminotransferase (AST) or ALT ≤2.5×ULN, Subjects with liver metastasis should be ≤5×ULN; Blood coagulation function International standardized ratio (INR) ≤1.5, prothrombin time (PT) and Activated partial thrombin time (APTT) ≤1.5×ULN; Routine urine urinary protein \ 38.5°C during screening/prior to initial administration. 9. Significant clinical bleeding symptoms or clear bleeding tendency occurred within 3 months before C1D1, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occultation blood ++ or above, vasculitis, etc.; Or arteriovenous thrombosis events occurring within 6 months prior to C1D1, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc.; Or long-term anticoagulant therapy with warfarin or heparin, or long-term antiplatelet therapy (aspirin ≥300mg/ day or clopidogrel ≥75mg/ day). 10. Active heart disease, including myocardial infarction, severe/unstable angina, etc., within 6 months before C1D1. Arrhythmias with poorly controlled left ventricular ejection fraction \ 450ms in men and \>470ms in women). 11. C1D1 has been diagnosed with any other malignancy within the previous 5 years, except for adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix. 12. known allergy to the study drug or any excipients thereof; Or severe allergic reactions to other monoclonal antibodies. 13. Human immunodeficiency virus (HIV) infection, active hepatitis B (hepatitis B surface antigen positive and HBV-DNA ≥500IU/ mL), hepatitis C (hepatitis C antibody positive and HCV-RNA higher than the detection limit of analysis method). 14. In the judgment of the investigator, there are concomitants (such as poorly controlled hypertension, severe diabetes, neurological or neurologic diseases, etc.) or any other conditions that seriously endanger the safety of the subjects, may confuse the results of the study, or may interfere with the completion of the study.",18.0,72.0,['advanced melanoma']
NCT03090074,Moderate or Extensive Carbohydrate Reduction in Risk Patients,To Lower Glucose Levels and Reduce Weight by Exclusion of Carbohydrates and Inclusion of Psychological Behavioral Support,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Diabetes without insulin. Patients at high risk for developing diabetes. Exclusion Criteria: * Severe kidney failure. Insulin therapy. Inability to understand instructions.,18.0,65.0,['glucose metabolism disorders']
NCT05444374,A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer,"A Single-Arm, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Patients With Untreated Recurrent or Metastatic Cervical Cancer",UNKNOWN,INTERVENTIONAL,FEMALE,"Inclusion Criteria: 1. Signed Informed Consent Form (ICF) 2. Women, age ≥ 18 years and ≤ 75 years at time of signing ICF 3. Histologically or cytologically confirmed cervical cancer (pathological types: squamous cell carcinoma, adenocarcinoma \[except mucinous adenocarcinoma\], adenosquamous carcinoma) 4. Recurrent, progressive, or metastatic cervical cancer that is not amenable to surgery or radiotherapy/chemoradiotherapy (other than palliative radiotherapy to bone lesions). Recurrent and metastatic lesions should provide cytological and/or pathological biopsy evidence of cervical cancer metastasis as far as possible. 5. No systemic anti-tumor treatment for this recurrent, progressive or metastatic tumor. Note: a. Patients with initially diagnosed stage IVb disease should not have received systemic anti-tumor treatment; b. For patients previously treated with platinum-based first-line (neoadjuvant) adjuvant chemotherapy/radical chemoradiotherapy, the time from the last chemotherapy to disease recurrence is \> 6 months; c. Patients treated with radiotherapy/concurrent chemoradiotherapy (only receiving platinum-based sensitization) can be enrolled after the completion of radiotherapy if they relapse outside the radiation field. If there is recurrence within the radiation field (RECIST 1.1 is met) and the target lesion is located in the radiation field, the patient can be enrolled more than 3 months after the completion of radiotherapy; d. For patients who have not received previous chemoradiotherapy, if chemoradiotherapy is required first (only platinum single agent sensitization is received), the patient can be enrolled more than 3 weeks after the completion of radiotherapy. 6. Prior anticancer TCM therapy must have ended ≥ 7 days prior to first study treatment (Cycle 1, Day 1) and all antineoplastic treatment-related AEs must have recovered to ≤ Grade 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) 5.0 (except Grade 2 alopecia). 7. At least one measurable target lesion as assessed by the investigator per RECIST 1.1 within 4 weeks prior to enrollment. Note: Measurable target lesions should not have received local therapy such as radiotherapy (for lesions located in previously irradiated areas, target lesions can also be selected in case of definite progression \[according to RECIST 1.1\]). 8. ECOG PS score of 0 or 1 within 7 days prior to enrollment. 9. Expected survival ≥ 12 weeks. 10. Hepatitis B surface antigen (HBsAg) (-) and hepatitis B core antibody (HBcAb) (-). Hepatitis B virus deoxyribonucleic acid (HBV-DNA) \ 1.5 × ULN (calculated according to Cockcroft-Gault formula) Coagulation function Activated partial thromboplastin time (APTT) ≤ 1.5 x ULN Prothrombin time (PT) or international normalized ratio (INR) ≤ 1.5 x ULN 13. Female patients must meet: i. Menopause (defined as no menses for at least 1 year and no other confirmed cause other than menopause), or ii. Have been surgically sterilized (removal of ovaries and/or uterus), or iii. Childbearing potential, but must meet: * Must have a negative serum pregnancy test within 7 days prior to randomization, and * Agree to practice contraception with an annual failure rate of \ 10 mg/day prednisone efficacy dose) or other immunosuppressive medications within 14 days prior to enrollment or during the study. However, patients were permitted to use topical or inhaled corticosteroids and adrenal glucocorticoid replacement at doses ≤ 10 mg/day prednisone for efficacy in the absence of active autoimmune disease. 14. Any active infection requiring systemic anti-infective therapy within 14 days prior to enrollment. 15. Major surgery within 28 days prior to enrollment, this study Major surgery is defined as surgery that requires at least 3 weeks of recovery from surgery to be able to receive treatment for this study. Patients with tumor aspirate or lymph node harvest biopsy were allowed to enroll. 16. The patient has previously received other antibodies/drugs against immune checkpoints, such as PD-1, PD-L1, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and other treatments. 17. Ongoing participation in another clinical study, or planned initiation of treatment in this study less than 14 days from the end of treatment in the previous clinical study. 18. Presence of free air in the abdomen that cannot be explained by puncture or recent surgical procedure. 19. Presence of bladder or rectal fistula at screening. 20. Acute intestinal obstruction or incomplete obstruction within 6 months. However, patients with complete response (CR) after surgical treatment may be enrolled. 21. Uncontrolled tumor-related pain. 22. Known history of serious allergy to any monoclonal antibody. 23. Known hypersensitivity to any of the cisplatin or paclitaxel components. 24. Pregnant or lactating women. 25. Patient has a known history of psychiatric drug abuse or drug abuse; patient has a history of alcohol abuse. 26. The patient has other factors that, in the judgment of the investigator, may lead to forced early termination of the study.",18.0,75.0,['cervical cancer']
NCT05407974,Pleurectomy Versus Pleural Abrasion in Patients With Spontaneous Pneumothorax,Pleurectomy Versus Pleural Abrasion in Patients With Spontaneous Pneumothorax,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * \- Patients presented with spontaneous pneumothorax; primary or secondary. * Age: all age groups are included * Approach: Video assisted thoracoscopic surgery Exclusion Criteria: * \- Refusal of procedure or participation in the study. * Patients with acquired pneumothorax (eg. Traumatic) * Patients with history of previous thoracic surgery on the same side of chest. * Approach: any open thoracotomy approach or switching from VATS to open thoracotomy,18.0,80.0,['pneumothorax']
NCT00103974,Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis,A Phase I Trial of Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Definite diagnosis of multiple sclerosis by the McDonald criteria. * Patients with relapsing remitting MS or secondary progressive MS are eligible. * 1-5 gadolinium enhancing (Gd+) lesions on the first Screening MRI or relapse in the previous 2 years, or disease worsening in the previous 2 years * Clinically stable for \> 1 month before screening evaluation and during screening. Patients who are stable on approved therapy are eligible only if they have intolerable side effects or other medical reasons for discontinuing approved therapy. * Off interferon for \> 1 month before screening evaluation. * Off immunosuppressive and cytotoxic therapy (e.g. mitoxantrone, cladrabine) \>12 months or \> 6 months with CD4 count \> 400. * EDSS ≥ 2.5 and \ 18 years. * Able to give informed consent. * WBC and platelets in normal range, hemoglobin \> 10.0 g/dl. * AST, ALT, bilirubin \ 500 mg methylprednisolone or equivalent) within previous month. * \>5 Gd+ lesions on the first Screening MRI. * Previous vaccine therapy, stem cell transplantation or total lymphoid radiation. * Glatiramer within previous 12 months. * Treatment with any statin in the previous 6 months or elevated cholesterol that requires treatment with a statin. * Pregnant or lactating women. * Unwilling to use a medically acceptable form of birth control. * History of positive test for HIV, hepatitis B or hepatitis C. * Clinically significant ECG abnormalities. * Medical condition or social circumstances that would in the opinion of the investigator prevent full participation in the trial or evaluation of study endpoints. * Implanted pacemakers, defibrillators or other metallic objects on or inside the body that limit performing MRI scans. * History of intolerable adverse events with statin therapy.",18.0,65.0,['multiple sclerosis']
NCT05797974,Does a Virtual Coach Offer a Better Solution for Weight Reduction in Ventral Hernia Patients With Obesity?,Does a Virtual Coach Offer a Better Solution for Weight Reduction in Ventral Hernia Patients With Obesity?,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Subjects between 18 and 90 years of age with a Body Mass Index (BMI) of 30 and above and diagnosed with Obesity by the ICD 10 Code: E66.9 who have been evaluated by a surgeon and offered elective ventral hernia repair. Also, participants must have a complete medical record that allows for all statistical calculations to be performed. Exclusion Criteria: * Pregnant females, patients with severe mental disorders, prescribed psychiatric medications associated with weight gain, a history of a Substance Use Disorder, patients on long-term steroid therapy, and patients with insufficient medical records.",18.0,90.0,"['obesity', 'ventral hernia']"
NCT02352974,GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1),"Open Label Pilot Trial in Adults With Recent-onset T1D to Evaluate the Safety, Diabetes Status and Immune Response of GAD-antigen (Diamyd®) Therapy Administered Into Lymph Nodes in Combination With an Oral Vitamin D Regimen",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Informed consent given by patients 2. Type 1 diabetes according to the ADA (American Diabetes Association) classification with \< 6 months diabetes duration 3. Age 12.00-29.99 years at diagnosis of Type 1 diabetes 4. Fasting C-peptide ≥0.12 nmol/L 5. Pos GADA(Antibodies to GAD with molecular mass 65,000) but \< 50 000 random units 6. Females must agree to avoid pregnancy and have a negative urine pregnancy test 7. Patients of childbearing potential must agree to using adequate contraception, until 1 year after the last administration of GAD-Alum. Exclusion Criteria: 1. Previous or current treatment with immunosuppressant therapy (although topical or inhaled steroids are accepted) 2. Continuous treatment with any inflammatory drug (sporadic treatment e.g. because of headache or in connection with fever a few days will be accepted) 3. Treatment with any oral or injected anti-diabetic medications other than insulin 4. Treatment with Vitamin D, marketed or not, or unwilling to abstain from such medication during the trial 5. A history of anaemia or significantly abnormal haematology results at screening 6. A history of epilepsy, head trauma or cerebro-vascular accident, or clinical features of continuous motor unit activity in proximal muscles 7. Clinically significant history of acute reaction to vaccines or other drugs in the past 8. Treatment with any vaccine, including influenza vaccine, within 4 months prior to planned first study drug dose or planned treatment with any vaccine up to 4 months after the last injection with study drug. 9. Participation in other clinical trials with a new chemical entity within the previous 3 months 10. Inability or unwillingness to comply with the provisions of this protocol 11. A history of alcohol or drug abuse 12. A significant illness other than diabetes within 2 weeks prior to first dosing 13. Known human immunodeficiency virus (HIV) or hepatitis 14. Females who are lactating or pregnant (the possibility of pregnancy must be excluded by urine βHCG (beta-human chorionic gonadotropin) on-site within 24 hours prior to the GAD-Alum treatment) 15. Males or females not willing to use adequate contraception until 1 year after the last GAD-Alum treatment 16. Presence of associated serious disease or condition, including active skin infections that preclude subcutaneous injection, which in the opinion of the investigator makes the patient non-eligible for the study 17. Deemed by the investigator not being able to follow instructions and/or follow the study protocol",12.0,30.0,"['diabetes mellitus, type 1']"
NCT04046874,Stratified Primary Care for Low Back Pain,Implementation of a Stratified Model of Care for Low Back Pain Patients in Primary Care Settings,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Clinical diagnosis of Low back Pain of any duration; * Age between 18 and 65 years; * Able to read and speak the Portuguese language. Exclusion Criteria: * Clinical signs of infection; * Clinical signs of tumor; * Clinical signs of osteoporosis; * Clinical signs of fracture; * Clinical signs of structural deformity; * Clinical signs of inflammatory disorder; * Clinical signs of radicular syndrome; * Clinical signs of cauda equine syndrome; * Clinical signs of severe depression or other psychiatric condition; * Pregnant women; * Patients that undergone a back surgery in the prior 6 months; * Patients that received any type of conservative treatment in the prior 3 months.,18.0,65.0,['low back pain']
NCT04782674,Study on the Application of Saliva EBV-DNA Detection in EBV Infection Related Diseases,A Prospective Study on the Application of Saliva EBV-DNA Detection in EBV Infection Related Diseases,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: 1. According to the HLH-04 diagnostic criteria, it meets the HLH diagnostic criteria. EBV infection occurs in cells with EBV-DNA copy number significantly increased in peripheral blood or tissue, or where EBV coding small RNA(EBER) is detected in tissue or peripheral blood. Or Straus' 1988 diagnostic criteria for CAEBV. 2. Informed consent Exclusion Criteria: 1. Patients who cannot cooperate with saliva collection 2. Patients who are unwilling to cooperate with the project research according to the project research plan.",3.0,65.0,['ebv infection']
NCT02021474,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis",Phase II Study to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Patients of any race, 18 to 65 years of age inclusive. 2. Patients with a history of migraine (with or without aura) according to the Headache Classification Committee of the IHS. Migraine attacks have to have had an onset before age 50 and have to have been present for at least 12 months. 3. Patients with 4-20 qualified migraine attacks per month over the past three months prior to Screening, as well as during the four weeks of the Baseline Phase will be eligible for entry into this study. The interval between two qualified migraine attacks should be at least 24 hours to be counted as distinct migraine attacks. A qualified migraine attack without aura is defined as a headache that lasts 4-72 hours (if untreated or unsuccessfully treated) or if successfully treated. This attack has at least two of the following characteristics: unilateral location, pulsating quality, moderate or severe intensity that inhibits or prohibits daily activities or aggravation by routine physical activities such as walking up stairs. In addition, at least one of the following symptoms must be present during the headache: nausea, vomiting, or photophobia and phonophobia. A qualified migraine attack with aura must fulfill the same criteria as the headache attack, plus have an associated aura as defined by the Migraine Criteria of the Headache Classification Committee of the International Headache Society. An aura alone that requires acute migraine treatment will also be considered a migraine attack. 4. Male and female patients will be eligible for enrollment. Females should be either of non-childbearing potential by reason of surgery, radiation, menopause (one year post onset), or of childbearing potential and practicing a medically acceptable method of contraception (eg, abstinence, a barrier method plus spermicide, or IUD) for at least one month before study randomization and for two months after the end of the study, and have a negative serum B-hCG at Screening. Pregnant and/or lactating females are excluded. Those women using hormonal contraceptives must also be using an additional approved method of contraception (eg, a barrier method plus spermicide, or IUD) starting with the Baseline Phase and continuing throughout the entire study period. 5. Patients who are willing to participate and have provided written informed consent prior to being exposed to any study-related procedures. Exclusion Criteria: 1. Patients with chronic daily headaches as defined by more than 20 headache days per month on average during the three months prior to Screening, 2. Patients with cluster headaches and other trigeminal autonomic cephalalgias, and other primary headaches (except tension-type headache) and secondary headaches (defined according to the Headache Classification Committee of the IHS 2004), 3. Patients with a history of being non-responsive to more than two classes of adequately conducted, prophylactic migraine treatments (e.g., beta blockers, calcium channel blockers, tricyclics, MAOIs, valproate (divalproex), topiramate, gabapentin), 4. Patients who use the following medications as described: * Use of marketed triptans for 12 days or greater per month on average, * Use of ergot-containing medications for 12 days or greater per month on average, * Use of NSAIDs, acetaminophen, or isometheptene-containing agents for 15 days or greater per month on average, * Use of opioids for 12 days or greater per month on average, ￼ - Use of any two or more of the above medications for 15 days or greater per month on average, 5. Patients with clinically significant neurological illness, other than migraine, that, in the opinion of the Investigators, may have the potential of altering pain perception or reporting, 6. Patients with a history of or currently having major psychiatric disorders including schizophrenia, major depressive disorder, or bipolar disorder, 7. Patients with elevations of liver enzymes, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) \>= 1.5 times the upper limit of normal (ULN), 8. Patients with evidence of significant active hematological disease; White blood cell (WBC) count cannot be \ = 450 msec for males and \>= 470 msec for females, 10. Patients with clinically significant active hepatic disease, cardiovascular, metabolic, respiratory, renal, endocrinological, gastrointestinal diseases, and bacterial or viral infections within 30 days prior to Screening or during the Baseline Phase, 11. Pregnant or lactating females 12. History of transmeridian travel (across \>3 time zones) or shift work (defined as permanent night shift or rotating day/night shift work) within the past 2 weeks or anticipates needing to travel (across \>3 time zones) at any time during the study.",18.0,65.0,['migraine prophylaxis']
NCT01002274,Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms,"Open-Label, 40-weeks Extension of Protocol MCS-2-TWN-a to Further Evaluate the Efficacy and Safety of MCS-2 for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects",COMPLETED,INTERVENTIONAL,MALE,Inclusion Criteria: * Subject has completed 12 weeks of treatment under the protocol MCS-2-TWN-a. * Subject is able to understand and willing to conform to the study procedures and has signed the informed consent form for participation in this extension study. Exclusion Criteria: * Subject has severe LUTS at the last visit under the protocol MCS-2-TWN-a. * Subject is considered ineligible for the study by the investigator(s).,40.0,65.0,"['lower urinary tract symptoms', 'benign prostatic hyperplasia']"
NCT01299974,Project PARIS: Parents and Residents in Session,Project PARIS: Parents and Residents in Session,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Residents in good standing in a pediatric residency at Mount Sinai Medical * Center who agree to participate in the study Exclusion Criteria: * Residents who did not agree to participate * Residents who have less than 3 months to complete their residency,18.0,65.0,['family-centered care']
NCT06414174,Comparison Between Split Septum and Mechanical Valve Needleless Connector in Preterm Babies,Comparison Between Split Septum and Mechanical Valve Needleless Connector in Preventing Central Line-Associated Bloodstream Infections in Very Preterm Babies or Birth Weight <1500 Grams at Cipto Mangunkusumo Hospital Neonatology Unit,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Preterm neonates with gestational age less than and equal to 32 weeks * Birth weight less than 1500 gram * Neonates indicated to use central line access * Parents are willing to participate in this study and has filled and signed the informed consent letter Exclusion Criteria: * Neonates who are previously diagnosed as CLABSI * Neonates who has other focus of infection that are diagnosed before the recruitment * Suffer from congenital abnormalities,28.0,32.0,"['sepsis, neonatal']"
NCT06663774,Development of a Judo Specific Reactive Agility Test: a Reliability and Validity Study,Development of a Judo Specific Reactive Agility Test: a Reliability and Validity Study,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Active judo training of minimum 300 minutes in a week. * At least 3 years of Judo experiance * No acute injury or illness that prevents judo training * No use of drug or medicine that can/may affect noromusculer control Exclusion Criteria: * Major trauma in 6 months prior to study * Judokas that can't complete the test properly,18.0,45.0,"['validation study', 'athletic performance']"
NCT06748274,The Brain-Heart-Gut Connection,The Brain-heart-gut Connection (BHG-CONNECT): Targeting the Frontal-vagal Pathway to Personalize Noninvasive Brain Stimulation,RECRUITING,INTERVENTIONAL,ALL,"In study arm 1, all participants are healthy between 18 and 65 years of age, and able to give written informed consent. In study arm 2, all participants must be between 18 and 65 years of age and additionally fulfill the following criteria: * Elevated autonomic symptom score (\> 20) on the Composite Autonomic Symptom Score * Depressive symptoms indicated by an elevated score (\>5) in the Patient Health Care Questionnaire (PHQ-9?) or elevated scores (\>9) in the Depression Anxiety and Stress Scale (DASS). * Elevated Score on Selected questions of the Subchapter ""symptoms in the Stomach or Intestines"" of the ""Rome IV Diagnostic Questionnaire for Adult Functional Gastrointestinal Disorders (Drossman, D. A. (Ed.). (2016). Rome IV: Functional Gastrointestinal Disorders - Disorders of Gut-Brain Interaction (4th ed.). Rome Foundation) For both arms, the following criteria must be fulfilled: * Normal or corrected-to-normal vision and hearing. * Willingness to participate and signed informed consent * No Medication with cognitive side effects (e.g. psychoactive medications or sleeping pills) or medication affecting gastric motility * No ectopic heartbeat * No history of epilepsy or seizure * No metal implants or devices (e.g. cardiac pacemakers) * No substance abuse or recent drug consumption * No pregnancy * No history of brain- heart- or gastrointestinal surgery * No skin conditions * BMI \<30",18.0,65.0,"['major depression', 'functional dyspepsia', 'autonomous dysfunction']"
NCT03906474,VAC063C: A Study to Assess Repeat Blood-stage P. Falciparum Infection,"A Clinical Study to Assess the Safety of Primary, Secondary and Tertiary Blood-stage Controlled Human Plasmodium Falciparum Malaria Infection of Healthy Malaria-naïve UK Adults, and to Characterise Parasite Growth Dynamics",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Healthy adults aged 18 to 50 years. * Able and willing (in the Investigator's opinion) to comply with all study requirements. * Willing to allow the Investigators to discuss the volunteer's medical history with their General Practitioner (GP). * For females only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and on the day prior to blood-stage CHMI, and prior to the start of antimalarial treatment. * Provide written informed consent. * Agreement to permanently refrain from blood donation, as per current UK Blood Transfusion and Tissue Transplantation Services guidelines. * Reachable (24 hours a day) by mobile phone during the period between CHMI and completion of antimalarial treatment. * Willingness to take a curative anti-malarial regimen following CHMI. * Answer all questions on the informed consent questionnaire correctly. * For Groups 1-2: completion of primary or secondary challenge in the VAC063 trial, curative anti-malarials and follow-up (up until at least the C+28 visit). Exclusion Criteria: * Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period. * Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data, as assessed by the Investigator. * Administration of immunoglobulins and/or any blood products at any time in the past. * Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed). * Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab). * History of malaria chemoprophylaxis within 30 days prior to CHMI. * Use of systemic antibiotics with known antimalarial activity within 30 days of CHMI (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and azithromycin). * History of allergic disease or reactions likely to be exacerbated by malaria infection. * Pregnancy, lactation or willingness/intention to become pregnant during the study. * History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ). * History of serious psychiatric condition likely to affect participation in the study. * Any other serious chronic illness requiring hospital specialist supervision. * Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 25 units every week. * Suspected or known injecting drug abuse in the 5 years preceding enrolment. * Seropositive for hepatitis B surface antigen (HBsAg) at screening. * Seropositive for HIV virus (antibodies to HIV) at screening * Seropositive for hepatitis C virus (antibodies to HCV) at screening (unless has taken part in a prior hepatitis C vaccine study with confirmed negative HCV antibodies prior to participation in that study, and negative HCV RNA PCR at screening for this study). * History of clinical malaria (any species - NOT applicable to prior challenge in VAC063 study for Groups 1 and 2). * Travel to a malaria endemic region during the study period or within the previous six months. * Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis. * Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data. Inability of the study team to contact the volunteer's GP to confirm medical history to allow Investigator to assess safety to participate. * History of sickle cell anaemia, sickle cell trait, thalassaemia or thalassaemia trait or any haematological condition that could affect susceptibility to malaria infection. * Laboratory evidence of G6PD deficiency at screening. * Laboratory evidence of haemoglobinopathy at screening. * Use of medications known to cause prolongation of the QT interval and existing contraindication to the use of Malarone. * Use of medications known to have a potentially clinically significant interaction with Riamet and Malarone. * Contraindications to the use of both Riamet and Malarone. * Any clinical condition known to prolong the QT interval. * Family history of congenital QT prolongation or sudden death. * Positive family history in both 1st and 2nd degree relatives \< 50 years old for cardiac disease. * History of cardiac arrhythmia, including clinically relevant bradycardia. * Volunteer unable to be closely followed for social, geographic or psychological reasons.",18.0,50.0,['malaria']
NCT01398774,Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a,Altered Resting Energy Expenditure as a Cause of Obesity in Pseudohypoparathyroidism 1a: A Pilot Study,TERMINATED,OBSERVATIONAL,ALL,Inclusion Criteria: * Diagnosis of pseudohypoparathyroidism 1a * Any body weight Exclusion Criteria: * Absence of above diagnosis,5.0,45.0,"['pseudohypoparathyroidism type 1a', 'albright hereditary osteodystrophy']"
NCT02723318,The Impact of Family Financial Support on Cognition,The Impact of Family Financial Support on Cognition,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Participants will be included if they are caregivers/parents of one or more dependents, have some form of income, and have a tax identification number. Exclusion Criteria: * Inability to take part in financial coaching due to disability or primary language other than English or Spanish.",18.0,65.0,['impaired cognition']
NCT07114718,Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study,Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Parental or legal authorized representative provide consent for study enrollment 2. Infants \< 6 months of age 3. Diagnosis of congenital heart defect with ductal-dependent pulmonary circulation requiring infusion of prostaglandins 4. Requires ductus arteriosus stent diameters of 3.5mm or 4mm and stent lengths between 16mm and 28mm Exclusion Criteria: 1. Active blood stream infection 2. Active or history of endocarditis 3. Body weight \<2.5kg 4. Gestational age \<32 weeks at birth 5. Complete heart block 6. Total Anomalous Pulmonary Venous Return 7. Anatomic variation judged to be inappropriate for ductal stenting per the treating interventionalist 8. Presence of an aortopulmonary collateral that is expected to require unifocalization 9. Non-confluent pulmonary arteries (i.e. isolated pulmonary artery of ductal origin) or bilateral patent ductus arteriosus (PDA) 10. Pulmonary atresia with intact ventricular septum with RV-dependent coronary circulation 11. Currently participating in an investigational drug study or another device study that would confound the study results 12. Patient who is on extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), or dialysis prior to ductal stenting procedure 13. Major co-morbidities which, in the opinion of the investigator, would negatively alter expected 1-year survival (e.g., intracranial hemorrhage, renal failure, etc.) 14. Patient who is undergoing another transcatheter procedure (e.g., atrial septostomy, aortic arch intervention, or right ventricular outflow tract intervention) during or within 24 hours prior to the ductus arteriosus stenting procedure 15. Patient who, at the time of enrollment, is deemed not to be a candidate for eventual stage II palliation of single ventricle heart disease, complete surgical repair, nor transcatheter treatment with resultant biventricular circulation 16. Patient who does not plan to return to the enrolling center or another participating center for stage II palliation, complete surgical repair, or definitive catheterization procedure 17. Contraindications to peri-procedural anticoagulation 18. Known to be non-responsive to aspirin or other antiplatelet therapies 19. Known hypersensitivity or allergy to Nickel 20. Known hypersensitivity to contrast media that cannot be adequately pre-medicated",0.0,6.0,"['congenital heart disease', 'congenital heart disease (chd)']"
NCT01262118,"Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis","An Exploratory Phase 1, Fixed Sequence, Open-Label Study To Assess The Effects Of CP-690,550 On The Kinetics Of Cholesterol Flux Through The High Density Lipoprotein/Reverse Cholesterol Transport Pathway In Patients With Active Rheumatoid Arthritis",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Males or females, 18 years of age or older with active rheumatoid arthritis; Or male and female healthy volunteers 18 years of age and older Exclusion Criteria: * Pregnant or lactating women * Clinically significant systemic disease (other than RA for RA arm) * Use of lipid-regulating agents",18.0,65.0,['rheumatoid arthritis']
NCT03517618,TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC,A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. histologically or cytologically confirmed colorectal adenocarcinoma; 2. metastatic and unresectable disease; 3. presence of at least one measurable tumor lesion which is defined as lesion that can be measured in at least one dimension (longest diameter) with a minimum size of: 1. 10mm by CT scan and MRI (no less than double the slice thickness and a minimum of 10mm); 2. 20mm by conventional techniques; 4. previously treatment to 1. fluoropyrimidine, oxaliplatin and irinotecan; 2. at least one targeted therapy 5. adequate hematopoietic function which is defined as below: 1. hemoglobin ≥ 9 g/dL; 2. absolute neutrophil count (ANC) ≥ 1,500/mm3; 3. platelet count ≥ 100,000/mm3; 6. adequate hepatic function which is defined as below: 1. total bilirubin ≤ 2 times upper limit of normal (ULN); 2. hepatic transaminases (ALT and AST) ≤ 3 x ULN. If there are known liver metastases, ALT or AST must be ≤ 5 x ULN; 7. adequate renal function which is defined as below: a. serum creatinine ≤ 1.5 x ULN; 8. age of 20 years or above; 9. ECOG performance status 0-2; 10. life expectancy of at least 12 weeks; 11. ability to take oral medication; 12. ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: 1. history or known presence of brain metastasis; 2. presence of mental disease or psychotic manifestation; 3. significant medical conditions that is contraindicated to study medication or render patient at high risk from treatment complications based on investigator's discretion; 4. presence of diarrhea ≥ grade 2 in common terminology criteria for adverse event version 4.0 (CTCAE v4.0); 5. other malignancy within the past 5 years (different site or histology) except for adequately treated basal or squamous cell skin cancer or cervical cancer in situ; 6. recent (within 30 days prior to study treatment) treatment of another investigational drug; 7. pregnant women or nursing mothers, or positive pregnancy test for women of childbearing potential. Patients with childbearing potential should have effective contraception for both the patient and his or her partner during the study.",20.0,65.0,['metastatic colorectal cancer']
NCT06233318,Sternotomy PIFB Block in Open Heart Surgery,"Efficacy of Bilateral Pecto-Intercostal Fascial Plane Block on Postoperative Pain in Adult Patients Undergoing Open Heart Surgery: a Randomized, Double-blind, Controlled Trial",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Adult male or female patients aged \> 18 * Undergoing primary cardiac surgery requiring sternotomy * Able to provide a signed written informed consent * Able to speak, read, and write in English * American Society of Anesthesiologists (ASA) physical status I-IV Exclusion Criteria: * Any documented cognitive or psychological disorders that, in the opinion of the principal investigator, can interfere with the patients' pain perception * Diabetes Mellitus with documented neuropathic pain * Vulnerable populations: pregnant females, prisoners, breast feeding * Contraindication to nerve block: local infections, bleeding disorders, chest wall deformity, allergy to local anesthetic or dexamethasone * Previous cardiac surgery * Previous history of chronic pain diseases requiring consistent analgesic therapy for at least 1 month prior to surgery * Presence of any medical condition that, in the opinion of the principal investigator, should exclude the patient from the study * BMI ≥ 40 kg/m2",18.0,65.0,['autonomic nerve block']
NCT04474418,Psychometric Characterization of Patients With Cardiac Arrhythmias,Be-PART: Berlin Psychometric Characterization of Patients With Cardiac ARrhyThmias,UNKNOWN,OBSERVATIONAL,ALL,Inclusion Criteria: * Age of majority (min. 18 years old) * no severe cognitive dysfunction * diagnosed cardiac arrhythmias * reason of admission is the treatment of cardiac arrhythmia Exclusion Criteria: * medium to severe cognitive dysfunction * doubt on capacity to give consent,18.0,65.0,"['cardiac arrhythmia', 'anxiety', 'personality', 'psychological stress', 'depression']"
NCT05258318,Double Rewire Versus Double Kissing Crush Stenting Technique in Left Main Bifurcation Lesions,Double Rewire Versus Double Kissing Crush Stenting Technique in Left Main Bifurcation Lesions,WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients between 18-90 years of age. * Patients who gave written informed consent for participation in the trial. * Lesions are eligible for percutaneous coronary intervention (PCI). * Patient has stable/unstable angina or myocardial infarction (MI): all-comers. * ULMb (Medina 1,1,1) with/without left main ostial/shaft lesions. Downstream lesions in LAD or LCX could be covered by two stents. Severe calcification needing rotational atherectomy, orbital atherectomy or Laser are included. * Diameter stenosis in LAD/LM and LCX ≥ 50% by visual estimation or minimal luminal area by IVUS in LM ≤6 mm2. Exclusion Criteria: * Restenotic lesions. * Patient was allergic to the study stent or protocol-required concomitant medications. * Patient is intolerable to dual anti-platelet therapy. * Patient has any other serious medical illness that may reduce life expectancy to \<12 months. * Patient is a woman who is pregnant or nursing. * Patient has a planned procedure that may cause non-compliance with the protocol or confound data interpretation. * Patient is participating in another clinical trial. * Patients in shock.",18.0,65.0,['coronary artery disease']
NCT04656418,CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy and Safety of Subcutaneous Administration of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Male or female ≥ 12 years of age; diagnosed with clinically confirmed C1-INH hereditary angioedema; experience ≥ 3 attacks during the 3 months before screening. Note: For subjects taking any prophylactic HAE therapy during the 3 months before Screening, ≥ 3 HAE attacks may be documented over 3 consecutive months before commencing the prophylactic therapy. Exclusion Criteria: * Concomitant diagnosis of another form of angioedema such as idiopathic or acquired angioedema, recurrent angioedema associated with urticarial or hereditary angioedema type 3",12.0,65.0,['hereditary angioedema']
NCT02216318,Energy-efficient and Health Promoting Light for Elderly People,A Study of Two Different Light Conditions for Healthy Subjects Above 65 Years,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * age 65 to 85 years Exclusion Criteria: * Conditions which will interfere by the primary endpoint as evaluated by the medical doctor,65.0,85.0,['sleep']
NCT00609518,A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer,Pemetrexed With Simplified Folate and Dexamethasone Supplementation Versus Pemetrexed With Standard Supplementation as Second-line Chemotherapy for Patients With Non-squamous Non-small Cell Lung Cancer,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Histologic or cytologic diagnosis of non-small cell lung cancer (NSCLC) with locally advanced or metastatic disease (Stage IIIA, IIIB or IV)that is of non-squamous histology * Patients must have failed only one prior chemotherapy regime and must be considered eligible for further chemotherapy following progression of their disease. * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 * Adequate organ function Exclusion Criteria: * Concurrent administration of any other anti-tumor therapy * Other co-existing malignancies * Pregnancy or breast feeding * Serious concomitant disorders * Inability or unwillingness to take folic acid or vitamin B12 supplementation",18.0,65.0,['non small cell lung cancer']
NCT07025018,Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations,"A Multicenter, Randomized Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of HMPL-306 in Patients With Gliomas Harboring IDH1 and/or IDH2 Mutations",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Fully informed about the study and voluntarily sign the informed consent form (ICF). 2. Age ≥ 18 years. 3. Safety Lead-In Phase: Patients with gliomas of a documented IDH1 and/or IDH2 mutation. Perioperative Study Phase: Patients with gliomas of definitive or suspected IDH1 and/or IDH2 mutations scheduled for surgery. 4. All patients must have at least one measurable lesion. 5. Karnofsky Performance Status (KPS) score ≥ 80% . 6. In the investigator's judgment, a life expectancy of ≥ 12 weeks. 7. Sufficient bone marrow and organ function. Exclusion Criteria: 1. Previous treatment with IDH inhibitors. 2. Unresolved toxicity from previous antitumor treatments not reverted to ≤ Grade 1 (except for alopecia, skin pigmentation changes, and ≤ Grade 2 peripheral neuropathy). 3. Patients assessed by researchers to have high-risk or unstable conditions. 4. Having other malignancies or a history of other malignancies within 5 years prior to screening. 5. History of clinically significant liver disease, including active infection with viral hepatitis, or other active hepatitis, alcoholic liver disease, cirrhosis, etc. 6. Patients with HIV infection. 7. Pregnancy (positive pregnancy test before dosing) or currently breastfeeding women. 8. Presence of diseases or conditions affecting drug absorption. 9. Any other conditions, in the investigator's judgment, unsuitable for the study drug, will result in exclusion.",18.0,65.0,['gliomas harboring idh1 and/or idh2 mutations']
NCT05461118,Osteotomy Accuracy Using Mixed Reality Assisted Navigation,Osteotomy Accuracy Using Mixed Reality Assisted Navigation,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Male or female aged 16 years and older * Has a benign or malignant mandibular or maxillary pathology who will require resection and who will undergo immediate reconstruction * Consents to have resective and reconstructive procedures completed with the aid of mixed reality assisted navigation. Exclusion Criteria: 1. Presence of acute infection at the time of surgery 2. Not able to speak in English or illiterate or lacking the decision-making capacity to consent for study. 3. Pregnant women because elective surgery is usually delayed until after delivery to avoid risks and complications associated with anesthetics,16.0,65.0,['osteotomy']
NCT03892018,The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol,"An Open-label, Crossover Study of the Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Signed written informed consent * Histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. * Measurable disease as per RECIST v1.1 criteria * Adequate hematologic status * Adequate liver function. * Adequate renal function * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Life expectancy of at least 3 months. * Women must be postmenopausal or surgically sterile. * Sexually active male subjects must use a barrier method of contraception during the study. * Able to consume the prescribed meals Exclusion Criteria: * Have not recovered to ≤ Grade 1 toxicity from previous anticancer treatments or previous investigational products (IPs). * Received IPs within 21 days or 5 half-lives of the first dosing day, whichever is shorter * Are currently receiving other medications or radiation intended for the treatment of their malignancy. Hormonal therapy is allowed. * Women of childbearing potential who are pregnant or breastfeeding. * Currently taking a concomitant medication, other than a premedication, that is: * A strong P-glycoprotein (P-gp) inhibitor or inducer. * An oral medication with a narrow therapeutic index known to be a P-gp substrate. * Medications known to be strong inhibitors or inducers of cytochrome P450 (CYP) 2C8 or medications known to be strong CYP3A4 inhibitors or inducers. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or any concomitant illness that would limit compliance with study requirements. * Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease that may interfere with oral drug absorption. * Cirrhosis of the liver or known active hepatitis B, hepatitis C, or HIV * History of hypersensitivity to paclitaxel, not attributed to a hypersensitivity-type reaction to Cremophor",18.0,65.0,"['solid tumor, adult']"
NCT02072018,Peyronie's Disease Treatment Protocol,"A Sequential, Randomized, Double-blind, Placebo-controlled, Prospective Study to Evaluate the Safety and Efficacy of the H-100 Treatment in Adult Male Volunteers With Peyronie's Disease",COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: 1. Have symptom(s) of Peyronie's disease (pain, curvature or plaque) 2. Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile 3. Voluntarily sign and date an informed consent agreement approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC). The subject must also sign an authorization form to allow disclosure of his protected health information (PHI). The PHI authorization form and informed consent form may be an integrated form or may be separate forms depending on the institution 4. Be able to read, complete and understand the informed consent and various rating instruments in English Exclusion Criteria: 1. Inability to understand study goals and risks 2. Inability to understand the informed consent 3. Inability to achieve erection with or without PDE5 inhibitor use adequate for penetration if penile curvature is not a limiting factor 4. Peyronie's disease symptoms greater than one year duration 5. Chordee in the presence or absence of hypospadias Thrombosis of the dorsal penile artery or vein Infiltration by a benign or malignant mass resulting in penile curvature Infiltration by an infectious agent, such as lymphogranuloma venereum Ventral curvature from any cause Presence of an active sexually transmitted disease Known active hepatitis B or C Known immune deficiency disease or be positive for human immunodeficiency virus (HIV) 6. Has previously undergone surgery for Peyronie's disease 7. Fails to have an erection which in the opinion of the investigator is sufficient to accurately measure the subject's penile deformity 8. Has an isolated hourglass deformity of the penis (curvature caused by a plaque that is noncontiguous with the hourglass deformity may be treated) 9. Has the plaque causing curvature of the penis located proximal to the base of the penis 10. Has previously received alternative medical therapies for Peyronie's disease administered by the intralesional route (including, but not limited to, steroids, verapamil, and the naturally occurring low molecular weight protein, interferon-α2b) within 3 months before the first dose of study drug or plans to use any of these medical therapies at any time during the study 11. Has received alternative medical therapies for Peyronie's disease administered by the oral (including, but not limited to, vitamin E \[\>500 U\], potassium aminobenzoate \[Potaba\], tamoxifen, colchicine, pentoxifylline, over-the-counter erectile dysfunction medications, or steroidal anti-inflammatory drugs) or topical routes (including, but not limited to, verapamil applied as a cream) within 3 months before the first dose of study drug or plans to use any of these medical therapies at any time during the study 12. Has had extracorporeal shock wave therapy (ESWT) for the correction of Peyronie's disease within the 6- month period before screening or plans to have ESWT at any time during the study 13. Has used any mechanical type device for correction of Peyronie's disease within the 2-week period before screening or plans to use any these devices at any time during the study 14. Has used a mechanical device to induce a passive erection within the 2-week period before screening or plans to use any of these devices at any time during the study 15. Has significant erectile dysfunction that has failed to respond to oral treatment with phosphodiesterase type 5 (PDE5) inhibitors 16. Has uncontrolled hypertension, as determined by the investigator 17. Has a known recent history of stroke, bleeding, or other significant medical condition, which in the investigator's opinion would make the subject unsuitable for enrollment in the study 18. Is unwilling or unable to cooperate with the requirements of the study including completion of all scheduled study visits 19. Has received an investigational drug or treatment within 30 days before the first dose of study drug 20. Has a known systemic allergy to any H-100 component 21. Has received any collagenase treatments within 30 days of the first dose of study drug",18.0,70.0,"[""peyronie's disease""]"
NCT06362018,Bioavailability of Five Mitopure Formulations,"A Comparative Pharmacokinetic Profiles of Five Urolithin A Formulations in Healthy Volunteers: A Randomized, Open-label, Single-dose, Parallel-arm Study",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Healthy male and female participants aged between 18 and 45 years (both inclusive); 2. Non-smoker subject or smoker of not more than 5 cigarettes a day; 3. Body Mass Index (BMI) between 18.50-30.00 kg/m2 inclusive; 4. Trial participants in normal health as determined by personal medical history, clinical examination including vital signs, and clinically acceptable results of laboratory examinations (including serological tests), individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator; 5. Normal ECG recording on a 12-lead ECG and/or chest X-ray (PA view) significant at the screening visit or considered not clinically significant (NCS) by investigators; 6. A negative alcohol breath test result at housing; 7. Trial participant able to communicate effectively, provide voluntary written informed consent and available for the entire study duration; 8. Trial participants willing to adhere to the protocol requirements as evidenced by written informed consent approved by the ethics committee; 9. Ability to fast for at least 14.00 hours and consume standard meals; 10. Accept to refrain consuming certain foods and supplements at least two weeks before inclusion; 11. Female participants must have a negative urine pregnancy test prior to housing; 12.Trial participants that can provide adequate evidence of their identity; 13.The participants agree to refrain from consuming dietary supplements that could potentially impact either muscle or mitochondrial function or contain Urolithin A, such as resveratrol, pomegranate and ellagitannins, nicotinamide riboside, whey protein, leucine, iso-leucine, l-carnitine, creatinine, coenzyme Q10, vitamin A, niacin, folic acids, vitamin C, vitamin E and probiotic foods and supplements, during the 2 weeks before inclusion and throughout the study; 14.Females of childbearing potential agree to use appropriate contraceptive measures like non-hormonal intrauterine devices, barrier methods, and spermicidal agents during the study and 07 days after completion of the study; 15.Male agreeing to use appropriate contraceptive measures like the Double Barrier method (Condom), and should not donate sperm, etc. during the study and 07 days after completion of the study. Exclusion Criteria: 1. Known hypersensitivity to Urolithin A or related product or any component of intervention, presence or history of drug hypersensitivity, allergic disease or lactose intolerance; 2. Any history or presence of clinically significant medical condition, such as, but not limited to, cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic or infectious disease, thyroid disease, adrenal dysfunction, or organic intracranial lesion; 3. Any treatment which could bring about induction or inhibition of the hepatic microsomal enzyme system within one month of starting the study; 4. History or presence of alcoholism or drug abuse; 5. History or presence of gastric and/or duodenal ulceration; 6. History or presence of cancer; 7. Difficulty with donating blood; 8. Use of any prescribed medication (including herbal remedies) during the two weeks before the start of the study or OTC medicinal products (including herbal remedies) during the week before study initiation and throughout the study; 9. Use of medications such as benzodiazepines, anticonvulsants, or barbiturates for one month before the start of the study and throughout the study; 10. Trial participant consumed tobacco/tobacco-containing products, pan or pan masala, gutkha, and masala (containing beetle nut and tobacco) for at least 48.00 hours before initiation of the study and throughout the study; 11. Trial participant consumed caffeine and/or xanthine-containing foods or beverages (i.e., coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.) and grapefruit juice and poppy-containing foods for at least 48.00 hours before initiation of the study and throughout the study; 12. Major illness during the 90 days before screening; 13. Participation in a drug research study within 90 days of screening; 14. Positive screening test result for any one or more of the following: HIV, Hepatitis B, Hepatitis C, and VDRL; 15. History or presence of easy bruising or bleeding; 16. Abnormal diet pattern for whatever reason (e.g., low sodium, fasting, and high protein diets) during the four weeks preceding the study; 17. Females of childbearing potential with any one of the following reported and documented on the medical history: i.Postmenopausal with spontaneous amenorrhea for at least one year, or ii.Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or iii.Total hysterectomy and an absence of bleeding for at least 3 months; iv.Female volunteers who have used implanted or injected hormonal contraceptives anytime during the 6 months prior to study or used hormonal contraceptives within 07 days before dosing; 18. Pregnant women and nursing mothers; 19. Male and females of childbearing potential unwilling to employ appropriate and reliable method of contraception like non-hormonal intrauterine devices, barrier methods, and spermicidal agents, Double Barrier method (Condom) during the study till 07 days after the completion of the study; 20. Male volunteers willing to donate sperm during the study till 07 days after the completion of the study.",18.0,45.0,['healthy adults']
NCT00506818,Cognitive and Emotional Impairment After Stroke,Cognitive and Emotional Impairment After Stroke,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * First ever stroke or TIA * No cognitive decline (IQCODE \< 3,7) * Survived the acute stroke * Expected to live at least for one year after stroke Exclusion Criteria: * Cognitive decline",18.0,65.0,"['stroke', 'cognitive impairment', 'vascular dementia']"
NCT04484818,"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study",A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE),ACTIVE_NOT_RECRUITING,INTERVENTIONAL,MALE,"Inclusion Criteria: * PRE-REGISTRATION INCLUSION (STEP 0) * Patient must have undergone a radical prostatectomy (RP) and must be registered to step 0 of this study at least 6 weeks after but not more than 16 weeks after their radical prostatectomy * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0- 2 * Patient with a prior or concurrent malignancy within 5 years of registration, whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * For patients with no previous Decipher score: Tumor tissue specimen from prostatectomy must be available and ready to be shipped * INCLUSION CRITERIA FOR RANDOMIZATION (STEP 1) * For patients who have previously had Decipher score performed by Decipher Biosciences, they must have score of \>= 0.6 * For patients who did not have a Decipher score previously performed by Decipher Biosciences, they must have had a Decipher score of \>= 0.6 assessed from the prostatectomy specimen submitted * For patients who did not have a Decipher score previously performed by Decipher Biosciences, patients must also have a CAPRA-S score \>= 3. The CAPRA-S score is calculated by assigning points for PSA in ng/mL, surgical margin status, seminal vesicle invasion, and extra-capsular extension. Lymph node involvement will serve as an exclusion criteria and will not count towards CAPRA-S inclusion score. A CAPRA-S score is not required for patients who had a Decipher score previously performed by Decipher Biosciences * Patient must have an undetectable PSA (\ = 3,000/mcL (obtained within 4 weeks prior to registration) * Absolute neutrophil count \>= 1,000/mcL (obtained within 4 weeks prior to registration) * Platelets \>= 75,000/mcL (obtained within 4 weeks prior to registration) * Total bilirubin =\ = 30 mL/min/1.73 m\^2 (obtained within 4 weeks prior to registration) Exclusion Criteria: * PRE-REGISTRATION EXCLUSION (STEP 0) * Patient must not have any previous treatment with androgen deprivation therapy (ADT), chemotherapy, or other physician prescribed systemic therapy for treatment of their prostate cancer * Patient must not have pathologic evidence of pelvic lymph node involvement * Patient must not have an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association class III and IV heart failure), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * EXCLUSION CRITERIA FOR RANDOMIZATION (STEP 1) * Patient must not have pre or post-operative radiographic evidence of cancer recurrence or metastasis by abdominal and pelvic imaging (computed tomography \[CT\] abdomen/pelvis, whole body magnetic resonance imaging \[MRI\], MRI abdomen/pelvis, or equivalent, AND bone scan) which must be done before or after prostatectomy prior to randomization. If pre-operative risk does not indicate a need for bone scan, post-operative Decipher score of \>= 0.6 indicates increased risk of metastatic disease and may be used to obtain CT abdomen/pelvis and bone scan prior to randomization",18.0,65.0,['prostate carcinoma']
NCT06649890,A Novel Surgical Irrigation Solution in Post-Mastectomy Reconstruction: Evaluating Xperience™,A Randomized Control Trial Evaluating the Efficacy of Xperience™ Surgical Irrigation Solution Versus Dilute Povidone-Iodine in Preventing Surgical Site Infections and Improving Postoperative Outcomes in Implant-Based Breast Reconstruction,RECRUITING,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Older than 18 years old * Willing to comply with all study-related procedures * Available for the duration of the study * Participants undergoing double mastectomy surgery followed by one of the following: (1) Immediate reconstruction with tissue expander placement, (2) Delayed reconstruction with tissue expander or implant placement, (3) Immediate reconstruction with implant placement, (4) Second-stage reconstruction with tissue expander to implant exchange Exclusion Criteria: * Participants unable to participate in follow-up visits * Participants undergoing unilateral mastectomy * Tissue expanders placed by a surgeon outside of the UNC Chapel Hill Hospital System * Undergoing autologous reconstruction * Participant is unable to provide signed and dated informed consent * Unwilling or unable to comply with all study-related procedures. * Known history of sensitivity or allergic reaction to any of the components of the Xperience™ irrigation solution or dilute povidone-iodine irrigation * Participant with any conditions that would be a contraindication to receiving surgery such as contraindications to general anesthesia * Pregnant, planning to become pregnant or breast feeding participants * Individuals providing informed consent with any mental impairment or condition that would make them unable to properly consent without use of legally authorized representative (LAR) or additional participant protections. * Incarcerated participants",18.0,65.0,"['surgical site infection', 'surgical complication', 'implant infection', 'implant complication']"
NCT03629990,Approach Bias Modification for the Treatment of Cannabis Use Disorder,Approach Bias Modification for the Treatment of Cannabis Use Disorder,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Be age 18-65 and must be able to provide informed consent. 2. Meet DSM-5 criteria for current moderate to severe CUD (past 60 days). 3. Identify cannabis as their primary substance of choice. 4. Consent to remain abstinent from alcohol and cannabis for 12 hours immediately prior to study visits and other drugs of abuse (except nicotine) for three days prior (see Additional Instrumentation below for methods); by restricting cannabis and other substance use as proposed, participants should not be under the acute effects of cannabis or other substances. Exclusion Criteria: 1. Evidence of, or a history of serious medical or neurological disease that may affect cognitive processing. 2. History of, or current psychotic disorder, bipolar disorder, and attention-deficit hyperactivity disorder, or current untreated major depressive disorder as these may interfere with subjective measurements. 3. Current use of psychotropic medications because these may affect subjective measurements (individuals taking antidepressants will be allowed). 4. Current suicidal ideation. Individuals who endorse suicidal ideation will be seen by a psychologist or psychiatrist in the office and will be referred to treatment as necessary. 5. Women who are pregnant, nursing or of childbearing potential and not practicing an effective means of birth control. 6. Moderate to severe DSM-5 substance use disorder within the past 60 days (other than nicotine or cannabis).",18.0,65.0,['cannabis use disorder']
NCT04621890,HCT Cash-Only INcentive to Promote Mealtime Insulin DOSE Engagement,Behavioral Incentive Meal Dose Engagement in Adolescents With Type 1 Diabetes,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Aged 12-17.99 years * The youth must have been diagnosed with T1D for at least 6 months * The youth must have attended at least 2 routine T1D standard of care visits in the past 12 months * The youth must be using an insulin delivery device capable of recording, storing, and downloading insulin bolus behaviors (insulin pump or smart Bluetooth insulin pen that can be uploaded to standard clinic upload software). * The youth must have a current A1C \>7.2% and/or be predicted to have a rise in A1C in of 0.3% or higher the next 90 days. * Not pregnant or planning to become pregnant by self-report. Exclusion Criteria: * Participants with any type of diabetes mellitus other than T1D * Participant has any disease causing anemia or affecting red blood cell physiology (which would impact A1C) * Participant has a physical disability, which in the opinion of the investigator would interfere with individual's ability to feed themselves or use one's hands to facilitate eating * Participants with no internet access or ability to upload device(s) to data aggregation software that is accessible to study team. For Focus Groups: Any parent or legal guardian whose child is eligible for the study is invited to participate in a focus group discussion.",12.0,18.0,['type 1 diabetes']
NCT00875290,The Effectiveness of Continuous Glucose Monitoring in Diabetes Treatment for Infants and Young Children,Gerber Pump Trial: Effectiveness of Continuous Subcutaneous Insulin Infusion (CSII) and Real-Time Sensor Augmentation (RTSA) in 0-3 Years Old Diabetes Patients; A One Year Randomized Controlled Clinical Trial.,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Children less than 4 years of age with Type I diabetes for at least 3 months Exclusion Criteria: * Children greater than 4 years of age * Monogenic diabetes,3.0,3.0,"['diabetes mellitus, type i']"
NCT04716790,Comparison Between the Effect of Ultrasound Debridement and Conventional Treatment in Diabetic Foot Ulcers (DFU).,"Randomized Clinical Trial to Elucidate the Effects of Low Frequency Ultrasound Debridement (LFU), in Patients With Diabetic Foot Ulcers, Compared to Its Conventional Treatment",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Male and female patients ≥18 years old. * Type 1 or type 2 diabetes mellitus with HbA1c ≤ 10%. * DFU grades IA, IIA, IB, IIB, IC, IIC, ID, IID, according to the University of Texas Classification. * DFU grades PEDIS 1-Absence of Infection, PEDIS 2-Mild infection and PEDIS 3-Moderate infection, according to the PEDIS-IDSA Classification. * Wound size between 1 cm² and 30 cm². * Evolution time DFU between 1 and 24 months. * Ankle-brachial index (ABI) ≤0.9 and ankle systolic blood pressure (ASBP) ≥70mmHg, or toe systolic blood pressure (TSBP) ≥50mmHg, ABI\>0.9, TSBP ≥50mmHg and toe-brachial index (TBI) ≤0.7 Exclusion Criteria: * Critical limb ischemia patients with ABI≤0.5 and ASBP\<70mmHg or TSBP\<50mmHg. * Clinical suspicion of osteomyelitis. * Pregnant or lactating women or women of childbearing potential who are not using effective contraception. * Patients diagnosed with hepatitis or human immunodeficiency virus (HIV)",18.0,65.0,['diabetic foot ulcer']
NCT01800890,Safety and Performance of New 2-piece Ostomy Product Concept Compared With SenSura Click in Subjects With Ileostomy,Investigating the Safety and Performance of New 2-piece Ostomy Product Concept Compared With SenSura Click in Subjects With Ileostomy,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Have given written informed consent and signed letter of authority form. 2. Be at least 18 years of age and have full legal capacity. 3. Be able to handle the appliances themselves 4. Have an ileostomy with a diameter between 15 and 40 mm. 5. Have had their ostomy for at least three months. 6. Use minimum 1 baseplate every third day. 7. Currently use 2-piece flat mechanical coupling product with open bag and a coupling size in the inter val of 43-55mm (both extremes included) 8. Must be able to use custom cut product 9. Accept to test three 2-piece products within the study. 10. Negative result of a pregnancy test for women of childbearing age. Exclusion Criteria: 1. Use irrigation during the study (flush the stoma with water). 2. Currently receiving or have within the past 2 months received radio- and/or chemotherapy. 3. Currently receiving or have within the past month received local or systemic steroid treatment in the peristomal area. 4. Are pregnant or breastfeeding. 5. Participating in other interventional clinical investigations or have previously participated in this investigation. 6. More than three days wear time as usual change pattern. 7. Currently using ostomy belt 8. Currently using extended wear product (Sensura Xpro, Assura TERA, Dansac NovaLife X3, Hollister Flextend, Convatec Durahesive) 9. Have a loop ileostomy 10. Known hypersensitivity towards any of the test products 11. Suffer from peristomal skin problems that preclude participation in the investigation (assessed by the investigation nurse)",18.0,65.0,['subjects with an ileostomy']
NCT01900990,Noninvasive Positive Pressure Ventilation for Difficult Weaning in Tracheotomy Patients,A Randomized Controlled Trial of Noninvasive Positive Pressure Ventilation for Weaning From Mechanical Ventilation in Tracheotomy Patients,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * age ≥ 18 years * tracheotomy mechanical ventilation patients Exclusion Criteria: * pregnancy * respiratory and hemodynamic instability * Recent oral，nasal，facial or cranial trauma or surgery * contra-indications for nasal or facial mask (facial skin lesions,...) * recent history of upper gastro-intestinal surgery * recent history of myocardial infarction * unconscious patients * non cooperative patient",18.0,65.0,['respiratory failure']
NCT04325490,"Tapioca Starch Stimutex AS, Aloe Barbadensis, Rose Hip Oil, Allantoin Comparing With Topical 1% Hydrocortisone Cream","A Randomized Controlled Trial of Efficiency and Safety of Liquid Powder Containing Tapioca Starch Stimutex AS, Aloe Barbadensis, Rose Hip Oil and Allantoin Comparing With Topical 1% Hydrocortisone Cream for Treatment of Intertrigo",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Patients who had age more than 18 years 2. One intertrigo lesion at inframammary fold, inguinal region, interdigital, axilla or abdominal region with mild to moderate which only has erythema no epidermal loss 3. Being diagnosed intertrigo by dermatologist. Patients will be clinical and investigational with KOH preparation and Wood's lamp diagnosed with intertrigo by dermatologist. Exclusion Criteria: 1. Patients receive topical steroids, topical anti-fungal drugs within 2 weeks prior the study 2. Patients with skin conditions including fungal/bacterial infection, Hailey-Hailey disease, pemphigus, granuloma, psoriasis, acanthosis, or Darier disease on intertriginous areas within 2 weeks prior to the study 3. Patients with an allergic to tapioca starch และ stimutex AS, aloe Barbadensis, rosa hip oil และ allantoin, or topical hydrocortisone 4. Pregnant or breastfeeding women 5. Patients with severe intertrigo treated with high potent topical steroid or systemic corticosteroid",18.0,65.0,['intertrigo']
NCT00606190,Prospective Randomized Study of Brain Protection During Aortic Arch Replacement,Prospective Randomized Study of Brain Protection During Aortic Arch Replacement,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Undergoing a total arch replacement * Less than 75 years old Exclusion Criteria: * EF less than 35% * Pt shows evidence of major illness e.g. severe hepatic disease, severe renal failure, active cancer or major infection * Pt unable to complete preop neuro assessment * Pt is unwilling or able to complete followup requirements * Pt is already enrolled in other new device or drug protocols that have not completed the primary endpoint or that clinically interferes with study endpoint * Pt is a female who is pregnant or lactating * Pt has history of stroke",21.0,74.0,['aneurysm of aortic arch']
NCT03886090,Facilitating Motor Skill Learning in Parkinson's Disease II (FaST-PD II),Facilitating Motor Skill Learning by Aerobic Training in Parkinson's Disease II,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Parkinson's disease stage 1-3 on Hoehn \& Yahr scale * Ability to stand unaided and walk without an assistive device * Stable medication during the study period * Unfamiliar to the motor learning task Exclusion Criteria: * On-off and wearing-off phenomena * Unstable medical or psychiatric illness * Clinically relevant cardiovascular or orthopaedic disease * Severe polyneuropathy * Cognitive impairment * Smoking \> 10 cigarettes/day * Caffeine \> 6 cups of coffee/day * Alcohol \> 50 g (two glasses)/day,18.0,65.0,['parkinson disease']
NCT06730490,ANS Function in HIE Infants Treated With Therapeutic Hypothermia,Autonomic Nervous System Function in Hypoxic-Ischemic Infants Treated With Therapeutic Hypothermia,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Patients with Moderate or Severe HIE: 3 or more categories of the modified Sarnat Score in stage 2 or 3 (qualify for therapeutic hypothermia). * Patients that are initiated on therapeutic hypothermia. * Patients with Mild HIE, not treated with TH (control) Exclusion Criteria: -No encephalopathy, defined normal neurological exam.",1.0,72.0,['hypoxic-ischemic encephalopathy']
NCT01890590,A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma,A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Participants must meet the following criteria on screening examination to be eligible to participate in the study: * Participants must have histologically or radiological evidence of Stage I (T1N0M0) renal cell carcinoma with a size no larger than 8 cm in greatest dimension measured by MRI or CT Scan * At least one (usually up to 3) gold fiducial placed in or around tumor, can be performed on the same day - after signing research informed consent. * No irreversible coagulopathies * Age ≥ 18 years old because no dosing or adverse event data are currently available on the use of Cyberknife Radiosurgery radiation in participants \<18 years of age, children are excluded from this study but will be eligible for future pediatric Phase II trials. * ECOG Performance Status ≤2 (Appendix A). * At least 12 month life expectancy * Ability to have CT and/or MRI imaging with or without contrast and must be performed within 120 days prior to registration. * No other cancer in previous 2 years with the exception of non-invasive skin cancers * All subjects meeting eligibility criteria irrespective of gender, minority or other underrepresented status will be eligible for enrollment into the study. * The effects of Cyberknife Radiosurgery on the developing human fetus are unknown. For this reason and because Radiation is known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * Ability to understand and the willingness to sign a written informed consent document and study specific consent form prior to study entry. * Labs: Serum Creatinin \<3 mg/dl, Urinalysis, INR \<2, PTT \<70 sec, AST, ALT ≤2.5x ULN, Abnormalities on urinalysis (i.e. proteinuria) will not exclude patients from participation on study. Exclusion Criteria: * Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study. * Irreversible coagulopathies that preclude fiducial placement * Prior upper abdominal external beam irradiation * Prior history of invasive malignancy within the last 2 years * Inability to deliver target dose with CyberKnife due to inability to image fiducials * Inability to deliver target dose with CyberKnife due to normal tissue dose constraints * Inability to have contrast CT or MRI to help define tumor volume for radiation planning * Decreased platelet count and / or anticoagulation parameters that would preclude transcutaneous placement of fiducials",18.0,65.0,['renal cell carcinoma']
NCT06070090,Tapping in Together: A Pilot Study on Group Acupuncture for Ketamine Experience Integration,Tapping in Together: A Pilot Study on Group Acupuncture for Ketamine Experience Integration,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * between ages 21-65 * participant in a group ketamine experience between October 1, 2023 and February 28, 2024 Exclusion Criteria: * currently pregnant or breastfeeding * has a terminal illness * does not pass medical clearance for ketamine prescription",21.0,65.0,['acupuncture']
NCT01941290,BIOFLOW III Asia Registry Orsiro Stent System,Biotronik-Safety and Performance Registry for an All-comers Diabetic Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice-III Asia,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Inclusion Criteria * Diabetes Mellitus: * Known Diabetic on Pharmacological treatment. * ACS NSTEMI with documented Hb A1c\> 7%, even if not on Pharmacological treatment for diabetes. * Patient has Symptomatic coronary artery disease * Target lesion must be a de novo lesion located in a native coronary artery with reference vessel diameter ≥2.25 mm \& ≤4.00 mm, lesion length ≤40 mm by visual estimate * Patient should be receiving up to 3 stents and up to 2 stents per artery. * Target lesion must be in a major coronary artery or branch with visually estimated stenosis ≥50% \& \<100% with TIMI flow≥1. * Subject provides signed informed consent for data release * Subject is geographically stable and willing to comply with protocol required follow ups * Subject is ≥ 18 years of age Exclusion Criteria: * Pregnant and/or breast-feeding females who intend to become pregnant during the period of the registry * Untreatable intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other anticoagulation / antiplatelet therapy required for PCI, stainless steel, Sirolimus or contrast media * Planned surgery within 6 months of PCI unless dual antiplatelet therapy will be maintained * Currently participating in another study and primary endpoint is not reached yet * If the subject has a high probability that a procedure other than predilatation, stent implantation and post dilatation will be required at time of index procedure for treatment of target vessel (e.g. atherectomy, cutting balloon or brachytherapy). * Patients admitted for treatment of Diabetic ketoacidosis ≥ 2 times in the past Six months (Brittle Diabetics).",18.0,65.0,"['coronary artery disease', 'myocardial ischemia', 'diabetes mellitus type 1 or 2']"
NCT01791790,Effects of Brain Stimulation During Nocturnal Sleep on Memory Consolidation in Elderly Healthy Subjects,Impact of Transcranial Slow Oscillating Stimulation on Memory Consolidation During Nocturnal Slow Wave Sleep in Elderly Healthy Subjects,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * elederly, healthy Subjects * unobtrusive, neuropsychological screening * age: 50-90 years * right handed Exclusion Criteria: * untreated severe internal or psychiatric diseases * epilepsy * other severe neurological diseases eg., previous major stroke, brain tumour, dementia * contraindications to MRI",50.0,90.0,['elderly subjects']
NCT00704990,Combination Natural Health Product in Children With Attention Deficit/Hyperactivity Disorder (ADHD),The Safety and Efficacy of a Compound Natural Health Product in Children With Attention Deficit/Hyperactivity Disorder: A Pilot Study,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Male and female children age 6-12 diagnosed with ADHD of any subtype according to DSM-IV criteria. A structured diagnostic interview (Kiddie Sads Present and Lifetime Version) will be conducted to confirm diagnosis of ADHD and assess for comorbid mental health disorders. * Primary caregiver (parent or guardian) has given informed consent; child participant gives ongoing assent throughout the study. Exclusion Criteria: * Changes to participants' ADHD medication within 6 weeks of study onset. * Diagnosis of additional mental health disorder using the Kiddie Sads. * Diagnosis of cancer. * Antibiotic use for periods greater than 2 weeks within the 10 weeks prior to the study * Diagnosis of Type 1 diabetes and insulin use * Low serum ferritin/iron deficiency (\<30 ng/ml),6.0,12.0,['attention deficit hyperactivity disorder']
NCT07143890,Iron Absorption From Plant Heme Iron,Iron Absorption From Plant-Derived Heme Iron: An Experimental Study in Iron-Deficient Women (PHIA),RECRUITING,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Serum ferritin \ 5 µg/L (inflammation) * Strict vegan and vegetarians * Any metabolic, gastrointestinal kidney or chronic disease * Consumption of mineral and vitamin supplements since screening and over the study period until last blood sample collection * Blood transfusion over the past 6 months * blood donation over the past 6 months * Significant blood loss (accident, surgery) over the past 6 months * Women who are pregnant or breast feeding * Smoker (\> 1 cigarette per week) * Continuous/long-term use of medication (except for contraceptives) * Therapeutic iron infusion over the past 6 months, * Known hypersensitivity or allergy to iron supplements, * Intention to become pregnant during the course of the studies, * Known or suspected non-compliance, drug or alcohol abuse, * Inability to follow the procedures of the studies, e.g. due to language problems, psychological disorders, dementia, etc. of the participant, * Participation in another study with investigational drug within the 30 days preceding and during the present studies, * Enrolment of the investigator, his/her family members, employees and other dependent persons",18.0,45.0,"['iron deficiency (id)', 'iron absorption']"
NCT03321890,Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL),"A Multicenter, Single-arm, Open II Phase Clinical Trial Evaluating the Efficacy of Chidamide Combined With Prednisone, Cyclophosphamide, Etoposide, and Methotrexate (PECM) in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Histopathologically confirmed peripheral T-cell lymphoma (PTCL) patients; 2. Patients who have had at least one systemic treatment (including chemotherapy, hematopoietic stem cell transplantation, etc.) who have not remission or relapsed after remission; 3. For various reasons can not be hematopoietic stem cell transplantation in patients; 4. The age of 18-75 years old, male, female open; 5. ECOG (Eastern Cooperative Oncology Group) physical scoring 0-1 points; 6. Absolute value of neutrophil≥1.5 × 109 / L, platelet≥90 × 109 / L, hemoglobin≥90g / L; 7. The expected survival time ≥ 3 months; 8. No radiotherapy, chemotherapy, targeted therapy or hematopoietic stem cell transplantation were performed within 4 weeks prior to enrollment. 9. Voluntary signature of written informed consent. Exclusion Criteria: 1. Pregnancy, breastfeeding women and unwilling to take contraceptive measures of reproductive age patients; 2. B-mode ultrasonography showed that the width of end-diastolic pericardial dark area was ≥10mm; 3. Patients receiving organ transplants; 4. Patients receiving symptomatic treatment of pre-bone marrow toxicity within 7 days prior to enrollment; 5. Patients with active bleeding; 6. Liver function abnormalities (total bilirubin\> 1.5 times the upper limit of normal, ALT( alanine aminotransferase) / AST (Aspartate aminotransferase)\> 2.5 times the upper limit of normal or hepatic involvement of ALT / AST\> 5 times the upper limit of normal), renal dysfunction Creatinine\> 1.5 times the upper limit of normal), electrolyte abnormalities; 7. Persons with mental disabilities / those who can not obtain informed consent; 8. Patients with drug abuse and long-term alcohol abuse that may affect the evaluation of test results; 9. The investigators determined that they were not fit to participate in the trial.",18.0,75.0,['peripheral t-cell lymphoma']
NCT00318890,Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck,A Phase I/II Trial of Induction Cisplatin and Docetaxel Followed by Concomitant Docetaxel/Radiotherapy With Subcutaneous Amifostine for Locally Advanced Squamous Cell Carcinoma of the Head and Neck,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * The patient has histologically proven primary or recurrent squamous cell carcinoma arising in the oropharynx, oral cavity, hypopharynx, larynx, or nasopharynx. * The patient has stage III or IV disease. * Performance status \ 12 months. * Age 19 years and above. * The patient is medically fit to tolerate a course of definitive radiation therapy. * The patient has: 1. adequate hepatic function with bilirubin \ 50 mL/min) 4. normal serum calcium 5. adequate hematologic function as: defined by an absolute neutrophil count \> 1500/ml, hemoglobin \> 8.0 g/dl, and platelet count \> 100,000/ml. * The patient may have had a prior malignancy but must be three years from treatment. * A history of superficial non-melanoma skin cancer or in situ carcinoma of the cervix less then three years will be allowed. * The patient must agree to use effective contraception if procreative potential exists, and continue contraception for at least 6 months following completion of the study. * Patient must sign informed consent. Exclusion Criteria: * The patient has received radiation therapy previously to the head and neck. * The patient has received prior chemotherapy for head and neck cancer. * The patient is pregnant or lactating. * Peripheral neuropathy \> Grade 2. * Serious non-malignant disease (e.g. congestive heart failure, uncontrolled atrial fibrillation, active hepatitis). * Any underlying psychological condition that would prohibit the understanding and rendering of informed consent. * Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 must be excluded.",19.0,65.0,"['cancer of head and neck', 'head cancer', 'head and neck cancer', 'neck cancer', 'neck neoplasms']"
NCT05223790,Assessment of the NIPE in Very Premature Infant Ventilated and Sedated in Neonatal Reanimation.,Assessment of the NIPE in Very Premature Infant Ventilated and Sedated in Neonatal Reanimation.,RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * Infant born very premature before 34 weeks of amenorrhoea + 0 day * Age ≤ 7 days * Admitted in neonatal reanimation * Sedated, intubated, ventilated Exclusion Criteria: * High frequency oscillation ventilation * Heart rate non sinusal * Inotropes and atropine * Opposition from the guardian of parental authority * Difficulty of comprehension or communication making the parental information impossible",0.0,7.0,"['neonatal', 'pain measurement', 'reanimation']"
NCT06946290,Intertransverse Process Block to Improve Quality of Recovery and Pain Management in Adult Cardiac Surgical Patients,Intertransverse Process Block to Improve Quality of Recovery and Pain Management in Adult Cardiac Surgical Patients: a Prospective Double-Blinded Randomized Controlled Trial,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * adult patients aged 18 or older * undergoing elective CABG, valve repair/replacement, or combined CABG/valve procedure via sternotomy Exclusion Criteria: * Emergency surgery * redo surgery * history of chronic pain or being on chronic opioids/sedatives * renal failure with an estimated glomerular filtration rate ≤30 ml/min (calculated by Cockcroft-Gault formula) * re-operation within 24 hours after surgery * intraoperative use of remifentanil * inability to provide informed consent.",18.0,65.0,['chronic postsurgical pain']
NCT02947490,Effectiveness of Self-monitoring and Treatment of Blood Pressure Following Stroke or Transient Ischaemic Attack,Trial of the Effectiveness and Cost Effectiveness of Self-monitoring and Treatment of Blood Pressure in Secondary Prevention Following Stroke or Transient Ischaemic Attack (TIA),COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Patients aged =/\> 18 years old with TIA or stroke of mild/moderate severity (NIHSS =\<15) who require BP management and are able and willing to undertake self BP measurement and guided alterations in therapy. Exclusion Criteria: * Those with terminal illness with life expectancy less than six months including end staged condition e.g. end stage COPD * Dementia or moderate to severe cognitive impairment * Those not receiving or expected to start anti-hypertensive therapy,18.0,65.0,['stroke']
NCT05678790,Mitochondrial Membrane Protein Neurodegeneration (MPAN),The Effect of 6-week Rehabilitation Program in Brothers With MPAN: A Report of Two Cases.,COMPLETED,INTERVENTIONAL,MALE,Inclusion Criteria: * Being diagnosed with MPAN Exclusion Criteria: * being involved in any other rehabilitation program,9.0,14.0,['mpan']
NCT03251690,Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression,Switching Tenofovir/Emtricitabine/Efavirenz to Tenofovir/Emtricitabine/Rilpivirine Versus Continuing Tenofovir/Emtricitabine/Efavirenz in HIV1-infected Patients With Complete Virological Suppression,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * on TDF/FTC/EFV for more than 3 months * Blood HIV RNA viral load \ 200 cells/mm3 * eligible to sign the informed consent Exclusion Criteria: * history of NRTI resistance * on medication that potentially interact with study drug * denied to participate in the study,18.0,65.0,"['anti-retroviral agents', 'efavirenz', 'hiv-1-infection', 'sustained virologic response', 'dyslipidemias', 'rilpivirine']"
NCT05147090,Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients,"Effects of Empagliflozin on Preventing Fibrosis and Cirrhosis Progression in Nucleos(t)Ide Analogue-treated Chronic Hepatitis B Patients With F2-F4 Fibrosis: a Randomized, Double-blind Placebo-controlled Trial",ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients will be recruited if they have significant/advanced fibrosis or cirrhosis confirmed by MRE Exclusion Criteria: 1. decompensated cirrhosis (variceal bleeding, ascites, hepatic hydrothorax, hepatic encephalopathy), 2. portal vein thrombosis, 3. alcohol intake \>20g within last 2 years, 4. concurrent chronic liver disease (chronic hepatitis C infection, autoimmune hepatitis, Wilson's disease, hemochromatosis, primary biliary cholangitis, drug-induced), 5. history of malignancy including hepatocellular carcinoma (HCC), 6. pregnancy, 7. contraindications to empagliflozin (estimated glomerular filtration rate (eGFR) \<45mL/min/1.73m2, recurrent genitourinary tract infections, gangrene, allergy), 8. contraindications to MRI (e.g., claustrophobia, implanted devices with ferromagnetic properties).",18.0,80.0,"['chronic hepatitis b', 'nafld', 'cirrhosis', 'fibrosis, liver', 'empagliflozin', 'sglt2 inhibitors']"
NCT04412590,Pilot Study of the Vermont Family Based Approach in Primary Care Pediatrics,Pilot Study of the Vermont Family Based Approach in Primary Care Pediatrics at the University of Vermont Medical Center,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Families with a 3 - 15 year-old child who receives his/her primary care at the University of Vermont Pediatric Primary Care Clinic Exclusion Criteria: * Families with a target child in the legal custody of the State of Vermont * Families where the parents' proficiency in English is not sufficient to participate in the protocol without an interpreter,3.0,15.0,['psychiatric disorder']
NCT03418090,Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Transplant,Evaluation of Hyperpolarized 129Xe MRI as Compared to 133Xe Scintigraphy for the Assessment of Pulmonary Function in Patients Being Evaluated for Possible Lung Transplant Surgery,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Male or female subjects ≥18 years of age. 2. Subject is being evaluated for possible lung transplant surgery (either single or bilateral). 3. Subject is able to undergo MRI imaging and able to fit in the MRI coil. 4. Subject is willing and able to comply with all study procedures. 5. Subject must understand and voluntarily sign an informed consent form (ICF) prior to any study specific assessments or procedures. Exclusion Criteria: 1. Baseline blood oxygen saturation (SpO2) \<90% at rest. For subjects requiring routine supplemental oxygen, SpO2 measurements should be taken with the patient's normal oxygen supplementation. 2. Subjects that have undergone a prior pneumonectomy surgery to either lung. 3. Female subjects of childbearing potential with a positive serum pregnancy test at screening, or who are not taking (or not willing to take) acceptable birth control measures through the Follow-up Period. Adequate birth control methods include with a monogamous partner who was sterilized more than 6 months prior to screening, or measures with a Pearl index of \<1 used consistently and correctly (including intrauterine devices, or implantable, injectable, oral, or transdermal contraceptives). Women are not considered to be of childbearing potential if they meet at least 1 of the following 2 criteria as documented by the Investigator: * They have had a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at a minimum of 1 menstrual cycle prior to signing the ICF; or * They are post-menopausal: for women ≥55 years of age, defined as ≥1 year since their last menstrual period, or for women \<55 years of age, defined as ≥1 year since their last menstrual period and have a follicle-stimulating hormone (FSH) level in the laboratory's normal range for post-menopausal phase. 4. Women who are lactating and insist on breast feeding. 5. Have received any other investigational therapy within 4 weeks prior to Screening. 6. Requires anesthesia or heavy sedation to undergo MRI testing. Mild sedation could be acceptable (i.e. a low dose oral acting anxiolytic medication such as alprazolam) as long as, in the opinion of the investigator, the subject meets Inclusion Criteria #4 and #5.",18.0,65.0,['pulmonary surgical procedures']
NCT01905397,Negative Pressure Wound Therapy to Reduce Surgical Site Infection,Evaluation of Negative Pressure Wound Therapy for Reduction of Postoperative Surgical Site Infection in Patients Undergoing Colorectal and Hepatopancreatobiliary Surgery,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Female and male patients 18 years of age or older * Scheduled for an elective surgery in either open CRS or open HPBS. This includes, but is not limited to: ileocecectomy, right hemicolectomy, extended right hemicolectomy, transverse colectomy, left hemicolectomy, sigmoidectomy, proctectomy, low anterior resection, or abdominoperineal resection gastrectomy, hepatectomy, bile duct reconstruction, duodenectomy, pancreatectomy, pancreaticoduodenectomy, or pancreatic duct reconstruction Exclusion Criteria: * The need for emergency surgery. * The need for use of only laparoscopic surgery. * Presence of bowel obstruction, strangulation, peritonitis or perforation. * The presence of local or systemic infection preoperatively. * ASA class ≥4. * Inability to provide informed consent and authorization. * Known allergy or hypersensitivity to silver. * Any clinically significant condition that, in the investigator's opinion, would significantly impair the subject's ability to comply with the study.",18.0,65.0,['patients undergoing hepatopancreatobiliary surgery']
NCT01854697,A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before,"A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With and Without Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon α-2a and Ribavirin in Treatment-Naïve Adults With Chronic Hepatitis C Genotype 1 Virus Infection (MALACHITE I)",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Males or females between 18 and 65 years, inclusive, at time of Screening * Females must be post-menopausal for more than 2 years or surgically sterile or practicing abstinence/specific forms of birth control * Subject has never received antiviral treatment for hepatitis C infection * Chronic HCV Genotype-1 infection prior to study enrollment Exclusion Criteria: * Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency virus antibody (HIV Ab) * Females who are pregnant or plan to become pregnant, or breastfeeding * Any current or past clinical evidence of cirrhosis * Screening laboratory analyses that showing abnormal laboratory results * Use of contraindicated medications within 2 weeks of dosing and subject with contraindication for telaprevir, pegIFN and RBV * Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol * Positive screen for drugs or alcohol",18.0,65.0,['chronic hepatitis c infection']
NCT00568997,10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus,A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two Years to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Elidel Cream 1% (Pimecrolimus),ACTIVE_NOT_RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * males and females * greater than or equal to 2 years and less than or equal to 17 years at enrollment * diagnosis of atopic dermatitis (confirmed by treating physician) * applied pimecrolimus cream 1 % 6 weeks out of past 24 weeks Exclusion Criteria: * past or present history of systemic malignancy, skin malignancy, or lymphoproliferative disease * past or present use of oral immunosuppressive therapy",2.0,17.0,['atopic dermatitis']
NCT00472797,Rebif New Formulation (RNF) Quality of Life (QOL) Study,"A Randomized, Multicenter, Two-arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QOL) Measures in Subjects With Relapsing Forms of Multiple Sclerosis (MS) Who Are Transitioning From Rebif® (Interferon Beta-1a) to Rebif New Formulation (RNF)",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Subject with a relapsing form of MS; diagnosis of MS is in accordance with the McDonald criteria 2. Subject currently taking Rebif 44mcg tiw, and has been on this treatment for at least 6 months (24 weeks) prior to study enrollment 3. Subject currently using Rebiject II and 29 gauge needle 4. Subject is between 18 and 60 years old inclusive 5. Subject is able to read and understand English 6. Subject is willing to follow study procedures 7. Subject has given written informed consent and signed HIPAA 8. Female subjects must not be either pregnant or breast-feeding and must lack childbearing potential, as defined by either: i) Being post-menopausal or surgically sterile, or ii) Using a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study. (Confirmation required within 30 days prior to start of the study) Exclusion Criteria: 1. Use of any other injectable medications on a regular basis during the week prior to the screening period or during the screening or treatment periods. Receiving a single injection for treatment or prophylaxis of a condition unrelated to the subject's multiple sclerosis or the subject's Rebif® therapy (e.g., receiving a influenza or pneumococcus vaccination) is acceptable 2. Subject receiving MS therapy in addition (i.e., combination therapy) to Rebif® within 3 months prior to study enrollment or at any time during study protocol. 3. Subjects who have previously been on Rebif New Formulation (RNF). 4. Subject with progressive forms of Multiple Sclerosis (MS). 5. Subject with history of any chronic pain syndrome. 6. Subject has any other disease apart from MS that could better explain the subjects signs and symptoms. 7. Subject has complete transverse myelitis or bilateral optic neuritis. 8. Subjects that use any investigational drug or experimental procedure within 12 weeks of visit 1. 9. Subject received oral or systemic corticosteroids or ACTH within 30 days of visit 1 (prior to enrollment). 10. Subject has inadequate liver function, defined by a total bilirubin, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or alkaline phosphatase \> 2.5 times the upper limit of the normal values. 11. Subject has inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 x lower limit of normal. 12. Subject suffers from other current autoimmune disease. 13. Subject suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol 14. Subject is pregnant or attempting to conceive 15. Visual or physical impairment that precludes completion of diaries and questionnaires.",18.0,60.0,['relapsing multiple sclerosis']
NCT02361697,DTI in Children With Multiple Sclerosis,Monitoring of Neurodegenerative Processes in Children With Multiple Sclerosis by Diffusion-weighed Magnetic Resonance Imaging (DTI),UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * informed consent * diagnosis of multiple sclerosis (MS) according to the McDonald criteria 2010 and the consensus recommendations of International Pediatric MS Study Group (IPMSSG) (Krupp et al 2013) * diagnosis of CIS according to the consensus recommendation of IPMSSG (Krupp et al 2013) * all types of medication/therapy Exclusion Criteria: * pregnancy * claustrophobia * allergic reaction of gadolinium (contrast medium) * implantation of cardiac device * implantation of neurostimulators * implantation of cochlea implants * presence of tattooing (over 20% of body surface) * presence of permanent-make-up * presence of permanent transdermal patches * presence of special catheter systems with temperature probes which cannot be removed * implantation of metalliferous implants or implants which could contain metal traces * implantation of artificial heart valves * implantation of stents or coils * presence of metal fragments in the eyes,5.0,18.0,"['multiple sclerosis - relapsing remitting', 'clinically isolated syndrome, cns demyelinating']"
NCT04563897,Prospective Multicenter Study on Clinical Application of Sonazoid in Liver Tumor,Contrast-enhanced Ultrasound in Liver Tumor by Sonazoid,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: * 1.Chinese citizen, ≥ 18 years old; 2.Conventional ultrasound shows that there is definite lesion in the liver, and there is liver parenchyma around the lesion; 3.There is enhanced MRI or enhanced CT finding. For patients with liver fibrosis after hepatitis, the results of liver parenchyma elastography can be added (optional); 4. If the subjects are female, they should be non pregnant and lactating women; 5.Patients voluntarily participate in the study and signe informed consent Exclusion Criteria: * 1.Subjects are known to be allergic to Perfluorobutane or any component of Sonazoid; 2.Patients with severe heart disease or severe lung disease; 3.Pregnant, potential pregnant or lactating patients; 4.No enhanced MRI or CT results are available; 5.The researchers consider that the subjects are not suitable for this study",18.0,65.0,['ultrasound']
NCT06511297,Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort,Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort (Pro-Metage),RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: Group 1 - Lean, young adults (n = 150) * Age 18 - 35 years * Body mass index (BMI) ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 12 months) Group 2 - Overweight, young adults (n = 150) * Age 18 - 35 years * BMI ≥ 28kg/m2 (≥ 12 months) Group 3 - Lean, older adults (n = 150) * Age ≥ 60 years * BMI ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 3 years) Group 4 - Overweight, older adults (n = 150) * Age ≥ 60 years * BMI ≥ 28 kg/m2 (≥ 3 years) * Subgroup A (n=75): with pre-existent cardiovascular disease defined as: history of myocardial infarction or evidence of coronary artery disease irrespective of revascularization status or history of ischemic or hemorrhagic stroke or presence of peripheral artery disease or heart failure with preserved ejection fraction (NYHA Class I-II). * Subgroup B (n=75): without pre-existent cardiovascular disease Group 5 - Nonagenerians Age ≥ 90 (n = 50) * Age ≥ 90 years * BMI ≥ 18.5 kg/m2 (≥ 3 years) Exclusion Criteria: Group 1 - Lean, young adults (n = 150) * Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\]) * Special diets (i.e. ketogenic diet and time-restricted eating) * Clinically significant metabolic or endocrine disorders * Claustrophobia * drug abuse, alcohol \> 15 drinks/week * Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions * Metal implants that prohibit 3T MRI * Pregnancy or breastfeeding Group 2 - Overweight, young adults (n = 150) * Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\]) * Special diets (i.e. ketogenic diet and time-restricted eating) * Active anti-obesity treatment (e.g. glucagon-like peptide 1 (GLP-1) analogues, polyagonists, naltrexone and bupropion) * Clinically significant metabolic or endocrine disorders * Claustrophobia * drug abuse, alcohol \> 15 drinks/week * Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions * Metal implants that prohibit 3T MRI * Pregnancy or breastfeeding Group 3 - Lean, older adults (n = 150) * Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\]) * Special diets (i.e. ketogenic diet and time-restricted eating) * Diabetes, overt hypo/hyperthyroidism * Claustrophobia * drug abuse, alcohol \> 15 drinks/week * Metal implants that prohibit 3T MRI * Known severe cardiovascular diseases (i.e. PAD IIa or higher, advanced heart failure = left ventricular ejection fraction (LVEF) \ 15 drinks/week * Metal implants that prohibit 3T MRI * No previous heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions up until the age of 35 years. * Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial. Group 5 - ""healthy"" Nonagenerians Age ≥ 90 (n = 50) * Claustrophobia * Clinically significant cognitive impairment compromising study adherence * Metal implants that prohibit 3T MRI * Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.",18.0,65.0,"['obesity', 'aging', 'aging problems', 'metabolic syndrome']"
NCT05195697,ACUTE-Acute Surgical Care- Risk Factors and Outcomes for Patients in Need of Acute Surgical Care,ACUTE-Acute Surgical Care- Risk Factors and Outcomes for Patients in Need of Acute Surgical Care,RECRUITING,OBSERVATIONAL,ALL,Inclusion Criteria: Patients admitted to Skåne University hospital in need of acute surgical care - Exclusion Criteria: Below 18 years old \-,18.0,65.0,"['risk factors', 'complication of surgical procedure', 'complication of treatment', 'complication of anesthesia', 'long term effects after emergency surgery', 'long term effects after gi bleeding']"
NCT05905497,The Study of Bemnifosbuvir in Healthy Japanese Subjects,"A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Bemnifosbuvir in Healthy Adult Japanese Subjects",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug * Females must have a negative pregnancy test at Screening and prior to dosing * Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/m2 * Willing to comply with the study requirements and to provide written informed consent * The subject must have been born in Japan and have both parents and 4 grandparents of Japanese descent * The subject must have lived outside of Japan for no more than 10 years Exclusion Criteria: * Pregnant or breastfeeding * Infected with hepatitis B virus, hepatitis C virus, HIV or COVID-19 * Abuse of alcohol or drugs * Use of other investigational drugs within 28 days of dosing * Other clinically significant medical conditions or laboratory abnormalities",18.0,64.0,['healthy volunteer study']
NCT01198197,PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A,PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [(11)C]NOP-1A,COMPLETED,INTERVENTIONAL,ALL,"* INCLUSION CRITERIA: Healthy Volunteers: Subjects must be adults between 18-50 years old. Subjects must be able and willing to give written informed consent. EXCLUSION CRITERIA: Current psychiatric illness or severe systemic disease based on history and physical exam. If women, pregnancy or breast feeding (betaHCG will be measured in all female patients within 24 hours of scan and must be negative) Clinically significant laboratory abnormalities. Serious medical problems including but not limited to chronic neurological disease such as multiple sclerosis, autoimmune diseases or any cardiopulmonary disease. Head trauma resulting in a period of unconsciousness lasting longer than 10 minutes. Recent exposure to radiation (i.e., PET from other research) which when combined with this study would be above the allowable limits. Positive urine drug screen at screening. Inability to lie flat on camera bed for about 2.5 hours Subjects who have metallic foreign bodies that would be affected by the MRI magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan.",18.0,50.0,"['pain', 'anxiety', 'depression']"
NCT04592497,Evaluation of the Safety and Performance of the Very High Power-Short Duration QDOT,Evaluation of the Safety and Performance of the Very High Power-Short Duration QDOT Strategy in Patients Referred for Atrial Fibrillation Ablation.,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Male and female \>18 years old. * Subjects must provide written informed consent to participate in the study. * Subject is willing to comply with the protocol requirements and return to the treatment center for all required clinical evaluations. Exclusion Criteria: * Pregnant women. * Patients with iodine contrast media allergy * Patients with renal failure (GFR \<60ml/min),18.0,65.0,['atrial fibrillation']
NCT01293097,Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI,Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention(PCI),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * 20-75 years old * Patients with clinical diagnosis of NSTE-ACS (unstable angina or NSTE acute myocardial infarction) or stable angina pectoris (SAP) scheduled for selective coronary angiography * Evidence of a personally signed and dated informed consent document Exclusion Criteria: * Patients presenting with ST-segment elevation acute myocardial infarction (STEMI) or high risk NSTE-ACS, warranting emergency coronary angiography: * Experienced STEMI within previous 30 days * Taking or, needing to take atorvastatin over than 20mg/d or any other equivalent statin (such as simvastatin 20mg/d, pravastatin 40mg/d, fluvastatin 80mg/d or rosuvastatin 5mg/d ) in the next 6 months, or needing to take fibrates simultaneously according to investigators' judgment. * Anticipated repeated PCI within 6 months * LDL-C \ 1.5UNL * Myopathy or increased creatine kinase (CK\>2 UNL) * White blood cell \ 3 mg/dl or 264μmol/L) * Allergic or experienced serious adverse reaction to HMG-CoA reductase, or ineligible to take statin as investigator's judgment * Severe aortic valve stenosis or severe mitral stenosis, Obstructive hypertrophic cardiomyopathy, pericardial diseases * Pregnancy, lactation, or child bearing potential women without any effective contraception * Accompanied with malignant disease or other disease, which cause life expectancy \< 6 months * Participating in other interventional clinical trails using drugs or devices * Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding",20.0,75.0,"['non-st segment elevation myocardial infarction', 'unstable angina pectoris', 'stable angina pectoris']"
NCT03492697,A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961,"A Phase 1, Open-label Study In Healthy Subjects To Evaluate The Pharmacokinetics Of Pf-06882961 Following Single Oral Administration Of Immediate Release Tablets And An Immediate Release Oral Solution In The Fed State, And Controlled Release Tablets In The Fed And Fasted States",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Healthy female subjects of nonchildbearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive * Body mass index (BMI) within 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb) * Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal (including pancreatitis), cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). * Any condition possibly affecting drug absorption (eg, gastrectomy). * A positive urine drug test. * History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects within 6 months before screening. * Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product (whichever is longer). * Subjects who have previously participated in prior studies with PF 06882961 as the investigational product. * Screening supine BP\>=140 mm Hg (systolic) or \>=90 mm Hg (diastolic), following at least 5 minutes of supine rest. * Screening supine 12 lead ECG demonstrating a QTc interval \>450 msec or a QRS interval \>120 msec. * Aspartate aminotransferase (AST) level \>= 1.25 × upper limit of normal (ULN); * Alanine aminotransferase (ALT) level \>= 1.25 × ULN; * Total bilirubin level \>=1.5 × ULN; * TSH \> ULN; * HbA1c \>=6.5%. * Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in the protocol for at least 28 days after the last dose of investigational product. * Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of investigational product * Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing. * History of sensitivity to heparin or heparin induced thrombocytopenia. * History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C antibody (HCVAb). * Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), or subjects with suspected MTC per the investigator's judgement. * Unwilling or unable to comply with the criteria in the Lifestyle Requirements section of the protocol. * Subjects who are investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study. * Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study",18.0,55.0,['healthy subjects']
NCT06233097,Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fasting Condition,A Bioequivalence Study of Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets in Healthy Thai Volunteers Under Fasting Condition,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Willingness to provide written informed consent prior to participate in the study. 2. Healthy Thai subjects are between 18 to 55 years of age. 3. The Body Mass Index (BMI) ranges from 18.5 to 30 kg/m2. 4. Comprehensive of the nature and purpose of the study and compliance with the requirement of the entire protocol and allow investigators to draw 7 mL of blood for monitoring subjects' safety after the completion of the study. 5. Negative urine pregnancy test for women and no breast-feeding. 6. Absence of significant diseases or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or surgery during the screening. Some of the laboratory values e.g. Complete blood count etc. that out of the normal range will be carefully considered by physician. Exclusion Criteria: 1. History or evidence of allergy or hypersensitivity to Esomeprazole, substituted benzimidazoles e.g. Omeprazole, Lansoprazole, Dexlansoprazole, Pantoprazole, Albendazole, Mebendazole or any of the excipients of this product. 2. Subject with B.P. is Systolic B.P \ 100 beats per minute. 3. Serum bilirubin greater than 1.5 times the upper limit of reference range (ULRR).\* 4. Serum creatinine greater than 1.5 times the upper limit of reference range (ULRR).\* 5. Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2 times the upper limit of reference range (ULRR).\* 6. Positive of hepatitis B or C virus or HIV. 7. Have more than one abnormal EKG, which is considered as clinically significant. \* 8. History or evidence of heart (unstable angina pectoris, myocardial infarction, cardiovascular), stroke, renal, hepatic disease, pulmonary obstructive disease, bronchial asthma, diabetes mellitus with vascular disease, gout disease, hypertension or glaucoma. 9. History or evidence of gastrointestinal disorder likely to influence drug absorption or previous GI surgery other than appendectomy. 10. Any major illness in the past 3 months or any significant ongoing chronic medical illness. 11. History of psychiatric disorder. 12. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study. 13. History of usually smoking (more than 10 cigarettes per day within past 1 year), if moderate smokers (less than 10 cigarettes per day) cannot stop at least 7 days before the study drug administration and until the completion of the study. 14. High caffeine consumption (more than 5 cups of coffee or tea per day) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study. 15. History of grapefruit, pomelo or grapefruit products consumption and cannot stop at least 7 days before the study drug administration and until the completion of the study. 16. History of St. John's Wort or St. John's Wort product consumption and cannot stop at least 7 days before the study drug administration and until the completion of the study. 17. Positive drug abused test in urine (Benzodiazepines, Marijuana (THC), Methamphetamine, Cocaine and Opioids). 18. Receipt of any prescription drug therapy within 14 days or 5 half-lives (whichever longer) preceding the first dose of study medication or over-the-counter (OTC) drugs or herbal medicines/food supplement within 7 days or hormonal methods of contraception within 28 days (Depo-Provera must be discontinued at least 6 months) prior to receiving the first dose of study medication. 19. History of difficulty in accessibility of veins in left and right arm. 20. Blood donation (one unit or 450 mL) within the past 3 months before the study. 21. Participation in any clinical study within the past 3 months before the study. 22. Subjects who are unwilling or unable to comply with the lifestyle guidelines described in this protocol. (\* Depend on decision of principal investigator and/or clinical investigator)",18.0,55.0,['healthy subjects']
NCT06157697,Social Transfers for Exclusive Breastfeeding in Brazil,"Social Transfers for Exclusive Breastfeeding in São Paulo, Brazil",RECRUITING,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Gave birth in the last 72 hours * Exclusively breastfeeding at time of recruitment and intend to continue to exclusively breastfeed * Part of or eligible Bolsa Familia or on the Bolsa Familia list (CAD Unico) * Lives in São Paulo * No illnesses that contraindicates breastfeeding * Had a healthy singleton infant of 37 weeks or more gestation with a birth weight of at least 2500 grams * Agrees to participate and sign an informed consent; if under age (12-17 years), a legal representative will also have to agree to sign the informed consent Exclusion Criteria: * Plans to move permanently outside study area * Has a medical, intellectual or psychological disability * Contraindication for breastfeeding * Preterm births * Children born with \< 2500 grams",18.0,50.0,"['breast feeding, exclusive', 'breastfeeding', 'development, child', 'development, infant']"
NCT04783597,Early Prediction of Preeclampsia Using arteriaL Stiffness in High-risk prEgnancies,Early Prediction of Preeclampsia Using arteriaL Stiffness in High-risk prEgnancies; a Multinational Study (PULSE),RECRUITING,OBSERVATIONAL,FEMALE,"Inclusion Criteria: * Singleton pregnancy * Presence of at least 1 high-risk factor or 2 moderate-risk factors for pre-eclampsia Exclusion Criteria: * \>14 weeks gestation * Multiple pregnancy * History of heart disease, stroke, or peripheral arterial disease * Infectious diseases/conditions, such as Hepatitis B/C, HIV, and COVID19",18.0,65.0,"['high risk pregnancy', 'arterial stiffness', 'pre-eclampsia']"
NCT01341197,Fecal Screening Assay for Taiwanese Population,A Pan-detecting Assay Based on Stool Samples for Taiwanese Population,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * subjects who received three fecal tests and receive confirmatory endoscopic diagnosis Exclusion Criteria: * subjects who had overt gastrointestinal bleeding (e.g., hematemesis, tarry stool, melena, and hematochezia) that would normally push the patients to seek immediate health care instead of participating in screening programs. * subjects who do not receive the fecal tests * subjects who do not receive the confirmatory endoscopic diagnosis * subjects who had undergone gastrectomy or colectomy",18.0,95.0,"['advanced colorectal neoplasms', 'throat cancer', 'esophageal cancer', 'gastric cancer', 'important lower and upper gastrointestinal tract lesions']"
NCT04734197,"A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease","A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Adults at least 18 years of age at the time of the Screening visit. 2. Willing and able to read, sign, and date the informed consent form (ICF) after the nature of the study has been explained and any questions have been answered, and prior to initiation of any study procedures or exams. 3. Willing and able to comply with all study procedures and attend all study visits. 4. Willing to suspend use of tear substitutes at least 72 hours prior to Visit 2 (Day 0) through Visit 7 (Day 98). 5. Best corrected visual acuity (BCVA) of 0.7 log of the minimum angle of resolution (logMAR) or better (Snellen equivalent score of 20/100 or better) in each eye at Visit 1 (Day -14 to Day 0). 6. Subject-reported history of dry eye in both eyes. 7. Meeting ALL of the following criteria in the same eye at Visit 1 (Day -14 to Day 0) and meeting ALL of the following criteria in the same eye at Visit 2 (Day 0) if Visit 2 is performed \>5 days after Visit 1: 1. Minimum score of greater than or equal to 5 but less than or equal to 9 on UNC DEMS questionnaire. 2. Schirmer Tear Test (with anesthesia) equal to or less than 10 mm, but more than 1 mm. 3. TBUT: Equal to or less than 5 seconds 8. A negative urine pregnancy test if female and of childbearing potential (those who are not surgically sterilized \[bilateral tubal ligation, hysterectomy, or bilateral oophorectomy\] or post-menopausal \[12 months after last menses\] or premenarchal) and must have used adequate birth control throughout the study period (through Visit 7 \[Day 98\]). Adequate birth control is defined as hormonal-oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as condom or diaphragm; intrauterine device; abstinence; or surgical sterilization of male partner. 9. Subjects with secondary Sjögren's syndrome (e.g., rheumatoid arthritis, systemic lupus erythematosus) or other autoimmune diseases (e.g., multiple sclerosis, inflammatory bowel disease) are eligible for study consideration provided the subject meets all other inclusion and exclusion criteria, AND are not in a medical state - in the opinion of the principal investigator - that could interfere with study parameters, are not taking systemic/ocular steroids, and are not immunodeficient/immunosuppressed (e.g., receiving systemic immunomodulating or immunosuppressive drugs to manage their baseline medical state). Exclusion Criteria: 1. Contraindications or known hypersensitivity to the study drug(s), including RESTASIS or XIIDRA, or their components. 2. Subjects who are employees or immediate family members of employees at the investigational site. 3. Subjects who are members of the same household. 4. Any ocular condition that, in the opinion of the investigator, may affect study parameters including, but not limited to, lid margin disorders (e.g., blepharitis including staphylococcal, demodex, or seborrheic; excessive lid laxity, floppy eyelid syndrome, ectropion, entropion), advanced conjunctivochalasis, Salzmann's nodular degeneration, and asthenopia-related conditions, allergic conjunctivitis, glaucoma, diabetic retinopathy, follicular conjunctivitis, iritis, uveitis, wet-exudative age-related macular degeneration, retinal vein occlusion, and/or active ocular inflammation. 5. Any condition that could affect trigeminal nerve function including facial or ocular Herpes Zoster/Shingle, a stroke or nerve palsy affecting the eye(s). 6. Use of any topical medication and/or antibiotics for the treatment of blepharitis or meibomian gland disease in either eye within 14 days prior to Visit 2 (Day 0). 7. Active or history of ocular herpes or any other ocular infection in either eye within the last 30 days prior to Visit 1 (Day -14 to Day 0). 8. Unwilling to avoid wearing contact lenses for 7 days prior to Randomization (Visit 2, Day 0) and for the duration of the study period (through Visit 7, Day 98). 9. Positive urine pregnancy test at Screening, nursing an infant or planning to become pregnant during the study. 10. Any blood donation or significant loss of blood within 56 days of Visit 1 (Day -14 to Day 0). 11. Any history of immunodeficiency disorder, human immunodeficiency virus (HIV), positive hepatitis B, C, or evidence of acute active hepatitis A (anti-hepatitis A virus immunoglobulin M), or organ or bone marrow transplant. 12. Any medication (oral or topical) known to cause ocular drying that is not administered as a stable dose for at least 30 days prior to Visit 1 (Day -14 to Day 0) and for the duration of the study (Visit 7, Day 98); antihistamines are not allowed at any time during the study. 13. Use of prohibited medications (topical, topical ophthalmic and/or systemic, during the appropriate pre-study washout period (see below) and during the study. Prohibited medications include topical cyclosporine or lifitegrast, use of any other ophthalmic medication (e.g., glaucoma medication, topical anti-inflammatory eye drops) for the duration of the study) NOTE: Supplements containing omega-3 are allowed if the subject has been taking said supplement for at least 3 months prior to Screening. Subjects are not allowed to begin taking supplements containing omega-3 during the study. The appropriate pre-study washout period is as follows: 1. Antihistamines (including ocular): 7 days prior to Visit 1 (Day -14 to Day 0). 2. Topical cyclosporine or lifitegrast or omega-3s within 14 days prior to Visit 1 (Day -14 to Day 0). 3. Corticosteroids or mast cell stabilizers (including ocular): 14 days prior to Visit 1 (Day -14 to Day 0). 4. Depot-corticosteroids in either eye at least 45 days prior to the first dose of study drug (Day 0) 5. All other topical ophthalmic preparations (including artificial tear substitutes other than the study drops): 72 hours prior to Visit 1 (Day -14 to Day 0). 6. Introduction of any new, nonsteroidal anti-inflammatory drugs (NSAIDs) including but not limited to topical, systemic (including sleep-aids containing NSAIDs), inhaled, or irrigation solution within 7 days prior to the first dose of study drug. Subjects who are on stable dose of NSAIDs (stable for at least 4 weeks prior to the first dose of study drug) are eligible for participation and should remain on a stable dose throughout the duration of the study (i.e., through Day 98). 7. Triamcinolone in either eye at least 90 days prior to the first dose of study drug (Day 0). 8. Inhaled, ingested, sublingual, transdermal or topical products containing marijuana, tetrahydrocannabinol (THC) or cannabidiol (CBD) at least 7 days prior to the first dose of study drug (Day 0). 9. Systemic pain relievers, analgesics (e.g., pregabalin, gabapentin, opioids) 14 days prior to the first dose of study drug (Day 0). 10. Any supplement, prescribed medication or over-the-counter product that the investigator feels may interfere with the study parameters, including homeopathic remedies, analgesics, and pain medication. 11. Oral doxycycline within 6 months of first dose of study drug (Day 0). 12. Diuretics: Within 28 days prior to Visit 1 (Day -14 to Day -1). 13. Punctal occlusion: i. Punctal cauterization: Randomization may not occur until 4 weeks following the procedure. ii. Permanent/semi-permanent punctal plugs (this includes 180-day punctal plugs): Randomization may not occur until 4 weeks following the procedure. If a punctal plug falls out during the study, it should be reinserted. iii. Temporary collagen punctal plugs: Not permitted. If subject has a history of use of temporary punctal plugs, randomization may not occur until 4 weeks since last insertion and puncta are plug-free, as determined by the investigator. 14. Any significant chronic illness that, in the opinion of the investigator, could interfere with the study parameters, including, but not limited to, severe cardiopulmonary disease, poorly controlled hypertension, and/or poorly controlled diabetes. 15. Use of any investigational product or device within 30 days prior to Visit 1 (Day -14 to Day 0) or during the study period. 16. History of LASIK or similar type of corneal refractive surgery within 12 months prior to Visit 1 (Day -14 to Day 0), and/or any other ocular surgical procedure within 12 months prior to Visit 1 (Day -14 to Day 0); or any scheduled ocular surgical procedure during the study period. 17. Use of any laser procedure for the eyes in the 30 days prior to Visit 1 (Day -14 to Day 0). 18. Known history of alcohol and/or drug abuse within the past 12 months that in the opinion of the principal investigator, may interfere with study compliance, outcome measures including safety parameters, and/or the general medical condition of the subject. 19. Subjects with dry eye secondary to scarring (such as that seen with irradiation, alkali burns, Stevens Johnson syndrome, cicatricial pemphigoid) or destruction of conjunctival goblet cells (as with vitamin A deficiency) are not eligible for the study. Subjects with incidental scars secondary to refractory surgery (i.e., LASIK surgery) that, in the opinion of the principal investigator, would not interfere with study compliance and/or outcome measures, are not excluded from the study. 20. Subjects who test positive for the COVID-19 virus within 30 days prior to Visit 1 (Day -14 to Day 0).",18.0,65.0,['dry eye disease']
NCT03006497,Exercise Program Based on Motor Learning and Forward Head Posture Correction,The Efficacy of Exercise Program Based on Motor Learning Principles in Correction of Forward Head Posture,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Students at Technological Educational Institute of Sterea Ellada, * Aged 18-26 years old * Males and females * Craniocervical angle \ 25 * Participation in any rehabilitation or physiotherapy sessions considering neck dysfunction the last 6 months * Change in physical activities during the research period of 6 weeks",18.0,26.0,"['musculoskeletal abnormalities', 'deformity']"
NCT01632397,Pre-exposure Prophylaxis Adherence Intervention for MSM,Optimizing Antiretroviral-Based Prevention by Enhancing PrEP Adherence in MSM,COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: * male sex at birth * being 18 years old or older * testing HIV-negative at screening * evidence of high risk for HIV acquisition defined by having unprotected anal sex (insertive or receptive) with an HIV-positive male partner OR at least a total of three episodes of unprotected anal sex with at least two partners in the last three months * medically cleared to take the study drug (ambulatory performance \>=60 on Karnofsky scale, adequate renal function, negative glucose and protein in urine, adequate hepatic function, adequate hematologic function) * able to understand and speak English (for consenting and counseling). Exclusion Criteria: * participants who are not able to consent due to psychiatric or cognitive concerns * those who have already been prescribed PrEP * having a history of or current medical conditions that would preclude taking the study drug (e.g., previously diagnosed active and serious infections, acute or chronic hepatitis B, history of pathological bone fractures not related to trauma) * receiving ongoing therapy with ART, other agents with significant nephrotoxic potential, other agents that may inhibit or compete for elimination via active renal tubular secretion, or other investigational agents * receiving or possibly receiving antiretroviral drugs for an anti-HIV vaccine in a clinical trial * active alcohol or drug use that would interfere with study participation * having other conditions (based on opinion of investigator or designee) that would preclude informed consent, make the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with study procedures",18.0,65.0,['medication adherence']
NCT04322097,Mechanisms of Upper Airway Obstruction,Characterizing Mechanisms of Upper Airway Obstruction During Drug-Induced Sleep Endoscopy (DISE),COMPLETED,INTERVENTIONAL,ALL,"Study A Inclusion Criteria: • Scheduled to undergo DISE as part of routine clinical standard of care. Study B Inclusion Criteria: * Adults (≥ 22yrs) willing and capable of providing informed consent * Implanted with the MRI-conditional Inspire hypoglossal nerve stimulator (Model 3028 or later) * Compliant with Inspire therapy (\> 20 hours/week over 2+ weeks) as a standalone treatment for sleep-disordered breathing * Inspire remote model 2500 or later. Study B Exclusion Criteria: * MRI contraindications (claustrophobia, ferromagnetic implants/foreign bodies, etc.) * Inspire Implant Model 3024 * Inspire Remote Model 3032 * Patients who have fallen asleep while during resulting in an accident or ""near miss"" accident within 1 year prior to device implantation. * Inability to sleep in the supine position (by self-report) * History of severe difficulty initiating or maintaining sleep in the laboratory * Pregnant women",22.0,65.0,['obstructive sleep apnea']
NCT06344897,The Effect of Kinesio Taping in Pediatric Surgery,Effectiveness of Kinesio Tape Applied After Open Appendectomy Surgery in Children: Randomized Controlled Study,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Open appendicitis surgery was performed, * Are between the ages of 6-12, * Conscious, literate and without hearing or speech problems, * Children who do not have a mental disorder and agree to participate in the research will be included. Exclusion Criteria: * Exclusion Criteria: * Do not apply analgesic treatment other than routine application. * Patients who develop complications during the operation will be excluded from the study. * Those with acute appendicitis or Angenesis appendicitis",6.0,12.0,"['appendicitis', 'surgery', 'pain, acute']"
NCT04548297,Clinical Factors Associated With Position Sense in Patients With Multiple Sclerosis,Clinical Factors Associated With Position Sense in Patients With Multiple Sclerosis,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * 18-65 years of age * Having a diagnosis of ""Multiple Sclerosis"" * Relapse free in the last 3 mounts * Ambulatory status (Expanded Disability Status Scale score ≤ 6 ) * No diagnosis of depression Exclusion Criteria: * Any cardiovascular, orthopedic, visual, and hearing problems that may affect the results of the research",18.0,65.0,['multiple sclerosis']
NCT05407597,Inhibition of Bradykinin in COVID-19 Infection With Icatibant,"Prospective, Randomised, Double-blind Trial of Icatibant Compared to Placebo in Patients With Early Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Infection",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Age \>18 years. 2. Documented evidence of COVID-19 and symptom onset of 7 days or less 3. Acute hypoxia which will be defined as either low resting saturations \ 94% Exclusion Criteria: 1. Patients known to be pregnant or breastfeeding. 2. Patients with unstable ischaemic heart disease or acute stroke 3. Patients enrolled in other clinical trials of an investigational medicine within the previous 28 day period 4. Patients who refuse to have blood samples taken. 5. Known hypersensitivity to Icatibant 6. Patients who at time of consent are likely to require imminent non-invasive/ invasive ventilatory support or patients already established on continuous positive airway pressure (CPAP). 7. Patients with chronic heart or lung disease whose oxygen levels are reduced, but are unchanged from baseline",18.0,65.0,['sars cov 2 infection']
NCT00879710,Effect of Diabetes Mellitus on Cholesterol Metabolism,"Effect of Diabetes Mellitus on Cholesterol Absorption, Synthesis and Statin Efficacy",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Type 1 DM: * Age \> 18 years * Subjects diagnosed with type 1 DM (diagnosed based upon history of ketoacidosis, proven insulin dependence, absent C-peptide and or positive autoantibody profile (such as anti-GAD etc.) * Stable A1C \ 18 years * Subjects diagnosed with type II DM (diagnosed as adult onset, not-insulin dependent and not on insulin) * Stable A1C \ 2.0) * Liver function test abnormalities, not previously worked up (AST or ALT \>4x upper limit of normal) * Active substance abuse including alcohol * History of severe Hypertriglyceridemia (untreated TG \> 500) and on therapy * Use of agents that interfere with cholesterol absorption (such as fiber, resins etc.) which can not be discontinued for the duration of the study * Actively enrolled in a weight loss program or following a special diet ( e.g.: Atkins diet) * History of malignancy \ 1 quart per day) * Proteinuria: more than or equal to 300mg/24 hours calculated from random urine specimen. * BMI \>31 * Anyone with hypersensitivity to either one of the study medications * Allergy to Soy bean products * Unable to consume milk products with or without Lactaid®",18.0,65.0,"['type 1 diabetes mellitus', 'type 2 diabetes mellitus', 'hypercholesterolemia']"
NCT04409210,Cardio-Cerebrovascular Co-Prevention and Co-Management Based on Internet+,"Development, Demonstration and Evaluation of Model of Cardiovascular and Cerebrovascular ""Co-Prevention and Co-Management"" Based on Internet+",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: Family physician teams: 1. The number of residents served is more than 30,000; 2. The proportion of high-risk population of cardio-cerebrovascular diseases is more than 8%; 3. manage the health records of residents; 4. have a health examination for the residents once a year; 5. Family doctors have smartphones. Participants: 1. Aged ≥18 years; 2. Meet any of the following indicators: 1\) LDL-C\>4.9mmol/L or TC\>7.2mmol/L; 2) Diabetic patients (age \>40 years old): 1.8mmol/L≤LDL-C\<4.9mmol/L（or）3.1mmol/L≤TC\<7.2mmol/L; 3) The predicted risks measured by China-PAR model of ≥10%; 4) Patients with predicted risks measured by China-PAR model of ≥5% and \<10%, and meet with two or more risk factors as following: 1. Systolic Blood Pressure ≥ 160mmHg or Diastolic Blood Pressure ≥ 100mmHg, 2. BMI≥28kg/m2, 3. Non- HDL-C≥5.2mmol/L, 4. Smoking, 5. HDL-C\<1.0mmol/L. (3) Local permanent residents (more than 5 years); (4) No severe physical disability, clear consciousness and normal communication; (5) The participants in the intervention group or their families have smartphones; (6) Disease and death are under the management of the local health department; (7) Sign the informed consent form voluntarily. Exclusion Criteria: Family physician teams: 1. The establishment of residents' health records is incomplete; 2. The main population served are temporary residents and floating population. Participants: 1. Temporary residents and floating population; 2. Those who have serious health conditions and are unable to participate in this study; 3. Those who are unwilling to accept the follow-up inspection; 4. According to the judgment of the researchers, it is not suitable to participate.",18.0,65.0,"['cardiovascular diseases', 'myocardial ischemia', 'cerebrovascular disorders', 'stroke', 'internet-based intervention']"
NCT03315910,Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites,Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: Site Eligibility (as per SC self-report) \& Must be designated as an American College of Radiology (ACR) designated lung cancer screening site * Reports at least one year of lung cancer screening experience * Reports conducting at least 20 new initial screenings per month Site Coordinator (SC) Eligibility (as per SC self-report) * Employed as a full-time Site Coordinator at participating lung cancer screening site Patient Eligibility (as per self-report) * Between the ages of 50-80 years old * Seeking baseline or annual follow-up LDCT lung cancer screening * Have at least a 20 pack-year history of smoking * Currently a smoker, defined as self-reported cigarette smoking (some days, every day) within the past 30 days. * Must be reachable by telephone * Must be English or Spanish speaking due to the study materials being available in only these languages and limited available resources for translation. Exclusion Criteria: Patient (as per self-report) * NRT is medically contraindicated (e.g., recent heart attack within the last 2 weeks or, unstable/worsening angina). * Smokers who are receiving other tobacco treatment services or have used cessation medications (NRT, bupropion, varenicline) within the past month.",50.0,80.0,['smoking cessation']
NCT05346510,Prone Positioning CT Scan and Ultrasound Assessing Axillary Lymph Nodes in Patients With Breast Cancer Official Title: Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer,Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer,RECRUITING,INTERVENTIONAL,FEMALE,Inclusion Criteria: * Preoperative chest CT and axillary Doppler ultrasound examination in the prone position * Perform ALND * Regular post surgery follow-up (short-term and long-term) Exclusion Criteria: •History of other benign or malignant tumors causing axillary lymphadenopathy,18.0,70.0,['breast cancer']
NCT04872010,Construction of a Database for the Life-cycle Sepsis-specific Disease Cohort,Construction of a Database for the Life-cycle Sepsis-specific Disease Cohort,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: 1. Patients with sepsis who meet the Sepsis 3.0 standard proposed by the 2016 International Sepsis Expert Consensus, that is, for patients with infection or suspected infection, when sepsis-related sequential organ failure (Sequential (Sepsis-related) Organ Failure) Assessment (SOFA) score increased by ≥ 2 points from the baseline can be diagnosed as sepsis; 2. It is estimated that the patient's ICU stay ≥24 hours; 3. Obtain informed consent and sign an informed consent form. Exclusion Criteria: 1. The patient's ICU hospital stay is less than 24 hours; 2. Participated in other clinical research; 3. Failed to sign the informed consent form.",1.0,100.0,['sepsis']
NCT05065710,A Study of ZL-1211 in Patients With Advanced Solid Tumor,"A Phase I, First-in-Human, Open-Label, Dose Escalation Study of ZL- 1211 in Patients With Unresectable or Metastatic Solid Tumor",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: Patients are eligible to be included in the study only if all the following inclusion criteria apply: 1. Adults≥ 18 years of age. 2. Willing and able to provide signed and dated informed consent prior to any study related procedures and willing and able to comply with all study procedures. 3. All patients from Phase I and Phase II are required to provide tumor tissue for CLDN18.2 IHC assessment, and only patients with CLDN18.2-positive tumors will be included in this study. 4. Patients with histologically or cytologically confirmed metastatic or locally advanced solid tumors, refractory to standard treatment 5. Evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 7. Adequate hepatic function 1. Total bilirubin ≤ 1.5 × upper limit of normal (ULN). 2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; AST or ALT ≤ 5 × ULN if liver metastases are present. 8. Adequate renal function, as defined by serum creatinine \ 40 mL/min, Cockroft-Gault Equation: 9. Hematological function defined as: 1. Absolute neutrophil count ≥ 1.5 × 109/L without growth factor support in the 2 weeks prior to screening. 2. Platelet count ≥ 100 × 109/L without transfusion in the 2 weeks prior to screening. 3. Hemoglobin ≥ 9 g/dL without transfusion in the 2 weeks prior to screening. 10. Prothrombin time, international normalized ratio or/and activated partial thromboplastin time \< 1.5 × ULN. 11. Recovery, to Grade 0-1, from AEs related to prior anticancer therapy except alopecia, \< Grade 2 sensory neuropathy, lymphopenia. Exclusion Criteria: 1. Patient with known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome related illness or known active or chronic hepatitis B virus infection or hepatitis C virus. 2. Any uncontrolled active infection. 3. Previous exposure to any CLDN18.2 antibody or CLDN18.2 chimeric antigen receptor T cell therapy. 4. Newly diagnosed or symptomatic brain metastases anticonvulsants are allowed. 5. Severe cardiovascular disease; New York Heart Association Class II-IV heart failure within 6 months of screening; uncontrolled arrhythmia within 6 months of screening. 6. Anticancer therapy or radiation therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to screening; palliative radiotherapy within 2 weeks prior to screening. 7. Major surgery within 4 weeks prior to first dose; minor surgery within 2 weeks prior to first dose. 8. Symptomatic intrinsic lung disease (chronic obstructive pulmonary disease, pulmonary fibrosis). 9. Gastrointestinal abnormalities including: 1. Documented unresolved gastric outlet obstruction or persistent vomiting defined as ≥ 3 episodes within 24 hours. 2. Active peptic ulcer disease required treatment in the past 3 months. 3. Gastrointestinal bleeding as evidenced by hematemesis, hematochezia, or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy. 4. Documented active colitis within 4 weeks prior to study entry, including infectious colitis, radiation colitis and ischemic colitis. 5. History of ulcerative colitis or Crohn's disease. 10. Patient has received systemic immunosuppressive therapy, including systemic corticosteroids 2 weeks prior to first dose of study drug.",18.0,65.0,['advanced solid tumor']
NCT02604810,Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency,"An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Pre-existing diagnosis of primary immunodeficiency with features of hypogammaglobulinemia requiring IgG replacement therapy * No serious bacterial infection within the last 3 months prior to or during Screening * Currently on IgG replacement therapy (via IV or SC infusion) for ≥3 consecutive months. Subjects receiving IGIV must be receiving a dosage of 300 to 800 mg/kg per infusion * Documented (at least once within previous 3 months) IgG trough level of ≥500 mg/dL on current IgG replacement therapy regimen Exclusion Criteria: * Known serious adverse reaction to immunoglobulin or any severe anaphylactic reaction to blood or any blood-derived product * History of blistering skin disease, clinically significant thrombocytopenia, bleeding disorder, diffuse rash, recurrent skin infections, or other disorders where SC therapy would be contraindicated during the study * Isolated IgG subclass deficiency, isolated specific antibody deficiency disorder, or transient hypogammaglobulinemia of infancy * Nephrotic syndrome, and/or a history of acute renal failure and/or severe renal impairment, and/or on dialysis * History (year prior to Screening or 2 episodes in lifetime ) of or current diagnosis of deep venous thrombosis or thromboembolism (eg, deep vein thrombosis, myocardial infarction, cerebrovascular accident or transient ischemic attack) * Acquired medical condition known to cause secondary immune deficiency, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (absolute neutrophil count less than 1000/μL \[1.0 x 10\^9/L\]), or human immunodeficiency virus infection/acquired immune deficiency syndrome * Known previous infection with or clinical signs and symptoms consistent with current hepatitis B virus or hepatitis C virus infection * Non-controlled arterial hypertension (systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>100 mmHg in adult subjects) * Receiving any of the following medications: (a) immunosuppressants including chemotherapeutic agents, (b) immunomodulators, (c) long-term systemic corticosteroids defined as daily dose \>1 mg of prednisone equivalent/kg/day for\>30 days Note: Intermittent courses of corticosteroids of not more than 10 days would not exclude a subject. Inhaled or topical corticosteroids are allowed.",2.0,75.0,['primary immunodeficiency']
NCT01168310,A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD),"A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Pharmacodynamic Response of Fluticasone Propionate in Fixed-Dose Combination With Formoterol Fumarate in Subjects With COPD",COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Able to understand the requirements of the study and provide written informed consent * A clinical diagnosis of COPD * A current or prior history of at least 10-pack years of cigarette smoking * Women of child-bearing potential (WOCBP) must have a negative pregnancy test at the screening visit and agree to avoid becoming pregnant for the duration of study Exclusion Criteria: * A clinical diagnosis of Asthma * Other significant disease than COPD * Subjects who radiation or chemotherapy within the previous 12 months * Subjects who had any lung resection * QTcB greater than 0.460 seconds * History of illegal drug abuse or alcohol abuse within the past 5 years,40.0,65.0,['chronic obstructive pulmonary disease']
NCT04554810,Pharmacists Improving Refugees' Adherence and Knowledge of Their Chronic Medications,Improving Syrian Refugees' Knowledge of Medications and Adherence Following a Randomized Control Trial Assessing the Effect of a Medication Management Review Service,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * being Syrian refugee ≥ 18 years, living in Jordan for more than six months prior to study recruitment and intending to stay for the whole study period * having one chronic condition at least or taking 5 or more medications or taking more than 12 doses of a medication per day Exclusion Criteria: * Patients with cognitive or sensory impairment that may prevent conducting the interview. * Patients who are planning to travel within the next six months after the baseline home-visit * Patients who are not capable of reading or writing",18.0,65.0,"['diabetes', 'hypertension', 'dyslipidemias', 'cardiac disease', 'asthma']"
NCT00570310,Neuropathic Pain Syndrome Patient Study (MK-0000-072),"A Double-Blind, Placebo-Controlled, Enriched-Enrollment, Randomized Withdrawal Study to Evaluate an Optimal Methodology for Conducting Proof of Concept Trials in Patients With Chronic Neuropathic Pain Syndromes Using Pregabalin as a Test Drug",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patient has moderate to severe nerve pain due to one of the following conditions: Postherpetic neuralgia, Painful diabetic neuropathy, Small fiber neuropathy or idiopathic distal sensory polyneuropathy * Patient is able to complete questionnaires in either English or Spanish * Patient is at least 18 years of age Exclusion Criteria: * Patient is either pregnant or breastfeeding * Patient has a history of angioedema (swelling beneath the skin surface) or peripheral edema (foot, leg, and/or ankle swelling) * Patient has a history of congestive heart failure * Patient has a seizure disorder * Patient has a history of drug and/or alcohol abuse within the past 1 year * Patient failed treatment due to lack of pain relief with more than three drugs for nerve pain * Patient has had cancer (except basal cell carcinoma) within the past two years * Patient anticipates the need for surgery while participating in the study * Patient has a reported history of hepatitis B, C, or HIV infection * Patient has another type of pain that is more painful than the nerve pain * Patient has generalized anxiety disorder, untreated depression, psychosis, or post-traumatic stress disorder * Patient is involved in litigation or receives worker's compensation related to nerve pain",18.0,65.0,"['neuralgia, postherpetic', 'diabetic neuropathy', 'painful small-fiber neuropathy', 'idiopathic distal sensory polyneuropathy']"
NCT05632510,PREVENTION OF PERINATAL DEPRESSION BY EPDS DURING THE FIRST PRENATAL CONSULTATION AT MATERNITY DEPARTMENT,PREVENTION OF PERINATAL DEPRESSION BY EPDS DURING THE FIRST PRENATAL CONSULTATION AT MATERNITY DEPARTMENT: A CLUSTER-RANDOMIZED CONTROLLED TRIAL,UNKNOWN,INTERVENTIONAL,FEMALE,"Inclusion Criteria: Adult women (aged \> 18 years) * Between 10 and 24 weeks pregnancy * Fluent in written and spoken French (can understand a self-administered questionnaire); * Affiliated to a social security scheme * Informed consent obtained Exclusion Criteria: * Reported diagnosis of schizophrenia or physical and intellectual state incompatible with a clinical evaluation * Persons unable to give their consent * Unable adults (maintenance of justice, tutelage, legal guardianship) * Person deprived of her liberty * Patient on AME (state medical aid)",18.0,65.0,['peripartum depression (ppd)']
NCT01360710,The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension,"The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial",UNKNOWN,INTERVENTIONAL,MALE,"Inclusion Criteria: * male age 18-30 years old * presence of central obesity and hypertension * no history of cardiovascular disease or depression * not on any medication Exclusion Criteria: * history of cardiovascular disease, depression or anxiety disorder",18.0,30.0,"['abdominal obesity', 'hypertension']"
NCT02559310,Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia,"A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Be male or female at least 18 years of age. 2. Provide written informed consent and be willing and able to adhere to the study-specified procedures and restrictions. 3. Have an acute illness (7 days duration) with at least 3 of the following symptoms consistent with a lower respiratory tract infection (new or worsening): * Dyspnea * New or increased cough * Purulent sputum production * Chest pain due to pneumonia 4. Have at least 2 of the following vital sign abnormalities: * Fever (body temperature \>38.0°C (100.4°F) measured orally or equivalent temperature from an alternate body site) or hypothermia (body temperature \ 100 beats/min) * Tachypnea (respiratory rate \>20 breaths/min) 5. Have at least 1 other clinical sign or laboratory finding of CABP: * Hypoxemia (i.e., O2 saturation \ 10,000 cells/mm3 or \ 15% immature neutrophils (bands) regardless of total WBC count 6. Have radiographically-documented pneumonia within 48 hours before enrollment (i.e., infiltrates in a lobar or multilobar distribution or diffuse opacities on chest x-ray or chest computed tomography scan consistent with acute bacterial pneumonia). 7. Have a Pneumonia Outcomes Research Team (PORT) Risk Class ≥III. Exclusion Criteria: 1. Have received more than a single dose of a short-acting oral or IV antibacterial for CABP within 72 hours before randomization 2. Require concomitant systemic antibacterial therapy potentially effective against CABP pathogens 3. Have been hospitalized for 2 or more days within 90 days prior to the onset of symptoms or have resided in a nursing home or long-term healthcare facility within 30 days prior to the onset of symptoms. NOTE: Residence in an independent living facility is permitted. 4. Have confirmed or suspected CABP caused by a pathogen known to be resistant to any of the study drugs (e.g., Pseudomonas aeruginosa, any pathogen of the Enterobacteriaceae Family) or attributable to etiologies other than community acquired bacterial pathogens (e.g., ventilator associated pneumonia, hospital acquired bacterial pneumonia, bacterial aspiration pneumonia, Pneumocystis jiroveci pneumonia or other fungal pneumonia, viral or mycobacterial infection of the lung). 5. Have a noninfectious cause of pulmonary infiltrates (e.g., pulmonary embolism, chemical pneumonitis from aspiration, hypersensitivity pneumonia, congestive heart failure, bronchial obstruction, lung cancer, cystic fibrosis). 6. Have confirmed or suspected pleural empyema (does not include sterile parapneumonic effusions). 7. Require mechanical ventilation.",18.0,65.0,['community acquired pneumonia']
NCT06511310,"Exercise, Brain Activity, and Weight Maintenance",Effects of Exercise Training on Brain Activity and Its Relation to Weight Maintenance and Appetite Regulation,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age 18-70 years * Body mass index (BMI) \>19 kg/m2 and body weight\ 160 mmHg or diastolic \>90 mmHg) * Inability to exercise for any reason * Any known contraindication to exercise testing based on current ACSM guidelines * MRI contraindications, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body * Known presence of a structural brain lesion (e.g. tumor, cortical infarct) * Presence of another neurologic disorder, which could impact findings (e.g. multiple sclerosis) * History of cardiovascular disease, stroke, congestive heart failure * Active hematological, renal, pulmonary or hepatic disorders * Active treatment for cancer * A history of active alcohol or substance abuse * Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol * History of claustrophobia and inability to tolerate an MRI * Body weight \>250kgr and largest body diameter of 70cm as there is a certain weight and diameter limit of the MRI scanner * Unwilling or unable to return for study visits, undergo neuropsychological testing and MRI imaging * Left-handedness",18.0,70.0,"['obesity', 'weight gain', 'bariatric surgery candidate', 'appetitive behavior']"
NCT02417610,Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid,"Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid to Viscosupplementation With Hyaluronic Acid in the Treatment of Osteoarthritis of the Knee. Randomized, Double-blind, Controlled Study",COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Age between 50 and 75 years * Patients informed consent * Knee OA (Osteoarthritis) (ACR classification) with a Kellgren Laurence from 1 to 4 * Knee pain from arisen at least 2 months * BMI lower than 40 Exclusion Criteria: * Pregnancy or lactation * Severe systemic disorders * History of drug abuse or alcoholism * Hypersensibility to Hyaluronic acid or Polynucleotide * No previous intra articular infiltration (from 3 months) * No steroidal or anticoagulant systemic therapy from one month * Knee articular deformity * Patients affected by rheumatoid arthritis or other inflammatory articular pathologies and hematological disorders * Focal skin lesion in the anatomical site of injections,50.0,75.0,['osteoarthritis']
NCT01017510,Comparative Study Examining the Effectiveness in Use of a DERMOJET and a Normal Syringe Treatment for Patients With Hair Loss - Alopecia Areata,Comparative Study Examining the Effectiveness in Use of a DERMOJET and a Normal Syringe Treatment for Patients With Hair Loss - Alopecia Areata,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: 1. Subjects over the age of 18 2. Men and women 3. The presence of at least two lesions (centers) in diameter of at least 1.5 cm on both sides of the scalp. 4. Healthy with no diseases that constitute the background against the total label use steroids Exclusion Criteria: 1. Pregnant women 2. Involvement of more then 50% of the scalp 3. Patients with immunodeficiency-related diseases 4. Patients receiving systemic steroids,18.0,65.0,['alopecia areata']
NCT06341010,The Role of Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis,The Role of Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis,RECRUITING,OBSERVATIONAL,ALL,Inclusion Criteria: Acute IF DVT life expectancy more than 1 year Exclusion Criteria: * Recurrence of DVT Chronic DVT The catheter cannot be used in vessels smaller than 6mm. Patients have contraindications for endovascular procedures Patients cannot tolerate contrast media In patients with lesions that cannot be accessed with the guide wire Pregnancy History of pelvic surgery with left iliac vein injury or pelvic radioactive therapy,18.0,60.0,['iliofemoral deep vein thrombosis']
NCT00006213,"BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia","Phase I Study of Farnesyl Transferase Inhibitor BMS-214662 (NSC 710086) in Acute Leukemias, Myelodysplastic Syndromes (RAEB and RAEB-T) and Chronic Myeloid Leukemia in Blast Phase",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients must have: * AML, ALL, or high-risk MDS (RAEB or RAEB-t) that has: * Not responded (no CR) to initial induction chemotherapy, or * Recurred after an initial CR of \ 1 year and failed to respond to an initial reinduction attempt, or * Recurred more than once, or * Chronic myeloid leukemia in myeloid blast phase * Patients with CML blast phase may receive BMS-214662 as their first therapy for blast phase or after failing other treatments for blast phase * Patients with refractory or relapsed acute promyelocytic leukemia are eligible provided they have failed an ATRA-containing regimen * Performance status of =\ = 5 x 10\^9/L and increasing by \>= 1 x 10\^9/L/24 hours) may receive treatment before 4 weeks from the previous treatment providing they have recovered from all toxic effects of that therapy; use of hydroxyurea on patients with rapidly proliferative disease is allowed up to 24 hours prior to the start of therapy * Bilirubin =\ = 60 mL/hr * Patients who are likely to benefit from allogeneic bone marrow transplantation (i.e., age \< 60 years of physiological age with histocompatible donor) should be excluded from this study unless such therapy is not feasible Exclusion Criteria: * Pregnant and nursing females will be excluded; patients of childbearing potential should practice effective methods of contraception * Patients with prolonged QTc interval on EKG are excluded",15.0,65.0,"['adult acute promyelocytic leukemia (m3)', 'blastic phase chronic myelogenous leukemia', 'childhood myelodysplastic syndromes', 'previously treated myelodysplastic syndromes', 'recurrent adult acute lymphoblastic leukemia', 'recurrent adult acute myeloid leukemia', 'recurrent childhood acute lymphoblastic leukemia', 'recurrent childhood acute myeloid leukemia', 'refractory anemia with excess blasts', 'refractory anemia with excess blasts in transformation', 'relapsing chronic myelogenous leukemia']"
NCT00794313,Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease,Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Parkinson's Disease * At least 21 years of age * Must be taking Oral levodopa * Must have dyskinesias by history or previous clinical observation Exclusion Criteria: * Significant cognitive impairment as measured by the Montreal Cognitive Assessment (MOCA) score of \< 25 * Subjects with unstable medical or psychiatric conditions (including hallucinations) * Use of dopamine receptor blocking medications (e.g., neuroleptics, certain antiemetics, tetrabenazine) * History of unstable medical conditions (ie active cardiovascular disease, recent unwellness or surgery etc.) * Use of anticoagulants * Current substance abuse * Previous adverse event on amantadine",21.0,65.0,"[""parkinson's disease""]"
NCT01778413,Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine,Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Adults (≥ 18 years) * HIV-1 infection, clinical stability, and treatment with ATRIPLA ® for the past two years. * Standard plasma viral load below the limit of detection for at least 2 years. * CD4 count above 350/mm3 at the time of the consideration for the study. * Negative pregnancy test in women of childbearing age, and commitment acceptable contraceptive use for at least 2 weeks before day 1 and until at least 6 months after the last dose of study drug. * Patients should be given written informed consent * In the opinion of the investigator, be able to follow the design of the protocol visits Exclusion Criteria: * Patients who have experienced virologic failure prior to any antiretroviral regimen * Evidence of previous mutations versus efavirenz, tenofovir and emtricitabine * Use of any other chronic treatment plus ATRIPLA has been introduced in the 6 months prior to entry of the patient in the study * Any contraindication to study drug * Any condition not ensure proper adherence to the study at the discretion of the attending physician of the patient * Uncontrolled preexisting psychiatric illness * Any current sign of alcoholism or other drug use.",18.0,65.0,['hiv']
NCT06403813,Adolescent Digital Mental Health-Kenya Effectiveness,"Testing the Effectiveness of a Digital Adolescent Behavioral Health Screening, Literacy, and Low-Intensity Intervention for Common Adolescent Mental Health Problems in Kenya",RECRUITING,INTERVENTIONAL,ALL,"Adult parent and adolescent child will be enrolled in this study as a family. Inclusion Criteria: * Parent is over 18 years of age * Parent has as an adolescent child between 11-14 years of age who attend one of our partnering schools/community-based organizations (CBOs). * Parent is willing and able to provide consent for themselves and provide assent for their child * Adolescent is between 11-14 years in age who attend one of our partnering schools/CBOs. * One of adolescents adult parent (\>18 years old) is ""interested in"" participating in this study * Adolescent is willing and able to provide child assent Exclusion Criteria: * Parents (including biological and non-biological) who have no contact with adolescents for over 1 month",11.0,65.0,['mental disorder in adolescence']
NCT01501513,A Safety Study of 3 Different Bowel Cleansing Preparations,"A Safety, Tolerance and Efficacy Evaluation of 3 Different Bowel Cleansing Preparations in Adult Subjects, Including the Elderly and Subjects With Hepatic or Renal Insufficiency",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication. * At least 18 years of age * If female, and of child-bearing potential, is using an acceptable form of birth control * Negative urine pregnancy test at screening, if applicable * In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study Exclusion Criteria: * Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon. * Subjects who had previous significant gastrointestinal surgeries. * Subjects who have uncontrolled clinically significant pre-existing electrolyte disturbances. * Subjects with severe liver or renal insufficiency. * Subjects with a history of congestive heart failure or other clinically significant cardiac abnormality. * Subjects with impaired consciousness that predisposes them to pulmonary aspiration. * Subjects undergoing colonoscopy for foreign body removal and decompression. * Subjects who are pregnant or lactating, or intending to become pregnant during the study. * Subjects of childbearing potential who refuse a pregnancy test. * Subjects allergic to any preparation components * Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures. * Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days.",18.0,65.0,"['colonoscopy', 'bowel preparation', 'endoscopy']"
NCT07270913,The Effect of a Gender Education Program Based on the Com-B Model Developed for Newlywed Couples and Home Monitoring on Individuals and Families,The Effect of a Gender Education Program Based on the Com-B Model Developed for Newlywed Couples and Home Monitoring on Individuals and Families,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * Married 1 month ago * The woman and her husband are literate in Turkish * Being a housewife * Growing up in Şanlıurfa and residing in the center * Authorizing participation. Exclusion Criteria: * \- Married for more than 1 month or single * Being a working woman * Not knowing Turkish * Not living in the center of Şanlıurfa * Currently participating in any other intervention program,18.0,40.0,"['newly married couples', 'gender equality', 'com_b model', 'home monitoring follow-up', 'family dynamics', 'education']"
NCT00119613,A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa,"A Randomized, Double Blind, Placebo-Controlled Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Pathologically proven SCLC, extensive-stage * Planned to receive chemotherapy of carboplatin or cisplatin plus etoposide every 3 weeks for 6 cycles * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Life expectancy greater than or equal to 3 months * Hemoglobin concentration greater than or equal to 9.0 g/dL and less than or equal to 13g/dL * Adequate renal, liver and hematopoietic function * Subjects must sign and date a written Institutional Review Board /Independent Ethics Committee-approved Informed Consent Form Exclusion Criteria: * Known primary hematologic disorder which could cause anemia * Brain metastases that are either symptomatic or treated with medications * Unstable or uncontrolled disease/condition, related to or affecting cardiac function * Other known primary malignancy within the past 5 years with the exception of curatively treated basal cell carcinoma, squamous cell carcinoma in situ cervical carcinoma or surgically cured malignancies * Iron deficiency * Known positive test for human immunodeficiency virus infection * Received greater than 2 units of packed red blood cells within 4 weeks of randomization or any RBC transfusions within 2 weeks before randomization * Received rHuEPO or darbepoetin alfa therapy within 4 weeks of randomization * Previous chemotherapy for SCLC * Previous radiotherapy except as symptom palliation for bone or brain lesions and at least 24 hours since prior radiotherapy for symptom palliation providing extent of radiotherapy makes marked bone marrow suppression unlikely * Less than 30 days since receipt of any drug or device that is not approved for any indication * Pregnant or breast-feeding * Not using adequate contraceptive precautions * Previously randomized into this study * Known hypersensitivity to recombinant mammalian-derived product or any other ingredients contained in the study drug * Any medical, mental, or other conditions that makes the subject unsuitable for participation",18.0,65.0,['small cell lung cancer']
NCT01509313,A Trial Comparing Morcellation With Electrical Resection for Removal of Uterine Polyps,A Randomised Controlled Trial Comparing Morcellation With Electrical Resection for Removal of Uterine Polyps,COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Finding of a benign polyp on diagnostic hysteroscopy * Patient considered able to tolerate outpatient hysteroscopic polypectomy based upon the response to preliminary diagnostic hysteroscopy. NB. all polyps diagnosed at hysteroscopy will be considered feasible to remove in the outpatient setting regardless of size, location or number. Patient factor(s) will be the only exclusion criteria following the diagnosis of benign, uterine polyp(s). * Need for polypectomy * Written informed consent Exclusion Criteria: • Hysteroscopic features suggesting malignant lesion",16.0,65.0,['endometrial polyps']
NCT02210013,Differences in Ovarian Aging Between Caucasian and Indian Women,Ethnicity as a Determinant of Ovarian Aging: Differences Between Caucasian and Indian Women,COMPLETED,OBSERVATIONAL,FEMALE,"Inclusion Criteria: * Women aged \< 42 years old, with both ovaries present, undergoing a first or second IVF treatment due to male factor, tubal disease or previous failed intrauterine insemination (IUI). Exclusion Criteria: * Women diagnosed of polycystic ovary syndrome according to Rotterdam criteria, endometriosis stage III-IV, or previous pelvic inflammatory disease.",18.0,42.0,['age of the patients and the body mass index in both groups']
NCT02468713,Effect on Blood Chemistry and Inflammatory Marker of Omega-3 Enriched Total Parenteral Nutrition,"An Open Label, Randomized, Single Dose, Crossover Study to Evaluate the Effect on Blood Lipid Profiles of Omega-3 Enriched Total Parenteral Nutrition in Healthy Korean Male Subjects",COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: * Healthy male subjects between the ages of 30 and 55 years * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>45 kg * An informed consent document signed and dated by the subject * Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease * Screening sitting blood pressure \>150 mm Hg (systolic) or \>90 mm Hg (diastolic) * Use of tobacco in excess of the equivalent of 20 cigarettes per day * Use of prescription or nonprescription drugs within 10 days * Blood donation within 2 months prior to dosing, or plasma donation within 1 month prior to dosing * Severe hyperlipidemic patients * Severe liver failure patients",30.0,55.0,['healthy']
NCT06670313,"Effect of Preop and Postop ESP Block on Analgesia, Hemodynamics and Patient Satisfaction in Laparoscopic Cholecystectomy","Effects of Preoperative and Postoperative Errector Spinal Plan (ESP) Block on Postoperative Analgesia Score, Hemodynamic Response and Patient Satisfaction in Patients Undergoing Laparoscopic Cholecystectomy Surgery",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * According to the physical classification of the American Society of Anesthesiologists (ASA), ASA I-II group, * between the ages of 18-65, Exclusion Criteria: * Patients who do not want to participate in the study; * BMI \>30, * Patients with contraindications for ESP block, * Uncooperative patients, * Those with renal failure, * Those with hepatic failure and * ASA III-IV-V group patients",18.0,65.0,['erector spinae plane block']
NCT03135613,Kinematics of Knees of Patients With Tumor Around Knee After Microwave Ablation With Plate Internal Fixation,Kinematics of the Healthy Knee and the Surgery Knee in Patients With Tumor Around Knee After Microwave Ablation With Plate Internal Fixation.,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. age \ 30. 2. For controls, injury or surgery in hip/knee/ankle. 3. For MF group, injury or surgery in hip/ankle; 4. Neuropathic disease. 5. Muscular disease. 6. Lack ability to finish the procedure physically or mentally. 7. Easy to fall. 8. Any other conditions that can influence gait parameters of the lower limbs.",18.0,40.0,"['knee tumor', 'microwave']"
NCT05777213,Potential Injection of Human Umbilical Cord Secretome in the Case of Trophic Ulcers (Pre-post Intervention),Effectiveness of Giving Injection of Human Umbilical Cord Secretome in the Case of Trophic Ulcers (Pre-post Intervention),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Chronic ulcers in Morbus Hansen's patients aged 18-80 years * Not recovering with routine therapy for at least 1 months * Trophic ulcers degrees 2 and 3 * Willing to take part in the study * As well as with the respondent's good health to follow this study. Exclusion Criteria: * Patients who took anticoagulants, * Patients had hypertension * Patients had any staging kidney failure * Patients had a history of blood disorders and pregnancy.",17.0,65.0,"['cm-msc', 'stem cell', 'trophic ulcer', 'leprosy', 'morbun hansen', 'secretom']"
NCT03611413,Feasibility and Effects of an Enhanced Recovery vs Conventional Care After Emergency Colon Surgery for Patients With Left Colon Perforation.,Feasibility and Effects of an Enhanced Recovery vs Conventional Care After Emergency Colon Surgery for Patients With Left Colon Perforation.,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * The inclusion criteria were patients over 18 years old with a low-moderate risk of mortality according to a Peritonitis Severity Score (PSS), between 6-11 points. Exclusion Criteria: * The exclusion criteria were patients under 18 years old and patients with a high risk of mortality according to a PSS equal to or greater than 12 points.",18.0,65.0,['colon perforation']
NCT04225013,Early Diagnosis as Strategy in Reducing the Incidence of Contrast-induced Nephropathy,Early Diagnosis as a Strategy in Reducing the Incidence of Acute Renal Failure and Mortality Associated With Contrast Media Administration in Cardiovascular Procedures,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * Patients of legal age who agree to participate in the study an do not comply with any of the exclusion criteria Exclusion Criteria: * Patients who are terminally ill * Patients who do not wish to sign the informed consent,18.0,100.0,"['kidney injury', 'contrast-induced nephropathy']"
NCT03047213,Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations,"An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation",ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 * Must have a histologically confirmed transitional cell carcinoma (TCC, also known as urothelial carcinoma), locally advanced or metastatic * Patient must have TCCs tumors harboring a TSC1 or TSC2 mutation identified by a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory * Unless the pre-screening was performed at Yale Clinical Molecular Pathology Lab (YCMPL), patients must have TCC tumor tissue available for submission in a form of at least 10 unstained slides or formalin-fixed paraffin-embedded (FFPE) block (FFPE block highly recommended and preferred) along with a buccal swab; if the number of slides is less than 10, a biopsy should be considered; if a biopsy is deemed unsafe, the case may be discussed with the study principal investigator (PI) and approval must be given for eligibility * Patient must have developed disease progression during or following treatment with at least one platinum-containing regimen (e.g., gemcitabine/cisplatin \[GC\], methotrexate-vinblastine-doxorubicin-cisplatin \[MVAC\], carboplatin, gemcitabine \[CarboGem\]) for inoperable locally advanced or metastatic urothelial carcinoma or disease recurrence, or must be unfit or ineligible for cisplatin-based chemotherapy; there is no restriction on the number of prior lines of chemotherapeutics agents received * Patients who progressed within 12 months of treatment with a platinum-containing neoadjuvant or adjuvant regimen are considered second-line patients; therefore, these patients may be also eligible * Patients who are unfit or ineligible for cisplatin-based chemotherapy as defined by any one of the following criteria are eligible for this trial: * Eastern Cooperative Oncology Group (ECOG) performance score of 2 * Creatinine clearance \ = 2 peripheral neuropathy * ECOG performance status =\ = 60 %) * Life expectancy of greater than 12 weeks * Hemoglobin \>= 9 g/dL * Fasting serum glucose =\ = 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Total bilirubin within normal institutional limits * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\ = 40 mL/min based either on Cockcroft-Gault estimate or based on urine collection (12 or 24 hour) * Patients with controlled diabetes are allowed on study; controlled diabetes is defined as fasting blood sugar (FBS) = 130 mg/dL or less, and patients whose FBS can be brought in this range with medical therapy are eligible for trial inclusion * The effects of MLN0128 (TAK-228) on the developing human fetus are unknown; fertility and developmental studies with MLN0128 (TAK-228) have not been conducted; on the basis of potential hazard of other mTOR inhibitors (i.e., rapamycin and other rapalogs) on the developing fetus, women of childbearing age should avoid becoming pregnant while taking any mTOR inhibitor including MLN0128 (TAK-228) * Female patients must: * Be postmenopausal for at least 1 year before the screening visit, OR * Be surgically sterile, OR * If they are of childbearing potential, agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated by local labeling \[e.g., United States product insert \[USPI\], summary of product characteristics \[SmPC\], etc.;\]) after the last dose of study drug, OR * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient; NOTE: periodic abstinence \[e.g., calendar, ovulation, symptothermal, postovulation methods\], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception; female and male condoms should not be used together * Male patients, even if surgically sterilized (i.e., status postvasectomy), must: * Agree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug, OR * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient (NOTE: periodic abstinence \[e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner\], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception; female and male condoms should not be used together) * AND agree not to donate sperm during the course of this study or within 120 days after receiving their last dose of study drug * Ability to swallow oral medications * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Patients who have had chemotherapy, immunotherapy, or investigational therapy, within 4 weeks (6 weeks for nitrosoureas or mitomycin C), or palliative radiotherapy within 2 weeks prior to the first dose of the study drug * Patients who have not recovered from adverse events due to prior anti-cancer therapy to grade 1 or baseline; patients with stable, controlled grade 2 adverse events (AEs) such as peripheral neuropathy, hypothyroidism, hypertension, adrenal insufficiency or alopecia are allowed after discussing with the PI * Patients with known symptomatic, untreated central nervous system (including brain, spinal cord); patients who have a history of brain/central nervous system (CNS) metastasis are eligible for the study provided that all the following criteria are met: * Brain/CNS metastases which have been treated * No evidence of disease progression for \>= 3 months before the first dose of study drug * No hemorrhage after treatment * Off-treatment with dexamethasone for 4 weeks before administration of the first dose of TAK-228 * No ongoing requirement for dexamethasone or anti-epileptic drugs * History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) * Subjects who are on systemic corticosteroids (intravenous (IV) or oral steroids, excluding inhaled, topical or ophthalmic corticosteroids), or anti-epileptic drugs for treated brain metastasis * Subjects taking strong inhibitors and/or inducers of cytochrome P450 (CYP) 3A4, CYP2C19 or CYP2C9 within 1 week preceding the first dose of MLN0128 (TAK-228); if a subject requires treatment with strong inhibitors and/or inducers of CYP3A4, CYP2C19 and/or CYP2C9, alternative treatment must be considered; if no alternative is available, one such medication may be allowed after discussing with the study principle investigator * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (excluding rate controlled atrial fibrillation/flutter), or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant and breastfeeding women are excluded from this study because fertility and developmental studies with MLN0128 (TAK-228) have not been conducted and there is a potential risk for adverse events including teratogenicity and risk of abortion; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228) * Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with MLN0128 (TAK-228); however, HIV patients treated with regimens that have low CYP450 inhibition may be allowed as long as the patient's general health and CD4 counts are within acceptable levels * Patients with baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated demonstration of QTc interval \> 480 milliseconds, or history of congenital long QT syndrome, or torsades de pointes) * Patients with untreated or active hepatitis B or C infection * Significant active cardiovascular or pulmonary disease at the time of study entry, including * Uncontrolled high blood pressure (i.e., systolic blood pressure \> 180 mm Hg, diastolic blood pressure \> 95 mm Hg) * Pulmonary hypertension * Uncontrolled asthma or oxygen (O2) saturation \< 90% by ABG (arterial blood gas) analysis or pulse oximetry on room air * Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement * Medically significant (symptomatic) bradycardia * Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128 (TAK-228) * Concomitant administration of any proton pump inhibitor (PPI) is not permitted during the study; patients receiving PPI therapy before enrollment must stop using the PPI for 7 days before their first dose of study drugs * History of any of the following within the last 6 months prior to study entry: * Ischemic myocardial event, including angina requiring therapy and artery revascularization procedures * Ischemic cerebrovascular event, including transient ischemic attack (TIA) and artery revascularization procedures * Requirement for inotropic support (excluding digoxin) or serious (uncontrolled) cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation or ventricular tachycardia) * Pulmonary embolism * New York Heart Association (NYHA) class III or IV heart failure * Placement of a pacemaker for control of rhythm * Subjects who have initiated treatment with bisphosphonates less than 30 days prior to the first administration of MLN0128 (TAK-228); concurrent bisphosphonate use is only allowed if the bisphosphonate was initiated at least 30 days prior to the first administration of MLN0128 (TAK-228) * Patients who received prior PI3K, AKT or mTOR inhibitors are not allowed * Patients who received radiation therapy within the last 4 weeks; radiation exposure may not exceed 30% of marrow area",18.0,65.0,"['locally advanced bladder urothelial carcinoma', 'metastatic transitional cell carcinoma', 'metastatic urothelial carcinoma', 'recurrent bladder carcinoma', 'stage iii bladder urothelial carcinoma ajcc v6 and v7', 'stage iv bladder urothelial carcinoma ajcc v7']"
NCT00214513,"A Randomized Trial of Effect of Low-Cost Maintenance Training on Exercise Capacity, Quality of Life and Morbidity","Maintain. A Randomized Trial of Effect of Low-Cost Maintenance Training on Exercise Capacity, Quality of Life and Morbidity",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. NYHA II-IV 2. Ejection Fraction ≤45% assessed by echocardiography within the last 6 months 3. Optimal medical treatment according to guidelines 4. Informed consent - Exclusion Criteria: 1. Hæmodynamically significant obstructive heart valve disease 2. Hæmodynamically significant valve insufficiency 3. Recent Myocardial infarction (8 weeks) 4. Significant arrythmia at exercise testing (NSVT, VT, VF or SVT with ventricular action \>150) 5. Significant ischaemia or angina at low strain(£ 50 W) 6. Disabilities that render physical training impossible 7. Dementia 8. Serious other illness with expected shortened survival 9. Participation in other scientific protocols that do not allow participation 10. Lack of informed consent 11. If the patient cannot train in a team supervised by only one physiotherapist, e.g. due to poor balance, the patient can be excluded within the first two weeks of inclusion.",18.0,65.0,['chronic heart failure']
NCT02394613,A Phase I Clinical Trial of DARC,"A Phase I, Storer Design, Open-label, Cross-sectional, Single Site Trial of ANX776 in Healthy Volunteers, Progressive Glaucoma/Glaucoma-suspect/Ocular Hypertensive Subjects and Non-arteritic Anterior Ischaemic Optic Neuropathy Subjects",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria All patients * ≥ 18 years * Clear optical media in the studied eye * No ocular or systemic disease (except glaucoma in the test group) * Refractive error not higher than spherical equivalent of 6D; best corrected visual acuity ≥ 6/24 at qualification * Proven ability to perform reliable visual field testing (HFA 640, central 24-2 program) to yield full thresholds, and have had good fundoscopy with assessment of the optic disc * Willing and able to comply with the scheduled visits and assessments. Informed Consent Form personally (or by legal representative) signed and dated * Women Not of Childbearing Potential (postmenopausal or permanently sterilised) * Male participants agree to double barrier contraception from consent until 6 weeks after treatment discontinuation GLAUCOMA patients • Show progression in any measured parameter; have at least one eye with a diagnosis of glaucoma (abnormal optic disc, visual field defect or both); be diagnosed as a glaucoma suspect or ocular hypertensive (elevated Intraocular Pressure (IOP)) NORMAL subjects * No evidence of any glaucomatous process (either optic disc, Retinal Nerve Fibre Layer (RNFL) of visual field abnormalities with normal IOPs) * Must provide a GP letter confirming their medical history GLAUCOMA \& NORMAL patients • Have performed at least 3 Visual Field tests, Heidelberg Retinal Tomography (HRT), and Optical Coherence Tomography (OCT) before or during Visit-1 POSITIVE CONTROL patients * Diagnosis of acute unilateral NAION in the first eye within 15 days of onset of symptoms * Snellen test (or equivalent) Visual acuity below 6/12 in the affected eye * Visual field defect and relative afferent pupillary defect (RAPD) * Normal motility of the pupillary sphincter muscle * Normal macula * Completion of 1 Visual field test, OCT and HRT examination at Visit-1 Exclusion criteria All patients * Terminal or mental illness, dementia, inability to comply with the study or follow-up procedures * Presence of ocular or systemic uncontrolled disease (unless deemed not clinically significant by Chief Investigator and Sponsor), except glaucoma in the test group * Central corneal thickness \ 650µm * History of current or severe, unstable or uncontrolled systemic disease (unless deemed not clinically significant by Chief Investigator and Sponsor) * Body weight \ 120kg * Evidence of another chronic neurodegenerative condition * Patients with active antiphospholipid syndrome or with diagnosis of circulating antiphospholipid antibodies * History of clotting diseases (including Deep Vein Thromboses), subjects taking anticoagulants * Diagnosis of thrombocytopenia, heart valve disease, and livedo reticularis * Pregnancy or lactation * Allergy to any study medication ingredient * Inclusion in a clinical trial of an IMP within 12 weeks prior to study entry * Ocular surgery within the past 3 months in the study eye * History of retinal laser photocoagulation * Media opacities or retinal pathology or amblyopia significantly limiting visual acuity, visual field test or retinal imaging * Expected need for ocular surgery during the study * Severe or acute or chronic medical or psychiatric condition or laboratory abnormality that, in the opinion of the Chief Investigator, makes the subject inappropriate for the study GLAUCOMA patients * Uncontrolled IOP \>24 mmHg * Angle closure/narrow glaucoma * Mean deviation at Humphrey Visual Field (HVF) \>12dB * Unilateral glaucoma * Secondary glaucoma NORMAL subjects * History of systemic vasculitis, collagenosis or ongoing treatment of cancer * Active uveitis * Evidence of previous retinal vascular disease NORMAL \& POSITIVE CONTROL subjects • History or evidence of glaucoma (fundoscopy and Visual Field) or clinical suspicion of glaucoma on presentation or IOP ≥ 24 mmHg in either eye at any time POSITIVE CONTROL patients * Any other aetiology to explain optic nerve disease * Evidence of giant cell arteritis (history, sedimentation rate) * Evidence for other optic neuropathy (even fellow eye) or multiple sclerosis (history, clinical examination) * History of other optic neuropathies * History of NAION in the same eye * Active/recurrent ocular inflammation that may prevent retinal imaging",18.0,65.0,"['glaucoma', 'ocular hypertension', 'glaucoma, suspect']"
NCT07207213,SOCIAL: Adaptation and Validation of the In-person PEERS® Program for Adolescents With Autism.,Italian Adaptation and Validation of the In-person UCLA-PEERS® Model for Adolescents With Autistic Spectrum Disorder,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * (a) age between 10 and 14 years; * clinical diagnosis of Autism Spectrum Disorder according to ICD-10 (WHO, 1992); * absence of intellectual disability (IQ over 85); * absence of a concomitant major psychiatric disorder (e.g., schizophrenia, bipolar disorder, psychiatric illness); * absence of oppositional/aggressive behavior (outside the family context); * difficulty developing and/or maintaining peer relationships; * self-motivation to participate in the treatment of both the adolescent and the family; * availability of a caregiver to regularly attend sessions with parents and to support the participant during the program; * consent of the parents and the adolescent to participate in all evaluations and to be recorded during treatment sessions Exclusion Criteria: * Full IQ below 85; * concomitant major psychiatric disorders",10.0,14.0,['autism spectrum disorder']
NCT07001813,Clinical and Radiographic Assessment of the Outcomes of Dental Implant Inserted After Xenograft Socket Preservation in Posterior Maxilla,Clinical and Radiographic Assessment of the Outcomes of Dental Implant Inserted After Xenograft Socket Preservation in Posterior Maxilla: A Randomized Controlled Study,COMPLETED,INTERVENTIONAL,MALE,Inclusion Criteria: * Male patients aged between 21 and 40 years. * General good health. * Absence of any relevant systemic disease. * Presence of a hopeless maxillary posterior tooth that requires extraction. * Extraction site suitable for replacement by a dental implant. * Cases have adequate bone width and length. * Volunteer subjects must sign an informed consent. Exclusion Criteria: * Poor oral hygiene with no possibility of improvement. * Smokers (more than 10 cigarettes per day). * Chronic treatment with any medication known to affect oral status and bone turnover. * Drug or alcohol abuse.,20.0,40.0,['implant therapy']
NCT00361413,Alefacept for Prevention of Graft Versus Host Disease (GVHD),An Investigator Initiated Double Blind Randomized Study of Alefacept Treatment Prevention of Graft Versus Host Disease in Myeloablative Stem Cell Transplantation,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Patient age 14-75 years old with a disease necessitating allogeneic SCT. 2. In order to increase security, only full matched donors will be allowed and must be willing and capable of donating peripheral blood stem cells preferably, or bone marrow progenitor cells using conventional techniques, and lymphocytes if indicated. 3. Patients must sign written informed consents. 4. Patients must have an ECOG PS ≤ 2; creatinine \ 40%; DLCO \> 50% of predicted; serum bilirubin \ 3 x normal values. Exclusion Criteria: 1. Not fulfilling any of the inclusion criteria. 2. Active life-threatening infection. 3. Overt untreated infection. 4. Hypersensitivity to alefacept. 5. HIV seropositivity, Hepatitis B or C antigen positivity with active hepatitis. 6. Pregnant or lactating women. 7. Donor contraindication (HIV seropositive confirmed by western blot). 8. Hepatitis B antigenemia. 9. Evidence of bone marrow disease. 10. Unable to donate bone marrow or peripheral blood due to concurrent medical condition. 11. Inability to comply with study requirements.",14.0,75.0,['graft versus host disease']
NCT05783713,Evaluation of the Effectiveness of a Flu Vaccination Campaign for Healthcare Workers of a Teaching Hospital: a Pre-post Study,"Evaluation of the Effectiveness of a Flu Vaccination Campaign for Healthcare Workers of the Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS and the Catholic University of the Sacred Heart (UCSC): a Pre-post Study",COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Health personnel employed by the Fondazione Policlinico Universitario ""A. Gemelli"" IRRCS Exclusion Criteria: \-",18.0,65.0,['influenza vaccination']
NCT02419313,Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach,Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Disease Tremor: A Customized Approach,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria. 1. Age more than 18 years 2. Both sexes 3. all races/ethnic groups. 4. Meeting the clinical diagnosis of Parkinson's disease with presence of moderate to severe Parkinson tremor that is refractory to standard medical treatments and which limits the patient""s functionality and/or poses significant discomfort. 5. Subjects who are able to read, speak, and understand English. Exclusion Criteria. 1. Existing significant acute medical condition (i.e. cardiovascular, endocrine, hematologic, neoplastic, infectious, or autoimmune disorders) or significant swallowing or breathing difficulties. 2. Pregnancy or planned pregnancy (determined by urine pregnancy test). 3. Active breast feeding. 4. Enrollment in any clinical trial (currently or within the past 3 months) in which treatments are imposed by a protocol. 5. Any subject for whom botulinum toxin treatment would be contraindicated; known allergy or sensitivity to medication. 6. Subjects who are younger than 18 years of age. Neuromuscular-junction disorders. 7. Evidence of acute pathology in neuro-imaging. 8. Axis I diagnosis determined by a neurologist or psychiatrist. 9. Use of Anesthetic medications within two weeks and corticosteroid injections within 4 weeks of enrollment. 10. Those who received botulinum toxin injections in the past 4 months.",18.0,65.0,"['parkinson', 'tremor']"
NCT05116813,Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy,An Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy With or Without Concomitant Dopaminergic Medications,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Completed an Addex randomized controlled study of dipraglurant and, in the judgement of the Investigator, may benefit from open-label treatment * Able to take study drug 3 times daily and no less than 3 hours apart * Must be taking levodopa not less than 3 times daily throughout the study * Must maintain stable regimen of antiparkinson's medications (including levodopa) and be willing to continue the same doses and regimens for the first 4 weeks of the study Exclusion Criteria: * Patient is judged by the Investigator to be inappropriate for the study (for reasons such as, but not limited to, significant noncompliance in the Addex randomized controlled study of dipraglurant) * Use of amantadine or amantadine ER throughout the study * Use of memantine throughout the study * Any use of marijuana or other cannabis/cannabinoid products for the first 4 weeks of study participation Other protocol-defined inclusion and exclusion criteria may apply",30.0,85.0,"['parkinson disease', 'dyskinesia, drug-induced', 'dyskinesias']"
NCT07272213,"Thyroid-Stimulating Hormone Levels in Pregnancy and Their Association With Depression, Anxiety, and Sexual Function","Evaluation of the Effects of Thyroid-Stimulating Hormone (TSH) Levels in Pregnancy on Depression, Anxiety, and Sexual Function",RECRUITING,OBSERVATIONAL,FEMALE,"Inclusion Criteria: Pregnant women aged 18-45 years Singleton pregnancy Gestational age ≥ 6 weeks Literacy and ability to provide informed consent Availability of a TSH result obtained within the past 4 weeks Cognitive ability sufficient to complete the psychometric questionnaires (Beck Depression Inventory, Beck Anxiety Inventory, ASEX, and YKK-13 Quality of Life Scale) Exclusion Criteria: Multiple pregnancy Previously diagnosed psychiatric disorder or active use of antidepressant/ anxiolytic medication Current treatment for thyroid disease History of thyroid surgery Major systemic illness or significant obstetric complications Age under 18 years or inability to provide informed consent Inability to complete the questionnaires adequately (missing or invalid data) Rationale: Multiple pregnancies are excluded because they differ significantly from singleton pregnancies in terms of hormonal profile, obstetric risks, and psychological stress levels. This exclusion aims to ensure a homogeneous study population.",18.0,45.0,"['thyroid disorders complicating pregnancy', 'maternal depression in pregnancy, unspecified trimester', 'anxiety disorder, unspecified', 'sexual dysfunction, unspecified']"
NCT02438813,Condition of Submental Fullness and Treatment Outcomes Registry,"CONTOUR: Condition of Submental Fullness and Treatment Outcomes Registry (A Registry of Submental Fullness, Treatment Options Administered, and Associated Outcomes)",COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Adult male and female patients, aged 18 years and above, presenting with SM fullness due to the accumulation of unwanted SMF, and considered by their treating physician to be a candidate to receive treatment of SM fullness by reduction of SMF, if the patient decides * Signed informed consent by the patient, obtained before any study-related activities are undertaken * Willing to complete all patient assessment questionnaires * Signed release form by the patient, permitting abstraction of the patient's medical records at baseline and during participation in the registry Exclusion Criteria: * Severe skin laxity, defined as superficial wrinkling, loose skin separated from deeper neck structures, and/or marked skin redundancy (draping and/or sagging), per the physician's judgment * Any other cause of fullness in the SM area (eg, thyroid enlargement, cervical adenopathy) other than localized SMF * Participating in an interventional clinical study, currently or within 30 days before enrollment",18.0,65.0,['submental fullness']
NCT07364513,Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies,A Phase 1b Open-Label Study of IMSB301 in Subjects With a Type 1 Interferonopathy,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. First subject must be at least 16 years of age and weighing at least 50 kg. Remaining subjects must be at least 12 years of age and weighing at least 40 kg. 2. Molecular diagnosis of one of the following: 1. Aicardi-Goutières Syndrome (AGS) with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, LMS11, or RNU7-11, or 2. Monogenic SLE with mutations in TREX1, RNASEH2A, RNASEH2B, or RNASEH2C, or 3. Familial chilblain lupus (CHBL) with mutations in TREX1 or SAMHD1, or 4. Neurological syndromes with mutations in ATAD3A, or 5. An unnamed interferonopathy with mutations in DNASE2, or 6. Coatomer Protein Complex subunit alpha (COPA) syndrome with mutations in COPA. The remaining subtypes of AGS and other type 1 interferonopathies are not eligible. 3. Clinical syndrome consistent with type 1 interferonopathy diagnosis based on clinical, CSF, or radiological findings. 4. Women of child-bearing potential (defined as a female who has experienced menarche and who has not undergone successful surgical sterilization \[hysterectomy, bilateral salpingectomy, or bilateral oophorectomy\]) or is not postmenopausal (defined as amenorrhea for at least 12 consecutive months with an appropriate clinical profile at the appropriate age, e.g., greater than 45 years) must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1. 5. Sexually active male and female subjects with reproductive potential must agree to use highly effective contraception or agree to abstain from heterosexual intercourse throughout the study and for at least 3 months after last study drug dose. 6. Subjects and caregiver must be willing and able to comply with scheduled visits, clinical assessments, blood sample collections, and other trial procedures. 7. Have the ability to provide informed consent or have legal representative of minor/vulnerable subjects who is willing and able to provide written informed consent, provided that assent is obtained from subjects at an age-appropriate level. Exclusion Criteria: 1. Presence of other significant neurological disorder that is not related to type 1 interferonopathy, brain tumor or other space-occupying lesion, or history of severe head injury. 2. The presence of significant concomitant disease that would, in the judgement of the Investigator, pose additional risk to the subject, interfere with the assessment of safety and tolerability, or significantly interfere with the metabolic disposition of study drug. 3. BMI above 33 kg/m2 or a total body weight in excess of 130 kg. 4. Have any of the following infection risks: 1. Evidence of active infection during screening or on Day 1 2. Symptomatic herpes zoster infection within 12 weeks prior to the screening period, or more than one episode of herpes zoster infection in the preceding two years 3. Positive hepatitis B, hepatitis C, HIV or TB test at screening 4. Household contact with a person with active TB and did not receive appropriate and documented prophylaxis for TB 5. Serious infection, defined as infection requiring admission to hospital or treatment with intravenously administered medication, within the six months. 5. Resting 12-lead ECG showing confirmed prolongation of QTc (Fridericia's correction) interval (QTc interval \> 470 for females and \>450 for males), or other baseline ECG abnormalities that, in the judgement of the Investigator, would pose additional safety risk to the subject. 6. A prior history of cancer, other than squamous cell carcinoma, basal cell carcinoma, or cervical intra-epithelial neoplasia that was successfully treated at least five years prior to the screening visit and which has shown no sign of clinical recurrence. 7. Receipt of an investigational drug within 30 days or five half-lives of the drug (whichever is longer) prior to Day -1. 8. Prior treatment with an immunomodulator including a JAK inhibitor within 14 days of screening. 9. Prior treatment with an interferon inhibitor within 3 months of screening. 10. Concurrent treatment of a nucleoside reverse transcriptase inhibitor or other antiviral drug. 11. Receipt of a strong inhibitor of CYP3A4 (APPENDIX A) within five half-lives prior to Day -1 12. Known allergy to IMSB301 or its components. 13. Known allergy to shellfish. 14. Female subjects who are breastfeeding or who have a positive pregnancy test at screening or Day -1. 15. Receipt of a vaccination within 3 weeks prior to Day -1.",12.0,65.0,['type 1 interferonopathies']
NCT04806113,COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases,COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria (all of the following): 1. Adults ages 18 years and older; 2. For the cases, established diagnosis of: 1. RA done by a rheumatologist according to the 2010 American College of Rheumatology (ACR) /European League Against Rheumatism (EULAR) criteria, OR 2. SLE done by a rheumatologist according to the 1997 revised ACR criteria and/or the 2013 SLICC lupus classification criteria and/or the 2019 EULAR/ACR criteria; 3. For the cases, stable treatment (≥3 months prior to enrollment for biologics/small molecules and MMF; \>3 weeks of a specific dose in case of steroids); 4. For the controls, people without a diagnosis of a chronic rheumatic disease who can have comorbidities as in patients with rheumatic diseases; 5. Able to comprehend the investigational nature of the protocol and provide informed consent; 6. Male or non-pregnant female; 7. Women of childbearing potential must agree to use at least one acceptable primary form of contraception. Exclusion Criteria (any of the following): 1. Positive pregnancy test either at screening or just prior to each vaccine administration. 2. Any medical disease or condition that, in the opinion of the site Principal Investigator (PI) or appropriate sub-investigator, precludes study participation. 3. Acute illness, as determined by the site PI or appropriate sub-investigator, with or without fever \[oral temperature \>38.0°C (100.40F)\] within 72 hours prior to each vaccination. 4. Diagnosis of hepatitis B, hepatitis C virus, or human immunodeficiency virus (HIV). 5. History of hypersensitivity or severe allergic reaction (e.g., anaphylaxis, generalized urticaria, angioedema, other significant reaction) to any previous licensed or unlicensed vaccines. 6. Participation in another clinical trial or plan to do so during the study. If a patient was on a drug trial, recruitment could occur following 2 half-lives of the study drug. 7. Vaccines within the 2 weeks prior to any dose of COVID-19 vaccine or until 30 days after any dose of COVID-19 vaccine. 8. Lactating female. 9. Immunoglobulin therapy or blood products within the past month. 10. Prior diagnosis of COVID-19 in the past 3 months. 11. Planned changes in baseline drug treatments (except prednisone) for rheumatic diseases prior to D57. 12. For patients required to be on cohort 8: Planned reduction of prednisone dose below 10 mg prior to D21.",18.0,65.0,"['covid19', 'rheumatic diseases', 'rheumatoid arthritis', 'sle']"
NCT04615260,Rate of Bony Fusion Using NanoBone® Synthetic Bone Graft Versus Local Autologous Bone Graft.,Comparison of Fusion Success Between NanoBone Synthetic Bone Graft and Local Autogenous Bone Graft in Posterolateral Spinal Fusion,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. The individual has signed and dated a study specific informed consent form approved by the Institutional Review Board at UMMHC. 2. The individual is 18 to 85 years of age. 3. The individual is skeletally mature. 4. The individual has been diagnosed with 1 or 2 level degenerative disc disease or spondylolisthesis grade 1-3 with or without spinal stenosis, requiring posterolateral spinal fusion surgery with bone grafting. 5. The individual is physically and mentally willing and able to comply with the postoperative scheduled clinical and radiographic evaluations and rehabilitation. Exclusion Criteria: 1. The individual has had any previous attempts at fusion, at any lumbar levels. 2. The individual is morbidly obese (defined as 100 lbs over the recommended ideal weight as described in the Metropolitan Life Height and Weight Tables for Men and Women and or having a BMI \>39). 3. Patients with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated. 4. Patients with systemic collagen, bone or mineralization dysfunction (such as Paget's disease, osteogenesis imperfecta, Ehlers-Danlos Syndrome). 5. Patients who suffer from uncontrolled diabetes mellitus type I or insulin-dependent diabetes mellitus type II. (definition based on the glycosylated Haemoglobin level) 6. Patients who are suffering from autoimmune disease. 7. Patients who previously underwent chemotherapy, immunosuppressive disease or radiation to the local area. 8. Patients who received or are currently receiving corticosteroids (\> 2 years \> 5 mg prednisolone equivalent/d). 9. Patients with active local or systemic infection. 10. Patients with any known active malignancy. 11. Patients with other concurrent physical or mental conditions which are likely to affect their outcome. 12. Patient unable to consent for themselves 13. Pregnant women 14. Non-English speaking subjects. These subjects are excluded because they would not be able to complete the English-language surveys required during this study. Only English language versions of these surveys have been validated. 15. Prisoners 16. Patients less than 18 years old",18.0,85.0,"['degenerative disc disease', 'spondylolisthesis']"
NCT05874960,Helicobacter Pylori Prevalence in Southern Region of Romania,Helicobacter Pylori Prevalence in Southern Region of Romania,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Adult voluntary participants to ""Medical services caravan"" project by Medcorp Association Exclusion Criteria: * Age \< 18 years old * No informed consent",18.0,65.0,"['infections, helicobacter']"
NCT00790660,A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.,"A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study to Assess the Safety and Tolerability of ASP1941 in Adult Subjects With Type 2 Diabetes Mellitus",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Established diagnosis of type 2 diabetes mellitus * HbA1c value between 7.0 and 10.0% * Body mass index between 20 and 45 kg/m2 Exclusion Criteria: * Established diagnosis of type 1 diabetes mellitus * Serum creatinine \> upper limit of normal range * Proteinuria (microalbumin/creatinine ratio \> 300 mg/g) * Urinary tract infection * Severe uncontrolled Hypertension * Significant renal, hepatic or cardiovascular disease * HIV Positive * History of drug or alcohol abuse/dependency",18.0,75.0,"['diabetes mellitus, type 2']"
NCT06115460,The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy,The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Type 1 Diabetes Mellitus and Diabetic Nephropathy,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * T1DM patients aged 12-18 years with at least 5 years disease duration defined according to the criteria of International Society for Pediatric and Adolescent Diabetes (ISPAD) . * Patients on insulin pump therapy using Medtronic advanced hybrid closed system (Medtronic, Northridge, USA) with Guardian™ 3 sensor or Guardian™ 4 sensor and Guardian link transmitter initiated at least 6 months before the study, patients with minimum daily insulin requirement of more than 8 units, willingness and ability to adhere to the study protocol, and access to the internet as well as a computer system that met requirements for uploading the study pump data. * Active diabetic nephropathy in the form of microalbuminuria (urinary albumin excretion ) 30-299 mg/g creatinine in two of three samples over a 3- to 6-months period despite angiotensin converting enzyme inhibitors). * Hemoglobin A1c (HbA1c) ≤8.5%. * Patients on regular visits to clinic. Exclusion Criteria: * patients with other diabetic microvascular complications (neuropathy or retinopathy) or with macrovascular complications. * Patients with history of liver disease or any disorder likely to impair liver functions or elevated liver enzymes. * Patients with any evidence of renal impairment due to causes other than diabetes. * Patients with hypertension. * Hepatitis virus infection (B or C) or any evidence of infection * Participation in a previous investigational drug study within 3 months preceding screening. * Hypoglycemic unawareness or recurrent severe hypoglycemic episodes in the last 6 months prior to recruitment. * Recurrent diabetic ketoacidosis (DKA) (more than 2 episodes in the previous 6 months). * Taking other oral hypoglycemic medications which could affect blood glucose. * Patients with known allergy to sitagliptin.",12.0,18.0,['type 1 diabetic nephropathy']
NCT02717260,Inhibition Transcranial Random Noise Stimulation,Inhibition Control Modulation by Transcranial Random Noise Stimulation (tRNS ) on the Prefrontal Cortex Measured by Change in Go no Test,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * age between 18 and 45 years Exclusion Criteria: * inability to give consent * Under 18 years * over 45 years * pregnant women * nursing mothers * History of neurological or psychiatric disorders and personality disorders in Cluster impulsivity (cluster B) according to Diagnostic and Statistical Manual (DSM) IV * french National Adult Reading Test (fNART): score below the 5th percentile * Contraindications to the practice of transcranial brain stimulation as international safety recommendations (Rossi et al., 2009) * Processing or recent psychotropic",18.0,45.0,"['impulsive behavior', 'inhibition']"
NCT05639660,Clinical Implication of Aflibercept in PCV Treatment in China,"Aflibercept Observational Study for the Clinical Use of PCV in China, Polycentric, Observational, Retrospective-prospective Study",UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: 1. Age ≥ 18 years, gender, unilateral or bilateral onset 2. Treatment-experienced or treatment-naïve patients diagnosed with PCV after ICGA examination 3. Signed informed consent, able to long-term follow-up 4. PCV patients previously treated with aflibercept were enrolled as retrospective cases, and PCV patients previously treated with other anti-VEGF, at least 1 month since the last treatment Exclusion Criteria: 1. Patients with anterior segment (including iris and angle) neovascularization or neovascular glaucoma 2. Received oral or intravenous antiangiogenic drugs within 180 days prior to the screening visit 3. The study eye has a history of idiopathic or autoimmune uveitis 4. Study eyes with active ocular inflammation or evidence of infectious blepharitis, corneal inflammation, scleritis, or conjunctivitis 5. The patient has a coagulation disorder or is taking oral warfarin, Plavix (clopidogrel) and other similar anticoagulation drugs. 6. The patient is receiving treatment for severe systemic infection 7. Patients with uncontrolled blood pressure (systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg when the subject is sitting) 8. Cerebrovascular accident and/or myocardial infarction within 180 days prior to the screening visit 9. Patients with renal insufficiency undergoing renal dialysis, renal failure requiring dialysis or renal transplantation 10. The investigator believes that based on the history of other diseases, metabolic dysfunction, physical examination results or clinical laboratory results, patients have a disease or condition that will increase the risk for complications from treatment 11. Pregnant or lactating women; women of childbearing potential with positive pregnancy test results at baseline or not receiving pregnancy test; postmenopausal women must have been amenorrhea for at least 12 months to not be considered fertile 12. Participated in any drug (except vitamins and minerals) or device therapy study within 30 days prior to the screening visit 13. The patient has received other anti-VEGF therapy within 30 days 14. Other patients deemed necessary to be excluded by the investigator",18.0,65.0,['polypoidal choroidal vasculopathy']
NCT05690360,Pregnancy Outcomes of Patients Having NC-FET Regarding the Progesterone Levels,Evaluation of the Pregnancy Outcomes and Time to Embryo Transfer Regarding the Progesterone Levels of Natural Cycle-FETs,UNKNOWN,OBSERVATIONAL,FEMALE,Inclusion Criteria: * patients with regular menstrual cycle * patients aged btw 20-40 * patients with pregnancy with NC-FET by using the progesterone for the detection of ovulation Exclusion Criteria: * Spontenous pregnancies * Multiple pregnancies,20.0,40.0,['infertility']
NCT02124460,Connect 4 Health: An Intervention to Improve Childhood Obesity Outcomes,Improving Childhood Obesity Outcomes: Testing Best Practices of Positive Outliers,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * child is age 2.0 through 12.9 years at baseline primary care visit, * child's BMI is equal to or exceeds the 85th percentile for age and sex at baseline primary care visit, * at least 1 parent has an active email address, * at least one parent is comfortable reading and speaking in English. Exclusion Criteria: * children who do not have at least one parent/legal guardian who is able to follow study procedures for 1 year, * families who plan to leave HVMA within the study time frame, * families for whom the primary care clinician thinks the intervention is inappropriate, e.g., emotional or cognitive difficulties, * children who have a sibling already enrolled in the study, * children with chronic conditions that substantially interfere with growth or physical activity participation.",2.0,12.0,"['overweight', 'obesity']"
NCT00174460,Somatropin Therapy In Children Born Preterm But Appropriate For Gestational Age,"Somatropin Therapy For Short Children Born Of Premature Gestation, A Controlled, Prospective Randomized, Multicenter Study With An Untreated Control Group.",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial: * Prepubertal caucasian boys between 4 and 10 years of age and girls between 4 and 9 years of age. * Girls: Tanner stage 1 breast development * Boys: Testis volume \ 7 ug/l following any routine GH stimulation test). * Written informed consent of both parents (legal guardians) and oral/written consent of subject due to age specific information. Exclusion Criteria: Subjects presenting with any of the following will not be included in the trial: * Other endocrine diseases except for well substituted hypothyroidism. * Severe chronic diseases or medication that might influence linear growth or insulin sensitivity (e.g. Glucocorticoids). * Positive GAD and IA-2 antibodies (for type 1 diabetes). * History of malignancy * Children who meet all of the following 4 criteria: * actual body height \ = 4 years and * growth velocity \ third degree or laser treatment as newborns. * Participation in any other clinical trial during active treatment phase. * Other severe acute or chronic medical or psychiatric condition or clinically relevant laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgement of the investigator, would make the subject inappropriate for entry into this trial.",4.0,10.0,"['growth hormone therapy', 'infant, very low birth weight']"
NCT05900960,Hot or Cold Beverages in Warm Weather,Hot or Cold Beverages in Warm Weather: A Double-blinded Randomized Controlled Trial.,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * 18 years or older * Must be able to ingest intervention * Must be able to be in the sun for 2x 13 minutes (using sunscreen and/or other relevant UV protection). Exclusion Criteria: * Fever on the day of the experiment.,18.0,65.0,['quality of life']
NCT04889560,Home-based Cognitive Treatment and Cognitive Impairment,Home-based Cognitive Treatment of Early Stages of Cognitive Impairment in Neurodegenerative Diseases: Home CoRe,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * presence of mild dementia, mild cognitive impairment; vascular cognitive impairment, subjective cognitive impairment; * age between 50 and 85 years; * educational level ≥ 5 years. Exclusion Criteria: * MMSE \ 1 * pre-existing cognitive impairment (e.g. aphasia, neglect); * severe disturbances in consciousness; * concomitant severe psychiatric disease or others neurological conditions (e.g. depression and behavioral disorders).",50.0,85.0,['cognitive impairment']
NCT00050960,"Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer",Randomized Phase III Trial Comparing Targretin Capsules/Carboplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non-Small Cell Lung Cancer,COMPLETED,INTERVENTIONAL,ALL,"Patients must have: * Pathologic (histologic or cytologic) confirmation of NSCLC * Stage IIIB with malignant pleural effusion or Stage IV disease * At least one measurable or evaluable NSCLC lesion that has not been previously irradiated unless radiation therapy was more than three weeks prior to entry in the study and the lesion has been shown to have progressed subsequent to the radiation therapy * ECOG performance status 0 or 1 * Adequate organ system function * Fasting serum triglycerides that are within the age-adjusted normal range (or normalized with appropriate intervention such as antilipid therapy prior to the initiation of Targretin capsule therapy). Patients must be able to complete at least four cycles of combination chemotherapy (i.e., approximately four months) Patients must not have had: * Brain metastasis * Prior chemotherapy for NSCLC * Prior platinum-based chemotherapy for any indication",18.0,65.0,['non-small cell lung cancer']
NCT00040820,Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer,A Treatment Access Program With Oxaliplatin for Previously Treated Colorectal Cancer Patients,COMPLETED,INTERVENTIONAL,ALL,"DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed adenocarcinoma of the colon or rectum that is not amenable to surgical resection or other potentially curative therapy * Locally advanced OR * Metastatic disease * Patients who progressed on a non-oxaliplatin-containing (control) arm in Sanofi-Synthelabo second-line regulatory trials OR * Patients who have exhausted all approved therapies for colorectal cancer (including fluorouracil and irinotecan) and have received at least 2 prior independent/different chemotherapy regimens * Documented radiological disease progression after last anticancer treatment PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Life expectancy: * Not specified Hematopoietic: * Absolute neutrophil count at least 1,500/mm3 * Platelet count at least 75,000/mm3 Hepatic: * SGOT or SGPT no greater than 6 times upper limit of normal (ULN) * Bilirubin no greater than 2 mg/dL * Alkaline phosphatase no greater than 5 times ULN Renal: * Creatinine no greater than 1.5 times ULN Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 6 months after study * Adequate organ function and medically stable * No known concurrent peripheral neuropathy * Absence of deep tendon reflexes as the sole neurologic abnormality is allowed PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * See Disease Characteristics * At least 30 days since prior chemotherapy * No prior oxaliplatin-based chemotherapy * No other concurrent investigational chemotherapy agents Endocrine therapy: * Not specified Radiotherapy: * At least 30 days since prior radiotherapy Surgery: * See Disease Characteristics * At least 30 days since prior major surgical procedure or intervention Other: * At least 30 days since other prior anticancer therapy * No other concurrent anticancer agents * No concurrent participation in any other investigational studies",18.0,65.0,['colorectal cancer']
NCT02959320,Direct Anterior vs. Anterolateral Approach for Hip Arthroplasty After Femoral Neck Fracture in the Senior Population,A Randomized Clinical Trial of Direct Anterior vs. Anterolateral Approach for Hip Arthroplasty After Femoral Neck Fracture in the Senior Population,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * isolated displaced femoral neck fracture (AO type 31-B2 and 31 B3) * age≥65 years * preinjury ambulation with or without a gait aid * surgical intervention ≤ 48 hours after fracture. Exclusion Criteria: * age \ 48 hours between fracture and surgery, presence or history of infection, active metastatic disease, previous ipsilateral hip prosthesis * active major psychiatric illness * active drug or alcohol abuse * BMI \>40, and actively failing contralateral hip prosthesis.",65.0,65.0,['femoral neck fractures']
NCT01801020,Different Modes of Temperature Measurement in the Emergency Department,Different Modes of Temperature Measurement in the Emergency Department,WITHDRAWN,INTERVENTIONAL,ALL,Inclusion Criteria: * patients who arrive to the emergency department Exclusion Criteria: * patients who refuse,18.0,65.0,['sepsis']
NCT03552120,Serving Women Using Opioids During Pregnancy,The Impact of a Mindfulness-based Intervention on Opioid Use During Pregnancy: A Mixed Methods Pilot RCT,TERMINATED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Currently pregnant * Taking opioids (prescription opioids, methadone, suboxone, heroin, kratom, etc.) * Fluent in English Exclusion Criteria: * Past experiences with mindfulness-based stress reduction, mindfulness-based relapse prevention, mindfulness-based cognitive therapy * Active suicidality * Active psychosis",18.0,50.0,"['opioid use', 'pregnancy related']"
NCT02178020,Outcome Study of Highly-cross Linked Polyethylene vs. Standard Polyethylene for Primary Posterior Stabilized (PS) Total Knee,"Prospective, Randomized Study of Highly-cross Linked Polyethylene vs. Compression Molded Polyethylene for Primary Posterior-stabilized Total Knee Arthroplasty",UNKNOWN,OBSERVATIONAL,ALL,Inclusion Criteria: * all patients indicated for primary total posterior stabilized knee arthroplasty Exclusion Criteria: * patients who refused participation * patients who did not comprehend the English language to give informed consent * patients with severe knee deformity thought to require a primary constrained condylar prosthesis,18.0,65.0,"['arthroplasty, replacement, knee']"
NCT00374920,Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder,"A Multicenter, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEM 1003 for the Treatment of Patients With Bipolar I Disorder Suffering Acute Manic or Mixed Episodes",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * bipolar I disorder with acute manic or mixed episode, with or without psychotic features * YMRS score of at least 20 * history of at least one previous manic or mixed episode requiring treatment in the last 10 years Exclusion Criteria: * history of failing to respond to treatment with two or more adequate trials of approved anti-manic medications for the current episode * Axis I or Axis II disorder (other than bipolar I disorder) that requires treatment or has been the primary subject of treatment in the past 3 months * defined substance abuse or dependency within the 3 months * schizophrenia, schizoaffective disorder, delusional disorder, mental retardation or pervasive developmental disorder * suicidal or danger to others",18.0,65.0,['bipolar disorder with manic or mixed episodes']
NCT07339020,Cyanoacrylate Versus Omentum for Staple-Line Reinforcement in Sleeve Gastrectomy,Cyanoacrylate Versus Omentum for Enforcement of the Staple Line in Sleeve Operation,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * Cases underwent LSG with age ≥18 years old and ≤65 years old and BMI ≥35 or ≥30 with comorbid disease related to obesity. * Candidate for Laparoscopic Sleeve Gastrectomy Exclusion Criteria: * Cases underwent previous bariatric surgery. * Multiple Extensive previous surgeries. * Crohn's Disease. * Elderly patients with extensive comorbidities * Severe gastroesophageal reflux disease (GERD) * Severe Bleeding disorders * Psychiatric illness or cognitive impairment affecting consent or compliance,18.0,65.0,['obesity']
NCT01650220,Cardiovascular Risk Markers in Veterans With Post Traumatic Stress Disorder,Cardiovascular Risk Markers in Veterans With PTSD,TERMINATED,OBSERVATIONAL,ALL,"Inclusion Criteria: * OEF/OIF veterans at the VASDHS * Between 28 and 38 years of age * Willing to complete structured diagnostic interview for PTSD, CIMT ultrasound and blood test * Willing to have a review of their medical records * Able to give informed consent * Have a negative urine pregnancy test, if a woman of child-bearing age Exclusion Criteria: * Do not meet inclusion criteria * History of schizophrenia, other neurocognitive illness (including severe TBI by INTRuST criteria)) or active alcohol and/or drug abuse determined by chart review, interview or AUDIT-C score * Inability to complete study tests within 18 months of study start * Pregnancy",28.0,38.0,"['cardiovascular disease', 'post traumatic stress disorder']"
NCT02842320,Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML),Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * patients for whom there is a strong suspicion of CML diagnosed as part of routine activity. * written informed consent Exclusion Criteria: * patient with atypical CML * patient with a non SMP CML * patients previously treated with interferon * patient enrolled in another study therapy or within the exclusion period thereof * pregnant or breast-feeding women * patient under guardianship, curator or under the protection of justice.",18.0,75.0,['chronic myeloid leukemia']
NCT03710720,Trauma Informed Prevention for Substance Use and Risky Sex,Mentorship and Research in HIV and Addiction Prevention Among Traumatized Youth,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Have experienced at least one traumatic event Exclusion Criteria: * Adolescents exhibiting psychotic symptoms * Significant cognitive disability * PDD * Active suicidal or homicidal ideations * Meets criteria for a DSM-5 moderate or severe substance use disorder,12.0,18.0,"['substance use', 'hiv/aids']"
NCT07092020,EDF IOL Versus Monofocal IOL,"A Prospective, Randomized, Controlled, Observer-masked, Multi-center Clinical Trial to Demonstrate the Safety and Effectiveness of the Extended Depth of Focus AT LARA 829MP Posterior Chamber Intraocular Lens for Correction of Aphakia",NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Patients of any gender, aged 18 years or older 2. Patient with clinically significant bilateral age-related cataracts planned for phacoemulsification cataract extraction and eligible for implantation of a posterior chamber intraocular lens as determined by investigator's medical judgement 3. Preoperative keratometric (corneal) astigmatism of 1.00 D or less (≤1.00 D) 4. Calculated lens power within the available range 5. Clear intraocular media other than cataract 6. Patient is willing and capable of providing informed consent 7. Patient is willing and capable of complying with visits and procedures as defined by this protocol Exclusion Criteria: 1. Preoperative corrected distance visual acuity (CDVA) better than 0.3 logMAR (0.5 decimal) 2. Endothelial cell count of less than 2000/mm2 3. Acute, chronic, or uncontrolled systemic disease that could increase the operative risk or confound the outcome including but not limited to poorly controlled diabetes mellitus, active cancer treatment, mental illness, dementia, immunocompromised, connective tissue disease, clinically significant atopic disease, etc. 4. Ocular condition that may predispose patient to future complications, per investigator's medical judgement, including but not limited to severe dry eye, anterior segment pathology, uncontrolled glaucoma, that would result in a visual acuity of 0.2 logMAR or worse during the study 5. Clinically significant corneal abnormalities, including corneal dystrophy (epithelial, stromal or endothelial dystrophy), irregularity or oedema as per Investigator's medical judgement; conditions including but not limited to kerato-uveitis, keratopathy, keratectasia 6. Previous intraocular or corneal/refractive surgery that might confound the outcome of the investigation or increase the risk to the patient (including corneal transplants, removal of pterygium, and LASIK, LASEK, PRK, RK limbal relaxing incision etc.) 7. Any clinically significant condition that could affect IOL stability (e.g. zonular dialysis, evident zonular weakness or dehiscence, etc.) 8. Patients with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders, optic nerve atrophy etc.) or any other pathologies of the eye that are predicted to result in a visual acuity of 0.2 logMAR or worse during the study 9. Current systemic or ocular pharmacotherapy that effects patients' vision with significant ocular side effects or any medications that could confound the outcome or increase subject risk 10. Clinically significant gonioscopic abnormalities 11. Amblyopia, strabismus, single eye status 12. Rubella, congenital, traumatic or complicated cataracts 13. History of or current anterior or posterior segment inflammation, including but not limited to iritis or uveitis 14. Microphthalmos or macrophthalmos 15. Pupil abnormalities (e.g. aniridia, abnormal shaped pupils, nonreactive pupils) 16. Pseudoexfoliation 17. Keratoconus or irregular astigmatism 18. Inability to measure keratometry or biometry (including but not limited to cataract density, etc.) 19. Pathologic miosis 20. Pregnant, plan to become pregnant, lactating during the course of the investigation, or another condition with associated fluctuation of hormones that could lead to refractive changes 21. Patients unable to meet the limitations of the protocol or likely of non-cooperation during the trial 22. Patients whose freedom is impaired by administrative or legal order 23. Concurrent participation in another clinical investigation in the last 30 days.",18.0,65.0,['cataract senile']
NCT02568020,LPD+α-ketoacids on Autophagy and Improving Muscle Wasting in CKD,Mechanisms of Low Protein Diet Supplemented With α-ketoacids on Autophagy and Improving Muscle Wasting in Chronic Kidney Disease: the Role of Autophagy in Muscle Wasting,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * patients agree to participate in this study; age≥18 years and\ 15 ml/min (three monthly consecutive measurements)；at least 6 months of follow up at our clinic before recruitment and haven't received any diet intervention. Exclusion Criteria: * pregnant patients; diabetes; heart or liver failure; a recent myocardial infarction (in the last 12 months); long term immobilization; chronic respiratory failure; cancer; any pharmacological treatment that could modify muscle structure or function such as glucocorticoids or insulin；Contraindications of Ketosteril, such as hypersensitivity to the active substances or to any of the excipients, hypercalcaemia, disturbed amino acid metabolism to the study protocol.",18.0,75.0,['muscular atrophy']
NCT03726320,Trial of Community Health Worker-led Decision Coaching,Randomized Trial of Community Health Worker-led Decision Coaching to Promote Shared Decision Making for Prostate Cancer Screening Among Black Male Patients and Their Providers,COMPLETED,INTERVENTIONAL,MALE,Inclusion Criteria: Patients: * Black * Male * Attending FQHC for routine primary care appointment Providers: * Provider at Sunset Park Health Council Federally Qualified Health Center (FQHC) * Caring for patients that fit inclusion criteria Exclusion Criteria: * Provider at Sunset Park Health Council Federally Qualified Health Center (FQHC) * Caring for patients that fit inclusion criteria,40.0,69.0,['prostate cancer']
NCT06426420,Endometriosis and ATR-FTIR Spectroscopy,Detection of Endometriosis Using ATR-FTIR Spectroscopy,RECRUITING,INTERVENTIONAL,FEMALE,Inclusion Criteria: * Female * Pelvic pain complain Exclusion Criteria: * Age under 18 or above 55 * Lack of informed consent,18.0,55.0,"['endometriosis', 'endometriomas']"
NCT04783220,PaREnting ProgrAm to Enhance PREterm Infants' Health and Development (PREPARE Trial),Comprehensive PaREnting ProgrAm to Enhance PREterm Infants' Health and Development: A Randomized Controlled Trial (PREPARE Trial),ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Couplets of parents and their preterm infants admitted to the NICU, who are \<35 weeks gestation at birth and who are deemed medically stable by their treating neonatologist. Exclusion Criteria: * Infants with significant neurologic disorder precluding meaningful interaction with the parents as determined by the neurologist * Infants with major congenital anomalies precluding meaningful interaction with the parents as determined by the neurologist * Infants with systemic medical and/ or surgical conditions precluding interaction with the parents, other than preterm-related intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL). * Parental refusal to participate * Absence of clearance from the neonatologist * Infants planned to be transferred to another facility for their NICU care.",1.0,21.0,"['behavioral assessment of children', 'early intervention']"
NCT06084520,Translation and Validation of the COMM and ASI-SR,Translation and Validation of the COMM and ASI-SR - Instruments for Assessing Substance Use Disorder Development in a Swedish Population of Patients With Long-term Pain Treated With Opioids,RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: Intervention group: * Patients with long-term, non-cancer-related pain (\>3 months) at least 3 days a week * opioid treatment for at least 1 month during last 6 months * age 18-75 years * fluent in spoken and written Swedish. Control group: * Patients with long-term, non-cancer-related pain (\>3 months) at least 3 days a week * no opioid treatment at inclusion and during last 3 months * age 18-75 years * fluent in spoken and written Swedish Exclusion Criteria: * ongoing diseases or conditions that prevents the patient from completing to the study according to the doctor's assessment * serious cognitive disorder that makes answering the questions impossible. - - ongoing or treated cancer in the last 10 years * Insufficient knowledge of Swedish",18.0,75.0,"['opioid use', 'opioid use disorder', 'alcohol use disorder', 'pain, chronic']"
NCT06279520,Driving Ability Evaluation System to Improve the Conditional Driving License System: Safety and Feasibility Study.,Driving Ability Evaluation System to Improve the Conditional Driving License System: Safety and Feasibility Study.,RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * Individuals over the age of 19 who are currently driving. * Individuals capable of understanding and following the researcher's instructions. * Individuals who can understand the purpose of the research and have consented to participate Exclusion Criteria: * Those who have not signed the consent form. * Individuals with a history of severe dizziness or epilepsy. * Patients with restrictions on sitting in a wheelchair or chair for more than 30 minutes. * Patients with severe shoulder pain. * Patients whose range of motion in major joints is restricted by more than 50%. * Pregnant women. * Patients with pressure sores. * Patients with limitations on simulator use due to heterotopic ossification. * Patients with acute fractures. * Other patients for whom participation in the study is expected difficult.,19.0,65.0,['automobile driving']
NCT04908020,Coping and Post Traumatic Distress in Children and Adolescents During Cancer Follow-up Care,Coping and Post Traumatic Stress Disorder in Children and Adolescents During Cancer Follow-up Care: a Prospective Observational Cohort Study,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * Patients in cancer follow-up care since less than 3 years * Scheduled to follow-up appointement * Italian speaking * Patients' and parents' consent Exclusion Criteria: \- Cognitive and/or developmental impairment,9.0,17.0,"['pediatric cancer', 'follow-up care']"
NCT06544720,SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas,A Phase 1 Clinical Study of Autologous TCR-T Cells (SCG142) Therapy for Advanced HPV Associated Carcinomas,RECRUITING,INTERVENTIONAL,ALL,"Key Inclusion Criteria: 1. Greater than or equal to 18 years of age 2. HPV associated carcinomas 3. Patients must have at least one measurable lesion defined by RECIST 1.1 4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Key Exclusion Criteria: 1. Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory. 2. Patients with active autoimmune diseases. 3. Patient has a known active Hepatitis B or Hepatitis C. 4. Other severe medical conditions that may limit subject\&#39;s participation in this trial.",18.0,65.0,"['human papillomavirus associated carcinomas', 'cervical cancer', 'head and neck cancers', 'anal cancer', 'vulva cancer', 'vaginal cancer', 'penile cancer', 'hpv-related malignancy']"
NCT03047720,Scheduled Awakenings for the Treatment of Nocturnal Enuresis,Scheduled Awakenings for the Treatment of Nocturnal Enuresis,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Benign nocturnal enuresis * Age: 5 - 17 * Must have or have access to an Apple iPhone, iPad, or iPod Touch Exclusion Criteria: * Diurnal Enuresis * Constipation * Neurogenic Bladder * Any serious underlying cardiopulmonary problems that require diuretics or antihypertensive medications to manage * Any bladder active medications * Age: \ 17 years of age * Cerebral Palsy * Mental disorders, mood disorders, or autism-spectrum disorder * Epilepsy or seizure history * Restless leg syndrome * Use of benzodiazepine/clonidine",5.0,17.0,['nocturnal enuresis']
NCT05086120,A Remote Electronically Delivered Integrated Care Pathway: A Feasibility Study,A Remote Electronically Delivered Integrated Care Pathway for Adolescents With Major Depressive Disorder: A Feasibility Study,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * 13-18 years old at baseline * Mood and Feelings Questionnaire - Childhood, long version (MFQ) score of ≥22 * Diagnosis of Major Depressive Disorder by impression from the referring psychiatrist and confirmed using the KSADS * Internet access at home * Access to a smartphone for personal and private use, with an associated standard data plan (ie. greater than or equal to 500 MB/month) * Able to speak and read English fluently Exclusion Criteria: * Individuals that arecurrently receiving structured psychotherapy * Clinically significant suicidal ideation that is defined as 'imminent intent' or attempted suicide in the past 6 months * Co-morbid diagnosis of borderline personality disorder (as assessed by the Childhood Interview for Borderline Personality Disorder) (Zanarini, 2003), schizophrenia, bipolar disorder, moderate-to-severe eating disorder, obsessive compulsive disorder and/or severe alcohol/substance use disorder in the past 3 months * Youth with known or clinically suspected intellectual disability or autism spectrum disorder * Youth who are not able to provide informed consent for any other reason",13.0,18.0,['major depressive disorder']
NCT02081820,Admission HbA1C in Aneurysmal Subarachnoid Hemorrhage,Observational Study on the Prognostic Relevance of Admission Glycated Hemoglobin (HbA1C) in Patients With Aneurysmal Subarachnoid Hemorrhage,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * confirmed aneurysmal subarachnoid hemorrhage * admission within 72hours after hemorrhage * Age \>18 years Exclusion Criteria: * non-aneurysmal SAH * admission \>72hours after hemorrhage * Age \<18 years,18.0,65.0,"['hyperglycemia', 'aneurysmal subarachnoid hemorrhage']"
NCT03835520,Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or Immunotherapy,Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or Immunotherapy,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * Patients with cancer treated with one of the following regimens: Molecular targeted agents or Immunotherapy * Paraffin-embedded tumor tissue available for immunohistochemistry and/or DNA extraction. * Patient able to give written informed consent. Exclusion Criteria: * Patients with cancer treated with other regimen,18.0,65.0,['cancer']
NCT04885920,A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA),"Prospective, Non-interventional, Observational Study in Patients With IBD Receiving IV or SC Vedolizumab Therapy to Observe Route of Administration Choices and Outcomes",COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: 1\. Has moderately to severely active IBD (UC or CD), initiating or ongoing IV induction treatment with vedolizumab in accordance with the current SmPC at baseline OR IBD participants receiving ongoing/maintenance IV vedolizumab treatment, with the option to switch to SC vedolizumab maintenance treatment. Exclusion Criteria: 1. Prior history of intolerability, hypersensitivity, or other contraindications (active severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections such as Progressive Multifocal Leukoencephalopathy) to vedolizumab therapy as defined in the current SmPC. 2. Current or planned participation in an interventional clinical trial for CD or UC. 3. Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.",18.0,65.0,"['inflammatory bowel diseases', 'crohns disease', 'colitis, ulcerative']"
NCT01084720,"Efficacy, Local Tolerance and Patient Acceptability of a Moisturizing Emollient in Patients With Uremic Xerosis","Efficacy, Local Tolerance and Patient Acceptability of a Moisturizing Emollient in Patients Undergoing Maintenance Renal Dialysis With Uremic Xerosis (MRD)",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients of both sexes, of at least 10 years of age * Patients undergoing either hemodialysis or peritoneal dialysis due to chronic renal failure * Patients whose xerosis is related to their renal insufficiency status * Patients suffering from moderate to severe xerosis, i.e. with a severity score of at least 2, on two symmetric areas of the lower legs (Phase I test areas) * Patients who have not experienced phototherapy within 8 weeks prior to study entry * Patients with no antipruritic treatment, or with stable antipruritic treatments (e.g. antihistamines, cholestyramine, opioid inhibitors, charcoal) at least 4 weeks before study entry * Written informed consent (Appendix II) from the patients or parents Exclusion Criteria: * Patients under 10 years of age * Patients undergoing renal dialysis for another reason than MRD * Patients whose xerosis or pruritus is due to another reason than their MRD status * Patients suffering from mild xerosis (score £ 1) on the lower legs * Patients with xerosis of non comparable severity between the lower legs * Patients with a known history of allergy to one of the ingredients contained in the test product * Patient with an intercurrent condition which may interfere with a good conduct or the study parameters of the study * Patients treated with any other emollient/moisturizing topical preparation within the 7 days prior to study entry * Patients with phototherapy within 8 weeks prior to study entry * Patients who started an antipruritic treatment other than phototherapy, or who experienced unstable dosage schedule of antipruritic treatments (e.g. antihistamines, cholestyramin, opiod inhibitors, charcoal) within 4 weeks prior to study entry * Patients who participated in a study within the 3 months prior to study entry * Patients who are not able or willing to follow the study instructions * Patients or parents who refuse to give written informed consent",10.0,65.0,['uremic xerosis']
NCT05897320,A Study of Eptinezumab in Pediatric Participants With Episodic Migraine,"Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Paediatric Patients (6 to 17 Years) for the Preventive Treatment of Episodic Migraine",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Diagnosis of migraine (with or without aura) according to the International Classification of Headache Disorders, 3rd edition (ICHD-3; in the opinion of the investigator) with history of migraine headaches of at least 6 months prior to the Screening Visit. * During the 28-day screening period, the participant (and their parent/caregiver, when applicable) must adequately complete the headache eDiary (≥23 of the 28 days) following the day of the Screening Visit. * During the 28-day screening period, the participant must have ≤14 headache days, of which at least 4 are migraine days as documented in the eDiary. Exclusion Criteria: * History or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes (previously referred to as complicated migraine), such as hemiplegic migraine (sporadic and familial), migraine with brainstem aura, recurrent painful ophthalmic neuropathy, or migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration, e.g., \>60 min). * History of moderate or severe head trauma or other neurological disorder or systemic medical disease that is, in the investigator's opinion, likely to affect the functions of the central nervous system. * Current psychiatric condition that is uncontrolled and/or untreated for a minimum of 6 months prior to the Screening Visit. Participants with a lifetime history of psychosis and/or mania are excluded. * Any other disorder for which the treatment takes priority over treatment of migraine or is likely to interfere with study treatment or impair treatment compliance. Other inclusion and exclusion criteria may apply.",6.0,17.0,['episodic migraine']
NCT05074420,A Study of Baricitinib (LY3009104) in Children With COVID-19,"A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Hospitalized with coronavirus (SARS-CoV-2) infection. * Male or female participants from 1 to \ 5 times AAULN. * Estimated glomerular filtration rate (eGFR) (Modification of Diet in Renal Disease \[MDRD\]) \<40 milliliter/minute/1.73 meters squared. * Have a known hypersensitivity to baricitinib or any of its excipients. * Are currently enrolled in any other clinical study involving an investigation product or any other type of medical research judged not to be scientifically or medically compatible with this study. Note: The participant should not be enrolled (started) in another clinical trial for the treatment of COVID-19 or SARS CoV-2 through Day 28. * Are pregnant, or intend to become pregnant or breastfeed during the study. * Are, in the opinion of the investigator or sponsor, at risk of immunosuppression or otherwise unsuitable for inclusion in the study. * Are using or will use extracorporeal blood purification (EBP) device to remove proinflammatory cytokines from the blood such as a cytokine absorption or filtering device, for example, CytoSorb®. * Are, in the opinion of the investigator, unlikely to survive for at least 48 hours after screening.",2.0,18.0,"['covid19', 'corona virus infection']"
NCT00567320,Efficacy of Varenicline in Methadone-Stabilized Cocaine Users,Efficacy of Varenicline in Methadone-Stabilized Cocaine Users,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Males and females between 18 and 55 years old will be eligible for this study. Females must not be pregnant as determined by pregnancy screening, nor breast feeding, and must be using acceptable birth control methods during study participation. * Current opioid dependence as evidenced by documentation of prior treatment for opioid dependence or signs of withdrawal, self-reported history of opioid dependence for consecutive 12 month period and a positive urine for opiates. * Subjects must fulfill Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for opioid dependence. * Subjects must have a history of cocaine use, with a reported street cocaine use of a minimum of 1/2 gram during the preceding 30 days. * Subjects must meet DSM-IV criteria for cocaine dependence or abuse, and have laboratory confirmation of recent cocaine use (positive urine for cocaine) during the month prior to study entry. * Subjects must be treatment-seekers for opioid and cocaine use. * Subjects must have smoked at least 10 cigarette per day for at least one year. Varenicline's safety has only been studied in smokers. Exclusion Criteria: * History of heart disease, left ventricular hypertrophy, ischemic ECG changes, chest pain, arrhythmia, hypertension. * History of severe renal or hepatic diseases. * History of psychosis, schizophrenia, bipolar or major depressive disorder. * History of seizure disorder. * Current diagnosis of alcohol, benzodiazepine and other drug abuse or dependence (other than opiates, cocaine, and nicotine). * Current use of over-the-counter or prescription psychoactive drugs (antidepressant, anxiolytics, antipsychotics, mood stabilizers, psychostimulants). * Liver function tests (ALT or AST) greater than 3 times normal. * Known allergy to varenicline or methadone.",18.0,55.0,"['cocaine dependence', 'nicotine dependence']"
NCT01713920,Efficacy and Tolerability of Combination Antihypertensive Drug in Non-Responders to ARB monoTHerapy Using 24h ABPM,Efficacy and Tolerability of Combination Antihypertensive Drug in Non-Responders to Angiotensin Receptor Blocker(ARB) monoTHerapy Using 24h ABPM.,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Male and female subjects \> 55 years 2. Subject who has consent to participate by signing on the informed consent form 3. Uncontrolled hypertensive patients defined as: * Uncontrolled hypertensive: subjects who are mean SBP ≥ 140 mmHg after being treated with ARB(Valsartan 80mg or Candesartan 8mg) monotherapy during at least 4 weeks. Exclusion Criteria: 1. Secondary hypertension 2. SeSBP ≥ 180mmHg 3. SeSBP difference ≥ 20mmHg or SeDBP difference ≥ 10mmHg 4. A history of hypertensive encephalopathy, unstable angina, transient ischemic attack, MI, or any type of revascularization procedure within the last 6 months 5. Heart failure, second- or third-degree heart block, significant arrhythmia or valvular heart disease 6. Significant cardiovascular, cerebrovascular, renal, gastrointestinal, or hematologic disease, at the discretion of investigator 7. Creatinine clearance\ 5.5mmol/L) 10. Patients with sodium depletion is not correct or Patients with fluid depletion is not correct 11. Chronic inflammation 12. Patients with severe eye-related disorders (Retinal bleeding within 6 months, Blindness, Hypertension complications with Retinal micro-aneurysms) 13. Diabetes mellitus 14. Hematologic/oncologic, neurologic and psychiatric diseases 15. Females who were pregnant, breastfeeding, planning a pregnancy or who were of childbearing potential 16. Contraindications for amlodipine, losartan, olmesartan medoxomil, or other ARBs 17. With known allergic reaction, lack of response or contraindication to Angiotensin II receptor antagonists 18. Mean DBP \> 110 mmHg 19. Patients who took antihyperlipidemic agents within 30 days 20. Subject who have participated in other clinical trial within the last one month 21. Any subjects who are unable to cooperate with protocol requirements and follow-up procedures or who are in medical condition that is not eligible to be entered in investigators' discretion",55.0,65.0,['hypertension']
NCT03800420,Efficacy and Safety of BBT-401-1S in Ulcerative Colitis,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of BBT-401-1S in Patients With Active Ulcerative Colitis",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Provision of signed and dated informed consent form (ICF) * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged \>=18 years * Diagnosed with active UC for at least 3 months prior to screening * Total Mayo score \>=5 and Endoscopic sub-score \>=1 * Stable dosing regimens of oral drugs (if currently administered) as follows: 5-ASA or sulfasalazine at a stable dose for at least 4 weeks, purine analogues (azathioprine, mercaptopurine, thiopurines) or methotrexate at a stable dose for at least 12 weeks, and low-dose oral corticosteroid (up to 20 mg prednisone/day or equivalent) for at least 4 weeks prior to the first dose of study treatment. Doses of oral drugs must remain stable until the end of study treatment (with possible exception for tapering steroid dose after 8 weeks) * For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 3 months after the last dose * For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 3 months after the last dose Exclusion Criteria: * Use of anti-TNF-a biologics or any other biologics for treatment of UC within 60 days prior to randomization. * Any rectal therapy for treatment of UC or intravenous corticosteroids within 2 weeks prior to randomization. * Presence of Crohn's disease, indeterminate colitis, ischemic colitis, fulminant colitis, ulcerative proctitis, or toxic mega-colon * Previous extensive colonic resection (subtotal or total colectomy) * Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine * Evidence of or treatment for Clostridium difficile infection or other pathogenic bowel infection within 60 days or for another intestinal pathogen within 30 days prior to randomization * Active infection with the HIV or Hepatitis B or C viruses * Clinically significant active extra-intestinal infection (e.g., pneumonia, pyelonephritis) * Clinically significant abnormal vital signs, physical examination or 12-lead electrocardiogram (ECG) at screening or baseline * Clinically significant abnormal results of liver function tests (ALT/AST, bilirubin and alkaline phosphatase) \> 2X the upper limit of normal (ULN) at screening * Other clinically significant abnormal laboratory results at screening in the investigator's opinion * History of any clinically significant medical condition that, in the investigator's opinion, would preclude participation in the study * Pregnancy or lactation * Treatment with another investigational drug or other intervention within 30 days prior to screening",18.0,65.0,['ulcerative colitis']
NCT04740320,COVID-19 SARS-CoV-2 Screening Protocol,Screening Protocol for a Dose Finding Human Experimental Infection Study in Healthy Subjects Using a GMP-produced SARS-COV-2 Wild Type Strain,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: 1. An informed consent document signed and dated by the participant and the Investigator. 2. Male or female, age between 18 and 30 years inclusive (at the time of the study consent) 3. Seronegative to the challenge virus SARS-CoV-2 4. Women of childbearing potential with a documented menstrual period within 28 days before the first dose (unless using a contraceptive method that suppressed menstruation as indicated in the study protocol) and willing and able to use contraception as described in the study protocol from 4 weeks before the scheduled date of viral challenge until 30 days after receipt of the final dose of study medication. Negative urine pregnancy test will be required at screening plus, on admission to the quarantine unit, a Negative serum beta human chorionic gonadotropin (β-hCG) is a required. Also a negative urinary pregnancy test prior to virus challenge is also required. 5. Men who are willing to use one of the contraception methods described in the study protocol, from the time of the date of viral challenge, until 90 days after receipt of the final dose of study medication. 6. In good health with no history of clinically significant medical conditions (as described in Exclusion criteria) that would interfere with subject safety, as defined by medical history, physical examination and routine laboratory tests, ECG, and Chest X-Ray\* and determined by the Investigator at a screening evaluation and/or at admission to the Quarantine Unit. 7. Subjects will have a documented medical history either prior to entering the study and/or following medical history review with the study physician at screening 8. Using the QCOVID tool, an absolute risk of COVID-associated death of 1 in 250,000 (0.0004%) or less and COVID-associated hospital admission of 1 in 5000 (0.02%) or less), or alternative risk threshold at the discretion of the CI with advice from the DSMB Exclusion Criteria: Any potential subject who meet any of the criteria below will be excluded from participating in this study. Clinical history 1. History or evidence of any clinically significant or currently active cardiovascular, (including thromboembolic events), respiratory, dermatological, gastrointestinal, endocrine, haematological, hepatic, immunological, rheumatological, metabolic, urological, renal, neurological, psychiatric illness. Specifically: a) Subjects with any history of physician diagnosed and/or objective test confirmed asthma, chronic obstructive pulmonary disease, pulmonary hypertension, reactive airway disease, or chronic lung condition of any aetiology or who have experienced: o Significant/severe wheeze in the past * Respiratory symptoms including wheeze which has ever resulted in hospitalisation * Known bronchial hyperreactivity to viruses b) History of thromboembolic, cardiovascular or cerebrovascular disease c) History or evidence of diabetes mellitus d) Any concurrent serious illness including history of malignancy that could interfere with the aims of the study or a subject completing the study. Basal cell carcinoma within 5 years of treatment or with evidence of recurrence is also an exclusion e) Migraine with associated neurological symptoms such as hemiplegia or vision loss. Cluster headache/migraine or prophylactic treatment for migraine f) History or evidence of autoimmune disease or known immunodeficiency of any cause. g) Other major disease that, in the opinion of the Investigator, could interfere with a subject completing the study and necessary investigations. h) Immunosuppression of any type. 2. Any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx, a clinically significant history of epistaxis (large nosebleeds) within the last 3 months, nasal or sinus surgery within 6 months of inoculation. 3\. Clinically active rhinitis (including hay fever) or history of moderate to severe rhinitis, or history of seasonal allergic rhinitis likely to be active at the time of inclusion into the study and/or requiring regular nasal corticosteroids on an at least weekly basis, within 30 days of admission to quarantine. 4\. History of anaphylaxis and/or a history of severe allergic reaction or significant intolerance to any food or drug, as assessed by the PI. 5\. History or presence of alcohol addiction, or excessive use of alcohol (average weekly intake in excess of 28 units alcohol; one unit being a half glass of beer, a small glass of wine or a measure of spirits). 6\. Psychiatric illness including subjects with a history of depression and/or anxiety with associated severe psychiatric comorbidities, for example psychosis. Specifically, a) Subjects with history of anxiety-related symptoms of any severity within the last 2 years if the Generalized Anxiety Disorder-7 score is ≥4 b) Subjects with a history of depression of any severity within the last 2 years if the Patient Health Questionnaire-9 score is ≥4 7\. Current smokers or subjects who have smoked ≥5 pack years at any time \[5 pack years is equivalent to one pack of 20 cigarettes a day for 5 years\]. • Subjects who have smoked \ 37.9ºC) Receipt of medications and interventions 8. Evidence of a live vaccine within 60 days prior to the planned date of viral challenge, a non-live vaccine within 30 days prior to the planned date of viral challenge, or intention to receive any vaccination(s) before the day 28 follow-up visit. (NB. No travel restrictions applied after the Day 28 Follow-up visit). 9. Receipt of blood or blood products, or loss (including blood donations) of 550 mL or more of blood during the 3 months prior to the planned date of viral challenge or planned during the 3 months after the final visit. 10. Medications a) Use of any medication or product (prescription or over-the-counter), for symptoms of hayfever, nasal congestion or respiratory tract infections or dermatitis/eczema including the use of regular nasal or medium-high potency dermal corticosteroids, antibiotics and First Defence™ (or generic equivalents) within 7 days prior to the planned date of viral challenge apart from those described and allowed in Permitted Medication or agreed by the Principle Investigator b) Receipt of any investigational drug within 3 months prior to the planned date of viral challenge. c) Receipt of three or more investigational drugs within the previous 12 months prior to the planned date of viral challenge. d) Prior inoculation with a virus from the same virus-family as the challenge virus. e) Receipt of systemic (intravenous and/or oral) glucocorticoids or systemic antiviral drugs within 6 months prior to the planned date of viral challenge. f) Over the counter medications (e.g., paracetamol or ibuprofen) where the dose taken over the preceding 7 days prior to the planned date of viral challenge had exceeded the maximum permissible 24-hour dose (e.g., \>4g per day of paracetamol over the preceding week). g) Use or anticipated use within 7 days prior to the planned date of viral challenge and during the conduct of the study of concomitant medications (prescription and/or non-prescription), including vitamins or herbal and dietary supplements within the specified windows. h) Chronically used medications, vitamins or dietary supplements, including any medication known to be a moderate/potent inducer or inhibitor of cytochrome P450 enzymes, within 21 days prior to the planned date of viral challenge. i) Subjects who have received any systemic chemotherapy agent, immunoglobulins, or other cytotoxic or immunosuppressive drugs at any time. 11. Prior participation in another human viral challenge study in the preceding 12 months taken from the date of viral challenge in the previous study to the date of expected viral challenge in this study. 12. Any nasal sampling procedure in the 6 months before date of expected viral challenge in this study. Nasal swabs are allowed. General 13. Subject was mentally or legally incapacitated in the opinion of the Investigator. 14. Females who: 1. Are breastfeeding within 6 months of study commencement, or 2. Had been pregnant within 6 months prior to the study, or 3. Had a positive pregnancy test at any point during screening or prior to inoculation with challenge virus 15. Those in close domestic contact (i.e. sharing a household with, caring for, or daily face to face contact) with children under 3 years, the elderly (\>65 years), immunosuppressed persons, or those with chronic respiratory disease Other 16. Was employed or was a first-degree relative of anyone employed by the Sponsor, a participating clinical trial site, or any Contract Research Organisation involved in the study. 17. Any other reason that the Investigator considered made the subject unsuitable to participate.",18.0,30.0,['covid19']
NCT03915782,Neuroprotective Effect of Remote Ischemic Conditioning in Ischemic Stroke Treated With Mechanical Thrombectomy,NeuroPRotective Effect of remOte Ischemic condiTioning in Ischemic strokE Treated With meChanical Thrombectomy (PROTECT-I Study),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age at least 18 years old, * Carotid ischemic stroke related to a full occlusion of the middle cerebral artery (occlusion of middle 1 (M1) and/or proximal middle 2 (M2) identified as candidate for endovascular intervention according to local criteria, * Brain Magnetic Resonance Imaging (MRI) performed within 6 hours from symptoms onset, * Acute stroke MRI including at least diffusion weighted imaging (DWI), fluid attenuated inversion recovery (FLAIR), intracranial vessel imaging with Magnetic Resonance Angiography (MRA) and perfusion weighted imaging (PWI), * Modified Rankin Score (mRS) score less than or equal to 1 before ischemic stroke, * Obtaining a written informed consent of the patient or a next of kin, or emergency inclusion process. Non inclusion Criteria: * Previous ischemic stroke or transient ischemic attack (TIA) in the previous 3 months, * Contraindications to iodinated contrast agents, * Sickle cell disease known (risk of vaso-occlusive crisis), * Life expectancy less than 90 days, * Pregnant or women of childbearing age who were not using contraception (oral diagnosis), * Patient without health coverage, * Patient under legal protection. * Any contraindication to Magnetic Resonance Imaging (MRI) (example cardiac pacemaker), * Intracranial bleeding, * Intracranial expansive process. Exclusion Criteria: * Recanalization of M1 or proximal M2 segment at the time of thrombectomy",18.0,65.0,"['stroke, ischemic']"
NCT01847482,Therapeutic Hypothermia With IntraVascular Temperature Management (IVTM) in Post-Cardiogenic Cardiac Arrest and Post-Return of Spontaneous Circulation Patients in Japan,"COOL-ARREST JP: A Multicenter, Prospective, Single-arm Interventional Trial to Evaluate Therapeutic Hypothermia With IntraVascular Temperature Management (IVTM) in Post-Cardiogenic Cardiac Arrest and Post-Return of Spontaneous Circulation Patients",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Non-traumatic in-hospital or out-of-hospital cardiac arrest 2. Unwitnessed cardiac arrest (Ventricular fibrillation), or witnessed cardiac arrest (ventricular fibrillation, pulseless electrical activity, asystole within 15 minutes following onset) 3. Patient is at least 20 years of age and less than 80 years of age with consent is given 4. In the judgement of an investigator or sub-investigator, the patient is unable to follow verbal instructions 5. Therapeutic hypothermia using the investigational device can be initiated within six hours of Return of Spontaneous Circulation (ROSC) 6. Written consent can be obtained from a legally acceptable representative Exclusion Criteria: 1. Traumatic cardiac arrest (blunt trauma, penetrating trauma, burns, exsanguination, suffocation, smoke inhalation, near drowning, etc) 2. Accidental hypothermia with core body temperature less than 35.0°C 3. Pregnant or of child bearing potential 4. Patient has given or indicated a Do Not Resuscitate (DNR) order 5. Femoral venous access is contraindicated by previous surgey, medical history, anatomy or the like 6. An inferior vena cava filter is in place 7. Patient has severe bleeding (Pulmonary hemorrhage, gastrointestinal hemorrhage, etc.) 8. Intracranial hemorrhage as confirmed by CT scanning 9. Hemodynamic instability despite use of vasopressor agents and cardiac stimulants 10. Heparin hypersensitivity 11. Serious systemic infectious diseases (sepsis, etc.) 12. Platelet count less than 30,000/mm3 13. Serious hepatic dysfunction 14. Serious renal impairment 15. Using percutaneous cardiopulmonary support (PCPS) 16. Using continuous hemodiafiltration (CHDF) 17. Therapeutic hypothermia has been otherwise implemented between ROSC and the start of the study (excluding the rapid infusion of non-glucose-containing cold electrolyte fluid, or non-glucose-containing cold plasma volume expander) 18. The patient's core body temperature cannot be monitored 19. Currently participating in another clinical trial or has participated in another clinical trial within the past six months 20. in the judgement of an investigator or sub-investigator, participation in this clinical trial is inappropriate for the patient",20.0,80.0,['cardiac arrest']
NCT05040282,The Amenorrhea With Etonogestrel Implant,The Rate and Predictors of Amenorrhea at 1-year Follow-up in Women Using Etonogestrel Implant,COMPLETED,INTERVENTIONAL,FEMALE,Inclusion Criteria: 1. Women aged between 18 and 40 years. 2. Women who are not lactating. 3. Non-pregnant women 4. Women have regular menstrual cycles every 21-35 days with a typical cycle length variation of no more than 5 days. 5. Women who will ESI only for pregnancy prevention for at least 12 months. 6. Have not any medical or gynecologic problems. Exclusion Criteria: 1. Women with any contraindications for progesterone-only contraception in accordance with WHO eligibility criteria. 2. Refuse participation in the study.,18.0,40.0,['contraception']
NCT03143582,Examining the Effects of a Team-based Running Program,Examining the Effects of a Team-based Running Program on the Mental Health and Cognition of Emerging Adults: A Pilot Study,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Healthy enough to participate in physical activity Exclusion Criteria: * NOT excluded on basis of mental health or addiction concerns,17.0,25.0,"['memory', 'learning', 'mood', 'attention', 'stress', 'sleep']"
NCT03668782,Cord Milking in Elective Cesarean Section,Efficacy of Umbilical Cord Milking in Elective Cesarean Section,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: singleton low risk pregnancy, gestational age of 39 to 40/0 weeks confirmed by a first trimester ultrasound, no evidence of active labor, 18 years of age, and (5) a written consent given by the woman. \- Exclusion Criteria:maternal medical and obstetric complications, severe anemia, clotting disorders and suspected intrauterine growth restriction \-",1.0,2.0,['placental transfusion']
NCT00000782,A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen,A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria Concurrent Medication: Allowed in Step 2 (PER 4/5/95 AMENDMENT): * Approved antiretroviral drugs. Patients must have: * Documented HIV infection. * CD4 count \>= 400 cells/mm3. * NO current active opportunistic infection or neoplasm (other than stable cutaneous Kaposi's sarcoma). Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Known hypersensitivity to insect proteins. Concurrent Medication: Excluded: * Antihistamine or anti-inflammatory medications for the 48-hour period between injection and skin test reading. * Topical steroids. Prior Medication: PER 4/5/95 AMENDMENT - Excluded: * Prior immunization with experimental HIV vaccines (strata 2 and 3 only). * Systemic corticosteroids, topical corticosteroids on the arms, or other systemic immunosuppressant agents or antineoplastic agents within 30 days prior to study entry. * Antihistamine or anti-inflammatory medications within 72 hours prior to intradermal injections. PREVIOUS VERSION - Excluded within 30 days prior to study entry: * Any antiretroviral drugs (other than AZT, ddI, ddC, or d4T for patients in stratum 3). * Systemic corticosteroids, topical corticosteroids on the arms, or other systemic immunosuppressant agents or antineoplastic agents. Excluded within 72 hours prior to intradermal injections: * Antihistamine or anti-inflammatory medications.",18.0,65.0,['hiv infections']
NCT00592982,Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging,Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Diagnosis of bisphosphonate-associated ONJ, osteomyelitis, osteoradionecrosis,and osteolytic lesions who received PET imaging at presentation Exclusion Criteria: * Anyone who has not been diagnosed with bisphosphonate-associated ONJ, osteomyelitis, osteoradionecrosis,or osteolytic lesions who received PET imaging at presentation",18.0,65.0,"['bisphosphonate-associated onj', 'osteomyelitis of the jaw', 'osteolytic lesions of the jaw', 'osteoradionecrosis of the jaw']"
NCT05694182,The Safety and Efficacy of an Oral Superfruits Supplement,The Safety and Efficacy of an Oral Superfruits Supplement for Skin Brightening and Wrinkle Reduction,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Malaysian citizen * Male and female (age 20-60 years old) Exclusion Criteria: * Participant who taking any dietary supplements for the past 4 weeks which can affect the study results * Participant who are on contraceptive pills for the past 3 months * Participant who undergo cosmetics treatments such as botox, filler and laser and light treatment within the last 3 months * Pregnant or plans to get pregnant and breastfeeding women",20.0,60.0,['healthy']
NCT04833582,A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma,A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination With Gemcitabine in Adult and Pediatric Subjects With Relapsed or Refractory Osteosarcoma,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age ≥ 12 years at the time of informed consent * Bodyweight ≥ 40 kg * Histologically documented relapsed or metastatic osteosarcoma. * Must have measurable disease according to RECIST Guideline version 1.1 criteria. * Adequate hematologic and organ function. * Female subjects of childbearing potential and male subjects must agree to use an effective method of contraception per institutional standard prior to the first dose and for 6 months after study treatment discontinuation. * Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: * Unresolved toxicity of Grade \>1 attributed to prior therapies (excluding: Grade ≤2 neuropathy, alopecia, or skin pigmentation) * Prior therapy with a WEE1 inhibitor * A serious illness or medical condition(s). * Pregnant or lactating females. Females of childbearing potential with a positive serum pregnancy test \ 470 ms, except for subjects with atrioventricular pacemakers or other conditions (e.g., right bundle branch block) that render the QT measurement invalid. * History or current evidence of congenital or family history of long QT syndrome or Torsades de Pointes (TdP). * Taking medications with a known risk of TdP. * Administration of strong and moderate CYP3A4 inhibitors/inducers and strong and moderate P-gp inhibitors.",12.0,65.0,['osteosarcoma']
NCT01573182,Herpes Zoster Vaccine for Bone Marrow Transplant Donors,A Phase II Clinical Trial of Vaccination of Stem Cell Donors With Zostavax to Reduce the Incidence of Herpes Zoster in Transplant Recipients - A Pilot Study,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Allogeneic HSCT Recipient-donor pair * Donor aged 50 years and over * Recipients and donors willing to be recruited as a pair to this study * Recipients undergoing myeloablative or non myeloablative non T cell depleted, allogeneic stem cell transplants from HLA identical or 1 HLA antigen mismatched siblings. Exclusion Criteria: * Lack of informed consent * Inability to recruit donor and recipient as a pair * Autologous transplant * Contraindication to Zostavax in donor * Donor aged \<50 years * Recipient VZV immunoglobulin G (IgG) negative pre-transplantation, * Donor VZV IgG negative * Pregnancy of donor at randomisation * Inability to follow study protocol (donor and recipient) * Malignancy or immunosuppression of HSC donor * Expected HSCT within 30 to 42 days",50.0,65.0,['herpes zoster']
NCT05891782,A HAPA-based Multicomponent Fall Intervention on Older Adults With Declines in Intrinsic Capacity in Nursing Homes,Effects of a HAPA-based Multicomponent Fall Intervention on Older Adults With Declines in Intrinsic Capacity in Nursing Homes,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Age ≥ 60 years. 2. Living in the nursing home for ≥ 3 months. 3. WHO screening tool identifies at least one dimension of decline in IC. 4. Ability to move independently (non-disabled) with a score of ≥ 4 on the SPPB. (4) Voluntary involvement in the trial and informed consent provided by the participant. Exclusion Criteria: 1. Have severe visual or hearing deprivation. 2. Have severe mental impairment or severe cognitive deficits (i.e., severe depression, schizophrenia). 3. Have severe and terminal heart, liver, brain, and kidney disease (i.e., tumors, brain trauma). 4. Other trials received within 6 months prior to the study.",60.0,65.0,['fall risk']
NCT06797882,Preventive Effects of Silver Diamine Fluoride on Early Enamel Caries,The Effectiveness of Silver Diamine Fluoride (SDF) in the Prevention of Early Enamel Caries Among Patients With Fixed Orthodontic Appliances: A Randomised Controlled Trial,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Subjects about to undergo fixed orthodontic treatment at the Faculty of Dentistry, UKM. * Subjects must be aged 18 years and above. * Consented for treatment. Patients will be informed of the risk and benefit of the study for each treatment group through the patient information sheet given to them before obtaining their consent. * Orthodontic brackets placed at least on the upper incisors. * Patients undergoing orthodontic treatment with conventional orthodontic brackets placed on the labial surface. * Any degree of malocclusion * Fit and healthy patient * Non-smoker * Subjects can understand and possessed basic command in English Exclusion Criteria: * History of fixed orthodontic treatment * Presence of any dental anomalies or developmental defects of enamel (DDE) on labial surfaces of teeth, such as preexisting fluorosis or enamel hypoplasia. * Presence of any or direct/indirect restorations on the labial surface of teeth * History of long-term antibiotic usage * Presence of untreated cavitated lesions, especially on upper and lower incisors and canines * Plaque levels \>30%. * Patient allergic to any of the content of the intervention material (sodium fluoride, silver diamine fluoride, potassium iodide). * Patients with lingual brackets.",18.0,65.0,"['demineralization, tooth', 'white spot lesion of tooth', 'fixed appliances', 'early caries lesions']"
NCT02236182,"Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD)","A Double-blind, Placebo Controlled Trial to Assess the Safety of Two-week Administration of 80 mcg q.i.d. and 160 mcg q.i.d. of Ipratropium Bromide, as Delivered by the RESPIMAT® Device, in Patients With Chronic Obstructive Pulmonary Disease",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: All patients must have a diagnosis of COPD and must meet the following spirometric criteria: * Patients must have relatively stable, moderate to severe airway obstruction with an FEV1 \ =90% for \>=92% of the recording time on overnight oximetry * All patients must sign an Informed Consent Form prior to participation in the trial (i.e., at least 24 hours (h) prior to the screening visit (Visit 1)) Exclusion Criteria: * Patients with clinically relevant diseases other than COPD will be excluded. A clinically relevant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease with may influence the results of the study or patient's ability to participate in the study * Patients with a recent history (i.e. one year or less) of myocardial infarction * Patients with a recent history (i.e. one year or less) of heart failure or patients with any past history or active cardiac arrhythmia requiring drug therapy * Patients who have a pacemaker * Patients with clinically relevant abnormal baseline hematology, blood chemistry or urinalysis. If the abnormality defines a disease listed as an exclusion criterion the patient is excluded * All patients with serum glutamic oxaloacetic transaminase / Aspartate aminotransferase (SGOT/AST) \>80 IU/L, serum glutamic pyruvic transaminase / Alanine transaminase (SGPT/ALT) \>80 IU/L, bilirubin \>2.0 mg/dl, or creatinine \>2.0 mg/dl will be excluded regardless of the clinical condition. Repeat laboratory evaluation will be not be conducted in these subjects * Patients who have a blood eosinophil count \>=600/mm3. A Repeat eosinophil count will be not be conducted in these patients * Patients with a history of cancer, other than treated basal cell carcinoma, within the last 5 years * Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis * Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reason should be evaluated per exclusion criterion No. 1 * Patients with a history of asthma, allergic rhinitis or atopy * Patients with a history of and/or active alcohol or drug abuse * Patients with known active tuberculosis * Patients with an upper respiratory tract infection or COPD exacerbation in the past 6 weeks prior to the screening visit (Visit 1) or during the baseline period * Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction * Patients with known narrow-angle glaucoma * Patients with current significant psychiatric disorders * Patients with regular use of daytime oxygen therapy * Patients who are being treated with cromolyn sodium or nedocromil sodium * Patients who are being treated with antihistamines * Patients using oral corticosteroid medication at unstable doses (i.e. less than six weeks on a stable dose) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day * Patients who are being treated with beta-blocker medication * Patients who have had changes in their therapeutic plan within the last six weeks prior to the screening visit (visit 1) * Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (e.g., oral contraceptive, intrauterine devices, diaphragm or Norplant®) * Patients with known hypersensitivity to ant cholinergic drugs or any other components of the ATROVENT® RESPIMAT™ solution including bacteriostatic agent benzalkonium chlorid (BAC) and edetic acid (EDTA) * Patients who have taken an investigational drug within 1 month or 6 half-lives (whichever is longer) prior to the screening visit (visit1) * Previous participation in this study",40.0,65.0,"['pulmonary disease, chronic obstructive']"
NCT03771482,Education of Providers on Prescribing Best Practices,Education of Providers on Prescribing Best Practices,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * All inpatient prescribing providers Exclusion Criteria: * none,18.0,65.0,['education']
NCT05713682,Peri-implantitis Between Periodontitis and Nonperiodontitis Sites With ARP,Prevalence of Peri-implantitis Between Periodontitis and Nonperiodontitis Sites Treated With Alveolar Ridge Preservation: A Retrospective Cohort Study,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria 1. patients aged ≥ 20 years 2. patients who required tooth extraction and implant therapy 3. at least two bite-wing radiographs: baseline and at least a 6-month follow-up Exclusion Criteria 1. a medical condition as a contraindication to dental surgery, autoimmune disorder, immunosuppression, or uncontrolled diabetes (HbA1c \> 7%); 2. ong-term nonsteroidal anti-inflammatory drug use 3. oral bisphosphonate therapy 4. pregnancy or lactation 5. the absence of follow-up bite-wing radiograph 6. cigarette consumption \>10 per day 7. a history of head and neck radiotherapy.",20.0,65.0,['peri-implantitis']
NCT05440682,Connectivity in Cranioplasty,Structural and Functional Connectivity as Outcome Markers of Cranioplasty Following Decompressive Craniectomy,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Diagnosis of sABI, a neurological condition due to a severe acquired brain damage (i.e., traumatic brain injury, ischemic stroke, hemorrhagic stroke) with a coma lasting at least 24 hours, according to a Glasgow Coma Scale equal or lower than 8 and/or complex and severe neurological disabilities treatable only in high specialty neurehabilitative settings. * Early DC, within 24 h; * Age between 18 and 75 years; * Intra-hospital rehabilitation setting (ordinary hospitalization or day hospithal); * Informed consent agreement. Exclusion Criteria: * Medical instability at enrollment, defined as the acute onset of an unexplained derangement of vital parameters (i.e., temperature, blood pressure, pulse rate, respiratory rate, oxygen saturation, level of responsiveness) outside the normal range (for example, fever, acute internist conditions, etc.) and/or the onset of any new medical condition requiring unexpected additional diagnostic procedures and treatments (for example, severe pain, reduction of urinary output, etc.); * Post-traumatic agitation; * Dehiscence, in progress, of the DC surgical wound; * CP already performed; * Magnetic Resonance Imaging (MRI) absolute contraindications.",18.0,75.0,"['acquired brain injury', 'traumatic brain injury', 'ischemic stroke', 'hemorrhagic stroke']"
NCT00635882,Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED),"A 2-Week Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Anti-Inflammatory Effects of Low, Medium, and High Dose Mometasone Furoate/Formoterol Fumarate MDI Formulation and Medium Dose Mometasone Furoate DPI and MDI Formulations in Adults and Adolescents With Persistent Allergic Asthma",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * To document asthma diagnosis, historical reversibility defined as an increase in absolute forced expiratory volume (in liters) in 1 second (FEV1) of \>= 12% and \>= 200 mL must have been performed within 12 months of Screening. For subjects without historical reversibility, one of the following methods can be used at the Screening Visit or at any time before the Baseline Visit: * Demonstration of an increase in absolute FEV1 of at least 12% and a volume increase of at least 200 mL within 15-20 minutes after administration of 4 inhalations of albuterol/salbutamol (total dose 360 to 400 mcg) or of nebulized short-acting beta agonist (SABA) (2.5 mg), if confirmed as standard office practice, OR * Demonstration of a peak expiratory flow (PEF) variability of more than 20% expressed as a percentage of the mean highest and lowest morning prebronchodilator PEF over at least 1 week, OR * Demonstration of a diurnal variation PEF of more than 20% based on the difference between the prebronchodilator (before taking albuterol/salbutamol) morning value and the postbronchodilator value (after taking albuterol/salbutamol) from the evening before, expressed as a percentage of the mean daily PEF value on any day during the open-label Run-in Period. {The calculation formula: Diurnal PEF Variation = Absolute \[(highest of 3 readings, PM Post-bronchodilator (BD) PEF from prior evening) - (highest of 3 readings, AM Pre-BD from morning value)\]/\[(highest PM Post-BD + highest AM Pre-BD)/2\] \* 100} * At Screening and Baseline Visits, a subject must have persistent allergic asthma with an FEV1 \>65% predicted. * A subject must be allergic to at least one common allergen (grasses, trees, weeds, house dust mites, molds, dog and cat) as demonstrated by clinical symptoms when exposed to the allergen(s), and by skin prick testing or a radioallergosorbent (RAST) class \>1 (excluding modified RAST procedure \[mRAST\]) within 2 years of inclusion in the study. * If, based upon the medical judgment of the investigator, there is no inherent harm in changing the subject's current asthma therapy, the subject and/or parent/guardian) must agree to discontinue prescribed inhaled corticosteroid (ICS), anticholinergics, leukotriene receptor inhibitors, and long-acting beta-2 agonists at the Screening Visit as per required washouts, and be transferred to treatment with SABA for relief for 2 weeks before the Baseline/Randomization Visit. * Clinical laboratory tests (complete blood count, blood chemistries, and urinalysis) conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator. * An electrocardiogram (ECG) performed at the Screening Visit or within 30 days prior to Screening Visit must be clinically acceptable to the investigator and have a QTc interval \ 30 parts per billion (ppb) at a flow rate of 50 mL/second. * At Screening or any time before Baseline, a subject must have a sputum eosinophil count \>3% of total cell count. * Willingness to give written informed consent and ability to adhere to dose and visit schedules. A subject 12 to 17 years of age must also provide written assent. * A nonpregnant female subject of childbearing potential (with a negative serum pregnancy test at Screening) must use a medically acceptable, adequate form of birth control. If not currently sexually active she must agree to use a double-barrier method if she becomes sexually active during the study. Exclusion Criteria: * Use of systemic glucocorticosteroids within 3 months before Screening. * Upper or lower respiratory tract infection within 4 weeks before Screening. * Decrease in absolute FEV1 \>20% between Screening and Baseline Visits. * Requirement for \> 8 inhalations per day of SABA MDI, or 2 or more nebulized treatments of 2.5 mg SABA, on any 2 consecutive days between the Screening and Baseline Visits. * A decrease in AM or PM PEF below the Run-in Period stability limit on any 2 consecutive days before Baseline. At Visit 1, the Run-in Period stability limit for PEF will be established based on the subject's personal best. If the subject does not have a historical personal best, the historical PEF measurement will be the PEF predicted based on the subject's sex, age, and height. PEF value to be multiplied by 0.70 to determine stability limit. * A clinical asthma exacerbation defined as a clinical deterioration of asthma that results in emergency treatment, hospitalization for asthma, or treatment with additional, excluded asthma medication (including oral or other systemic corticosteroids but allowing SABA), as per investigator, between Screening and Baseline Visits. * Inability to induce sputum after 1 or 2 trys.",12.0,65.0,"['asthma', 'airway inflammation']"
NCT06286982,The Oral Symptom Assessment Scale in Older Patients With Frailty,Oral Symptoms in Older Patients With Frailty: a Prospective Observational Study Using the Oral Symptom Assessment Scale,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria * Age ≥ 65 years old * Clinical Frailty Score ≥ 5 * No known history of dementia * The attending clinician should have no concerns about a participant's capacity to consent for this research Exclusion Criteria: * Inability to provide informed consent * Inability to complete the questionnaire * Abbreviated Mental Test Score -4 (AMT4) \<4,65.0,65.0,"['frailty', 'older adults']"
NCT03534882,Effects of Prostaglandin Analogue Washout Following Long-term Therapy in Adults With Primary Open Angle Glaucoma,"Prospective, Randomized, Single-blind Controlled Trial of Topical Prostaglandin Analogue Washout Following Chronic Monotherapy in Adults With Suspected or Proper Primary Open Angle Glaucoma",COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Diagnosis of glaucoma or or ocular hypertension * Prostaglandin analogue responder \>20% intraocular pressure (IOP) reduction from baseline * Age \>18 years * Baseline IOP (pre-treatment) ≥21 mmHg * Prostaglandin analogue treatment duration \> 6 months Exclusion Criteria: * Diagnosis of acute angle closure glaucoma * Treatment with \> 1 glaucoma medication * Topical steroid \> 3 consecutive weeks * Intraocular surgery in last 6 months prior to enrollment * Glaucoma laser intervention in last 12 months prior to enrollment * Best Corrected Visual Acuity (BCVA) \< 70 letters (EDTRS or Snellen equivalent) * Visual field mean deviation \<-3,18.0,65.0,"['primary open-angle glaucoma, mild stage', 'glaucoma, suspect', 'ocular hypertension']"
NCT00352482,Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension,Sildenafil Treatment in Patients With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - a Pilot Cross-over Study,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * IPF, diagnosed according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) consensus statement (with or without surgical lung biopsy) * Pulmonary hypertension, defined as mean pulmonary artery pressure (MPAP) greater than or equal to 25 mm Hg by right heart catheterization (RHC) Exclusion Criteria: * Interstitial lung disease due to conditions other than IPF * Recent lung or upper respiratory tract infection within 4 weeks of study entry * Acute or chronic impairment other than dyspnea (e.g., angina pectoris, intermittent claudication) limiting the ability to comply with study requirements (e.g., 6-minute walk test) * Known hypersensitivity to sildenafil * Known or suspected coronary artery disease (CAD) * Unstable angina * Nitrate use * Known or suspected aortic stenosis (AS) * Known or suspected heart attack, stroke, or life-threatening arrythmias within 1 month of study entry * Severe chronic heart failure, defined as New York Heart Association (NYHA) class III/IV and/or left ventricular ejection fraction less than 25% * Known penile deformities * Known kidney or liver dysfunction * Uncontrolled diabetes (blood glucose less than 60 mg/dl or greater than 300 mg/dl) * Severe serum sodium abnormalities (serum sodium less than 130 mEq/L or greater than 150 mEq/L) * Condition that may predispose participant to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia) * Retinitis pigmentosa * Known or suspected idiopathic hypertrophic subaortic stenosis (IHSS) * Low blood pressure (systolic blood pressure \[SBP\] less than 100 mm Hg or diastolic blood pressure \[DBP\] less than 50 mm Hg) * Uncontrolled systemic high blood pressure (SBP greater than 180 mm Hg or DBP greater than 100 mm Hg) * Cardiopulmonary rehabilitation program started within 8 weeks of study entry or likely to start prior to the conclusion of the study * Treatment with an endothelin receptor antagonist, iloprost, epoprostenol, inhibitors of CYP3A4 (e.g., cimetidine, erythromycin, ketoconazole, itraconazole, mibefradil), protease inhibitors (e.g., amprenavir, indinavir, or ritonavir), rifampin, alpha-blockers (e.g., doxazosin), or other phosphodiesterase-5 inhibitors * Current use of alcohol, grapefruit juice, or St. John's wort * Pregnant or breastfeeding",19.0,65.0,"['pulmonary fibrosis', 'hypertension, pulmonary']"
NCT04830982,Safety and Efficacy of IV Diazoxide as an Additive to Hyperkalemic Cardioplegia in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass,A Randomized Placebo Controlled Single Center Phase 1 Study to Evaluate Safety and Efficacy of IV Diazoxide as an Additive to Hyperkalemic Cardioplegia in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass,WITHDRAWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Age 18 years or older * Scheduled for cardiac surgery with cardiopulmonary bypass and cardioplegic arrest * Patient scheduled for elective cardiac surgery Exclusion Criteria: * Patient with Diabetes Mellitus on sulfonylurea medications * Scheduled for left ventricular assist device (LVAD) or heart transplant * Left ventricular ejection fraction \< 30% * Pre-operative placement or planned use of mechanical circulatory support during surgery * Allergy to Thiazide and its derivatives * History of gout * Patient is pregnant or breastfeeding,18.0,65.0,['myocardial stunning']
NCT03670524,"Health, Environment and Action in Louisville (HEAL) Green Heart Louisville Project","Health, Environment and Action in Louisville (HEAL) Green Heart Louisville Project",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * 30-70 years of age. * Live within the targeted study location Exclusion Criteria: * Unwilling or unable to provide consent. * HIV/AIDS, active treatment for cancer, active bleeding including wounds. * Body weight less than 100 pounds or BMI\>40. * Prisoners and other vulnerable populations. * Anyone that PI thinks is unsafe to participate in study.",30.0,70.0,"['cardiovascular diseases', 'metabolic health']"
NCT05985824,The Effect of Pranayama Breathing Exercise on Quality of Life in Lung Cancer Patients,Comparison of the Effect on the Quality of Life of Lung Cancer Patients Who Underwent Prnayama Breathing Exercise and Did Not Apply Any Exercise.,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Over 18 years old, 2. Lung Cancer Stage III and IV, 3. Being literate, 4. Having sufficient communication skills, 5. Does not have any ailment that will reduce the ability to comprehend and understand, 6. Agreeing to participate in the research, 7. Knowing the diagnosis, 8. Receiving chemotherapy treatment, 9. ECOG performance score ≤ 2, 10. Not using opioids or sedating drugs, 11. Patients who can use smart phones themselves or their relatives will be included in the study Exclusion Criteria: 1. Lung Cancer I., II., stage, 2. Receiving radiotherapy, 3. Having a history of Brain Metastasis, 4. Using integrated health practices in the treatment process, 5. Those who exercise regularly 6. For patients over 65 years of age, patients with a score below 24 on the mini mental test were not included in the study. Research Termination Criteria Intervention Group 1. Developing additional health problems, 2. Unwilling to continue the practice of pranayama breathing exercise, 3. Those who lost their lives during the research process, 4. Those who do not practice pranayama breathing exercise as recommended or cannot do it effectively, 5. The study will be terminated with patients who want to withdraw from the study. Control Group 1. Developing additional health problems, 2. Those who lost their lives during the research process, 3. The study will be terminated with patients who want to withdraw from the study.",18.0,65.0,['lung cancer']
NCT03552224,Evaluation of the Global Auditory Nerve Activity for Exploration of Hearing in Humans,Evaluation of the Global Auditory Nerve Activity as a New Method of Electrophysiological Exploration of Hearing in Humans - 2,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * 18 - 80 years ( inclusive borders) * patient having to undergo surgery at the level of the ponto-cerebellar angle (microvascular decompression, vestibular neurotomy, tumor resection of the meningioma type or schwannoma) and * Unaffected by neuro-sensory hearing loss, defined by mean auditory thresholds of less than 20 dB in tone audiometry in bone conduction on the side of the ear to be operated (N = 15, Group 1) or * Showing mild to moderate hearing loss defined by average hearing loss (average of 500, 1000, 2000 and 4000 Hz thresholds) greater than 20 dB and less than 55 dB in air conduction threshold tone audiometry (N = 15 Group 2). * Voluntary subjects to participate in the study, * Subjects having signed written consent to participate in the study, * Easily accessible topics. Exclusion Criteria: * Subjects unable to understand the nature and goals of the study and / or having difficulty communicating with the investigator, * Subjects refusing to participate, subjects whose free and informed consent has not been sought, subjects for which a consent form has not been signed, * Subjects for whom there is a contraindication to general anesthesia, * Subjects with a central neurological pathology that can disrupt electrophysiological recordings * Not affiliated to a French social security scheme or not benefiting from such a scheme, * Majors protected by law, * Pregnant women, * deprived of liberty by judicial or administrative decision, * Infectious or inflammatory pathology of the middle ear.",18.0,80.0,['hearing loss']
NCT02783924,"The GLOBAL Vitamin D Study. A Genomic, Transcriptomic, Proteomic and Metabolomic Approach","The GLOBAL Vitamin D Study. A Genomic, Transcriptomic, Proteomic and Metabolomic Approach to the Effects of Vitamin D in Adipose Tissue and Peripheral Blood",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * serum 25OHD in the range 20 - 40 nmol/L * no change in medication last 4 weeks Exclusion Criteria: * women \< 60 yrs of age (to avoid influence of menstrual cycle) * reduced kidney function * serious diseases (cardio-vascular, diabetes, etc) * taking vitamin d supplementation",20.0,70.0,['vitamin d deficiency']
NCT05645224,VR-PAT for Pain and Anxiety Management During Pediatric Dermatologic Laser Procedures,Pilot Feasibility Clinical Trial of Virtual Reality for Pain Management During Repeated Pediatric Laser Procedures,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * dermatology patients (5+ years) who are undergoing first laser procedure at the Nationwide Children's Outpatient Laser * have a legal guardian present for patients less than 18 years old for the procedure (for informed consent) * can communicate orally Exclusion Criteria: * any wounds that may interfere with study procedures * usage of a diode laser (VR safety has not been established yet) * vision, hearing, or cognitive/motor impairments preventing valid administration of study measures * history of motion sickness, seizure disorder, dizziness, or migraine headaches precipitated by visual auras * minors in foster care * unable to communicate in English * pregnant women * prisoners",5.0,25.0,"['procedural anxiety', 'procedural pain']"
NCT04455724,Negative Pressure Incisional Wound Therapy for High-risk Ventral Hernia Repair,Negative Pressure Incisional Wound Therapy for High-risk Ventral Hernia Repair: a Randomized Controlled Trial,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. patients undergoing surgical repair of ventral or incisional hernias greater than 3 cm in largest diameter 2. have one or more of the following risk factors for post-operative surgical site complications: 1. Body Mass Index (BMI) greater than or equal to 30 2. diagnosis of diabetes mellitus (either type I or II) 3. previous history of hernia recurrence 4. active smoker 5. presence of colostomy or ileostomy 6. age greater than 64 7. chronic obstructive pulmonary disease 8. chronic kidney disease 9. clinically immunocompromised. Exclusion Criteria: 1. the abdomen is left open post-operatively, or 2. if the patient has a sensitivity to silver.",18.0,65.0,['ventral hernia']
NCT01633424,"The ""Stanford Integrated Psychosocial Assessment for Transplant"" (SIPAT)","The ""Stanford Integrated Psychosocial Assessment for Transplant"" (SIPAT): Psychometric Characteristics of a New Scale for the Prediction of Post-transplant Psychosocial and Medical Outcomes.",COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Patients identified through chart review who were transplanted with heart, kidney, liver, and lung between 6/1/2008 and 7/31/2011 and underwent the SIPAT evaluation before treatment. Exclusion Criteria: * Patients identified through chart review who were transplanted with heart, kidney, liver, and lung between 6/1/2008 and 7/31/2011, who did not undergo the SIPAT evaluation before treatment.",18.0,65.0,['organ transplantation']
NCT03738124,Evaluation of the Valiant Mona LSA Thoracic Stent Graft System in Thoracic Aortic Aneurysms and Chronic Dissections,Evaluation of the Valiant Mona LSA Thoracic Stent Graft System in Thoracic Aortic Aneurysms and Chronic Dissections,WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Subject is at least 18 years of age. * Subject understands and has signed an Informed Consent * Subject must be considered a candidate for revascularization of the LSA. * Subject must be able to tolerate a surgical revascularization of the LSA. * Subject has a descending thoracic aneurysm (DTA) which will require coverage of the LSA * Subject has a healthy, non-diseased aortic proximal seal zone of at least 10 mm from the left carotid to the LSA and at least 5 mm landing zone distal to the LSA and proximal to the start of the aneurysm/ulcer/or the proximal entry tear for dissection. * Subject has a non-diseased aortic diameter between 25 mm and 42 mm (fusiform/saccular aneurysms or penetrating ulcers) or 28 mm to 44 mm (chronic type B dissections), * Subject has a LSA with a diameter between 8 mm and 13 mm. * Subject has sufficient landing zone within the LSA to accommodate the BSG without occlusion of any significant vessels * Subject has patent brachial arteries, iliac or femoral arteries (without circumferential calcifications and a diameter of ≥ 10mm), or can tolerate a conduit that will allow endovascular access to the aneurysmal site with the delivery system of the appropriate sized device chosen for treatment. * Subject has a condition requiring prospective revascularization of the LSA Exclusion Criteria: * Subject has an aneurysmal, tortuous, or atherosclerotic LSA, conflicting the branch graft insertion. * Subject has an aortic atheroma classified as grade IV or grade V. * Subject has prohibitive calcification, occlusive disease, or tortuosity of intended fixation sites. * Treatment with the Valiant Mona LSA Thoracic Stent Graft system would require intentional coverage of the left common carotid artery with the stent graft fabric. * Subject has significant and/or circumferential aortic mural thrombus at either the proximal or distal attachment sites that would compromise fixation and seal of the device. * Subject is a pregnant or breastfeeding female. * Subject has a known allergy or intolerance to the device components. * Subject is in acute renal failure or has renal insufficiency with a serum creatinine ≥ 2.0 mg/dL or is on dialysis. * Subject has coronary artery disease with unstable angina and has not received treatment. * Subject has a connective tissue disease (e.g. Marfan's syndrome, medial degeneration). * Subject has active systemic infection and/or a mycotic aneurysm. * Subject is currently participating in an investigational drug or device clinical trial that would interfere with the observations of this study. * Subject has other medical, social, or psychological problems that, in the opinion of the investigator, will interfere with treatment and follow-up procedures. * Subject has a life expectancy of less than 1 year. * Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion. * Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment.",18.0,65.0,"['aortic aneurysm, thoracic']"
NCT02451124,Non-endoscopic Brushing of the Esophagus Using a Non-endoscopic Inflatable Balloon of the Esophagus in Screening for Barrett Esophagus,Office Based Screening Test for Barrett's Esophagus,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Patients are undergoing clinically indicated esophagogastroduodenoscopy (EGD) * Patients can provide informed consent * Patients have no known coagulopathy and no known history of esophageal varices Exclusion Criteria: * Patients are not undergoing clinically indicated EGD * Patients have known coagulopathies or history of esophageal varices * Patients do not have the ability to give informed consent,18.0,65.0,['barrett esophagus']
NCT01408524,Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol and Diltiazem,A Comparative Study in the Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol (Avexa) and Diltiazem,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * patients who scheduled for craniotomy for tomor removal Exclusion Criteria: * allergic to labetalol or diltiazem * Bradycardia \< 60 beat/min * Second or third degree heart block * Severe asthma or severe COPD * Brain stem tumor,18.0,65.0,"['hypertension', 'craniotomy']"
NCT04757324,Breast Milk and Breastfeeding Education Given in the Antenatal Period,The Influence of Breast Milk and Breastfeeding Education Given in the Antenatal Period on Breastfeeding Success and Breastfeeding Self-efficacy: Randomize Control Trials,COMPLETED,INTERVENTIONAL,FEMALE,"inclusion criteria Being above 18 years of age, Having completed the 26th gestational week (At training phase), Having no problem with vision and hearing, Having no disease that can prevent breastfeeding, Having a pregnancy with no risk, Having no systemic disease, Planning to breastfeed after birth excusion criteria the mother stops researching. treating the baby in neonatal intensive care",18.0,65.0,['breastfeeding']
NCT02894424,Effect of the Membrane Blue Dual® Dye on the Retinal Sensitivity in Macular Hole Surgery,Pilot Study of the Effect on the Retinal Sensitivity of the Membrane Blue Dual® Dye Used for Peeling of the Internal Limiting Membrane in Macular Hole Surgery,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * age ≥ 18 years * lower idiopathic macular hole inferior or equal to 600 micron millimeter * undergoing macular hole surgery Exclusion Criteria: * Myopia \> -3 diopters * pregnant women * no Health Insurance coverage * refusal to participate in the study,18.0,65.0,['macular hole surgery']
NCT06615024,Screening of Coexistence Between Sickle Cell Anaemia and G6PD Deficiency,Newborn Screening of Coexistence Between Sickle Cell Anaemia and G6PD Deficiency in NEW VALLEY GOVERNORATE,NOT_YET_RECRUITING,OBSERVATIONAL,ALL,Inclusion Criteria: \- All new born with good general health Exclusion Criteria: * 1-new born with high reticulocytic count 2-new born with bad general health,1.0,28.0,['sickle cell disease and g6pd deficiency']
NCT02269124,Use of Amplification in Children With Unilateral Hearing Loss,Use of Amplification in Children With Unilateral Hearing Loss,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: Children ages 6-12 years with mild to moderately severe unilateral hearing loss, with thresholds across 4 frequencies ≥ 25 dB but \< 70 dB in the worse hearing ear; Normal hearing in the contralateral ear, defined as thresholds ≤ 20 dB from 250 Hz to 8000 Hz; Unaided word recognition scores of ≥ 80% in worse hearing ear Exclusion Criteria: Contralateral hearing loss; Significant cognitive impairment; Middle ear disease that has not been addressed; Inability to commit to treatment program",6.0,12.0,['unilateral hearing loss']
NCT01776424,Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease,A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: \- Meet criteria for CAD and/or PAD Subjects with CAD must also meet at least one of the following criteria: * Age ≥65, or * Age \<65 and documented atherosclerosis or revascularization involving at least 2 vascular beds, or at least 2 additional risk factors Exclusion Criteria: * Stroke within 1 month or any history of hemorrhagic or lacunar stroke * Severe heart failure with known ejection fraction \<30% or New York Heart Association (NYHA) class III or IV symptoms * Estimated glomerular filtration rate (eGFR)\<15 mL/min * Need for dual antiplatelet therapy, other non-aspirin antiplatelet therapy, or oral anticoagulant therapy",18.0,65.0,['prevention & control']
NCT01564823,Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease,Adalimumab on Preventing Postoperative Recurrence of Crohn's Disease,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age ≥ 18 years of age at the time of signing informed consent. * Patients with Crohn's disease who have undergone an ileocecal/ileocolic resection (L1 or L3). The study and the treatment must be initiated within the two first weeks after the resection (+/- 5 days). * Patients with surgical reconstruction by ileocolic anastomosis. * Women of childbearing age must not be breastfeeding and must have a negative urine pregnancy test and must agree to use contraceptive methods with a \<1% failure rate (e.g., sexual abstinence, oral contraceptives, double barrier methods, intrauterine devices), unless they only have one partner who is sterile. * Patients who have signed and dated the informed consent form before performing any specific screening study procedure. Exclusion Criteria: * Resection that requieres Temporal ileostomy. * Urgency resection which doesn´t permit the initial assessment protocol completion. * Resection due to inactive short indolent stenosis (\<10 cm). * Resection with mucosal macroscopic residual disease in anastomosis. * Previous intolerance or adverse reaction (moderate or severe) to adalimumab or azathioprine. * Any contraindications or unwillingness to perform the scheduled colonoscopies or resonances. * Contraindications to Adalimumab treatment, among which the following are included: active tuberculosis, severe infections such as sepsis or opportunistic infections, moderate or severe heart failure (NYHA class III or IV), central nervous system demyelinating diseases, history of malignant neoplasm or autoimmune diseases. * Severe associated Extraintestinal manifestations. * Previous postoperative recurrence prevention treatments with adalimumab, asathiprine o mercaptopurine which resulted in failure. * Any other disease or patient condition that according to investigator criteria, inadequates patient´s participation in the study.",18.0,65.0,['crohn´s disease']
NCT02711423,"A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers","A Single-Center, Randomized, Investigator/Subject-Blind Single-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Gantenerumab Following SC Administration in Healthy Subjects",COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: * Healthy males 18 to 45 years of age, inclusive * Body mass index (BMI) 20.0 to 32.0 kilograms per meter-squared (kg/m\^2), inclusive Exclusion Criteria: * History of cancer or any clinically significant disease affecting one of the major organ systems * Prior administration of gantenerumab * Clinically significant laboratory test results * Clinically relevant history of hypersensitivity or allergic reaction following exposure to a drug, food, or environmental agent * Known hypersensitivity to gantenerumab or excipients of study drug formulation * Abnormal skin condition or potentially obscuring tattoo, pigmentation, or lesion in the area intended for SC injection * Familial history of early-onset Alzheimer's disease",18.0,45.0,['healthy volunteer']
NCT05337423,Photobiomodulation in the Treatment of Hand-foot Syndrome,"Photobiomodulation in the Treatment of Palmar-plantar Erythrodysesthesia: Clinical, Randomized, Controlled Study",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * over 18 years of age, * hospitalized or outpatients, * with oncological pathology (confirmed by anatomo-pathological or cytological diagnosis) * undergoing chemotherapy treatment (oral capecitabine and 5-Fluorouracil in continuous infusion, following the treatment plans protocolized by the institution: Xelox Bevacizumab, Capecitabine, Capecitabine + Radiotherapy, Folfoxiri, Xeliri-Bevacizumab, Folfox4-Bevacizumab , Docetaxel-CDDP-5-Fluorouracil (Colony Stimulating Factors), mFolfirinox q/14 days, Flot.) * who develop hand-foot syndrome of greater or equal toxicity to 1 on the CTC scale NCI v. 5.0 and on Saif scale. Et al. for dark skin Exclusion Criteria: * Patients with palmo-plantar skin comorbidities, * autoimmune comorbidities, * amputated limbs, * systemic infection, * localized or regional limb infection, * respiratory isolation, * contact isolation * insulin-requiring diabetics.",18.0,100.0,['erythrodysesthesia syndrome']
NCT01844323,A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract,"A Phase 1, Open-Label 4 Sequence 4 Period Crossover Study In Healthy Volunteers To Estimate The Effect Of Active Pharmaceutical Ingredient Particle Size And Lubrication On The Bioavailability Of A Single 125 Mg Dose Of Palbociclib (PD-0332991) Administered Under Fasted Conditions",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Healthy male subjects and/or female subjects with no physical possibility of getting pregnant. * Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study. * Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. * Any condition possibly affecting drug absorption (eg, gastrectomy). * A positive urine drug screen. * History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening. * Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) preceding the first dose of study medication. * Pregnant females; breastfeeding females; females with physical possibility of getting pregnant .",18.0,55.0,['healthy']
NCT02919423,TMS Modulation of Insula-related Brain Networks.02,TMS Modulation of Insula-related Brain Networks.02,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * generally healthy * between the ages of 18-55 * right-handed Exclusion Criteria: * significant health problems (e.g., current and uncontrolled liver, lung, or heart problems) or presence of medical illness likely to alter brain morphology (including history of seizure, history of epilepsy in self or first degree relatives, stroke, brain surgery, head injury, and known structural brain lesion) * current diagnosis of Axis I psychiatric disorders (e.g., depression, anxiety disorder, schizophrenia) * meet DSM-5 criteria for current substance use disorder other than nicotine * use of psychoactive medications that would result in a positive urine drug screen * Current use of medications known to lower the seizure threshold * positive breath alcohol concentration * presence of conditions that would make MRI unsafe (e.g., metal implants, pacemakers) * among women, a positive urine pregnancy test * vision that cannot be corrected to 20/40",18.0,55.0,['healthy subjects']
NCT02249923,Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry,Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry,RECRUITING,OBSERVATIONAL,ALL,Inclusion Criteria: * The subject's age of onset of pulmonary hypertension must be prior to age 18 years * The person providing consent must be able to read either Spanish or English. * The subject (and/or parent/legal guardian) must be able to provide informed consent Exclusion Criteria: * Diagnosed with pulmonary hypertension after age 18 * Refusal to sign informed consent,1.0,21.0,"['pulmonary vascular disease', 'pulmonary arterial hypertension']"
NCT01147523,Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease,The Effect of Spironolactone and Vitamin E Versus Vitamin E on Serum Adipocytokines Levels in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease-A Phase II Study,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Bright liver on ultrasound imaging and increased liver function tests for at least 6 months before liver biopsy * Biopsy-proven NAFLD (either NAFL or NASH) according to NAFLD Activity Score (NAS) Exclusion Criteria: * Ethanol consumption more than 20 g/day * Known intolerance to spironolactone or vitamin E * History of liver disease (chronic viral hepatitis, autoimmune hepatitis, drug-induced liver disease, primary biliary cirrhosis, hemochromatosis, Wilson's disease and α1-antitrypsin deficiency) * Previous exposure to hepatotoxic drugs * Spironolactone or vitamin E administration within one year before screening * Type I Diabetes Mellitus * Pancreatitis * Uncontrolled hypothyroidism or hyperthyroidism * Adrenal Insufficiency * Renal Failure * Cancer * Pregnancy Exclusion criteria were generally the same as those proposed for PIVENS trial design with two modifications: a) known intolerance to spironolactone as an exclusion criterion and b) the inclusion of patients with T2DM not receiving thiazolidinediones or insulin.",18.0,75.0,"['fatty liver', 'steatohepatitis']"
NCT01141023,"Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression",The Parkinson's Progression Markers Initiative (PPMI),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: Parkinson Disease (PD) Subjects: * A diagnosis of Parkinson disease for 2 years or less at Screening. * Confirmation from imaging core that screening DAT scan is consistent with dopamine transporter deficit, or if applicable a VMAT-2 PET scan consistent with vesicular monoamine transporter deficit. * Not expected to require PD medication with at least 6 months from Baseline. * Male or female age 30 years or older at time of PD diagnosis. Healthy Control (HC) Subjects: • Male or female age 30 years or older at Screening. Exclusion Criteria: Parkinson Disease (PD) Subjects: * Currently taking levodopa, dopamine agonists, MAO-B inhibitors, amantadine or other PD medication. * Has taken levodopa, dopamine agonists, MAO-B inhibitors or amantadine within 60 days of Baseline. * Has taken levodopa or dopamine agonists prior to Baseline for more than a total of 60 days. * Received any of the following drugs that might interfere with DAT imaging: Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or amphetamine derivative, within 6 months of Screening. * Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude safe completion of the lumbar puncture. If applicable, currently taking medications that are known to cause QT-prolongation, or are currently taking tetrabenazine (TBZ or amphetamine type medications. * Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia. * Use of investigational drugs within 60 days prior to Baseline (dietary supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme Q10). Healthy Control (HC) Subjects: * Current or active neurological disorder. * First degree relative with idiopathic PD (parent, sibling, child). * MoCA score \< 26. * Received any of the following drugs that might interfere with DAT imaging: Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or amphetamine derivative, within 6 months of Screening. If applicable, currently taking medications that are known to cause QT-prolongation, or are currently taking tetrabenazine (TBZ) or amphetamine type medications. * Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude safe completion of the lumbar puncture. * Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia. * Use of other investigational drugs within 60 days prior to baseline (dietary supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme Q10). SWEDD Subjects: All PD criteria apply, as above, except a SWEDD subject must have confirmation from imaging core that screening dopamine transporter SPECT scan shows no evidence of dopamine transporter deficit or if applicable a VMAT-2 PET scan shows no evidence of vesicular monoamine transporter deficit. Prodromal Subjects: Inclusion Criteria (Prodromal Subjects) 4.2.7.1. Subjects must have at least one of the following characteristics: Hyposmia: 1. Male or female age 60 years or older 2. Confirmation from olfactory core that olfaction as determined by UPSIT is at or below the 10th percentile by age and gender REM Behavior Disorder (RBD): 1. Male or female age 60 years or older 2. Confirmation from sleep core that subject's Polysomnography (PSG) meets criteria for RBD LRRK2: 1. Male or female age 60 years or older 2. Written confirmation or documentation from testing facility that the individual is LRRK2 mutation positive 4.2.7.2. Confirmation from imaging core that screening dopamine transporter SPECT scan is read as eligible (see below). About 80 subjects will have a range of DAT deficit similar to subjects with early PD (mild to moderate DAT deficit). About 20 subjects will be selected with no DAT deficit or minimal DAT deficit similar in age, gender, and risk profile to those with mild to moderate DAT deficit. 4.2.7.3. Ability to provide written informed consent in accordance with Good Clinical Practice (GCP), International Conference on Harmonization (ICH), and local regulations. 4.2.7.4. Willing and able to comply with scheduled visits, required study procedures and laboratory tests. 4.2.7.5. Women may not be pregnant, lactating or planning pregnancy during the course of the study. Includes a negative urine pregnancy test on day of screening scan prior to injection (DaTSCAN). Exclusion Criteria (Prodromal Subjects) 1. Current or active clinically significant neurological disorder or psychiatric disorder (in the opinion of the Investigator). 2. GDS score greater than or equal to 10 (GDS score of 5 - 9 requires Investigator discretion to enter study). 3. STAI Form Y-1 greater than or equal to 54 requires Investigator discretion to enter study. 4. A clinical diagnosis of dementia63 as determined by the investigator (Appendix 1). 5. A clinical diagnosis of Parkinson disease at the Screening visit as determined by the Investigator. 6. Received any of the following drugs that might interfere with dopamine transporter SPECT imaging: Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or amphetamine derivative, within 6 months of Screening. 7. Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude safe completion of the lumbar puncture. 8. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia. 9. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation. 10. Use of investigational drugs or devices within 60 days prior to Baseline (dietary supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme Q10). 11. Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator). Genetic Cohort: Parkinson Disease Subjects - Inclusion: 1. Patients must have at least two of the following: resting tremor, bradykinesia, rigidity (must have either resting remor or bradykinesia) or either asymmetric resting tremor or asymmetric bradykinesia. 2. A diagnosis of Parkinson Disease for 7 years or less at screening. 3. Hoehn and Yahr state \<4 at baseline 4. Male or female age 18 years or older 5. Willingness to undergo genetic testing and to be informed of genetic testing results. 6. Confirmation of mutation in LRRK2, GBA or SNCA 7. For subjects taking any drugs that might interfere with dopamine transporter SPECT imaging (Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine or amphetamine derivative must be willing and able from a medical standpoint to hold the medication for at least 5 half-lives prior to screening DatSCAN(TM) imaging. Exclusion: 1. Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude safe completion of the lumbar puncture. 2. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis or clinically significant coagulopathy or thrombocytopenia. Genetic cohort - Unaffected Individuals Inclusion: 1. Male or female age 45 years or older at baseline with LRRK2 or GBA mutation and/or first degree relative with a LRRK2 or GBA mutation or 2. Male or female age 30 years or older at baseline with a SNCA mutation and/or a first degree relative with a SNCA mutation. 3. Unaffected subjects at high risk of LRRK2, GBA or SNCA mutation due to first degree relative with a LRRK2, GBA or SNCA mutation may choose either to be informed of the results or remain unaware of the results. 4. Unaffected subjects from an ethnic or geographic group knkown to have relatively high risk of LRRK2, GBA or SNCA mutation such as people of Ashkenazi Jewish or Basques descent) and who have a family member (either alive or deceased) who has/had PD must be willing to be informed of their own testing results. 5. Willingness to undergo genetic testing 6. For subjects taking any of the following drugs that might interfere with dopamine transporter SPECT imaging (neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine or amphetamine derivative) must be willing and able from a medical standpoint to hold the medication for at least 5 half-lives prior to DatSCAN imaging. Exclusion: 1. A clinical diagnosis of PD 2. Current treatment with anticoagulants (e.g. coumadin, heparin) that might preclude safe completion of the lumbar puncture. 3. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis or clinically significant coagulopathy or thrombocytopenia. Genetic Registry - Inclusion: 1. Individual with a LRRK2, GBA or SNCA mutation and/or a first degree relative with a LRRK2, GBA or SNCA mutation. 2. Male or female age 18 years or older 3. Willingness to undergo genetic testing, but may choose either to be informed of the results or remain unaware of the results.",30.0,65.0,['parkinson disease']
NCT05401123,Comparison of Breast Milk Content in Mothers Using a Expressing Pump and Milking by Hand,Comparison of Breast Milk Content in Mothers Using a Expressing Pump and Milking by Hand,UNKNOWN,INTERVENTIONAL,FEMALE,"Inclusion Criteria: Between the ages of 20-35 * Postpartum 1-5. between the day * Those who gave birth after the 37th week of pregnancy * The baby does not have any condition that prevents sucking * Those whose baby is not hospitalized in the neonatal intensive care unit * Those who do not have literacy problems, mental disabilities and communication problems * Mothers who agreed to participate in the study voluntarily Exclusion Criteria: Those who want to quit working voluntarily * Inaccessible, cut off communication during operation * Mothers whose babies were hospitalized during the study * Hospitalized during the study * Not completing study post-tests * Who does not do any milking for a day * Mothers who express only once a day for two consecutive days",20.0,35.0,"['breastfeeding', 'human milk']"
NCT03637023,Virtual Reality for Parkinson's Disease,"Clinical and Rest-fMRI Effects of Virtual Reality Practice on Motor and Cognitive Symptoms in Parkinson's Disease, a Randomized Control Trial",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * To be 50 years old and older * Clinical diagnosis of PD within the -framework of Brain Bank criteria * Getting a stable antiparkinsonian medication at least for the last 1 month (or the treatment has not changed) Exclusion Criteria: * Having a story of unstable medical condition * History of head trauma, stroke, or exposure to toxic substances * Implying Parkinson plus syndromes in neurological examinations; pyramidal, cerebellar examination findings, gaze paresis, autonomic dysfunction * Being diagnosed with Dementia",50.0,85.0,"['parkinson disease', 'virtual reality therapy', 'functional magnetic resonance imaging']"
NCT00003123,Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome,A Phase II Trial of Ethyol (Amifostine) in Adult Patients With Advanced Myelodysplastic Syndromes,UNKNOWN,INTERVENTIONAL,ALL,"DISEASE CHARACTERISTICS: Histologically proven advanced myelodysplastic syndrome (MDS), including: Refractory anemia Refractory anemia with ringed sideroblasts Refractory anemia with excess blasts Refractory anemia with excess blasts in transformation MDS with at least bicytopenia No chronic myelomonocytic leukemia No acute leukemia PATIENT CHARACTERISTICS: Age: 17 and over Performance Status: ECOG 0-2 Life Expectancy: Greater than 6 months Hematopoietic: Hemoglobin less than 8.5 g/dL Absolute granulocyte count less than 1,000 g/dL Platelet count less than 70,000/mm3 Hepatic: No major hepatic problems Renal: No major renal problems Cardiovascular: No major cardiac disease Other: Prior transfusion of blood products is allowed Not pregnant Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Prior cytokine therapy is allowed Chemotherapy: No prior chemotherapy Endocrine therapy: Prior steroid therapy is allowed Radiotherapy: Not specified Surgery: Not specified Other: Prior leucovorin calcium and pyridoxine allowed",17.0,65.0,['myelodysplastic syndromes']
NCT01215123,An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer,Avastin in First Line Metastatic or Recurrent Breast Cancer. Retrospective Phase IV Study,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * Patients with metastatic breast cancer in first line treatment who have completed treatment with Avastin Exclusion Criteria: * Patients not willing or unable to signed written consent form,18.0,65.0,['breast cancer']
NCT01810523,"Stories to Educate Patients With Ankle, Foot, and Knee Injuries","Comparative Effectiveness of Descriptive Versus Narrative Emergency Department Discharge Instructions for Patient Education on Unnecessary Testing for Ankle, Foot and Knee Injuries",WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Acute traumatic knee, ankle or foot injury presenting to ED * No indication for X-ray by Ottawa Rules criteria * ED provider planning to discharge patient Exclusion Criteria: * X-ray obtained * Need for X-ray by established Ottawa Rules criteria * Children * Pregnant women * Patient to be admitted to the hospital * Patient non-English speaking or illiterate",18.0,65.0,['injury']
NCT05563623,The Beijing Angle Closure Progression Study,The Beijing Angle Closure Progression Study (BAPS),RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * ""Static"" gonioscopy identifying 6 or more clock hours of angle circumference in which the posterior (usually pigmented) trabecular meshwork cannot be seen in both eyes with no peripheral anterior synechiae, and normal intraocular pressure (IOP), optic nerve and visual field. * Able to provide informed consent Exclusion Criteria: * Any evidence of primary angle closure (a narrow angle as defined above, but with PAS and/or IOP \> 21 mmHg) or primary angle closure glaucoma (visual field defect or glaucomatous optic neuropathy). * Previous intraocular surgery or laser treatment, such as cataract surgery, laser trabeculoplasty, trabeculectomy, laser peripheral iridectomy, and laser iridoplasty * Sign of prior acute attack, such as glaucomatous fleck, keratic precipitates, or iris atrophy. * Anterior segment structural abnormalities shown by examination, such as iris or ciliary body tumor. * Severe health problems precluding follow-up such as end-stage heart disease, kidney disease, or lung disease, or terminal cancer. * Severe eye diseases, such as cataract, macular disease, and retinal detachment.",40.0,75.0,['angle-closure glaucoma']
NCT06519123,Ambient Digital Scribes Populating Clinical Notes,Assessing the Impact of Ambient Digital Scribes Populating Clinical Notes on Patient and Clinician Satisfaction,COMPLETED,INTERVENTIONAL,ALL,Patient Inclusion Criteria: * 18 years or older * able to speak and read English Patient Exclusion Criteria: * unable to speak and read English Clinician Inclusion Criteria: * delivering care in a clinic in which Ambient Digital Scribes are being employed Clinician Exclusion Criteria: * not delivering care in a clinic in which Ambient Digital Scribes are being employed,18.0,65.0,"['patient satisfaction', 'clinician satisfaction']"
NCT04963023,Biomarkers of Chronic Obstructive Pulmonary Disease,Specific Biomarker Identification of Different Subgroups of Chronic Obstructive Pulmonary Disease,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * BPCO patients * ACOS patients * asthmatic patient without BPCO Exclusion Criteria: * infection * exacerbation * immunosuppressive treatment * immunosuppressive disease,18.0,65.0,"['copd', 'asthma-copd overlap syndrome', 'asthma']"
NCT00125723,FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy,"A Multicenter, Open-label, Phase 4 Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: - Pathologically confirmed diagnosis of the following malignancies: breast, non-Hodgkin's lymphoma (NHL), Hodgkin's disease, ovarian, colorectal, lung or other - Planned administration of a new myelosuppressive every 14 (q14), q21, or q28 day chemotherapy - Written informed consent for participation in the study before any study-specific procedures are performed, including screening and registration Exclusion Criteria: - Planned concomitant therapeutic radiation - Diagnosis of acute or chronic leukemia or myelodysplastic syndrome - Prior stem-cell transplantation (includes bone-marrow transplantation) - Medical diagnosis of chronic neutropenia of any cause not related to cancer - Current cytotoxic, biologic, or immunologic therapy for unrelated conditions - Subject has active infection requiring treatment - Known HIV-positive subjects - Subject of child-bearing potential is evidently pregnant (e.g., positive HCG test) or is breast feeding - Subject of child-bearing potential is not using adequate contraceptive precautions - Known sensitivity to E. coli derived drug products (e.g., filgrastim, HUMULIN® insulin, L-asparaginase, HUMATROPE® growth hormone, INTRON A®) - Any psychiatric, addictive or other kind of disorder which compromises the ability of the subject to give written informed consent and/or to comply with study protocol procedures - Subject is currently enrolled in, or has not yet completed at least 30 days since ending another device or drug trial(s) or is receiving, or plans to receive, other investigational agent(s) not approved by the Food and Drug Administration (FDA)",18.0,65.0,['neutropenia']
NCT00084123,Healing Touch and Relaxation Therapies in Cervical Cancer Patients,Healing Touch in Advanced Cervical Cancer Patients: Immune Effects and Mechanisms,COMPLETED,INTERVENTIONAL,FEMALE,Inclusion Criteria: * Stage Ib1-IVa cervical cancer * Treatment with concurrent chemotherapy and radiation at the University of Iowa Hospitals and Clinics Exclusion Criteria: * Immunosuppressive disorders * Use of immunosuppressive medications * Transplant recipient * Metastatic or recurrent cervical cancer * History of any other type of cancer,18.0,65.0,['cervix neoplasms']
NCT07334223,Comparison of Intravenous Ondansetron and Low Dose Ketamine in Preventing Post Spinal Shivering,Comparison of Intravenous Ondansetron and Low Dose Ketamine in Preventing Post Spinal Shivering,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients of either gender aged 20-60 years with ideal body * weight of 50 to 80 kg. * Patients meeting ASA classification I and II determined by * anesthesiologist. * Patients undergoing elective surgeries under spinal anesthesia. * Duration of surgery should not be more than 3 hours. Exclusion Criteria: * Patients having a documented history of severe adverse reactions to ketamine or ondansetron. * Patients with cardiovascular disease documented in history. * Patients with hepatic disease documented in history and supported by lab results (AST 32-40U/L), ALT(10-40U/L). * Patients with renal disease documented in history and supported by lab results. Urea (10-50mg/dl) S/Creatinine (0.3-1.5mg/dl). * Patients with hyperthyroidism documented in history and supported by lab results. * Patients with history of mental illness, seizures and glaucoma. * Patients with known hypertension (BP greater than 140/90). * Haemodynamically unstable patients (BP\<100mmHg). * Patients with coagulopathy or other bleeding diathesis documented in history and supported by lab results. * Complicated prolonged surgeries in spinal anesthesia.",20.0,70.0,"['postoperative shivering', 'postspinal shivering']"
NCT03609723,Combined Use of a Novel Cardioplegic Formula With MPS ® Using the MiECC in Isolated CABG Versus OPCABG,Combined Use of a Novel Cardioplegic Formula With MPS ® Using the MiECC in Isolated CABG Versus OPCABG,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * CABG using MPS® or OPCABG Exclusion Criteria: * use of other colloid solution than Cardioplexol ® for MPS® * other inventions than CABG * myocardial infarction \<7 days before CABG * patients denial of data use,18.0,65.0,"['complication of coronary artery bypass graft', 'complication of extracorporeal circulation']"
NCT04791423,Study of GRAd-COV2 for the Prevention of COVID-19 in Adults,"A Phase II/III, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GRAd-COV2 Vaccine in Adults Aged 18 Years and Older",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Adult female and male, ≥ 18 years of age at the time of consent 2. Medically stable such that, according to the judgment of the investigator, hospitalization within the study period is not anticipated and the participant appears likely to be able to remain on study through the end of protocol-specified follow-up. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months prior to enrollment 3. Able to understand and comply with study requirements/procedures based on the assessment of the investigator 4. Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies 5. Female participants, (a) Women of childbearing potential must: Have a negative pregnancy test on the day of screening and on Day 1; use one highly effective form of birth control for at least 28 days prior to Day 1 and agree to continue using one highly effective form of birth control through 60 days following administration of study intervention. 6. Capable of giving signed informed consent. Exclusion Criteria: 1. History of allergy to any component of the vaccine 2. History of Guillain-Barré syndrome or any other demyelinating condition 3. Significant infection or other acute illness, including fever \> 37.3 °C on the day prior to or day of randomization 4. History of laboratory-confirmed SARS-CoV-2 infection 5. Any confirmed or suspected immunosuppressive or immunodeficient state, including asplenia (only for phase II) 6. Recurrent severe infections and use of immunosuppressant medication within the past 6 months 7. History of primary malignancy except for: (a) Malignancy with low potential risk for recurrence after curative treatment (for example, history of childhood leukaemia) or metastasis (for example, indolent prostate cancer) in the opinion of the site investigator. (b) Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease (c) Adequately treated uterine cervical carcinoma in situ without evidence of disease (d) Localized prostate cancer (only for phase II) 8. Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or vene puncture 9. Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, and neurological illness, as judged by the Investigator (mild/moderate well-controlled comorbidities are allowed) (only for phase II) 10. Any other significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data 11. Receipt of, or planned receipt of investigational or licensed products indicated for the treatment or prevention of SARS-CoV-2 or COVID-19 12. Receipt of any vaccine (licensed or investigational) other than licensed influenza vaccines within 30 days prior to and after administration of study intervention 13. Receipt of immunoglobulins and/or any blood products within 3 months prior to administration of study intervention or expected receipt during the period of study follow-up 14. Involvement in the planning and/or conduct of this study (applies to both Sponsor staff and/or staff at the study site) 15. For women only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding 16. Has donated ≥ 450 mL of blood products within 30 days prior to randomization or expects to donate blood within 90 days of administration of study intervention.",18.0,65.0,['covid19']
NCT02893423,Ropivacaine Transversus Abdominis Plane Blocks for Cesarean Section Analgesia,The Dose Dependent Effect of Ropivacaine Transversus Abdominis Plane Blocks on Postoperative Analgesia After Cesarean Section,TERMINATED,INTERVENTIONAL,FEMALE,Inclusion Criteria: * Pregnant patients undergoing elective c-section Exclusion criteria: * Allergy to local anesthetics * Contraindication to tap blocks,18.0,65.0,['postoperative pain']
NCT04688723,Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI,RE-DUAL PCI Real Life Registry Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age ≥ 18 years * Patients having an indication for a NOAC or will start with oral anticoagulation (NOAC). Permanent, persistent or paroxysmal atrial fibrillation are eligible. * PCI and successful stenting with DES for ACS (unstable angina pectoris, NSTEMI, STEMI) * Written informed consent. Exclusion Criteria: * Patients unable or unwilling to comply with the protocol or with life expectancy shorter than the duration of the study * Glomerular filtration rate \ 3x upper limit of normal) or liver disease (like hepatitis A, B, C) * Lesion or condition with a significant risk of serious bleeding, such as; current or recent gastrointestinal ulceration; malignant neoplasms with more bleeding risk; recent brain / spinal cord injury; recent surgery on the brain, spinal cord or eyes; recent or history of intracranial haemorrhage; oesophageal varices; arteriovenous malformations; vascular aneurysms; o severe intraspinal or intracerebral vascular abnormalities. * comedication with cyclosporine, itraconazole, ketoconazole (systemic) and glecaprevir / pibrentasvir, dronedarone, rifampicine, carbamazepine, St. Jan's wort or phenytoin o Comedication with tacrolimus is not recommended. * Allergy to for Dabigatran, Ticagrelor or Clopidogrel * Pregnancy * Significant thrombocytopenia (platelet count \< 50x10 9/L) * Major bleeding according to BARC ≥3 within the past 6 months. * Weight \< 50 kg",18.0,99.0,"['coronary artery disease', 'myocardial ischemia', 'myocardial infarction', 'atrial fibrillation']"
NCT07188623,Virtual Reality-Enhanced Behavioral Activation for Older Adults With Depression,VR-Enhanced BA for Older Adults With Major Depressive Disorder,RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * Patient must meet DSM V criteria for MDD * Patient must be at least 65 years of age * Patient must be English speaking * Without cognitive impairment Exclusion Criteria: * Substance Use Disorders in past year * Any psychosis or bipolar I disorder * Any seizure in the last 6 months or untreated epilepsy * Current nonsuicidal self-injury or parasuicidal behavior * Current suicidal urges and intent * Changing psychotherapy treatment within three months of study entry * Changing psychotropic medication(s) within two months of study entry,65.0,65.0,"['depression - major depressive disorder', 'older adults (65 years and older)', 'behavioral activation treatment', 'virtual reality therapy']"
NCT03568123,A Comparison of the Persona Total Knee Arthroplasty System Using CR or MC Polyethylene,A Prospective Randomized Control Study on CR vs MC Polyethylene Bearing With Persona Total Knee System in Total Knee Arthroplasty,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Clinical and radiological osteoarthritis of the knee set to receive a primary unilateral total knee replacement * \>18 years of age * Participants must be able to speak and understand Danish * Participants must be able to give informed consent and be cognitively intact * Participants must be able to complete all post-operative controls * Participants must not have severe comorbidities, American Society of Anesthesiologists Physical Status Classification System (ASA) score ≤ 3 * Clinically suitable to receive a Cruciate Retaining (CR) implant (no severe deformity and/or ligament instability) Exclusion Criteria: * Age under 18 years. * Terminal illness * Revision knee replacement surgery * Rheumatoid Arthritis * Traumatic etiology * Prior surgery on the affected knee that includes osteosynthesis, anterior cruciate ligament (ACL) and/or posterior cruciate ligament (PCL) and/or collateral ligament surgery. Arthroscopy with meniscectomy / cartilage surgery / house cleaning is allowed. * Altered pain perception and / or neurologic affection due to diabetes or other disorders. * Patients will be excluded intraoperative if CR implant is not suitable.",18.0,65.0,['knee osteoarthritis']
NCT03131323,Nasal Findings in Reactive Airway Diseases,Nasal Findings in Reactive Airway Diseases,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: * All children having chest wheezes, aged from two years to eighteen years, attending emergency unit of Assiut University Pediatric Hospital, during the period 1⁄6∕2017 to 1∕6⁄2018. They will be examined in Otolaryngology Department, Assiut University Hospital Exclusion Criteria: * Refusal of endoscopic nasal examination by care givers.and patients with definite diagnosis of wheeze (bronchiolitis,pneumonia)",2.0,18.0,"['reactive airway disease', 'wheezing']"
NCT00004923,Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors,Dose Escalation Trial of Docetaxel Plus Irinotecan in Patients With Advanced Cancer,COMPLETED,INTERVENTIONAL,ALL,"DISEASE CHARACTERISTICS: Histologically proven solid malignancy for which no effective therapy is currently available CNS metastases allowed if CNS disease is stable for at least 4 weeks following completion of surgery and/or radiotherapy PATIENT CHARACTERISTICS: Age: Over 18 Performance status: At least 3 months Life expectancy: ECOG 0-2 Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 1.2 mg/dL SGOT and/or SGPT no greater than 1.5 times upper limit of normal (ULN) (no greater than 2.5 times ULN allowed if alkaline phosphatase no greater than ULN) Alkaline phosphatase no greater than 2.5 times ULN (no greater than 4 times ULN allowed if SGOT and/or SGPT no greater than ULN) Renal: Creatinine clearance at least 55 mL/min Other: HIV negative No active infection Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No concurrent medical condition that would preclude compliance with study PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy regimens containing topotecan, irinotecan, or docetaxel At least 4 weeks since other prior chemotherapy (6 weeks since prior nitrosoureas, melphalan, or mitomycin) Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics At least 4 weeks since prior wide field radiotherapy No prior radiotherapy to greater than 20% of bone marrow Surgery: See Disease Characteristics Recovered from any prior surgery Other: No other concurrent investigational agents",18.0,65.0,"['unspecified adult solid tumor, protocol specific']"
NCT03119623,Comparing ARNI With ACE Inhibitor on Endothelial Function,Prospective Comparison of an ARNI With an ACE Inhibitor on enDOthelial Function by Brachial Artery Reactivity (PARADOR),WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Willing to provide written informed consent * Willing to comply with all study procedures and be available for the duration of the study * Male or female, at least 18 years of age * Documented diagnosis of heart failure * Documented history of left ventricular ejection fraction \< 40% in the 6 months of randomization * NYHA functional class II or III * Current treatment with an ACEI at a stable dose of at least enalapril 5 mg twice daily or equivalent for at least 30 days * Stable heart failure medications (ACEi, +/-beta blocker, +/-mineralocorticoid receptor antagonist) for the past 30 days (with the exception of diuretics) Females of childbearing potential must have a negative urine pregnancy test prior to randomization and agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to randomization, for the duration of study participation, and for 7 days following completion of therapy. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). Exclusion Criteria: * Documented or self-reported history of hereditary or idiopathic angioedema * History of acute coronary syndrome, cardiac bypass procedure, stroke, or transient ischemic attack within three months of randomization * Placement of a biventricular pacemaker device within 6 months of randomization * History of hypersensitivity or allergy to any of the study drugs or drugs of similar chemical classes * Current use of sacubitril/valsartan * Previous intolerance to ACE inhibitors * Baseline Estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73 m2 per the Modification of Diet in Renal Disease (MDRD) formula * History of bilateral renal artery stenosis * History of hepatic dysfunction * Baseline serum potassium greater than 5.2 mmol/L * Baseline systolic blood pressure less than 110 mmHg or greater than 180 mmHg * Enrolled in another clinical trial or has used of any investigational drugs, biologics, or devices within 30 days prior to randomization * Women who are pregnant or breast-feeding * Not suitable for study participation due to other reasons at the discretion of the investigator",18.0,65.0,['heart failure with reduced ejection fraction']
NCT07373223,Virtual Reality Schema Therapy Exercises With Parent and Child Modes,VR-STEM: Virtual Reality Schema Therapy Exercises With Parent and Child Modes,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * 18-65 years of age * In treatment at a tertiary treatment facility (UCP, UMCG) * Whose current psychological distress is related to early life experiences as indicated by a clinician * Score of \>3 on one of three schema modes on the SMI (Lobbestael et al., 2010) Exclusion Criteria: * Insufficient command of the Dutch language * Primary diagnosis of a substance use disorder, or organic brain disease (such as dementia) * Unable to provide informed consent",18.0,65.0,['psychiatric disorders']
NCT06234059,Modulation of Sensory Acuity With Transcranial Magnetic Stimulation (TMS),Behavioral and Neural Measures of Speech Motor Control,WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria (Control): * English-speaking adults * normal hearing and speech * no history of stroke or neurological conditions Exclusion Criteria: * Native language other than English * Any neurological disorders other than the disorder of interest * Any history of hearing disorders * Uncorrected vision problems that prevent participants from seeing visually-presented stimuli * Significant cognitive impairments that prevent participants from carrying out the task or from giving informed consent * Vulnerable populations (minors and prisoners) * Additional exclusionary criteria for TMS: * Implanted paramagnetic materials (metal clips, plates, pacemakers, etc.) * Increased risk in the event of a seizure * Serious heart disease * Increased intracranial pressure * Pregnancy * History of seizures * Family history of epilepsy * Epileptogenic medications * Chronic or transient disruption of sleep (including jet lag) * History of fainting * Chronic or transient increase in stressful experiences * Use of illegal drugs * If the TMS visit involves a visual acuity task at the same time as TMS\] Use of glasses at the research study visit",18.0,70.0,['speech']
NCT05273359,Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD),Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD),UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: Current smoker or ex-smoker with a tobacco history of ≥10 pack-years (1 pack year = 20 cigarettes smoked per day for 1 year). (Note: electronic cigarette \[e-cigarette\] use does not contribute to the pack-year count for eligibility). History of moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) with a post-bronchodilator forced expiratory volume in the first second (FEV1)/forced vital capacity (FVC) \ =220 cells/microliter. For the 15 patients in the comparison group, blood eosinophil count \ 4.0 liters/minute (L/min). While breathing supplemental oxygen, patients should demonstrate an oxyhemoglobin saturation ≥ 89%. In order to be admitted to the study, patients on long-term oxygen therapy have to be ambulatory and be able to attend clinic visits. 8. Use, or need for chronic use, of any non-invasive positive pressure ventilation device (NIPPV). Note: Patients using continuous positive airway pressure (CPAP) for Sleep Apnea Syndrome are allowed in the study. 9. History of known immunodeficiency disorder including a positive test for human immunodeficiency virus, HIV-1 or HIV-2. 10. Active liver disease. Chronic stable hepatitis B and C (including positive testing for hepatitis B surface antigen or hepatitis C antibody), or other stable chronic liver disease are acceptable if patient otherwise meets eligibility criteria. Stable chronic liver disease is defined by the absence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice, or cirrhosis. 11. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥ 3 times the upper limit of normal (ULN), confirmed by repeated testing during the run-in period. Transient increase of AST/ALT level that resolves by the time of randomization is acceptable if, in the investigator's opinion, the patient does not have an active liver disease and meets other eligibility criteria. 12. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to standard of care therapy. 13. History of alcohol or drug abuse within the past year, which may compromise the study data interpretation as judged by investigator. 14. Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin or cervical carcinoma-in-situ treated with apparent success more than 1 year prior to Visit 1. Suspected malignancy or undefined neoplasms. 15. Patients who, in the opinion of the investigator or qualified designee, have evidence of active Tuberculosis (TB). Patients with a recent (within 2 years) first-time or newly positive purified protein derivative (PPD) test or Quantiferon test need to complete an appropriate course of treatment before being considered for enrollment. Evaluation will be according to the local standard of care and may consist of history and physical examinations, chest X-ray, and/or TB test as determined by local guidelines. 16. Patients participating in, or scheduled for, an intensive (active) COPD rehabilitation program (patients who are in the maintenance phase of a rehabilitation program are eligible to take part). 17. Patients with a history of surgical or endoscopic (e.g. valves) lung volume reduction within the 6 months prior to enrollment. Patients with a history of partial or total lung resection (single lobe or segmentectomy is acceptable). 18. Scheduled major surgical procedure during the course of the study. Minor elective procedures are allowed. 19. History of anaphylaxis to benralizumab or any other biologic therapy. Prior/concomitant therapy 20. Receipt of blood products or immunoglobulins within 30 days prior to randomization. 21. Receipt of any marketed or investigational biologic product for any reason within 4 months or 5 half-lives prior to randomization, whichever is longer. 22. Receipt of live attenuated vaccines 30 days prior to randomization. 23. Chronic use of immunosuppressive medication (including but not limited to: methotrexate, troleandomycin, cyclosporine, azathioprine, rectal corticosteroids, and systemic corticosteroids) or expected need for chronic use during the study. 24. Chronic use of antibiotics if duration of treatment is \<9 months prior to randomization (Visit 3). Chronic macrolide or other antibiotic therapy is allowed provided the patient has been on a stable dose/regimen for ≥ 9 months prior to randomization and has had ≥ 2 COPD exacerbations in the past year while on stable therapy. If the patient was previously on chronic antibiotic but is no longer taking it, the patient cannot be randomized until 6 weeks after the last dose. Prior/concurrent clinical study experience 25. Receipt of any investigational non-biologic product within 30 days or 5 half-lives prior to enrollment, whichever is longer. 26. Receipt of benralizumab within 12 months prior to enrollment. 27. Known history of allergy or reaction to any component of the intraperitoneal (IP) formulation. Other exclusions 28. Donation of blood, plasma, or platelets within the past 90 days prior to enrollment. 29. Pregnant, breastfeeding, or lactating women. 30. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). 31. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements. Lifestyle restrictions Women of childbearing potential must use highly effective contraceptive methods from enrollment throughout the study and for at least 12 weeks (≥ 5 half-lives) after last administration of the IP, as stated in inclusion criterion 11. Patients must abstain from donating blood, plasma, or platelets from the time of informed consent and for 12 weeks (≥ 5 half-lives) after last dose of IP. \-",40.0,85.0,['chronic obstructive pulmonary disease (copd)']
NCT02031159,"Correlation, Accuracy, Precision and Practicability of Zero Heat Flux Temperature Monitoring","Correlation, Accuracy, Precision and Practicability of Zero Heat Flux Method in Comparison With Sublingual and Nasopharyngeal Temperature Measurement",COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * elective surgery in gynecology or trauma surgery * planned surgery time \> 60 min * patients older than 16 years Exclusion Criteria: * emergency surgery * need for post-surgery ventilation * patient's denial to take part in the study,17.0,65.0,['hypothermia']
NCT06352359,"Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors","Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Must have ECOG score ≤ 1. The body weight should be ≥40 kg. * A histological or cytological diagnosis of solid tumors and metastatic disease or locally advanced disease. * Must have measurable target lesion according to RECIST V1.1. * Adequate organ function as determined by laboratory tests. * Voluntary agreement to participate as evidenced by written informed consent. * Female patient: negative pregnancy test and agreement on contraceptive methods. * Male patient: agreement on contraceptive methods. * Agree to give archival or other diagnostic tissue recut slides or an optional new tumor biopsy. Exclusion Criteria: * Patients who have not recovered to NCI CTCAE grade ≤ 1 from an adverse event (AE) due to cancer therapeutics except the chemotherapy-associated peripheral neuropathy (motor or sensory) or alopecia. Patients with ongoing and adequately controlled endocrine immune-related AEs are considered stable and eligible for enrollment. * The washout period for cancer therapeutic drugs should be 5 half-life or 21 days for chemotherapy, whichever is shorter; or 28 days for monoclonal antibody therapy. Palliative radiotherapy for painful metastases or metastases in potentially sensitive locations (e.g., epidural space) ≥ 7 days prior to the first dose of study drug. Best supportive care, such as thyroxine, insulin, steroid replacement treatment, blood transfusion and therapy for non-cancer conditions are allowed. * Patients who are currently enrolled in any other clinical trial testing an investigational agent or device, or with concurrent anticancer treatment (except palliative bone-directed radiotherapy), immune therapy, or cytokine therapy or anticipated to require another antineoplastic therapy during the study. * Patients who are on chronic systemic steroid therapy at doses higher than 10 mg/day prednisone or equivalent within 7 days before first treatment. * Patients who have active brain metastases or leptomeningeal metastases. Patients who have active brain metastases or leptomeningeal metastases. Patients are eligible if brain metastases are adequately treated, and patients are asymptomatic or neurologically stable (except for residual signs or symptoms related to the central nervous system (CNS) treatment). Note: Patients with previously treated brain metastases may participate provided they are radiologically stable (i.e. no evidence of progression for ≥4 weeks by repeat imaging performed during study screening), clinically stable, and not requiring steroid treatment within 14 days before the first dose of study treatment. * Patient with a different cancer other than the one treated under this protocol, which requires systemic treatments within 24 months prior to C1D1. * Patient has history of grade ≥3 allergic or hypersensitivity to IV infusion medications, or severe allergic reactions to food, pollen, oral medications, or atopic dermatitis or asthmatic episodes that required hospitalization. * Within past 6 months with history of significant cardiovascular acute myocardial infarction, acute coronary syndrome, ischemic or hemorrhagic stroke, revascularization procedures, acute pulmonary embolism or any disorders resulted in LVEF \< 40% at the time of screening or colitis, small bowel obstruction, hepatitis or pancreatitis adrenal insufficiency, or severe immunotherapy related AE (irAE≥ grade 3). * Patients who have acute infections which require systemic treatments within 14 days prior to C1D1. * Patients who, in the opinion of the treating Investigator, have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or make study participation not in the best interest of the patient, in the opinion of the treating Investigator. Investigators should discuss the case with the Sponsor and/or study leaders. * Patients with known psychiatric or substance abuse disorders may interfere with cooperation with the requirements of the trial. * Patients who are pregnant or breastfeeding or plan pregnancy or fathering the child during the study or within 6 months after the last dosing of study drug",18.0,65.0,['advanced solid tumor']
NCT05357859,Vitamin D for Cognition in Bipolar Disorder,Effect of Vitamin D Supplement for Cognitive Function in Patients With Bipolar Disorder- Randomized Double-Blind Controlled Trial,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Patients who diagnosed with BD-I based on the Diagnostic and Statistical Manual (DSM-IV) criteria are consecutively referred by board-certified psychiatrists in Taipei City Hospital, Songde branch. 2. Age of participants should range from 20 to 65 years old. 3. No history of vitamin D supplementation within three months before the study. 4. The BD patients in their euthymic state (both Hamilton Depression Rating Scale and Young Mania Rating Scale ≤ 8) and no change of their psychoactive medications in recent three months. Exclusion Criteria: 1. With known substance use disorder (except nicotine use disorder) 2. With any disorder with known neurological symptoms or complications (ex. brain injury, stroke or brain lesions) 3. Comorbid with schizophrenia spectrum disorders 4. With active physical condition (such as renal impairment, hepatic failure…) or pregnancy 5. Inability to complete the standard assessment or incapability of providing informed consent",20.0,65.0,['bipolar disorder']
NCT06951659,Investigating Visual Verticality Disorder and Lateropulsion in a Neurosurgical Cohort of Patients With Brain Tumours,"Clinical, Rehabilitation and Neuroimaging Investigation of Lateropulsion, Graviceptive Neglect and Verticality Perception in Neurosurgical Patients With Brain Tumours: A Prospective Cohort Study",RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * Patients of age 18 to 80 admitted to SCGH under the neurosurgery team with a confirmed diagnosis of a brain tumour. * Only patients who undergo partial or full brain tumour resection and are medically stable. * Able to provide written informed consent or consent provided by a Research Decision-Maker with the approval of an Independent Medical Practitioner (IMP) as per the Guardianship and Administration Act 1990 (GAA). * Patients with a support network that enables them to accommodate to travel commitments for assessments if travel to the hospital is required. Exclusion Criteria: * Patients who undergo only biopsy will not be included. * Unable to follow any instructions and complete assessments due to significant medical deterioration. * Patients who are pregnant. * Current diagnosis of COVID-19 or respiratory syncytial virus (RSV), or any type of influenza. * Patients without a support network that enables them to accommodate to travel commitments for assessments if travel to the hospital is required. * An Advanced Care Health Directive prohibiting decision making by Research Decision-Maker.",18.0,80.0,['brain tumours']
NCT02607059,Epidemiologic Registry PETHEMA LMA 2015,Epidemiologic Registry of Patients Diagnosed With Acute Myeloid Leukemia (PETHEMA LMA 2015),UNKNOWN,OBSERVATIONAL,ALL,Inclusion Criteria: * Patients diagnosed with acute myeloid leukemia Exclusion Criteria: * No exclusion criteria,18.0,65.0,['aml']
NCT02310659,Study to Evaluate the Association of Testosterone Levels With Coronary Artery Calcification,Study to Evaluate the Association of Testosterone Levels With Coronary Artery in Patients With Stable Coronary Artery Disease,UNKNOWN,OBSERVATIONAL,MALE,Inclusion Criteria: * Elderly male patients (age ≥ 65 years old) with stable angina and proven coronary artery disease Exclusion Criteria: * Less than 65 years old * Acute coronary syndrome * History of PCI or coronary artery bypass grafting * History of myocardial infarction * Renal dysfunction defined by glomerular filtration rate \< 30 mL/min,65.0,65.0,['coronary artery disease']
NCT00352859,Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib,A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Male or female patients above 18 years of age with advanced RCC who have received sorafenib as their first and only systemic anti-tumor therapy for RCC prior to randomization * Patients must have previously tolerated a minimum dose of sorafenib 400 mg daily for at least six weeks prior to study entry and have radiographically documented progressive disease while on sorafenib * Patients must have experienced clinical benefit, partial response, complete response or stable disease during their previous course of sorafenib therapy * Life expectancy \> 12 weeks * Patients must meet the Memorial Sloan-Kettering Cancer Center (MSKCC) risk category of low or medium at randomization * Patients must give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice * Patients must have at least one uni-dimensional measurable lesion by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST) * Patients must not have brain metastases * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 * In addition, the following patients may be included, provided all other inclusion and exclusion criteria are met * Patients who have received the vaccines cG250 (monoclonal antibody to carbonic anhydrase IX) or HSPPC-96 (Heat Shock Protein Peptide Complex 96) are eligible provided that they have received no other systemic anti-cancer therapy * Patients who were enrolled in the ARCCS treatment protocol Exclusion Criteria: * Patients must not have experienced more than three weeks from documented disease progression to randomization * Any medical condition requiring the use of systemic corticosteroids during IFN therapy * Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis \& T1) or any cancer curatively treated within the last three years prior to study entry * Severe renal impairment or receiving dialysis * More than a two week interruption in sorafenib dosing immediately prior to randomization * Patients with a best response of disease progression on their previous course of sorafenib * Patients who meet the MSKCC high risk category at randomization * Hemorrhagic episode \>= Grade 2 NCI CTC AE v3.0 within last six months * History of cardiac disease: congestive heart failure\> NYHA class 2; active cardiovascular disease (MI more than six months prior to study entry is allowed); cardiac arrhythmia requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension * Active clinically serious bacterial or fungal infections (\>= Grade 2 NCI CTCAE v3.0) * Known history of Human Immunodeficiency Virus (HIV) infection or chronic hepatitis B or C * Symptomatic metastatic brain or meningeal tumors unless the patient is \> six months from definitive therapy, has a negative CNS imaging study within four weeks of study entry, and is clinically stable off steroids. The patient must not be undergoing acute steroid taper * Patients with seizure disorder requiring medication (such as steroids or anti-epileptics) * Ongoing substance abuse, medical, psychological or social conditions that may interfere with the patients participation in the study or evaluation of the study results * Known or suspected allergy to the investigational agent or any agent given in association with this trial, including history of sensitivity to E. coli-derived products * Any condition that is unstable or that could jeopardise the safety of the patient and his/her compliance in the study. Patients with a history of severe depression; patients with clinically significant active autoimmune disorders; history of organ allograft * Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within seven days of the start of study treatment. Both men and women enrolled in this trial must use adequate birth control measures during the course of the trial * Patients who have had a significant surgical procedure within the past four weeks are excluded Excluded Therapies and Medications, Previous and Concomitant: * Any prior or concurrent systemic anti-cancer therapy including chemotherapy, monoclonal antibodies, hormonal therapy or investigational therapy, except for bisphosphonates and sorafenib * Biological response modifiers, such as G-CSF or GM-CSF, within three weeks prior to study entry or during study. G-CSF and other hematopoietic growth factors may only be used in the management of acute toxicity such as febrile neutropenia when medically indicated or at the discretion of the Investigator. However, they may not be substituted for a required dose reduction of any study drug * Patients taking erythropoietin are permitted provided no dose adjustment is undertaken within two months prior to the study or during the study * Concomitant rifampicin or St. John's Wart * Palliative therapy will be allowed, patients may receive palliative and supportive care for any underlying illness",18.0,65.0,"['carcinoma, renal cell']"
NCT01711359,A Study in Participants With Moderate to Severe Rheumatoid Arthritis,"A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Have a diagnosis of adult-onset rheumatoid arthritis (RA) as defined by American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) 2010 Criteria for the Classification of RA * Have documented history of positive rheumatoid factor and/or cyclic citrullinated peptide (CCP) antibody test * Have moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints * Have a C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP) measurement ≥1.2 times the upper limit of normal (ULN) * Have had limited or no treatment with methotrexate (MTX) Exclusion Criteria: * Have received conventional disease-modifying antirheumatic drugs (DMARDs) other than MTX (eg, gold salts, cyclosporine, leflunomide, azathioprine, hydroxychloroquine, sulfasalazine or any other immunosuppressives) * Are currently receiving corticosteroids at doses \>10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization * Have started treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or within 6 weeks of planned randomization * Have started a new physiotherapy treatment for RA in the 2 weeks prior to study entry * Have ever received any biologic DMARD * Have received interferon therapy within 4 weeks prior to study entry or are anticipated to require interferon therapy during the study * Have received any parenteral corticosteroid administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require a parenteral injection of corticosteroids during the study * Have had 3 or more joints injected with intraarticular corticosteroids or hyaluronic acid within 2 weeks prior to study entry or within 6 weeks prior to planned randomization * Have active fibromyalgia that, in the investigator's opinion, would make it difficult to appropriately assess RA activity for the purposes of this study * Have a diagnosis of any systemic inflammatory condition other than RA, such as, but not limited to, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, active vasculitis, or gout (Participants with secondary Sjogren's syndrome are not excluded.) * Have a diagnosis of Felty's syndrome * Have had any major surgery within 8 weeks of study entry or will require major surgery during the study that, in the opinion of the investigator in consultation with Lilly or its designee, would pose an unacceptable risk to the participant * Have experienced any of the following within 12 weeks of study entry: myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association Stage IV heart failure * Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product or could interfere with the interpretation of data * Are largely or wholly incapacitated permitting little or no self care, such as, being bedridden or confined to a wheelchair * Have an estimated Glomerular Filtration Rate (eGFR) based on the most recent available serum creatinine using the Modification of Diet in Renal Disease (MDRD) method of \ 1.5 times the ULN or the most recent available total bilirubin ≥1.5 times the ULN * Have a history of, lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for \<5 years * Have been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination) * Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection * Have had symptomatic herpes zoster infection within 12 weeks prior to study entry * Have a history of disseminated/complicated herpes zoster (eg, multidermatomal involvement, ophthalmic zoster, central nervous system involvement, postherpetic neuralgia) * Are immunocompromised and, in the opinion of the investigator, are at an unacceptable risk for participating in the study * Have a history of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) * Have screening laboratory test values, including thyroid-stimulating hormone (TSH), outside the reference range for the population or investigative site that, in the opinion of the investigator, pose an unacceptable risk for the participant's participation in the study * Have screening electrocardiogram (ECG) abnormalities that, in the opinion of the investigator or the sponsor, are clinically significant and indicate an unacceptable risk for the participant's participation in the study * Have symptomatic herpes simplex at the time of study enrollment * Have evidence of active or latent tuberculosis (TB)",18.0,65.0,['rheumatoid arthritis']
NCT03050580,"An Evaluation of the ""Treatment Group Model for Abused Women"" in Shelters in Hong Kong","An Evaluation of the ""Treatment Group Model for Abused Women"" in Shelters in Hong Kong",COMPLETED,INTERVENTIONAL,FEMALE,Inclusion Criteria: * Abused women of family violence aged 18 or older * Receiving services from shelters of Po Leung Kuk Exclusion Criteria: * Unable to communicate (possible reasons: dialects used by targets but not understandable by interviewers; mentally challenged) * Unable to give consent to participate in the study,18.0,65.0,['abused women']
NCT01718080,The Effects of Puberty and Weight on Sugar Metabolism in Children,The Role of Puberty and Insulin Resistance in the Development of Hyperglucagonemia,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: All groups: Healthy lean and otherwise healthy overweight children and adolescents between the ages of 8 and 17. Exclusion Criteria: Same for all groups The subjects will be excluded if they have: * a history of chronic disease * allergy to acetaminophen * evidence or history of chemical abuse * abnormal lab values * pregnancy,8.0,17.0,"['overweight', 'leanness', 'adolescent']"
NCT06122480,Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma,Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma (PHOLIPANC): A Phase II Single Arm Trial,RECRUITING,INTERVENTIONAL,ALL,"1. Inclusion Criteria at the Pre-Screening Enrollment * Histologically confirmed diagnosis of treatment-naïve limited hepatic or pulmonary metastatic adenocarcinoma of the pancreas Meet the definition of limited hepatic or pulmonary metastasis according to CT/MRI that is done prior to the starting of any anticancer treatment. Either CT scan of chest, abdomen, and pelvis with intravenous contrast or a combination of MRI of abdomen and pelvis and CT scan of chest is acceptable radiographic imaging. CT/MRI can be done at an outside facility, but must be reviewed by a Johns Hopkins Medicine radiologist. * Measurable disease according to RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Being a candidate for the chemotherapy with FOLFIRINOX or modified FOLFIRINOX * Patients ≥18 years at the time of signing the informed consent * Patient's written informed consent prior to any trial-specific procedure * Patient's legal capacity to consent to participation in the clinical trial 2. Exclusion Criteria at the Pre-Screening Enrollment * Acinar cell carcinoma and/or neuroendocrine carcinoma of the pancreas * Symptomatic clinically significant ascites * Evidence of any distant metastases other than limited hepatic or pulmonary metastasis as defined in inclusion criterion 1. * Evidence of simultaneous pulmonary and hepatic metastases * Any tumor-specific pretreatment of the adenocarcinoma of the pancreas (including but not limited to surgery, radiation therapy, chemotherapy or ablative procedures). Currently being on FOLFIRINOX or modified FOLFIRINOX (mFOLFIRINOX) is allowed, unless more than 2 treatments of FOLFIRINOX or mFOLFIRINOX has been given. * Any malignancies other than adenocarcinoma of the pancreas in the 2 years before the start of the clinical trial except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, breast cancer, prostate cancer or superficial bladder tumors (Ta, Tis and T1) * Known HIV seropositivity * Known active or chronic Hepatitis B or Hepatitis C infection * Any other severe concomitant disease or disorder, which could influence patient's ability to participate in the clinical trial and his/her safety during the trial or interfere with interpretation of results, e.g., severe hepatic, renal, pulmonary, cardiovascular, metabolic or psychiatric disorders 3.2 Eligibility Criteria for Study Entry Enrollment at the Pre-Surgery phase 3.2.1 Inclusion Criteria for study continuation at the Pre-Surgery phase * ECOG performance status 0-1 * Received FOLFIRINOX, modified FOLFIRINOX or the further modified forms including FOLFIRI, FOLFOX, 5FU or capecitabine. Liposomal irinotecan is permitted. Switching to gemcitabine/nal-paclitaxel due to intolerability of FOLFIRINOX is also permitted. * Radiographical evidence of disease response or stable disease with CA19-9 decrease \> 20% from the baseline or CA19-9 that is not detectable * Patients ≥18 years at the time of signing the informed consent * Patient's written informed consent prior to any trial-specific procedure * Patient's legal capacity to consent to participation in the clinical trial 3.2.2 Exclusion Criteria for Study Entry Enrollment at the Pre-surgery phase * Symptomatic clinically significant ascites * Evidence of any distant metastases other than limited hepatic or pulmonary metastasis as defined in inclusion criterion 1. * Evidence of simultaneous pulmonary and hepatic metastases * Any malignancies other than adenocarcinoma of the pancreas in the 2 years before the start of the clinical trial except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, breast cancer, prostate cancer or superficial bladder tumors (Ta, Tis and T1) * Pregnant or breast-feeding female * Radiographic evidence of severe portal hypertension * Liver cirrhosis ≥ Child Pugh B * Known HIV seropositivity * Active or chronic Hepatitis B or Hepatitis C infection * Clinically significant cardiovascular or vascular disease or disorder ≤6 months before enrolment into the clinical trial (e.g., myocardial infarction, unstable angina pectoris, chronic heart failure New York Heart Association (NYHA) ≥ Grade 2, uncontrolled arrhythmia, cerebral infarction) * Any other severe concomitant disease or disorder, which could influence patient's ability to participate in the clinical trial and his/her safety during the trial or interfere with interpretation of results, e.g., severe hepatic, renal, pulmonary, cardiovascular, metabolic or psychiatric disorders. * Hepatic metastasis that are only amenable to ablation. However, if liver lesions are found intraoperatively and subsequently ablated and if the pancreatic surgery is distal pancreatectomy, the patients would still be considered evaluable. Ablation of liver lesions during the pancreatoduodenectomy is not allowed. * Radiographical evidence of disease progression.",18.0,100.0,"['pancreatic ductal adenocarcinoma', 'oligometastatic disease']"
NCT06191380,Effects of Cycling and Virtual Reality on Thinking Speed in Persons With MS (PACE-MS),Effects of a Single Bout of Moderate Intensity Aerobic Cycling Exercise Combined With Virtual Reality on Processing Speed in Persons With Multiple Sclerosis and Mobility Disability,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Speak English as their primary language * Confirmed MS diagnosis by a neurologist * Be relapse and steroid-free for at least 30 days * Mild-to-moderate self-report mobility disability Exclusion Criteria: * History of neurological disorders besides MS or history of uncontrolled psychiatric disorders (ex: major depression) * Have contraindications to exercise, based on the Physical Activity Readiness Questionnaire (PAR-Q) * Currently use medications that may impact cognition (ex: steroids, benzodiazepines) * Currently pregnant * Severe cognitive impairment as measured by the Modified Telephone Interview of Cognitive Status (TICS-M) * No indication of age-related mild cognitive impairment or dementia, based on the MOCA-Blind (i.e., MOCA-Blind ≥19). * High likelihood of motion sickness * Regular cyclist, defined as cycling for at least 150 minutes/week",18.0,70.0,['multiple sclerosis']
NCT01699880,Efficacy of High Flow Nasal Cannula Oxygen to Reduce Desaturation During Tracheal Intubation,High Flow Nasal Cannula Oxygen for Pre and During Procedure Oxygenation During Tracheal Intubation: Comparison With High FiO2 Non Rebreathing Bag Reservoir Facemasks,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * ICU patient requiring tracheal intubation Exclusion Criteria: * age \< 18 years * cardiac arrest * acute respiratory failure requiring immediate high flow nasal cannula oxygen, defined as patient with SpO2 \< 95% while under 15 L:min oxygen with a nonrebreathing facemask",18.0,65.0,"['need for intubation', 'oxygenation before and during intubation']"
NCT04762680,Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: -Aged 18 years or older on the day of inclusion. - -A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: Is of non-childbearing potential. To be considered of non-childbearing potential, a female mut be post-menopausal for at least 1 year or surgically sterile. OR Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the last vaccination (ie, second dose of primary series or booster injection). A participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 4 hours before any dose of study intervention. - -Informed consent form has been signed and dated. Able to attend all scheduled visits and to comply with all study procedures. SARS-CoV-2 rapid serodiagnostic test performed at the time of enrollment to detect presence of SARS-CoV-2 antibodies (Original Phase 2 Cohort). For persons living with human immunodeficiency virus (HIV), stable HIV infection determined by participant currently on antiretrovirals with CD4 count \> 200/mm3. Does not intend to receive an authorized/approved COVID-19 vaccine from first vaccination to 3 weeks after the second vaccination despite encouragement by the investigator to receive the authorized vaccine available to them at the time of enrollment. Supplemental cohorts: for participants originally enrolled in the Phase II cohort of the study, informed consent has to be signed and dated for transitioning to Supplemental Cohort 2. Supplemental cohorts, Booster arms: received a complete primary vaccination series with an authorized/conditionally approved mRNA COVID-19 vaccine (mRNA-1273 \[Moderna\] or BNT162b2 \[Pfizer/BioNTech\]) or adenovirus-vectored COVID-19 vaccine (ChAdOx1 nCoV-19 \[Oxford University/AstraZeneca\] or Ad26.CoV2.S \[J\&J/Janssen\]), with the last dose administered a minimum of 4 months prior to inclusion but not longer than 10 months prior to inclusion. Exclusion Criteria: -Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances. Dementia or any other cognitive condition at a stage that could interfere with following the trial procedures based on Investigator or designee's judgment. Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination based on Investigator's judgment. Bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating IM vaccination based on Investigator's judgment. Unstable acute or chronic illness that in the opinion of the Investigator or designee poses additional risk as a result of participation or that could interfere with the study procedures. Receipt of solid-organ or bone marrow transplants in the past 180 days. Receipt of anti-cancer chemotherapy in the last 90 days. Receipt of immunoglobulins, blood, or blood-derived products in the past 3 months. Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C \[≥ 100.4°F\]). A prospective participant should not be included in the trial until the condition has resolved or the febrile event has subsided. Receipt of any vaccine in the 30 days preceding or on the day of the first study vaccination or planned receipt of any vaccine between the first study vaccination and in the 30 days following the second study vaccination except for influenza vaccination, which may be received at any time in relation to study intervention. Applicable to Original Phase II Cohort, Supplemental Cohort 1 and Cohort 2 Comparator Group: Prior administration of a coronavirus vaccine (SARS-CoV-2, SARS-CoV, Middle East Respiratory Syndrome \[MERS-CoV\]). Participation at the time of study enrollment (or in the 30 days preceding the first study vaccination) or planned participation during the present study trial period in another clinical study investigating a vaccine, drug, medical device, or medical procedure. Exclusion criterion for the Supplemental Cohort 1 and Cohort 2 comparator group: positive rapid diagnostic test for SARS-CoV-2 antibodies at time of enrollment. Exclusion criterion for participants in Supplemental Cohort 2 who were primed as participant in the Original Phase II Cohort of the present study: Receipt of authorized/conditionally approved COVID-19 vaccine after enrollment in Original Phase 2 Cohort. Exclusion criterion for all Booster groups: Documented virologically-confirmed SARS-CoV-2 infection (by NAAT) after first dose of primary immunization.",18.0,65.0,['covid-19']
NCT02431780,A Multicentre Clinical Investigation of a Decision Support Algorithm for Neonatal Seizure Detection,"A Multi-centre, Randomised, Controlled, Clinical Investigation of a Standalone Decision Support Algorithm for Neonatal Seizure Recognition",COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Neonates 36 weeks - 44 weeks corrected gestational age in whom EEG monitoring is indicated because they are deemed to be * at high risk of seizures or * are experiencing seizures Exclusion Criteria: * • No parental/guardian consent,36.0,44.0,"['seizures', 'brain diseases', 'central nervous system diseases', 'epilepsy', 'nervous system diseases', 'neurologic manifestations']"
NCT02877680,Strengths-Based Behavioral mHealth App for Parents of Adolescents With Type 1 Diabetes-Pilot Study,Development and Pilot of a Strengths-Based Behavioral mHealth Intervention to Promote Resilience in Adolescents With Type 1 Diabetes,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Diagnosis of type 1 diabetes according to American Diabetes Association criteria for at least 6 months * Treated for type 1 diabetes at Texas Children's Hospital Diabetes Care Center * Parent and adolescent fluency in English * Parent has mobile device with data plan Exclusion Criteria: * Serious medical, cognitive, or mental health comorbidity in parent or adolescent that would preclude ability to participate",12.0,17.0,"['diabetes mellitus, type 1']"
NCT03157180,The Clinical Study on Pseudo-allergic Reaction to Anesthetic Drugs During General Anesthesia,The Clinical Study on Pseudo-allergic Reaction to Anesthetic Drugs During General Anesthesia,UNKNOWN,OBSERVATIONAL,ALL,Inclusion Criteria: * general anesthesia There is allergic reaction during anesthesia Sign informed consent Exclusion Criteria: * general anesthesia There is no allergic reaction during anesthesia Sign informed consent,18.0,65.0,['general anesthetic drug allergy']
NCT04423380,A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors,"A Phase I, Open-Label Study to Determine Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of SH3051 Capsule in Patients With Advanced Solid Tumors",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age between 18 and 70 years inclusive; * Histologically or cytologically confirmed advanced malignant solid tumors, eligible patients have failed standard treatment, have no standard treatment, or are not suitable for standard treatment at this stage as determined by the investigator. * Must have at least one evaluable lesion in dose escalation period and one unidimensional measurable lesion according to RECIST version 1.1; * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; * Life expectancy ≥3 months; * Adequate hematological and biological function, confirmed by the following laboratory values:ANC≥1.5×10\^9/L;PLT≥75×10\^9/L;Hb≥90g/L;TBIL≤1.5×ULN;AST and ALT≤3×ULN(ALT and AST≤5×ULN for subjects with liver cancer or hepatic metastases);CLcr\>50 mL/min(according to Cockcroft-Gault);Child-Pugh score between 0\~7 for subjects with primary hepatic carcinoma;APTT≤1.5×ULN;INR≤1.5×ULN. * Men and women of childbearing potential are willing to employ an effective method of contraception for the entire duration of study and 6 months after the last dose, and female subjects of childbearing potential have a negative pregnancy test at baseline. * Provision of signed and dated, written informed consent prior to any study-specific evaluation. Exclusion Criteria: * Previous treatment with any TGF-β inhibitors. * Anticancer treatment including radiation therapy, chemotherapy, hormonal therapy, molecular targeted therapy, or immunotherapy within 4 weeks prior to the first dose of SH3051(use of mitomycin or nitrosoureas within 6 weeks prior to the first dose;use of oral oral fluorouracil and small molecule targeted drugs within 2 weeks ,or 5 half-lifes prior to the first dose;use of Chinese herbal anti-tumor treatment with 2 weeks prior to the first dose). * Have systematic hormonal therapy(prednisone\>20mg/d or similar drugs with equivalent dose)or immunosuppressor therapy with 14 days prior to the first dose of study drug, except using topical,ocular,intra-articular,intranasal,inhaled corticosteroids,and preventive therapy using corticosteroids in short period(for instance,to prevent hypersensitivity to contrast media). * Participate in other clinical trials within 4 weeks prior to study entry. * Concomitant use of any strong inhibitors or inducers of CYP3A4(except drug withdrawal within one week prior to first dose of study drug). * History of allogeneic hematopoietic stem cell transplantation or organ transplantation. * Adverse events occurred during previous anticancer therapy have not been recovered to ≤1(CTCAE 5.0)except toxicity with no significant risk determined by investigators such as alopecia. * Evidence of central nervous system (CNS) metastases accompanied with clinical symptoms, or other evidence of uncontrolled CNS metastases Judged by investigators that the patient should not participate in the study. * Presence of grade 3 or 4 gastrointestinal bleeding or esophageal and gastric varices. * Have moderate or severe cardiac disease, including but not limited to severe arrhythmias or abnormal cardiac conduction, such as ventricular arrhythmias requiring clinical intervention, degree II-III atrioventricular block,QTcF≥450 ms for male, QTcF≥470 ms for female, or other structural heart disease with high risk as determined by investigators;history of acute coronary syndrome, congestive heart failure,aortic dissection,stroke or other≥grade 3 cardiovascular and cerebrovascular events within 6 months prior to the first dose of study drug;New York Heart Association (NYHA) Class II or greater heart failure, or LVEF\ 1.25×ULN;uncontrolled hypertension;any risk factors to increase QTc or arrhythmias, including heart failure,hypokalemia,congenital long QTc syndrome,family history of long QT interval syndrome or history of unexplained sudden death occurred in first degree relative less than 40 years of age, or using any concomitant medication known to produce QTc prolongation. * Have active infection requiring systemic with one week prior to the first dose the study drug. * Infection with hepatitis B virus(HBV)and hepatitis C virus(HCV) (volunteers with HBsAg positive but HBV-DNA negative, or volunteers with HCV antibody positive but HCV-RNA negative can be enrolled). * History of immune deficiency including HIV antibody positive. * Major surgery(not include biopsy),or significant traumatism,or requiring selective operation within 4 weeks prior to study entry. * Inability to swallow the drug, or severe gastrointestinal disease affecting absorption of the drug. * Uncontrolled effusion in the third space, not suitable for entry as determined by the investigator. * With alcohol or drug abuse disorder. * With mental disorders or non-compliance. * Women who are pregnancy or breastfeeding. * Judgment by the investigator that the patient should not participate in the study.",18.0,70.0,['advanced solid tumor']
NCT04372680,WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound.,"WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound: a Prospective, Multicenter, Randomized, Open-label, Parallel-group Clinical Trial",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * ICU admission for severe acute respiratory distress syndrome (ARDS, as previously defined5 by a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen of less than 150) related to COVID-19. * Non paralyzed because of neuromuscular blocking agents. * Ventilated patient in pressure support mode for at least 6 hours and at most 24 hours. * Surrogate decision maker's consent. * Affiliated person or beneficiary of a social security scheme. Exclusion Criteria: * Reduction or cessation of active treatment. * Paraplegia with medullar level more than T8. * Tracheostomy before hospital admission. * History of severe respiratory illness. * Patient under juridical protection. * Pregnancy or nursing woman. * Enrolled in another trial evaluating mechanical ventilation.",18.0,65.0,"['covid-19', 'ards, human', 'mechanical ventilation']"
NCT07244380,Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.,A Phase II Clinical Trial of S101 Autologous CAR-T Cell Injection for the Treatment of CD7-Positive Relapsed or Refractory T-Lymphoblastic Lymphoma/Leukemia (T-LBL/ALL).,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * 1.The subject or guardian must provide voluntary informed consent; 2.Heavily pretreated patients with relapsed or refractory T-LBL/ALL who lack effective therapeutic alternatives; 3.At screening, CD7 positivity of tumor cells must be documented by flow cytometry (on bone marrow or peripheral blood samples) and/or by immunohistochemistry (IHC) confirming CD7 expression on an extramedullary lesion biopsy; 4.If malignant cells are detected in the peripheral blood at screening, they must demonstrate a CD4-negative and CD8-negative (double-negative) immunophenotype as assessed by flow cytometry; 5.Male or female subjects, aged 18 to 75 years (inclusive); 6.Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2; 7.Estimated survival time\>12 weeks. Exclusion Criteria: * 1.Patients with a history of allogeneic hematopoietic stem cell transplantation within the past 6 months are excluded; 2.Active or uncontrolled infection requiring systemic treatment at screening, excluding mild genitourinary and upper respiratory infections； 3.Participation in another clinical trial within 4 weeks prior to signing the informed consent form (ICF), OR the date of ICF signing occurring within 5 half-lives of the last dose from a previous investigational drug trial (whichever timeframe is longer); 4.Patients with previous treatment involving CAR-T cells or other gene-modified cell therapies are excluded; 5.Patients with acute GVHD (aGVHD) or moderate-to-severe chronic GVHD (cGVHD) within 4 weeks prior to screening, or those who have received systemic pharmacologic therapy for GVHD within 4 weeks prior to infusion; 6.Patients who have received extensive radiotherapy within 4 weeks prior to ICF signing, with the exception of non-target lesion radiotherapy administered for symptomatic palliation that may be permitted during the study period; 7.Women who are pregnant or lactating; 8.Any condition that, in the judgment of the Investigator, could increase the subject's risk or compromise the interpretation of the trial results.",18.0,75.0,['t lymphoblastic leukemia/lymphoma']
NCT03565380,Effectiveness of a Community-based Multi-modal Tai Chi Rehabilitation Program for Patients After Total Knee Arthroplasty,"Acceptability and Feasibility of a Community-based Strength, Balance and Tai Chi Rehabilitation Program in Improving Physical Function and Balance of Patients After Total Knee Arthroplasty: a Pilot Randomized Controlled Trial",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. 60 years or above; 2. candidates for primary unilateral TKA who are placed on the TKA waiting list for less than 1 month before their surgery; 3. living independently in the community Exclusion Criteria: 1. living in assisted living facilities, requiring nursing care, or planning to reside away from the hospital district within 1 year. 2. unstable medical conditions, 3. fracture of lower limbs, 4. malignancy in the last five years, 5. lower limb prosthesis/amputation, 6. congenital defect that is considered to cause the present complaint, 7. systemic inflammatory and autoimmune diseases, 8. previous osteotomy, 9. neurological diseases (e.g. Parkinson's disease, stroke), 10. blindness, revision TKA, 11. complications after primary TKA, 12. cognitive impairment with a Mini-Mental State Examination score \< 19 13. prior experience in practicing Tai Chi exercise for at least 3 months",60.0,80.0,['total knee arthroplasty']
NCT01614080,Outcome of Patients Treated by iv Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA,Outcome of Patients Treated by iv Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA in the Administered Rt-PA,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * Being treated by iv tPA for acute cerebral ischaemia Exclusion Criteria: * absence of reliable informant * no rtPA left in the syringe after treatment,18.0,65.0,"['stroke, acute', 'drug toxicity']"
NCT01337180,Airway Inflammation Among Workers in the Silicon Carbide Processing Industry,Exposure to Aerosols and Airway Inflammation Among Workers in the Silicon Carbide Processing Industry,WITHDRAWN,OBSERVATIONAL,ALL,Inclusion Criteria: * Employment at SiC plant in Porsgrunn; Exclusion Criteria for sputum study: * smoking * active airway infection or less then 3 weeks after recovery * active allergy,18.0,65.0,"['obstructive lung disease', 'inflammation']"
NCT01355679,Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma,A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Refractory or Recurrent Neuroblastoma,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients must have histologically proven neuroblastoma and confirmation of refractory or recurrent disease with histologic confirmation at diagnosis or at the time of recurrence/progression * Patients must be age \> 12 months and ≤ 21 at initial diagnosis. * Life expectancy must be more than 3 months * If measurable disease, this must be demonstrated by residual abnormal tissue at a primary or metastatic site measuring more than 1 cm in any dimension by standardized imaging (CT or MRI); tumor must be accessible for biopsy. Patients with bone marrow only disease expected to be \> 75% are eligible to enroll. * Current disease state must be one for which there is currently no known curative therapy * Lansky or KarnofskyScore must be more than 50 * Patients without bone marrow metastases must have an ANC \> 750/μl and platelet count \> 50,000/μl * Adequate liver function must be demonstrated, defined as: * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age AND * SGPT (ALT) \ Grade 2 by National Cancer Institute Common Toxicity Criteria for Adverse Events NCI-CTCAE V4.0 * A negative serum pregnancy test is required for female participants of child bearing potential (≥ 13 years of age or after onset of menses) * Both male and female post-pubertal study subjects need to agree to use one of the more effective birth control methods during treatment and for six months after treatment is stopped. These methods include total abstinence (no sex), oral contraceptives (""the pill""), an intrauterine device (IUD), levonorgestrol implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended. * Informed Consent: All patients and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines. Voluntary consent for optional biology studies will be included. Exclusion Criteria: * Patients who have received any chemotherapy within the last 7 days prior to enrollment and 14 days prior to study treatment start date. * Patients who have received any radiotherapy within the last 30 days must have another site of disease to follow. * Patients receiving anti-tumor therapy for their disease or any investigational drug concurrently * Patients with serious infection or a life-threatening illness (unrelated to tumor) that is \> Grade 2 (NCI CTCAE V4.0), or active, serious infections requiring parenteral antibiotic therapy. * Patients with any other medical condition, including malabsorption syndromes, mental illness or substance abuse, deemed by the Investigator to be likely to interfere with the interpretation of the results or which would interfere with a patient's ability to sign or the legal guardian's ability to sign the informed consent, and patient's ability to cooperate and participate in the study",1.0,65.0,['neuroblastoma']
NCT06641479,JiAngSu Maternal and INfant HEalth Database,JiAngSu Maternal and INfant HEalth Database(JASMINE): Using Electronic Health Records to Improve Maternal and Child Health Care and Outcomes in China,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,ALL,Inclusion Criteria: * Pregnant women and their offspring who registered at the Jiangsu maternal and child health information platform. Exclusion Criteria: * None.,18.0,65.0,"['pregnant women', 'children']"
NCT06945679,Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients,Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: 1. Patients who are confirmed dengue fever by positive NS1 dengue Antigen and/ Dengue IgM antibody. 2. Day of illness ≤ 5 days Exclusion Criteria: 1. Children (\ 150 U/L 8. Patient with serum creatinine \>1.4 mg/dl,18.0,65.0,['dengue fever']
NCT00675779,Efficacy Study of Atorvastatin in Pelvic Pain Relief in Women With Endometriosis,"Comparison of Pain Relief and Inflammatory Status in Women With Surgically Confirmed Endometriosis Treated With Atorvastatin, Oral Contraceptive or Combined Oral Contraceptives and Atorvastatin: Open Randomized Controlled Trial",UNKNOWN,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * informed written consent * premenopausal women aged 18-45 * clinical signs and symptoms of endometriosis for minimum 3 months with endometriosis confirmed at laparoscopy or laparotomy within last 4 months - 5 years (preferably with histological confirmation) * pain symptoms of moderate intensity (dysmenorrhoea + dyspareunia + nonmenstrual pelvic pain \> 6 points on Biberoglu \& Behrman scale \[1981\]) * no clinical signs of sexually transmitted disease Exclusion Criteria: * cancer of the ovary, adrenals, endometrium, uterine cervix, breasts * pregnancy or lactation * unexplained uterine/cervical bleeding * hormonal therapy within last 3 months (for GnRH analogs 6 months) * irregular menses (\> 35 days) or secondary amenorrhoea (\>3 months) * other chronic disease affecting pelvic or abdominal cavity (including PID, ulcerating colitis , Crohn's disease, recurrent interstitial cystitis) * sexually transmitted disease (gonorrhoea, Chlamydia) * uncontrolled diabetes mellitus type I or II, VTE or other contraindications to medicine used in the study * chronic therapy with CYP3A4 inhibitors (including ketoconazole, erythromycin and others)",18.0,45.0,"['endometriosis', 'pain']"
NCT07134179,Insufficient Regional Anesthesia for Cesarean Section: Mothers' Experiences A Qualitative Study,Insufficient Regional Anesthesia for Cesarean Section: Mothers' Experiences A Qualitative Study,NOT_YET_RECRUITING,OBSERVATIONAL,FEMALE,"Inclusion Criteria: * Women undergoing elective or emergency cesarean delivery within the last 2 years, with the experience of pain during surgery * Regional (spinal or epidural or combined epidural-spinal) anesthesia NOT converted to general anesthesia * Age ≥18 years Exclusion Criteria: * Does not speak Danish or English * Does not wish to participate",18.0,65.0,"['caesarean section', 'regional anesthesia']"
NCT03410979,"A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects","A 2-part, Randomized, Double-blind, Placebo-controlled, Sequential Group, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG2737 in Healthy Male Subjects",COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: 1. Male between 18-50 years of age, inclusive, on the date of signing the Informed Consent Form (ICF). 2. Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and clinical safety laboratory tests prior to the initial study drug administration. Clinical safety laboratory test results must be within the laboratory reference ranges for males or test results that are outside the reference ranges for males need to be considered non clinically significant in the opinion of the investigator. One retest is allowed if deemed appropriate by the investigator. 3. Liver function tests must meet the following criteria: 1. aspartate aminotransferase (AST), ALT or alkaline phosphatase (ALP) \<1.2x the upper limit of normal (ULN) 2. Bilirubin not greater than ULN, however documented Gilbert's syndrome is acceptable. One retest is allowed if deemed appropriate by the investigator. 4. Subject's screening ECG is considered normal or abnormal but clinically non-significant. QTcF must not exceed 450 msec. First degree heart block will not be considered as a significant abnormality. 5. Forced expiratory volume in 1 second (FEV1) ≥ 80% of predicted normal for age, gender and height at screening. 6. Discontinuation of all medications (including over-the-counter and/or prescription medication, dietary supplements, nutraceuticals, vitamins and/or herbal supplements) except occasional paracetamol (maximum dose of 2 g/day and maximum of 10 g/2 weeks) at least 2 weeks prior to the first study drug administration. 7. Negative drug and alcohol screen (opiates, methadone, cocaine, amphetamines \[including ecstasy\], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol) prior to dosing. 8. Able and willing to comply with the prohibitions and restrictions as described in the protocol and with the contraceptive requirements as described in the protocol. 9. Able and willing to sign the ICF as approved by the IEC, prior to any screening evaluations. Exclusion Criteria: 1. Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization. 2. Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) or history of hepatitis from any cause with the exception of hepatitis A. 3. History of or a current immunosuppressive condition (e.g., human immunodeficiency virus \[HIV\] infection type 1 and 2). 4. Clinically significant illness in the 3 months before screening. 5. Presence or having sequelae of gastrointestinal, liver (except for Gilbert's syndrome), kidney (creatinine clearance ≤ 80 mL/min using the Cockcroft-Gault formula: if calculated result ≤ 80 mL/min, a 24 hour urine collection to determine actual value can be done) or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs. 6. History of malignancy within the past 5 years (except for basal cell carcinoma of the skin that has been treated and with no evidence of recurrence). 7. Treatment with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months of 5-half-lives of the drug (whichever is longer) before the initial drug administration. 8. Active drug or alcohol abuse (an average intake of more than 21 glasses of wine or beer or equivalent/week) within 2 years prior to screening. 9. Participation in a drug, drug/device or biologic investigational research study within 12 weeks or 5 half-lives of the investigational drug, if the half-life is known (whichever is longer) prior to screening. 10. Any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.",18.0,50.0,['healthy']
NCT04252079,Endovascular Repair of Juxtarenal Aortic Aneurysm,Endovascular Repair of Juxtarenal Aortic Aneurysm,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * • Subject is ≥18 years old * Subject is scheduled for treatment of the juxtarenal aortic aneurysm with a short infrarenal neck aortic neck length \ 60%, conical neck) (i.e. denovo cases). * Subject is able and willing to comply with the protocol and to adhere to the follow-up requirements. * Subject has provided written informed consent. Exclusion Criteria: * Subject is participating in a concurrent study which may confound study results * Subject has a life expectancy ≤1 year * Subject has an aneurysm that is: * Mycotic * Inflammatory * Pseudoaneurysm * Subject requires emergent aneurysm treatment, for example, trauma or rupture * Subject has previously undergone surgical treatment for abdominal aortic aneurysm * Subject is a female of childbearing potential in whom pregnancy cannot be excluded * Subject has a known hypersensitivity or contraindication to anticoagulants, anti-platelets, or contrast media, which is not amenable to pre-treatment.",18.0,65.0,['juxtarenal aortic aneurysm']
NCT03750279,Inflammatory Targeted Laser Treatment of Knee Osteoarthritis,Inflammatory Targeted Low-level Laser Treatment of Knee Osteoarthritis - A Randomized Clinical Trial,COMPLETED,INTERVENTIONAL,ALL,"Inclusion criteria: * Any gender * Age ≥ 50 years * Pain on movement ≥ 40 mm Visual Analog Scale * Knee pain for the last ≥ 3 months * KOA verified with the American College of Rheumatology criteria using a history and physical examination, i.e. knee pain and at least three of the following: ≥ 50 years old, ≤ 30 minutes of morning stiffness, crepitus on active range of motion, bony tenderness, bony enlargement, and no palpable warmth of synovia Exclusion criteria: * Knee alloplastic * Total meniscectomy * Intra-articular steroid injection and/or oral steroid treatment within the last six months * Cancer * Rheumatoid arthritis * Severe cognitive deficit * Neurological deficits affecting the knee * Inability to speak and understand English/Norwegian",50.0,65.0,['knee osteoarthritis']
NCT06293079,The Effect of Hybrid Telerehabilitation-Based Structured Exercise Programs in Patients With Multiple Sclerosis,"The Effect of Hybrid Telerehabilitation-Based Structured Exercise Programs on Gait, Functional Capacity, EMG Muscle Activation and Fatigue in Patients With Multiple Sclerosis",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * EDSS score of 0 - 4.0 * Having high-speed internet access via smartphone or computer * Getting at least 24 points from the Mini Mental Test * Being at Stage 3 or above according to the Functional Ambulation Scale. Exclusion Criteria: * Having hearing or vision problems. * Participating in any exercise program. * Having other accompanying neurological, cardiovascular or orthopedic disorders * A history of MS attacks or a change in medication in the last 6 months. * Being in a physical condition that cannot do the exercises. * Comorbid conditions that negatively affect oxygen transport (severe anemia, peripheral artery diseases, etc.)",18.0,65.0,['multiple sclerosis']
NCT04912479,Can Connected Devices Increase the Success Rate of Benzodiazepine Withdrawals in the Elderly?,Can Connected Devices Increase the Success Rate of Benzodiazepine Withdrawals in the Elderly?,RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * Unassisted mobility (1/1 for the locomotion item on KATZ Activities of Daily Living scale) * Mini-Mental State Examination (MMSE) ≥ 20 * With a daily consumption of benzodiazepine for more than 3 months * Smartphone and/or tablet with internet connection Exclusion Criteria: * Patient under legal protection * Patient refuses to participate * Patient does not speak French,65.0,65.0,['benzodiazepine withdrawal']
NCT00621179,Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF,Do Endometrial Implantation Markers Predict in Vitro Fertilization-embryo Transfer Cycle Outcomes in Endometriosis Patients Pretreated With Leuprolide Acetate in Depot Suspension?,COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Infertility * Surgical diagnosis of endometriosis * Normal ovarian reserve testing * Regular menses Exclusion Criteria: * Irregular menses * Undiagnosed abnormal uterine bleeding * Pregnancy * Prior adverse reaction to any GnRH agonist * Ovarian cystic or solid mass \> 3cm in mean diameter at study entry * Use of a depot preparation of a GnRh agonist or any hormonal therapy for endometriosis within 6 months of study entry * Current hepatic, renal, hematologic or psychiatric disorder",21.0,42.0,"['endometriosis', 'infertility']"
NCT07313579,Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer,Observational Prospective Cohort Study on Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer,RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: 1. Age 18-80 2. Hystologicaly proven gastric adenocarcinoma 3. ECOG status 0-1 4. Written consent to participate in the study 5. Medically and technically operable gastric tumor 6. Only T4a or T4b tumours with any peritoneal cytology status 7. Cytologically positive peritoneal washings (cyt+) with any T and N criteria 8. Adequate haemopoetic, renal and hepatic function (Hb \> 120, PLT \> 150\*10\^9/l, ALT \< 60, AST \<40, total bilirubin \< 21 µmol/l, Creatinine clearance (male - 90-140, female - 80-130 ml/min) Exclusion Criteria: 1. Pregnancy/breastfeeding 2. ECOG status 2-4 3. Concomitant malignancy 4. Mitomycin and/or Cisplatin hypersensitivity 5. Uncontrollable chronic diseases 6. Patients with coexisting malignancy other than basal cell carcinoma of the skin within the last five years. 7. Presence of metastases other than regional or peritoneal (such as liver, lungs, bone, brain, distant lymph nodes) 8. History of allergic reactions associated with cisplatin and Mitomycin C 9. Patients with psychiatric illness/social situations with impaired compliance 10. •Refusal to participate",18.0,80.0,"['gastric cancer (gc)', 'hipec', 'peritoneal metastases from gastric cancer', 'hyperthermic intraperitoneal chemoperfusion']"
NCT01531179,Lactobacillus Reuteri for Prevention of Necrotizing Enterocolitis in Very Low-birth Weight Infants,Role Of Lactobacillus Reuteri in Preventing Necrotizing Enterocolitis in Very Low Birth Weight Infants,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Very low birth weight infants \< 1500 gr * Gestational age \< 32 weeks Exclusion Criteria: * Genetic anomalies * Short bowel syndrome * Not willing to participate * Allergy to Lactobacillus reuteri components,1.0,6.0,"['necrotizing enterocolitis', 'very low birth weight infants']"
NCT02720679,Investigation of the Genetics of Hematologic Diseases,Investigation of the Genetics of Hematologic Diseases,RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * An individual (proband) receiving therapy or expert consultation regarding a non-malignant hematologic disorder, MDS or MPN. * A biologically-related individual to the identified proband to include: first, second or third degree relatives. Exclusion Criteria: * None",18.0,65.0,"['bone marrow failure syndromes', 'erythrocyte disorder', 'leukocyte disorder', 'hemostasis', 'blood coagulation disorder', 'sickle cell disease', 'dyskeratosis congenita', 'diamond-blackfan anemia', 'congenital thrombocytopenia', 'severe congenital neutropenia', 'fanconi anemia', 'myelodysplastic syndromes', 'myeloproliferative diseases']"
NCT05381779,Comparison the Effects of Inspiratory Muscle Training and Aerobic Exercise Training in Patients With Post COVID-19,Comparison the Effects of Inspiratory Muscle Training and High Intensity Interval Aerobic Exercise Training in Patients With Post COVID-19,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Between the ages of 18-75 * Diagnosed with COVID-19 * COVID-19 Polymerase Chain Reaction (PCR) test result negative * Volunteer to participate in the study Exclusion Criteria: * Body mass index \>35 kg/m2 * Acute pulmonary exacerbation, acute upper or lower respiratory tract infection * Aortic stenosis, complex arrhythmia, aortic aneurysm * Serious neurological, neuromuscular, orthopedic, other systemic diseases or other diseases affecting physical functions * Cognitive impairment that causes difficulty in understanding and following exercise test instructions * Participated in a planned exercise program in the last three months * Bulla formation in the lung * Uncontrolled hypertension and/or diabetes mellitus, heart failure and cardiovascular disease * Contraindication for exercise testing and/or exercise training according to the American College of Sports Medicine",18.0,75.0,"['covid-19', 'aerobic exercise', 'inspiratory muscle training', 'physical activity', 'oxygen consumption']"
NCT04896879,"Experiences and Needs of Patients, Their Informal Caregiver and Healthcare Professionals Regarding LARS","Rectal Cancer Survivorship, the Struggle of the Low Anterior Resection Syndrome (LARS). Experiences and Needs of Patients, Their Informal Caregiver and Healthcare Professionals",COMPLETED,OBSERVATIONAL,ALL,PATIENTS Inclusion Criteria: * adult patients (18+) * confronted with major low anterior resection syndrome after rectal cancer surgery Exclusion Criteria: * stoma at time interview * abdominal perineal resection INFORMAL CAREGIVERS Inclusion criteria * Adults (18+) * Nominated by the participating patient as their principal caregiver Exclusion criteria None HEALTHCARE PROFESSIONALS inclusion criteria * Adults (18+) * Caring for patients with LARS Exclusion criteria None,18.0,65.0,"['low anterior resection syndrome', 'rectal cancer']"
NCT00051779,An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer,"A 24-Week Blinded Study Conducted at Multiple Centers, Evaluating the Safety and Effectiveness of Various Doses of the Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) When Randomly Assigned to Patients With Breast Cancer That Has Metastasized to Bone",COMPLETED,INTERVENTIONAL,FEMALE,"Major Inclusion Criteria - Others Stipulated within the Protocol The study physician must assure you have/are: * Must be a female at least 18 years of age and be using an effective form of birth control. * A documented history of breast cancer and at least one bone metastasis that has not been previously treated by radiation or surgery, and is not anticipated to be treated within the next 24 weeks. * A total body bone scan and other radiographic scan(s) performed on you within 4 weeks prior to or during the screening period sufficient to image all sites of bone metastases. * You must be willing to perform a daily telephone diary and be willing to keep a paper diary and provide voluntary consent to participate in this study. Major Exclusion Criteria - Others Stipulated within the Protocol The study physician must assure you do not have/are not: * A change in analgesic (pain relief) type medication during the screening period (example, non-narcotic to narcotic). * Received radiation therapy to any bone metastasis or started a new course of chemotherapy within 3 weeks prior to the screening visit or during the screening period. * Used any bisphosphonate type drug during the 30 days prior to the anticipated first dose of study drug * Vertebral spine or weight-bearing bone metastasis that would place you at imminent risk for fracture or surgical intervention. * Evidence of active infection or immune deficiency, renal failure, abnormal liver function, or a serum calcium level \> 10.1 mg/dL. * Use of any investigational drug within 30 days prior to screening.",18.0,65.0,"['breast neoplasms', 'breast cancer', 'metastasis']"
NCT01938079,Pharmacokinetic Alterations During ECMO,Pharmacokinetic Alterations During ECMO (Ketamine and Extracorporeal Membrane Oxygenation),COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Receiving ECMO for acute respiratory failure * Requiring deep sedation (RASS -5) Exclusion Criteria: * Allergy to ketamine,18.0,90.0,['acute respiratory failure']
NCT02169479,Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa,"Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa: a Doubleblind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects",COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: 1. Availability for the entire study period and willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the volunteer prior to participation in the study. 2. Male volunteers. 3. Volunteers of at least 18 years of age but not older than 45 years. 4. Volunteers with body mass index (BMI) greater than or equal to 19 and below 30 kg/m2. 5. Volunteers who are non- or ex-smokers. An ex-smoker is defined as someone who completely stopped smoking for at least 12 months before day 1 of this study. 6. Volunteers who are healthy as determined by pre-study (at screening) medical history, physical examination, vital signs, complete neurological examination and 12-lead ECG. 7. Volunteers who have clinical laboratory test results judged clinically acceptable (within the laboratory's stated normal range; if not within this range, they must be without any clinical significance) at screening and admission to first treatment period. 8. Volunteers who have negative tests for hepatitis B surface antigen (HBsAg), anti-hepatitis C antibodies (HCV Ab), and Human immunodeficiency viruses -1 and -2 antibodies (HIV-1 and HIV-2 Ab) at screening. 9. Volunteers who have negative screen of ethyl alcohol and drugs of abuse at screening. 10. Due to unknown risks and potential harm to the unborn fetus, sexually active men must agree to use a medically acceptable form of contraception throughout the study. Exclusion Criteria: 1. Volunteers who do not conform to the above inclusion criteria, or in case of 2. Volunteers who have a clinically relevant surgical history. 3. Volunteers who have a clinically relevant family history. 4. Volunteers who have a history of relevant atopy. 5. Volunteers who have a significant infection or known inflammatory process at screening or first admission. 6. Volunteers who have acute gastrointestinal symptoms at the time of screening or first admission (e.g., nausea, vomiting, diarrhoea, heartburn). 7. Volunteers who are vegetarians, vegans or have medical dietary restrictions. 8. Volunteers who cannot communicate reliably with the investigator. 9. Volunteers who are unlikely to co-operate with the requirements of the study. 10. Significant history of hypersensitivity to BIA 9-1067, tolcapone, entacapone, levodopa, carbidopa or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs. 11. Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects. 12. History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability. 13. Presence or history of significant cardiovascular, pulmonary, hematologic, neurologic, psychiatric, lymphatic, musculoskeletal, genitourinary, endocrine, immunologic, dermatologic or connective tissue disease. 14. Suicidal tendency, history of or disposition to seizures, state of confusion, clinically relevant psychiatric diseases. 15. Presence of significant heart disease or disorder according to ECG. 16. Presence of suspicious undiagnosed skin lesions or a history of melanoma. 17. Previous history of Neuroleptic Malignant Syndrome (NMS) and/or nontraumatic rhabdomyolysis. 18. Presence or history of significant glaucoma. 19. Use of prescription medications including MAO inhibitors within 28 days before day 1 of the study. 20. Use of over-the-counter (OTC) products within 7 days before day 1 of the study. 21. Maintenance therapy with any drug, or significant history of drug dependency (drug abuse) or alcohol abuse (\> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic). 22. Any clinically significant illness in the previous 28 days before day 1 of this study. 23. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin and rifampin), in the previous 28 days before day 1 of this study. 24. Volunteers who took an Investigational Product (in another clinical trial) or donated 50 mL or more of blood in the previous 28 days before day 1 of this study. 25. Poor motivation, intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with the protocol requirements or inability to cooperate adequately, inability to understand and to observe the instructions of the physician. 26. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study. 27. Positive urine screening of ethyl alcohol or drugs of abuse at admission to any treatment period. 28. Any history of tuberculosis and/or prophylaxis for tuberculosis. 29. Positive results to HIV, HBsAg or anti-HCV tests. 30. Participation in any previous clinical study with BIA 9-1067 within 84 days before day 1 of the study.",18.0,45.0,"[""parkinson's disease (pd)""]"
NCT04320979,Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients,Postmastectomy Prophylactic Internal Mammary Nodal Irradiation for High-risk Patients With Non-metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Eastern Cooperative Oncology Group Performance Status Scale 0-2 * Histologically confirmed invasive breast cancer * Underwent total mastectomy/breast-conserving surgery and axillary dissection(10 or more axillary lymph nodes detected) and negative margins * Patients who had ≥4 positive axillary lymph nodes; or 1-3positive axillary lymph nodes and T3-4; or 1-3positive axillary lymph nodes and T1-2, and score≥3 based on the following high risk factors: age≤40 years(score 1), primary tumor in the inner quadrant (score 1), 2-3 positive axillary lymph nodes (score 1), positive vascular invasion (score 1), re-staged based on eighth Cancer Staging System staging system(IB-IIA score 1， IIB-IIIA score 2); or ypN+ after neoadjuvant chemotherapy * No supraclavicular or internal mammary nodes metastases based on images before system therapy * No distant metastases * Could tolerate radiotherapy * Treated with chemotherapy (anthracycline and/or taxane-based combined chemotherapy, ≥6 cycles) * Anticipated to receive endocrine therapy for 5 years if indicated * Anticipated to receive anti-HER2 therapy for 1 years if indicated * LVEF≥50% based on echocardiogram * Willing to follow up * Written,informed consent Exclusion Criteria: * Simultaneous bilateral breast cancer * Sentinel lymph node biopsy only without axillary dissection * Had received internal mammary node dissection * No imaging assessment of the internal mammary nodal before system therapy * One-stage breast reconstruction * Severe cardiac insufficiency; myocardial infarction or uncorrected unstable arrhythmia or uncorrected unstable angina in the last 3 months; pericardial disease * Had history of chest wall or supraclavicular radiotherapy * Had simultaneous or previous secondary malignancies, except for non-malignant melanoma skin cancer, papillary thyroid / follicular carcinoma, cervical carcinoma in situ, contralateral non-invasive breast cancer",18.0,70.0,['breast cancer']
NCT01873196,Food Aid Quality Review: Feasibility and Acceptability Study of Corn Soy Blend and Fortified Vegetable Oil in Malawi,Food Aid Quality Review: Feasibility and Acceptability Study of Corn Soy Blend and Fortified Vegetable Oil in Malawi,COMPLETED,INTERVENTIONAL,ALL,"All Beneficiary Mothers/Caretakers receiving supplementary food for their children at the selected FDPs implementing a program change or the control FDPs , are considered part of the subject pool. All beneficiaries will be receiving a program change (consistent with additional oil ration and education on preparation in Phase I, and repackaged CSB in Phase II) in the selected FDPs. Participation in individual interviews, focus group discussions, and observations constitutes subject participation. Subject Categories * Beneficiary Children that are part of the taste tests in preparation for Phase I * Beneficiary Mothers/Caretakers that participate in interviews, focus group discussions, and in home observations * Care Group Lead Mothers that participate in individual interviews and FGD * Health Care Workers that participate in individual interviews * PVO staff members that participate in individual interviews * Store owners/Market Vendors that participate in individual interviews Beneficiary Children (Children Under five years old,U5): Inclusion Criteria: * Child enrolled in Supplementary Feeding Program (SFP) to receive ration (CSB13 and FVO) from 1 of the 16 Food Distribution Points * Child has an SFP ration card * Subject's whose mother/caretaker or CSB preparer was contacted to participate in taste test FGD * Subject's whose mother/caretaker is voluntarily willing to consent to their child's participation in taste tests Exclusion Criteria: \- All children enrolled in the SFP in the selected program change FDPs are eligible Beneficiary Mothers/Caretakers (Mothers/Caretakers of Children Under five years old,U5): Inclusion Criteria: * Beneficiary Mother/Caretaker enrolled in Supplementary Feeding Program (SFP) to receive ration (CSB13 and FVO) for her child from 1 of the 16 Food Distribution Points * Beneficiary Child has an SFP ration card * Beneficiary Mother/Caretaker has no age restrictions for inclusion (Note: Mothers/caretakers or CSB preparers will be asked to participate regardless of age and consented appropriately) * Subject who is voluntarily willing to participate by signing the consent form (or if minor, adult is willing to sign on their behalf). Note: This should will only come after the subject has been educated on all that appertains to their her involvement in this study, the consent script read aloud for them and given the chance to make her own non-coerced, non-persuaded and autonomous decision. Exclusion Criteria: \- Beneficiary Mothers/Caretakers who were interviewed once for this study will not be interviewed a second time during a later Phase of the study. Care Group Lead Mothers Inclusion Criteria: * Lead mother who covers the catchment area of the selected 16 FDP's * Lead mother has been present during the program change period * Subject who is voluntarily willing to participate by signing the consent form Exclusion Criteria: \- None Health Care Workers (Health Surveillance Agents, Health Promoters, Resource Persons) Inclusion Criteria: * Health Care Workers serving within the catchment area for the 16 FDPs * Health Care Worker has been present during the study period * Subject who is voluntarily willing to participate by signing the consent form Exclusion Criteria: -None PVO Staff Members Inclusion Criteria: * All staff members from Catholic Relief Services, Africare, Save the Children, Project Concern International (PCI) * Subject who is voluntarily willing to participate by signing the consent form Exclusion Criteria: \- PVO Staff members who joined too recently to have experience of the program change Store Owners/Market Vendor Inclusion Criteria: * Store owner/market vendor in study districts (i.e. Machinga, Balaka, Chiradzulu and Mulanje districts) who trades in the relevant products (food vendors) * Subject who is voluntarily willing to participate by signing the consent form Exclusion Criteria: \- Vendors who do not sell food.",6.0,59.0,['child malnutrition']
NCT05142696,"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase",ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Key Inclusion Criteria: * Participant is \>= 18 years on the day of signing informed consent form * Histologically or cytologically confirmed ES-SCLC * Presence of measurable disease * No prior systemic treatment for ES-SCLC (except the first cycle of chemotherapy with or without atezolizumab of the induction period * ECOG status =\ = 6 months Key Exclusion Criteria: * Participant has received prior therapy with an antibody or drug against immune checkpoint pathways * Active autoimmune diseases or history of autoimmune diseases that may relapse * Severe chronic or active infections (including active tuberculosis, HBV, or HCV infection) requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks before Cycle 1 Day 1 * Any major surgical procedure requiring general anesthesia =\< 28 days before Cycle 1 Day 1 * History or current diagnosis of electrocardiogram (ECG) abnormalities indicating significant risk of safety for participants participating in the study * Known hypersensitivity to the active substances or any of the excipients of the study drugs * Concurrent participation in another therapeutic clinical study",18.0,100.0,['extensive stage small cell lung cancer']
NCT05929196,Feasibility Evaluation - Blood Glucose Level Monitoring by Microwave Metamaterial Sensor in Blood Samples.,Feasibility Evaluation - Blood Glucose Level Monitoring by Microwave Metamaterial Sensor in Blood Samples.,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * blood glucose can be measured with standard biochemical analyzer Exclusion Criteria: * minimum age limit 18 years,18.0,65.0,['diabetes']
NCT05224596,"AssesSment of Early-deteCtion basEd oN liquiD Biopsy in GASTRIC Cancer, ASCEND-Gastric",Gastric Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria for Cancer Arm Participants: * Age 40-75 years at the day of consenting to the study. * Able to provide a written informed consent. * No prior cancer treatment (local or systematic) with either of the following: A. Pathologically confirmed cancer diagnosis within 42 days prior to blood draw. B. High suspicious for cancer diagnosis by imaging tests or other routine clinical examinations, with confirmed pathological cancer diagnosis within 42 days after the blood draw. Exclusion Criteria for Cancer Arm Participants: * Insufficient qualified blood samples. * During pregnancy or lactation. * Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant. * Recipient of blood transfusion within 7 days prior to blood draw. * Recipient of anti-tumor drugs to treat non-cancer diseases within 30 days prior to blood draw. * With other known malignant tumors or multiple primary tumors. Inclusion Criteria for Benign Disease Arm Participants: * Age 40-75 years at the day of consenting to the study. * Able to provide a written informed consent. * Able to provide sufficient and qualified blood samples for study tests. * Have either of the following: A. Pathological confirmed diagnosis of benign diseases within 90 days prior to the study blood draw, with no prior treatment such as surgical resection. B. High suspicious for benign diseases diagnosis by radiological or other routine clinical assessments, with confirmed benign diseases diagnosis within 42 days after study blood draw. Exclusion Criteria for Benign Disease Arm Participants: * Insufficient qualified blood sample for study test. * During pregnancy or lactation. * Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant. * Recipient of blood transfusion within 7 days prior to study blood draw. * Recipient of anti-tumor drugs to treat non-cancer diseases within 30 days prior to blood draw.",40.0,75.0,['cancer']
NCT00838396,A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. History of GERD symptoms (e.g. heartburn episodes) at least 3 times per week 2. Discontinuation of drugs used to treat GERD (PPIs, H2-blockers) and/or drugs known to cause GERD symptoms (e.g. nonsteroidal anti-inflammatory drugs \[NSAIDs\]) for 7 days prior to baseline (Visit 2); 3. Had greater then or equal to 20 postprandial reflux episodes/2 hours recorded using impedance/pH monitoring during Screening/Baseline period (Visit 2) Exclusion Criteria: 1. History of gastrointestinal disorders other than GERD that may have significantly affected the assessment of reflux episodes or GERD symptoms (e.g. Barrett's Esophagus, active gastric or duodenal ulcer disease, achalasia, scleroderma, etc.). 2. Medical conditions that could have affected assessments of reflux episodes or GERD symptoms (e.g. history of nausea and/or vomiting, neurologic/psychiatric disorders, cardiac disease \[e.g. angina\], lung disease \[e.g. asthma, cough\], etc.)",18.0,65.0,['gerd']
NCT04174196,A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma,A Pilot Study Evaluating Lenalidomide and CC-486 in Combination With Radiotherapy For Patients With Plasmacytoma (LENAZART Study),ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: Cohort 1: Must meet all the following 3 criteria: * Histologically confirmed newly diagnosed or recurrent solitary plasmacytoma/lytic lesion (recurrent solitary plasmacytomas will be considered based on treating physician discretion for cases where they clinically plan to treat with RT alone) - Minimal marrow involvement (Detectable clonal bone marrow plasma cells by multicolor flow cytometry and \ /= 18 years * Surgical resection of plasmacytoma or stabilization surgery is permitted if necessary based on physician judgement * ECOG performance status of 0-1 * Anticipated lifespan greater than 3 months * Able and willing to give valid written informed consent * Creatinine clearance \>/=30ml/min by Cockroft-Gault method. See section below, ""Dosing Regimen"", regarding lenalidomide dose adjustment for calculated creatinine clearance \>/= 30ml/min and \ /= 9 g/dL, platelets \>/= 50,000 and ANC \>/= 1 Exclusion Criteria: Subjects should not enter the study if any of the following exclusion criteria are fulfilled: * Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking azacitidine). * Uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment) * History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism or excretion of the study drug and/or predispose the subject to an increased risk of gastrointestinal toxicity * Abnormal coagulation parameters without any known etiology (PTT \> 45 seconds, and/or INR \> 1.5). Patients currently on therapeutic anti-coagulation treatment are exempt from these parameters. * Significant active cardiac disease within the previous 6 months including: NYHA class 4 CHF Unstable angina Myocardial infarction * known or suspected hypersensitivity to azacitidine or mannitol * Known hypersensitivity to thalidomide or lenalidomide * The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs * Active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) as determined by a positive Polymerase Chain Reaction (PCR) will be excluded. Patients who are seropositive because of HBV vaccine are eligible. Seropositive status-antibody positive patients with negative PCR on two occasions will be eligible * Concurrent systemic chemotherapy with drugs other than CC-486 and lenalidomide. * Patients on tacrolimus therapy",18.0,65.0,"['plasmacytoma', 'plasmacytoma of bone', 'multiple myeloma']"
NCT07208396,Upper Cervical Mobilization Versus Integrated Neuromuscular Inhibition Technique in Patients With Levator Scapulae Syndrome,UPPER CERVICAL MOBILIZATION VERSUS INTEGRATED NEUROMUSCULAR INHIBITION TECHNIQUE IN PATIENTS WITH LEVATOR SCAPULAE SYNDROME,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Patients with a primary complaint of chronic neck pain (assessed by VAS) for more than 3 months. 2. Subjects with pain provocation and reduced mobility at the upper cervical segment (assessed by passive accessory intervertebral movements (PAIVMs) and reduced mobility at cervical spine (assessed by CROM) will be included in the study. 3. Participants will be recruited from both genders with age ranged from 18 to 45 years old, and BMI from 18 to 30kg/m2 Exclusion Criteria: * 1\) Previous spine surgery 2) Pregnant and breast feeding women 3) Diabetic patients 4) Hypertensive patients 5) Neck pain associated with cervical radiculopathy 6) Whiplash injuries 7) Cervical spine fracture 8) Vertebrobasilar insufficiency. 9) Red flags suggesting of cancer, infection, vascular insufficiency",18.0,45.0,['levator scapulae syndrome']
NCT03699696,A Pilot Analysis of the Association Between Anesthesia Induction Dosing and AKI in the Elderly Population,A Pilot Analysis of the Association Between Anesthesia Induction Dosing and Acute Kidney Injury (AKI) in the Elderly Population,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Patients age 65 or older who underwent induction of general anesthesia at YNHH * Only first surgery for each patient within the time period is counted * Only include patients who underwent intubation * Only include patients who underwent induction by propofol bolus * Only include patients who got at least 0.3mg/kg of propofol Exclusion Criteria: * Patients under the age of 65, patients who underwent monitored anesthetic care/conscious mediation for their procedures. * Patients with renal failure and/or chronic kidney disease * Patients who have a pre-operative systolic blood pressure \<100",65.0,65.0,"['acute kidney injury', 'hypotension', 'anesthesia', 'adverse effect']"
NCT02745496,Advanced Magnetic Resonance Imaging (MRI) in Men With Suspected Prostate Cancer,Multiparametric Magnetic Resonance Imaging Characterization and Guided Biopsy of the Prostate in Men Suspected of Having Prostate Cancer,COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: * Males between the age of 40-75 at referral * With at least 10 years life expectancy * With clinically localised PCa: Prostate Specific Antigen (PSA) ≤20 ng/ml * And/or abnormal Digital Rectal Examination (DRE) but \< T3 disease * Ability to informed consent Exclusion Criteria: * Unable to give informed consent * Prior prostatic biopsy within 12 months * Contraindications to biopsy * Poor general health and life expectancy \< 10 years * Previous diagnosis of acute prostatitis within 12 months * History of prostate cancer * Prior transurethral prostatectomy * Contraindications to MRI (cardiac pacemakers, allergic reaction to gadolinium based contrast, renal function with baseline eGRF 30 ml/min, intracranial clips, claustrophobia) * Previous hip replacement",40.0,75.0,['prostate cancer']
NCT01318096,Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients,"A Randomized, Pilot Estimation Study to Compare the Safety and Efficacy of Raltegravir+TDF+3TC Versus TDF+3TC+EFV in HBV/HIV Co-infected Patients",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Ability and willingness to provide written informed consent * HIV-1 infection, documented in patient medical record. Acceptable forms of documentation include positive HIV antibody or detectable HIV RNA * HIV-1 antiretroviral therapy naïve * Chronic HBV infection, defined as HBsAg positive \>6 months. Both HBeAg positive and negative subjects will be eligible * Detectable HBV DNA ( \> 300 copies/ml) * Serum alpha-fetoprotein (AFP) of ≤ 50 ng/ml within 4 weeks of study entry, or if elevated \> 50 ng/ml, an imaging study demonstrating no evidence of hepatic tumor within 4 weeks of enrollment Exclusion Criteria: * Allergy or sensitivity to study drug * Pregnancy, breastfeeding or unwillingness/inability to adhere to contraceptive methods for the duration of the study (Female study volunteers must not participate in a conception process (e.g., active attempt to become pregnant). If participating in sexual activity that could lead to pregnancy, the female study volunteer must use the following forms of contraception while receiving study-specific medication(s) and for 30 days after stopping the medication. One of the following methods MUST be used appropriately: (1)Condoms\* (male or female) with or without a spermicidal agent; (2)Diaphragm or cervical cap with spermicide; (3)IUD; (4)Hormonal-based method.Condoms are recommended because their appropriate use is the only contraception method effective for preventing HIV transmission. * Prisoners or subjects who are incarcerated * Receipt of the following drugs with anti-HBV activity within 90 days prior to study entry or anticipated receipt during the course of the study including: ADV, telbivudine, alpha interferon, and other investigational agents with anti-HBV activity * Active opportunistic infection * Other causes of chronic liver disease identified (autoimmune hepatitis, haemochromatosis, Wilsons disease, alfa-1-antitrypsin deficiency) * Concurrent malignancy requiring cytotoxic chemotherapy * Decompensated or Child's C cirrhosis * Any other condition which in the opinion of the investigator might interfere with compliance or outcome of the study",18.0,65.0,"['hbv coinfection', 'hiv infections']"
NCT01947296,Impact of a Coordinated Regional Organization to Secure Patient's Care Treated by Oral Antineoplastic Agents,Evaluation of the Impact of a Coordinated Regional Organization to Secure Patient's Care Treated by Oral Antineoplastic Agents,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * patients affected by cancer (breast, colorectal, liver, lung, kidney, gastrointestinal stromal tumor, pancreas) * treated by capecitabine, erlotinib, gefitinib, imatinib, lapatinib, sorafenib, sunitinib, vinorelbine, Evérolimus, Pazopanib, Etoposide, Topotécan * 18 years old or more Exclusion Criteria: * refusal to participate * lack proficiency in French , * having a Performance Status \> 2, * home based care, * patient enrolled in clinical trials * patient enrolled in therapeutic education program * patient under administrative supervision or legal guardianship * not affiliated with Patient Social Security or CMU (recipient or beneficiary)",18.0,65.0,['cancer']
NCT04838496,Induction Chemotherapy for Locally Advanced Rectal Cancer,"Neo-adjuvant FOLFOXIRI and Chemoradiotherapy for High Risk (""Ugly"") Locally Advanced Rectal Cancer",NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * 18 years or older * WHO performance score 0-1. * Histopathologically confirmed rectal cancer. * Lower border of the tumour located below the sigmoidal take-off as established on MRI of the pelvis. * Confirmed high-risk locally advanced rectal cancer, meeting one of the following imaging based criteria: * Tumour invasion of mesorectal fascia (MRF+) * The presence of grade 4 extramural venous invasion (mrEMVI) * The presence of tumour deposits (TD) * The presence of Extramesorectal lymph nodes with a short-axis size \> 7mm (LNN) * Resectable disease as determined on magnetic resonance imaging (MRI) or deemed resectable disease after neoadjuvant treatment. Expected gross incomplete resection with overt tumour remaining in the patient after resection, tumour invasion in the neuroforamina, encasement of the ischiadic nerve and invasion of the cortex from S3 and upwards are considered not resectable • Written informed consent. Exclusion Criteria: * Evidence of metastatic disease at the moment of inclusion or within six months prior to inclusion except for patients with enlarged iliac or inguinal lymph nodes and aspecific lung noduli. * Homozygous DPD (Dihydropyrimidine dehydrogenase) deficiency. * Any chemotherapy within the past 6 months. o Any contraindication for the planned systemic therapy (e.g. severe allergy, pregnancy, kidney dysfunction and thrombocytopenia), as determined by the medical oncologist. * Radiotherapy in the pelvic area within the past 6 months. * Any contraindication for the planned chemoradiotherapy (e.g. severe allergy to the chemotherapy agent or no possibility to receive radiotherapy), as determined by the medical oncologist and/or radiation oncologist. * Any contraindication to undergo surgery, as determined by the surgeon and/or anaesthesiologist. * Concurrent malignancies that interfere with the planned study treatment or the prognosis of the resected tumour.",18.0,65.0,['rectal cancer']
NCT04531696,UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research,UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age ≥ 18 years. * Signature of informed consent by the subject. * Metastatic breast cancer, or hereditary cancer syndrome with a moderate to high lifetime risk of breast cancer, for which the patient is treated/followed in UZ Leuven or treated in another hospital and referred to UZ Leuven specifically for the trial. Additional inclusion criteria for the different substudies: * Pilot phase: no additional inclusion criteria. * ILC substudy: histologically confirmed history of ILC. * IBC substudy: history of IBC, fulfilling the following criteria described by Dawood et al: rapid onset of breast erythema, oedema and/or peau d'orange and/or warm breast with or without an underlying palpable mass, duration of history of no more than 6 months, erythema occupying at least one-third of the breast and pathological confirmation of invasive carcinoma. * Hereditary cancer syndrome substudy: confirmed presence of a germline mutation known to be associated with a moderate to high lifetime risk of BC (e.g. known pathogenic variants in the genes BRCA1/2, CHEK2, TP53, PALB2) and presence of at least one malignant lesion at time of inclusion (of any origin) . * Other substudies: no additional inclusion criteria. Exclusion Criteria: * Presence of a transmissible disease that can form a risk to the health of researchers or others handling the body or patient samples. This includes but is not limited to the following infectious diseases: human immunodeficiency virus (HIV), active hepatitis C virus (HCV), encephalitis of unknown cause, Creutzfeldt-Jakob disease, rabies, active malaria, active tuberculosis, active SARS-CoV-2 infection. * Presence of any factors that could logistically or organizationally impede the study or the performance of sampling within a reasonable post-mortem time frame. This includes but is not limited to: residence of the subject at a faraway distance from the UZ Leuven hospital; residence of the subject on territory outside of Belgium; impossibility to notify the clinician confirming the death and the researchers within a reasonable time frame in case of death. Additional exclusion criteria for the different substudies: \- ILC substudy, IBC substudy: diagnosis of a malignancy other than breast cancer in the 5 years prior to inclusion. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin and in situ cervical carcinoma.",18.0,65.0,"['breast cancer', 'hereditary diseases']"
NCT01160796,Lcr35® for Bacterial Vaginosis Prevention,"Study of the Efficacy and Safety of Treatment With Total Freeze-dried Culture of Lactobacillus Casei Var. Rhamnosus (Lcr35®) Administered Intravaginally in the Prevention of Bacterial Vaginosis. Randomized, Phase III, Multi-centre, Double-blind, Placebo-controlled Superiority Trial",COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Patient presenting with a symptomatic vaginosis characterised by the presence of the following 3 clinical criteria (among the 4 Amsel criteria) at V1: * greyish uniform vaginal discharge, * characteristic ""rotten fish"" smell caused by the spontaneous release of amine or during the potassium test or ""sniff test"", * vaginal pH greater than 4.5. * Patient with a Nugent score ≥ 7 (using the sample taken at V1). * Patient clinically cured (none of the 3 Amsel criteria) after a 7-day course of Metronidazole (Flagyl®) Female. * Patient over 18 years of age. * For women with childbearing potential: * negative urine pregnancy test, * use of a contraceptive method deemed effective by the Investigator (excluding spermicides). * Patient having received information and voluntarily signed a written Informed Consent Form. * Patient covered by a national insurance scheme. Exclusion Criteria: * Presence of a yeast infection that is bacterial (other than vaginosis) or viral in origin presumed or proven to be gynaecologically-linked, whether or not treated within the month preceding inclusion or present at the time of inclusion. * Presence of an existing gynaecological infection that may interfere with the assessment of the trial treatment(fibroma, severe dysplasia of the cervix or in situ carcinoma, invasive carcinoma, intra-epithelial cervical neoplasia, squamous intra-epithelial lesions etc.) * Antibiotics or antifungals taken by general route during the month preceding the screening visit, excluding treatment for an earlier episode of vaginosis. * Use of probiotics in the month preceding the screening visit, excluding treatment for an earlier episode of vaginosis. * Use of intravaginal antiseptics in the month preceding the screening visit, excluding treatment for an earlier episode of vaginosis. * Use of prebiotics (acidifiers) during the two weeks preceding the screening visit. * Use of products containing topical oestrogens during the month preceding the screening visit. * Allergy to one of the active ingredients or one of the excipients in the products. * patient in post-menopausal time * Patient unable to comply with the constraints of the Protocol. * Breastfeeding patient. * Patient with menstrual bleeds lasting more than 12 days a month. * Patient having taken part in a clinical trial in the 3 months preceding inclusion in the present Protocol. * Patient with a severe acute or chronic disease deemed by the Investigator to be incompatible with participation in the trial, or a serious infection that is life-threatening in the short term. * Immuno-suppressed patient. * Patient presenting with a previous illness which, according to the Investigator, is likely to interfere with the results of the trial or expose the patient to an additional risk. * Patient linguistically or mentally unable to understand and sign the Informed Consent Form. * Patient deprived of her liberty by order of the Courts or civil authorities or subject to a guardianship order. * Patient likely not to comply with treatment. * Patient unable to be contacted in the case of an emergency.",18.0,65.0,['bacterial vaginosis']
NCT06694896,Microarray Application in Newborns With Multiple Congenital Anomalies,Microarray Application in Newborns With Multiple Congenital Anomalies: Genotype-Phenotype Correlation,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Newborns with two major or one major and two minor, or three or more minor congenital anomalies were included Exclusion Criteria: * Newborns with examination findings suggesting a recognizable numerical chromosome anomaly * History of teratogenicity",1.0,30.0,['multiple abnormalies']
NCT00480896,Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment,"Clinical Study on Tacrolimus Ointment Over the Long-term. ""CONTROL Study - Children""",COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Male or female patient of any ethnic group * Patient was at least 2-15 years old and suffered from mild to severe atopic dermatitis (Rajka/Langeland score of at least 3) Exclusion Criteria: * Patient had a genetic epidermal barrier defect such as Netherton's syndrome or generalised erythroderma * Patient had a clinically significant skin infection on the affected (and to be treated) area,2.0,15.0,"['dermatitis, atopic']"
NCT03266796,Shared Decision Making in Physical Therapy: a Cross-sectional Observational Study,Shared Decision Making in Physical Therapy: a Cross-sectional Observational Study,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: musculoskeletal disorders First treatment German speaking Exclusion Criteria: n/a,18.0,65.0,['shared decision making']
NCT02407496,Neurophysiological Attention Test (NAT) for Objective Assessment of Attention Deficit Hyperactivity Disorder (ADHD),Neurophysiological Attention Test (NAT) for Objective Assessment of Attention Deficit Hyperactivity Disorder (ADHD),COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Specific inclusion criteria for ADHD are: 1. meet established DSM-5 criteria for ADHD predominately inattentive or combined subtype with clinically significant levels of impairment, diagnosed by structured clinical interview, the Mini International Neuropsychiatric Interview, and corroborating information 2. Clinical Global Impression-Severity (CGI-S) score ≥ 4 for ADHD 3. no lifetime history of DSM-5 bipolar disorder, psychotic disorder, pervasive developmental disorder, obsessive-compulsive disorder, substance abuse, or substance dependence (except nicotine) as assessed wit the MINI 4. able in the opinion of the investigator to complete all required study procedures. Exclusion Criteria: * Exclusion criteria for both groups are: 1. History of diagnosis of childhood disorder other than ADHD (e.g. autism, dyslexia) 2. history of any general medical condition likely to require chronic use of medication with identified CNS effects suspected to alter cognitive performance 3. history of seizure disorder, brain tumor, other major neurological disorder or head injury resulting in loss of consciousness 4. serious oxygen deprivation 5. current psychopathology requiring ongoing treatment with antipsychotic medications, mood stabilizers, benzodiazepines, or anticonvulsants 6. current untreated psychopathology which is rated to be primary in terms of severity (greater than ADHD severity) 7. current treatment with guanfacine.",18.0,40.0,['attention deficit hyperactivity disorder (adhd)']
NCT06928896,Friction or Frictionless: What is the Most Effective Method for Retracting Anterior Teeth?,Friction or Frictionless: What is the Most Effective Method for Retracting Anterior Teeth?,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Angle class I malocclusion on one or both sides * Without any previous orthodontic treatment * Indications for fixed appliances, premolar extraction to create space during treatment * Consented to participate in the study Exclusion Criteria: * History of craniofacial traumas, anomalies, congenital defects, or systemic diseases related to osteogenic metabolisms, e.g. diabetes mellitus, kidney diseases, osseous diseases * Patients took anticoagulant drugs that affected bone metabolism (eg., for example, heparin, warfarin, NSAIDs, cyclosporine, glucocorticoids, medroxyprogesterone acetate, etc.) * Mini screw, and hook failure",16.0,65.0,"['angle class i', 'alveolar bone loss']"
NCT04378296,Economic Evaluation in Teledermatology,Economic Evaluation in Dermatology: Teledermatology Versus Conventional Monitoring of Patients in the Hospital,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * 1\. Be over 18 years old. * 2\. Having any skin disease. * 3\. Accept to participate in the study. Exclusion Criteria: * 1\. Non-dermatological disease. * 2\. Be participating in another study. * 3\. Refuse to participate in the study.,18.0,65.0,['skin diseases']
NCT00289796,"Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine","Assess the Feasibility of an Investigational Vaccination Regimen, Compared to a 3-dose Primary Vaccination With GSK Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib Vaccine) Following Hepatitis B Vaccination at Birth. Primary Vaccination is Followed in the 2nd Year of Life by a Booster Dose of Infanrix-hexa",COMPLETED,INTERVENTIONAL,ALL,"Inclusion criteria For the primary vaccination phase * Healthy newborn male or female infant 2 to 5 days old at the time of the first vaccination \& written informed consent taken from the parents/guardians of the subject * Born at term (gestational age 37-42 weeks) after an uncomplicated pregnancy * Birth weight \>= 2.5 kg and 5 minute Apgar \>= 7 * Mother seronegative for Hepatitis B surface antigen (HBsAg) For the booster vaccination phase * A healthy male or female between, and including, 12 and 23 months of age at the time of booster vaccination who has completed the primary vaccination course in the primary vaccination phase with written informed consent obtained from the parent or guardian of the subject Exclusion criteria For the primary vaccination phase * Mother known or suspected to be seropositive for HIV (testing not required for inclusion) * Planned use of any investigational or non-registered product (drug or vaccine) other than the study vaccines during the study * Planned administration of immuno-suppressants or other immune-modifying drugs, administration of immunoglobulins and/or any blood products since birth or planned administration during the study. * Administration of immunoglobulins and/or any blood products to the mother during pregnancy * Neonatal jaundice requiring parenteral treatment (light therapy for physiological jaundice is allowed) * At risk of pneumococcal disease or planning to receive Prevenar™ during the study period * Administration or planned administration of BCG vaccination during the study period * Acute disease at the time of vaccination. For the booster vaccination phase * Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the booster dose, or planned use during the booster phase. * Evidence of previous diphtheria, tetanus, pertussis, polio, hepatitis B and/or Hib booster vaccination since the study conclusion visit of the primary vaccination phase. * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection. * Administration/ planned administration of a vaccine not foreseen by the study protocol, administration/ planned administration of immunoglobulins and/or any blood products during the period starting 30 days before the administration of the booster dose and ending 30 days after the booster dose. * Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccine dose.""",2.0,5.0,['hepatitis b']
NCT03391596,Internet-based Intervention for Enhancing the Psychological Well-being of Elderly Caregivers,CareACT - Internet-based Intervention for Enhancing the Psychological Well-being of Elderly Caregivers,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria for all groups: * family caregiver * at least 60 years of age Inclusion Criteria for the experimental and active comparator group - depressive symptoms and/or psychological distress Exclusion Criteria for all groups: * parallel psychological treatment * severe mental disorder Additional inclusion criteria for the experimental group: \- computer and Internet connection or willingness to use a tablet provided by the study,60.0,65.0,"['depressive symptoms', 'psychological distress', 'quality of life']"
NCT01240096,Mirtazapine Versus Placebo in Functional Dyspepsia,Phase 4 Study of Mirtazapine in Functional Dyspepsia Patients With Weight Loss,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Functional dyspepsia according to Rome II criteria * Weight loss of \> 5% body weights Exclusion Criteria: * Organic GI pathology * History of upper gi tract surgery * Major depression or anxiety * Use of antidepressants in the last 2 months * Prokinetic drugs or spasmolytic drugs * Analgesic use (except paracetamol) * Pregnancy or lactation,18.0,75.0,['functional dyspepsia']
NCT05246696,Perceptions of Their Own Body and of the Body of Their Child Among Young Mothers With Anorexia Nervosa,Perceptions of Their Own Body and of the Body of Their Child Among Young Mothers With Anorexia Nervosa,WITHDRAWN,OBSERVATIONAL,FEMALE,"Inclusion Criteria: * adult woman, understanding and reading French, delivering in the CHU (Centre Hospitalier Universitaire) Clermont-Ferrand maternity hospital between 01/15/2020 and 01/14/2021, and with active or in remission anorexia nervosa diagnosed according to DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders) * able to accept participating to the study * Affiliated to the national healthcare system Exclusion Criteria: * delivery before 32 weeks of amenorrhea (significant prematurity and extreme prematurity) * death in utero or medically-motivated induced termination * infant death during labour or post-partum * refusal to participate",18.0,65.0,"['anorexia nervosa', 'eating disorders']"
NCT05787496,"A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms","A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. The subject is willing to provide written informed consent for the trial. 2. Be ≥ 18 years of age on the day of signing informed consent. 3. Subject has one of the following Myeloid Neoplasms determined by pathology review at the treating institution: 1. Relapsed or Refractory AML, Note: Active, relapsed, or refractory AML is defined as any one of the following: * Primary induction failure, or (PIF) after 2 or more cycles of therapy, * First early relapse after a remission duration of fewer than 6 months, * Relapse refractory to salvage combination chemotherapy second or subsequent relapse, or * Relapsed or refractory AML with at least 5% blasts by bone marrow biopsy or aspirate, or at least 1% blasts in peripheral blood. 2. Relapsed or Refractory Myelodysplastic syndrome (MDS) after prior hypomethylating agents. Note: Subject must have sub-type MDS-EB2 with 10-19% blasts by bone marrow biopsy or aspirate. 3. Relapsed or Refractory Chronic myelomonocytic leukemia (CMML) with progressive disease or lack of response to hypomethylating agents 4. A male subject must agree to use approved contraception (based on institutional guidelines) and refrain from sperm donation or expecting to father a child, from Screening through the treatment period and for at least 90 days after the last dose of study treatment. 5. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: 1. Not a woman of childbearing potential (WOCBP); 2. A WOCBP agrees to follow approved contraceptive guidance (based on institutional guidelines) from Screening through the treatment period and for at least 90 days after the last dose of study treatment. 6. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. 7. Life expectancy greater than or equal to 12 weeks as judged by the Investigator. 8. Have adequate organ function as defined in the protocol. Exclusion Criteria: 1. Has a diagnosis of acute promyelocytic leukemia (M3, APL), accelerated phase or blast crisis of chronic myeloid leukemia. 2. History or presence of clinically relevant CNS pathology such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis. 3. Patients with active Central Nervous System (CNS) involvement (such as leukemic infiltration, blast in the spinal fluid, or subjects with extramedullary disease). 4. A WOCBP who has a positive pregnancy test (within 72 hours) prior to treatment. 5. History or evidence of any other clinically significant disorder, condition or disease (e.g., symptomatic congestive heart failure, unstable angina pectoris, symptomatic myocardial infection, uncontrolled cardiac arrhythmia, pericardial disease or heart failure New York Heart Association Class III or IV), or severe debilitating pulmonary disease, that would potentially increase patients' risk for toxicity and in the opinion of the Investigator, would pose a risk to patient safety or interfere with the study evaluation, procedures or completion. 6. Chronic respiratory disease or any other medical condition that requires continuous oxygen that in the opinion of the Investigator, would adversely affect his/her participation in this study. 7. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. 8. Is currently participating in or has participated in a study of the following prior to the first dose of study treatment: 1. An investigational biologic or an investigational device within 4 weeks or 5 half-lives (whichever is longer); 2. An investigational oral agent within 2 weeks or 5 half-lives (whichever is shorter). 9. Has not recovered to ≤ Grade 1 from toxic effects of prior therapy (including prior chemotherapy, immunotherapy and radiation therapy) and/or complications from interventions before starting therapy. 10. Has previously had an allogeneic solid organ transplant. 11. Autologous HSCT within 6 weeks before the start of study treatment. 12. Allogeneic HSCT within 6 months before the start of study treatment. 13. Any active acute or chronic graft-versus-host disease (GvHD), grade 2-4, or active chronic GvHD requiring systemic treatment. 14. Any systemic therapy (e.g. calcineurin inhibitors (CNI), steroids, etc.) against GvHD within 4 weeks before the start of study treatment. 15. Any Grade ≥ 2 persistent non-hematological toxicity related to allogeneic transplant, such as those requiring systemic immunosuppressive therapy. 16. Previous CAR-T therapy. 17. Known concurrent malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry after treatment with curative intent. 18. Has severe hypersensitivity (≥ Grade 3), known allergy or reaction to Immunoglobulins or NC525, and/or any of their excipients. 19. Uncontrolled systemic fungal, bacterial, viral, or other infection despite appropriate anti-infection treatment at the time of eligibility confirmation. 20. Has a known history of HIV infection. 21. Has a known active chronic hepatitis B infection or chronic hepatitis C infection with the exception of those with an undetectable viral load within 3 months. 22. Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate, in the opinion of the treating investigator. 23. Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the study.",18.0,65.0,"['relapsed or refractory acute myeloid leukemia', 'relapsed or refractory chronic myelomonocytic leukemia', 'relapsed or refractory myelodysplastic syndrome']"
NCT01839396,Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease,Implantable Neurostimulator for the Treatment of Parkinson's Disease,COMPLETED,INTERVENTIONAL,ALL,"Key Inclusion Criteria: * Diagnosis of bilateral idiopathic PD (H\&Y ≥ 2) with a duration of PD ≥ 5 years. * Persistent disabling Parkinson's disease symptoms or drug side effects (e.g., dyskinesias, motor fluctuations, or disabling ""off"" periods) despite optimal medical therapy. * Able to understand the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed. Key Exclusion Criteria: * Any intracranial abnormality or medical condition that would contraindicate DBS surgery. * Have any significant psychiatric condition likely to compromise the subject's ability to comply with requirements of the study protocol * Any other active implanted devices including neurostimulators and /or drug delivery pumps * Any previous thalamotomy, pallidotomy or subjects who have undergone a DBS procedure. * Have any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints. * A female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception.",22.0,75.0,"[""parkinson's disease""]"
NCT06615596,Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation,Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation: DESTINATION Study,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age ≥18 years * Diagnosed paroxysmal, persistent, or longstanding persistent AF * Successful procedure (defined as restoration of sinus rhythm after PV isolation for paroxysmal AF, restoration of sinus rhythm after PV isolation and completion of additional ablation for persistent AF, according to 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation) and no recurrence within 3 months of ablation, using a cooled tip RF-, laser- or cryo-balloon-catheter * No periprocedural complications * Signed informed consent * Male with CHA2DS2-VASC score ≥1, female with score ≥2. Exclusion Criteria: * Valvular AF (moderate- severe mitral insufficiency; relevant mitral stenosis with a mean pressure gradient \&gt;5mmHg) * Reversible AF (e.g. uncontrolled hyperthyroidism) * Prior AF ablation (including surgical ablation) * History of left atrial appendage occlusion/ligation/excision * Concomitant surgical ablation * Left atrial diameter \&gt;50 mm * Left atrial or LAA thrombus * Pregnancy/breast feeding * Women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception throughout the study * Patient has a non-arrhythmic condition necessitating long-term oral anticoagulation (i.e. PE, ventricular thrombus, peripheral thrombosis, etc) * Recent myocardial infarction, NYHA class IV heart failure, patent foramen ovale, recent trauma or other prothrombotic conditions * Patient with special risk factors for stroke unrelated to AF, specifically known thrombophilia/ hypercoagulability, uncontrolled hypertension (systolic blood pressure \&gt;180 mmHg and/or diastolic blood pressure \&gt;100 mmHg within 4 days of enrollment), untreated familial hyperlipidemia, known vascular anomaly (intracranial aneurysm/ arteriovenous malformation or chronic vascular dissection), or known severe carotid disease. * Patient has bleeding contra-indication to oral anticoagulation (such as bleeding diathesis, hemorrhagic disorder, significant gastrointestinal bleeding within 6 months, intracranial/intraocular/ atraumatic bleeding history, fibrinolysis within 48 hours of enrollment). * Patient has other contraindication to oral anticoagulation or treatment with antiplatelet agent * Patient has been on strong CYP3A inducers (such as rifampicin, phenytoin, phenobarbital, or carbamazepine) or strong CYP3A inhibitors (such as ketoconazole or protease inhibitors) within 4 days of enrolment * Structural congenital heart disease * Recent stroke or intracranial hemorrhage within 6 months * Inability to adequately understand nature, significance, implications and risks of study precipitation and to comply with follow-up (i.e. bipolar disorders, severe depression, suicidal tendencies, among others) as judged by the local physician, ongoing drug or alcohol addiction (\&gt; 8 drinks/week) * Patients who are \&gt; 85 years of age * Patients who are critically ill or who have a life expectancy \&lt;3 years * Patient is unable or unwilling to provide informed consent * Patient is included in another randomized clinical trial or a clinical trial requiring an insurance",18.0,65.0,['atrial fibrillation (af)']
NCT05990296,"Evaluating Strategies to Improve Guideline Directed Medical Therapy: The GDMT Research, Education & Assist Trial for Heart Failure Care","Evaluating Strategies to Improve Guideline Directed Medical Therapy: The GDMT Research, Education & Assist Trial for Heart Failure Care (GREAT-HF Care)",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients aged 18 years or older AND * Completed visit at included Geisinger cardiology outpatient clinics (office visit or telemedicine) AND * Clinicians are on a list of currently active Geisinger clinicians in outpatient cardiology clinics who can prescribe heart failure medications AND * Active problem list diagnosis of HFrEF at time of Cardiology clinic encounter OR Left Ventricular Ejection Fraction (LVEF) \< 40: most recent to the cardiology clinic encounter within 2 years of the visit. Exclusion Criteria: * Currently in hospice or palliative care (ICD 10 code: Z51.5) * Patient is allergic to each category of GDMT * Patient is prescribed medications from all four categories of GDMT, including ARNI specifically",18.0,65.0,"['heart failure', 'heart failure with reduced ejection fraction']"
NCT05592496,Bilateral Retromuscular Rectus Sheath Block Catheters Usage for Early Postoperative Analgesia After Laparotomic Gastrectomy.,Bilateral Retromuscular Rectus Sheath Block Catheters Usage for Early Postoperative Analgesia After Laparotomic Gastrectomy.,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Open Laparotomy and gastrectomy Exclusion Criteria: * acute surgery,18.0,65.0,['postoperative pain']
NCT03927196,Primary Prevention Program,The Program to Assess the Influence of Routing and Extended Statin Counseling of Patient With Cardiovascular Risk Factors on the Choice of Medicine and Treatment Compliance,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: Men and women 40-65 years old with the presence of: * moderate cardiovascular risk (\ 50% in the absence cerebrovascular diseases and the level of cholesterol-LDL ≥1.8 mmol / l, which do not have contraindications to taking statins and not taking drugs of this group in currently. Exclusion Criteria: * The presence of the following clinically significant events in anamnesis: myocardial infarction, stroke, myocardial infarction * The presence of the following diseases at the time of statin administration: ischemic heart disease; heart failure; atherosclerotic disease of peripheral arteries; atherosclerotic stenosis of the brachiocephalic arteries in the presence of cerebrovascular disease; chronic renal failure with creatinine clearance \<30 ml / min; liver disease with an increase in AST and ALT levels of more than 3 times, compared to the upper limit of normal; history of muscular or neuromuscular diseases, with elevated CPK; alcoholism, oncological, mental and other severe concomitant diseases; intolerance to statins in anamnesis; use of other lipid-modifying agents.",40.0,65.0,['primary prevention of cardiovascular disease']
NCT05596396,The Caring Universities Project: LifeHack,"Feasibility and Acceptability of a Guided E-health Program (LifeHack), With and Without a Fixed Structure, to Improve Well-being in University Students.",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: To be eligible to participate in this trial, a subject must meet all the following criteria: * Being fluent in Dutch and/or English * Being enrolled as a student of the seven participating universities * Being 16 years of age or older * Having access to a PC or mobile device with internet access * Provide informed consent before participation Exclusion Criteria: * None. All interested students are eligible to participate.",16.0,65.0,['well-being']
NCT01474096,Implementation Strategy for a Breastfeeding Guideline in Primary Care,Effectiveness of Implementation Strategy for a Breastfeeding Guideline in Primary Care: Cluster Randomised Trial,COMPLETED,INTERVENTIONAL,FEMALE,Inclusion Criteria: * Mothers of children born during the study period (6 months) * Mothers who come to the health centre on 1st visit (child attention programme) * Mothers who give their consent to participate. Exclusion Criteria: * Breastfeeding Contraindications,18.0,65.0,['breastfeeding']
NCT06501196,A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome,"A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)",RECRUITING,INTERVENTIONAL,ALL,"Inclusion criteria: * ≥18 years. * Diagnosis of relapsed/refractory acute myelogenous leukemia (R/R) AML or higher-risk myelodysplastic syndrome (HR-MDS) with ≥5% bone marrow blast at time of inclusion. * Prior treatment history must include 1-5 prior lines of therapy. * ECOG performance status ≤2. * Adequate organ function evidenced by the following laboratory values: * Hepatic: Transaminase levels aspartate aminotransferase \[AST\]/ alanine transaminase \[ALT\] ≤ 2.5 × upper limit of normal (ULN). In cases of liver involvement by AML or MDS, AST and ALT \< 5.0 × ULN is acceptable. Total bilirubin ≤ 1.5 × ULN in the absence of documented Gilbert's disease. * Renal: Measured or calculated creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula) The above are a summary, other inclusion criteria details may apply. Exclusion Criteria: * Diagnosis of acute promyelocytic leukemia or chronic myeloid leukemia with blast crisis. * Prior allogeneic HSCT within 3 months or donor lymphocyte infusion within 30 days of start of therapy; * Active and uncontrolled infections. * Unresolved AEs greater than Grade from prior therapies. * History of other active malignancy (with certain exceptions) * Prior treatment with a CLK inhibitor. * Any acute or chronic graft versus host disease requiring systemic therapy within 4 weeks prior to study drug administration with the exception of topical steroids or the equivalent of 20 mg of prednisone or less. The above is a summary, other exclusion criteria details may apply.",18.0,65.0,"['leukemia', 'leukemia, myeloid', 'leukemia, myeloid, acute', 'preleukemia', 'myelodysplastic syndromes', 'refractory acute myeloid leukemia']"
NCT01897896,Alternatives for Reducing Chorea in Huntington Disease,"An Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington Disease",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Participant is at least 18 years of age or the age of majority (whichever is older) at Screening. * Participant has been diagnosed with manifest HD, as indicated by characteristic motor exam features, and has a documented expanded cytosine adenine guanine (CAG) repeat (greater than or equal to \>= \[37\]) at or before Screening. * Participant meets either of the following: 1. Has successfully completed participation in the First-HD Study (SD-809-C-15) or 2. Has been receiving an Food and Drug Administration (FDA)-approved dose of tetrabenazine that has been stable for \>=8 weeks before Screening and is providing a therapeutic benefit for control of chorea. * Participant has a Total Functional Capacity (TFC) score \>=5 at Screening. * Participant is able to swallow study medication whole. * Participant has provided written, informed consent or, a legally authorized representative (LAR) has provided written informed consent and the subject has provided assent. * Participant has provided a Research Advance Directive. * Female participants of childbearing potential agree to use an acceptable method of contraception from screening through study completion. * The participant has a reliable caregiver who interacts with the participant on a daily basis, oversees study drug administration, assures attendance at study visits and participates in evaluations, as required. * Participant is able to ambulate without assistance for at least 20 yards (Note: The use of assistive devices (such as; walker, cane) are permitted during ambulation). * Has sufficient reading skills to comprehend the participant completed rating scales. Exclusion Criteria: * Participant has a serious untreated or under-treated psychiatric illness, such as depression, at Screening or Baseline. * Participant has active suicidal ideation at Screening or Baseline. * Participant has history of suicidal behavior at Screening or Baseline. * Participant has evidence for depression at Baseline. * Participant has an unstable or serious medical illness at Screening or Baseline. * Participant has received tetrabenazine within 7 days of Baseline (Rollover participants only). * Participant has received any of the following concomitant medications within 30 days of Screening or Baseline: Antipsychotics, Metoclopramide, Monoamine oxidase inhibitors (MAOI), Levodopa or dopamine agonists, Reserpine, Amantadine, Memantine (Rollover participants only) * Switch participants may receive Memantine if on a stable, approved dose for at least 30 days * Participant has significantly impaired swallowing function at Screening or Baseline. * Participant has significantly impaired speaking at Screening or Baseline. * Participant requires treatment with drugs known to prolong the QT interval. * Participant has prolonged QT interval on 12-lead electrocardiogram (ECG) at Screening. * Participant has evidence of hepatic impairment at Screening. * Participant has evidence of significant renal impairment at Screening. * Participant has known allergy to any of the components of study medication. * Participant has participated in an investigational drug or device trial other than SD-809-C-15 within 30 days (or 5 drug half-lives) of Screening, whichever is longer. * Participant is pregnant or breast-feeding at Screening or Baseline. * Participant acknowledges present use of illicit drugs at Screening or Baseline. * Participant has a history of alcohol or substance abuse in the previous 12 months.",18.0,65.0,['chorea associated with huntington disease']
NCT04742062,First in Human Clinical Trial of ApTOLL in Healthy Volunteers,"First in Human Dose Ascending, Randomized, Placebo-Controlled Clinical Trial to Assess Tolerability and Pharmacokinetics of ApTOLL in Healthy Volunteers",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Male or female subjects (women without possibility of becoming pregnant) willing and able to give their written consent to participate in the trial. 2. Healthy subjects aged within: 18 to 55 years (limits included). 3. Clinical history and physical examination results within normality. 4. Vital signs and electrocardiogram without clinically significant pathologic abnormalities and with QTc (Corrected QT space) values lower than 450 ms. 5. Body weight between 65 and 85 kg, inclusive. 6. BMI (Body Mass Index) between 19.0 and 30.0 kg/m2. 7. No clinically significant abnormalities in haematology, biochemistry, serology (Ag HBV (Hepatitis B Virus), HCV (Hepatitis C Virus) antibodies, HIV (Human Immunodeficiency Virus) antibodies) and urine tests. Exclusion Criteria: 1. Any chronic medical condition (such as type 1 diabetes) requiring chronic treatment. 2. Evidence of active infection requiring antibiotic therapy within 14 days prior to screening. 3. Medical history of vasculitis or any autoimmune disease excluding seasonal allergic rhinitis and childhood history of atopic dermatitis. 4. Subject having at screening examination a sitting blood pressure more than or equal to 140/90 mm Hg or lower than or equal to 90/50 mmHg. 5. Subject having at screening examination a pulse more than 100 beats per minute or a body temperature more than 37.7 °C. or a respiratory rate outside the normal range of (14-20 breath per minute). 6. History of any treatment for cancer within the past 2 years, other than basal cell or squamous cell carcinoma of the skin. 7. Clinically significant abnormalities in screening laboratory tests. 8. Any prescription, over-the-counter and herbal medications within 10 days prior to study dosing. 9. Use of an investigational drug within 3 months prior to dosing in this study. 10. Psychiatric history of current or past psychosis, bipolar disorder, clinical depression, or anxiety disorder requiring chronic medication within the past 5 years. 11. Pregnant or breastfeeding women. 12. History of substance abuse, including alcohol. 13. Smokers. 14. History of substance or drug dependence, or positive urine drug screen at screening visit. 15. History of head injury. 16. History of sensitivity to any drug. 17. Having donated blood in the last month before start of the study. 18. Any reason or opinion of the investigator that would prevent the subject from participation in the study. 19. Inability to follow the instructions or an unwillingness to collaborate during the study.",18.0,55.0,['stroke']
NCT06924762,Interleukin-2 for Refractory Chronic Spontaneous Urticaria,"Efficacy and Safety of Interleukin-2 Treatment in Moderate to Severe Chronic Spontaneous Urticaria With Poor Control by Antihistamines: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Gender: Not limited; Age: at least 18 years old and less than 75 years old; 2. Diagnosed with chronic spontaneous urticaria (CSU) (including patients overlapped with chronic inducible urticaria) according to the 2021 EAACI/GA²LEN/EDF/AAAAI guidelines; 3. Disease course of CSU for at least 12 weeks; 4. The patient has been treated with second-generation antihistamines (one or more types, up to 4 tablets per day) every day for 2 weeks or more but still experiences significant symptoms of wheals and/or itching, with a UAS7 score ≥16 or a UCT score \<12; 5. UAS7 ≥16 on the date prior to randomization (according to complete daily symptom log data recorded in the past 7 days before randomization); 6. Willing and able to complete daily symptom logs throughout the entire study period; 7. The patient voluntarily consents to participate in this research project and has signed the informed consent. Exclusion Criteria: * Pregnant or breastfeeding women, or women planning to conceive within 6 months; * Has used corticosteroids, immunosuppressants, leukotriene receptor antagonists, H2 receptor antagonists, intravenous immunoglobulin (IVIG) therapy, and/or undergone plasma exchange in the past 4 weeks; * Has received omalizumab or other biologic treatments in the past 12 weeks; * Has previously undergone interleukin-2 treatment; * Has a history of anaphylactic shock; * Plans or anticipates the use of any prohibited drugs or treatments during the screening and/or treatment periods; * Currently has active or recurrent severe infections, such as active tuberculosis; * Has a congenital or acquired immunodeficiency disorder; * Has a history of drug or alcohol abuse, mental disorders, or poor compliance, making them unable to adhere to treatment; * Currently enrolled in another clinical trial; * Is an employee of the clinical research facility or directly involved in the study, or is an immediate family member of such an individual; * Any other reason that makes participation in this trial inappropriate.",18.0,74.0,['chronic spontaneous uriticaria']
NCT01022762,Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment,"A 16-week, Multicentre, Randomised, Open-label, Parallel Group Study to Investigate the Efficacy and Safety Profiles of Repaglinide Monotherapy Compared to Gliclazide Monotherapy in Chinese Antidiabetic-naïve Subjects With Type 2 Diabetes",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Type 2 diabetes * Oral anti-diabetic drug (OAD) naïve (unsystematic OAD treatment 6 months prior to this trial is allowed) * Insulin naïve (less than 1 week of daily use of insulin therapy before trial start is allowed) * Lipid-lowing agent naïve * HbA1c: 6.5-8.5% * Fasting glucose: 6.1-13.0 mmol/L (110-234 mg/dl) * Body Mass Index (BMI): 20-35 kg/m\^2 * Be able and willing to perform self-monitored plasma glucose (SMPG) * Be able and willing to eat 3 main meals per day * Only applicable to subjects who will participate in the subgroup study: Be able and willing to perform and complete IVGTT (intravenous glucose tolerance test) at additional visits Exclusion Criteria: * Known or suspected allergy to repaglinide, gliclazide, or related products (for example sulfonamide or other sulphonylureas (SUs)), or any of the excipients in the study drugs * Previous participation in this study * Participation in a study of another investigational drug within 1 month prior to study start",18.0,75.0,"['diabetes', 'diabetes mellitus, type 2']"
NCT02927262,"A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission","A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FLT3/ITD AML in First Complete Remission",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Subject is considered an adult according to local regulation at the time of obtaining consent form (ICF). * Subject consents to allow access to subject's diagnostic bone marrow aspirate or peripheral blood sample and/or the DNA derived from that sample, if available, that may be used to validate a companion diagnostic test for gilteritinib. * Subject has confirmed morphologically documented AML, excluding acute promyelocytic leukemia (APL), in CR1 (including CRp and CRi). For the purposes of enrollment, CR will be defined as \ 40 mL/min/1.73m\^2 as calculated with the 4-parameter Modification of Diet in Renal Disease (MDRD) equation. * Serum total bilirubin ≤ 2.5 mg/dL (43 μmol/L), except for subjects with Gilbert's syndrome. * Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \ 450 msec (average of triplicate determinations based on central reading). * Subject with Long QT Syndrome. * Subject with hypokalemia and hypomagnesemia at screening (defined as values below LLN). * Subject has clinically active central nervous system leukemia. * Subject is known to have human immunodeficiency virus infection. * Subject has active hepatitis B or C. * Subject has an uncontrolled infection. If a bacterial or viral infection is present, the subject must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to randomization. If a fungal infection is present, the subject must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to randomization. * Subject has progressing infection defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection. * Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, congestive heart failure New York Heart Association (NYHA) class 3 or 4 or subject has a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 1 month prior to study entry results in a left ventricular ejection fraction that is ≥ 45%. * Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP) 3A. * Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P-glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject. * Subject requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject. * Subject has a serious medical or psychiatric illness likely to interfere with participation in this clinical study. * Subject has prior malignancies, except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent \< 5 years previously will not be allowed. * Subject has any condition which makes the subject unsuitable for study participation.",18.0,65.0,"['acute myeloid leukemia (aml)', 'acute myeloid leukemia with fms-like tyrosine kinase (flt3) / internal tandem duplication (itd) mutation']"
NCT05125562,Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19: A Phase II Clinical Trial,WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Eligibility for study enrollment includes meeting all the following criteria: Provision of signed and dated informed consent form (either by the individual or by the individual's healthcare proxy). Stated willingness to comply with all study procedures and availability for the duration of the study. Male or female aged 18-85. COVID-19 positive as defined by positive Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) SARS-CoV-2 determination \ 35 Have chronic kidney disease Have diabetes Have immunosuppressive disease Are currently receiving immunosuppressive treatment Are \>65 years of age Are \>55 years of age AND have Cardiovascular disease, OR Hypertension, OR Chronic obstructive pulmonary disease/other chronic respiratory disease. Patients who received SARS-CoV-2 monoclonal antibody treatment will be excluded from the study. Vital sign abnormalities: temperature ≥ 38 °C, temperature \< 35 °C; systolic blood pressure (SBP) \< 90 mmHg, SBP ≥ 170 mmHg; diastolic blood pressure (DBP) \< 50 mmHg, DBP ≥ 100 mmHg; heart rate (HR) \< 50 beats per minute (BPM), HR ≥ 120 BPM. Lab abnormalities: WBC ≥ 12,000 /μL, Creatinine ≥ 1.5 mg/dL, AST ≥ 100 IU/l, and/or ALT ≥ 100 IU/I Patients who received COVID-19 vaccination within last 28 days.",18.0,85.0,['covid-19']
NCT01819662,Optimised Pacing Program,Stratified Management of Patients With Pacemakers,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Pacemaker implantation Exclusion Criteria: * Dementia, unwilling to fill in quality of life questionnaires, unwilling to sign consent form",16.0,65.0,"['pacemaker complication', 'congestive heart failure']"
NCT01966562,PAHA Study: Psychological Active and Healthy Ageing,"Psychological Well Being, Proactive Attitude and Happiness Effects of Whole-body Vibration vs. Multi-component Training in Aged Women: a Randomized Controlled-trial Study Protocol",COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Women; * Age ranged between 55-75 years old. Exclusion Criteria: * Male sex; * Age lower than 55 years old; * Present levels of DMO lower than 70 g/cm2; * Being treated for a disease that can affect bone structure or neuromuscular system; * Have orthopedic prosthetic implants in the lower limbs and / or spine; Have herniated discs; * Suffer ocular diseases that affect the retina; * Suffer severe cardiovascular diseases; * Have a pacemaker, or osteosynthesis material; * Severe mental illness (active psychosis/suicide risk/severe dementia); * Linguistic limitations (such as stuttering/untreated audio impairment); * A significant functional problem (such as unconsciousness/connection to respiration device/confinement to a wheelchair or bed/severe walking disability/need of help with basic daily activities), major depression, anxiety according to DSM-IV criteria.",55.0,75.0,['aged']
NCT02461862,Vital Signs and Pain During Insertion of IUD,Assessment of Vital Signs and Pain During Insertion of Intra Uterine Device,COMPLETED,OBSERVATIONAL,FEMALE,Inclusion Criteria: * age older than 18 years * cytology without abnormalities * classification for Category 1 or 2 of the WHO eligibility criteria for IUD / IUS. Exclusion Criteria: * patients with cardiac arrhythmias * gynecological disorders,18.0,60.0,"['contraception', 'acute pain']"
NCT00424762,Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride,Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * type 2 diabetes mellitus (prior clinical diagnosis and current use of hypoglycemic medical therapy or by new diagnosis according to ADA criteria) with at least one of the following: * prior diagnosis of cardiovascular disease (CAD, MI, revascularization, CVA/TIA, carotid or peripheral arterial disease) * at least one additional CVD risk factor (smoking, hypertension, hypercholesterolemia, albuminuria, family history of premature CAD, or documented hsCRP\>3) Exclusion Criteria: * treatment with a TZD within prior 6 months * documented intolerance to TZD * history or evidence of CHF * AST/ALT\>3X upper limits of normal * creatinine \>2.5",18.0,65.0,"['diabetes mellitus, type 2']"
NCT04086862,Effect of Ultrasound Therapy on Bilateral Masseter Myalgia: Comparison of 1 Megahertz Versus 3 Megahertz,Effect of Ultrasound Therapy on Bilateral Masseter Myalgia: Comparison of 1 Megahertz Versus 3 Megahertz,COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Adult females * Bilateral myalgia based on Diagnostic Criteria for TMD (DC-TMD) criteria * An average pain of 5 or more on a 0 to 10 scale over the last 30 days. Exclusion Criteria: * A history or diagnosis of systemic musculoskeletal disorders or rheumatologic diseases (e.g. fibromyalgia, muscular atrophy). * Certain conditions such as neoplasms or fractures. * Neuropathies or neurological disorders. * Currently taking muscle relaxants or analgesics. * Undergone any form of physical therapy within the last 60 days. * Severe bruxism requiring mouth-guard treatment.",18.0,65.0,"['adult females', 'bilateral masseter myalgia']"
NCT01009762,Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection,Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * HIV-1 seropositive with measurable viral load \>10e3 copies/ml and CD4+ T-cell count \>400 CD4+ cells/µl * Not in Antiretroviral Therapy (\>1 year) * Male or female with age between 18 and 60 years, where females are not breastfeeding, are not pregnant and use contraception until at least 3 months after end of vaccinations * Normal values for the area of liver and kidney enzymes, blood cell count with differential counts e.g. white blood cells, lymphocytes, platelets, thrombocytes, and Hemoglobin * Expected to follow the instructions * Written informed consent after oral and written information Exclusion criteria: * Vaccinated with other experimental vaccines within 3 months before the first vaccination * Treated with immune modulating medicine within 3 month before the first immunization * Other significant active chronic infectious diseases likely to influence the HIV-1 infection, like Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) * Significant medical disease as judged by the investigators, for example severe asthma/chronic obstructive lung disease (COLD), badly regulated heart disease, insulin-dependent diabetes mellitus * Severe allergy or earlier anaphylactic reactions * Active autoimmune diseases * Simultaneous treatment with other experimental drugs * Laboratory parameters outside the 'normal' range for the area and which are considered clinically significant * Pregnancy and/or brest feeding",18.0,60.0,['hiv infections']
NCT02538146,Effect of Acetyl-L-carnitine on Chronic Pancreatitis,Acetyl-L-carnitine as Pain Therapy in Chronic Pancreatitis,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Only patients with chronic pancreatitis are included. Exclusion Criteria: * Patients with pancreatic pseudocysts, abscesses, pseudoaneurysms, pancreatitic fistulas, pancreatic adenocarcinoma, * Females that are pregnant or lactating * Children are excluded. * Patients suffering from seizure or thyroid disorders are also excluded due to possible exaggeration of their symptoms from taking ALC according to manufacturer.",20.0,90.0,['chronic pancreatitis']
NCT01529346,Efficacy Of PF-05089771 In Treating Postoperative Dental Pain,"A Randomized, Double-blind, Double-dummy, Parallel Group, Placebo Controlled Study Assessing The Efficacy Of Single Doses Of Pf-05089771 For The Treatment Of Postoperative Dental Pain Using Ibuprofen 400 Mg As Positive Control",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Oral surgery having removed 2 unilateral third molar teeth. * Pre-dose pain intensity score (100 mm VAS \[VAS\]) of at least 50mm within 5 hours of oral surgery * Pre-dose pain intensity score of moderate or severe within 5 hours of oral surgery Exclusion Criteria: * Presence or known history of any clinically significant hematological, hepatic, renal, endocrine, cardiovascular, neurological, psychiatric, gastrointestinal, pulmonary, allergic (including known drug hypersensitivities or allergies, but excluding untreated asymptomatic seasonal allergy) or any metabolic disorder that may increase risk associated with study participation, investigational drug administration or may interfere with interpretation of study results. * Prior use of any type of analgesic or NSAID within 5-half lives of that drug or less before taking the first dose of study medication, except for anesthesia for the procedure. * Active dental infection at the time of surgery. * Recent (within the previous 12 months) history of chronic analgesic or tranquiliser dependency. * Any significant oral surgery complication at the time of surgery or in the immediate postoperative period, or oral surgery that has lasted more than 30 minutes (time from first incision to last suture placement). Subjects who smoke more than 1 pack (20 cigarettes) per day, more than 3 cigars per day or use smokeless tobacco on a daily basis are excluded from the study.",18.0,55.0,['postoperative dental pain']
NCT01927146,Lauren Classifications and HER2 Status in Gastric Cancer Patients,Retrospective Study of Lauren Classifications and HER2 Status in Chinese Patients With Resectable Gastric Adenocarcinoma,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: 1. Patients' admission date: 1996-2006. 2. Histologically confirmed gastric adenocarcinoma patients and underwent gastrectomy. 3. Adequate paraffin- embedded tumor tissue sample for pathologic and human epidermal growth factor receptor 2 (HER2) status analysis. 4. Integrity medical records with regular survival follow up, the overall survival (OS) could be sourced. Exclusion Criteria: 1. Age\<18 years old. 2. Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma.",18.0,65.0,['gastric cancer']
NCT01772446,Effectiveness of SMS in Diabetes Control,Effectiveness of Sending Sms Text Messages to Mobile Phone Patients to Remind Upcoming Appointments and Improve the Control of Diabetic Patients in Primary Care,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Type 2 diabetic patients with or without hypertension or lipid metabolism disorder, * Aged between 35 and 74 years old with or without hypertension or lipid metabolism disorder, * Mobile phone holder, * Able to read messages via mobile phone. Exclusion criteria: * Pregnant women, * Patients whose next date for HbA1c control is less than 2 months * Patients with HbA1c \<7%",35.0,74.0,['diabetes']
NCT00002646,Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer,"PHASE III DOUBLE-BLIND, PLACEBO-CONTROLLED, PROSPECTIVE RANDOMIZED COMPARISON OF ADJUVANT THERAPY WITH TAMOXIFEN VS. TAMOXIFEN AND FENRETINIDE IN POSTMENOPAUSAL WOMEN WITH INVOLVED AXILLARY LYMPH NODES AND POSITIVE RECEPTORS",COMPLETED,INTERVENTIONAL,FEMALE,"DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the breast Pathologic stage T1-3, N1-2, M0 No clinical or pathologic T4 disease No primary tumor fixed to chest wall No axillary nodes fixed to chest wall or neurovascular bundle No preoperative arm edema No clinical skin involvement (microscopic focal dermal invasion or dermal lymphatic involvement eligible) No clinical N2 disease Modified radical mastectomy or lumpectomy required prior to entry Sentinel node biopsy allowed Randomization required within 12 weeks from definitive surgery Surgery dated from mastectomy or axillary dissection for lumpectomy No positive deep mastectomy margins Radiotherapy planned within 12 weeks following axillary node dissection for lumpectomy patients Synchronous bilateral breast cancer eligible If tumor is at least 2 cm, then nodes not involved If no tumor is at least 2 cm, then at least 1 node must be involved Both invasive primaries receptor-positive Previously treated, noninvasive breast cancer eligible No prior invasive breast cancer No adenoid cystic, squamous, or sarcomatous histology Hormone receptor status: Estrogen- or progesterone-receptor positive, i.e.: At least 10 fmole/mg cytosol protein by ligand-binding assay OR Receptor positive by immunocytochemistry PATIENT CHARACTERISTICS: Age: 65 and over OR Postmenopausal and ineligible/inappropriate for or declined other active node positive adjuvant studies Sex: Female Menopausal status: Postmenopausal, defined as: At least 1 year since last menstrual period Hysterectomized with bilateral oophorectomy Hysterectomized with 1 or both ovaries remaining and either: Over 60 FSH in postmenopausal range Not surgically castrated, under 60, and on HRT FSH elevated 2 weeks after HRT discontinued Performance status: Not specified Life expectancy: At least 7 years except for breast cancer Hematopoietic: WBC greater than 3,000/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than 1.5 mg/dL AST less than 2 times normal Renal: Creatinine no greater than 2.0 mg/dL BUN no greater than 25.0 mg/dL Other: No extensive macular degeneration on exam within 1 year of entry, e.g.: No exudative or atrophic macular lesions that reduce corrected vision to less than 20/40 Health adequate for protocol treatment No nutritional supplementation except single daily multivitamin No other vitamin A supplements Gynecologic exam within the past year required of women who retain a uterus No second malignancy within the past 10 years except: Inactive nonmelanomatous skin cancer Carcinoma in situ of the cervix Prior noninvasive contralateral breast cancer PRIOR CONCURRENT THERAPY: No prior chemotherapy or hormonal therapy for breast cancer except: Up to 1 month of tamoxifen if started by a non participating physician At least 2 weeks since hormone replacement therapy No concurrent megestrol",18.0,65.0,['breast cancer']
NCT05766046,Lung Cancer Prevention Screening Programme in Italy,Early Diagnosis of Lung Cancer of the Italian Pulmonary Screening Network (RISP): Comparative Analysis for the Use of Low Dose Computed Tomography and Promotion of Primary Prevention Interventions in Subjects at High Risk for Lung Cancer,RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * Active smoker (≥ 30 packs/year) * Former heavy smoker for ≤ 15 years (≥ 30 packs/year) * Absence of tumors for at least 5 years * Signature of informed consent for studio enrollment and processing of personal data Exclusion Criteria: * Severe chronic disease (e.g. severe respiratory and/or renal and/or hepatic and/or cardiac failure) * Severe psychiatric problems * Abuse of alcohol or other substances (including previous),55.0,75.0,"['lung cancer', 'copd (chronic obstructive pulmonary disease) with acute lower respiratory infection', 'cardiovascular diseases']"
NCT05789446,Confirmatory Efficacy of the Building a Strong Identity and Coping Skills Program,Confirmatory Efficacy of the Building a Strong Identity and Coping Skills Program for Low-income and Minoritized Young Adolescents,RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * Children ages 11-14 at intake * Family income at or below 200% federal poverty level * Child speaks English * Parent speaks English or Spanish Exclusion Criteria: * Intellectual disability * Autism spectrum disorder * High suicidal risk (score of 17 or more on the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-Kid)) * Severe depression (score of 19 or more on Patient health questionnaire (PHQ).,11.0,65.0,"['chronic stress', 'anxiety', 'depression']"
NCT05691946,Acute Effects of Kinesiology Taping in Handball Players,Acute Effects of Kinesiology Taping On Functional Performance And Physical Parameters In Handball Players: Randomised Placebo-Controlled Trial,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Licensed handball player * Volunteer to participate the study Exclusion Criteria: * Any discomfort that is contraindicated for the measurements * Have suffered any injury in the last 6 months,18.0,35.0,['kinesiology taping']
NCT00735046,Cognitive Behavioural Therapy of Early Dementia,Cognitive Behavioural Resource-based Therapy of Early Dementia in the Everyday Setting,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Mild dementia (MMSE \> 21) in Alzheimer's disease (ICD-10), proxy available Exclusion Criteria: * Acute of unstable psychiatric or physical disease, proxy unavailable * Participation in another trial",18.0,95.0,['dementia']
NCT02590146,Non-Pharmacologic Patient Centered Pain Control Adjuncts During First Trimester Abortion,Non-Pharmacologic Patient Centered Pain Control Adjuncts During First Trimester Abortion,COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * English speaking, able to read and understand consent form * Age 18 + (minors eligible with parental consent) * Seeking in-office aspiration termination of pregnancy * Gestational age less than 14 weeks Exclusion Criteria: * Not able to read or understand English * Unable to understand consent * Minors without parental consent * Requesting narcotic or sedative analgesics * Currently incarcerated * Gestational age greater than 14 weeks * Seeking medication abortion",18.0,65.0,"['pregnancy termination', 'pain management']"
NCT02976246,Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients,"Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients: A Prospective, Randomized Placebo-controlled Double Blind Trial",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age ≥ 18 years old * Life expectancy \> 2 years * Written consent following oral information * Permanent treatment with dialysis ≥ 3 months with either peritoneal or hemodialysis Exclusion Criteria: * Treatment with vitamin K or vitamin K-antagonist by the beginning of the trial or 1 months within. * Chronic GI-malabsorption leading to a slower bowel transit (e.g. Celiac disease, Short bowel syndrome). * Ongoing malignancy (ongoing treatment/clinical controlled visits or diagnosed less than 5 years ago), excl. Non-Melanoma-Skin-Cancer (NMSC). * Abuse of alcohol or other euphoric drug. * Women who are pregnant or breast-feeding and women who are in the childbearing age without contraception. * Total/subtotal parathyroidectomy * Treatment with recombined PTH. * Treatment with bisphosphonates or other anti-osteoporotic drugs (Selective Estrogen Reuptake Modulators (SERM), strontium, renalat, denosumab). Only RenaKvit-kar (vessel): * Atrial fibrillation/other arrhythmia of significance * Aortic stenosis of significance * Agatston score \< 100 by heart-CT-scan * Bilateral upper arm fistula * Amputation above metatarsal level Criteria of withdrawal: * Kidney transplantation * Starting treatment with vitamin K-antagonists * Wish to with draw from the participant * Unacceptable side effect to ingestion of vitamin K or placebo * Reasonable suspicion of lacking compliance regarding medication",18.0,65.0,"['vitamin k supplementation', 'endstage renal disease', 'cardiovascular disease', 'bone disease']"
NCT00416546,"Safety of AEB071 in Healthy Volunteers and to Compare the Ethnicity, Metabolic, and Safety Effects Between Caucasian and Japanese Healthy Subjects","A Double Blind, Randomized, Placebo-Controlled Study of AEB071 in Healthy Volunteers to Evaluate the Safety/Tolerability of 14 Day Multiple-Dose AEB071 and Measure the Effect of Ethnicity on Pharmacokinetics, Pharmacodynamics and Safety/Tolerability in Caucasian and Japanese Subjects Receiving Single and Multiple Doses of AEB071",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Healthy, male or female subjects having provided written, informed, consent before entering the study. Light smokers (≤10 cigarettes/day) will be eligible for inclusion in this study. Smokers will be defined as any subject who reports cigarette use or has a urine cotinine greater than 500 ng/mL. * Female subjects must be either surgically sterilized at least 6 months or practicing an acceptable form of birth control (i.e. double barrier method - intrauterine device plus condom, spermicidal gel plus condom). * Subjects must have a body weight between 45 and 90 kg and a body mass index (BMI) between 18-28 kg/m2. * Japanese subjects of 1st, 2nd, or 3rd generation ethnic origin or Caucasian. * Japanese subjects will be defined as being of Japanese ethnicity with all 4 grandparents of Japanese descent. Generations will be defined as follows: * 'First generation' Japanese are subjects who were born in Japan to parents of Japanese ethnicity. * 'Second generation' will be defined as subjects who were born outside of Japan to 1st generation Japanese parents. * 'Third generation' will be defined as subjects born outside of Japan to 2nd generation Japanese parents, i.e. 4 grandparents from Japan but both parents and subject born elsewhere. * Caucasians are defined as subjects with all four grandparents of European descent. Exclusion Criteria: * Presence and/or history of a clinically significant illness within two weeks prior to dosing, history of drug or alcohol abuse within the 12 months prior to dosing, use of any prescription drug or over-the-counter (OTC) medication (acetaminophen is acceptable) within 14 days prior to dosing. * Presence of a clinically significant systemic illness, active infectious process (viral or bacterial), e.g., cold sore, or documented drug allergies that may deteriorate or affect the subject's safety or ability to cooperate during the study. * Laboratory or clinical evidence suggestive of liver or renal disease, history of heart disease, history of autonomic dysfunction (e.g. history of fainting, orthostatic hypotension, sinus arrhythmia), history of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated), history of major gastrointestinal disease, history or clinical evidence of pancreatic injury or pancreatitis * Subjects with a resting heart rate \< 50 beats per minute (bpm) * Subjects with systolic blood pressure \< 90 or diastolic blood pressure \< 50. * Subjects with lymphocyte counts less than 1200/mm3 or total white blood cell (WBC) greater than 10000/mm3 at baseline * A past medical history of clinically significant electrocardiogram (ECG) abnormalities or a family history of a prolonged QT-interval syndrome. * Subjects who intend to or have received any live attenuated vaccines 4 weeks prior to or during the study period. Other protocol-defined inclusion/exclusion criteria may apply.",18.0,50.0,['healthy']
NCT05946746,The Effects of PeptiStrong and Exercise to Enhance Muscle Strength in Young Subjects,"A Randomised, Double-blind, Placebo Controlled Study to Evaluate the Effect of PeptiStrong Supplementation in Conjunction with an Exercise Program to Enhance Muscle Strength in Young Subjects",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Males \& females between 19 and 40 years of age * BMI between 18.5 to 29.9 kg/m2, inclusive * Females not of childbearing potential, defined as those who have undergone a sterilisation procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening, or, Individuals of child bearing potential must have a negative baseline urine pregnant test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control include: Hormonal contraceptives including oral contraception, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant. Double-barrier method Intrauterine devices Non-heterosexual lifestyle or agrees to use contraception if planning to change to heterosexual partner Vasectomy of partner at least 6 months prior to screening Abstinence and agrees to use contraception if planning on becoming sexually active * Willing and be capable of performing the recommended physical training and exercise regimen (3 x/week) for the duration of the study, as determined by the QI * Motivated to comply with exercise guidelines as assessed by the Self-motivation Questionnaire at screening * Self-reported stable body weight for the past 3 months defined as not having gained or lost more than 5 kg of body weight throughout the 3 months prior to baseline as assessed by the QI. * Agrees to refrain from taking NSAIDs and alcohol consumption for 24 and 48 hours, respectively, prior to each clinic visit * Agrees to avoid vigorous exercise (e.g. running, swimming laps, tennis singles, uphill hiking, weight lifting) for 48 hours prior to the exercise challenge. * Agrees to maintain current lifestyle habits as much as possible throughout the study depending on ability to maintain the following: diet and caloric intake, medications, supplements and sleep * Willingness to complete questionnaires, records and diaries associated with the study and to complete all study assessments * Provided voluntary, written, informed consent to participate in the study * Healthy as determined by medical history, physical examination, ECG, and vital signs, as assessed by the QI Exclusion Criteria: * Individuals who are pregnant, breast feeding, or planning to become pregnant during the study * Allergy, sensitivity, or intolerance to the investigational product or placebo ingredients * Has participated in structured resistance/power exercise training for \>3 hours/week in the 6 months prior to baseline, as assessed by the QI * Currently experiencing any medical condition (e.g., orthopedic injury, surgery, neuromuscular problems, musculoskeletal injury and/or disease) that may interfere with the ability to undergo physical strength testing during the study and/or ability to complete exercise guidelines as assessed by the QI * Metal implants or other physical characteristics/limitations that may affect DEXA scan results, as assessed by the QI * Participants who have followed a specific diet (e.g. ketogenic, paleo, high-protein, vegetarian etc) or have had a change of diet within 30 days of baseline as assessed by the QI * Have a history of being diagnosed with phenylketonuria or another disease affecting amino acid metabolism (i.e., maple syrup urine disease, etc.) * Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis * Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI * Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI * Current or history of significant diseases of the gastrointestinal tract, as assessed by the QI * Current unstable significant psychiatric condition (e.g., clinical depression, eating disorders) and/or sleep disorders, as assessed by the QI * Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable * Type I or Type II diabetes * Current unstable diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months * Current use of any prescribed or over-the-counter medications and/or supplements that may affect muscle mass, muscle strength, or metabolism, as assessed by the QI * Alcohol intake average ˃2 standard drinks per day as assessed by the QI * Alcohol or drug abuse within the last 12 months * Regular use of tobacco, vapes or nicotine products within 6 months of baseline and during the study period, as assessed by the QI * Blood donation 30 days prior to screening, during the study, or a planned donation within 30 days of the last study appointment as assessed by the QI * Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI * Individuals who are unable to give informed consent * Any other condition, chronic disease, or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",19.0,40.0,['muscle injury']
NCT05504746,A Phase I Study of SHEN26 Capsule in Healthy Participants,"A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SHEN26 Capsule in Healthy Participants",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Healthy participants aged 18-45 years (including boundary values, based on the time of signing the informed consent); 2. Body mass index (BMI) within the range of 19.0-26.0 kg/m\^2 (including boundary values), with body weight of not less than 50.0 kg for males and 45.0 kg for females; 3. Participants were evaluated by the investigator on the basis of their medical history, physical examination, vital signs, 12-lead electrocardiogram, laboratory tests (CBC, CMP, urinalysis, urine microalbumin test, urinary NAG test, coagulation test, serum virology, blood alcohol content, drug abuse screening test, and blood pregnancy test, etc.), abdominal ultrasound, ophthalmologic examination, and chest CT for overall good health status (normal or abnormal test results without clinical significance); 4. Fully understand the purpose, nature, methods, and possible adverse events of the trial, volunteer as a participant, and sign an informed consent form; 5. The participant and their female partner have no birth plan and voluntarily use effective contraception methods and have no plans to donate sperm or eggs from 2 weeks prior to screening until 6 months after the last dose of the study drug, and to ensure the use of one or more non-pharmacological contraceptive methods during sexual intercourse from 2 weeks prior to screening until 1 month after the last dose of the study drug. Exclusion Criteria: 1. Persons with pre-screening or ongoing disease with abnormal clinical manifestations to be excluded, including but not limited to diseases of the nervous/psychiatric system, respiratory system, cardiovascular system, digestive system (any history of gastrointestinal disorders affecting drug absorption), hematologic and lymphatic system, urinary system, endocrine system, and immune system； 2. Persons with a history of febrile illness within 14 days prior to screening； 3. Persons with dysphagia, history of gastrointestinal surgery or other related medical conditions that may interfere with the absorption and/or elimination of oral medications； 4. Persons who have undergone major surgical procedures (excluding diagnostic surgery) within 3 months prior to screening that, in the judgment of the investigator, may interfere with this trial, or who are expected to require major surgery during the trial; 5. Persons who have used or anticipate using any drug that induces or inhibits hepatic metabolic enzymes from 28 days prior to screening through the end of the trial; 6. Persons who have used or expect to use inhibitors of BCRP prior to screening up to 72 h after the last dose; 7. Persons who have used or expect to use inhibitors or inducers of P-gp prior to screening up to 72 h after the last dose; 8. Persons who have used any prescription, over-the-counter, herbal or nutraceutical drug within 14 days prior to screening; 9. Persons who have a history of substance abuse within 5 years prior to screening or who have used drugs in the 3 months prior to screening; 10. Persons with a history of drug or other allergies, particularly to the test drug or any component of the test drug; 11. Persons who have received any vaccine within 1 month prior to screening or who are scheduled to receive a vaccine during the trial; 12. Persons who have a history of blood donation or blood loss of more than 400 mL within 3 months prior to screening, or plan to donate blood during the trial; 13. Persons who have participated in other drug clinical trials and used other clinical trial drugs within 3 months prior to screening; 14. Persons who have difficulties with venous blood collection or have a history of dizziness from needles and blood; 15. Persons who smoked more than 5 cigarettes per day or habitually used nicotine-containing products within 3 months prior to screening, or cannot discontinue use of any tobacco product during the trial; 16. Persons who have consumed more than 14 units of alcohol per week (1 unit of alcohol = 360 mL of beer or 45 mL of 40% alcohol spirits or 150 mL of wine) within 3 months prior to screening or have consumed alcohol-containing products 48 h prior to receiving the test drug, or are unable to abstain from alcohol during the trial; 17. Persons who have ingested any food or beverage containing or metabolized to produce caffeine or xanthine (e.g., coffee, tea, chocolate) within 48 h prior to the administration of the drug; 18. Persons who have taken any food or beverage containing enzymes that induce or inhibit liver metabolism (e.g. grapefruit, etc.) within 7 days prior to recruitment; 19. Persons who have special dietary requirements and cannot accept a unified diet; 20. Female participants who are pregnant or breastfeeding during the trial; 21. Persons who have a positive SARS-CoV-2 test result (oropharyngeal swab PCR test); 22. Any other circumstances that, in the opinion of the investigator, may affect the participant's ability to provide informed consent or follow the trial protocol, or the participant's participation in the trial may affect the trial results or their own safety.",18.0,45.0,['healthy participants']
NCT02239146,Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass,"A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Subject is undergoing his/her first myocardial revascularization Exclusion Criteria: * Previous participation (randomisation and dosing) in this trial * Subject has a history of cerebrovascular event (including thrombotic or haemorrhagic stroke or transient ischaemic attack (TIA)) and/or extra-myocardial thromboembolic events, e.g., deep vein thrombosis (DVT) or pulmonary embolus (PE) * Subject required a pre-operative (within 30 days) transfusion of any blood and/or blood product * Subject has a current atrial fibrillation or history of atrial fibrillation",35.0,70.0,"['acquired bleeding disorder', 'cardiac surgery requiring cardiopulmonary bypass']"
NCT06739746,Research on the Sources of Noise in Post Anesthesia Care Unit and the Impact of Noise on Medical Staff,Research on the Sources of Noise in Post Anesthesia Care Unit and the Impact of Noise on Medical Staff,NOT_YET_RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * Currently working as nurses, doctors, or technicians in the Post Anesthesia Care Unit; * Have at least continuous 6 months of work experience in the Post Anesthesia Care Unit; * Able to read and answer questionnaires in Chinese fluently. Exclusion Criteria: * Have hearing impairments or other conditions affecting auditory perception; * Have participated in similar studies and completed related surveys within the past 6 months.",18.0,65.0,['noise exposure']
NCT02987946,Leiden Trial in Prevention of Post-Operative ThromboEmbolic Events,Optimizing Anti Coagulant Therapy in Neurosurgical Interventions in Patients with an Increased Risk for Thrombo-embolic Complications,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria:• Intracranial surgery; * Tumour surgery (spinal or intracranial); * \>180 min estimated surgical intervention time; * \>240 min time under anaesthesia; * Spine trauma surgery; Exclusion Criteria: * • Age under 18 years; * Perioperative continuation of anti coagulant therapy indicated other than prophylactic LMWH;,18.0,65.0,['deep-venous thrombosis']
NCT04328246,Pressure injuRy preventiOn by inTermittent EleCtrical sTimulation,The PROTECT Study: Pressure injuRy preventiOn by inTermittent EleCtrical sTimulation,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Modified Braden Scale score of 14 or less. The Modified Braden Scale score is calculated as follows: Braden Scale score (Ranges from 6 to 23) * 1 for Low Serum Albumin * 1 for Type II Diabetes 2. Anticipated length of stay of at least 4 days 3. BMI \< 35 4. Participants capable of giving informed consent, or if appropriate, participants having an acceptable individual capable of giving consent on the participant's behalf. Exclusion Criteria: 1. Existing pressure injuries above Stage II and injuries classified as DTI or unstageable 2. Neuromuscular blocking drugs \& myasthenia gravis: may prevent the ability of electrical stimulation to induce muscular contraction 3. Unstable spinal, pelvic, or hip fractures that may be displaced by a forced contraction 4. Rhabdomyolysis 5. Use of a Pacemaker 6. Skin breakdown over the gluteal regions that would preclude the use of surface electrodes.",18.0,65.0,['pressure injury']
NCT00428246,Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation,Anti-Inflammatory and Endothelial Protectant Effects of Paricalcitol,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients with chronic kidney disease with estimated GFR of 30 mL/minute or more. * Patients receiving stable dose of ACE inhibitor or Angiotensin receptor blockers for at least one month. * Patients not currently hypertensive more than 180/110 mmHg by clinic blood pressure. * Hemoglobulin A1C\ 10 mg/dL * Phosphorus\>6 mg/dL * Patients with anticipated need of dialysis in the next 6 weeks * Patients unstable in the opinion of the investigator * Patients who have emergent need for starting IV iron * Patients who will be started on statins within the next 6 weeks * Patients currently taking PDE5 inhibitors * Patients allergic to radiocontrast, Zemplar or who can not take nitroglycerin * Patients known to be HIV positive * Patients who can not give informed consent",18.0,65.0,"['chronic kidney disease', 'endothelial dysfunction', 'inflammation', 'hypertension']"
NCT01466088,"Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)","Double-Blind, Positive Comparator, Randomized, Parallel Study of Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients With Mild to Moderate Dementia of the Alzheimer's Type",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. A clinical diagnosis of AD per NINCDS-ADRDA criteria; mild to moderate severity as defined by Mini-Mental State Examination (MMSE) scores of 12 to 22. 2. AD diagnosed at least 12 months prior to Screening, and supported by brain imaging studies within 6 months prior to Screening. 3. Absence of vascular dementia both per AIRENS criteria and as defined by modified Hachinski ischemia score (HIS) of \ 4 (i.e., vascular dementia is consistent with a modified HIS \> 4).",60.0,85.0,"[""alzheimer's disease""]"
NCT05176288,"Avelumab, Palbociclib and Axitinib in Advanced RCC","Avelumab, Palbociclib and Axitinib in in Treatment Naive Metastatic Clear Cell Renal Cell Carcinoma.",WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Histologically or cytologically confirmed unresectable advanced or metastatic renal cell carcinoma with a clear cell component. Patient with sarcomatoid histology are accepted. * A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block from a de novo tumor biopsy obtained during screening will be required (biopsied tumor lesion should not be a RECIST target lesion). Alternatively, a recently obtained archival FFPE tumor tissue block (not cut slides from a primary or metastatic tumor resection or biopsy) can be provided if the following criteria are met: * The biopsy or resection was performed within 1 year of registration AND * The patient has not received any intervening systemic anti-cancer treatment from the time the tissue was obtained and registration onto the current study. If an FFPE tissue block cannot be provided as per documented regulations then 15 unstained slides (10 minimum) will be acceptable * Availability of an archival FFPE tumor tissue block from primary diagnosis specimen (if available and not provided per above). If an FFPE tissue block cannot be provided as per documented regulations, then 15 unstained slides (10 minimum) will be acceptable * Additional tumor biopsies for research purposes prior to starting therapy, after 2 months of therapy and at end of treatment are optional. * Measurable disease as per RECIST 1.1. See section 11 for the evaluation of measurable disease. * Age ≥ 18 years. * ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A). * Normal organ and marrow function as defined below: * Absolute neutrophil count ≥1.5×109/L * Platelets ≥100×109/L * Hemoglobin ≥9g/dL (transfusions allowed) * Total bilirubin ≤2 × institutional upper limit of normal (ULN) with the following exception: patients with known Gilbert disease should have a serum bilirubin ≤ 3 x ULN * AST(SGOT)/ALT(SGPT) ≤3 × ULN with the following exception: patients with known liver metastases should have AST and ALT ≤ 5 × ULN * Creatinine clearance ≥30 mL/min according to the Cockcroft-Gault equation. (APPENDIX F) * Urine protein \ 10 mg/day prednisone or equivalent. A repeat MRI or CT brain to show stability is required. * Participants who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy to at least grade 1. * Untreated deep vein thrombosis or pulmonary embolism, or event of deep vein thrombosis or pulmonary embolism within 2 weeks of treatment start. Patient should be on at least 1 week of anticoagulation before C1D1. * Major surgery within the past 4 weeks or major radiation therapy within 2 weeks prior to treatment start. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided it has been completed at least 48 hours prior to patient randomization. * The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease - also see 3.2.22, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \[e.g. estimated creatinine clearance \ 1; however, sensory neuropathy Grade ≤2 is acceptable. * Current or prior use of immunosuppressive medication within 7 days prior to randomization, except the following: * Intranasal, inhaled, topical steroids, or local steroid injections (eg. intra-articular injection). * Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or equivalent. * Steroids as premedication for hypersensitivity reactions (eg. CT scan premedication). * Known severe hypersensitivity reactions to monoclonal antibodies (Grade≤3) or any history of anaphylaxis. * Active autoimmune disease that might deteriorate when receiving an immunostimulatory agents. Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible. * Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines (for example, inactivated influenza vaccines). * Grade≥3 hemorrhage within 4 weeks of registration * Patient with active systemic bacterial infection (requiring IV antibiotics at the time of initiating study treatment), fungal infection, or detectable viral infection. Patients with known viral infection (such as HIV) are excluded given the potential for interactions between antiretroviral agents and palbociclib and axitinib, and the potential for increased risk of life-threatening infection with therapy that is myelosuppressive. If patients are not known to have HIV, a HIV test is required. * Patients with known Hepatitis B or Hepatitis C infection are excluded only if there is evidence of active infection (detectable Hepatitis B surface antigen, detectable Hepatitis C RNA). * Prior allogenic stem cell or solid organ transplant. * Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of oral drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection). * Participants who are currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant. Therapeutic use of low molecular weight heparin and factor Xa inhibitors (eg. apixaban, rivaroxaban) is permitted. * Other malignancy diagnosed within 2 years of treatment start unless negligible risk of metastases or death according to the investigator (included but not limited to carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, ductal carcinoma in situ of the breast, non-muscle invasive urothelial carcinoma, or other malignancy not deemed to impact patients 5-year life expectancy). * Has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), sudden cardiac arrest. * Has had any major cardiovascular event within 6 months prior to treatment start, including but not limited to: myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic event or New York Heart Association Class III or IV heart failure. * Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2 or prolongation of the QTc interval to \>500 msec. * History of interstitial lung disease or other restrictive lung disease, as well as history of symptomatic respiratory condition considered clinically significant by the investigator. Individuals with a history of radiotherapy to the thorax will be excluded. * Active or ex-smokers with a history of cigarette smoking greater than 30pack-yrs (i.e., # of packs of cigarettes smoked per day x # of years patient has smoked \> 30). * Participants with a known hypersensitivity to the study compounds or to its excipients. * Current use or anticipated need for treatment with drugs or foods that are known strong CYP3A4/5 inhibitors, including their administration within 10 days prior to treatment start (eg. grapefruit juice or grapefruit/grapefruit-related citrus fruits \[eg. Seville oranges, pomelos\], ketoconazole, miconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, amprenavir, fosamprenavir nefazodone, lopinavir, troleandomycin, mibefradil, and conivaptan). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed. * Current use or anticipated need for drugs that are known strong CYP3A4/5 inducers, including their administration within 10 days prior to treatment start (eg. phenobarbital, rifampin, phenytoin, carbamazepine, rifabutin, rifapentin, clevidipine, St John's wort). * Participants who have taken herbal medications within 7 days prior to treatment start. Herbal medications include, but are not limited to St. John's wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng. * Females that are pregnant or lactating. * Judgement by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.",18.0,65.0,['advanced clear cell renal cell carcinoma']
NCT03738488,3D-biomodels for Surgical Planning in Patients With Renal Cancer and Vascular Involvement,3D-biomodels for Surgical Planning in Patients With Renal Cancer and Vascular Involvement,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Signature of informed consent. * Age over 18 years or between 14 and 18 with the authorization from mother / father / guardian. * Diagnosed of renal cancer with vascular involvement in the HUVR or HURC between 2018 and 2021 Exclusion Criteria: * Pregnant. * Immunosuppression. * No signature of informed consent. * Impossibility of monitoring or follow up.,14.0,65.0,"['renal cell carcinoma', 'three-dimensional', 'venous thromboses']"
NCT06005688,A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants,"An Interventional, Phase 1, Open-Label, Fixed Sequence, 2-Period Study to Estimate the Effect of Multiple Doses of Carbamazepine on the Pharmacokinetics of Single Dose Vepdegestrant (ARV-471, PF-07850327) 200 mg Under the Fed Condition in Healthy Adult Males and Females of Nonchildbearing Potential",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Male participants, and female participants of non-childbearing potential aged 18 years or older (or the minimum age of consent in accordance with local regulations) at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. 2. BMI of 16-32 kg/m2; and a total body weight \>45 kg (99.2 lb). 3. Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the ICD and in this protocol. 4. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations and other study procedures. Exclusion Criteria: 1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). * Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy). * History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, HBcAb, or HCVAb. Hepatitis B vaccination is allowed. 2. Participants shown to carry or be positive for HLA-B\*1502 and/or HLA-A\*3101 (genotyping alleles/markers related with carbamazepine-associated SJS or TEN). 3. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. 4. Use of prescription or non-prescription medications, including vitamins, herbal and dietary supplements, grapefruit/grapefruit containing products, and Seville orange/Seville orange containing products within 7 days prior to the first dose of study intervention with the exception of: * Moderate/strong CYP3A4 inducers which are prohibited within 14 days plus 5 half-lives prior to the first dose of study intervention. * Moderate/strong CYP3A4 inhibitors which are prohibited within 14 days plus 5 half-lives prior to the first dose of study intervention. 5. Previous administration with an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). 6. A positive urine drug test. A single repeat for positive drug screen may be allowed. 7. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic) for participants \ 1.05× ULN; 10. Renal impairment as defined by an eGFR \<60 mL/min/1.73m². Based upon participant age at screening, eGFR is calculated usding the recommended CKD-EPI equations to determine eligibility and to provide a baseline to quantify any subsequent kidney safety events. 11. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit, or 3 ounces (90 mL) of wine). 12. History of use of tobacco or nicotine-containing products in excess of the equivalent of 5 cigarettes/day or 2 chews of tobacco/day. 13. History of sensitivity to vepdegestrant and Tegretol or any of the formulation components of vepdegestrant and Tegretol. 14. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.",18.0,65.0,['healthy participants']
NCT03322488,Fistulodesis Pilot Study for Closure of Perianal Fistulae,"Local Installation of Acetylcysteine, Doxycycline and Fibrin Glue and Surgical Closure of Fistula Openings for Treatment of Perianal Fistulae. An Open Label, Prospective, Multicentric Pilot Study",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * All patients: * Signed informed consent * Male or female patients ≥18 years of age * Perianal fistula existing for at least 3 months * Perianal fistula that requires an examination under anaesthesia (EUA) * Women of childbearing potential must agree to use effective contraception (for details see chapter 8.6) for the duration of the trial * Women of childbearing potential: A negative pregnancy test before inclusion into the trial is required * Simple fistula, the whole fistula system must be accessible by curettage or brushing * Crohn's disease (CD) patients only: * CD diagnosis established for ≥3 months * CD in remission (Harvey-Bradshaw Index ≤4) Exclusion Criteria: * All patients: * More than 2 external fistula openings * History of irradiation of the anorectum * Acute perianal abscess. * Perianal operation during the last 4 weeks. * Known allergy or non-tolerance against either acetylcysteine, doxycycline, Evicel®, metronidazole or ciprofloxacin. * Current antibiotic therapy * Severe uncontrolled additional medical, surgical or psychiatric condition, requiring active management * Current enrollment into a clinical trial interfering with the endpoints or enrollment in another study for treatment of perianal fistula during the last 4 weeks * Inability to follow the procedures of the study, e.g. due to language problems, psychiatrical disorders, dementia, etc. of the participant, * Previous enrollment into the current study * Women who are pregnant or breastfeeding * Intention to become pregnant during the course of the study * Large pocket (≥ 1cm) within fistula tract * Horseshoe shape of the fistula tract * Superficial fistula according to clinical examination and/or ultrasound: (Male patients: Fistula tract involves less than 30% of anal sphincter apparatus, Female patients: Fistula tract involves less than 10% of anal sphincter apparatus) * Crohn's disease patients only: * Evidence of active inflammation in the rectum (besides the fistula) * Systemic intake of steroid-medication (currently or during the last 4 weeks) in a dose of \>20mg prednisone or equivalent * New immunosuppressant medication for Crohn's disease within the last 4 weeks before inclusion into the study (changes in 5-ASA medication or rectal treatment with 5-ASA or budesonide are permitted)",18.0,65.0,"['perianal fistula', 'crohn disease']"
NCT06755788,Effects of Intraoperative Glycemic Management Strategies Assisted with RT-CGM on TIR and Postoperative Recovery,Effects of Intraoperative Glycemic Management Strategies Assisted with RT-CGM on TIR and Postoperative Recovery During Pancreaticoduodenectomy: a Randomized Controlled Trial,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * Age ≥ 18 * Scheduled for pancreaticoduodenectomy * ASA classification I-III Exclusion Criteria: * Emergency surgery * scheduled for MRI the day before surgery * Allergy to CGM sensor * Communication barriers or refusal to participate * BMI \< 18.5 kg/m²,18.0,65.0,['continuous glucose monitoring']
NCT07006688,A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment,"A Phase 1, Multicenter, Open-Label, Safety and Pharmacokinetic Study of Orally Administered Ivosidenib in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment",NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Participants with hematologic malignancies (including but not limited to acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms, clonal cytopenia of unknown significance with a high-risk score \[CHRS ≥12.5\], chronic myelomonocytic leukemia, multiple myeloma, and non-Hodgkin's lymphoma) or solid tumors excluding glioma, with a locally confirmed IDH1 R132 mutation before Cycle 1 Day 1. * Based on renal and hepatic function, participants within the: a. Moderate HI group, must have: i. Total bilirubin \>1.5 to 3 × upper limit of normal (ULN), not linked to Gilbert's disease, and any aspartate aminotransferase (AST) value, ii. Adequate renal function as evidenced by creatinine clearance (CrCl) ≥60 mL/min estimated according to the Cockcroft-Gault formula. b. Severe HI group, must have: i. Total bilirubin \>3 × ULN and any AST value, ii. Adequate renal function as evidenced by CrCl ≥60 mL/min estimated according to the Cockcroft-Gault formula. c. Severe RI group, must have: i. CrCl ≥15 to 29 mL/min estimated according to the Cockcroft-Gault formula, ii. Adequate hepatic function as evidenced by: 1. Blood total bilirubin ≤1.5 × ULN, unless due to Gilbert's disease, where participants should have blood total bilirubin ≤3 × ULN; 2. AST, alanine aminotransferase, and alkaline phosphatase ≤3.0 × ULN * Participants of the control groups with adequate hepatic or renal function characterized as: 1. Hepatic control group: Adequate hepatic function as evidenced by total bilirubin and AST ≤ULN, and normal to mild RI (CrCl ≥60 mL/min estimated according to the Cockcroft-Gault formula). 2. Renal control group: Adequate renal function as evidenced by CrCl ≥90 mL/min (estimated according to the Cockcroft-Gault formula) and normal to mild HI (total bilirubin ≤1.5 × ULN, participants with Gilbert's disease should have blood total bilirubin ≤3 × ULN). * Participants previously or currently treated with ivosidenib are eligible if treated at the 500 mg QD dose or if treated at the 250 mg QD dose due to strong cytochrome P450 (CYP)3A4 inhibitor intake. Participants with a hematologic malignancy on co-treatment with azacitidine are also eligible. * WOCBP must agree to abstain from sexual intercourse or use 2 effective methods of birth control (a highly effective method and a barrier method) from the time of giving informed consent throughout the study and for 90 days after the last dose of ivosidenib. Hormonal contraception alone is not considered an acceptable method of contraception and should be combined with a barrier method. Exclusion Criteria: * Have undergone hematopoietic stem cell transplant (HSCT) within 60 days of the first dose of ivosidenib, or on immunosuppressive therapy post-HSCT at the time of screening, or with active acute or chronic graft-versus-host-disease (GVHD) requiring systemic therapy. (Participants with GVHD managed by minimal interventions \[a physiologic dose of steroids\] are permitted with the medical monitor's approval.) * Have received systemic anticancer therapy (with the exception of azacitidine), investigational agent treatment, or radiotherapy \<14 days, or had surgery \<4 weeks before planned Cycle 1 Day 1 of ivosidenib, and/or did not recover from the AEs associated with these therapies and/or surgeries. In addition, the first dose of ivosidenib should not occur before a period of ≥5 half-lives of the study drug has elapsed. * Have hematological diseases (other than AML or MDS) or solid tumors that are eligible for other treatments known to provide clinical benefit. * Have received calcineurin inhibitors within 4 weeks prior to enrollment. * Have significant active cardiac disease within 6 months before the start of ivosidenib, including NYHA Class III or IV congestive heart failure, myocardial infarction, unstable angina, and/or stroke. * Use of any medications that are known to prolong the QT interval unless they can be transferred to other medications within ≥5 half-lives before dosing or unless the medications can be properly monitored during the study. (If equivalent medication is not available, QTcF should be closely monitored). * Planned use of any strong CYP3A4 inducer or sensitive CYP3A4 substrate with a narrow therapeutic window or certain antifungals that are CYP3A4 substrates while the participant is receiving ivosidenib. Participants who are taking these medications must have the minimum washout period of ≥5 half-lives before the first dose of ivosidenib and not take the medications for the duration of their participation in the study. * Have known active inflammatory gastrointestinal disease, chronic diarrhea, previous gastric resection or laparoscopic gastric banding, short-gut syndrome, gastroparesis, or other active conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally. Gastroesophageal reflux disease under medical treatment is allowed (assuming no drug interaction potential). * Have a known familial history of sudden death or polymorphic ventricular arrhythmia.",18.0,65.0,['idh1-mutated malignancies']
NCT05705388,POSE2.0 With GLP-1 Agonist for Obesity Management,Comparison of Efficacy and Safety of POSE 2.0 Procedure Compared to GLP-1 Agonist in a Cohort of Patients for Management of Obesity: a Single-center Randomized Crossover-controlled Trial,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Participants will be adult patients (22 years of age or above and less than 60 years of age) * Body mass index (BMI) ≥30 and \ 3 cm) by history or as determined by pre-enrollment endoscopy. * Pancreatic insufficiency/disease. * History of gastroparesis or symptoms that would be suggestive of gastroparesis or generalized dysmotility (e.g. esophago-gastric motility issues and lower esophageal sphincter abnormalities). * Pregnancy or plans of pregnancy in the next 12 months. * History of a known diagnosis or pre-existing symptom of rheumatoid arthritis, scleroderma, system lupus, or other autoimmune connective tissue disorder. * Immunosuppressive medications or systemic steroids (i.e., oral prednisone) within 6 months of Visit 1. Intranasal/inhaled steroids are acceptable. * Unable or unwilling to avoid use of aspirin and/or non-steroidal anti-inflammatory drugs (NSAIDs), or other medications known to be gastric irritants beginning two weeks prior to enrollment and throughout the entire study. * History of inflammatory disease of the GI tract; coagulation disorders; hepatic insufficiency or cirrhosis. * Active gastric erosion, lesion, or gastric/duodenal ulcer. * History of or current platelet or coagulation dysfunction, such as hemophilia. * History or present use of insulin or insulin derivatives for treatment of diabetes. * Type II Diabetes Mellitus (as defined by HgbA1c \>6.5%) for greater than 11 years at the time of enrollment. * If smoker, plans to quit smoking in the year after enrollment. * Portal hypertension and/or varices. * Patient has a history of drug or alcohol abuse or positive at screening for drugs of abuse. - Patient is currently using marijuana/cannabis for either medicinal or recreational use, or has plans to start using over the next 12 months. * Present or history of psychosis, bipolar disease, or obsessive-compulsive disorder after pre-enrollment history and medical /psychological assessment. * Uncontrolled depression after pre-enrollment psychological and medical assessment. * If significant findings for depression and/or suicidal ideation are identified, the psychologist(s) assigned to the study will be contacted and arrangement will be made for immediate intervention according to the Institution's standard procedure. * Non-ambulatory or has significant impairment of mobility (i.e. cannot ambulate for 30 minutes). * Known hormonal or genetic cause for obesity including untreated hypothyroidism (TSH \>5.0 U/ml). * Participating in another clinical study. * Subjects with a personal history of allergic/anaphylactic reactions including hypersensitivity to the drugs or materials that will be utilized in the study procedure. * Physician's assessment that the subject is not an appropriate candidate. * Breastfeeding * Personal or family history of medullary thyroid cancer or MEN2 * Suicidal ideation and behavior. * Injection site reaction",22.0,60.0,['obesity']
NCT04818788,Hematological Indices and Fecal Calprotectin Predict Histological Remission in Ulcerative Colitis,Hematological Indices and Fecal Calprotectin as Predictors of Histological Remission in Ulcerative Colitis Patients Receiving Biological Therapy,UNKNOWN,OBSERVATIONAL,ALL,Inclusion Criteria: * 24 patients (males and females at the age between 18 and 55 years) of ulcerative colitis indicated to biological therapy Exclusion Criteria: * \- Ulcerative colitis pregnant women * Patient receiving biological therapy for extra intestinal manifestation * Patients on corticosteroids more than 20 mg as it affects leucocytic count * Patients under the age of 18 years,18.0,55.0,['ulcerative colitis']
NCT00275288,MRI Imaging in Borderline Personality Disorder,"""Brain Correlates Of Affect Regulation In BPD""",COMPLETED,OBSERVATIONAL,FEMALE,"Inclusion Criteria: Female subjects ages 18-45 whom meet criteria for BPD will be included in the study. The healthy controls will also be females between the ages 18-45. The healthy controls will undergo the same diagnostic and symptom evaluations as the female patients - these interview schedules will be used mainly for determining exclusion criteria. \- Exclusion Criteria: 1. Neither borderline personality disorder subjects or healthy controls may have a history of schizophrenia, schizoaffective disorder, bipolar illness, major depression with psychotic features, Obsessive-Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), or Generalized Anxiety Disorder (GAD). 2. Patients and healthy controls may not have a serious neurologic or other metabolic disorder or any medical condition or treatment known to affect the parameters of this study. 3. Neither patients nor healthy controls will be included in the study if they are receiving a medical treatment that requires a medication that may have psychotropic effects. 4. Neither patients nor healthy controls can have any contraindications to MRI scanning such as a metal implant, a pacemaker, or a history of claustrophobia. At the Center for Magnetic Resonance Research (CMRR), we have developed a highly specific and detailed questionnaire to ensure the safety of all participants. This questionnaire is administered prior to any and all scans. 5. Pregnant women will be excluded from the study. This will be assessed by history, date of last menstrual period and urine pregnancy test if necessary. 6. Neither patients nor healthy controls who fulfill criteria for developmental deficiency will be included. 7. Healthy controls with more than two borderline personality disorder criteria will not be eligible for study. This is to reduce the possibility of healthy controls being ""near misses"" to the patients and diminishing the possibility of finding difference between the patients and the healthy controls. \-",18.0,45.0,['borderline personality disorder']
NCT02496988,Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas,A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Subjects with documented histologically confirmed primary grade 4 advanced malignant glioma. * No more than 3 prior relapses or prior systemic treatments. * Recurrent disease documented by MRI after prior therapy. * Must have at least one site of bidimensionally measurable disease: archived tissue from the initial diagnosis of advanced malignant glioma or upon transformation to advanced malignant glioma are available for central review within approximately 4 weeks after enrollment. * Completed at least one full cycle of temozolomide of 200 mg/m2/day administered on Days 1-5 of a 28-day cycle, without unacceptable toxicity or progression. * Karnofsky performance status of 60 or more. Adequate organ and bone marrow function as defined by hematological and serum chemistry limits. * At least 18 years old. * Both men and women must practice adequate contraception. * Informed consent. Exclusion Criteria: * Progressed while on temozolomide. * Evidence of acute intracranial or intratumoral hemorrhage \> Grade 1. * Not recovered from the toxic effects of prior therapy. * Pregnant or breast feeding. * History of diabetes mellitus. * Uncontrolled intercurrent illness. * Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study. * HIV positive. * Diagnosis of another malignancy may exclude subject from study.",18.0,80.0,"['cytokine-induced killer cells', 'advanced milignant gliomas']"
NCT06500988,Mobile Health Technology-Enabled AFib Management,Patient Centered Mobile Health Technology-Enabled Atrial Fibrillation Management: Phase 2,RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: 1. Aged 18 or older at time of consent 2. Diagnosis of paroxysmal (Afib lasting less than 7 days) or persistent (7 days or longer) atrial fibrillation 3. BMI (Body Mass Index) ≥ 27.0 Exclusion Criteria: 1. Permanent Afib (decision has been made not to attempt sinus rhythm) 2. Severe valvular disease 3. Moderate mitral valve stenosis 4. Prior cardiac surgery 5. Presence of implanted cardiac device 6. History of cardiac arrest 7. Left ventricular ejection fraction (LVEF) ≤ 35% 8. Life expectancy \< 1 year 9. Non-English speaking 10. Treating clinician deems unsafe for exercise 11. Any other reason that makes patient unsuitable for study at the discretion of the PI,18.0,65.0,"['atrial fibrillation', 'behavior']"
NCT03813888,Effect of Arshvidya After School Program on Cognitive Processes in Elementary School Children,Effect of Arshvidya After School Program on Cognitive Processes in Elementary School Children,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Be 8 - 11 years of age at the start of the intervention * Healthy Children * Not start new activity within the intervention period * Parental conset * Parents to allow and participate where needed in intervention Exclusion Criteria: * Serious chronic illnesses and diseases * Diagnosed with any psychiatric illness * Intake of medication that may affect study outcomes * not able to continue for 12-weeks of participation,8.0,11.0,['cognitive change']
NCT02181088,A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5,A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Healthy adults aged 18 to 50 years * Able and willing (in the Investigator's opinion) to comply with all study requirements * Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner * For females only, willingness to practice continuous effective contraception during the study and a negative pregnancy test on the day(s) of screening and vaccination * Agreement to refrain from blood donation during the course of the study * Provide written informed consent Exclusion Criteria: * Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period * Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the trial data. * Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate * Any confirmed or suspected immunosuppressive or immunodeficient state, including human immunodeficiency virus (HIV) infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed) * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products. * Any history of anaphylaxis in reaction to vaccination * Pregnancy, lactation or willingness/intention to become pregnant during the study * History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ) * History of serious psychiatric condition * Any other serious chronic illness requiring hospital specialist supervision * Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week * Suspected or known injecting drug abuse in the 5 years preceding enrolment * Seropositive for hepatitis B surface antigen (HBsAg) * Seropositive for hepatitis C virus (antibodies to HCV) * History of clinical malaria (any species) * Travel to a malaria endemic region during the study period or within the previous six months * Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis * Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data * Inability of the study team to contact the volunteer's general practitioner (GP) to confirm medical history and safety to participate",18.0,50.0,"['malaria', 'plasmodium falciparum']"
NCT05987488,ShigETEC Vaccine Study in Bangladesh,"Early Clinical Development of a Live, Attenuated Combination Vaccine Against Shigella and ETEC Diarrhoea: Phase 1b Clinical Trial of ShigETEC Vaccine in Bangladeshi Adults and Three Paediatric Age Groups",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Male or female adults, children, toddlers, and infants aged between 18-45 years, 2-5 years, 12-23 months, and 6-11 months, respectively at the time of vaccination. * Free of obvious health problems as determined by medical history and clinical examination before entering into the study. * Normal bowel habits. * Informed consent form signed. * Negative pregnancy tests before each vaccination for females of childbearing potential. Adult participants agree to use birth control steps or abstinence. Exclusion Criteria: * Nursing and breast-feeding women. * Presence of any known significant medical or psychiatric condition / systemic disorder. * History of congenital abdominal disorders, intussusception, abdominal surgery, any other congenital disorder, any neurologic disorders or seizures. * Clinically significant abnormalities in screening hematology, serum chemistry. * Known or suspected HIV, hepatitis infection. * Clinical evidence of active gastrointestinal illness or acute disease at the time of enrolment. * Prior receipt of any Shigella or ETEC vaccine, blood transfusion or blood products. * History of febrile illness within 48 hours prior to vaccination or fever at the time of immunization. * History of diarrhoea within 7 days and / or acute diarrhoea due to culture confirmed Shigella or ETEC infections within one month prior to vaccination. * Screening stool positive for any Shigella or ETEC strain by culture. * Participation in research involving another investigational product within 30 days before before planned date of first vaccination concurrent participation in another clinical trial. * Receipt of antimicrobial drugs for any reason within 7 days before vaccination. * Allergy to quinolone, sulfa, and penicillin classes of antibiotics * Any conditions which, in the opinion of the investigator, might jeopardize the safety of study participants or interfere with the evaluation of the study objectives.",6.0,45.0,['healthy volunteers']
NCT06844188,The Effect of Prenatal Education on Primary Cesarean Rate,The Effect of Prenatal Education at Pregnancy School on Primary Cesarean Rate,COMPLETED,OBSERVATIONAL,FEMALE,"Inclusion Criteria: All women who gave birth between January 2024 and December 2024 and attended antenatal classes (gebe okulu) will be included in the study. For the control group (women who did not attend antenatal classes), participants will be randomly selected, matching the case group (antenatal class attendees) in terms of age, education level, and parity. Exclusion Criteria: Women with a history of previous cesarean sections who are undergoing a repeat cesarean in this pregnancy will be excluded. Women with high-risk pregnancies, such as preeclampsia, preterm labor, preterm premature rupture of membranes, multiple pregnancies, previous cesarean section, or placental abruption, will not be included in the study.",18.0,50.0,"['prenatal care late', 'cesarean delivery affecting fetus']"
NCT05429788,"Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)","A Phase 1b/2a Randomized, Double-Blind, Placebo Controlled, Parallel Study to Evaluate the Safety, Tolerability, and Efficacy of Two Doses of RLS103 (CBD Technosphere® Inhalation Powder) in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)",WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Must sign an informed consent form (ICF) indicating that they understand the purpose of the study and the procedures required for the study and are willing to participate in the study and attend all visits and requirements. * Male or female 18 through 65 years of age, inclusive. * Current diagnosis of SAD as defined in the MINI. * Clinician-rated LSAS total score ≥75 at Screening (Visit 1). * Clinician-rated Hamilton Depression Score 17-items total score \ 1.5 × the ULN * Total bilirubin \>1.5 × ULN (isolated bilirubin \>1.5 ×ULN is acceptable if total bilirubin and direct bilirubin \ 38°C) or symptomatic viral or bacterial infection within 2 weeks prior to Screening, including confirmed active COVID-19. * Had major surgery (general anesthetic) in the last 3 months or minor surgery (local anesthetic) in the last 1 month prior to Screening or have any pre-planned surgery or procedures that would interfere with the conduct of the study. * Is an employee of the Investigator or study site, with direct involvement in the proposed study or other studies under the direction of that Investigator or study site, as well as family members of the employees or the Investigator.",18.0,65.0,['social anxiety disorder']
NCT00952588,"Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients","A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged ≥ 60 With Newly Diagnosed Acute Myeloid Leukaemia (AML)",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Provision of written informed consent * Newly diagnosed male or female patients aged 60 and over * De Novo or Secondary AML * Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following:Age ≥75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status \>2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia Exclusion Criteria: * Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product * Administration of LDAC is clinically contraindicated * Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL) * Patients with blast crisis of chronic myeloid leukaemia",60.0,65.0,['acute myeloid leukemia']
NCT01312688,Early Goal-directed Therapy and Myocardial Dysfunction,The Effect Early Goal-directed Therapy on Myocardial Dysfunction and Survival in ICU Patients With Severe Sepsis and Septic Shock: A Prospective Randomized Controlled Trial,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Intensive care unit patients with severe sepsis or septic shock, age 18 or above. Exclusion Criteria: * Pregnant women * Patients with known significant valvular or coronary heart disease * Patients with poor quality echocardiography imaging",18.0,65.0,"['sepsis', 'septic shock', 'myocardial dysfunction']"
NCT00961688,The Impact of Polycystic Ovary Syndrome (PCOS) on Quality of Life and Healthcare Beliefs,The Impact of PCOS on Quality of Life and Healthcare Beliefs,COMPLETED,OBSERVATIONAL,FEMALE,Inclusion Criteria: * Women with Polycystic Ovary Syndrome (PCOS) between the age of 18 and 55 Exclusion Criteria: * N/A,18.0,55.0,['polycystic ovary syndrome']
NCT01212588,Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD),"Preliminary, Double Blind, Placebo Controlled Trial of the Effect of Glucocorticoid Receptor Antagonist Treatment on Biologic and Symptom Outcomes in Patients With Borderline Personality Disorder and Histories of Childhood Abuse",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * 18-64 years of age at study entry * Female or Male * Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of borderline personality disorder (confirmed by SCID II) with history of abuse prior to the age of 18. * Able to provide informed consent * Inpatient or outpatient * Clinical stability as defined by: * Subjects must not have experienced an exacerbation of their illness within 4 weeks prior to randomization, leading to an intensification of psychiatric care in the opinion of the principal investigator. Examples of intensification of care include, but are not limited to: inpatient hospitalization, day/partial hospitalization, outpatient crisis management, or psychiatric treatment in an emergency room AND * Psychotropic treatment stability for at least 2 weeks prior to randomization (no change in dosing or addition of any new psychotropic medication) * Female subjects of childbearing potential must test negative for pregnancy at screening visit and agree to use the double-barrier method, as defined by 2 physical barriers such as a condom, diaphragm, or cervical occlusive cap, coupled with an additional barrier such as spermicidal foam, gel, film, cream or suppository for the duration of the study. Subjects having undergone a hysterectomy or bilateral oophorectomy or other form of female sterilization or patients having been medically confirmed to be post-menopausal, would not require any other method of contraception. * Minimum severity of a total score \> 3 on the The Clinical Global Impression severity (CGI-S) * Must agree not to consume tonic water and grapefruit or grapefruit product for 3 days prior to beginning medication and until the final study visit Exclusion Criteria: * DSM-IV TR diagnosis of (confirmed by SCID) schizophrenia or a related psychotic disorder, bipolar I disorder, or dementia * Subjects who are considered prisoners per the Indiana University Standard Operating Procedures for Research Involving Human Subjects. * Subjects with current acute, serious, or unstable medical conditions, including, but not limited to: inadequately controlled diabetes, asthma, Chronic obstructive pulmonary disease (COPD), severe hypertriglyceridemia, recent cerebrovascular accidents, acute systemic infection or immunologic disease, unstable cardiovascular disorders, malnutrition, renal gastroenterologic, respiratory, endocrinologic (particularly illnesses related to the HPA-axis, e.g., Cushing's Syndrome), neurologic, hematologic, or infectious diseases * Clinically significant electrocardiogram (ECG) abnormality prior to randomization including: subjects with a corrected QT interval (Bazett's; QTcB) \>470 msec prior to randomization (based on the cardiologist overread). Repeat ECGs will be conducted at the discretion of the principal investigator or medical designee * Use of any exclusionary medications listed in the protocol Attachment 2: Concomitant Medications * Pregnant or lactating women or women who plan to become pregnant or will be lactating within one month after cessation of study medication * Known Intelligence quotient (IQ) \ 3 × upper limit of normal (ULN) * Subjects considered a high risk for suicidal acts, as determined by the principal investigator. * Subjects who have participated in a clinical trial with any pharmacological treatment intervention for which they received study-related medication in the 4 weeks prior to screening OR Subjects currently receiving treatment (within 1 dosing interval plus 4 weeks) with an investigational depot formulation of an antipsychotic medication * Subjects who demonstrate overtly aggressive behavior or who are deemed to pose a homicidal risk in the principal investigator's opinion * Psychosocial treatment changes 14 days prior to randomization * History of unexplained vaginal bleeding, endometrial hyperplasia with atypia, or endometrial carcinoma",18.0,64.0,['borderline personality disorder']
NCT02682888,Trait Anxiety and Defensive Networks,Trait Anxiety Modulates Resting State Functional Connectivity of Defensive Networks,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Healthy subjects without past or current psychiatric or neurological disorders Exclusion Criteria: * females should not be pregnant or during menstruation.,18.0,35.0,['healthy']
NCT07251088,"Dyadic, App-supported Collaborative Care Intervention Trial for Family Caregivers of People Living With Dementia","Dyadic, App-supported Collaborative Care Intervention Trial for Family Caregivers of People Living With Dementia - The Multi-center Living@Home Study",NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * formal dementia diagnosis * living in their own home for the person with dementia * access to a smartphone and internet for the informal caregiver * informed consent of the participant Exclusion Criteria: * not able to provide written consent * if a legal representative is present, they may give their consent",18.0,65.0,"['dementia', 'nurse care coordination', 'informal caregiver']"
NCT01089088,"Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)",A Phase II Single-Arm Trial to Evaluate Cisplatin and Gemcitabine Chemotherapy in Combination With Sunitinib for First-Line Treatment of Patients With Advanced Transitional Carcinoma of the Urothelium,COMPLETED,INTERVENTIONAL,ALL,"DISEASE CHARACTERISTICS: * Histologically confirmed transitional cell carcinoma of the urothelium * Pure or mixed histology * Upper or lower urinary tract * Radiologically measurable, locally advanced and/or metastatic disease not amenable to curative treatment with surgery or radiotherapy meeting 1 of the following criteria: * T4b (bladder) or T4 (renal pelvis/ureter), any N, any M * Any T, N2-3, any M * Any T, any N, M1 * No urothelial cancer for which subsequent radical treatment is being considered with a view to possibly cure the disease * No history of CNS metastases PATIENT CHARACTERISTICS: * WHO performance status 0-2 * Life expectancy \> 3 months * Absolute neutrophil count ≥ 1.5 x 10\^9/L * Platelet count ≥ 100 x 10\^9/L * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * ALT and ALP ≤ 2.5 times ULN * GFR ≥ 60 mL/min (uncorrected for surface area and measured by isotopic means) * PT or INR ≤ 1.5 times ULN * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Fit to receive cisplatin-containing combination chemotherapy * No previous malignancy other than nonmelanoma skin cancer, carcinoma in situ of the cervix, or incidental localized prostate cancer * No known HIV positivity or chronic hepatitis B or C infection * No uncontrolled hypertension * No symptomatic coronary artery disease, myocardial infarction within the past 6 months, congestive cardiac failure (NYHA class III-IV disease), or uncontrolled or symptomatic cardiac arrhythmia * No clinically significant bacterial or fungal infection * No concurrent grapefruit juice PRIOR CONCURRENT THERAPY: * At least 1 month since prior radiotherapy or radiotherapy involving more than 30% of total bone marrow volume * At least 1 month since prior investigational drug * No prior systemic therapy for locally advanced or metastatic disease * Patients who have received prior neoadjuvant or adjuvant chemotherapy for urothelial cancer (up to 4 courses), completed at least 6 months prior to first documented disease progression, are eligible * No concurrent anticoagulant therapy with warfarin or unfractionated heparin * Patients requiring anticoagulation may be entered on study after successful conversion to low molecular weight heparin * No concurrent medications that have known adverse interactions with sunitinib malate (i.e., strong CYP3A4 inhibitors or inducers) * No prior or concurrent live vaccines (e.g., measles, mumps, rubella, oral polio, bacille Calmette-Guérin \[BCG\], yellow fever, varicella, and TY21a typhoid vaccines)",16.0,120.0,"['bladder cancer', 'transitional cell cancer of the renal pelvis and ureter', 'urethral cancer']"
NCT05208788,Urinary Biomarkers in Paediatric Kidney Transplantation (pKTx),Estimation of Kidney Function Through a Combination of Renal Urinary Biomarkers in Paediatric Renal Transplant Patients - A Multi-centre Prospective Observational Study,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: i) Group 1 (patients \< 18 years of age)- obtaining reference values without any of the pre-defined events * renal transplant patients with stable renal function parameters (mean SCr (or cystatin C) or mean eGFR based on creatinine and / or cystatin C defined as changes ≤ ±15 % for at least three consecutive ambulatory controls). * patients with CKD IV-V (and maintained urine output, without renal replacement therapy and without pre-defined events). * healthy controls. Study patients from group 1 may be assigned to the group 2 in the following conditions: ii) Group 2 (patients \< 18 years of age)- obtaining biomarker-specific characteristic in the presence of any of the pre-defined events * renal transplant recipients with living or deceased kidney transplantation. * patients with CKD IV-V (and maintained urine output without renal replacement therapy). * healthy controls. Exclusion Criteria: i) Healthy controls * any comorbidity / medication which may have an impact on urinary biomarker profile (e.g. primary kidney or liver disease, metabolic disease, vasculitis or other immunological disease other than the pre-defined events). * for group 1: presence of any of the pre-defined event. ii) CKD IV-V * any comorbidity / medication which may have an impact on urinary biomarker profile (e.g. liver disease, metabolic disease, vasculitis or other immunological disease other than the pre-defined events). * for group 1: presence of any of the pre-defined event. iii) Renal transplant patients for group 1: presence of any of the pre-defined event. * Primary non-function of the renal transplant organ. * Blood group (AB0) incompatible. * Detection of donor specific antibody (DSA) positive (panel-reactive antibodies) at time of enrolment. * any comorbidity / medication which may have an impact on urinary biomarker profile (e.g. liver disease, metabolic disease, vasculitis or other immunological disease) other than the pre-defined events. * Presence of other transplanted organs or co-transplanted organs. * Intention to not use a standard maintenance immunosuppression regimen consisting of calcineurin inhibitor (CNI), antimetabolite (mycophenolate or azathioprine), inhibitor of mechanistic target of rapamycin (mTOR) (Sirolimus / Everolimus) with/without corticosteroids. * Any condition that, in the opinion of the investigator, would pose risk to the subject's safe participation, or interfere with their ability to comply with the study requirements, or may impact the quality of the interpretation of the data (e.g. detection of malignancy). * Failure to collect urine samples or incomplete additional CERTAIN dataset (for collecting information about pre-defined events).",0.0,17.0,"['renal transplantation', 'chronic kidney insufficiency', 'healthy controls']"
NCT02091388,Bioavailability of LY03004 and Risperdal® Consta®,"A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Male or female patients aged 18 to 65 years old 2. Patients must have a DSM-IV-TR diagnosis of schizophrenia or schizoaffective disorder based on the Mini-International Neuropsychiatric Interview (MINI) 3. Patients must be clinically stable on antipsychotic medications other than risperidone or paliperidone or clozapine for at least 4 weeks prior to screening, based on clinical assessments AND a Positive and Negative Syndrome Scale (PANSS) total score less than or equal 70 at Screening Visit 4. Patients with a Body Mass Index in range of 18.0 to 35.0 5. Patients with an Informed Consent Form signed by the patient or legally authorized representative Exclusion Criteria: 1. Patients with a mental disorders other than schizophrenia or schizoaffective disorder, according to the DSM-IV-TR 2. Patients who received oral risperidone or paliperidone or clozapine within 14 days prior to screening, or Risperdal® Consta® within 100 days prior to screening or paliperidone palmitate within 10 months prior to screening 3. Patients with neuroleptic malignant syndrome or physical fatigue associated with dehydration or malnutrition 4. Patients who pose a significant risk of a suicide attempt based on history, investigator's judgment or have answered ""yes"" to the questions 4 or 5 for current or past 30 days on the screening form of the Columbia Suicide Severity Rating Scale (C-SSRS) 5. Patients with a history of sensitivity to akathisia and other EPS, especially with previous use of risperidone or paliperidone 6. Patients with uncontrolled diabetes mellitus as indicated by a HbA1c level greater than or equal to 7% 7. Patients with a history of or currently having epilepsy or convulsion disorders 8. Patients who have had electroconvulsive therapy within the past 2 months prior to screening 9. Patients who used medication known to be an inducer or inhibitor for CYP 2D6 within 2 weeks prior to screening 10. Patients with a history of allergic reaction to risperidone or to the excipients of LY03004 11. Patients who have met DSM-IV-TR criteria for substance abuse or dependence with the exception of caffeine or nicotine in the past 6 months prior to screening 12. Patients with a history of clinically relevant cardiac arrhythmia's, cardiovascular disease, thyrotoxicosis, parkinsonism, or hemorrhagic diathesis 13. Patients who are currently taking medications with primarily CNS activities such as antidepressants, mood stabilizers or anticonvulsants 14. Patients who have participated in a clinical trial of another investigational drug within 30 days prior to screening 15. Female patients who are pregnant or are breastfeeding or are of childbearing potential without adequate use of contraception 16. Patients who have any clinically relevant hepatic, renal and cardiac dysfunction, or other medical condition or laboratory abnormality, which in the judgment of the investigator would interfere with the subject's ability to participate in the study",18.0,65.0,"['schizophrenia', 'schizoaffective disorder']"
NCT05663788,Web-based Learning Module on Optical Diagnosis of Early Colorectal Cancer,Web-based Learning Module to Increase the Accuracy of Optical Diagnosis for Detecting the Invasive Pattern of Colorectal Polyps (LODIP Study). Randomised Controlled Trial,RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * Gastroenterologists who have performed \> 300 colonoscopies without supervision and are in the last training year or had finished the Gastroenterology residency after 2014. Exclusion Criteria: * Endoscopists who have learned the invasive pattern in a centre where endoscopists have published a high diagnostic accuracy for predicting deep submucosal invasion (Japanese centres).,28.0,65.0,"['colorectal cancer', 'colorectal cancer stage i']"
NCT03204188,"Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)",COMPLETED,INTERVENTIONAL,ALL,"* INCLUSION CRITERIA: * Men and women with histologically confirmed CLL or SLL * Active disease as defined by at least one of the following IWCLL consensus criteria: * Weight loss greater than or equal to 10% within the previous 6 months. * Extreme fatigue. * Fevers of greater than 100.5 degrees F for greater than or equal to 2 weeks without evidence of infection. * Night sweats for more than one month without evidence of infection. * Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia. * Massive or progressive splenomegaly. * Massive nodes or clusters or progressive lymphadenopathy. * Progressive lymphocytosis with an increase of \>50% over a 2-month period, or an anticipated doubling time of less than 6 months. * High-risk disease defined by meeting at least one of the following three criteria: * Relapsed and/or refractory CLL/SLL. * Presence of high-risk mutations detected by FISH or targeted sequencing, regardless of prior treatments status. * FISH: deletion 17p (or TP53), complex cytogenetics (3 or more abnormalities) * Targeted sequencing: TP53 mutations, SF3B1 mutations, or NOTCH1 mutation. Pathologic mutations occurring at the coding regions are accepted as relevant mutations. * MYC aberration. Aberration includes rearrangement, amplification, and tissue expression by immunohistochemistry * CLL or SLL with disease transformation with Hodgkin-like cells regardless of prior treatment status. * Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1. * Adequate organ function as defined by the study protocol. * Agreement to use acceptable methods of contraception during the study and for 90 days after the last dose of study drug if sexually active and able to bear or beget children. * Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty. * Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information. * Individuals greater than or equal to 18 years old EXCLUSION CRITERIA: * Transformation of CLL into lymphomas other than those with Hodgkin-like cells. * Currently receiving or previously participated to receive an investigational agent within 4 weeks prior to study treatment. * Currently receiving or previously received monoclonal antibodies, immunomodulatory therapy, chemotherapy, radiation, or radioimmunotherapy within 4 weeks prior to study treatment, or has not recovered from non-hematologic adverse events due to a previously administered agent. * Major surgery within 4 weeks of first dose of study drug * Currently receiving systemic steroid therapy (i.e. prednisone) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. * Prior therapy with BTK inhibitor, anti-PD-1, anti-PD-L1, or anti-PD-L2 agent. * Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g.., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. * Known additional malignancy that is progressing or requires active treatment. * Known history of, or any evidence of active, non-infectious pneumonitis that required steroids. * Known bleeding disorders (i.e., von Willebrand s disease or hemophilia). * Known HIV infection * Active hepatitis B or hepatitis C infection. * Recent known active infection requiring systemic therapy that was completed less than or equal to 14 days before the first dose of study drug. * Known history of active tuberculosis. * Any uncontrolled active systemic infection. * Known hypersensitivity to ibrutinib, fludarabine, or pembrolizumab. * Requires concomitant anticoagulation with Coumadin (warfarin) or other vitamin K antagonists. * Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction * History of stroke or intracranial hemorrhage within 6 months before the first dose of study drug * Subjects who received a strong cytochrome P450 (CYP) 3A inhibitor within 7 days prior to the first dose of ibrutinib or subjects who require continuous treatment with a strong CYP3A inhibitor * Currently active, clinically significant cardiovascular disease including uncontrolled or symptomatic arrhythmias, Class 3 or 4 congestive heart failure as defined by New York Heart Association Functional Classification, or a history of myocardial infarction, unstable angina or acute coronary syndrome within 6 months of screening. * Life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib and fludarabine, or put the study outcomes at undue risk * Female patients who are currently in pregnancy, or unwilling to use acceptable methods of contraception or refrain from pregnancy if of childbearing potential or currently breastfeeding. Male patients who are unwilling to follow the contraception requirements described in this protocol. * Psychiatric illness/social situations that would limit the patient s ability to tolerate and/or comply with study requirements. * Unable to understand the investigational nature of the study or give informed consent. * Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification. * Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.",18.0,65.0,"['b-cell chronic lymphocytic leukemia', 'b-lymphocytic leukemia, chronic', 'chronic lymphocytic leukemia', 'leukemia, chronic lymphatic', 'leukemia, chronic lymphocytic, b-cell', 'leukemia, lymphocytic, chronic', 'leukemia, lymphocytic, chronic, b-cell', 'lymphocytic leukemia, chronic, b cell', 'lymphocytic leukemia, chronic, b-cell']"
NCT04039503,A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin,"Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide Versus Placebo in Patients With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Have been diagnosed with type 2 diabetes mellitus (T2DM) and have been treated with insulin glargine (U100), once daily with or without metformin ≥3 months prior to screening visit. * Have HbA1c between ≥7.0% and ≤10.5%. * Have a stable weight (± 5%) for at least 3 months before screening. * Have a body mass index (BMI) ≥23 kilograms per meter squared (kg/m²) at screening. Exclusion Criteria: * Have type 1 diabetes mellitus. * Have had chronic or acute pancreatitis any time prior to study entry. * Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring acute treatment. * Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss. * Have an estimated glomerular filtration rate \<30 mL/minute/1.73 m² \[for participants on metformin, estimated glomerular filtration rate \<45 mL/min/1.73 m2 (or lower than the country-specific threshold for using the protocol-required dose of metformin per local label)\] * Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months. * Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2. * Have been taking weight loss drugs, including over-the-counter medications during the last 3 months.",18.0,65.0,['type 2 diabetes']
NCT01163903,Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours,A Phase I Study Evaluating the Proton Pump Inhibitor Pantoprazole in Combination With Doxorubicin for Advanced Cancer Patients With an Extension Cohort of Patients With Solid Tumours,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Patients must have histologically or cytologically proven advanced solid tumours for whom no standard anticancer therapy exists 2. Measureable and non-measureable disease are both eligible, but disease must be evaluable as defined by RECIST 1.1. 3. Patients \>18 years old 4. At least 21 days since last chemotherapy regimen and/or radiotherapy 5. Recovery from all reversible adverse events of previous anticancer therapies to baseline or to grade \ 50% by multi-gated nuclear angiogram 9. Patient consent must be obtained according to Institutional REB requirements. The patient must sign the consent form prior to registration. 10. Patients must be accessible for treatment and follow-up. 11. Previous Therapy 1. Chemotherapy: Patients can have had limited exposure to prior anthracyclines defined as no more than a total dose of 240 mg/m2 of doxorubicin or 300 mg/m2 of epirubicin (e.g. as received in the AC x 4 or FEC x 3 adjuvant regimens). Patients with prior exposure to other cardiotoxic anticancer drugs (e.g. mitoxantrone) are not eligible. 2. Radiation: Patients may have had prior radiation therapy (including that to the breast or chest wall) provided that has not exceeded 25% of the bone marrow reserve. 3. Previous Surgery: Previous surgery is permitted provided that wound healing has occurred. 4. Hormonal Therapy: Patients may have had prior hormonal therapy. All hormonal agents must be discontinued at least 3 weeks prior to study entry. 12. Laboratory Requirements (must be done within 7 days prior to registration) 1. Neutrophil count (ANC) \> or = 1.5 x 10\^9/L 2. Hemoglobin \> or = 90 g/L 3. Platelet count \> or = 100 x 10\^9/L 4. Bilirubin \ or = 50mL/min Exclusion Criteria: 1. Patients who have previously received more than 240 mg/m2 doxorubicin or 300 mg/m2 epirubicin. 2. Patients receiving concurrent treatment with experimental drugs or anti-cancer therapy. 3. Patients who are receiving drugs that are known to interact with pantoprazole, including: 1. The anti-fungal agents fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole; 2. The antiviral agents: atazanavir, delavirdine, indinavir, nelfinavir, raltegravir, saquinavir, tipranavir; 3. The anticoagulant agents: clopidogrel, dabigatran; 4. The immunosuppressive agent: mycophenolate 5. The anti-inflammatory agent: mesalamine 4. Patients who are receiving oral pantoprazole or other PPI inhibitors may participate if these agents are discontinued at least 7 days before trial entry. 5. Patients with untreated brain or meningeal metastases. (MR or CT scans are not required to rule this out unless there is a clinical suspicion of CNS disease). Patients with treated and stable brain metastases are eligible providing that they have radiological evidence of disease stabilization of at least 3 months duration and are asymptomatic. 6. Patients who have a history of clinically significant cardiac disease, including: 1. Unstable angina/ acute coronary syndrome 2. Congestive heart failure 3. Myocardial infarction within the past year 4. Clinically significant arrhythmia 5. Pericarditis or myocarditis 6. Symptomatic valvular disease Patients with well-controlled hypertension, uncomplicated mitral valve prolapsed or other stable cardiac conditions are eligible. 7. Patients with active or uncontrolled infections or with serious illnesses or medical conditions that would not permit the patient to be managed according to the protocol. 8. Patients with a known bleeding disorder. Patients who are on stable anticoagulation with warfarin or s.c. heparin products are eligible. Patients receiving clopidogrel are excluded. 9. Patients unable or unwilling to give written, informed consent prior to study participation. 10. Women who are pregnant or nursing.",18.0,65.0,['advanced solid tumours']
NCT03892603,Does The Type of Exercise Influence Outcome in Rotator Cuff Related Shoulder Pain,Rotator Cuff Related Shoulder Pain: Does The Type of Exercise Influence Outcome? - A Randomized Controlled Trial,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Pain of at least 3 months duration * At least one positive response in the three following categories 1. Painful arc of movement (flexion; abduction) 2. Positive shoulder impingement test (Neer; Kennedy-Hawkins) 3. Pain during resisted isometric shoulder contraction (external rotation; abduction; Jobe) Exclusion Criteria: * Clinical signs of massive rotator cuff tears (gross weakness of rotator cuff muscles in the absence of pain) * Other shoulder disorders (arthritis, adhesive capsulitis, fracture, acromioclavicular joint pathology) * Undergone previous shoulder surgery on the same side * Presence of significant co-morbidity (neurological disorders, rheumatoid arthritis) * Symptomatic cervical spine pathology defined as reproduction of symptoms with active physiological cervical spine movement * Inability to understand French or English",18.0,75.0,"['shoulder pain', 'rotator cuff injury', 'rotator cuff tendinitis', 'rotator cuff impingement syndrome']"
NCT00495703,The Activity Intervention for Chemobrain,Exercise Intervention for Chemotherapy-Related Cognitive Dysfunction,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: \- Non-metastatic cancer and received at least 4 cycles of chemotherapy, and report the onset of persistent cognitive difficulties following treatment Age 18+ yrs Exclusion Criteria: 1. Have no prior diagnosis of cancer of the central nervous system, 2. Not have engaged in regular exercise in the past year (i.e., 5+ days/wk, 20+ min/d, 3+ months), 3. No cardiovascular disease or orthopedic problems that could be worsened by exercise as reported on the Physical Activity Readiness Questionnaire 4. No major systemic diseases (e.g., liver, kidney or adrenal diseases).",18.0,65.0,"['cancer', 'chemotherapy', 'cognitive impairment']"
NCT01698203,Continuous Wound Catheter Analgesia Associated With Intravenous Morphine PCA After Thoracotomy,Postoperative Analgesia After Thoracotomy Without Thoracic Epidural Analgesia: Continuous Wound Catheter Analgesia Associated With Intravenous Morphine Patient-Controlled-Analgesia (PCA),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: Patients scheduled for thoracotomy who presented with contraindications to TEA. Contraindications to TEA are : * Patient's refusal after informations about advantages and risks of the technique * Anti platelets treatment that can't be discontinued * Anticoagulants at a curative dosage * haemostasis and/or coagulation disorders: thrombopenia \ 1,5 / control, PTT \< 75% * Systemic or local infection of the puncture point * 2 and 3 grade atrio-ventricular heart block without pacing * Severe aortic valve stenosis * Kyphoscoliosis * certain neurological disorders Exclusion Criteria: * Patient's refusal to participate in the study * Psychiatric disorder (impossibility to collect the informed consent) * Patient under juridical protection * On going an other study * Pregnancy, breastfeeding * Non balanced epilepsy * 3 grade auriculo-ventricular heart block without pacing * Severe hepatocellular insufficiency * Anti arrhythmic treatment : class III of the Vaughan William's classification * Skin infection of the puncture point * Allergy to aminoamides local anaesthetic * Surgical difficulties to insert paravertebral catheter",18.0,80.0,"['pain', 'thoracotomy']"
NCT01301703,"Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis",The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Patients suffering from RA * Aged 18 to 64 years old Exclusion Criteria: * Active disease requiring a change in drug regimen * Known allergy to vaccine,18.0,64.0,['rheumatoid arthritis']
NCT01930903,"PaneLux PTCA : Proposing an Alternative Treatment to patiEnts for Whom DES Implantation is Not Indicated, Thanks to Pantera LUX Drug Eluting Balloon","Proposing an Alternative Treatment to patiEnts for Whom DES Implantation is Not Indicated, Thanks to Pantera LUX Drug Eluting Balloon",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Subject has provided a written informed consent 2. Subject \>/= 18 years. 3. Patient affiliated to social security 4. Patient acceptable candidate who accept to be contacted at different terms of clinical follow up (1, 6 and 12 months) 5. Subject eligible for percutaneous coronary intervention AND undergoing a chronical oral anticoagulant treatment OR undergoing any semi-urgent invasive or non cardiac surgical planned intervention with major bleeding risks 6. Subject eligible for Dual Anti Platelet Therapy (DAPT) of acetyl salicylic acid and clopidogrel for at least 3 weeks 7. De Novo coronary lesions: \>/= 50% - \ /=2.5mm and \ 8 days after the initial angioplasty 16. Documented left ventricular ejection fraction (LVEF) \</= 30% 17. Target lesion requiring before stent implantation a device other than a pre-dilatation balloon (including, but not only restricted to laser, cutting balloon, directional coronary atherectomy, rotational atherectomy etc…) 18. Known allergies to acetylsalicylic acid, active agent such Paclitaxel, Expicients like BHTC (Butiriltri-n-hexyl citrate), CoCr, Silicon Carbide.",18.0,65.0,"['coronary artery disease', 'high bleeding risk patients']"
NCT03217903,High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE),High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE),UNKNOWN,INTERVENTIONAL,ALL,Pre-inclusion Criteria: * patient benefiting from social welfcare * patient followed at the University Hospital of Nancy * patient aged 18 years or older * patient informed on research organization and having signed an informed pre-inclusion consent * No personal history of myelodysplastic syndrome * clinical exam adapted to research * one or more blood cytopenia Inclusion Criteria: * patient benefiting from social welfcare * patient followed at the University Hospital of Nancy * patient aged 18 years or older * patient informed on research organization and having signed an informed inclusion consent * definitive diagnosis of high risk myelodysplastic syndrome with excess blasts * eligibility to an Azacytidine therapy as first-line treatment Exclusion Criteria: * personal history or current other cancer * immediate acute myeloid leukemia * personal history of demethylation treatment * pregnant or breast feeding women * life-theatening condition * guardianship * imprisoned patients,18.0,65.0,['high-risk myelodysplastic syndromes with excess blasts']
NCT03964103,qQ-lab Daily-IBS for Irritable Bowel Syndrome,"Efficacy and Colon Attachment of gQ-lab Daily for Patients With Irritable Bowel Syndrome: Randomized, Double-blind, Placebo-controlled, Parallel-group Study",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Korean men and women aged over 19 and 80 2. Patients with IBS meeting the ROME III criteria (Diagnosed with IBS with abdominal discomfort or abdominal pain in the past 3 months and meeting at least two of the following conditions: (1) improvement in defecation; (2) onset of symptoms associated with changes in stool frequency; (3) association with changes in stool form) 3. Patients who underwent colonoscopy in the past 5 years and have been confirmed to have no organ abnormalities 4. Women who are surgically infertile or fertile women who are negative during pregnancy diagnostic tests (urine or seron- hCG). Fertile women who have ""almost no chance of becoming pregnant"" during the study period owing to the use of appropriate contraception (e.g., oral contraceptive pills, IUD, double-barrier method, or hormone implants) or men who have agreed to this 5. People who have no problems in their nerves and mental systems and who can make their own doctors clear 6. The person who agreed in writing to this test Exclusion Criteria: 1. Persons with hypersensitivity to probiotics 2. Pregnant or lactating women 3. People who have received other clinical trial drugs within the first 3 months of visit 1. (If the patient has received any other clinical trial drug within the past 3 months, contact the client's monitor to determine eligibility on a case-by-case basis.) 4. A person who believes that the participant is in a condition or situation in which participation in the clinical trial may be hazardous to the participant 5. Patients with severe congestive heart failure or severe angina 6. If the patient is diagnosed as having lactose intolerance or immunosuppression 7. Patients who are taking or taking medications (medicine for intestinal disorders, lactic acid bacteria) that may affect the test food, probiotics, or during the test period. However, if you are taking the drug, you can take the test after two weeks of abstinence. 8. If the systolic blood pressure measured at Visit 1 is greater than 160 mmHg or diastolic blood pressure is greater than 100 mmHg and hypertension is not controlled regardless of whether the medication is administered or not. 9. Patients with uncontrolled endocrine diseases (such as diabetes), metabolic diseases (e.g. secondary hyperlipidemia) or hypothyroidism (subjects with a history of hypothyroidism) should receive a stable thyroid hormone supplement for at least 4 weeks prior to visit 1 If you are on therapy, you can participate in this test only if the TSH level measured at Visit 2 is within the normal range.) 10. If kidney function is impaired at visit 1 (creatinine\> 2.0 mg / dL) or nephrotic syndrome is observed 11. If the cancer has developed within the past 5 years (unless it is determined to be cured) 12. If there is a history of mental instability and drug / alcohol abuse within the past 5 years, or if major psychiatric illnesses are not adequately controlled and stabilized by medication 13. Visits 1 If you have taken mental nerve agents within the previous 3 months 14. If you take a systemic steroid preparation within 1 month before visit 1 15. Patients who underwent abdominal surgery except for appendectomy, hernia surgery, and cesarean section 16. Any person deemed inappropriate for the judgment of the clinician",18.0,80.0,['irritable bowel syndrome (ibs)']
NCT04137003,Laval University Rouge et or Post ACL Surgery Program Effectiveness,Laval University Rouge et Or Post Anterior Cruciate Ligament Surgery Readaptation Program Effectiveness With Amateur Athletes: A Randomised Clinical Trial,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Amateur athlete aged from 18 to 35 years old doing sports at least 3 times a week * Having suffered from an Anterior Cruciate Ligament rupture * Having undergone Anterior Cruciate Ligament surgery either with an anterior approach (with the patellar tendon) or a posterior approach (with the semitendinosus tendon) * Having a functional deficit (score 85% or under at Knee Outcome Survey - Activity of Daily Living Scale questionnaire and/or score 80% or under at International Knee Documentation Committee questionnaire) * Being available for follow up and actively follow the programme attributed. Exclusion Criteria: * Having suffered from multiple surgery for other ligaments in the same knee. * Having undergone total meniscus removal * Having suffered form Posterior Cruciate Ligament rupture. * Having other injuries that could affect the functional performance and prevent from training.,18.0,35.0,"['anterior cruciate ligament injuries', 'acl']"
NCT05927103,Differences Between Coffee and Non-coffee Drinkers in the Gut Microbiome and Microbiota-Gut-Brain Axis,Differences Between Coffee and Non-coffee Drinkers in the Gut Microbiome and Microbiota-Gut-Brain Axis,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: 1. Be able to give written informed consent. 2. Be between 30 and 50 years of age. 3. Be in generally good health as determined by the investigator. 4. Drink moderate amounts of coffee daily (3-5 cups/day) Exclusion Criteria: 1. Are less than 30 and greater than 50 years of age. 2. Have a significant acute or chronic coexisting illness \[cardiovascular, gastrointestinal (GI) \[to include functional GI disorders, inflammatory bowel disease, coeliac disease, lactose intolerance, food allergies\], immunological, psychiatric \[to include formal or as determined by MINI Psychiatric interview, diagnosis of current major depression, anxiety disorder, bipolar spectrum disorder, schizophrenia, other DSM-IV Axis I disorder\], neurodevelopmental disorders, immunological, metabolic disorders \[to include type I or II diabetes\], or any condition which contraindicates, in the investigators judgement, entry to the study, 3. Have a condition or taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results; all psychoactive medications \[to include anxiolytics, antipsychotics, antidepressants, anticonvulsants, centrally acting corticosteroids and opioid pain relievers), laxatives, enemas, antibiotics, anti-coagulants, over-the counter non-steroidal anti-inflammatories (NSAIDS). Subjects should have a wash-out period of 4 weeks. 4. Be hypertensive. 5. Current prebiotic or probiotic supplement use (a wash-out period of 4 weeks after cessation will allow entry to the study), or habitual consumption of foods deemed by the investigator to be particularly rich in prebiotic fibres or probiotic strains or are vegan. 6. Females who are pregnant or planning a pregnancy, or lactating. 7. Participants who are not fluent in English. 8. Participants who have dyslexia or dyscalculia. 9. Are a current habitual daily smoker. 10. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial. 11. Subjects receiving treatment involving experimental drugs. If the subject has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study. 12. Have a malignant disease or any concomitant end-stage organ disease. 13. Have already done a study in the lab in the past 4 years",30.0,50.0,['healthy']
NCT01403103,Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer,Evaluation of the Effect of 25-OH-Vitamin D3 Therapy on 15-Prostaglandin Dehydrogenase Expression in Primary Tumor and Normal Colorectal Mucosa in Patients With Colorectal Cancer,WITHDRAWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Patients with a suspected diagnosis of adenocarcinoma of the rectum or sigmoid colon (e.g. based on appearance of mass or histology) referred to colorectal surgery who are expected to undergo routine proctosigmoidoscopy or flexible sigmoidoscopy in the surgeon's office as well as resection and/or endorectal ultrasound (EUS) as part of their routine care * The tumor must be accessible for biopsy and suitable for multiple biopsies * Eastern Cooperative Oncology Group (ECOG) performance status of =\ 40 ng/ml,18.0,65.0,"['mucinous adenocarcinoma of the colon', 'mucinous adenocarcinoma of the rectum', 'signet ring adenocarcinoma of the colon', 'signet ring adenocarcinoma of the rectum', 'stage i colon cancer', 'stage i rectal cancer']"
NCT01322503,Susceptibility of Human Volunteers With Different Histo-Blood With Different Histo-Blood Group Antigens to Norovirus,Evaluation of the Susceptibility of Human Volunteers With Different Histo-Blood Group Antigens to Norovirus,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Healthy adults between the ages of 18 and 49 years * Willing and able to provide written informed consent * Able to comply with all study procedures * Have a body mass index of at least 19 * Have a serum IgG antibody titer of \ 1:1600 * Clinically significant findings on history or physical examination * Clinically significant history of diseases or treatments that may affect the immune system's function * Receipt of systemic corticosteroids for greater than 7 days within the past six months * Abnormal screening electrocardiogram (ECG) * Clinically significant respiratory disease, endocrine disease, liver disease, renal disease, or neurological disease * History of malabsorption or maldigestion disorder, major gastrointestinal (GI) surgery, or any other chronic GI disorders that would interfere with the study * Clinically significant abnormalities of the health screening laboratory work * Use of antibiotics within 7 days prior to entry into the inpatient isolation facility (Day -1) * Any medical illness requiring a new prescription medication or hospitalization during the screening period * Temperature ≥38.0°C * Diarrhea or vomiting during the 7 days prior to challenge administration * Allergy to sodium bicarbonate solution * Treatment within the past year for an eating disorder * History of alcohol or drug abuse within past 3 years * Receipt of any vaccine, licensed or investigational, or any investigational product within 30 days of challenge administration or plan to receive any vaccine or investigational product through the study duration * Use of any H2 receptor antagonists or prescription acid suppression medication or over-the-counter (OTC) antacids within 72 hours of investigational product administration (Day 0) * Use of prescription and OTC medications containing acetaminophen, aspirin, ibuprofen, and other non-steriodal anti-inflammatory drugs within 48 hours prior to investigational product administration * Regular use of laxatives or anti-motility agents * Receipt of blood or blood products within the past six months * Subjects who are unwilling or unable to cease smoking for the duration of the inpatient stay * Any other condition, such as a medical, psychiatric, or social condition or occupational responsibility that, in the judgment of the investigator, would interfere with or serve as a contraindication to the subject's participation in the study or assessment of the investigational product * Plan to be living in a confined environment within 3 weeks after receiving the challenge strain * Commercial food handlers, day care workers, or health care workers involved in direct patient contact * Provide child day care services either in a home or in a nonresidential facility * Provide direct care to individuals over 65 years of age, young children (\<2 years) at home or with household contacts who are: * Immunocompromised * Pregnant, or * Breast feeding",18.0,49.0,['healthy adults']
NCT05855603,Cardioinhibitory Reflex Syncope. Permanent Pacemaker Therapy or Cardioneuroablation?,Recurrent Cardioinhibitory Reflex Syncope. PermANent PAcemaker Therapy or CardionEuroablation? A Multicenter RAndomized Clinical Trial,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Aged more than 40 years. * Having a 12-month history that includes at least two documented episodes of spontaneous reflex syncope or one episode that led to injury in addition to at least two presyncopal events, refractory to all recommended types of standard treatment. * Bradycardia-syncope correlation (at least 3 seconds of asystole due to sinus arrest or atrio-ventricular block) confirmed by ECG during spontaneous syncope. * If lacking ECG evidence during spontaneous syncope, a cardioinhibitory response (VASIS type 2A or 2B) on tilt test. * Displaying indicators for pacing such as those suggested in the ESC guidelines for a class I recommendation for patients with reflex syncope. * Significantly decreased quality of life due to syncope. * Sinus rhythm on ECGs. * Obtained written informed consent. Exclusion Criteria: * Intrinsic sinus or atrioventricular nodal disease with a proven indication for permanent pacemaker implantation. * Evidence of structural heart disease. * Contraindications to ablation in the right or left atrium. * Life expectancy \<12 months. * Lacking willingness to comply with the randomization procedure.",40.0,65.0,['reflex syncope']
NCT02521103,Triathlon Tritanium Cone Augments Outcomes Study,"A Prospective, Post-market, Multi-center Evaluation of the Clinical Outcomes of the Triathlon TS Total Knee System With Triathlon Tritanium Cone Augments",ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patient has signed an Institutional Review Board (IRB)/Ethics Committee (EC) approved, study specific Informed Patient Consent Form. * Patient is a male or non-pregnant female, skeletally mature and age 18 years or older at time of study device implantation. * Patient is a candidate for revision of all femoral and tibial components of a total knee replacement. * Patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation. Exclusion Criteria: * Patient has a Body Mass Index (BMI) \> 45. * Patient has an active or suspected latent infection in or about the affected knee joint at time of study device implantation. * Patient has a neuromuscular or neurosensory deficiency, which limits the ability to evaluate the safety and efficacy of the device. * Patient is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's disease) leading to progressive bone deterioration. * Patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. \> 30 days). * Patient has a failed unicondylar knee prosthesis. * Patient has a known sensitivity to device materials. * Patient is a prisoner.",18.0,65.0,"['arthroplasty', 'replacement', 'knee']"
NCT01468103,Laser Iridotomy Versus Surgical Iridectomy in Early Angle Closure,Laser Peripheral Iridotomy Versus Surgical Peripheral Iridectomy in Early Angle Closure:a Randomized Clinical Trial,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. more than 50 years old 2. Diagnosis of either: Primary angle closure suspects, Primary angle closure in need of laser iridotomy or surgical iridectomy 3. Able to give Informed concent Exclusion Criteria: 1. Ophthalmic diseases other than glaucoma and cataract 2. pseudophakic or aphakic patients 3. inability to attend regular follow-up assessment or to give informed written consent 4. Secondary causes of angle closure e.g. subluxed lens, uveitis, trauma and neovascular glaucoma 5. Participating in another study 6. monocular patients",50.0,80.0,"['intraocular pressure changes', 'peripheral anterior synechiae increasing']"
NCT03689803,the Related Factors of Bariatric Surgery on Lipidemia,The Impact of Bariatric Surgery on Estimated Lipidemia in Chinese Obesity Patients: a Retrospective Cohort Study,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: -For the choice of surgical approach, numerous studies have shown that BMI ≧ 45, the general choice of gastric bypass surgery, BMI \<45, you can choose sleeve gastrectomy. The remission rate for T2DM, sleeve gastrectomy has a good result for young patients with shorter duration. In the investigator's country, the BMI less than 45 is majorities. Exclusion Criteria: -BMI\<27.5",18.0,65.0,"['bariatric surgery', 'lipidemia']"
NCT00000903,Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen,"A Phase III Randomized, Controlled Trial of Efavirenz (EFV) or Nelfinavir (NFV) in Combination With Fixed-Dose Combination Lamivudine/Zidovudine (3TC/ZDV) and Indinavir (IDV) in HIV-Infected Subjects With Less Than or Equal to 200 CD4 Cells/mm3 or Greater Than or Equal to 80,000 HIV RNA Copies/ml in Plasma",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria Concurrent Medication: Allowed: * Chemoprophylaxis for Pneumocystis carinii pneumonia. * Topical and oral antifungal agents (except for oral ketoconazole and itraconazole). * All antibiotics as clinically indicated (unless otherwise excluded). * Treatment, maintenance, or chemoprophylaxis with approved agents for opportunistic infections as clinically indicated (unless otherwise excluded). * Systemic corticosteroids for 21 days or less for acute problems. * Recombinant erythropoietin (rEPO) and granulocyte colony-stimulating factor (G-CSF, filgrastim). * Regularly prescribed medications such as antipyretics, analgesics, allergy medications, antidepressants, sleep medications, oral contraceptives, megestrol acetate, testosterone. * Alternative therapies such as vitamins. Patients should report the use of these therapies. * \[AS PER AMENDMENT 2/16/99: Rifabutin can be administered at a reduced dose.\] * \[AS PER AMENDMENT 4/3/00: Systemic cytotoxic chemotherapy. Study team should be notified.\] * \[AS PER AMENDMENT 4/3/00: Expanded access and compassionate use drugs are allowed as part of Step 2 treatment only.\] Allowed with caution: * \[AS PER AMENDMENT 4/3/00: Viagra (sildenafil citrate) at a reduced dose unless otherwise approved by the protocol chair.\] * \[AS PER AMENDMENT 4/3/00: Lovastatin or simvastatin with PIs is not recommended. Caution should be exercised with the use of all other statins when used concomitantly with PIs.\] Concurrent Treatment: Allowed: * Alternative therapies such as acupuncture and visualization techniques. Patients should report use of these therapies. Patients must have: * Documented HIV-1 infection. * CD4 count less than or equal to 200 cells/mm3 or a plasma HIV RNA greater than or equal to 100,000 copies/ml \[AS PER AMENDMENT 2/16/99: * 80,000 copies/ml\] within 60 days prior to entry. * Other lab values performed within 14 days prior to entry. Prior Medication: Allowed: * Zidovudine (ZDV), didanosine (ddI), stavudine (d4T), or zalcitabine (ddC) therapy alone or in combination any time prior to study entry. Exclusion Criteria Concurrent Medication: Excluded: * All antiretroviral therapies other than study medications. \[AS PER AMENDMENT 4/3/00: Compassionate use and expanded access drugs are allowed as part of Step 2 treatment.\] * Investigational drugs without specific approval from the Study Chair. \[AS PER AMENDMENT 4/3/00: Compassionate use and expanded access drugs are allowed as part of Step 2 treatment.\] * Systemic cytotoxic chemotherapy. \[AS PER AMENDMENT 4/3/00: Systemic cytotoxic chemotherapy is allowed. Study team should be notified.\] * Alprazolam, amiodarone, astemizole, bepridil, bupropion, cisapride, clorazepate, clozapine, diazepam, encainide, ergot alkaloids and derivatives of ergot alkaloids, estazolam, flecainide, flurazepam, itraconazole , ketoconazole, meperidine, midazolam, piroxicam, propafenone, propoxyphene, quinidine, rifabutin, rifampin, terfenadine, triazolam, or zolpidem. \[AS PER AMENDMENT 2/16/99: Amiodarone, astemizole, cisapride, ergot alkaloids or drugs containing derivatives of ergot alkaloids, itraconazole, midazolam, triazolam, quinidine, rifampin, terfenadine.\] \[AS PER AMENDMENT 4/3/00: Amiodarone, astemizole, bepridil, cisapride, ergot alkaloids and derivatives of ergot alkaloids, Hypericum perforatum (St. John's wort), itraconazole, midazolam, quinidine, rifampin, terfenadine, triazolam.\] * Vitamin E supplements. \[AS PER AMENDMENT 4/3/00: Multivitamins containing vitamin E are allowed.\] Avoided: * Herbal medications. Patients should report use. Patients with the following prior conditions are excluded: * Acute therapy for an infection or other medical illnesses within 14 days prior to study entry. \[AS PER AMENDMENT 2/16/99: Acute therapy for a serious infection or other serious medical illnesses that are potentially life-threatening and require systemic therapy and/or hospitalization within 14 days of study entry.\] Prior Medication: Excluded within 30 days prior to entry: * More than 1 day experience with lamivudine (3TC), nonnucleoside reverse transcriptase inhibitor, or protease inhibitor. * Erythropoietin, G-CSF, or GM-CSF. * Interferons, interleukins, HIV vaccines, or any experimental therapy. Excluded within 14 days prior to entry: * Alprazolam (Xanax), amiodarone (Cordarone), astemizole (Hismanal), bepridil (Vascor), bupropion (Wellbutrin, Zyban), cisapride (Propulsid), clorazepate (Tranxene), clozapine (Clozaril), diazepam (Valium), encainide (Enkaid), ergot alkaloids or drugs containing derivatives of ergot alkaloids, estazolam (ProSom), flecainide (Tambocor), flurazepam (Dalmane), itraconazole (Sporanox), ketoconazole (Nizoral), meperidine (Demerol), midazolam (Versed), piroxicam (Feldene), propafenone (Rythmol), propoxyphene (Darvon, Darvocet), quinidine, rifabutin (Mycobutin), rifampin (Rifadin, Rifamate, Rifater, Rimactane), terfenadine (Seldane), triazolam (Halcion), or zolpidem (Ambien). \[AS PER AMENDMENT 2/16/99: Agents excluded within 14 days prior to entry are now as follows: * amiodarone, astemizole, cisapride, ergot alkaloids or drugs containing derivatives of ergot alkaloids, itraconazole, midazolam, quinidine, rifampin, terfenadine, and triazolam. Note: * Rifabutin can be administered at a reduced dose of 150 mg/day.\]",13.0,65.0,['hiv infections']
NCT02162303,Colchicine in Vascular Inflammation Assessed With PET Imaging,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Colchicine on Vascular Inflammation as Assessed With Position Emission Tomography (PET) Imaging in Patients With Atherosclerotic Vascular Disease (COLPET)",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Male and female patients providing informed consent * Patient must have evidence of coronary artery disease (CAD) as evidenced by at least one of the following: * Angiographic evidence of at least 50% stenosis in one coronary artery (except for left main coronary artery stenosis, in which 30% is acceptable) * History of prior percutaneous coronary intervention (PCI) * History of prior acute coronary syndrome (ACS) event (ST elevation myocardial infarction (STEMI), non-STEMI or unstable angina) * Patient has a carotid or ascending aorta atherosclerotic plaque inflammation TBR of 1.6 or more as determined by 18F-FDG uptake measured by PET scanning * Patient must be on a stable dose for at least 8 weeks before baseline if taking medications used to control angina, hypertension, serum lipids (including statins) or any medication that can have an effect on inflammation * Female patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practices a birth control method throughout the study and for 30 days after study completion * Patient is judged to be in good general health as determined by the principal investigator * Patient must be able and willing to comply with the requirements of this study protocol Exclusion Criteria: Poorly controlled medical condition, such as uncontrolled diabetes, documented history of recurrent infections, unstable ischemic heart disease, congestive heart failure, a left ventricular ejection fraction of less than 40%, recent stroke (within the past 3 months), chronic leg ulcer or any other condition which, in the opinion of the investigator, would put the patient at risk if participating in the study * History of ACS, PCI, myocardial infarction, carotid revascularization or hospitalization for a cardiac condition within 12 weeks of baseline * Prior coronary artery bypass graft * Planned change in medical treatment during the study, that can have effect on inflammation, for angina, serum lipids, and other conditions * History of cancer or lymphoproliferative disease other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix * History of listeriosis, treated or untreated tuberculosis, persistent chronic infections, or recent active infections requiring hospitalization or treatment with intravenous anti-infective agent within 30 days or oral anti-infective agent within 14 days prior to baseline * Hepatitis B or hepatitis C viral infection * Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or patient with chronic diarrhea * Pre-existent progressive neuromuscular disease or patient with creatine phosphokinase (CPK) level \> 3 times the upper limit of normal at baseline * Current use or plans to use anti-retroviral therapy at any time during the study, or with active chronic disease often treated with a protease inhibitor, including AIDS * Diagnosed with immune deficiency or as immunocompromised * Any of the following: hemoglobin \ 3 times the upper limit of normal, Aspartate aminotransferase (AST) \> 3 times the upper normal limit, total bilirubin \> 2 times the upper normal limit, creatinine \> 150 umol/L, creatinine clearance \< 30 mL/min, or history of cirrhosis or severe hepatic disease * Pregnant or breast-feeding or considering becoming pregnant during the study or for 6 months after the last dose of study medication * History of clinically significant drug or alcohol abuse in the last year * Previous bilateral carotid surgery * Other indications for colchicine use (mainly chronic indications represented by Familial Mediterranean Fever or gout) * History of an allergic reaction or significant sensitivity to constituents of study drug * Use of an investigational chemical agent less than 50 days or 5 half-lives prior to baseline (whichever is longer) * Judged by the investigator to be an unsuitable candidate for the study",18.0,75.0,['atherosclerotic vascular disease']
NCT04919603,Impact of Exercise Intervention on the Phenome,Impact of Exercise Intervention on the Phenome (Metabolism and Predictive Complications) in Well Characterised Pre-diabetes and New Onset Type 2 Diabetes Cohorts in China,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Men and women aged 18-65 years; 2. Normal glucose metabolism or pre-diabetes or newly diagnosed type 2 diabetes Normal glucose metabolism: * FBG\ 180 mmHg and/or diastolic blood pressure \> 100 mmHg; 3. Myocardial ischemia indicated by resting ECG; 4. Cardiac dysfunction indicated by Echocardiogram; 5. Abnormal HS-TNT or NT-proBNP concentration; 6. Foot ulcers, peripheral neuropathy or skeletal disorders; 7. Taking high intensity exercise more than 75 minutes or moderate intensity exercise more than 150 minutes per week during the screening phase 8. ALT or AST levels more than three times the upper limit of the normal range or active liver diseases; 9. eGFR \ 1.5 mg/dl for men or 1.3mg/dl for women; or macro albuminuria (urine albumin/creatinine\>300mg/g) 10. Malignant tumor in active-stage, or in remission stage but less than 5 years from the most recent treatment 11. Past or present confirmed psychiatric illness or drug dependence; 12. Currently taking medications known to affect weight (e.g. anti thyroid drugs, glucocorticoids); 13. Known to have weight-affecting diseases (e.g. malabsorption, functional bowel disease, uncontrolled low sodium/hyperthyroidism, eating disorders); 14. Known to have metabolism-affecting diseases; 15. Other acute diseases supported by clinical evidence which may contradict to the interventions; 16. Pregnancy, currently trying to become pregnant, or of child-bearing potential and not using birth control; 17. Currently participating in another intervention study; 18. Failure to obtain informed consent from participant; 19. Any factors judged by the clinic team to be likely to limit adherence to interventions; 20. Any other medical condition judged by the clinic team not eligible for the trial.",18.0,65.0,"['overweight and obesity', 'physical activity']"
NCT06705803,"Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)","Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)",RECRUITING,OBSERVATIONAL,MALE,"Inclusion Criteria: * Male sex * ≥22 years of age * Histologic diagnosis of prostate cancer * Scheduled to undergo or have already undergone ablation of the prostate as part of routine clinical care or any ongoing clinical trials * Prostate ablation performed with any of the following energy sources: cryotherapy, high-intensity focused ultrasound, irreversible electroporation, laser, microwave, radiofrequency ablation, or photodynamic therapy. Newer methods and instrumentation continue to be developed to ablate tissue, and these energy sources can be entered into the registry as clinical use begins Exclusion Criteria: * Under 21 Years of age.",22.0,65.0,['prostate cancer']
NCT02518503,High Potency Statins and the Risk of Diabetes,"Higher Potency Statins and the Risk of New Diabetes: Multicentre, Observational Study of Administrative Databases",COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Admitted to hospital with a diagnosis (principal or secondary) for acute myocardial infarction or stroke or a procedure for coronary artery bypass graft or percutaneous coronary intervention during their stay in hospital, with no record of a diabetes diagnosis during their hospitalization * Receipt of a prescription for a statin within 90 days of hospital discharge * Patients who are at least 40 years of age at cohort entry * Patients with at least one year of history in the database Exclusion Criteria: * Patients under the age of 40 (\<66 in jurisdictions with drug data for seniors only) * Patients with less than one year of history in the database * Patients who received any cholesterol lowering drugs or diabetes medication/diagnosis in the previous year",40.0,65.0,"['diabetes mellitus, type 2', 'cardiovascular disease']"
NCT06867627,Effect of Combined Aerobic and Resistance Exercise on Semen Quality Among Chinese College Students,Effect of Moderate-intensity Combined Aerobic and Resistance Exercise on Semen Quality in Chinese College Students,COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: 1. College student, 18 to 22 years old. 2. Good health with no eating disorders, mental health disorders, chronic diseases (such as diabetes and cardiovascular diseases), serious systemic illnesses, genitourinary diseases or infections. 3. Assessed as ""low"" physical activity trajectory on the self-reported International Physical Activity Questionnaire (IPAQ) over the past year. 4. In the past year, sperm progressive motility of less than 32% on at least two evaluations at three-month intervals. Exclusion Criteria: 1. Smoking and alcohol dependence. 2. Use of drugs that affect sperm production function, such as hormones and antibiotics, in the past 3 months. 3. History of reproductive system surgery (e.g., cryptorchidism, postoperative varicocele).",18.0,22.0,['semen quality']
NCT06654427,Trauma-Informed Obstetric Care: Development and Implementation of a Toolkit for Obstetrics (OBTIC),Trauma-Informed Obstetric Care: Development and Implementation of a Stakeholder- Informed Toolkit for Obstetric Providers and Patients,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion criteria for pregnant and postpartum patients for individual interviews: * ≥ 18 years old * under the care of an obstetrician or nurse practitioner in the U.S., * English-speaking * have had ≥2 prenatal care encounters, and postpartum if they delivered a surviving infant within the past 12 months * received care at either of the pilot sites during the pilot trial. * Pregnant and postpartum participants will be eligible for the trauma-exposed group if they * report a history of trauma in childhood or adulthood, * are ≥1 year from the time of the traumatic experience * are not currently at-risk for harm from self or others * are willing to discuss experiences related to trauma and are able to do so without experiencing undue distress. * Patient participants will be eligible for the non-trauma group if they deny trauma. * Patients' stratification as White or Women of Color (any racial identity other than non-Hispanic White) will be determined by self-identification in the demographics questionnaire, rather than pre-defined groups, in order to most accurately capture participants' lived experiences. Inclusion criteria for provider participants: * Practicing physicians or nurses * ≥ 6 months of experience in obstetrics * English speaking * Clinician Participants (providers in the participating clinics) will be enrolled in the pilot trial of the obstetric trauma-informed care toolkit intervention. * Clinician participants will be enrolled for group or individual interviews if they consent to do so and meet above criteria. Exclusion Criteria: Patient participants will be excluded from the study interviews if they report * a current unsafe environment (determined by the Assessment of Immediate Safety) * report suicidal ideation (as determined by the PHQ9) * report difficulty discussing experiences related to trauma. Provider participants will be excluded from the study if they do not work at one of the pilot clinics. Provider participants will be excluded from the study interviews if they do not consent to be interviewed.",18.0,99.0,"['trauma', 'obstetrics trauma', 'pregnancy related']"
NCT04493827,Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center,Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * Lung adenocarcinoma * Patients diagnosed at a metastatic stage * Patient who benefited an oncogenic driver research on their histologic samples * Medical follow-up entirely done in Nancy Central Hospital Exclusion Criteria: * Patients with double histology * Synchronous cancer * Patients with surgical care,18.0,65.0,"['adenocarcinoma of lung stage iv', 'adenocarcinoma of lung, response to tyrosine kinase inhibitor in, somatic']"
NCT05150327,Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients,Multicenter Retrospective Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria * Age: from birth * Subject with a liver transplant in one of the centers participating in the study * Invasive fungal infection with filamentous fungus between 2007-2021 * Proven or probable infection with filamentous fungi according to EORTC/MSGERC criteria: * Invasive aspergillosis * Mucormycosis * Fusariosis * Scedosporiosis * Other infection with filamentous fungus * Subject or legal representative for minors, who has not expressed, after information, his opposition to the reuse of his data for scientific research purposes. Exclusion Criteria * Subject or (legal representative for minors) who has expressed his opposition to participating in the study * Subject not with a liver transplant * Subject under guardianship, curatorship or legal protection",18.0,65.0,['fungal infection']
NCT06731127,Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People With HIV,Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People With HIV,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Participants will fall into any of the HIV-positive arms or the HIV-negative control arm. Inclusion criteria for HIV-positive participants are: * Ability to provide signed written informed consent * Documented HIV diagnosis for 1+ year * Antiretroviral therapy for 1+ year * 55 years of age or older * Good general health as shown by medical history and screening laboratory tests at the screening visit: * Hemoglobin ≥ 85 g/L White blood cell (WBC) count = 3300 to 12,000 cells/mm3 * Total lymphocyte count ≥ 800 cells/mm3 * Platelets = 50,000 to 550,000/mm3 * Chemistry panel: alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase \ 550 X109/L * AST or ALT \> 5X the upper limit of normal * Creatinine \> 250 µmol/L * Participant with a malignancy or undergoing chemotherapy * Participant with other significant underlying disease (non-HIV-1) that might impinge upon disease progression or death * Active infection with hepatitis virus (HAV, HBV, HCV) or tuberculosis * Prior surgery or radiation therapy within 30 days of study screening or receipt of any other experimental compound within 30 days of signing informed consent * Any concurrent condition requiring the continued use of immunoglobulin, antineoplastic agents, glucocorticoids (other than corticosteroid nasal spray for allergic rhinitis; topical or ophthalmic corticosteroids for acute, uncomplicated dermatitis or conjunctivitis; over the counter medications for acute, uncomplicated dermatitis for treatment period not longer than 14 days) or other immunomodulator medications (other than NSAIDS which will be allowed for any length of time) * Receipt of any blood product within 3 months prior to screening * Receipt of any vaccine within 1 month prior to screening * Active drug or alcohol use/dependence that, in the opinion of the investigator, would interfere with adherence to study requirements * Any illness or conditions including acute illnesses that, in the opinion of the investigator, may affect the safety of the participant or the evaluation of any study endpoints * Any other conditions judged by the investigator that would limit the evaluation of a participant * Positivity for sexually transmitted infections at the screening visit * Use of any unproven registered and unregistered treatments for COVID-19; Administration of immunoglobulins and/ or any blood products within the three months preceding the planned administration of the vaccine candidate * Any confirmed or suspected immunosuppressive or immunodeficient state (except HIV infection for Group-3), asplenia, recurrent severe infections and chronic use (more than 14 days) immunosuppressant medication within the past 6 months (topical steroids are allowed) * For HIV-negative participants: immune-compromising conditions or on medication which suppresses the immune response.",55.0,65.0,['hiv infections']
NCT04083027,Non-mass Enhancement in Breast MRI,Patterns of Non-mass Enhancement of Breast MRI Using the BI-RADS Lexicon Fifth Edition With Histopathologic Correlation,COMPLETED,OBSERVATIONAL,FEMALE,"Inclusion Criteria: * all female with mean age 50 ± 17 having breast MRI Exclusion Criteria: * Contraindications of MRI as pacemakers, aneurysmal clipping, retained metallic foreign bodies, or claustrophobic patients * Pregnant women especially in the first trimester.",33.0,70.0,['breast neoplasm']
NCT06270927,A Feasibility Study for Randomization of Code Stroke Imaging Strategies,• Code Stroke Imaging (CSI): MRI Or CT As First Scan For Acute Stroke Evaluation And Management,RECRUITING,OBSERVATIONAL,ALL,Inclusion Criteria: * Age ≥ 18 years * Time last known well to presentation ≤ 24 hours * Code-stroke (suspected treatable ischemic stroke) called prior to or upon arrival to Emergency Department * Presenting to Emergency Department for first time during study period Exclusion Criteria: * Transfer patients * Contraindication for brain perfusion scan * Prior inclusion in study,18.0,120.0,['brain ischemia']
NCT06797427,A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers,"An Open-label, Prospective, Randomised, Cross-over Trial to Assess the Pharmacokinetics of an Amorphous Formulation of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Willing and able to give written informed consent for participation in the trial, including consenting to the planned restrictions during the trial. 2. Healthy male or female participant aged 18 to 65 years, inclusive. 3. Body mass index (BMI) ≥18.5 and ≤30.0 kg/m2 at the time of the screening visit. 4. Medically healthy participant without abnormal clinically significant medical/surgical history, physical findings, vital signs, ECG, and laboratory values at the time of the screening visit, as judged by the Investigator. 5. Female trial participants: Only female participants of non-childbearing potential will be considered eligible for participation. Female participants of non-childbearing potential are defined as: * pre menopausal females who have undergone hysterectomy and/or bilateral salpingectomy and/or bilateral oophorectomy, * post menopausal females, defined as having undergone at least 12 months of amenorrhea. In questionable cases a blood sample with detection of follicle stimulating hormone (FSH) \>25 IU/L will be confirmatory. Male trial participants: Male participants must be willing to use condoms during sexual intercourse to prevent pregnancy and/or the drug exposure of a partner from the first IMP administration at Visit 2 and until 3 months after the last IMP administration at Visit 12. In addition, any female partner of a male participant who is of childbearing potential must use contraceptive methods with a failure rate of \ 5 cups (1 cup = approximately 240 mL) of caffeine-containing beverages, as judged by the Investigator. 21. Plasma donation within 1 month of screening or blood donation (or corresponding blood loss) during the last 3 months prior to screening. 22. The Investigator considers the participant unlikely to comply with trial procedures, restrictions, and requirements.",18.0,65.0,['healthy']
NCT01314027,Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer,Adjuvant Gemcitabine Versus NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer: a Randomized Multicenter Phase III Study (NEOPAC Study),TERMINATED,INTERVENTIONAL,ALL,"Inclusion criteria: * resectable adenocarcinoma of the pancreatic head (requiring duodeno-pancreatectomy) * T1-3, Nx, M0 (UICC 6th version, 2002) * infiltration of the portal vein (\ 18 years * written informed consent Exclusion criteria: * contraindication for Whipple procedure * an infiltration \>180° of the portal vein * abutment of the tumor to the superior mesenteric artery * infiltration of the superior mesenteric artery or the celiac trunk * chronic neuropathy \> grade 2 * WHO performance score \>2 * uncorrectable cholestasis (bilirubin \> 100mmol/l despite drainage attempts for more than four weeks prior to inclusion) * female patients in child bearing age not using adequate contraception (oral or subcutaneous contraceptives, intrauterine pessary (IUP), condoms) * pregnant or lactating women * mental or organic disorders which could interfere with giving informed consent or receiving treatments * Second malignancy diagnosed within the past 5 years, except non-melanomatous skin cancer or non-invasive cervical cancer * percutaneous biopsy of the primary tumor",18.0,65.0,['pancreatic cancer']
NCT00003927,"Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer","High-Dose Infusional Taxol, Amifostine, Doxorubicin, and Cyclophosphamide Followed by Stem Cell Rescue for High Risk Primary and Responsive Metastatic Breast Cancer",COMPLETED,INTERVENTIONAL,ALL,"DISEASE CHARACTERISTICS: Histologically proven breast cancer including: Stage IV metastatic disease with current partial or complete response to prior induction chemotherapy High risk primary disease with less than 60% chance of progression free survival at 3 years Stage II tumors with 10 or more axillary node involvement Stage IIIA or IIIB tumors No bone marrow metastases No CNS metastases No more than 10 bone metastases Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age: 59 and under Menopausal status: Not specified Performance status: Karnofsky 80-100% Life expectancy: Not specified Hematopoietic: Neutrophil count greater than 2,000/mm3 Platelet count greater than 150,000/mm3 Hemoglobin greater than 9 g/dL (blood transfusions allowed) Hepatic: Bilirubin no greater than 1.2 mg/dL SGOT or SGPT less than 1.5 times upper limit of normal Renal: Creatinine no greater than 1.2 mg/dL Creatinine clearance at least 80 mL/min No prior hemorrhagic cystitis Cardiovascular: Ejection fraction at least 55% by MUGA No prior valvular heart disease or arrhythmia Pulmonary: DLCO at least 60% lower limit of predicted pCO2 no greater than 43 mmHg on room air pO2 greater than 85 mmHg on room air FEV 1 at least 2 liters Other: No other prior malignancy except basal or squamous cell skin cancer, or carcinoma in situ or stage I carcinoma of the cervix Not pregnant HIV negative Hepatitis B negative No prior history of disabling psychosocial disorder No other CNS dysfunction PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy No more than 2 prior chemotherapy regimens for metastatic disease Prior total doxorubicin dose no greater than 180 mg/m2 Prior total paclitaxel dose no greater than 750 mg/m2 Endocrine therapy: At least 4 weeks since prior hormonal therapy Radiotherapy: At least 4 weeks since prior radiotherapy No prior radiotherapy to the left chest wall No prior radiotherapy to greater than 20% of bone marrow (excluding syngeneic transplantation candidates) Surgery: Not specified",18.0,59.0,['breast cancer']
NCT06722027,CCSH (Compassion-Centered Spiritual Health) for Teams,Compassion-Centered Spiritual Health Interventions for Teams (CCSH-TI) With Faculty and Staff,RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * Full-time employees working in oncology teams at Winship Cancer Institute; * Employees working in intensive care at Emory University St. Joseph hospital. Exclusion Criteria: * Less than 18 years old,18.0,65.0,['health behavior']
NCT07005427,Comparison of Traditional Dysphagia Therapy and Developed Protocol for Dysphagia Patients in Intensive Care Unit,Development of Dysphagia Management Protocol for Adult Patients in Intensive Care Unit,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Adult patients (≥18 years) admitted to ICU with confirmed dysphagia by bedside evaluation within 72 hours of admission * GCS more then 8 Exclusion Criteria: * Preexisting neurological disorders affecting swallowing, head and neck cancer, inability to follow commands, expected ICU stay \<48 hours",18.0,65.0,['dysphagia']
NCT07009327,Efficacy and Safety of Photodynamic Therapy for CIN3,Efficacy and Safety of Photodynamic Therapy for Cervical Intraepithelial Neoplasia 3(CIN3):A Multicenter Prospective Cohort Study,RECRUITING,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * CIN3, photodynamic therapy was required, * type 1 2 transformation area, colposcopy was sufficient * the lesion boundary was completely visible * The ECC did not indicate high-grade lesions Exclusion Criteria: * coexistence or suspicion of cancer; * TCT HSIL * involving glands * Porphyria patients, or suspected allergic to red and blue light. * severe medical comorbidities；",18.0,65.0,['precancerous cervical lesion']
NCT06555627,Embracing Morning BReakfast and Activity for Classroom Engagement,Project EMBRACE: Embracing Morning BReakfast and Activity for Classroom Engagement,RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * 6-11 years old * Enrolled at the participating school Exclusion Criteria: * Younger than 5 years old * Older than 12 years old * Not enrolled in a participating school * Allergic to dairy or gluten,6.0,11.0,['child development']
NCT03104127,Effect of Using a Lower Limb Robotic Device for Patients With Chronic Stroke,"Effect of a Community-based, Bionic Leg Rehabilitation Program on Biomechanical, Cardiovascular and Performance Outcomes in Patients With Chronic Stroke",COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Patients with diagnosis of stroke within 3-60 months * Community patients that are medically stable and currently receiving therapeutic input from Hobbs Rehabilitation * Individuals who are able to stand and step with an aid or assistance * Cognitively aware of task demands * Height: 5ft 2-6ft 3 (158-192 cm) * Weight: \<25 stone (\< 159kg) Exclusion Criteria: * Unresolved deep vein thrombosis * Unstable cardiovascular conditions * Open wounds * Active drug resistant infection * Recent fractures of involved limb * Peripheral arterial disease * Incontinence * Severe osteoporosis * Non weight bearing,18.0,65.0,"['gait, hemiplegic', 'quality of life', 'vascular stiffness', 'stroke']"
NCT03093727,Characterization of Pulmonary Langerhans Cell Histiocytosis,Functional and Genetical Characterization of Pulmonary Langerhans Cell Histiocytosis: Diagnostic and Therapeutical Implications.,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion criteria * Men and women with no age limitation * Established histiological diagnosis of histiocytosis of langerhans cells. * HCLP-compatible clinical-radiological picture. * Signed informed consent Exclusion criteria * Non-acceptance of informed consent. * Absence in clinical history of clinical, radiological and functional variables essential for the diagnosis of HLCP. * Psychiatric disorder or limitation for study compression (including language, socio-cultural problem, etc.). * Radiological findings suggestive of another chronic lung disease. * Active respiratory infection.",18.0,65.0,['langerhans cell histiocytoses']
NCT01506427,A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients,"A Phase I/II, Open Label, Nonrandomized, Multi-Center Study of [F-18]HX4 Positron Emission Tomography (PET) in Head and Neck Cancer Patients",WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patient is \>18 years and male or female of any race / ethnicity. * Patient or patient's legally acceptable representative provides written inform consent Patient is willing and able to comply with protocol procedures. * Patient has newly diagnosed histologically confirmed squamous cell carcinoma of the head and/or neck whose primary origin is from the oral cavity, oropharynx, hypopharynx, larynx or nasopharynx. * Patient is scheduled to have or already has had a clinical \[F-18\]FDG PET/CT scan prior (recommended to be within 14 days prior) to the \[F-18\]HX4 PET/CT scan. * Patient has a primary tumor ≥ 2.0 cm in longest axis measured by CT or MR; or lymph node ≥ 2.0 cm in shortest axis measured by CT or MR if primary tumor \< 2 cm on CT or MR; CT may be part of required \[F-18\]FDG PET/CT scan or a separate pre-surgery CT scan. * Patient is scheduled to undergo complete tumor resection within 7 days for his/her cancer care after the \[F-18\]HX4 PET/CT scan is performed. * Patient has not had nor will have neoadjuvant treatment, including radiation and chemotherapy, prior to patient's planned tumor resection. Exclusion Criteria: * Female patient is pregnant or nursing. * Patient is not capable of remaining still for duration of imaging procedure (\~ 4 hours). * Patient has undergone an investigative, radioactive research procedure within 7 days prior to study participation, or is scheduled to undergo such a procedure during the study participation period. * Patient has chronic renal function failure or is on renal dialysis * Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data.",18.0,65.0,['head and neck cancer']
NCT03911427,Oat and Cholesterol,Impact of Oat Product on LDL Cholesterol in Healthy Men and Women With Elevated LDL-cholesterol,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Fasting LDL cholesterol 116-193 mg/dl (3-5 mmol/L) 2. Males and non-pregnant, non-lactating females 18-65 years 3. Agree to consume the investigational product three times daily for the duration of the study 4. BMI 18.5 to 39.9 kg/m2 5. Blood pressure \ 0.9 times lower limit of normal and \ 20g fiber/per 1000 Kcal or \>40g fiber/day (including soluble fiber supplements) 6. Consumption of more than 2 drinks of alcohol per day, or more than 14 drinks per week 7. Extreme dietary habits 8. Smoking \>5 cigarettes or equivalent per day 9. Use of cholesterol lowering medication or prescription drug or for treating diabetes mellitus within 4 weeks of randomization 10. Active major gastrointestinal disorder 11. Major trauma or hospitalization for a medical condition or major surgical event within 6 months of randomization 12. History of cancer within two years or randomization, except for non-melanoma skin cancer 13. Any condition or substance use which might, in the opinion of the PI, make participation dangerous for the participant, lead to poor attendance or compliance or affect the results",18.0,65.0,['elevated ldl cholesterol']
NCT02507427,Monitoring and Mapping of Erectile Nerve During RALP (MMEN Study),Safety and Efficacy of Pelvic Autonomic Nerve Monitoring and Mapping During Robot Assisted Laparoscopic Radical Prostatectomy for Preservation of Erectile Function,COMPLETED,INTERVENTIONAL,MALE,Inclusion Criteria: * pathologically proven localized prostate cancer (≤cT3a) * patients to undergo robot-assisted laparoscopic prostatectomy at our center Exclusion Criteria: * prior hormone therapy * prior radiation treatment on prostate or pelvis * refused to participate,19.0,80.0,['prostate cancer']
NCT07050927,Long-Term Effect of Online Occupational Therapy-Based Parent Training on Feeding Problems in Infants,Long-Term Effect of Online Occupational Therapy-Based Parent Training on Feeding Problems in Infants: A Randomized Controlled Longitudinal Study,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,FEMALE,Inclusion Criteria: * Mothers of typically developing infants aged between 18 and 24 months * Mothers who report a stress level of 7 or above on a visual analog scale regarding their child's feeding process * Mothers who have the necessary technical equipment to follow the occupational therapy training via online platforms Exclusion Criteria: * Infants born prematurely or diagnosed with significant neurological or developmental conditions * Infants who receive any diagnosis during the intervention or follow-up period * Mothers in the intervention group who miss more than one training session * Mothers who are currently receiving or have previously received occupational therapy or feeding counseling,18.0,65.0,"['feeding difficulties', 'feeding problems', 'food neophobia']"
NCT03318627,Influence of Intraoperative Repair Tension on Postoperative Healing of Full-thickness Rotator Cuff Tears,Influence of Intraoperative Repair Tension on Postoperative Healing of Full-thickness Rotator Cuff Tears,WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Signed informed consent * Male/female from 18-99 years * All arthroscopic reparable transmural supra-/infraspinatus tears * German speaking Exclusion Criteria: * Previous operation on the ipsilateral rotator cuff * Irreparable rotator cuff tear (supra- and / or infraspinatus and / or subscapularis) * static antero-superior subluxation of humeral head * dynamic antero-superior subluxation of humeral head * pseudoparalysis for anteflexion, hornblow sign, dropping- arm sign * fatty infiltration goutallier 3-4 (MRI) * reduced acromiohumeral distance \<7mm (RX) * intraoperative not reparable * Mild/severe osteoarthritis (RX, Hamada II-IV) * Inability of patient (language problems, mental illness, dementia)",18.0,65.0,['rotator cuff tear']
NCT05731427,Research on the Mechanism Affecting Progression of Bronchiectasis,Research on the Mechanism Affecting Progression of Bronchiectasis Based on Omics Method,RECRUITING,OBSERVATIONAL,ALL,Inclusion criteria: * 18 years or older * Bronchiectasis confirmed by high-resolution computed tomographic scan(HRCT) * Chronic expectoration with ability to provide a sputum sample at the study visit * Provision of written informed consent Exclusion criteria: * Traction bronchiectasis * Lack of important clinical information,18.0,65.0,['bronchiectasis']
NCT00940927,Dose-response of Albuterol in Asthmatics,Exclusion of Asthmatics From Clinical Trials Due to the 15 Percent Rule,COMPLETED,INTERVENTIONAL,ALL,"Eligibility Criteria: * Well-defined history of physician diagnosed asthma * Any ethnic background * 8 to 65 years old * Baseline pre-bronchodilator FEV1 of 40% to 80% predicted for age, height, and gender * No oral corticosteroid use, emergency room visits, or hospitalizations within the previous 3 months * Nonsmokers or less than a 5 pack-year history with no smoking in the previous year * Normal physical exam and no confounding diseases were selected * Able to withhold inhaled short-acting b2-agonists or inhaled anticholinergic drugs for 8 hours, oral antihistamines for 5 days, theophylline for 24 hours, and cromolyn, nedocromil, and inhaled corticosteroids for 2 hours prior to the study.",8.0,65.0,['asthma']
NCT03076827,"Effects of Surgery Start Time on Postoperative Interleukin-6, Interleukin-8, and Cortisol",Comparison of Cortisol and Cytokines in Morning and Afternoon Surgerys According to Circadian Rhythm of Cortisol,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Patients scheduled for hip hemiarthroplasty * Patients scheduled for total hip replacement Exclusion Criteria: * Sleep disorder * Mental disorder * Psychiatric medication,20.0,100.0,"['hemiarthroplasty', 'arthroplasty, replacement, hip']"
NCT07264127,Clinical Performance of the I-arch System During the Initial Stage of Orthodontic Treatment,I-arch in Action: Early Clinical Impact From a Randomized Controlled Trial,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Moderate crowding of mandibular anterior teeth (3-6 mm) according to Little's irregularity index (LII) in patients with age of 12 years or older. 2. Full complement of permanent dentition should be present, except for the third molars. 3. Brackets should be placed on maxillary and mandibular anterior teeth without any interference by the existing overbite and overjet. 4. The maxillary and mandibular incisors should not be previously subjected to trauma or root resorption. Exclusion Criteria: 1. Patients with history of previous orthodontic treatment. 2. Severe maxillary and mandibular anterior crowding which is greater than 6 mm (LII). 3. Presence of teeth that are severely misaligned out of the dental arch and cannot be engaged with the aligning arch wire. 4. Prescence of periodontally compromised teeth and previous loss of attachment.",12.0,65.0,['effectiveness of i-arch system']
NCT04042727,Controlling Rapid Atrial Fibrillation With Dexmedetomidine,Controlling Rapid Atrial Fibrillation With Dexmedetomidine (C-RAD) Trial,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Adult patients in a SBU Hospital ICU with rapid-AF (with ventricular rates \>100 bpm). * Patient screening will be conducted prior to patient or LAR consent. Exclusion Criteria: * Patients age \ 400lbs (protocol dosing restriction); * Untreated, symptomatic hypotension (SBP\<90mmHg); * Received amiodarone, lidocaine, or mexiletine w/in 4hrs prior to consent.",18.0,65.0,"['rapid atrial fibrillation', 'heart rate control']"
NCT04942327,Awareness Among Hearing Enhancement Interventions and Reimbursement Criteria of Hearing Implants,How Well Informed is a Otorhynolaryngologist in a Secondary Setting About the Hearing Enhancement Interventions and Reimbursement Criteria Related to Hearing Implants?,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Otorhinolaryngologists working in a secondary setting * Dutch and French speaking Exclusion Criteria: * Otorhinolaryngologists working in a tertiary setting attached to a university,25.0,70.0,"['awareness', 'hearing impairment', 'otorhinolaryngologic surgical procedures', 'implant']"
NCT05008627,PERSONAL PROTECTION EQUIPMENT AND SARS-CoV-2 CONTAMINATION,PERSONAL PROTECTION EQUIPMENT AND SARS-CoV-2 CONTAMINATION: An Observational Quality Control Study,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * Age limit * Staff members who worked in CORONA UNIT Exclusion Criteria: * Staff members who did not work in CORONA UNIT,20.0,65.0,['contaminated medical or biological substances']
NCT04112927,Acoustic OSA Prediction During Wakefulness and Monitoring During Sleep,Acoustic OSA Prediction During Wakefulness and Monitoring During Sleep,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * 1\) age between 18 to 70 years. * 2\) suspected of OSA and referred to full PSG study by a doctor. Exclusion Criteria: * 1\) being diagnosed with a chronic respiratory disease including pulmonary fibrosis, emphysema, respiratory infectious disease, nocturnal asthma, obstructive pulmonary lung disease, pulmonary hypertension, congestive heart failure, sleep related hypoventilation and neuromuscular disorders. * 2\) having insomnia or restless leg. * 3\) drug addiction. * 4\) under the current, direct supervision of the PI of this study.",18.0,70.0,['obstructive sleep apnea']
NCT07008027,Real World Asparaginase Therapy Toxicity,Real World Asparaginase Therapy Toxicity,NOT_YET_RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * Diagnosis of acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia * Enrolled on INITIALL and no more than 10 days after initiation of post-INITIALL therapy * Post-INITIALL therapy is: * Standard of Care (SOC)/Non Protocol Treatment Plan (NPTP) as per Total therapy or * SJALL23T and not scheduled to receive venetoclax Exclusion Criteria: * Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.",18.0,65.0,['drug toxicity']
NCT02010827,Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion,Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: Patients with T2DM * Caucasions above 35 years of age with diet and/or tablettreated T2DM of at -least three months (diagnosis acording to WHO) * Normal haemoglobin * Informed consent Healthy Subjects * Normal fasting plasma glucose (FPG) and normal HbA1C (according to the -World Health Organization (WHO) criteria) * Normal haemoglobin * Age above 35 years * Informed consent Exclusion Criteria: * Inflammatory bowel disease * Nephropathy (serum creatinine \>150 µM and/or albuminuria) * Severe liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) \>3×normal values) * Pregnancy and/or breastfeeding * Age above 80 years * Any condition that the investigator feels would interfere with trial participation Patients with T2DM Healthy Subjects * Diabetes mellitus (DM) * Prediabetes (impaired glucose tolerance and/or impaired FPG) * First degree relatives with DM * Inflammatory bowel disease * Intestinal resection and/or ostomy * Nephropathy (serum creatinine \>150 µM and/or albuminuria * Liver disease (ALAT and/or serum ASAT \>2×normal values) * Pregnancy and/or breastfeeding * Age above 80 years * Any condition that the investigator feels would interfere with trial participation,35.0,80.0,['type 2 diabetes mellitus']
NCT03721627,Chronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease.,Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination Therapy in Treatment of Chronic Hepatitis C Infection in Egyptian Children With Gaucher Disease,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Aged 6 to \<18 years * Parent or legal guardian must provide written informed consent * Treatment naïve or experienced children with chronic HCV infection * Chronic HCV infection (≥ 6 months) documented by medical history or liver biopsy * Screening laboratory values within defined thresholds * No History of solid organ or bone marrow transplantation * No history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage) Exclusion Criteria: * Patients with other sever comorbidities of chronic medical illness (e.g. decompensated heart disease, chronic kidney insufficiency) * Concomitant hepatitis B virus (HBV) or Human immunodeficiency virus (HIV) infection * Medications (systemic steroids, immunosuppressives) * Patients or guardians who are unwilling to participate or sign informed consent",6.0,18.0,"['gaucher disease', 'hcv']"
NCT00417027,Programmed Intermittent Epidural Bolus Time Interval and Injection Volume,Effect of Manipulation of the Programmed Intermittent Bolus Time Interval and Injection Volume on Total Drug Use for Labor Epidural Analgesia: a Randomized Controlled Trial,COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Healthy * nulliparous women * term gestation (greater than or equal to 37 weeks gestation) * spontaneous labor or with spontaneous rupture of membranes Exclusion Criteria: * Systemic disease (e.g., diabetes mellitus, hypertension, preeclampsia) * use of chronic analgesic medications * systemic opioid labor analgesia prior to the initiation of neuraxial labor analgesia * cervical dilation less than 2cm or greater than 5cm at time of initiation of neuraxial analgesia * delivery within 90 minutes of intrathecal injection",18.0,45.0,['labor pain']
NCT00396461,"ICULIP, Influence of Two Lipid Emulsions in the Nosocomial Infection in Critical Patients","Phase IV-IV. ICULIP,a Prospective,Multi-centre,Randomised,Comparative,Double-blind Study to Evaluate Two Different Types of Lipid Emulsions Used for Total Parenteral Nutrition in Critical Patients and Their Influence on Nosocomial Infection.",TERMINATED,INTERVENTIONAL,ALL,"INCLUSION CRITERIA: Patients of both sexes, prospective admission to Intensive Care Units (ICUs), over 18 years, where TPN is required as a nutritional metabolic support for a minimum period of 5 days and where said patients have signed the informed consent form. The indications for administration of parenteral nutrition shall be those recommended by the American Society of Parenteral and Enteral Nutrition (ASPEN), and in particular: * Severe malnutrition * Major intra-abdominal surgery * Peritonitis * Intestinal ischaemia * Intestinal occlusion * Gastrointestinal fistulas * Small intestine Patients of both sexes, over 18 years, that commencing nutritional support with enteral diets in the first 3 days of admission to ICU require parenteral nutrition as: * 75% of the calculated energy requirements have not been reached after three days receiving enteral nutrition. * Gastrointestinal complications have been suffered as a result of enteral nutrition that cannot be treated or are persistent in the first 3 days of admission. In this case EN will be suspended and the patient will be included in the protocol receiving PN. EXCLUSION CRITERIA: * APACHE II \ 400 mg/day) of any kind * Serious chronic neurological disease defined by one of the following criteria: 1. Cerebrovascular accident with persistent neurological deficit in the past six months 2. Neurological deficit that necessitates chronic confinement * Neoplastic patients with metastasis and a life expectancy of less than six months * Patients that underwent chemotherapy or radiotherapy during the month prior to the study * Patients that received chronic treatment with corticoids in the month preceding admission to ICU. Patients receiving treatment with corticoids since admission to ICU for septic shock should not be excluded. * Continuous infusion treatment for more than 24 hours with propofol or with other pharmaceuticals where lipid emulsions are used as the vehicle * Infectious diseases transmitted through the blood, products derived from blood or urine: hepatitis B, C and HIV * Inclusion in another clinical trial * Having received TPN in the month prior to inclusion in the study * Pregnancy * Refusal to participate in the study",18.0,65.0,['critical illness']
NCT00751361,Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial,"Prospective, Randomized, Controlled Clinical Study Evaluating the Efficacy of Rheopheresis for Dry Age-Related Macular Degeneration Dry AMD Treatment With Rheopheresis Trial - ART",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * 50 to 85 years old * diagnosis of AMD in both eyes * must have dry AMD in the study eye * Study eyes with best-corrected ETDRS-visual acuity of 0.1-0.8 * peripheral veins allowing vascular access to establish the extracorporal circuit. Exclusion Criteria: * other retinal or choroidal disorders than AMD * optic nerve disease, glaucoma * conditions that limit the view of the fundus * acute bleeding in any eye General exclusion criteria for the treatment of Rheopheresis: * anaemia * haemorrhagic diathesis or coagulopathy * diabetes * serious acute or chronic kidney or liver failure * hypotension systolic \< 100 mmHg * chronic viral infection (HIV, hepatitis B, C) * epilepsia, psychosis or dementia * a malignant disease or any other condition with life expectancy \< 12 months * known history of alcohol or drug abuse and long term serious nicotine abuse",50.0,85.0,['dry age related macular degeneration']
NCT01060761,Involvement of Patients and Relatives in the Course of Cancer Disease,Involvement of Patients and Relatives in the Course of Cancer Disease With a Particular View to Rehabilitation and the Life With Cancer,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Both the patient and their relative must agree to participate together * Patient admitted to the Hospital * Patient admitted with a lung cancer diagnosis or * Patient admitted with a gynecological cancer diagnosis Exclusion Criteria: * The cancer diagnosis was not verified.,18.0,65.0,"['rehabilitation', 'cancer', 'relatives']"
NCT06996561,Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management,Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. All adult men or women 2. Age 18 to 70 years 3. ASA criteria 1,2 and 3 4. Abdomino-pelvic surgeries (open hernia repair, appendicectomy, open cholecystectomy, laparotomy, hysterectomy, cystectomy) lasting 2-4 hours Exclusion Criteria: 1. Surgical procedure duration lasting more than 4 hours 2. Patients taking anti fungal fluconazole, anticoagulant (Warfarin or Clopidogrel) SNRI (Amitryptalline), Rifampicin or Buprenorphine, 3. History of hypersensitivity or allergy to opioids, 4. Pregnant or breastfeeding mothers, 5. History of narcotic dependency, addiction, and withdrawal 6. Patients experiencing any adverse side effects or complications during surgical procedure requiring intensive care admission 7. Refusing to participate in the study 8. Surgical procedures utilizing other modes of intraoperative analgesia e.g epidural analgesia or nerve blocks",18.0,70.0,"['cholecystectomy', 'hernia, abdominal', 'appendectomy', 'open colorectal surgery', 'laparatomy', 'postoperative pain', 'hysterectomy', 'cystectomy']"
NCT02966561,Pedometer-based Behavioural Intervention for Individuals With COPD to Stay Active After Rehabilitation,Effects of a Brief Pedometer-based Behavioural Intervention for Individuals With COPD During In-patient Pulmonary Rehabilitation on 6-weeks and 6-months Objectively Measured Physical Activity - A Randomised Controlled Trial,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Main diagnosis for the Pulmonary Rehabilitation is an International Classification of Diseases-Code J44.- (Other chronic obstructive pulmonary disease) at all 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Classifications A-D and stages 1-4. Exclusion Criteria: * Considerably reduced health status (severe concomitant disease, which will affect the results of the outcome parameters, for example, cancer or severe cardiac, neurological or orthopaedic comorbidities) * Considerable reduction of sight and hearing * Severe psychiatric condition as secondary diagnosis * Lack of ability to speak German",18.0,80.0,['chronic obstructive pulmonary disease (copd)']
NCT03433261,Ketogenic Diet for Reduction of CNS Oxygen Toxicity in Working Divers,Ketogenic Diet for Reduction of Oxygen Toxicity in Working Divers,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Males \& females between 18 and 50 years old * Able to pedal a bicycle ergometer continuously for 15 minutes * Non-smoker * No history of cardiovascular disease, including coronary artery disease, valvular disease, cardiomyopathy or hypertension. * No history of lung disease Exclusion Criteria: * Prolonged QTc on initial ECG * Currently pregnant or attempting to become pregnant. * Have a history of: 1. Smoking 2. Coronary artery disease 3. Hypertension 4. Seizures 5. Exercise intolerance 6. Psychiatric disorder 7. Previous pneumothorax or pneumomediastinum 8. Hypo or hyperglycemia 9. Diabetes * Regularly take any medications which may alter heart rate, blood pressure, neurotransmitter function, mood or affect.",18.0,50.0,"['cns oxygen toxicity, ketogenic diet']"
NCT02174861,A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.,An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Subject has provided informed consent prior to initiation of any study-specific activities/procedures 2. Completed the 12-week study visit and did not end IP early during the double-blind treatment period of the AMG 334 20120295 (NCT02066415) parent study, and is appropriate for continued treatment. Exclusion Criteria: 1. Development of any unstable or clinically significant medical condition, laboratory or electrocardiogram (ECG) abnormality following randomization into the parent study, that in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion. 2. Systolic blood pressure (BP) 160 mm Hg and/or diastolic BP 100 mm Hg or greater at screening/Day 1. 3. Subject who used excluded concomitant medications between week 8 and week 12 of the parent study",18.0,66.0,['treatment for prevention of chronic migraine']
NCT06702761,Prevalence and Severity of Depression Among Cardiothoracic Surgery Healthcare Workers in Baghdad: A PHQ-9 Cross-Sectional Study,Assessing the Prevalence and Severity of Depression Among Cardiothoracic Surgery Healthcare Workers in Baghdad Using the PHQ-9: A Cross-Sectional Study,RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * Healthcare professionals actively working in cardiothoracic surgery departments in Baghdad, including surgeons, anesthesiologists, nurses, and support staff. * Participants who provide informed consent for participation in the study. * Able to complete questionnaire form. Exclusion Criteria: * Individuals with a previously diagnosed psychiatric condition other than depression that could confound the results. * Incomplete or missing responses on the PHQ-9 questionnaire. * Refusal to provide informed consent. * Participants are currently undergoing treatment for depression or other mental health conditions. * Healthcare workers on long-term leave or who have not actively worked in the cardiothoracic surgery department for the past 3 months.",18.0,65.0,['depression disorders']
NCT06359561,Assessment of Effectiveness and Stimulation Coverage of Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy in Patients with Cervical Lead Placement,Assessment of Effectiveness and Stimulation Coverage of Closed-loop Spinal Cord,ENROLLING_BY_INVITATION,OBSERVATIONAL,ALL,"Inclusion Criteria: * Subject is deemed a suitable candidate for SCS trail and permanent implant and has been routinely scheduled to undergo an SCS trial phase with the Evoke SCS System. * Subject is ≥ 18 years old. * Subject is not pregnant or nursing. * Subject is willing and capable of giving informed consent. Exclusion Criteria: * Subject currently has an active implantable device including pacemakers, spinal cord stimulator or intrathecal drug delivery system. * Subject is incapable of understanding or responding to the study questionnaires. * Subject is incapable of understanding or operating the patient programmer handset.",18.0,65.0,"['chronic pain syndrome', 'multi focal pain', 'failed neck surgery syndrome', 'polyneuropathies']"
NCT05268861,The Role of Cognition in Motor Learning After Stroke,The Role of Cognition in the Use of Enhanced Intrinsic Feedback for Motor Learning After Stroke,RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * Sustained a first cortical/sub-cortical ischemic/hemorrhagic stroke less than 3 years previously and are medically stable. * Are no longer receiving treatment. * Normal or corrected-to-normal vision. * Have arm paresis (Chedoke-McMaster Arm Scale 2-6/7) and spasticity (Modified Ashworth Scale ≥ 1/4) but can voluntarily flex/extend the elbow to approximately 30 degrees in each direction. Exclusion Criteria: * Other major neurological or musculoskeletal problems that may interfere with task performance. * Marked elbow proprioceptive deficits (\ 6 mm). * Uncorrected vision. * Depression (≥ 14 Beck Depression Inventory II).,40.0,75.0,"['stroke hemorrhagic', 'stroke, ischemic', 'cognitive impairment']"
NCT03260361,Hypnosis and MEOPA in Regional Painful Syndrome Complex,Combined Therapy of Hypnosis Kinesitherapy and MEOPA in Patients With Regional Painful Syndrome Complex,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Regional Painful Syndrome Complex Exclusion Criteria: * deaf people,18.0,65.0,['algodystrophy of hand']
NCT02330861,Relationship Between Pressure and Flow Velocity on Coronary Physiology,Relationship Between Pressure and Flow Velocity on Coronary Physiology,WITHDRAWN,INTERVENTIONAL,ALL,Inclusion Criteria: * A patient who are planned to do percutaneous coronary intervention for stenosis in the left circumflex artery without any lesions in other coronary arteries * Or a patient who is performed coronary angiography without significant stenosis lesion in 3-coronary vessel Exclusion Criteria: * A patient with coronary stenosis with LAD * Hemodialysis * Acute coronary syndrome * Congestive heart failure * A patient with shock vitals,18.0,65.0,['coronary stenosis']
NCT06711861,Multicenter Retrospective Study on Streptobacillus Moniliformis Infections in France,Multicenter Retrospective Study on Streptobacillus Moniliformis Infections in France,RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * Minor patient aged 1 to 17 years * Adult patient ≥18 years * Proven Streptobacillus moniliformis infection between 01/01/2007 and 31/12/2023 * Subject not objecting, after being informed, to the reuse of their data for the purposes of this research * Holders of parental authority not objecting, after being informed, to the reuse of their data for the purposes of this research their child for the purposes of this research Exclusion Criteria: * Subject and/or holder of parental authority having expressed opposition to participating in the study",1.0,65.0,['streptobacillus moniliformis infections']
NCT04347161,Implementation Strategies for Monitoring Adherence in Real Time,Implementation Strategies for Monitoring Adherence in Real Time,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Adult patient (age \> 18 years) with NSCLC at UPHS who is receiving one of the following nine oral therapies: afatinib, erlotinib, dacomitinib, gefitinib, osimertinib, alectinib, brigatinib, crizotinib, or lorlatinib. * Patient possession of a mobile device that can send/receive SMS texts * Ability to respond to questions and engage with ""Penny"" in English * Ability to provide informed consent to participate in the study * Approval from the patient's medical oncologist to be approached Exclusion Criteria: * Inability to respond to questions and engage with ""Penny"" in English * Inability or unwillingness to provide informed consent to participate in the study * Inability to engage with SMS text-messaging platform * Concurrent enrollment in a therapeutic clinical trial * Taking more than one oral targeted therapy or concurrent chemotherapy during the study window * Lack of approval from the patient's oncologist",18.0,65.0,"['lung cancer', 'medication adherence', 'symptoms and signs']"
NCT00183261,Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection,A Randomized Phase II Study of Therapeutic Immunization and Treatment Interruption Among Subjects Who Began Potent Antiretroviral Therapy Within 30 Days of Diagnosis of Acute or Recent HIV Infection,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Initiated HAART within 30 days of an acute or recent HIV-1 infection diagnosis. More information on this criterion can be found in the protocol. * Initiated HAART within 30 days of documented acute or recent HIV-1 infection without interruption for more than 7 days * Sustained viral suppression, defined as a viral load of 500 copies/mL or less 12 months prior to baseline with an undetectable HIV-1 RNA viral load between 60 to 7 days prior to baseline * CD4 count of 450 cells/mm3 or more OR 35% or more between 60 to 14 days prior to baseline * Ad5 neutralizing antibody titer of 200 or less at screening * Willing to follow all study procedures and schedules * Willing to interrupt HAART for at least 24 weeks following completion of the vaccination stage * Negative for hepatitis B surface antigen (HBsAg) at screening * Willing to use acceptable forms of contraception * Infected with HIV-1 subtype B, if this information is available Exclusion Criteria: * Virologic relapse, defined as 2 consecutive measurements of viral load of 500 copies/mL or more at least 7 days apart within 12 months of baseline visit * Received more than 7 days of continuous HAART other than that received within 16 days of acute or recent HIV-1 infection. Participants who received HAART as part of post-exposure prophylaxis (PEP) more than 6 months prior to the start of initial HAART may be eligible, provided that they did not acquire HIV-1 infection from the event that required PEP. * History of anaphylaxis or allergy to vaccine components, including Tris buffer, magnesium chloride, and polysorbate 80 (Tween) * History of clinically significant heart, lung, kidney, liver, pancreatic, gastrointestinal, or neurological disease that, in the opinion of the study investigator, may interfere with the study * Contraindication to intramuscular (IM) injection, such as anticoagulant therapy or thrombocytopenia * Receipt of any immune globulin or blood products within 3 months prior to baseline * Receipt of any live vaccine within 30 days prior to baseline or any inactivated vaccine within 14 days prior to baseline * Previous receipt of any HIV vaccine. Participants that were documented to have received only placebo are not excluded. * History of any AIDS-defining illness. If a participant's sole AIDS-defining illness is Kaposi's sarcoma limited to the skin and is not anticipated to require systemic chemotherapy, that participant is not excluded. * Currently receiving drugs or biologics not approved by the Food and Drug Administration (FDA) other than investigational HIV medications * Current or past participation in other studies that might alter the participant's response to the study vaccination * Use of any immunomodulatory agents, including but not limited to interleukin-2 (IL-2), granulocyte/macrophage-colony stimulating factor (GM-CSF), and systemic corticosteroids, within 30 days prior to baseline * Active alcohol or substance use that, in the investigator's opinion, may interfere with the study * Any other criteria or condition that, in the investigator's opinion, may interfere with the study * Unwilling or unable to contribute to the planned peripheral blood mononuclear cell (PBMC) blood collection * Pregnancy or breastfeeding",18.0,55.0,['hiv infections']
NCT06908161,Functional Assessments in Vision Impairment,A Novel Approach for Capturing Real-world Functional Assessment Outcomes in Participants With a Vision Impairment,NOT_YET_RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: 1. Willing to provide signed informed consent. 2. Be available for study visits. 3. Willing to comply with study assessments. 4. In good general health and ambulant. 5. Aged over 18 years of age. 6. Have a vision impairment caused by any ocular condition which affects independent mobility. 7. Agree to allow the research team into their home and local environments. 8. Participate in assessments in public settings Exclusion Criteria: 1. Significant co-morbidities which prohibit involvement in study visits. 2. Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study. 3. Cognitive deficiencies, including dementia or progressive neurological disease. 4. Have a psychiatric condition that, in the investigator's opinion, precludes compliance with the protocol including past or present psychoses and bipolar disorder. 5. Deafness or significant hearing loss. 6. Inability to converse in English.",18.0,65.0,"['retinitis pigmentosa (rp)', 'diabetic retinopathy (dr)', 'age related macular degeneration (amd)', 'glaucoma', 'retinal dystrophy']"
NCT04930861,Study of Codivir in Patients With COVID-19,Phase 1 Clinical Study of Codivir in Outpatients With COVID-19,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Age between 18 and 60 years; 2. Male or female; 3. SARS-CoV-2 infection indicated by rapid test and confirmed by RT-PCR. 4. Mild or moderate COVID-19: * The oxygen saturation in room air \>93%; * \<30 breaths per minute; 5. No signs of hemodynamic decompensation. 6. Absence of pregnancy in women of childbearing age. 7. Able to understand and comply with the requirements of the protocol. 8. Consent to participate Exclusion Criteria: 1. Participants in need of O2 supplementation by catheter or mask, invasive mechanical ventilation, or vasopressors. 2. Onset of symptoms or rapid test or positive RT-PCR for more than 72 hours of inclusion. 3. Participants in use or expected to use within 24 hours prior to the inclusion of drugs that are under clinical investigation as a therapeutic option for the treatment of COVID-19 (eg hydroxychloroquine, chloroquine, ivermectin, nitazoxanide, among others) during the study period; 4. Body mass index less than 19.9 or greater than 35; 5. Comorbidities such as: other serious infections, active malignancies, autoimmune diseases, liver, kidney or heart failure; another systemic disease and / or laboratory abnormality, which, in the investigator's opinion, prevent the patient from participating in the study; 6. Concomitant HIV, HBV or HCV infection. 7. Pregnancy or lactation; 8. Participation in another clinical trial in the 12 months preceding inclusion; 9. Anti-COVID-19 vaccination at any time; 10. Vaccination for any other infection in the 4 weeks prior to inclusion; 11. Any condition that increases the risk of participating in the study, in the opinion of the investigator.",18.0,60.0,['covid19']
NCT06966661,Peer-Supported E-Health Intervention for College Student Weight Management and Mental Health,Peer-Supported E-Health Intervention for College Student Weight Management and Mental Health,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Full-time undergraduate students aged 18-25 years * Baseline BMI ≥ 24.0 kg/m² * Able to provide informed consent * Owns a smartphone or computer with internet access * Willing to attend monthly lectures and complete online modules Exclusion Criteria: * Current participation in another weight-management or psychological intervention program * Diagnosis of an eating disorder, severe psychiatric illness, or medical condition affecting weight (e.g., hyperthyroidism) * Pregnant or planning pregnancy during the study period * Any physical limitation precluding participation in light-to-moderate physical activity * Inability to communicate in the language of intervention materials",18.0,25.0,"['depression - major depressive disorder', 'psychological well being', 'obesity prevention']"
NCT03747861,"Measuring Accuracy of Wristband for Registration of ECG RR-Intervals for One Hand, SenceBand in Comparison to Holter","An Open Clinical Study of Measuring Accuracy of RR- Intervals and Determining the Heart Rate Variability With a Wristband for Registration of ECG RR Intervals for One Hand, SenceBand Compared to the Holter Monitor.",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Subject has given written informed consent; 2. Subject is male or female, aged 18-75; 3. Subject has understood and complied with the requirements of the study protocol and; 4. Subject is fluent in Ukrainian. Exclusion Criteria: 1. Subject has cardiac pacemakers; 2. Subject is a pregnant woman; 3. Subject has an allergy on polyurethane; 4. Subject refers to vulnerable groups of the population; 5. In investigator's opinion subject is not able physically or intellectually to fulfill the requirements of protocol.",18.0,75.0,['hrv']
NCT05527561,Effect of Latin Dance on Middle School Girls' Social Physique Anxiety and Physical Self-esteem,Effect of Latin Dance on Social Physique Anxiety and Physical Self-esteem of Middle School Girls,UNKNOWN,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * The population must be middle school girls and between the ages of 13 and 15; * Contestants must be in good health, but must not have a Latin dance background; * Only students who can complete these training requirements can be included in the research data. Exclusion Criteria: * Boys in middle school should be excluded from this study; * Some girls' students with professional dance foundation should be excluded; * Participants were not healthy middle school students such as patients, mental patient, drug addiction, or special students who were seriously depressed, sub-health; * Students who are consistently late or absent from training sessions will eventually be excluded.",13.0,15.0,"['mental health issue', 'physical illness']"
NCT05414461,Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer,Efficacy of PD-1-inhibitor-based Combination Therapy in Patients With Metastatic Colorectal Cancer,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * patients who had both baseline measurable lesion(s) and at least one post-baseline radiological disease reassessment * patients with identified genomic status Exclusion Criteria: * patients who received immune monotherapy * patients who stopped treatment for any reason without identified response assessment.,18.0,65.0,['colorectal cancer']
NCT06753461,Intrahepatic Blood Flow Occlusion and Cardiac Injury Risk in Partial Hepatectomy,Intrahepatic Blood Flow Occlusion Strategies and Postoperative Cardiac Injury Risk in Partial Hepatectomy: a Ten-Year Retrospective Study,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: Hospitalized patients aged ≥18 years who underwent partial hepatectomy between November 28, 2004, and May 20, 2024. Exclusion Criteria: 1. End-stage renal disease patients (requiring renal replacement therapy) 2. ASA score ≥ 4 3. Lack of intraoperative hepatic portal occlusion data 4. Insufficient perioperative myocardial injury biomarker measurement data",18.0,65.0,"['perioperative myocardial injury', 'myocardial injury after non-cardiac surgery', 'hypotension', 'ischemia reperfusion injury']"
NCT04617561,Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II,Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II：A Randomized Controlled Open-label Clinical Trial,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Patients aged 18-75 years; 2. The diagnosis of PBC is clear and does not meet the Paris criteria for diagnosing PBC overlap AIH, but it needs to meet 3xULN \< ALT \< 5xULN or 3xULN \< AST \< 5xULN or 1.3xULN \< IgG \< 2xULN, and liver pathological biopsy excludes moderate or higher interface inflammation; 3. Agreed to participate in the trial, and assigned informed consent. Exclusion Criteria: 1. The presence of hepatitis A, B, C, D, or E virus infection; 2. Patients with presence of cirrhosis; 3. Patients with presence of fulminant liver failure; 4. Liver damage caused by other reasons: such as primary sclerosing cholangitis, non-alcoholic steatohepatitis, drug induced liver disease or Wilson's disease; Pregnant and breeding women and women of childbearing age in need of reproduction; 5. Severe disorders of other vital organs, such as severe heart failure, cancer; 6. Parenteral administration of blood or blood products within 6 months before screening; 7. Recent treatment with drugs having known liver toxicity; 8. Taken part in other clinic trials within 6 months before enrollment. 9. patients with contraindications of glucocorticoid",18.0,70.0,"['hepatitis, autoimmune', 'primary biliary cholangitis']"
NCT00878761,Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA),"Randomized Double-Blind, Placebo-Controlled, Single and Multiple Dose, Dose-Escalation Study of STX 100 in Renal Transplant Patients With Biopsy Proven Interstitial Fibrosis and Tubular Atrophy (IF/TA)",WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Consenting adult patients, 18 (or the legal age of consent) to 65 years old, male or female. * eGFR ≥ 25 ml/min (Cockcroft-Gault formula). * Six to 60 months post renal transplant at the initiation of screening. * Qualifying renal biopsy obtained within 8 weeks prior to randomization with histologic evidence of ≥ Grade 2 IF/TA (Banff score) without morphologic evidence of a treatable etiology (e.g., BK virus nephropathy, chronic obstruction). * Adequate bone marrow and liver function * Weight between 40-110 kg. * Female patients must be surgically sterile, postmenopausal (minimum 1 year without menses and verified by follicular-stimulating hormone \[FSH\] levels), or agree to use contraception from the time of signing the informed consent form through 16 weeks following the last injection of study medication. Male patients must also agree to use birth control for either themselves or their partner, as appropriate, from the time of signing the informed consent form through 16 weeks following the last injection of study medication. Exclusion Criteria: * Recipient of a multi-organ transplant. * History of T-cell mediated rejection (TCMR) within 3 months prior to randomization. * Patients who are receiving high dose corticosteroids at the time of screening. * Histologic evidence of acute TCMR (≥ Banff Grade 1A) on a qualifying renal biopsy for this study. Patients with 'borderline' changes (Banff criteria) on a qualifying renal biopsy are eligible for this study if the Principal Investigator believes treatment for TCMR is not warranted. * Prior or current histologic evidence of polyomavirus BK virus nephropathy. * Any histologic finding on the qualifying renal biopsy that the Investigator believes warrants modifying the patient's current therapy. * Evidence of active tissue invasive cytomegalovirus or Epstein-Barr virus infection. * History of malignancy, including carcinoma or post-transplant lymphoproliferative disorder. * History of chronic pulmonary disease or smoker within the past 5 years or more than 15 pack-years exposure. * Serious local infection or systemic infection within 3 months prior to screening. * Surgery within 3 months prior to Day 1 (other than minor cosmetic surgery, minor dental procedures, or percutaneous kidney transplant biopsy). * Positive test for HBsAg, HCV, or HIV antibody at screening. * Treatment with another investigational drug, investigational device, or approved therapy for investigational use within 1 month prior to dosing.",18.0,65.0,['chronic allograft dysfunction']
NCT06048861,Evaluation of Joint Position Sense in Carpal Tunnel Syndrome,Evaluation of Joint Position Sense With Two Different Electrogoniometers in Mild and Moderate Carpal Tunnel Syndrome,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * mild to moderate CTS confirmed with EMG * having symptoms for at least 3 months * not receiving medical treatment and physiotherapy until 3 months before the study at the latest Exclusion Criteria: * having trauma in the affected extremity in the last 6 months * having cervical radiculopathy * having brachial plexopathy * having cognitive problems * having neurological problems * being pregnant,22.0,65.0,['carpal tunnel syndrome']
NCT06203561,Effect of Intermittent Oro-esophageal Tube vs Nasogastric Tube in Tracheostomized Patients With Intracerebral Hemorrhage,Comparative Study of Intermittent Oro-esophageal Tube Feeding vs Nasogastric Tube Feeding in Tracheostomized Patients With Intracerebral Hemorrhage: Improving Clinical Outcomes and Safety,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * meeting the diagnostic criteria for Intracerebral Hemorrhage. * with placement of a tracheotomy tube. * requiring enteral nutrition support. * age over 18 years. * able to cooperate with treatment and questionnaire investigation, (Generally with a Mini-Mental State Examination (MMSE) score ≥ 24) . Exclusion Criteria: * combined with tumors in the head, neck, esophagus, or gastrointestinal tract * an abnormal structure observed in the oral, pharyngeal, nasal regions or esophagus * with unstable vital signs or severe dysfunction of organs including heart, liver, lungs, or kidneys * with severe hemorrhagic disease or bleeding tendency; 5) with contraindications for enteral nutrition * with dysphagia caused by non-stroke-related reasons in the past",18.0,65.0,['intracerebral hemorrhage']
NCT03896061,A Videographic Study to Evaluate the Impact of a Pulsed Firing Technique on Staple Line Interventions in Laparoscopic Sleeve Gastrectomy,A Videographic Study to Evaluate the Impact of a Pulsed Firing Technique on Staple Line Interventions in Laparoscopic Sleeve Gastrectomy,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Willingness to sign a Video, Audio and Digital Data Release consent for participation; and * Scheduled for a laparoscopic sleeve gastrectomy procedure. Exclusion Criteria: * Prophylactic use of buttressing material * Other staple line reinforcement",18.0,65.0,['hemostasis']
NCT06657742,Validity and Reliability of SCIM-SR,Validity and Reliability of the Turkish Version of the Spinal Cord Independence Measure Self-Report,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * SCI \>1 month * 18-70 years * agree to participate * give written consent Exclusion Criteria: * not read Turkish, * not write Turkish, * cognitive problems",18.0,70.0,['spinal cord injuries']
NCT01018342,Fed Study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg,Single-Dose Food In Vivo Bioequivalence Study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules (100 mg; Mylan) and Macrobid® Capsules (100 mg; Procter & Gamble) in Healthy Volunteers.,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * healthy, adult subjects, 18 years and older * able to swallow medication Exclusion Criteria: * institutionalized subjects * history of any significant disease * use of any prescription or OTC medications within 14 days of start of study * received any investigational products within 30 days prior to start of study",18.0,65.0,['healthy']
NCT03520842,Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer,Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Histologic or cytologic confirmed diagnosis of non-squamous non-small cell lung cancer that is recurrent or metastatic. * Documentation of pathogenic KRAS mutation * Previous receipt of at least one systemic therapy for recurrent or metastatic disease OR previous receipt of adjuvant systemic therapy within 6 months of enrollment; there is no limit on number of prior therapies allowed * Prior systemic therapy must be completed within 2 weeks of study treatment, with either improvement of clinically significant treatment-related toxicities to grade 0-1 OR stabilized to a new baseline * Previously treated OR asymptomatic non-progressing \ 1.5x ULN * Total bilirubin ≤ 1.5x ULN OR direct bilirubin ≤ ULN for patients with total bilirubin levels \> 1.5x ULN * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x ULN (≤ 5x ULN for patients with liver involvement of their cancer) * Must be able to swallow and retain oral medication * Women patients of childbearing potential and men patients with women partners of childbearing potential must agree to use adequate contraception or agree to abstain from heterosexual activity beginning at the time of signing informed consent until at least 3 months after the last dose of study treatment; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not considered childbearing Exclusion Criteria: * Previously treated with regorafenib * Known allergy to regorafenib or methotrexate * Currently receiving another systemic standard or investigational anti-cancer therapy; prior investigational therapy must be completed within 4 half-lives (if known) or 2 weeks, whichever is longer; the maximal washout of investigational therapy will not exceed 4 weeks prior to study treatment; bone medications such as bisphosphonates and receptor activator of nuclear factor kappa-Β (RANK) ligand inhibitors permitted * Leptomeningeal disease as documented by cerebrospinal fluid (CSF) cytology * Clinically significant cardiovascular related disease including: * Uncontrolled hypertension (systolic pressure \> 140 mm Hg or diastolic pressure \> 90 mmHg on repeated measurements, i.e., 3 or more separate days within one week) despite optimal medical management * Congestive heart failure - New York Heart Association (NYHA) class III or greater * Active coronary artery disease (i.e., unstable or new onset angina within 3 months of study treatment; myocardial infarction within 6 months of study treatment) * Clinically significant cardiac arrhythmias other than atrial flutter/fibrillation * Stroke, including transient ischemic attacks, within 6 months of study treatment * Other clinically significant arterial events, except for controlled asymptomatic pulmonary embolism, within 6 months of study treatment * Clinically significant hemorrhage or bleeding event within 1 month of study treatment * Uncontrolled symptomatic pleural effusion or ascites * Known active additional malignancy that is undergoing or expected to undergo systemic treatment during duration of study participation * Known history of human immunodeficiency virus (HIV) infection or known current active hepatitis B (i.e., hepatitis \[Hep\] B deoxyribonucleic acid \[DNA\] positive in prior 3 months) or hepatitis C infection (i.e., Hep C ribonucleic acid \[RNA\] positive in prior 3 months) * Major surgical procedure (e.g., involving the opening of a major body cavity) within 4 weeks of study treatment; this does not apply to low risk procedures (i.e., thoracentesis; paracentesis; chest tube / PleurX catheter placement; line placement; needle biopsy of tumor; and bronchoscopy) * Presence of a clinically significant non-healing wound, non-healing ulcer, or bone fracture * Concomitant therapy required at time of first dose of study treatment, including: * Strong CYP3A4 inhibitors and CYP3A4 inducers * Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors, and probenecid * Women who are pregnant or breast feeding * Any condition which, in the investigator's opinion, including substance abuse, medical, psychological or social conditions that makes the patient unsuitable for trial participation or may interfere with the patient's participation in the study",18.0,65.0,"['kras gene mutation', 'metastatic malignant neoplasm in the brain', 'recurrent non-small cell lung carcinoma', 'stage iv non-small cell lung cancer ajcc v7']"
NCT06825442,AAGL 2021 Classification and Surgical Complications in Women With Endometriosis,AAGL 2021 Classification System And Risk Of Surgical Complications In Women Undergoing Surgery For Endometriosis,NOT_YET_RECRUITING,OBSERVATIONAL,FEMALE,Inclusion Criteria: * 18 years to 55 years; * Pelvic ultrasound and/or radiological (MRI/ CT scan with rectal insufflation) diagnosis of endometriosis and surgery; * At least 90 days of follow-up after surgery; * Acquisition of informed consent for participation in the study and processing of data Exclusion Criteria: * Gynaecological oncology; * Incomplete resection of macroscopic endometriotic lesions,18.0,55.0,['endometriosis']
NCT04339842,Eating Habits of Adults During the Quarantine,Eating Habits of Adults During the Quarantine,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * Being between the ages of 18-80 * Spending most of their time at home in quarantine because of the Coronavirus outbreak not to contract the virus * Having internet access * Being able to read and comprehend English language Exclusion Criteria: * Having any mental impairment or degeneration * Having any life-threatening health condition,18.0,80.0,"['health behavior', 'eating behavior']"
NCT00967642,Intravenous Insulin in Patients With Diabetes After Percutaneous Coronary Intervention (PCI),Intravenous Insulin for 24 Hours in Patients With Diabetes Mellitus Submitted to Percutaneous Coronary Intervention With Stent: Effects Upon Oxidative Stress and Inflammatory Markers,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients with Diabetes Mellitus submitted to Percutaneous Coronary Intervention with Stent bare metal * Age: 18-80 years old Exclusion Criteria: * Restenosis * Drug elution stent * Acute coronary syndrome at last 30 days * Use anti inflammatory, antibiotic, vitamin E * Inflammatory disease or oncologic",18.0,80.0,"['diabetes mellitus', 'percutaneous coronary intervention']"
NCT05339542,Platelet Rich Plasma in Plantar Fasciitis,Musculoskeletal Ultrasound Changes in the Plantar Fascia After a Single Injection of Platelet Rich Plasma Compared to Steroid,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: \* Clinical diagnosis of plantar fasciitis Exclusion Criteria (history or current): * Rheumatic diseases * Foot Trauma * Neurological diseases * Thyroid disease * Diabetes mellitus * Chronic Renal Failure,18.0,65.0,['plantar fascitis']
NCT04888442,Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL,A Phase I Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Diagnosed with B-ALL，and meet one of the following conditions: 1. First-line or multiple-line salvage chemotherapy did not achieve complete remission； 2. Early relapse after complete remission (\ 60; 8. No serious mental disorders; 9. The function of important organs is basically normal: 1. Heart function: echocardiography indicates that the cardiac ejection fraction is ≥50%, and the electrocardiogram has no obvious abnormalities; 2. Renal function: serum creatinine≤2.0×ULN; 3. Liver function: ALT and AST ≤3.0×ULN; 4. Total bilirubin and alkaline phosphatase≤2.0×ULN (Gilbert syndrome ≤ 3.0×ULN); 5. Blood oxygen saturation\>92%. 10. Have standards for apheresis or venous blood collection, and no other cell collection contraindications; 11. The patient himself or his guardian agrees to participate in the clinical trial and signs the ICF, indicating that he understands the purpose and procedures of the clinical trial and is willing to participate in the research. Exclusion Criteria: 1. With central nervous system disease at the time of screening; 2. Have received CAR-T therapy or other genetically modified cell therapy; 3. Participated in other clinical studies within 1 month before screening; 4. Have received the following anti-tumor treatments before screening: received chemotherapy, targeted therapy or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter); 5. Have received a live attenuated vaccine within 4 weeks before screening; 6. Cerebrovascular accident or seizure occurred within 6 months before signing the ICF; 7. Suffered from any of the following heart diseases: 1. NYHA stage III or IV congestive heart failure; 2. Myocardial infarction or CABG occurred ≤6 months before enrollment; 3. Clinically significant ventricular arrhythmia, or history of unexplained syncope (except for cases caused by vasovagal or dehydration); 4. History of severe non-ischemic cardiomyopathy. 8. Uncontrollable infection in the 2 weeks before screening； 9. Active autoimmune diseases； 10. Patients with malignant tumors other than acute lymphoblastic leukemia within 5 years before screening, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and duct in situ after radical resection cancer； 11. HBsAg or HBcAb positive and HBV DNA is greater than the normal range; HCV antibody is positive and HCV RNA greater than the normal range; HIV antibody positive; syphilis positive; CMV DNA positive; 12. Women who are pregnant or breastfeeding, and male or female subjects who plan to have children within 1 year after receiving pCAR-19B cell reinfusion; 13. Other situations considered by the researcher to be unsuitable to participate in the study.",22.0,70.0,"['acute lymphoblastic leukemia, in relapse', 'refractory acute lymphoblastic leukemia']"
NCT00331942,Breast Cancer Associated Antibodies,Study of Breast Cancer Associated Antibodies,UNKNOWN,OBSERVATIONAL,FEMALE,"Inclusion Criteria BC: * Subjects 18 years or over. * Patients diagnosed with suspected breast cancer, (positive mammography or ultrasound or physical examination) and have a positive biopsy. * Patients willing to participate as evidenced by signing the written informed consent. Exclusion Criteria BC: * Subjects less than 18 years * Patients with prior history of other tumors (except skin cancer) * Hematologic systemic disorders * Patients that have undergone chemotherapy * Patients that have been under anesthesia in the last three months. * Patient not willing to sign written informed consent. Inclusion Criteria Control - * Subjects 18 years or over * Patients willing to participate as evidenced by signing the written informed consent * Subjects had a negative mammography in the past three months. Exclusion Criteria Control - * Subjects less than 18 years * Hematological malignancies * History of any past tumors * Other breast pathology * Patients that have been under anesthesia in the last three months * Patients treated with immuno-suppressant drugs * Patient not willing to sign written informed consent",18.0,65.0,['breast cancer']
NCT05646342,PLR in a Good Helath After 24 Week of Preganancy,PLR in a Good Helath Women After 24 Week of Preganancy,UNKNOWN,OBSERVATIONAL,ALL,Inclusion Criteria: * All Pregnante Women in good health after 24 week of preganancy Exclusion Criteria: * All young women under 18 years old * unhealthy women,18.0,65.0,"['itv sosu aortique', 'cardiac output, high', 'plr']"
NCT06140342,A Music-Based Mobile App for People Living With Alzheimer's Disease and Related Dementias (ADRD),A Music-Based Mobile App to Combat Neuropsychiatric Symptoms in People Living With ADRD,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria for person with dementia * A person with ADRD exhibits neuropsychiatric symptoms of dementia such as agitation, restlessness, depressed mood, etc. * Stability with or without psychotropic or anti-depressant medications * Ability to hear with or without an assistive device Inclusion Criteria for Caregivers * Family or close friend caregiver of persons with dementia * Must be able to read and write in basic English Exclusion Criteria for all participants * Inadequate hearing * History of psychosis or other mental disorders other than depression * Presence of substance or alcohol abuse",18.0,65.0,"['dementia', 'agitation', 'depressive symptoms']"
NCT02197442,Bioequivalence Study of Valsartan 320mg Tablets Under Fasting Conditions,"An Open Label, Balanced, Randomized, Two-treatment, Four-period, Two-sequence, Single Oral Dose, Crossover, Fully Replicate Bioequivalence Study of Two Formulations of Valsartan 320 mg Tablet in Healthy, Adult, Human Subjects Under Fasting Condition",COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: 1. Healthy, adult, human volunteers between 18 to 45 years of age (both inclusive) living in and around Ahmedabad city or western part of India. 2. Having a Body Mass Index (BMI) between 18.5-24.9 (both inclusive), calculated as weight in kg/height in meter2. 3. Not having any significant disease in medical history or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, 12- lead ECG and X-ray chest (P/A view) recordings. 4. Able to understand and comply with the study procedures, in the opinion of the investigator. 5. Able to give voluntary written informed consent for participation in the trial. 6. In case of female subjects: * Surgically sterilized at least 6 months prior to study participation; Or * If of child bearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study. And • Pregnancy test must be negative. Exclusion Criteria: 1. Known hypersensitivity or idiosyncratic reaction to valsartan or any of the formulation excipients or any related drug. 2. History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system. 3. Sitting blood pressure less than 110 /70 mm Hg and pulse rate less than 60 or more than 100 beats per minute at the time of screening. 4. Presence of orthostatic hypotension. 5. If the QTc interval were to be more than 450 ms on ECG measurement at the time of screening. 6. Inability to remain in an upright position at the time of dosing. 7. Ingestion of a medicine (including herbal remedies) at any time within 14 days before dosing in period-I. In any such case subject selection were at the discretion of the Principal Investigator. 8. Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAIDs induced urticaria. 9. A recent history of harmful use of alcohol (less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc) or consumption of alcohol or alcoholic products within 48 hours prior to receiving study medicine. 10. Smokers, who smoke 10 or more than 10 cigarettes/day or inability to abstain from smoking during the study. 11. The presence of clinically significant abnormal laboratory values during screening. 12. Use of any recreational drugs or history of drug addiction or testing positive in pre study drug scans. 13. History or presence of psychiatric disorders. 14. A history of difficulty in donating blood. 15. Donation of blood (1 unit or 350 mL) or receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication. Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study. Note: In case the blood loss is ≤ 200 mL; subject may be dosed 60 days after blood donation or last sample of the previous study. 16. A positive hepatitis screen including hepatitis B surface antigen and/or HCV antibodies. 17. A positive test result for HIV antibody. 18. An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to receiving the study medicine in period-I. In any such case subject selection were at the discretion of the Principal Investigator. 19. Consumption of grapefruit or grapefruit products within 48 hours prior to dosing. 20. Nursing mothers (females).",18.0,45.0,['healthy']
NCT00060242,Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer,Phase II Trial Of Combretastatin A-4 Phosphate (CA4P) In Advanced Anaplastic Carcinoma Of The Thyroid,COMPLETED,INTERVENTIONAL,ALL,"DISEASE CHARACTERISTICS: * Histologically confirmed\* anaplastic or poorly differentiated variant thyroid cancer, including 1 of the following: * Recurrent/regionally advanced disease no longer amenable to definitive curative surgery or radiotherapy * Untreated metastatic disease NOTE: \*If original/diagnostic tumor blocks are unavailable, tumor must be accessible for pretreatment core needle biopsy * Must have relapsed or progressed during or after prior combined modality therapy (e.g., systemic chemotherapy and radiotherapy) for regionally advanced (but not metastatic) disease * Measurable or evaluable disease * Patent trachea and airway by screening direct and indirect laryngoscopy\* NOTE: \*For patients with bulky thyroid/neck masses and/or suspected airway obstruction * No active brain metastases, as evidenced by any of the following: * Symptomatic involvement * Cerebral edema by CT scan or MRI * Radiographic evidence of progression since definitive therapy * Continued requirement for corticosteroids PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 Life expectancy * At least 12 weeks Hematopoietic * Absolute granulocyte count at least 1,500/mm\^3 * Platelet count at least 75,000/mm\^3 * Hemoglobin at least 8.5 g/dL Hepatic * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * ALT and AST no greater than 3.5 times ULN Renal * Creatinine no greater than 1.5 times ULN Cardiovascular * LVEF at least 50% by MUGA * EKG normal * No evidence of prior myocardial infarction (e.g., significant Q waves), QTc greater than 450 msec, or other clinically significant abnormalities * No history of angina (even if controlled by medication) * No congestive heart failure * No uncontrolled atrial arrhythmias * No clinically significant arrhythmias, including any of the following: * Conduction abnormalities * Nodal junctional arrhythmias and dysrhythmias * Sinus bradycardia or tachycardia * Supraventricular arrhythmias * Atrial fibrillation or flutter * Syncope or vasovagal episodes * No significant heart wall abnormality or heart muscle damage by MUGA * No uncontrolled hypertension (blood pressure consistently greater than 150 mm Hg systolic and 100 mm Hg diastolic regardless of medication) * Patients with previous hypertension are allowed provided there is clinical documentation of controlled blood pressure for 2 months prior to study enrollment * No symptomatic peripheral vascular disease * No symptomatic cerebrovascular disease Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No grade 2 or greater preexisting motor or sensory peripheral neuropathy * No uncontrolled hypokalemia or hypomagnesemia * No concurrent serious infection * No other nonmalignant medical illness that is uncontrolled or whose control may be jeopardized by study therapy * No psychiatric disorders or other conditions that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent biologic therapy * No concurrent immunotherapy * No concurrent prophylactic colony-stimulating factors (e.g., filgrastim \[G-CSF\] or sargramostim \[GM-CSF\]) Chemotherapy * See Disease Characteristics * At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) * No other concurrent chemotherapy Endocrine therapy * See Disease Characteristics * No concurrent hormonal therapy, except any of the following: * Gonadotropin-releasing hormone agonists for hormone-refractory prostate cancer * Hormone replacement therapy * Oral contraceptives * Megestrol for anorexia/cachexia Radiotherapy * See Disease Characteristics * More than 4 weeks since prior radiotherapy with progressive disease beyond radiation ports * No prior radiotherapy to more than 30% of the bone marrow * No concurrent radiotherapy Surgery * See Disease Characteristics * More than 4 weeks since prior major surgery Other * At least 6 weeks since other prior therapy associated with delayed toxicity * No prior therapy for metastatic disease * No concurrent medication(s) known to prolong the QTc interval, unless medication(s) can be held for at least 72 hours before, during, and for at least 6 hours after study drug administration * No other concurrent investigational therapy * No other concurrent antineoplastic or cytotoxic therapy",18.0,65.0,['head and neck cancer']
NCT02643342,A 2-year Longitudinal Study on the Structural and Optical Effects of Orthokeratology Treatment on Eye,A 2-year Longitudinal Study on the Structural and Optical Effects of Orthokeratology Treatment on Eye,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * 6 to 10 years old * Myopia: between 0.50 D and 4.00 D in both eyes * Astigmatism: \<1.50 D; ≤ 1.25 D for with-the-rule astigmatism (axes 180 ± 30); ≤ 0.50 D for astigmatism of other axes in both eyes * Anisometropia: ≤ 1.50 D * Symmetrical corneal topography with corneal toricity \<2.00 D in both eyes * Agree for randomization Exclusion Criteria: * Contraindications for orthokeratology wear (e.g. limbus-to-limbus corneal cylinder and dislocated corneal apex) * Any type of strabismus or amblyopia * Myopic treatment (e.g. refractive surgery and progressive lens wear for myopic control) before and during the study period * Rigid contact lenses (including orthokeratology lenses) experience * Systemic condition which might affect refractive development (for example, Down syndrome, Marfan's syndrome) * Ocular conditions which might affect the refractive error (for example, cataract, ptosis) * Poor compliance for lens wear or follow-up",6.0,10.0,['myopic progression']
NCT00419042,Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC),A Multicenter Randomized Phase II Trial in NSCLC Stage IV et IIIB in Elderly Dependent Patients With Evaluation of the Sequence Gemcitabine First Line Followed by Erlotinib When Progression Versus Erlotinib First Line Followed by Gemcitabine When Progression.,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Age \> 65 * Comorbidities score, PS and frailty score according to table 1 * No dementia, faecal or urinary incontinence, repeated falls * ADL = 0, IADL = 0-1 * Life expectancy at least 12 weeks * Creatinin clearance \> = 30 ml/mn (according to Cockcrofts-Gault formula) * Competency to give written informed consent * Haematological functions as follows : neutrophiles count \> 1.5 x 109/l and platelets \> 100 x 109/l hemoglobin \> 9,5 g/dl - Hepatic function as follows : Bilirubin \ 0 and IADL \> 1- performance status \>2 (ECOG) * peripheral neuropathy grade 2 or more * dementia, repeated falls, urinary or faecal incontinence * contra-indication to corticosteroids * contra indication to a product of this study * unwilling or unable to comply with study requirements, for personal, family, sociologic, geographic or any other reason * inability of the subject to give written informed consent * lack of liberty following legal or administrative decision * hypersensitivity to polysorbate * hypersensitivity to erlotinib or any excipients of this product * unusual hereditary disorders, as galactosemia, deficit in lactase and syndrome of malabsorption in glucose or galactose * participation in concomitant clinical trial * bronchioloalveolar or neuroendocrine or composite carcinoma * superior vena cava syndrome",65.0,65.0,['non small cell lung cancer']
NCT01485042,Dose Escalation Study of Pazopanib Plus TH-302,Phase I Dose Escalation of Pazopanib Plus TH-302 in Advanced Solid Tumors,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Histologically and/or cytologically confirmed malignant solid tumor that is refractory to standard therapies, or for which no standard therapies exist, or for whom pazopanib would be considered a therapeutic option. * Disease must be measurable by RECIST 1.1 criteria (see Appendix 1). * Age ≥ 18 years * Karnofsky Performance status ≥ 80% (see Appendix 2) * Life expectancy of at least 3 months * Adequate bone marrow function as shown by: * ANC ≥ 1.5 x 109 * Platelets ≥ 100 x 109/L * Hemoglobin ≥ 9 g/dL; Erythropoietin and transfusion support is permitted provided treatments are not required more than every 8 weeks. Hemoglobin must be stable above or equal to 9 g/dL for at least 2 weeks prior to day 1of study drug without blood transfusion to maintain hemoglobin level. * Adequate liver function as shown by: * serum bilirubin ≤ 1.5x ULN * PT/PTT/INR ≤ 1.5x ULN * ALT and AST ≤ 2.5x ULN * Adequate renal function: creatinine clearance (estimated) ≥ 50 cc/min by Cockroft-Gault or 24 hour urine (see Appendix 6). * Baseline MUGA or ECHO must demonstrate LVEF ≥ 50% * TSH, T3 and T4 within normal limits; Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism. * Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days from day 1 of study drug; both men and women must be willing to use two methods of contraception, one of them being a barrier method during the study and for 6 months after last study drug administration. * Signed informed consent Exclusion Criteria: * Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks from day 1 of study drug (including investigational agents, chemotherapy, radiation therapy, antibody based therapy, etc.) * Patients who: * have had a major surgery or significant traumatic injury within 4 weeks from day 1 of study drug, * have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or * are anticipated to require major surgery during the course of the study. * Patients who have exhibited hypersensitivity reactions to pazopanib and/or a structural compound, biological agent, or formulation. * Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent with the following exceptions: * Intermittent steroids (not to exceed 4 mg every day) may be used on an as-needed basis * Patients on physiologic replacement doses of steroids due to adrenal insufficiency for any reason may remain on these medications. * Topical, inhaled or intra-articular corticosteroids * Active brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases. Treated, asymptomatic metastases are permitted provided the patient has been off steroids for at least 1 month prior to day 1 of study drug. * Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or O2 saturation \ 100 bpm) * Previous history of CVA, TIA, angina pectoris, acute MI or history of recent re-perfusion procedures (e.g. PTCA), pulmonary embolus or untreated deep vein thrombosis (DVT) within 6 months from day 1 of study drug. NOTE: Subjects with recent DVT who have been therapeutically anti-coagulated for at least 6 weeks are eligible. * Congestive heart failure (New York Heart Association (NYHA classification, see Appendix 4 functional classification III-IV). * Proteinuria at screening demonstrated by urine analysis (UA) \> 1+ or 24 hour urine protein ≥ 1 gram/24 hours. * Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study as so judged by the treating physician. Examples include but are not limited to: * Severely impaired lung function (e.g. use of home O2, history of Idiopathic Lung Disease (ILD), any evidence of ILD on scan. * Active or uncontrolled severe infections requiring treatment with antibiotics. * Liver disease * Poorly controlled hypertension \[defined as systolic blood pressure (SBP of \>140 mmHg or diastolic blood pressure (DBP) of \>90 mmHg\] NOTE: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. Following antihypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals. At least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement. * Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of oral medications (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection). * Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to day 1 of study drug * History of hemoptysis within 1 month prior to day 1 of study drug. * History of abdominal fistula or gastrointestinal perforation at any point within 6 months prior to day 1 of study drug, unless surgically repaired. * Active peptic ulcer disease inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other gastrointestinal conditions with increased risk of perforation or gastrointestinal bleeding. * Use or need for full dose anticoagulation other than low molecular weight heparin (e.g. Lovenox and no other bleeding risk). * Invasion or encasement of a major artery. Abutment without invasion or encasement is permitted. * Serious, non-healing wound, active ulcer, or untreated bone fracture as judged by treating physician. * Active, bleeding diathesis. * Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage. * Known history of HIV or Hepatitis B or C seropositivity. * Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. Two acceptable forms of contraceptives must be continued throughout the trial by either sex. Hormonal contraceptives are not acceptable as a sole method of contraception. (Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to day 1 of study drug). * Concomitant use of CYP3A4 inducers, strong inhibitors or substrates with a narrow therapeutic window. * Corrected QTc interval \> 480 msec. If QTc interval is \> 480 msec, then 2 additional ECGs should be obtained over a brief period of time (e.g., within 15-20 minutes) to confirm the abnormality. * Patients unwilling to or unable to comply with the protocol.",18.0,65.0,['solid tumors']
NCT03039842,Combination of Dextromethorphan and Memantine in Treating Bipolar Disorder,Combination of Dextromethorphan and Memantine in Treating Bipolar Disorder,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * A 2-day minimum for hypomania to diagnose bipolar II disorder * A total of Hamilton Rating Scale for Depression scored at least 18 or Young Mania Rating Scale scored at least 14 at the screening stage * Must allow to ensure acceptable compliance and visit Exclusion Criteria: * Pregnant females or nursing * Women of childbearing potential not using adequate contraception * Received dextromethorphan, memantine, other antiinflammatory medication within 1 week prior * Clinically significant medical condition (cardiac, hepatic and renal disease) * Received electroconvulsive therapy patients within 4 weeks prior to the first dose of double-blind medication * Increase in total SGOT, SGPT, BUN and creatinine by more than 3X upper limit of normal.",18.0,65.0,['bipolar disorder ii']
NCT00515242,Therapeutic Massage for Generalized Anxiety Disorder,Therapeutic Massage for Generalized Anxiety Disorder,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Member of Group Health, Seattle metropolitan area * Generalized Anxiety Disorder confirmed by SCID * At least moderate anxiety Exclusion Criteria: * Serious mental health co-morbidity * Any life threatening condition * Currently receiving psychotherapy * Substantial alcohol use * Contraindications for massage",18.0,70.0,['generalized anxiety disorder']
NCT06959342,Modification of Inhibitory Control and Craving Through Transcranial Direct Current Stimulation (tDCS) as an Add-On Treatment for Substance Use Disorder,Modification of Inhibitory Control and Craving Through Transcranial Direct Current Stimulation (tDCS) as an Add-On Treatment for Substance Use Disorder,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * main diagnosis: alcohol use disorder according to DSM-5 * patients of any gender aged 18 to 65 * normal vision or correctable visual impairment. * sufficient ability to communicate verbally and in writing * ability to give fully informed consent after reviewing thorough written information Exclusion Criteria: * withdrawal of consent * severe internal, neurological, or psychiatric comorbidities (e.g., lifetime schizophrenia, bipolar disorder, or other severe mental disorders according to ICD-10 and DSM-5, such as severe depression or PTSD within the last 12 months). * Exclusion criteria for an EEG/tDCS examination (e.g. metal implants in the head, epilepsy, etc.) * severe withdrawal symptoms (CIWA-R \> 7) * alcohol intoxication (breath alcohol concentration \> 0 ‰) * Pharmacotherapy with psychoactive substances within the last 14 days (exceptions: clomethiazole or benzodiazepines used in withdrawal treatment, provided they were discontinued at least 3 days prior; antidepressants or anxiolytics taken at stable doses). * drug or alcohol use within the last 7 days * for women: pregnancy * suicidal tendencies or danger to others",18.0,65.0,"['alcohol use disorder', 'substance use disorders']"
NCT07259642,Comparison of Different Debonding Techniques of Clear Aligner Attachments,"Clinical Comparison of Different Debonding Techniques of Clear Aligner Attachments: A Single-center, Split-Mouth Randomized Clinical Trial",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients aged 18 to 44 years with permanent dentition * No history of taking medication in the last 24 hours (e.g., painkillers, corticosteroids, and antiflu drugs) * Patients with no missing teeth except for third molars * Patients who underwent clear aligner treatment (Invisalign®) without an extraction protocol by one of the co-authors of the present study * Patients who completed aligner treatment and reached the attachment removal stage * Patients with at least 4 attachments in each quadrant of the mouth and a total of at least 16 attachments * Patients in good general and oral health with no periodontal disease Exclusion Criteria: * Patients with endodontic treatment, large restorations, and buccal restorations * Patients with a history of previous orthodontic treatment * The presence of systemic diseases that may cause dentin and enamel hypersensitivity * Patients who underwent surgical treatment and displayed signs of gingival recession * Patients who received teeth whitening in the last 8 weeks.",18.0,44.0,"['orthodontic pain (d013850)', 'orthodontic patient experience', 'orthodontic aligners', 'orthodontic']"
NCT05914142,Study on the Safety and Effectiveness of Varian ProBeam Proton Therapy Equipment in the Treatment of Solid Tumors,Study on the Safety and Effectiveness of Varian ProBeam Proton Therapy Equipment in the Treatment of Solid Tumors,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1.18≤ age≤ 80 years; 2.First-diagnosed patients with tumors of the nervous system, head and neck, chest, abdomen, spine, pelvic cavity, limbs, etc. by tissue/cell pathology; 3.ECOG physical condition is graded as 0 to 2; 4.Women of childbearing had negative results in the blood pregnancy test (Human Chorionic Gonadotropin, HCG) 7 days prior to the first treatment; 5.The subject or subject's guardian is able to understand the purpose of the study, demonstrate sufficient compliance with the protocol and sign informed consent form Exclusion Criteria: 1. The subject with radiotherapy contraindications, including the known genetic tendencies that increase the sensitivity of normal tissue radiotherapy or the accompanying diseases that lead to hypersensitivity to radiotherapy; 2. The subject with other uncontrolled tumors except that to be treated according to medical history or the investigator's estimation, or with other malignant tumors within five years prior to enrollment; 3. Implanted pacemakers or other metal prosthesis within the scope of proton therapy; 4. Other situations that investigator determines not suitable for enrollment",18.0,80.0,"['solid tumor', 'radiation therapy', 'proton therapy']"
NCT02045342,The Effect of a Carbohydrate Drink on Cognitive Function and Exercise Performance,The Effect of a Carbohydrate Drink on Cognitive Function and Exercise Performance,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * healthy, 18 to 35 year old man or woman. Exclusion Criteria: * smoker * pregnancy * taking part in other research. * followed a weight loss diet in the previous 6 months. * history of gastrointestinal, endocrine, cardiovascular disease or diabetes. * neurological or psychiatric condition that may cause cognitive dysfunction.",18.0,35.0,['fatigue']
NCT00999986,Low Dose Cyclophosphamide Treats Genital Warts,Phase III Study of the Treatment of Genital Warts by Low Dose Cyclophosphamide,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Clinical diagnosis of large genital warts Exclusion Criteria: * HPV type 6 or 11 was detected negatively by PCR method.,18.0,60.0,['genital wart']
NCT00451386,"Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)","A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Local Tolerability, and Clinical Outcome of Ertapenem Versus Ceftriaxone in Pediatric Patients With Complicated Urinary Tract Infection, Skin and Soft Tissue Infection, or Community-Acquired Pneumonia",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients with UTI must have white blood cells and bacteria in the urine with bladder catheterization or urologic abnormality, kidney infection or both * Patients with SSTI must have a recent infection * Patients with CAP must have a chest x-ray indicating bacterial pneumonia and a fever Exclusion Criteria: * Patients with complete urinary tract blockage or kidney abscess * Patients with infected burn wounds, bone infection, or bacterial arthritis * Patients on mechanical ventilation or those with cystic fibrosis, chronic lung disease or puss in the space between the chest wall and lung",3.0,17.0,"['urinary tract infections', 'bacterial pneumonia', 'soft tissue infections']"
NCT04684186,Comparison Between Endovascular and Bronchoscopic Tumor Marker Insertion for Real-time Stereotactic-guided Radiotherapy in Lung Cancer,Real-time Guided Stereotactic Radiotherapy in Lung Cancer Using Endovascular Coils for Tumor Marking: Head-to-head Comparison Between Endovascular and Bronchoscopic Fiducial Marker Insertion,RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * Lung cancer (primary or secondary, any histological type) * Early stage lung cancer: patients diagnosed with stage I for which operation is contra-indicated, for example because of cardiac or pulmonary comorbidities. * Locally advanced lung cancer stages II - IIIB * Metastatic lung cancer stage IV (palliative care) * 18 y ≤ age ≤ 85 y Exclusion Criteria: * age \<18y * incapacity of judgment * Absence of a signed consent form",18.0,65.0,"['lung cancer', 'lung metastases', 'radiotherapy']"
NCT03901586,Satisfaction and Long-term Anatomic Efficacy Study on Patients Who Underwent a Richter Intervention in the Obstetric and Gynecology Department of Foch Hospital Since 2008,Satisfaction and Long-term Anatomic Efficacy Study on Patients Who Underwent a Richter Intervention in the Obstetric and Gynecology Department of Foch Hospital Since 2008,COMPLETED,INTERVENTIONAL,FEMALE,Inclusion Criteria: * Patient who underwent a Richter intervention between 01/01/2008 and 31/12/2017 in the Gynecology Department of Foch Hospital Exclusion Criteria: * None,18.0,65.0,['genital prolapse']
NCT03609086,Melatonin in Pregnancy,Investigation of Melatonin Production in Pregnancy: a Pilot Study to Define the Contribution of the Placenta,COMPLETED,OBSERVATIONAL,FEMALE,"Inclusion Criteria: * Scheduled for elective caesarian section * Singleton pregnancy * Aged 16-45 * Taking no regular medication other than pregnancy related vitamins or supplements Exclusion Criteria: * Pregnancy non-viable * Twins or higher multiple pregnancies * Outside age range * Diabetes or pre-existing hypertension, chronic kidney disease or autoimmune disorders",16.0,45.0,['pregnancy']
NCT03264586,The Effect of Lidocaine - Prilocaine Cream (EMLA) Versus Mepivacaine Infiltration on Pain Relief During And After Mediolateral Episiotomies,The Effect of Lidocaine - Prilocaine Cream (EMLA) Versus Mepivacaine Infiltration on Pain Relief During And After Mediolateral Episiotomies: A Randomized Clinical Trial,UNKNOWN,INTERVENTIONAL,FEMALE,Inclusion Criteria: 1. Gestational age 37 weeks or more 2. Singleton gestation. 3. Uncomplicated pregnancy. 4. Vertex presentation. Exclusion Criteria: 1. Epidural analgesia request. 2. Operative delivery. 3. No other methods are used for pain control 2hours befor episiotomy 4. Previous adverse reaction to local anesthetic.,19.0,39.0,['episiotomy pain']
NCT05880186,Influence of the Time of Day in the Effect of Caffeine on Maximal Fat Oxidation During Exercise in Women,"Influence of the Time of Day in the Effect of Caffeine on Maximal Fat Oxidation During Exercise in Women. A Randomized, Crossover, Double-blind, and Placebo-controlled Study",COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * To be non-smokers. * To have low caffeine intake (i.e., \< 50 mg of caffeine per day in the previous 2 months) * To show no previous history of cardiopulmonary diseases or having suffered musculoskeletal injuries in the previous 6 months. * To have a regular duration of their menstrual cycle for the previous 6 months. * To confirm no existence of any type of menstrual disorders such as dysmenorrhea, amenorrhea, or strong symptoms associated with pre-menstrual syndrome. Exclusion Criteria: \-",18.0,40.0,['dietary supplement']
NCT05559086,N/LP Ratio as Predictor of Mortality in Septic AKI Patients,Neutrophils to Lymphocytes and Platelets Ratio (N/LP) as Predictor of Mortality in Septic- Acute Kidney Injury Patients,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: 1. aged 18 and older 2. Diagnosed as Septic -AKI AKI was diagnosed according to kdigo definition and staging Sepsis was diagnosed according to the third international consensus definitions as an acute change in total Sequential Organ Failure Assessment (SOFA) score ≥2 points consequent to the infection. 3. CRP as marker of sepsis 4. CBC as marker of sepsis, N/LP ratio is calculated as: (Neutrophil count × 100)/(Lymphocyte count × Platelet count). the N/LP ratio lower than 14 is predictive of patient survival, which further reflects that lower inflammation is associated with lower mortality in critically ill septic patients. Thus, highlighting the role of the N/LP ratio as a significant marker of systemic inflammatory response at ICU admission. Exclusion Criteria: * 1.prerenal and post renal AKI 2.Contrast induced AKI 3\. Drugs induced AKI 4.CKD patients and ESRD patient 5.Active Lupus, LN 6.Malignancies",18.0,80.0,['acute kidney injury due to sepsis']
NCT03258086,Vitamin D in Diabetic Children,Assessment of Vitamin D in Children With Type 1 Diabetes,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age (5 years - 15 years ). * Type 1 diabetes patients. Exclusion Criteria: * Patients aged more than 15 years, less than 2 years. * Type 2 diabetes. * Neonatal diabetes. * Patients with any complications from diabetes.",5.0,15.0,['vitamin d deficiency']
NCT01430286,Web-based Psycho-Educational Program to Support Carers of Alzheimer's Patients,Evaluation of a Web-based Psycho-Educational Program for Informal Caregivers of Patients With Alzheimer's Disease (AD).,COMPLETED,INTERVENTIONAL,ALL,"Inclusion criteria : * Family caregivers of AD patients DSM IV-TR (American Psychiatric Association 2004) or NINCDS/ADRDA (McKhann et al. 1984). * Age: over 18 years old * score 12 or over on the Perceived Stress Scale 14 items (PSS-14, Cohen) Need for information or help * Sign informed consent Exclusion criteria : * Professional or paid caregiver * Physical or mental disease incompatible with patient's management * Impossibility to participate in the educational program * Absence of perceived stress * Ongoing psychotherapy or a similar program in parallel",18.0,65.0,['alzheimer disease']
NCT02747186,Clinical Outcomes Maxilla: Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine,Pilot Study: Comparison of Buffered 1% vs. Non-Buffered 2% Lidocaine Used in Dental and Oral Surgical Procedures: Clinical Outcomes Maxilla,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * American Society of Anesthesiologists Risk Classification I Willingness to participate in two sessions Exclusion Criteria: * Allergy to lidocaine class of anesthetic drugs Local anesthetic drug use in past week Current symptoms teeth or oral mucosa,18.0,30.0,['anesthesia']
NCT07364786,"Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma","Intratumoral Pressure, Intratumoral Partial Oxygen Pressure, and Inflammatory Cytokines in Antisecretory Factor Treatment of Glioblastoma",RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: 1. Suspected glioblastoma 2. Age 18-75 years 3. Planned diagnostic biopsy 4. Informed consent of subject Exclusion Criteria: 1\. Known egg yolk allergy,18.0,75.0,['glioblastoma']
NCT00646386,Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis,Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Moderate to severe PsA * Inadequate response to DMARD therapy * Corticosteroid stable dose \<= 10 mg QD * DMARDs must have been taken for 3 months and stable dose for 4 weeks * MTX maximum dose = \<= 30 mg/week * Active chronic plaque PS or documented history of chronic plaque PS Exclusion Criteria: * No other active skin disease,18.0,65.0,"['arthritis', 'psoriatic']"
NCT04387786,Dornase Alfa Administered to Patients With COVID-19 (DACOVID),Nebulized In-line Endotracheal Dornase Alfa and Albuterol Administered to Mechanically Ventilated COVID-19 Patients: A Case Series,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * mechanically ventilated patients with COVID-19 Exclusion Criteria: * healthy, non-ventilated",18.0,85.0,"['covid-19', 'mechanical ventilation']"
NCT06973486,Causes of Spinal Failure in Cesarean Section,"The Effects of Social, Emotional and Attitudinal Dynamics on Spinal Anesthesia Outcomes in Cesarean Delivery",NOT_YET_RECRUITING,OBSERVATIONAL,FEMALE,Inclusion Criteria: * spinal anesthesia for term pregnancy and cesarean section * age ≥ 18 * knowing the gestational week when participating in the study * answering all research questions * using the internet and social media tools Exclusion Criteria: * mental and physical disability * diagnosis and treatment for psychiatric disorders * clinically significant physical health problemı,18.0,65.0,['causes of spinal failure']
NCT06703086,"Gene Modulation of NLRP3, IL-1β and TNF-α in Peripheral Blood of Patients With Exogenous Obesity Treated With Berberine","Gene Modulation of NLRP3, IL-1β and TNF-α in Peripheral Blood of Patients With Exogenous Obesity Treated With Berberine",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * • Patients with BMI ≥ 30kg/m2 * With risk factors for type 2 diabetes (history of diabetic parents or siblings, sedentary habits) * Fasting blood glucose ≤ 126 mg/dL or glycosylated hemoglobin \ 18 years of age * Accept and sign the informed consent Exclusion Criteria: * • Pregnancy patients * Diabetics patients * Presenting any serious adverse effect * Patients who decide to withdraw from the protocol",18.0,65.0,"['obesity', 'overweight', 'berberine']"
NCT05631886,Combination of CAR-DC Vaccine and ICIs in Malignant Tumors,A Pilot Clinical Trial of Autologous EphA-2-Targeting Chimeric Antigen Receptor Dendritic Cell Vaccine Loaded With TP53 Mutant Peptide Plus ICIs for Local Advanced/Metastatic Solid Tumors or Relapsed/Refractory Lymphomas.,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Age 18-75 (inclusive). 2. ECOG performance status ≤2 and Estimated life expectancy of more than 3 months. 3. Local advanced/metastatic solid tumors or R/R lymphomas confirmed by histopathology or cytology with documentation of tumor EphA2 positive (≥20%) and TP53 mutation (R273H or R175H or R248Q or R249S) within 6 months prior to screening. The second malignancy is allowed. 4. No clinical response to standard frontline therapy or no standard therapy exists for solid tumors. Relapse after treatment with ≥2 lines systemic therapy or refractory disease for lymphomas. Patients who have declined standard therapy or have no access to standard therapy may be enrolled and the reasons for a lack of access need to be documented. Previous treatment with anti-PD-1/PD-L1 antibodies or anti-CTLA4 antibody are allowed, regardless of the level of PD-1/PD-L1 expression, dMMR and TMB. 5. At least one measurable lesion at baseline per RECIST version 1.1 or Lugano response criteria 2014. 6. Adequate organ function as defined by the following criteria: ANC ≥1000 cells/μL; Platelet count ≥80,000/μL; Hemoglobin ≥8.0 g/dL (hemocytopenia caused by lymphoma invasion of bone marrow is not subject to conditions); Serum AST and serum ALT, ≤3.0 x ULN (≤5 x ULN for patients with liver metastases); Total serum bilirubin ≤3.0 x ULN); Serum creatinine ≤2 x ULN or creatinine clearance of ≥45 mL/min. 7. Willing to undergo either excised or large-needle lymph node or tissue biopsy, or provide formalin-fixed paraffin-embedded (FFPE) tumor tissue block or freshly cut unstained slides. 8. Willing to complete all scheduled visits and assessments at the institution administering the therapy. 9. Able to read, understand and provide written informed consent. Exclusion Criteria: 1. Having TP53 (R273H or R175H or R248Q or R249S) germline mutation. 2. Active central nervous system disease involvement (but allow patients with prior brain metastases treated at least 4 weeks prior to enrollment that are clinically stable and do not require intervention), or prior history of NCI CTCAE Grade ≥3 drug-related CNS toxicity. 3. Prior organ allograft transplantations or allogeneic hematopoietic stem cell transplantation. 4. Evidence of active uncontrolled viral, bacterial, or systemic fungal infection. 5. Known positive test result for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS). 6. Active infection of hepatitis B virus (HBV), or hepatitis C virus (HCV). 7. Patients with history (within the last 5 years) or risk of autoimmune disease who have immunosuppressive medications or immunosuppressive doses of systemic corticosteroids (\>10 mg/day prednisone or equivalent) within 28 days prior to enrollment. However, patients who received a short course of corticosteroids (eg, premedication prior to antibody drug) will be eligible for study entry. 8. Major trauma or major surgery within 4 weeks prior to enrollment. 9. Previous treatment involving TP53 mutant (R273H or R175H or R248Q or R249S) and EphA2. 10. Systemic chemotherapy and other intervene within 2 weeks prior to vaccination. 11. Being participating or withdrew any other trials within 4 weeks. 12. Any serious underlying medical (eg, pulmonary, renal, hepatic, gastrointestinal, or neurological) or psychiatric condition or any issue that would limit compliance with study requirements. 13. Vaccination within 30 days of study enrollment. 14. Pregnant, lactating, or breastfeeding females. 15. Researchers believe that other reasons are not suitable for clinical trials.",18.0,75.0,"['solid tumor, adult', 'lymphoma', 'epha2 overexpression', 'tp53 r273h', 'tp53 r175h', 'tp53 r248q', 'tp53 r249s']"
NCT02829086,Evaluation of the Refugee Family Strengthening (RFS) Program,Evaluation of the U.S. Committee for Refugees and Immigrants (USCRI): Refugee Family Strengthening (RFS) Program,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Refugee or Immigrant Exclusion Criteria: * Individuals under the age of 16 * Individuals that are not identified as refugees or immigrants,16.0,65.0,['health behavior']
NCT00219986,"Phase I/II, Open-Label Trial of Three Monoclonal Antibodies","A Phase I/II Single Site Open Label Trial of the Safety and Antiviral Activity of C2F5, C2G12, and C4E10 Monoclonal Antibody Infusions in Well-Suppressed HAART-Treated Individuals Treated During Acute and Early HIV-1 Infection",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry. Acute or early HIV-1 infection at the time of HAART initiation defined by HIV-1 RNA detectable with a negative serology or a negative detuned ELISA. HAART for at least 15 months and no more than 1 detectable HIV-1 RNA value (above the 50 copy/mL) for at least 6 months prior to screening. Laboratory values * Absolute neutrophil count (ANC) equal to or greter than 750/mm3. * Hemoglobin equal to or greater than 9.5 g/dL. * Platelet count equal to or greater than 50,000/mm3. * Calculated creatinine clearance (CrCl) equal to or greater than 80 mL/min according to the Cockcroft-Gault formula: Men: (140-age in years) x (wt in kg) = CrCl (mL/min) 72 x (serum creatinine in mg/dL) Female: (140-age in years) x (wt in kg) x 0.85 = CrCl (mL/min) 72 x (serum creatinine in mg/dL) * AST (SGOT), ALT (SGPT), and alkaline phosphatase equal to or less than 5 x ULN. * Total bilirubin equal to or less than 2.5 x ULN. * Serum Lipase equal to or less than 1.5 x ULN Negative serum pregnancy test within 14 days. All females of childbearing potential must agree to practice active birth control measures (barrier methods such as condoms, diaphragms, cervical cap, etc. or an intrauterine device such as a coil) to avoid pregnancy while receiving the study drugs and for 30 days after the last dose of the study drugs. Additionally, men enrolled in the study should practice active birth control for the same period of time with their female partners of childbearing potential. Men and women age \>18 years. Ability and willingness of subject to give written informed consent - Exclusion Criteria: More than 1 detectable HIV-1 RNA value (\>50 copies/mL) within 6 months of screening visit Pregnancy and breast-feeding. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements. Serious illness (requiring systemic treatment and/or hospitalization) until subject either completes therapy or is clinically stable on therapy, in the opinion of the investigator, for at least 30 days prior to study entry. \-",18.0,65.0,['hiv infections']
NCT03794986,Peer Online Motivational Interviewing for Sexual and Gender Minority Male Survivors,Peer Online Motivational Interviewing for Sexual and Gender Minority Male Survivors,COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: * 18 years or older * English-speaking; men who have sex with men or individuals identifying as SGM males * Individuals who report a history of sexual abuse and individuals who self-report a minimum cut-off score of 3.0 or higher on emotional distress, using a 4-question symptom inventory. Exclusion Criteria: * Individuals who endorse active psychosis * Individuals who have a cognitive dysfunction * SGM men who report that they are currently in formal mental health counseling",18.0,65.0,['sexual abuse']
NCT02436486,Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men,"Interventional, Randomised, Double-blind, Placebo- and Positive Controlled, Single-dose, Cross-over Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men",COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: * Body weight at least 50 kg and Body Mass index \>18.5 and \< 30 kg/m2 * Good general health ascertained by a detailed medical history, laboratory tests and physical examination * Use of contraception. Exclusion Criteria: * The subject has evidence of cardiac conduction abnormalities as calculated by the ECG equipment and evaluated by the investigator, at the Screening Visit or at the Baseline visit * The subject has a history of long QT syndrome, history of cardiac arrhythmia, or history of cardiac disease (eg, coronary artery disease, valvular disease, etc.). Other protocol defined inclusion and exclusion criteria do apply",18.0,45.0,['healthy volunteers']
NCT03157986,Effects of Whole-Body Vibration Training Versus Balance Training in Patients With Severe Chronic Obstructive Pulmonary Disease,Effects of a Three Week Whole Body Vibration Training Versus Conventional Balance Training in Patients With Severe Chronic Obstructive Pulmonary Disease,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * COPD stage III or IV according to the global initiative for chronic obstructive lung disease * impaired exercise capacity (6 Minute walk distance of less than 70% of the reference value from Troosters et al.) Exclusion Criteria: * current acute exacerbation of COPD * carbon dioxide pressure of more than 45 mmHg at rest * any contraindication for vibration Training (e.g. acute deep vein thrombosis),50.0,80.0,['chronic obstructive pulmonary disease']
NCT04093986,Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation,Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation,RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * Medical records or data available from previous clinical care prior to June 20, 2019 of pregnant females with SCD, including women who miscarried, had a still birth, or completed labor at any gestational stage, with any hydroxyurea exposure during either pregnancy and/or while breastfeeding. * Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women. Exclusion Criteria: * Unavailable medical records or lack of information about hydroxyurea exposure.",18.0,65.0,"['sickle cell disease', 'sickle cell anemia']"
NCT00236886,Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients,"Prospective Pilot Study on Metabolism and Weight Changes in Subjects With Diagnosed Partial Onset Epilepsy, With or Without Secondarily Generalized Seizures and Treated With Topiramate.",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * A diagnosis of partial onset epilepsy, with or without secondary generalization. Patients with a diagnosis of epilepsy characterized by primary generalized tonic-clonic seizures may also qualify * Currently taking one or more anti-epileptic medications on a stable dose for one month * Weight between 40 and 130 kg (88 to 286 lbs) * Female patients must be postmenopausal for at least 1 year, surgically incapable of childbearing, practicing an acceptable method of contraception (requires negative pregnancy test). Exclusion Criteria: * Patients with rapidly progressive disorders that may impair their weight or their reliable participation in the study * Patients prone to severe malabsorption and/or metabolic disorders * Patients who have mental retardation or impairment which would confound the interpretation of this study * History (within the past six months) of a psychiatric or mood disorder requiring medical treatment * History of poor compliance with past anti-epileptic drug therapy * Suicide attempt in the past five years",16.0,65.0,"['epilepsy', 'epilepsies, partial', 'epilepsy, generalized', 'seizures']"
NCT05335486,Investigating RELEARN Neurofeedback as Treatment for Chronic Musculoskeletal Pain,Investigating RELEARN Neurofeedback as Treatment for Chronic Musculoskeletal Pain,WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Age 18-65 years old 2. Knee arthrosis (Kellgren-Lawrence score of ≥ 2) 3. 24h VAS ≥ 4 4. Ongoing pain, lasting more than three months Exclusion Criteria: Participants who meet any of the below criteria will be excluded from the investigation: 5. Pregnant or lactating woman 6. Use of opioids or cannabis 7. Active drug addiction defined as the use of cannabis, opioids, or other drugs 8. Previous or current neurologic, systemic, or mental illness, including any liver, kidney or metabolic disease. 9. Rheumatoid arthritis 10. Evidence of other pain types such as visceral, neuropathic, or malignant pain. 11. Evidence of other sources of ongoing pain such as root affect, traumas, or congenital malformation 12. Severe inflammation in the area of interest 13. Blindness or deafness 14. Consumption of alcohol, caffeine, nicotine on test day 15. Recent history of fractures or surgery in the area of interest 16. Participation in other clinical trials throughout the study period and one month prior to participation 17. History of epilepsy 18. Obesity class III and above. I.e. BMI \> 39,9",18.0,65.0,"['chronic knee pain', 'chronic pain', 'osteoarthritis']"
NCT00741286,Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler,Study for the Multi-Center Placebo-Controlled Double-Blind Clinical Trial for the Evaluation of the Effect of Cilostazol on Pulsatility Index of Transcranial Doppler in the Acute Lacunar Infarction Patients,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients with first ever lacunar infarction within 7 days after the onset of symptoms * Age: more than 45 years of age Exclusion Criteria: * Patients with any contraindications to the treatment with antiplatelet therapy * Patients with potential cardiac embolic source; prosthetic valve, atrial fibrillation, atrial flutter, left atrial/atrial appendage thrombus, sick sinus syndrome, left ventricular thrombus, dilated cardiomyopathy, akinetic or hypokinetic left ventricular segment, atrial myxoma, Infective endocarditis, mitral valve stenosis or prolapse, mitral annuls calcification, left atrial turbulence, nonbacterial endocarditis, congestive heart failure, recent myocardial infarction (within 4 weeks) * Bleeding diathesis * Chronic liver disease (ALT \> 100 or AST \> 100) or chronic renal disease (creatinine \> 3.0mg/dl) * Anemia (hemoglobin \< 10mg/dl) or thrombocytopenia (platelet count less than 100,000/mm3) * Nonatherosclerotic vasculopathy; patients with clinical characteristics suggesting arterial dissection, moyamoya disease, Takayasu's arteritis, radiation associated angiopathy, and other vasculitis. * Pregnant or lactating patients * Patients with hyperthyroidism or COPD * Patients with current anticoagulation or antiplatelet therapy * Patients with poor temporal window in transcranial Doppler",45.0,65.0,['cerebral infarction']
NCT04568486,Social Support Intervention for Older Adults With T2DM,Seed-alter Dyad Social Support Intervention for Rural Dwelling Older Adults With T2DM,COMPLETED,INTERVENTIONAL,ALL,"""Seeds"" Inclusion Criteria: * confirmed diagnosis of T2DM via electronic medical record * age 65 years or older * lives within Leslie County * able to provide consent * have had at least one clinic visit in the past year ""Seeds"" Exclusion Criteria: * no diagnosis of T2DM via electronic medical record * under 65 years of age * unable to speak and understand English * unable to consent ""Alters"" Inclusion Criteria * 18 years of age or older * able to provide consent * has at least weekly contact with the seed ""Alters"" Exclusion Criteria * under 18 years of age * unable to speak and understand English * unable to consent",18.0,99.0,['type 2 diabetes']
NCT02748486,Efficacy of Metacognitive Training Single Modules: Jumping to Conclusions and To Empathize...,Efficacy of Metacognitive Training Single Modules: Jumping to Conclusions and To Empathize... Among Patients of Psychiatric Rehabilitation Ward With Diagnosis of Schizophrenia.,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * diagnosis of psychotic disorders * informed consent Exclusion Criteria: * neurological disorders,18.0,65.0,"['schizophrenia', 'psychotic disorders']"
NCT03588286,Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD),Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD),RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * 2-40 days (inclusive) following a myocardial infarct * Impaired left ventricular systolic function (LVEF≤40% or at least moderately impaired) Exclusion Criteria: 1. Age \ 85; 2. Pregnancy; 3. Nursing home resident dependent on one or more activities of daily living; 4. Significant non-cardiac co-morbidity with high likelihood of death within 1 year (this would include any metastatic malignancy, or other terminal disease); 5. Significant psychiatric illnesses that may be aggravated by device implantation or that may preclude regular follow up; 6. Intravenous drug abuse (ongoing); 7. Unresolved infection associated with risk for hematogenous seeding; 8. Pre-existing implantable cardioverter-defibrillator (ICD); 9. Secondary prevention indication for an ICD (i.e. sustained ventricular arrhythmias occurring more than 48 hours after qualifying myocardial infarction (patients with ventricular arrhythmias occurring ≤48 hours of myocardial infarction, or with non-sustained ventricular tachycardia at any time, are not excluded)); 10. On the heart transplant list; 11. Recurrent unstable angina despite revascularisation (defined as ongoing chest pain or ischemic symptoms at rest or with minimal exertion despite adequate treatment with anti-anginal medications);\*\* 12. Congestive heart failure New York Heart Association class IV, defined as shortness of breath at rest, which is refractory to medical treatment (not responding to treatment)\*\* \*\*NOTE: patients who meet exclusion based on (11) or (12) can be reviewed again in 2-3 days and if symptoms have resolved or treatment performed can be re-considered for inclusion.",18.0,85.0,['sudden cardiac death']
NCT02082886,HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry,Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * Eligible to undergo cytoreductive surgery followed by HIPEC performed by the PI at Edward Hospital * Provides consent by signing informed consent form Exclusion Criteria: * Not eligible for surgery or for potential cytoreductive surgery and/or HIPEC as determined by the PI * Does not consent to participate,18.0,65.0,"['peritoneal neoplasms', 'neoplasm metastasis', 'adenocarcinoma', 'sarcoma']"
NCT02046486,OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study (the LIQUID Study),OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Age ≥18 years old 2. Patients with STEMI (onset of pain\ 52%) at randomization * Periprocedural IIb/IIIa inhibitor administration * Thrombolysis administration * Recent (\< 6 weeks) major surgery or trauma, including GABG. * Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A inducers (rifampin /rifampicin, phenytoin, carbamazepine). * Patients considered by the investigator to be at increased risk of bradycardiac events. * Dialysis required. * Severe uncontrolled chronic obstructive pulmonary disease * Known severe hepatic impairement",18.0,65.0,['st elevation myocardial infarction']
NCT03044886,Effects of Vitamin D on Moderate to Severe Periodontitis,Effects of Vitamin D on Chronic Periodontitis,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Age from 30 years old to 70 years old 2. More than 20 teeth remaining in the mouth 3. Clinical diagnosis of moderate to severe periodontitis 4. Not receiving periodontal treatment within 6 months 5. Not taking antibiotic drugs within 3 months. Exclusion Criteria: 1. Diabetes, thyroid and parathyroid endocrine associated diseases 2. Severe systemic diseases, such as cancer 3. Taking vitamin D and / or calcium drugs during observation 4. Taking aspirin, non-steroidal anti-inflammatory drugs, and steroids 5. Pregnant or prepare to pregnant within one year 6. Have been suffering from hypercalcemia, malabsorption syndrome.",30.0,70.0,['chronic peritonitis']
NCT02032186,A Randomized Clinical Trial of Oral Magnesium Supplementation in Pregnancy,A Randomized Clinical Trial of Oral Magnesium Supplementation In Pregnancy for the Prevention of Preterm Birth and Perinatal and Maternal Morbidity,COMPLETED,INTERVENTIONAL,FEMALE,Inclusion Criteria: * gestational age before 20th * low risk pregnancy Exclusion Criteria: * high magnesium serum,18.0,40.0,"['magnesium deficiency', 'preterm birth', 'extreme immaturity']"
NCT05524870,The Effect of Manual Therapy on Central Sensitization,Movement With Mobilization Technic Plus Exercising Versus Exercising Alone for Central Sensitization in Patients With Subacromial Pain: a Sham-controlled Randomized Clinical Trial,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * To have confirmed unilateral subacromial pain (positive testing at Neer Impingement and Hawkins-Kennedy tests), * To have \<40 score in central sensitization inventory. Exclusion Criteria: * To have bilateral subacromial pain, * To have any pathology (except subacromial pain) that give rise to central sensitization (This pathologies are summarized in central sensitization inventory - part B) * To have severe osteoarthritis or subluxation in shoulder joint, * To have adhesive capsulitis, * Being treated with physiotherapy for this disorder at least one month before the start of the study. * To have severe cervical or lumbar radiculopathy,",18.0,65.0,"['subacromial pain syndrome', 'central sensitisation']"
NCT00041470,"Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial","Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial",TERMINATED,INTERVENTIONAL,ALL,"PATIENT ELIGIBILITY Inclusion Criteria: * Patient has stage IV, microscopically-confirmed carcinoma of the breast with histologic slides and/or blocks available for review. * Patient has had one or less prior regimens for metastatic disease. Prior paclitaxel by 3, 24 or 96-hour infusion is permitted as long as it did not result in any neuropathy. Prior docetaxel on an every 3-week schedule is permitted. * Measurable (bidimensionally) or evaluable disease. * Age \> 18. * Karnofsky Performance Status \> 70% (ECOG, \ 16 weeks. * Prior irradiation is permitted, provided: * Prior irradiation does not exceed 25% of the estimated bone marrow volume. (See Appendix I) * Measurable/evaluable disease must exist outside the radiation field OR there must be histologic proof of progressive disease within a radiation field. * Informed consent must be obtained prior to registration. * Patients must be \> 2 weeks from prior surgery; \> 3 weeks from radiation therapy to the pelvis, spine or long bones; \> 3 weeks from prior chemotherapy (\> 6 weeks for mitomycin C or nitrosureas), or \> 2 weeks from prior hormonal therapy. * All patients must have placement of appropriate central venous access device. * Tumor HER2/neu expression must be determined prior to study enrollment. Assessment may be by fluorescence in situ hydridization (FISH) assay or by immunohistochemistry (ICC). If determination is intermediate by ICC, FISH must be performed. For enrollment purposes, the phase I portion of the study will not discriminate based on HER2 status. However, documentation of patients' HER2 status will be maintained and Herceptin will be prescribed for all HER2 positive patients. The phase II portion of the study will enroll 30 patients who are documented HER2 overexpressors and 30 patients who are non-overexpressors. Exclusion Criteria: * Granulocytes \ 2.0 mg/dl. * Total bilirubin \> 2 mg/dl. * Visceral crisis characterized by rapidly progressive hepatic or lymphangitic lung metastases. * Medically unstable as judged by the patient's physician. * Pregnancy or lactation; failure to employ adequate contraception. * Uncontrolled CNS disease. * Pre-existing clinically significant peripheral neuropathy except for abnormalities due to cancer. * Psychological, familial, sociological or geographical conditions which do not permit weekly medical follow-up and compliance with the study protocol. * Prior therapy with vinorelbine or prior therapy with a taxane that resulted in neuropathy. * Known hypersensitivity to E. coli-derived proteins, Filgrastim, or any component of the product as Neupogen® is contraindicated in such subjects.",18.0,65.0,['breast cancer']
NCT02510170,Fetal and Maternal Head Circumference During Pregnancy in Israeli Population,Fetal and Maternal Head Circumference During Pregnancy,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Singleton pregnancy * Valid first trimester sonogram Exclusion Criteria: * Women under 18 years of age * Women over 40 years of age * Multi fetal pregnancy * No accurate dating of pregnancy age * Participant non compliance or cannot complete contact details * Technical difficulty measuring fetal or maternal skull * Abnormal fetal or maternal skull * Familial hereditary disease, mental retardation * Chronic maternal illness * Maternal on chronic medication * Abnormal screening test during current pregnancy * Abnormal sugar metabolism or Hypertension during current pregnancy",18.0,40.0,"['maternal-fetal relations', 'microcephaly']"
NCT03612570,Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia,Evaluation of Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Males or females * Presents with at least 2 and up to 5 clinically visible SH lesions * Understands that 1 lesion will remain untreated to act as a reference * Lesions must measure no greater than 2.5 x 2.5 at the outside margin * Wishes to have at least 1 and perhaps 2 NPS treatments to each study lesion * Selection of the non-treated reference lesion will be randomly identified * Willing to return for 4 or 5 total study visits at specified intervals over 60 or 90 days * Agrees to photographic or other image capture methods of both the treated and untreated lesions. * Agrees to avoid any other treatment to the NPS treated and untreated SH lesions until the end of the NPS study * Has no evidence of active infection in the designated tissue prior to treatment and reports no infection within 90 days * Is not allergic to Lidocaine or Lidocaine-like products Exclusion Criteria: * Presence of Implantable electronic devices that cannot be removed. e.g., pacemaker or automatic defibrillator * Taking medications prescribed for cardiac arrhythmia at any time within 6 months prior to exposure to the NPS device * SH lesions are located within the eye orbit or on the nose * Active infection or history of infection in designated test area within 90 days prior to study initiation * Use of oral steroid and/or retinoid use within the last 12 months * Prior treatment to the identified SH lesions targeted for the study which occurred within 6 months prior to study start * Is known to be immune-compromised and/or received immunosuppressant therapy within 6 months prior to study start * Taking blood thinning medications * Has Insulin dependent diabetes * Is known to be pregnant or lactating female",18.0,70.0,"['skin lesion', 'skin abnormalities', 'sebaceous hyperplasia']"
NCT03755570,How is COGNItive Function Affected by Cardiac Resynchronisation Therapy?,How is COGNItive Function Affected by Cardiac Resynchronisation Therapy?,SUSPENDED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Undergoing implant of a CRT system with an LVEF of ≤35% (main group), or ICD or PPM system with an LVEF of ≤35% (control group) * Are 20 - 89 years of age * Be able to provide written informed consent prior to investigational related procedure, and be willing and able to comply with the described protocols and follow-up schedules listed in the PIS * Be literate to a level in which the cognitive function tests can be completed effectively * Mental capacity to provide informed consent and undertake cognitive function tests * Geographically stable and able to return for the Post-Implant 6-Month Device Follow-Up Visit Exclusion Criteria: * Are ≤19 years of age (due to specifications outlined in cognitive function test requirements) * Are ≥90 years of age (due to specifications outlined in cognitive function test requirements) * Are pregnant at time of enrolment * Is participating in an investigational drug investigation * Be experiencing a condition at the time of data collection which affects mental capacity (lack capacitiy), such as dementia, Alzheimer's, psychosis, schizophrenia (excluding depression and anxiety). * Recent Cerebral Vascular Event (CVE) which may have affected cognitive function * Heavy substance abuse, drugs or alcohol",20.0,89.0,"['cognitive impairment', 'cognitive change', 'heart failure, systolic', 'heart failure', 'cognitive impairment, mild', 'left ventricular dysfunction', 'left ventricular systolic dysfunction', 'systolic dysfunction', 'systolic heart failure']"
NCT06914570,Cardiac Implantable Electronic Device- Induced Remodelling of Tricuspid Valve and Right Chambers,Cardiac Implantable Electronic Device- Induced Remodelling of Tricuspid Valve and Right Chambers,RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * Age ≥ 18 years * Patient able and willing to give informed consent in written form before the index procedure * Patient understands the purpose, the potential risks as well as benefits of the study and is willing to participate in all parts of the follow-up * Patients undergoing any new CIED implantation with or without transvalvular lead * Sufficient imaging quality on transthoracic echocardiography to assess TR severity grade and morphology of right-sided heart chambers Exclusion Criteria: * Previous or present CIED * Life expectancy \< 12 months due to non-cardiac condition * Tricuspid valve stenosis of any severity or severe TR planned for intervention (transcatheter, surgical) within the next 12 months * Previous tricuspid valve intervention (transcatheter, surgical) * Participation in another study, which would lead to deviations from this trial protocol",18.0,65.0,"['cardiac pacing, artificial', 'tricuspid valve regurgitation, non-rheumatic']"
NCT06729970,"A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants","A Phase 1, 6-part, Open-label, Fixed-sequence Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Single-dose Pharmacokinetics of KarXT and Effects of KarXT on the Single-dose Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Healthy male and female \[individual not of childbearing potential (INOCBP)\] participants as determined by no clinically significant deviation from normal in medical history, physical examination, 12-lead ECG, vital signs, and clinical laboratory determinations. * BMI of 18.0 to 32.0 kg/m2, inclusive. Exclusion Criteria: * History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, GI, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results. Note: Any grade of hepatic impairment (Child-Pugh Grade A or higher) is excluded. * Parts B and D only: History of pancreatitis. * Any significant acute or chronic medical illness, in the opinion of the investigator. * History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma or known history of prostate hypertrophy or nocturia. * Parts E \& F only: history of skin rash and mucus ulcerations of no obvious cause and Gilbert's syndrome * Other protocol-defined Inclusion/Exclusion criteria apply.",18.0,65.0,['healthy volunteers']
NCT03283670,Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies,Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria 1. Adults 18-75 years of age; 2. Current diagnosis of unipolar major depressive disorder (MDD) without psychosis as confirmed by structured clinical interview for DSM-IV disorders; 3. A score of \>= 9 on the Montgomery-Åsberg Depression Rating Scale (MADRS); 4. Documented (i.e., chart review) lifetime failure to respond to \>=3 adequate dose/duration antidepressant treatment trials, ≥1 medication failure in the current depressive episode; 5. Good command of the English language. Exclusion Criteria 1. Meets criteria for any DSM-IV diagnosis for schizophrenia, bipolar, schizoaffective, obsessive-compulsive, personality, or panic disorders; 2. Any recent (within past 12 months) history of substance dependence or abuse (except tobacco), determined by reported history or urine drug screen; 3. Ability to become pregnant and not using effective contraception; 4. Contraindication against the use of nitrous oxide: 1. Pneumothorax 2. Bowel obstruction 3. Middle ear occlusion 4. Elevated intracranial pressure 5. Chronic cobalamin and/or folate deficiency treated with folic acid or vitamin B12 6. Pregnant patients 7. Breastfeeding women 5. Inability to provide informed consent; 6. Any other factor that in the investigators' judgment may affect patient safety or compliance",18.0,75.0,"['depressive disorder, major', 'depressive disorder, treatment-resistant']"
NCT05606770,The Adaptive Physical Activity Study for Stroke,Development and Evaluation of an Adaptive Mobile Health Physical Activity Intervention Post-stroke: a Sequential Multiple Assignment Randomised Trial,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * 18 years+ * Clinician-confirmed stroke- ischaemic or haemorrhagic subtype * Living within 90km of University * Person in the first 6 months post-stroke * No longer receiving inpatient or outpatient or community-based physical activity rehabilitation * modified Rankin Scale score of 0-3 * People post-stroke who are able to express their basic needs verbally * Have access to relevant technology to enable mHealth intervention delivery * Have cognitive capacity to provide informed consent * Medical clearance for participation in the TAPAS programme. Exclusion Criteria: -Contraindications for undertaking physical activity e.g. safety, presence of unstable heart disease",18.0,65.0,['stroke']
NCT04480970,Placement of Nasogastric Tubes for Gastric Decompression in Patients With Bronchiolitis,Placement of Nasogastric Tubes for Gastric Decompression in Patients With Bronchiolitis,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Diagnosis of bronchiolitis by the attending physician * On high flow nasal cannula (4 liters or greater) * Ages 0 months to 23 months Exclusion Criteria: * Diagnosis of bacterial pneumonia * History of cranio-facial anomalies * History of congenital heart disease * History of G-tube dependence * History of short gut syndrome * History of tracheostomy or current tracheostomy,1.0,23.0,['bronchiolitis']
NCT00244270,Cystic Fibrosis and Totally Implantable Vascular Access Devices,Cystic Fibrosis and Totally Implantable Vascular Access Devices: Evaluation of the Incidence of Venous Thrombosis Related to the Catheter and Study of the Genetic and Acquired Risk Factors,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Children or adults with cystic fibrosis (identified either by 2 abnormal sweat tests and/or two CFTR \[cystic fibrosis transmembrane conductance regulator\] mutations) who need a totally implantable vascular access device. * Signed informed consent Exclusion Criteria: * Refusal of participation in the study * Patients on a waiting list for pulmonary or hepatic transplantation * Patients who received a pulmonary or hepatic graft,18.0,65.0,"['cystic fibrosis', 'venous thrombosis']"
NCT03706170,Emotion Assessment to Study Consciousness in Awakening Patients,Emotion Assessment to Study Consciousness in Awakening Patients,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: For Patients : * age between 18 and 80 * acquired brain lesion (brain injury, stroke, anoxia) with a delay since the insult superior to 1 month * level of consciousness assessed with the coma recovery scale revised (CRS-R) * patient with health insurance * informed consent signed by the patients or his representative For Healthy participants: * age between 18 and 80 * participant able to understand instructions and normal hearing * patient with health insurance * informed consent signed Exclusion Criteria: For Patients : * non controlled epilepsy * dysautonomic crisis * unstable medical state * pregnancy or breath feeding for women * Persons under guardianship, curatorship For Healthy participants: * neurological disorder * pregnancy or breath feeding for women * Persons under guardianship, curatorship or any other administrative or judicial measure of deprivation of rights or liberty",18.0,80.0,['persistent vegetative state']
NCT06883370,Analgesia Evaluation of an Ultrasound-guided Technique for Inguinal Hernia Surgery in Children in Children,Analgesic Evaluation of Ultrasound Guided Transversalis Fascia Plane (Tfp) Block With 0.4 ml/kg of Ropivacaine 0.375 % in Paediatric Laparoscopic Inguinal Hernia Repair.,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: All ASA I or II patients undergoing inguinal hernia repair Exclusion Criteria: Parent's refusal, allergic to study drug",6.0,12.0,"['inguinal hernia', 'surgery', 'paediatric']"
NCT04651270,Assessment of the Wide Field of View Provided by the SurroundScope,Assessment of the Wide Field of View Provided by the SurroundScope,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Age greater than or equal to 18 2. Capable of giving informed consent 3. Scheduled for general or gynecology laparoscopic surgery or open procedure that in the surgeon's opinion can be performed laparoscopically with the 270System Exclusion Criteria: 1. Unfit for surgery: concomitant disorders incompatible with the study or surgery (at the discretion of the investigator) 2. Patients with contraindications to undergo surgery 3. Patients with ASA class\* \>3 4. Advanced cirrhosis with failure of hepatic function 5. Patients who have participated in another interventional clinical study in the last month 6. Pregnancy 7. Unable to consent (due to cultural, language or neurological barriers)",18.0,65.0,['laparoscopic surgery']
NCT06129370,Testing of Medication Dosing Software,Testing of a Medication Dosing Software for Pediatric Emergency Care,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: -Healthcare professionals who have worked or who are currently working at a healthcare facility and involved in the calculation or preparation of IV medication. Exclusion Criteria: * Healthcare professionals who cannot read, speak, or understand English or French as the simulations will be conducted in English or French. * Performance of physically strenuous activity 30 min prior to study. * Physical limitations that affect performance on required tasks (e.g., inability to place arm cuff on mannequin's arm, inability to handle weight estimation and touchscreen devices).",18.0,60.0,['pediatric emergency medicine']
NCT03544970,An Audit of the Posterior Fossa Characterization in Open Spina Bifida Based on Tertiary Center Experience,An Audit of the Posterior Fossa Characterization in Open Spina Bifida Based on Tertiary Center Experience,COMPLETED,OBSERVATIONAL,FEMALE,"Inclusion Criteria: * patients were those having fetal MR examination for additional assessment because of the prenatal diagnosis of SBA on ultrasound. * appropriate gestational age - matched controls. The latter were fetuses assessed for other congenital anomalies, which do not affect the central nervous system (CNS) or were scanned for suspected CNS abnormalities with normal prenatal US, fetal MR and normal postnatal evaluation Exclusion Criteria: * twin pregnancy, syndromal pathology, fetal hydrops or anhydramnios. * poor image quality",18.0,65.0,"['fetal anomaly', 'spinal dysraphism', 'chiari malformation type 2']"
NCT03027570,The Impact of Incorporating an Exergame Activity Application in a Treatment Regimen for Overweight Children,The Impact of Incorporating an Exergame Activity Application in a Treatment Regimen for Overweight Children,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Children aged 5-13 from the center for the treatment of overweight children in the MACABI health organization * BMI≥85%. Exclusion Criteria: * Children with physical disabilities, that don't allow participation in physical activity during the study. * Children who don't own a mobile phone or don't have an access to a computer to activate the app for one hour a day. * BMI\<85%",5.0,13.0,"['body mass index', 'blood', 'sugar, high', 'lipid disorder', 'body image']"
NCT02478970,Specular Microscopy Study,Comparison of Clinical Evaluation of Endothelial Cells With Paracentral and Central Specular Microscopy,WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age 18 years and older; * Patients with primary corneal endotheliopathies (posterior polymorphous dystrophy, congenital hereditary endothelial dystrophy, Fuchs' dystrophy, iridocorneal endothelial syndrome; * Healthy patients without corneal endotheliopathies. Exclusion Criteria: * Patients with history of corneal and/or intraocular surgery; * Patients with existing corneal and/or anterior segment disease, except for the inclusion criteria; * Intraocular pressure ≥21mmHg; * Contact lens wearer; * History of ocular trauma; * Patients with diabetes mellitus.",18.0,65.0,['endotheliopathies']
NCT00003370,Irofulven in Treating Children With Recurrent or Refractory Solid Tumors,A Trial of MGI 114 in Children With Solid Tumors: A Pediatric Oncology Group Phase I Cooperative Agreement Study,COMPLETED,INTERVENTIONAL,ALL,"DISEASE CHARACTERISTICS: * Histologically or cytologically proven recurrent or refractory solid tumors * No leukemia * Patients with brain tumors are not eligible until the first 2 patients at each dose level are evaluable for toxicity PATIENT CHARACTERISTICS: * Age: 21 and under * Performance status: Karnofsky 50-100% Lansky play scale 50-100% (for infants) * Life expectancy: At least 8 weeks * Absolute neutrophil count at least 1,000/mm3 * Hemoglobin at least 9 g/dL * Platelet count at least 75,000/mm3 * Bilirubin less than 1.5 mg/dL * SGPT less than 5 times upper limit of normal * Creatinine normal for age OR GFR at least 70 mL/min * Cardiac shortening fraction at least 27% OR institutional normal OR cardiac ejection fraction greater than 50% OR institutional normal * Neurologic deficits in patients with CNS tumors must be stable for at least 2 weeks * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 6 months after the study * No uncontrolled infection PRIOR CONCURRENT THERAPY: * At least 1 week since prior growth factor therapy and recovered * At least 6 months since prior bone marrow transplantation and no evidence of graft versus host disease * At least 2 weeks since prior myelosuppressive chemotherapy and recovered * At least 6 weeks since prior nitrosourea and recovered * At least 2 weeks on stable dexamethasone for patients with CNS tumors * No concurrent chemotherapy * At least 2 weeks since prior palliative radiotherapy (small port) * At least 6 months since prior substantial bone marrow radiation * At least 6 months since total abdominal, pelvic, chest, mantle, and Y ports radiotherapy * No other concurrent anticancer therapy or investigational agents",18.0,21.0,"['unspecified childhood solid tumor, protocol specific']"
NCT04948970,Steroid Panel for One-step Diagnosis of Adrenal Diseases,Development of New Technology for One-step Diagnosis of Adrenal Diseases Based on Adrenal Hormone Panel,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Patients who are diagnosed with adrenal diseases Exclusion Criteria: * Taking medications that can affect steroid metabolism * Major depression, chronic alcoholism * Suspected cancer metastasis to adrenal glands * Other acute stress conditions",18.0,65.0,['adrenal disease']
NCT05758870,A Prospective Randomized Controlled Study Comparing the Clinical Effects of Surgical and Non-surgical Treatment of Low Rib Fractures,Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: * Patients with chest trauma only and unilateral low rib fractures Three rib fractures and more Displacement of the broken end of the fracture (bicortical fracture and not in the same line) Time from injury to hospital \ 60mmHg, carbon dioxide partial pressure \ 5 under calm breathing Exclusion Criteria: * Difficult airway History of esophageal reflux Myasthenia gravis Coagulation disorders Gastrointestinal ulcer Gastrointestinal bleeding Anesthetic drugs allergy history Asthma Chronic obstructive pulmonary disease Pregnant women",18.0,70.0,['rib fracture multiple']
NCT06122870,CampETEC Hyperimmune Bovine Colostrum (HBC),"Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of CampETEC Hyperimmune Bovine Colostrum (HBC) for the Prevention of Campylobacter-Mediated Diarrheal Diseases",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Adult between 18 and 50 years of age, inclusive. * General good health, without significant medical illness, abnormal physical examination findings, or clinical laboratory abnormalities, as determined by principal investigator (PI) or PI in consultation with the research monitor and sponsor. * Demonstrate comprehension of the protocol procedures, requirements, and CHIM by passing a written examination (passing grade ≥ 70%). * Willing to participate, as evidenced by signing the informed consent document. * Available for all planned follow-up visits. * Negative serum pregnancy test at screening and negative serum and/or urine pregnancy test on the day of admittance to the inpatient phase for participants of childbearing potential. Participants of childbearing potential must agree to use an efficacious hormonal or barrier method of birth control during the study. Abstinence from intercourse with a male partner is acceptable. Participants who no longer have childbearing potential must have this documented (e.g., tubal ligation or hysterectomy). Exclusion Criteria: General health issues * Presence of a significant medical condition (e.g., psychiatric conditions such as significant anxiety, depression, or somatization disorder; gastrointestinal disease, such as peptic ulcer, symptoms or evidence of active gastritis/dyspepsia, gastroesophageal reflux disease, inflammatory bowel disease, irritable bowel syndrome (as suggested by the functional bowel disorder survey or medical diagnosis); alcohol or illicit drug abuse/dependency; or laboratory abnormalities that in the opinion of the investigator preclude participation in the study. Significant medical conditions include HIV, active Hepatitis B or C infection, ongoing immunosuppression for any reason, autoimmune disease, evidence of cardiac, pulmonary, endocrine, or renal disease that is uncontrolled or poorly controlled, any gastrointestinal illness (chronic reflux, inflammatory bowel disease, ulcer), any diabetes mellitus, and other such illnesses that can put a volunteer at increased risk. Exclusionary laboratory abnormalities include any abnormality that is grade 2 or above. * Immunosuppressive illness or evidence of immunoglobulin A( IgA) deficiency (serum IgA \ 80 years old or infirm or immunocompromised. * Employment as a healthcare worker with direct patient care, in a daycare center (for children or the elderly), or direct food handler; includes individuals who work directly with food in commercial establishments. * History of microbiologically confirmed Campylobacter infection in the last 3 years. * Serological immunological evidence of prior Campylobacter exposure as Campylobacter antigen-specific (GE) specific anti glycine extract serum IgA endpoint tier \> 1:4,000. * Occupation involving handling of Campylobacter currently, or in the past 3 years. * Symptoms consistent with travelers' diarrhea concurrent with travel to countries where Campylobacter, Salmonella, Shigella, Typhoid or ETEC infection are endemic (most of the developing world) within 3 years prior to dosing, OR planned travel to endemic countries during the length of the study. * Vaccination for or ingestion of Campylobacter, Cholera, Salmonella, Shigella, Typhoid or ETEC, within 5 years prior to dosing. * Other dietary or environmental exposures that may place the participant at high risk for prior Campylobacter exposure (to be determined on a case by case basis by the PI).",18.0,50.0,['healthy volunteer']
NCT01632670,"Functional Change in Endothelium After Cardiac cAtheterization, With and Without Music Therapy","FEAT: Functional Change in Endothelium After Cardiac cAtheterization, With and Without Music Therapy",COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: 1. Age \>18 years 2. Referred for clinically-indicated cardiac catheterization Exclusion Criteria: 1. Refusal or inability to provide signed informed consent 2. Significant hearing loss,18.0,65.0,"['coronary artery disease', 'endothelial dysfunction']"
NCT02069470,The Effect of CME on Early Cancer Diagnosis in General Practice,The Effect of Continuing Medical Education (CME) on Early Cancer Diagnosis in General Practice,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * GP should be a GP principal * The referring GP should complete the registration form * Patients should be referred directly from practice to hospital on cancer suspicion in the inclusion period September 2012- May 2013 Exclusion Criteria: * Patients already registered with one cancer, diagnosed within 5 years * Patients self-inflicted in delay",18.0,65.0,['cancer']
NCT04054570,The Geneva Lake Study Update : An Overview of Home Non-Invasive Ventilation 15 Years Later,The Geneva Lake Study Update : An Overview of Home Non-Invasive Ventilation 15 Years Later,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * All patients aged over 18 years old undergoing long term home NIV for at least 3 months and living in the Cantons of Geneva or Vaud were eligible for the study. Exclusion Criteria: * The only exclusion criteria was invasive ventilation (tracheostomy).,18.0,65.0,['home non-invasive ventilation']
NCT02748070,Perioperative Oral Steroids for Chronic Rhinosinusitis Without Polyps (CRSsNP),The Role of Perioperative Systemic Steroids in Patients With Chronic Rhinosinusitis Without Polyps (CRSsNP),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * CRSsNP as defined by Clinical Practice Guideline (Update) on Adult Sinusitis * scheduled to undergo endoscopic sinus surgery Exclusion Criteria: * chronic rhinosinusitis with polyps (CRSwNP) * Aspirin exacerbated respiratory disease * Cystic fibrosis * Immunosuppressive states (Human immunodeficiency virus, transplant) * Oral steroid use within 30 days of surgery",18.0,65.0,"['chronic rhinosinusitis', 'endoscopic sinus surgery', 'chronic rhinosinusitis without polyps', 'oral steroids']"
NCT04798170,Fetal Nasal Bone Length Nomogram at 11-13wk+6days in Upper Egyptian Pregnant Women,Fetal Nasal Bone Length Nomogram at 11-13wk+6 Days in Upper Egyptain Pregnant Women,UNKNOWN,OBSERVATIONAL,FEMALE,Inclusion Criteria: Normal antenatal women of gestational age between 11 to 13week +6days. Single pregnancy. Viable fetus. No fetal malformation. No previous history of fetal malformation Exclusion Criteria: Medical diseased women . Multiple gestations . Fetal malformations . Missed abortion .,18.0,65.0,['nasal bone length']
NCT07015970,Real-life Follow-up of the Physical Activity in Type 1 Diabetes Participants Equipped With an Insulin Pump With Hybrid Closed Loop,Suivi en Vie Réelle de l'Activité Physique de Patients Présentant un Diabète de Type 1 Sportifs Equipés d'Une Pompe à Insuline Avec Délivrance Automatisée d'Insuline,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Adult participants with diabetes mellitus type 1 * User for at least 3 months of one the three automated insulin delivery systems available in France at the time of the study (Minimed 780G pump + Guardian 4 sensor + PID-IFB algorithm; or T:Slim X2 pump + Dexcom G6 sensor + Control-IQ algorithm; or mylife Ypsopump + Dexcom G6 sensor + CamAPS FX app) * Engaged in regular physical activity as part of daily life (at least 2 structured sessions per week, each lasting more than 30 minutes) * Able to download data from the pump * Willing and able to complete the physical activity log and self-questionnaires in French * Having received the information sheet and given their oral consent (non-opposition) to participate in the study and for their data processing Exclusion Criteria: * Participants currently enrolled in a clinical trial * Pregnancy or breastfeeding women or women planning a pregnancy during the study * Adults under legal protection (guardianship, curatorship, or judicial safeguard) * Participants with decompensated retinopathy * Participants with decompensated cardiac disease * History of severe hypoglycemia during physical activity in the past 6 months * Participants with unresolved diabetic foot trophic disorders",18.0,65.0,"['diabetes mellitus type 1', 'glucose metabolism disorder', 'glycemic control for diabetes mellitus', 'fear of hypoglycemia', 'treatment satisfaction', 'quality of life', 'hypoglycaemia']"
NCT07365670,Comparison of the Best Method for Measuring Anti-Xa Activity in Children Receiving Unfractionated Heparin in Cardiac Intensive Care (COMPAXE-HNF),Comparison of the Best Method for Measuring Anti-Xa Activity in Children Receiving Unfractionated Heparin in Cardiac Intensive Care (COMPAXE-HNF),NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Minors aged 0 to 17 inclusive * Weight greater than or equal to 3.5 kg * Admitted to resuscitation or congenital cardiac intensive care * Requiring treatment with unfractionated heparin at curative doses administered via central venous access * Equipped with a central arterial and venous catheter * Affiliated with or beneficiary of a social security scheme * Free, informed, and written consent signed by one of the two representatives of parental authority and the investigator (no later than the day of inclusion and before any examination required by the research). Exclusion Criteria: * Newborns \< 37 weeks gestation * Patients treated by a humanitarian organization",1.0,17.0,"['congenital heart disease', 'unfractionated heparin', 'anti xa activity']"
NCT00453973,Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU),"An Open-Label, Multi-Center, Extension Study to Evaluate the Safety and Tolerability of Peginesatide for the Long-Term Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Participant is informed of the investigational nature of this study and has given written, informed consent in accordance with institutional, local, and national guidelines. * Males or females ≥ 18 years of age. * Premenopausal females (with the exception of those who are surgically sterile) must have a negative pregnancy test at screening; those who are sexually active must practice a highly effective method of birth control for at least 4 weeks prior to study drug administration, and must be willing to continue contraception until at least 4 weeks after the last dose of study drug. * Participant who has received at least 24 weeks of peginesatide dosing in a previous Affymax-sponsored study. * One hemoglobin value of ≥ 10.0 grams per deciliter (g/dL) in the 4 weeks prior to study drug administration. Exclusion Criteria: * Known intolerance to peginesatide or pegylated products. * History of antibodies to any erythropoiesis stimulating agent (ESA) or history of pure red cell aplasia (PRCA). * High likelihood of early withdrawal or interruption of the study (e.g., participant suffers from any clinically significant medical disease or condition that may, in the Investigator's opinion, interfere with safety, assessment, or follow-up of the participant) * Anticipated life expectancy \< 18 months * Receipt of any ESA other than peginesatide at any time after participant enrollment in the previous Affymax-sponsored study",18.0,65.0,"['chronic renal failure', 'chronic kidney disease', 'anemia']"
NCT03286673,Comparison of Three Calcium Supplements,Comparison of Three Calcium Supplements With Regard to Their Metabolic Effects in Healthy Adults,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * age 18 - 40 years Exclusion Criteria: * diseases of the gastrointestinal tract * pregnancy * the intake of any medication (e. g. for thyroid gland) * intake of dietary supplements,18.0,40.0,['healthy']
NCT00204373,Treatment of Zollinger-Ellison Syndrome With Prevacid,Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Diagnosed with Zollinger-Ellison syndrome Exclusion Criteria: * Pregnant or lactating females,19.0,65.0,"['zollinger-ellison syndrome', 'multiple endocrine neoplasia']"
NCT06582173,Mapping the Healthcare Pathway to Multidisciplinary Assessment of 12-25 Year Olds With Somatic Symptom Disorder,Mapping the Healthcare Pathway to Specialised Multidisciplinary Assessment of 12-25 Year Olds With Somatic Symptom Disorder: a Monocentric Descriptive Study Based on Interviews Assisted by a Biographical Grid,NOT_YET_RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: Criteria relating to the population studied: * Age between 12 and 25 years old * Diagnosis of somatic symptom disorder and derivatives (DSM 5) after specialized multidisciplinary evaluation by the team of the Maison des Adolescents of Cochin hospital (Maison de Solenn). Criteria relating to the additional population participating in the research: \- Being a parent of a subject who has received the diagnosis of somatic symptom disorder and derivatives (DSM 5) after specialized multidisciplinary evaluation at the Maison des Adolescents of Cochin Hospital (Maison de Solenn). Exclusion Criteria: Criteria relating to the population studied: * Age less than 12 years or greater than 25 years at the time of assessment, * Subject presenting ongoing psychiatric decompensation, that is to say a state of mental health breaking with their baseline state and requiring rapid care which does not allow a research interview to be carried out. Criteria relating to the additional population participating in the research: None",12.0,65.0,"['somatic symptoms', 'medically unexplained symptoms', 'somatoform disorders']"
NCT07334873,Effect of Inhaled Nitric Oxide Therapy in Adults With Moderate-to-Severe Acute Respiratory Distress Syndrome,"Evaluation of the Efficacy of Inhaled Nitric Oxide Therapy in Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Multicenter, Prospective, Randomized Controlled Clinical Trial (ENARCT-ARDS)",NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age ≥ 18 years. * Patients diagnosed with moderate-to-severe ARDS according to the 2023 Global (or international) criteria. Exclusion Criteria: * Known allergy to iNO. * Congenital methemoglobinemia. * End-stage chronic lung disease (e.g., lung cancer, prior pneumonectomy/lung transplant). * Shock (norepinephrine \>0.5 μg/kg/min or equivalent for \>6 hours) at treatment initiation. * Pulmonary hypertension (PASP \>45 mmHg by echo or mPAP ≥25 mmHg by catheterization). * Serum creatinine \>2.5 mg/dL (221 μmol/L). * Major bleeding (e.g., intracranial, pulmonary) or platelet count \<20×10⁹/L. * Expected ICU/mechanical ventilation \<24 hours. * Pre-enrollment ECMO therapy. * Any investigator-assessed unsuitability for the study.",18.0,65.0,['ards (moderate or severe)']
NCT06417073,Effects of Task-Oriented Station Training on Cognitive Levels and Hand Functions in Geriatric Residents of Nursing Homes,"Effects of Task-Oriented Station Training on Cognitive and Hand Functions in Nursing Home Elders: Comparing Tele-Rehabilitation, Face-to-Face, and Home-Based Interventions",COMPLETED,INTERVENTIONAL,ALL,"\*\*Inclusion Criteria:\*\* * Age 65 years and older. * Residency in a nursing home. * Able to provide informed consent, either directly or through a legal guardian. * Sufficient cognitive function to participate in the intervention, as indicated by a Mini-Mental State Examination (MMSE) score of 18 or higher. * Physically able to participate in task-oriented activities, with or without assistive devices. * Stable medical condition, with no hospitalizations due to acute illness in the last three months prior to the study commencement. \*\*Exclusion Criteria:\*\* * Diagnosed with severe dementia or any cognitive impairment severe enough as per the healthcare provider to interfere with participation in the study. * Any medical condition that significantly limits physical activity or requires intensive medical care during the study period, such as unstable cardiovascular disease, severe osteoarthritis, or recent fractures. * Participation in any other experimental rehabilitation or drug trials concurrently. * Severe sensory deficits that would prevent participation in the tasks (e.g., severe vision or hearing loss not correctable with aids). * Life expectancy less than 6 months as estimated by a physician. * Significant psychiatric disorders that might impair the ability to comply with study protocols.",60.0,85.0,"['cognitive decline', 'motor function disorders', 'geriatric health']"
NCT04062773,Time-Restricted Feeding on Glucose Homeostasis and Quality of Life,"A Pilot Study to Evaluate the Effect of Time-Restricted Feeding on Blood Glucose, Insulin Sensitivity and Quality of Life",UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Must agree to follow time restricted feeding protocol if randomized to the TRF arm. * Age 21-65 years * T2DM with any diabetes medication * BMI of 25-45 kg/m2 * Wake up at a regular time between 5-8 am * Able to provide informed consent. Exclusion Criteria: * Weight loss of more than 5 kg within the past 6 months * HbA1c of \ 12% * Serious current or recent illness including cancer or severe or unstable heart failure. * Participation in another clinical research trial. * Current treatment with anti-obesity drugs. * Substance abuse * Learning difficulties * Presence of an eating disorder * Purging behaviour * Pregnancy or consideration of pregnancy * Hospital admission for depression or use of antipsychotic drugs. * Regularly eat within a \<9-hour period each day * Inability or unwillingness of individual or legal guardian/representative to give written informed consent.,21.0,65.0,"['diabetes mellitus, type 2', 'time restricted feeding']"
NCT02327273,"Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects","Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects",COMPLETED,INTERVENTIONAL,ALL,"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs and clinical laboratory determinations * Body Mass Index (BMI) of 27 to 40 kg/m2 inclusive. BMI = weight (kg)/ \[height (m)\]2 * Females (not of childbearing potential and males, ages 18 to 55 years, inclusive. Female subjects must have documented proof that they are not of childbearing potential * Azoospermic males and women who are not of child-bearing potential (i.e. are postmenopausal or surgically sterile; see section 3.3.3 for the definition of WOCBP) are exempt from contraceptive requirements. However, women must still undergo pregnancy testing as described in this section Exclusion Criteria: * Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population * Any of the following on 12-lead electrocardiogram (ECG) prior to study drug administration, confirmed by repeat. i)PR ≥ 210 msec ii)QRS ≥ 120 msec iii)QT ≥ 500 msec iv)QTcF ≥ 450 msec * Positive urine screen for drugs of abuse * Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1, -2 antibody * Moderate anemia (hemoglobin \ 1.3x ULN * alanine aminotransferase (ALT) \> 1.3x ULN * Total bilirubin \> 1.3x upper limit of normal (ULN) * estimated glomerular filtration rate (eGFR) \ 6.5% * Fasting total cholesterol \> 300 mg/dl * Fasting triglycerides \> 400 mg/dl * Systolic blood pressure \> 160 mm Hg and/or diastolic blood pressure \> 95 mm Hg, confirmed by repeat measurement * History of any significant drug allergy (such as anaphylaxis or hepatotoxicity). * History of lactose intolerance",18.0,55.0,['healthy']
NCT01698073,Effect of a Culturally-based Intervention on Sexual Risky Behavior Among Young American Indian Adolescents,Teen Pregnancy Prevention Among Native Youth of the Northern Plains,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * 10-12 years old at baseline * A member of participating Native Boys and Girls Club * Signed Parental Consent Form * Signed Parental Permission Form * Signed Child Assent Form Exclusion Criteria: * None Noted,10.0,12.0,['teen pregnancy prevention']
NCT04923373,Telerehabilitation After Total Knee Arthroplasty,Early Function Recovery in Geriatric Patients With Total Knee Arthroplasty by Telerehabilitation,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * total cemented knee arthroplasty with posterior stability (PS -cruciate sacrificing, posterior stabilized), * informed consent to participate in the study, * full medical record, * patients' regular control visits, * knee degenerative disorder stage II and III according to Altman classification, * ability to understand and independently perform the complete physiotherapeutic programme Exclusion Criteria: * partial arthroplasty, * deformation aetiology other knee degenerative disorder, * cognitive disorders resulting in inability to fill out the study questionnaire, - degenerative disorders of multiple joints, * poor general health that prevented the patient from understanding or performing the full physiotherapeutic programme, * intraoperative and postoperative complications preventing the patient from understanding or performing the full physiotherapeutic programme, * lack of informed consent to participate in the study.",50.0,80.0,"['telerehabilitation', 'total knee arthoplasty', 'physiotherapy']"
NCT01080573,Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis,A Questionnaire Based Survey to Identify Issues With Patient Compliance and to Develop Solutions to Improve Rebif Compliance and Improve Patient Outcomes,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * Subjects who have been prescribed Rebif and referred to Bupa Home Healthcare service by one of the participating referring centres Exclusion Criteria: * Subject unwilling to give informed consent * Subjects visiting private clinics,18.0,65.0,['multiple sclerosis']
NCT01126073,Niacin/Laropiprant and Endothelial Function,"A Double Blind, Randomized Study to Compare Influence of Niacin/Laropiprant on Functional and Morphological Characteristics of Arterial Wall and Parameters of Inflammation in Subjects With Coronary Heart Disease Already Treated With a Statin",COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: * Age 35-55 * Confirmed CHD (post MI patients, coronarography and/or cycloergometer) * Already treated for dyslipidemia with a statin and reaching ESC LDL target * HDL-C \ 1,7 mmol/l and LDL \ 200 mmol/l * Acute disease within 6 weeks prior to inclusion * Hypersensitivity to nicotinic acid * Other cardiac medication stable for at least 4 weeks prior to enrollment * Acute MI, CABG, PCI within past 3 months * Congestive heart failure (CHF) \_ NYHA 2 * Ejection fraction \ 7% * Hypo/hyper thyroidism * Alcohol or drug abuse",35.0,55.0,['coronary heart disease']
NCT04733573,Pressure Algometry Evaluation of Two Occlusal Splint Designs in Bruxism Management - RCT,"Pressure Algometry Evaluation of Two Occlusal Splint Designs in Bruxism Management - Randomized, Controlled Clinical Trial",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * I. Nocturnal Bruxism according to International Classification of Sleep Disorders, Second Edition (ICSD-2). A. The patient reports or is aware of tooth-grinding sounds or tooth clenching during sleep. B. One or more of the following is present: a. Abnormal wear of teeth b. Jaw muscle discomfort, fatigue, or pain and jaw lock upon awakening. c. Masseter muscle hypertrophy upon voluntary forceful clenching. C. The jaw muscle activity is not better explained by another current sleep disorder, medical or neurological disorder, medication use, or substance use disorder. II. Additional questionnaire for detecting bruxers: Has anyone heard you grinding your teeth at night? Is your jaw ever fatigued or sore in the morning? Are your teeth or gums ever sore on awakening in the morning? Do you ever experience temporal headaches on awakening in the morning? Are you aware of grinding your teeth during the day? Are you ever aware of clenching your teeth during the day Can you imitate a sound of grinding using your teeth. Exclusion Criteria: * unrestored tooth losses * patients wearing removable dentures of any kind * psychiatric conditions undermining/preventing occlusal splint usage",18.0,65.0,"['bruxism', 'sleep disorder']"
NCT04183673,Laser + Cryo-thermal Therapy Following Total Knee Replacement Surgery,Efficacy of Laser + Cryo-thermal Therapy in Rehabilitation Following Total Knee Replacement Surgery: a Randomized Controlled Trial,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * good general physical conditions * first total knee replacement Exclusion Criteria: * diabetic neuropathy * renal or hearth disease * allergic reactions * Reynaud's disease * lupus * rheumatoids arthritis * peripheral vascular disease,50.0,85.0,['knee arthropathy']
NCT03763773,Prediction of Outcomes With a Miniaturized Transesophageal Echocardiography Probe in Patients With Acute Respiratory Distress Syndrome,Prediction of Outcomes With a Miniaturized Transesophageal Echocardiography Probe in Patients With Acute Respiratory Distress Syndrome,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Patients hospitalized in Resuscitation, Emergency or Intensive Care Units at the Roger Salengro Hospital at Lille University Hospital. * With acute respiratory distress syndrome of intermediate or severe severity (1) for less than 24 hours. * Mechanical ventilation with tracheal intubation or tracheostomy, in controlled assisted ventilation (VAC) mode. * Patient adapted to mechanical ventilation (no triggering of spontaneous ventilation cycle in VAC mode verified by the equality between the respiratory rate prescribed on the ventilator and the actual respiratory rate of the patient). Exclusion Criteria: * Patient under extracorporeal respiratory assistance at the time of inclusion. * Anomalies or pathologies that make it dangerous or impossible to introduce an ETO probe: * Fistula, perforation, stenosis, varicose vein or diverticulum of the esophagus and / or stomach * History of esophageal and / or gastric surgery * Caustic lesions of the esophagus and / stomach * Tumor or history of oropharyngeal surgery * Unstable lesions of the cervical spine * Coagulopathy (thrombocytopenia \<50 109 / L and / or TP \<50%). * Impossibility of measuring the diameter of the superior vena cava and cVCS in ETO due to poor echogenicity. * Pregnant woman. * Therapeutic limitation measures limiting the treatment of organ failure.",18.0,65.0,['acute respiratory distress syndrome']
NCT01969773,Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment,"Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients with IC/PBS who have failed conventional treatments for at least 6 months will be enrolled. * A diagnosis of IC/PBS has been established based on characteristic symptoms and cystoscopic findings of glomerulations, petechia, or mucosal fissures after hydrodistention. * All patients have been treated with at least two types of treatment modalities including non-steroid anti-inflammatory drugs, oral pentosan polysulfate sodium (PPS), intravesical instillation of heparin, hyaluronic acid, or tricyclic antidepressant for at least 6 months but the symptoms remained unchanged or relapsed. Exclusion Criteria: * Exclusion criteria proposed by NIDDK * Automatic exclusions: 1. Age \ 400ml, absence of sensory urgency * Automatic inclusions: 1.Hunner's ulcer * Positive factors: (two positive factors are necessary for inclusion) 1. Pain on bladder filling relieved by emptying 2. Pain (suprapubic, pelvic, urethral, vaginal or peripheral) 3. Glomerulations on endoscopy 4. Decreased compliance on cystometrogram 5. Bladder distention is defined arbitrarily as 80 cm water pressure for 1 minute * Use of Anticholinergic drugs, for the treatment of lower urinary tract symptoms who have an effect. * Patients with severe cardiopulmonary disease and such as congestive heart failure, arrhythmia, poorly controlled hypertension, not able to receive regular follow-up. * Patients with bladder outlet obstruction on enrollment. * Patients with urinary retention, PVR≥150 ml. * Patients with uncontrolled confirmed diagnosis of acute urinary tract infection. * Patients have laboratory abnormalities at screening including: 1. Alanine aminotransferase (ALT) \> 3 x upper limit of normal range 2. Aspartate aminotransferase (AST) \> 3 x upper limit of normal range. 3. Patients have abnormal serum creatinine level \> 2 x upper limit of normal range. * Can not be used in the treatment of patients with transurethral catheter treatment. * Pregnant and lactating women or women who intend to become pregnant during the study or have myasthenia gravis, Eaton Lambert syndrome. * Patients with any other serious disease or condition considered by the investigator not suitable for entry into the trial. * Patients participated investigational drug trial within 1 month before entering this study. * Written informed consent has been obtained. * Patient who did not complete the 3-day micturition diary according to the instruction. * Intestinal bladder augmentation patients receive angioplasty for the treatment of overactive bladder.",20.0,85.0,['interstitial cystitis']
NCT05253573,Mobile Health Technology for Personalized Tobacco Cessation Support Among Cancer Survivors in Laos,Mobile Health Technology for Personalized Tobacco Cessation Support Among Cancer Survivors in Laos,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Aged ≥18 years * Self-reported current combustible cigarette smokers (smoked at least 100 cigarettes in lifetime and currently smoke ≥1 cigarette/day) * Willing to set a quit date within 2 weeks of study enrollment * Able to provide written informed consent to participate * Able to read Lao (score ≥4 points on the Rapid Estimate of Adult Literacy in Medicine-Short Form). Exclusion Criteria: * History of a medical condition that precludes use of NRT * Ineligibility to participate based on medical or psychiatric conditions diagnosed by a physician/clinician * Enrollment in another cessation program or current use of other cessation medications,18.0,65.0,['cigarette smoking']
NCT04979273,The Role of Hypertonic Dextrose Spray as Endoscopic Topical Hemostatic Agent for Acute Non-Variceal Upper GI Bleeding,The Role of Hypertonic Dextrose Spray as Endoscopic Topical Hemostatic Agent for Acute Non-Variceal Upper Gastrointestinal Bleeding: A Randomized Controlled Trial,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients with acute non-variceal upper gastrointestinal bleeding caused by peptic or duodenal ulcer, polyps, tumors or malignancy * Patients consented to study participation Exclusion Criteria: * Patients with thrombocytopenia (thrombocyte count \<100.000 cells/ul) and other forms of coagulopathy",18.0,65.0,['gastro intestinal bleeding']
NCT00772473,Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine,Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: 1. Ability to read, understand, and sign the informed consent 2. Subject is between the ages of 18 and 65, either male or female 3. Negative pregnancy test for those of childbearing potential. 4. Adequate birth control as approved by the investigator if of childbearing potential 5. Subjects must fulfill criteria for IHS migraine (1.1 or 1.2) with a history of 1-6 migraines per month within the past 3 months and at least 15 headache free days though out the previous three month time period Exclusion Criteria: 1. Pregnant or breast feeding 2. Presence of any condition or symptoms that would knowingly alter the content of the saliva 3. Presence of any medical disease or condition that would interfere with the conduct of the study 4. Current use of other medications that would be contraindicated in those patients that will take triptan medications for treatment of migraine symptoms, ie. MAO inhibitors, lithium, methyergonovine, methysergide, or ergotamine-containing products 5. Use of migraine preventive medications in the three months prior to screening 6. History of drug or alcohol abuse that would interfere with the study 7. Any pathology of the salivary glands such as sialadenitis (e.g., Sjorgen's syndrome, viral or bacterial sialadenitis, obstructive sialadentitis) 8. History of hypersensitivity or allergy to triptan medications 9. Presence of diabetes, salivary gland tumors, liver disease, alcoholism, and neuropathy 10. More than 15 days per month of headache within the past 3 months 11. Participation in another investigative drug study within the past 30 days",18.0,65.0,"['headache, migraine']"
NCT06280469,Single-operator Versus Double-operator in Single-Balloon Enteroscopy,"Single-operator Versus Double-operator in Single-Balloon Enteroscopy：a Prospective, Multicenter, Non-inferiority, Randomized Controlled Study",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * age greater than eighteen years; * Suspected small bowel disease with proposed enteroscopy Exclusion Criteria: * patients with a history of small bowel surgery; * patients who fail to perform bowel preparation as required; * patients at high risk for esophageal varices with risk of bleeding; * patients who have not planned a deep small bowel examination before enteroscopy, such as a lesion clearly located in the duodenum, proximal jejunum or terminal ileum; * patients who are in extremely poor physical condition and are not suitable for general anesthesia, as defined by an ASA score greater than 3; * Pregnant or lactating women; * Inability to provide written informed consent.",18.0,65.0,"['single-balloon enteroscopy', 'operation']"
NCT02250469,A Randomised Pilot Study to Assess Differences in Stimulation Induced Paresthesia Between 2 Spinal Cord Stimulation Systems,A Randomised Pilot Study to Assess differenCes in tHe Subjects' Experience of stimulAtion-Induced paRaesthesiA Between Two Different Spinal Cord sTimulation dEvices: the Axium® DoRsal Root Ganglion Stimulation System Versus the Prime Advanced Dorsal Column Stimulation System,TERMINATED,INTERVENTIONAL,ALL,Inclusion Criteria: 1. Subject is appropriate for SCS implantation according to standard criteria 2. Subject is \>18 to \ 6 months) uni/bi-lateral neuropathic pain in the lower limb(s) (below the knee) with predominant foot pain 5. Minimum baseline pain rating of 50 mm on the VAS in the primary region of pain 6. Subject is able to provide written informed consent Exclusion Criteria: 1. Subject has no other exclusion criteria for SCS implantation according to standard criteria 2. Subject has had corticosteroid therapy at an intended site of stimulation within the past 30 days 3. Subject has had radiofrequency treatment of an intended target DRG within the past 3 months 4. Subject has participated in another clinical study within 30 days 5. Subject has been previously treated with and failed to respond to an implantable neuromodulation therapy,18.0,75.0,['chronic pain']
NCT03948269,The Effect of Internet- and Mobile-based Group Treatment in Menopausal Women,Internet- and Mobile-based Group Treatment of Menopausal and Psychological Health of Chinese Women: a Study Protocol for a Randomized Non-inferiority Trial,UNKNOWN,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * aged 40\~60, in menopausal transition or post-menopause, according to the STRAW +10 definition * have Internet access * have mobile phone access * have sufficient knowledge of the Chinese language * have scored in the clinical range for menopause syndrome from the psychiatric interview * have signed a consent form that will be provided to eligible participants. Exclusion Criteria: * not completing informed consent * presence of any of the following diseases: hyperthyroidism, coronary atherosclerotic heart disease, hypertension (BP≥140/90 mmHg), pheochromocytoma, neurasthenia, psychosis, or other diseases closely related to the main disease * troublesome drinking * drug use (hypnotics or hormone therapy) in the past 14 days, which might affect mood.",40.0,60.0,['menopausal syndrome']
NCT02294669,A Feasibility Study to Evaluate the TURRIS Facet Fusion System in Lumbar Spinal Surgery,A Feasibility Study to Evaluate the TURRIS Facet Fusion System as an Adjuvant to Unilateral Pedicle Screw Fixation in Lumbar Spinal Surgery,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * one-level fusion at L4/L5 with dorsal instrumentation and, if required, with monolateral decompression and/or intervertebral disc removal and implantation of an intervertebral implant Exclusion Criteria: Patient * had previous surgical stabilizations at the involved or adjacent levels * has lytic spondylolisthesis * has degenerative spondylolisthesis grade II or higher * has radiographic signs of significant instability and/or hypermobility of the segment (\>3mm translation, \>11° rotation difference from adjacent level) * has scoliosis \> 10° at the involved segment * has osteoporosis to a degree that spinal instrumentation would be contraindicated. * has presence of active malignancy. * has overt or active infection, either local or systemic * is less than 18 years old * is pregnant or plan a pregnancy during the study duration * has a BMI \> 35 * has a progressive neuromuscular disease * has a condition which requires postoperative medications that may interfere with bone metabolism * has a history of autoimmune disease * has a history of endocrine or metabolic disorders known to affect osteogenesis * is mentally ill or incompetent * is an alcohol and/or drug abuser * is not available for follow up visits",18.0,65.0,['spinal disease']
NCT05605769,Evaluation of the Performance of Rapid Diagnostics for SARS-CoV-2 Self-testing in the Hands of Untrained,Evaluation of the Performance of Rapid Diagnostics for SARS-CoV-2 Self-testing in the Hands of Untrained Users,COMPLETED,OBSERVATIONAL,ALL,"Phase 1 Inclusion Criteria: * 18 years of age * Able to speak and read local language depending on site of recruitment * Provided voluntary written consent to participate in this stud Phase 11 inclusion Criteria: * 18 years of age * Able to speak and read local language depending on site of recruitment * Suspected to have COVID-19 (as per WHO or national guidelines). * SYMPTOMATIC group) * Contacts of confirmed cases of COVID-19 * Individuals residing or working in an area with high risk of transmission of virus * Individuals residing or travelling to an area with community transmission * Individuals working in any health care setting, including within health facilities or within the community * Written consent * Provided the required number of specimens suitable for testing. Exclusion criteria * Participated in Phase I or Phase II of the study * Prior medical or clinical laboratory training * Prior experience with self-testing for SARS-CoV-2 * Hemodynamic instability as determined by the treating physician * unable to cooperate with respiratory sample collection or on oxygen therapy * Recent history of excessive nose bleeds * Any condition which, in the opinion of the investigator feels unable to participate in the study",18.0,65.0,['covid-19']
NCT01441869,Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc,Bioequivalence Study of the Fixed-dose Combination of Saxagliptin/Metformin XR Tablets Relative to Saxagliptin (Onglyza� ) Tablets and Australia-sourced Diabex XR Tablets Coadministered to Healthy Subjects in the Fed State During Steady-state Administration,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Provision of signed and dated informed consent prior to any study specific procedures * Males or females aged 18 to 55 years (inclusive) and with a weight of at least 50 kg and a body mass index (BMI) between 18 and 35 kg/m2, inclusive * Females must have a negative urine pregnancy test at screening and negative serum pregnancy test on admission to the unit, must not be lactating, and must be using an acceptable method of contraception for at least 1 month before dosing * Female volunteers of childbearing potential (including perimenopausal women who have had a menstrual period within 1 year) must be using appropriate birth control (defined as a method which results in a low failure rate, ie, less than 1% per year * Oral contraceptive and hormone replacement medications are allowed in this study if used together with a barrier contraceptive method. Exclusion Criteria: * History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate * History or presence of gastrointestinal, hepatic, renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs (except for cholecystectomy) * Glomerular filtration rate of less than 60 mL/min (to be estimated at screening only) * Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of investigational product (IP) * History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator (eg, seasonal allergies) or history of hypersensitivity to drugs with a similar chemical structure or class to saxagliptin or metformin",18.0,55.0,"['bioequivalence, log-transformed aucss and cmax,ss values for saxagliptin and metformin']"
NCT03672669,Comparison of the Effect of A-PRF and L-PRF on Outcomes After Removal of Impacted Mandibular Third Molar,Comparison of the Effect of Advanced Platelet-rich Fibrin and Leukocyte- and Platelet-rich Fibrin on Outcomes After Removal of Impacted Mandibular Third Molar: A Randomised Split-mouth Study,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * age≥18 * the presence of bilaterally symmetrically impacted mandibular third molar, which requires an extraction for prophylactic reasons * absence of systemic diseases * absence of chronic opioid taken; * not being pregnant * not smoking and no alcohol usage * the absence of allergy to penicillin or any other drugs used during standardized postoperative therapy. Exclusion Criteria: * tooth needed to be sectioning during the operation * operation time exceeding 30 minutes * the cases with severe periodontal disease or acute pericoronitis, * the cases using antibiotics for an existing infection * the cases not capable of following postoperative instructions",18.0,26.0,"['pain, postoperative', 'trismus', 'swelling']"
NCT07193069,Clinical and Biological Signs of Dapagliflozin Overdose in ICU Patients With Metformin Poisoning,Clinical and Biological Signs of Dapagliflozin Overdose in ICU Patients With Metformin Poisoning,RECRUITING,OBSERVATIONAL,ALL,Inclusion Criteria: * Adults aged 18 years or older * Admission to an intensive care unit (ICU) due to acute drug poisoning * Documented exposure to either: * Metformin alone * Metformin in combination with dapagliflozin Exclusion Criteria: * Patients under 18 years of age * No exposure to metformin * Exposure to dapagliflozin without metformin,18.0,65.0,"['drug overdose', 'metformin', 'dapagliflozin', 'lactic acidosis', 'diabetic ketoacidosis', 'intensive care units']"
NCT02194569,"Magnesium Balance of Citrate-based Continuous Venovenous Hemofiltration, Effect of Citrate Dose.","Magnesium Balance of Citrate-based Continuous Venovenous Hemofiltration, Effect of Citrate Dose.",COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Critically ill patients requiring CRRT for AKI (RIFLE criteria) * Written informed consent from the patient or legal representative Exclusion Criteria: * pre-existing chronic renal insufficiency requiring dialysis * chronic immunosuppression * liver cirrhosis Child-Pugh C * severe or shock-related hepatitis * Pregnancy,18.0,65.0,"['critically ill', 'acute kidney injury']"
NCT04352569,Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia,"Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia: A Double Blind, Randomized Controlled Study",RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * Schizophrenia according to DSM-V. * Refractory auditory hallucinations(despite two antipsychotics trials). * Right-handed patients. * Written informed consent. Exclusion Criteria: * Presence of other psychiatric disorders than schizophrenia (except addiction to tobacco or caffeine ). * History of severe head trauma or coma. * History of epilepsy or neurological disorder or a general medical condition. * Presence of intracranial metallic objects or pacemaker. * Hospitalized patients without consent. * pregnant women .,18.0,65.0,"['schizophrenia', 'hallucinations', 'refractory schizophrenia']"
NCT03758469,A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules,"A Single-Center, Open-Label, Randomized, Two-Stage, Two-Way Crossover Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules in Healthy Subjects.",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Healthy males or females with full capacity for civil conduct, aged ≥18 and ≤45 years old. Both male and female subjects should be enrolled; 2. Male subjects weighing ≥50 kg, female subjects weighing ≥45 kg. All subjects should have a body mass index (BMI) of ≥19.0 and ≤26.0 kg/m2; 3. Blood pressure between 100-139/60-89 mmHg; heart rate between 60-99 beats/min; body temperature between 35.8-37.5 °C; respiratory rate between 12-20 breaths/min; SpO2 when inhaling ≥95%; 4. Normal physical examinations, laboratory examinations (blood routine, blood biochemistry and urine routine), and 12-lead electrocardiogram (ECG), or abnormal but without clinical significance as judged by the investigators; no significantly potential difficult airway (modified Mallampati score I-II); 5. No previous history of major organ primary diseases, such as liver, kidneys, digestive tract, blood, and metabolic diseases; no history of malignant hyperthermia and other genetic conditions; no history of mental/neurological diseases; no history of epilepsy; no contraindications for deep sedation/general anesthesia; no clinically significant history of anesthesia accidents; 6. Subjects must understand the procedures and methods of this study, and be willing to provide informed consent and to complete the trial in strict accordance with trial protocol. Exclusion Criteria: 1. Known sensitivity to excipients in HSK3486 injectable emulsion (soybean oil, glycerin, triglyceride, egg lecithin, sodium oleate and sodium hydroxide), rifampin, or contraindications mentioned in the prescribing information of rifampin; history of drug allergies (including anesthetics), allergic diseases, or those with hyperactive immune response; 2. In receipt of any one of the following medications or treatments during screening/baseline: 1. History of drug abuse or any signs of chronic benzodiazepines use (such as insomnia, anxiety, spasms) within 3 months prior to screening, or a positive urine drug test during baseline; 2. Participated in clinical trials involving any medications or medical devices within 3 months prior to screening, or subjects who have participated in 3 or more drug clinical trials within the past year; 3. In receipt of rifampin within 4 weeks prior to screening; 4. Serious infection, trauma or major surgery within 4 weeks prior to screening; or acute disease with clinical significance (determined by the investigator) within 2 weeks prior to screening, including GI diseases or infections (such as respiratory or CNS infections); 5. In receipt of propofol, other sedatives/anesthetics and/or opioid analgesics or compounds containing analgesics within 1 week prior to baseline; 6. In receipt of prescription drugs, Chinese herbal medicines, over-the-counter drugs or food supplements (such as vitamins and calcium supplements) other than contraceptives, paracetamol, oral non-steroidal anti-inflammatory drugs, topical over-the-counter preparations, within 2 weeks prior to baseline; unless the principal investigator (PI) and the sponsor agree that the medication has no effect on the safety and PK/PD results of the trial; 3. A history or evidence of any one of the following diseases prior to screening/baseline: 1. History of cardiovascular diseases such as: postural hypotension, severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within 6 months before screening, tachycardia/bradycardia requiring medication, third-degree atrioventricular block or QTcF interval ≥450 ms (Fridericia's correction formula); 2. Respiratory insufficiency, history of obstructive pulmonary disease, history of asthma, sleep apnea; history of failed tracheal intubation; history of bronchospasm requiring treatment within 3 months prior to screening; acute respiratory infection, and with obvious symptoms such as fever, wheezing, nasal congestion or cough within 1 week prior to baseline; 3. History of GI tract diseases: Gastrointestinal obstruction, active GI bleed, potential for reflux and aspiration; 4. Laboratory results that meet any of the following during screening/baseline: 1. Positive result for either HBsAg, HCV, HIV, or syphilis; 2. Abnormal hepatic or renal function confirmed after re-examination; * ALT or AST \> 1×ULN; * Creatinine \> 1×ULN; * TBIL \> 1.0×ULN; 5. History of alcohol abuse within 3 months prior to screening, abuse defined as average of \> 2 units of alcohol per day (1 unit = 360 mL beer or 45 mL liquor with 40% alcohol or 150 mL wine), or positive result for breath alcohol test during baseline; 6. Smoke more than 5 cigarettes per day and a total of more than 60 cigarettes within 3 months prior to screening; 7. Blood donation or blood loss ≥200 mL within 30 days prior to screening; plasma donation or plasma exchange within 7 days prior to screening; 8. Subjects who consume any beverages or foods containing alcohol, grapefruit juice or methylxanthine (such as coffee, tea, coca-cola, chocolate, functional drinks), to participate in strenuous physical activities and other factors that may affect drug absorption, distribution, metabolism, and excretion within 2 days prior to enrollment; subjects who are unable to fast for 8 hours prior to dose administration; 9. Subjects expected to have surgery or hospitalization during the trial; 10. Subjects unsuitable for arterial blood collection, such as subjects who have positive Allen's test; 11. Women who are pregnant or breastfeeding; women of child-bearing potential or men who are unwilling to use contraception during the trial; subjects who are planning pregnancy within 1 month after the completion of the trial (including male subjects); 12. Subjects judged by the investigator to be unsuitable for participating in this trial for any reason.",18.0,45.0,"['anesthesia', 'sedation']"
NCT01876069,Comparing Newly Developed PreCore Needle With Conventional Fine Needle in Suspected Unresectable Pancreatic Cancer,Comparing Newly Developed PreCore Needle With Conventional Fine Needle in Endoscopic Ultrasonography-guided Sampling of Suspected Unresectable Pancreatic Cancer,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Patients who agree to participate in research * 18 years of age and older patients less than 80 years old * Patients who have suspected unresectable pancreatic cancer in imaging studies Exclusion Criteria: * Contraindication to endoscopy * Patients younger than 18 years old or older than 80 years old * Bleeding tendency * Cardiopulmonary dysfunction * Pregnancy,18.0,80.0,['pancreatic cancer']
NCT01551069,Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion,"A Randomized, Double Blind, Baseline Controlled Study Using Placebo as Reference for Assessing the Efficacy and Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus in the Presence of Active Lupus Erythematosus Specific Skin Lesion",COMPLETED,INTERVENTIONAL,ALL,Inclusion criteria : * Patients diagnosed as cutaneous lupus erythematosus (CLE) Exclusion criteria: * Patients receiving corticosteroid more than 15mg/day of the equivalent dose of prednisolone. * Patients whose CLASI activity scores were less than 4 point at the initiation of Screening (Visit 1) and Day1 (Visit 2) (evaluated by a dermatology specialist). * Patients whose fluctuations of CLASI activity scores were ≥20% between Visit 1 and Visit 2 (evaluated by a dermatology specialist). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.,18.0,65.0,['cutaneous lupus erythematosus-systemic lupus erythematosus']
NCT03978169,Pulmonary Impacts of Anaesthetic Modalities Evaluated by Ultrasound,Pulmonary Impacts of Anaesthetic Modalities Evaluated by Ultrasound: A Prospective Study in Scheduled Knee Arthroplasty,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: * Patient undergoing scheduled primary knee arthroplasty : * Partial knee replacement surgery * Total knee replacement surgery • Type of Anaesthesia * General anaesthesia with orotracheal intubation * General anaesthesia with laryngeal mask * Spinal anaesthesia * Major Patient * Oral non opposition collected after oral information of the study Exclusion Criteria: * Refusal to participate * Preoperative pleural pathology (pleural effusion, pleural symphysis) * Pregnancy * Patient under authorship or curators * non-affiliation to a social security scheme",18.0,65.0,['anesthesia']
NCT05509569,A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema,Specified Drug Use Surveillance of FIRAZYR Subcutaneous Injection 30mg Syringe for Pediatric Subjects With Hereditary Angioedema (All-Case Investigation),COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: \- All participants with HAE who are 2 to \<18 years of age, treated with Icatibant subcutaneous injection 30 mg syringe for the first time. Exclusion Criteria: \- Participants who have been treated with Icatibant subcutaneous injection 30 mg syringe in clinical trials or transfer cases, and so on.",2.0,17.0,['hereditary angioedema (hae)']
NCT04916769,Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition,"A PHASE 1, OPEN-LABEL, RANDOMIZED, 3-PERIOD, 6-SEQUENCE, CROSSOVER STUDY TO EVALUATE THE BIOAVAILABILITY OF BOSUTINIB ADMINISTERED AS CAPSULE CONTENTS MIXED WITH APPLESAUCE OR YOGURT RELATIVE TO INTACT CAPSULES IN HEALTHY PARTICIPANTS UNDER FED CONDITION",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Female participants of non childbearing potential and/or male participants must be 18 to 54 years of age, inclusive, at the time of signing the informed consent document (ICD). * Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, dermatological, or allergic disease. * Any condition possibly affecting drug absorption. * Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary: 1. estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\]) \ upper limit of normal (ULN); 3. Serum (total and direct) bilirubin level \> ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is \ ULN.",18.0,55.0,['healthy participants']
NCT02130869,A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,COMPLETED,INTERVENTIONAL,ALL,"The transplant recipient will be evaluated for eligibility at two time points during study participation. The first phase will be when the autologous stem cell product is collected. The recipient will later need to meet specific eligibility criterion at the time of the autologous stem cell infusion. The two phases and the respective criteria are described below. Inclusion criteria for autologous stem cell collection (Phase 1 - transplant recipient): * Less than or equal to 21 years of age. * Malignancy at high risk of treatment failure for which autologous hematopoietic stem cell transplantation is considered within standard practice. * Group A: High-risk neuroblastoma * Group B: Recurrent or refractory Hodgkin lymphoma; recurrent or refractory non-Hodgkin lymphoma * Group C: High-risk, recurrent or metastatic sarcoma; recurrent or advanced stage Wilms tumor; desmoplastic small round cell tumor; metastatic or recurrent retinoblastoma, high-risk germ cell tumors, and high-risk brain tumors * Sarcoma or Wilms tumor diagnosis (Group C) will require evaluation by physician in the St. Jude Solid Tumor Division, other than the referring physician, attesting that autologous SCT provides the prospect of direct benefit for the participant. * Has a potentially suitable human leukocyte antigen (HLA) haploidentical donor available. * Research participant or legal guardian/representative must be willing to give written informed consent * Does not have any active or prior malignant or pre-malignant condition of the bone marrow, excluding metastasis of the primary malignancy. * Has no known allergy to murine products or positive human anti-mouse antibody (HAMA). * (Female only) Negative serum or urine pregnancy test (to be conducted within 7 days prior to enrollment). * (Female only) Not breastfeeding. Inclusion criteria to proceed with autologous stem cell transplantation (Phase 2 - transplant recipient): * Has a confirmed suitable HLA haploidentical donor available. * Previously collected autologous stem cell product met the minimum collection target and minimum infusion target as described in the protocol. * At least two weeks since receipt of any biological therapy, chemotherapy, and/or radiation therapy. * Has recovered from all acute NCI Common Toxicity Criteria grade II-IV non-hematologic toxicities from prior therapy per the judgment of the PI. * Shortening fraction greater than or equal to 25%. * Creatinine clearance or glomerular filtration rate greater than or equal to 50 mL/min/1.73 m\^2. * Pulse oximetry greater than or equal to 92% on room air. * Alanine aminotransferase (ALT) and aspartate transaminase (AST) less than or equal to 3 times the upper limit of the institution-established normal range. * Direct bilirubin less than or equal to 3.0 mg/dL. * Karnofsky or Lansky performance score of greater than or equal to 50. * Has not received a prior hematopoietic stem cell transplant within 3 months. * Has no known allergy to murine products or positive human anti-mouse antibody (HAMA) * (Female only) Is not pregnant (negative serum or urine pregnancy test to be conducted within 7 days prior to admission for transplant). * (Female only) Is not breastfeeding. * Does not meet donation eligibility requirements as outlined by 21 CFR 1271 and agency guidance. Inclusion criteria for haploidentical NK cell donor: * At least 18 years of age. * Partially HLA matched family member. * Human immunodeficiency virus (HIV) negative. * (Female only) Is not pregnant (negative serum or urine pregnancy test to be conducted within 7 days prior to enrollment). * (Female only) Is not breastfeeding.",18.0,21.0,"['neuroblastoma', 'lymphoma', 'high-risk tumor']"
NCT02597569,Building Capacity in the System to Support Persons With Stroke and Cognitive Impairment,"Building Capacity in the System to Support Persons With Stroke and Cognitive Impairment: An Evidence-based, Multi-faceted, Knowledge Translation Approach",COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: \- Patients who score lower than 26 on the Montreal Cognitive Assessment (MoCA) Test (indicates some level of cognitive impairment) Exclusion Criteria: * neurological diagnoses other than stroke * the presence of major psychiatric illness * capacity issues requiring the use of a substitute decision maker under Ontario's Substitute Decision Maker Act,18.0,65.0,['stroke']
NCT04551469,A Randomized Clinical Trial to Measure Efficacy of Music on Cardiac Surgery Patients,A Randomized Clinical Trial to Measure Efficacy of Music on Cardiac Surgery,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients in the Cardiac Surgical Intensive Care Unit or the Cardiac Surgical Step Down Unit after undergoing heart valve replacement/repair and/or coronary artery bypass surgery, or aortic repair over the age of 18 years, hemodynamically stable, extubated and able to hear music. Exclusion Criteria: * Patients that are deaf, hemodynamically unstable, intubated, and on infectious disease precautions after surgery.",18.0,90.0,['cardiac surgery']
NCT03507569,"Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513","A Non-Randomized Open Label, Adaptive, Parallel Group, Human Positron Emission Tomography (PET) Study to Assess Occupancy of Brain alpha5-Containing GABAA Receptors of Ro7017773 Using [11C] Ro15-4513 Following Single Oral Doses in Healthy Participants",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Healthy (absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemisty, serology, and urinalysis), as judged by the Investigator. * Males and women of non-childbearing potential (WONCBP) Exclusion Criteria: * History of convulsions (other than benign febrile convulsions of childhood) including epilepsy, or personal history of significant cerebral trauma or CNS infections * Clinically significant abnormal finding from the MRI performed after the initial screening examination * Abnormal blood pressure, i.e, systolic blood pressure (SBP) greater than 140 or less than 90 mm Hg, and diastolic blood pressure (DBP) greater than 90 or less than 50 mm Hg * Abnormal pulse rate, resting pulse rate greater than 100 or less than 40 bpm * History or presence of clinically significant ECG abnormalities before study drug administration or cardiovascular disease * Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies * Positive result on hepatitis B (HBV) or hepatitis C (HCV), presence of hepatitis B surface antigen (HBsAg) or positive hepatitis C antibody test result at screening or within 3 months prior to starting study treatment",23.0,55.0,['autism spectrum disorder']
NCT03373669,Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine,Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Age ≥1 year, stratified into different age groups 2. Living in the Waya Clinic Catchment Area 3. Good health condition, without clinically significant medical history (by participant or guardian, in case of minor) 4. Not pregnant for female subjects. 5. Available to participate for the study duration, including all planned follow-up visits for up to 9 months from screening. 6. Signed informed consent Exclusion Criteria: 1. Presence of a significant medical or psychiatric condition (Examples include: Diagnosis and treatment of tuberculosis (TB) or HIV; renal insufficiency; hepatic disease; oral or parenteral medication known to affect the immune function, such as corticosteroids, other immunosuppressant drugs; or behavioural or memory issues) 2. Ever having received oral cholera vaccine. 3. Receipt of an investigational product (within 30 days before vaccination). 4. History of diarrhoea in 7 days prior to first dose of vaccine (defined as ≥3 unformed loose stools in 24 hours). 5. History of chronic diarrhea (lasting for more than 2 weeks in the past 6 months) 6. Current use of laxatives, antacids, or other agents to lower stomach acidity? 7. Planning to become pregnant in the next 2 years.",1.0,65.0,"['cholera', 'vibrio cholerae infection']"
NCT02844569,A Volumetric Analysis of Soft and Hard Tissue Healing for Ridge Preservation and Socket Seal After Tooth Extraction,A Volumetric Analysis of Soft and Hard Tissue Healing for Ridge Preservation and Socket Seal After Tooth Extraction,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Subjects must be adult males or females age 18 to 80 years (inclusive). * Subjects must be able and willing to follow study procedures and instructions in English. * Subjects must have read, understood and signed an informed consent form in English. * Subjects must have a maxillary premolar, canine, lateral incisor, or central incisor with a restorative or periodontal hopeless prognosis (Kwok and Caton 2007), in which an implant is indicated without any sinus lift required. * Subjects undergoing implant placement should be in adequate periodontal health prior to implant placement. This includes having probing depth ≤ 4 mm for all remaining teeth at the same quadrant of the proposed implant placement. Patients with periodontal probing sites with probing depths of up to 5 mm may also be included if bleeding on probing in these sites is absent. Each subject should be considered to be periodontally stable prior to the implant surgery. Exclusion Criteria: * Individuals who have a chronic disease with oral manifestations. * Individuals who exhibit gross oral pathology. * The use of either antibiotics or chronic use (more than 7 days) of NSAIDs within 1 month prior to screening examination. * Individuals that require antibiotic prophylaxis prior to dental treatment. * Chronic treatment (i.e. two weeks or more) with any medication known to affect periodontal status (e.g. phenytoin, calcium antagonists, cyclosporine, Coumadin) within 1 month prior to screening examination. * Uncontrolled diabetes mellitus (HbA1c \>7) within 3 months prior to screening examination. * Individual with uncontrolled parafunctional habits, such as clenching and bruxing on objects, that could adversely impact implant survival. * Individuals with a history of intravenous bisphosphonates. * Individuals with active infectious diseases such as hepatitis, HIV or tuberculosis. * Current cigarette smokers. * Individuals who are known to be pregnant, breastfeeding or planning to become pregnant within 6 months. * Individuals with blood disorders (hemophilia) and /or currently taking anticoagulant medications, such as heparin, warfarin, or clopidogrel. * Individuals receiving any therapy known to affect healing, such as high dose corticosteroids, radiation therapy or chemotherapy. * Individuals allergic to topical or local anesthesia. * Individuals who require maxillary sinus augmentation prior to dental implant therapy. * Individuals with dehisced, fenestrated, or fractured labial/buccal alveolar bone plate determined after baseline CBCT or after tooth extraction where more than 50% of the buccal bone height is not present. In this case, if the surgeon determines that guided bone regeneration (bone graft and membrane) is needed to repair the defect, it will be done at no cost to the subject, but the subject will be excluded from the study protocol.",18.0,80.0,['tooth extraction']
NCT04005469,Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation,A Phase I/II Study Evaluating the Preliminary Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During De Novo Adult Kidney Transplantation,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Male and female patients who will receive a deceased donor kidney aged 18 to 65 (inclusive) and are currently on the active transplant list at RIH. 2. Documentation of a diabetes diagnosis as evidenced by one or more clinical features consistent will be noted for all patients. 3. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. Exclusion Criteria: 1. Under the age of 18 years 2. Difficult venous access 3. BMI \> 40 kg/m2 4. Patients with severe clinical gastroparesis as determined by repeated vomiting 5. Prior GI surgery except for cholecystectomy, appendectomy, or Nissen fundoplication 6. Known or history of inflammatory bowel disease or bezoars 7. History of diverticulitis, diverticular stricture, and other intestinal strictures 8. Be receiving any investigational drug other than treprostinil or participating in any other investigational study 9. Be receiving any prostanoid therapy to treat portopulmonary hypertension 10. Have any known hypersensitivity to prostaglandins, prostacyclin or treprostinil 11. Have had a failed kidney transplant within the previous 180 days 12. Be receiving any non-standard immunosuppression protocol or other non-standard treatment that could affect interpretation of the study results 13. Those with significant cardiovascular disease including treatment with inotropes 14. If female, be pregnant or nursing (confirmed by urine test) 15. Presence of a condition or abnormality that in the opinion of the Investigators that would compromise the safety of the patient or the quality of the data",18.0,65.0,"['ischemia reperfusion injury', 'delayed graft function']"
NCT02360969,Effect of Neuromuscular Blockade on the Oculomotor by Not Squinting Child,Effect of Neuromuscular Blockade on the Oculomotor by Not Squinting Child,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * normal visual acuity for age: 10/10 (Test of Cadet) Rossano 2 for 4-6 years old. 10/10 (scale Monoyer) Parnaud 1.5 for 7-15 years old. * normal oculomotor examination: Examination under normal alternating display eliminating strabismus * Binocular vision less than or equal to 60 sec/arc for the stereoscopic vision test * Refraction WITHOUT cycloplegia within normal limits: below 2 dioptries myopia, hyperopia less than 1.5d, below 1 dioptry astigmatism, anisometropia less than 1 dioptry. * Examination of the fundus without normal pupillary dilation * Axial length 6 normal for age as measured by noncontact biometer to eliminate refractive offset anomaly axial length by abnormal Exclusion Criteria: * presence of anterior eye history * children whose behavior suggests a poor cooperation when taking photo awakeness * children with abnormal limb * scheduled surgery without the use of curare",3.0,15.0,['strabismus']
NCT06989983,"A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462","An Open-Label, Two-Period Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462 in Healthy Male Participants",COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: * Healthy males aged 30 to 65 years inclusive * BMI in the range 18.0 - 32.0 kg/m2 inclusive and body weight ≥ 50 kg and ≤ 100 kg * Regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day) Exclusion Criteria: * History of any clinically significant disease or disorder * History or presence of clinically significant gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs * History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity * History of active malignancy within 2 years, or under investigation for any form of cancer * Participants who do not have suitable veins for multiple venepunctures/cannulation * Clinically significant abnormal clinical chemistry, haematology or urinalysis * Any clinically significant abnormalities in vital signs * Any clinically significant abnormalities on 12-lead ECG * Abnormal renal function * Radiation exposure exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years, occupationally exposed worker, or have been administered IMP in a radiolabelled ADME study in the last 12 months. * Use of any prescribed or non-prescribed medication including antacids, analgesics, herbal remedies, vitamins and minerals * Current smokers or known or suspected history of alcohol or drug abuse * Excessive intake of caffeine-containing drinks or food",30.0,65.0,['heart failure']
NCT05497583,HEMA-free Universal Adhesives for Restoring Non-carious Cervical Lesions,Clinical Performance of Acetone Based HEMA-Free Universal Adhesive Versus Isopropanol Based HEMA-Free Universal Adhesive For Restoring Non-Carious Cervical Lesions Over A Period Of 18-Months Follow Up Using FDI Criteria: A Randomized Controlled Trial,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Participants had to be in good general health, be at least 18 years old * have an acceptable oral hygiene level * Participants were required to have NCCLs in different teeth preferably anterior or posterior that needed to be restored. * These lesions had to be noncarious * deeper than 1 mm * involve both the enamel and dentin of vital teeth without mobility. Exclusion Criteria: * Uncooperative behavior, limits the use of adhesive due to hampering of adequate field or isolation techniques throughout the procedure. * Patients allergic to the adhesive material. Patients with extremely poor oral hygiene * severe or chronic periodontitis * heavy bruxism habits * Pulp involvement",18.0,60.0,['universal adhesive']
NCT03433183,SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors,SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age ≥ 12 years of age * Patients with unresectable or metastatic histologically confirmed sporadic or NF1 associated MPNST. * Patients must have measureable disease by RECIST. * Patients must have experienced progression after one or more prior regimens of cytotoxic chemotherapy. Patients who have refused cytotoxic chemotherapy or for whom treatment on this protocol prior to receiving cytotoxic chemotherapy is felt to be in the best interest for the patient by the local investigator will also be eligible. * Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering on this study. * No limitation on the number of prior chemotherapy regimens that the patient may have received prior to study entry. * The last dose of all myelosuppressive anticancer drugs must be at least 3 weeks prior to study entry. * The last dose of immunotherapy (monoclonal antibody or vaccine) must be at least 4 weeks prior to study entry. * The last dose of all biologic agents for the treatment of the patient's cancer (such as retinoids or tyrosine kinase inhibitors) must be at least 7 days prior to study entry. * The last dose of radiation to more than 25% of marrow containing bones (pelvis, spine, skull) must be at least 4 weeks prior to study entry. The last dose of all other local palliative (limited port) radiation must be at least 2 weeks prior to study entry. * At least 2 months post-autologous stem cell transplant or at least 3 months post-allogeneic transplant and recovered from toxicities without evidence of graft versus host disease and on stable doses of immunosuppressive medications if required. * The last dose of colony stimulating factors, such as filgrastim, sargramostim, and erythropoietin, must be at least 1 week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be at least 2 weeks prior to study entry. * No other anti-cancer therapy (chemotherapy, biological therapy, radiation therapy) is permitted. * Karnofsky performance level ≥ 50%. * Patients who are unable to walk because of paralysis or motor weakness, but who are up in a wheelchair will be considered ambulatory for the purpose of calculating the performance score. * Peripheral absolute neutrophil count (ANC) of ≥1000/μL * Platelet count ≥75,000/μL (transfusion independent (no transfusion within at least 7 days prior to enrollment) * Total bilirubin must be ≤ 1.5 times the upper limit of normal (ULN) * SGPT (ALT) must be ≤ 3.0 times ULN * Serum creatinine ≤ ULN or creatinine clearance \>60 ml/min/1.73 m2 * Serum triglyceride level ≤300 mg/dL and serum cholesterol level ≤ 300 mg/dL (Patient may be on lipid-lowering medicine) * Normal ejection fraction by ECHO or cardiac MRI \>55% * QTcF ≤ 450ms * Fertile men and women of childbearing potential must agree to use an effective method of birth control. * Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression or stable disease at 4 weeks. Exclusion Criteria: * Patients receiving other anti-cancer agents are not eligible. * Patients who cannot swallow whole pills. * Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent (for example cyclosporine). Topical or inhaled corticosteroids are allowed. * Patients should not receive immunizations with attenuated live vaccines within four weeks of study entry or during study period. * Any recent major surgery within a minimum of 4 weeks, with the exception of surgical placement for vascular access, or minor surgery (excluding tumor biopsies) within 14 days. * Patients who any known severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: * Severely impaired lung function defined as spirometry and DLCO that is 50% of the normal predicted value corrected for hemoglobin and alveolar volume and/or O2 saturation that is 88% or less at rest on room air. For patients who do NOT have respiratory symptoms (e.g. dyspnea at rest, known requirement for supplemental oxygen), pulmonary function test is not required. * Cardiac conditions as follows: * Uncontrolled hypertension (blood pressure ≥150/95 mmHg despite medical therapy). * Acute coronary syndrome within 6 months prior to starting treatment * Uncontrolled angina despite medical therapy * Symptomatic heart failure NYHA Class II-IV prior or current cardiomyopathy, or severe valvular disease * Prior or current cardiomyopathy * Uncontrolled Type 1 or 2 diabetes as defined by fasting serum glucose \>1.5 x ULN * Uncontrolled infection * Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome, or renal tubular acidosis. * Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of small bowel, symptomatic inflammatory bowel disease, or ulcerative colitis, or partial or complete bowel obstruction. * Ophthalmological conditions as follows: * Current or past history of retinal pigment epithelial detachment (RPED)/central serous retinopathy (CSR) or retinal vein occlusion * Intraocular pressure (IOP) \> 21 mmHg or uncontrolled glaucoma * Supplementation with vitamin E greater than 100% of the daily recommended dose. * Hypersensitivity to active or inactive excipients of rapamycins (sirolimus, temsirolimus or everolimus) or selumetinib or drugs with similar chemical structures or class to sirolimus or selumetinib. * Patients unwilling or unable to comply with the protocol. * Seville orange, star fruit, grapefruit and their juices, and St. John's Wort use are not allowed while on study. * Exposure to strong or moderate inhibitors or inducers of CYP3A4/5, Pgp (MDR1) and BCRP if taken within the stated washout periods before the first dose of study treatment. * Exposure to specific substrates of drug transporters OATP1B1, OATP1B3, MATE1 and MATE2K within the appropriate washout periods (a minimum of 5 x reported elimination half-life) before the first dose of study treatment.",12.0,65.0,"['malignant peripheral nerve sheath tumors', 'neurofibromatosis 1']"
NCT01422083,Glenohumeral Internal Rotation Deficit (GIRD),Correlation Between Loss of Internal Rotation Range of Motion and Size of the Subacromial Space and the Influence of a Home Stretching Program.,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * overhead athletes: at least 3 hours/week training * male and female * 18-30 years of age * No shoulder pain during last 3 months for which a doctor was consulted * No shoulder surgery * No neck diseases Exclusion Criteria: \-,18.0,30.0,['glenohumeral internal rotation deficit (gird)']
NCT00287183,6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria,"Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multicenter Study In Patients With Type 2 Diabetes And Persistent Albuminuria To Evaluate The Safety And Efficacy Of A Six Month Regimen Of Orally-Administered TTP488",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Male or female outpatients 31 years of age or older. * Females must no longer be of child-bearing potential, must have a negative serum pregnancy test, and cannot be breast-feeding. * Non-vasectomized male must be willing to abstain from sexual intercourse or willing to use a condom in addition to having their female partner use another form of contraception. * Diagnosis of probable Type 2 diabetes after the age of 30 and for at least 6 months prior to the screening visit and: not requiring insulin within first year of diagnosis; no history of diabetic ketoacidosis (DKA); body mass index (BMI) of 40 or less at the screening visit * Presence of persistent albuminuria with a UACR of 6.7 - 203 mg/mmol Must be taking the highest tolerated dose of an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) and have been maintained on that dose for at least 3 months prior to the Baseline visit * Blood pressure(BP) must be stable and well controlled by the judgement of the investigator (goal of the control of BP is 130/80 or less). If required, the use of anti-hypertensives in addition to an ACE inhibitor or an ARB is acceptable. * Patients with a calculated creatinine clearance of greater than or equal to 30 mL/min and without the presence of clinically significant hematuria or red or white cell casts can be included in the study. Exclusion Criteria: * Diagnosis of Type 1 diabetes * Hemoglobin A1c (HbA1c) \>10% * Females cannot be breast-feeding * Known renal artery stenosis * Calculated creatinine clearance \ 450 msec for females or \>430 msec for males (a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle) * Known family history of prolonged QT syndrome * History of symptomatic congestive heart failure within the last 2 years * History of syncope in the lst 2 years or recurrent hypokalemia, including that caused by diuretics * Myocardial infarction or signs or symptoms of unstable coronary artery disease with the last year * Pulmonary disease or evidence of clinically significant pulmonary symptoms. * Active neoplastic disease. (Excised cutaneous basal cell carcinomas are not excluded). Patients with stable prostate cancer may be included at the discretion of the Medical Monitor. * Any clinically significant hematologic or coagulation disorder * Any clinically significant hepatic disease * Use of excluded medications: drugs known to significantly increase QTc and/or have increased risk of torsades de point, immunosuppressive agents, cancer chemotherapeutic agents, oral corticosteroids other than maintenance doses equivalent to 7.5 mg prednisone per day, and radiotherapy * Use of an investigational drug within 30 days or within 5 half-lives of the investigational agent, whichever is longer, or use of an investigational medical device within 2 weeks before or after the study * Any other disease or condition that, in the opinion of the investigator, makes the patient unsuitable to participate in this study",31.0,65.0,['diabetic nephropathy']
NCT05830383,Application of PDCA Circular Management to Improve Critical Thinking Skills of ICU Nurses Within Five Years of Employment,Application of PDCA Circular Management to Improve Critical Thinking Skills of ICU Nurses Within Five Years of Employment,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: (1) ICU nurse within five years of joining the ICU (2) Voluntary participation in this study. \- Exclusion Criteria:(1) Clinical nurses who have worked for more than 5 years (2) Involuntary participation in this study. \-,18.0,35.0,['pdca circular management']
NCT03171883,Ultrasound of Supraspinatus Muscle Tears,The Value of Ultrasound in the Diagnosis of Supraspinatus Muscle Tears,UNKNOWN,OBSERVATIONAL,ALL,Inclusion Criteria: * patients of different age groups presented with clinical diagnosis department of shoulder impingement and diagnosed by magnetic resonance imaging as supraspinatus Exclusion Criteria: * patients with previous shoulder surgery,18.0,65.0,"['supraspinatus tear or rupture, not specified as traumatic']"
NCT04110483,Thulium Fiber Laser En-bloc Resection vs Conventional Transurethral Resection of Non-muscle-invasive Bladder Cancer,Safety and Short-term Oncological Outcomes of Thulium Fiber Laser En-bloc Resection of Non-muscle-invasive Bladder Cancer,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: • Primary Ta or T1 bladder cancer (NMIBC) Exclusion Criteria: • Pure carcinoma in situ,18.0,65.0,['bladder cancer']
NCT03434483,The Microbiome as a Target for Precision Medicine in Atherosclerosis,"Microbiome, Inflammation and Genetics as a Target for Precision Medicine in AThERosclerosis",COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria Acute coronary syndrome group: * Diagnosis of acute coronary syndrome * Signature of informed consent for the study (Annex I). Exclusion Criteria Acute coronary syndrome group: * Previous Ejection fraction of VI less than 30%. * History of heart failure * Systemic inflammatory diseases * In treatment with corticosteroids or immunomodulators * In treatment with antibiotics during the last month Aditional Inclusion Criteria for angiographic substudy group: * Clinical indication of coronary angiography in the acute phase (in the first 72 hours after its hospital diagnosis). * At least one non-causal coronary lesion in a coronary segment with reference diameter\> 2 mm, stenosis between 40-80%, and TIMI 3 flow in this vessel (angiographic criteria, only confirmed after performing coronary angiography) * Signature of informed consent for the substudy (Annex II). Aditional Exclusion Criteria for angiographic substudy group: * Renal insufficiency with creatinine clearance less than 30 ml / h * Hepatic insufficiency: patients with cirrhosis in Child B or C stages will be excluded. Inclusion Criteria Chronic atherosclerosis group: * Angiographic diagnosis, using catheterization or computed tomography of coronary atherosclerotic disease. * Clinical situation of stable chronic ischemic heart disease. * Signature of informed consent for the study (Annex III). Exclusion Criteria Chronic atherosclerosis group: * Previous Ejection fraction of VI less than 30%. * History of heart failure * Systemic inflammatory diseases * In treatment with corticosteroids or immunomodulators * In treatment with antibiotics during the last month",18.0,65.0,"['acute coronary syndrome', 'atherosclerosis']"
NCT06685783,Vis-Rx Prime Micro-Imaging Catheter Study,Vis-Rx Prime Micro-Imaging Catheter Clinical Evaluation Study,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,ALL,Inclusion Criteria: * Patients 18 years of age or older * Patients willing and able to provide written informed consent to participate in evaluation * Patients who are candidates for transluminal interventional procedures for their coronary arteries (also known as PCI) Exclusion Criteria: * Bacteremia or sepsis * Major coagulation system abnormalities * Severe hemodynamic instability or shock * Acute renal failure * Disqualified for Coronary Artery Bypass Graft surgery * Disqualified for Percutaneous Coronary Intervention * Patients currently enrolled in another study to evaluate an investigational device or medication * Any target vessel which has undergone a bypass procedure The lesion-specific exclusion criteria assessed from angiography are: * Total occlusion * Coronary artery spasm * Large thrombus (as visible under angiography),18.0,65.0,['coronary artery disease']
NCT01727583,Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients,Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients,COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: * BMI : 19 - 24.9 kg.m-2 * Normal fasting glycemia * Having obtained his informed consent. Exclusion Criteria: * Gastro-intestinal disease (ulcer), pancreatic disease, hepatic disease, metabolic diseases / disorders (diabetes, dyslipidemia), renal disease, cardiovascular disease (arterial hypertension), as determined by the medical screening visit and a blood analysis. * Have had a gastrointestinal surgery (with the exception of appendices resection). * Malabsorption disorders * Lactose intolerance * Significant weight loss during the past three months (more than 5% of initial weight) * Have a regular consumption of medication * Regular supplements (vitamins and minerals) intake during the previous month * Have an alcohol intake: \> 2 units a day * Smoker (more than 2 cigarettes a day) * Illicit substances intake, as stated on the medical screening questionnaire * Allergy to any food or medication * Anaemia defined by a number of erythrocytes or hemoglobin Hb or hematocrit Ht which are inferior to laboratory normal ranges * Having given blood in the past three months or willing to give blood in the 3 months following the completion of the study * Intense physical activity \> 3 hours per week * Currently participating or having participated in another clinical trial during the past month. * Volunteer who cannot be expected to comply with the protocol, including consuming rapidly the study products, chronic medication intake",20.0,40.0,['healthy']
NCT05273983,Pilot Study of a Brief Behavioural Activation Intervention for Depressed Patients in Primary Care,Pilot Study of a Brief Behavioural Activation Intervention for Depressed Patients in Primary Care,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Depression is the primary concern; * Score of 10 or greater on a depression screening tool; * Have access to an iPhone or iPad. Exclusion Criteria: * Another psychological disorder is the primary concern (e.g., anxiety disorder, personality disorder); * Concurrent alcohol or drug use disorder; * Unstable dose of psychotropic medication (i.e., any psychotropic medication doses will need to be stable for at least four weeks prior to enrolment); * Current participation in other regular psychological treatment (e.g., cognitive behavioral therapy, counselling); * At a high risk/emergent risk for suicide.",18.0,65.0,['major depressive disorder']
NCT04781283,Study Comparing the Kinetics of Endothelial Cell Loss Associated With the XEN® Implant Versus Traditional Filtering Surgery for Glaucoma,Prospective Randomized Study Comparing the Kinetics of Endothelial Cell Loss Associated With the XEN® Implant Versus Traditional Filtering Surgery for Glaucoma,WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Man or woman aged ≥ 18 years * French-speaking patient * Patients followed for primary or secondary open-angle glaucoma in the ophthalmology department of the GhPSJ * Patient with an indication for surgery with placement of Xen® or NDPS alone or combined with cataract surgery by phacoemulsification of the lens * Patient affiliated to social security or, failing that, to another health insurance system * Patient capable of giving free, informed and express consent. Exclusion Criteria: * Patient with another associated ophthalmological disease, apart from a simple cataract already operated on or operated simultaneously with NDPS or the Xen® break without complications during or after the operation * History of filtering surgery, history of vitrectomy * Closed-angle glaucoma * Pseudo capsular exfoliation (connective tissue disease affecting the eye) * Uveitic glaucoma (glaucoma related to inflammation which can itself have an effect on the cornea) * Prolonged postoperative hypertonia (7 days)\> 40 mmHG (because this can damage the cells of the cornea) * Pre-existing endothelial dystrophy, irido-corneo-endothelial syndrome (ICE) (glaucoma with corneal pathology) * Postoperative athalamy (contact between the iris and the cornea generating endothelial cell loss) * Endothelial cell count \<1000 cells * Patient under guardianship or curatorship * Patient deprived of liberty * Patient under legal protection.",18.0,65.0,['glaucoma']
NCT05249283,Self and Body Perception in Otoneurological Disorders: Translation and Validation of Measurement Scales,Self and Body Perception in Otoneurological Disorders: Translation and Validation of Measurement Scales,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: For patient: * Age ≥ 18 years * Patient with acute or chronic otoneurological disorders * Patient having or having experienced dizziness and / or balance disorders * Patient with PPPD * Fluency in French * Having given free and informed written consent * Being affiliated with or benefiting from social security For control subjects: * Age ≥ 18 years * Fluency in French * Having given free and informed written consent * Being affiliated with or benefiting from social security. Exclusion Criteria: For patient: -Past or present psychiatric and neurological disease (other than otoneurological or PPPD, as declared by the participant) For control subjects: -Past or present psychiatric and neurological disease (as declared by the participant) and vestibular and/or auditory system disorders (as declared by the participant) For all participants: * Persons still in a period of exclusion from another study and persons simultaneously participating in another study * Subject to a measure for the protection of justice",18.0,65.0,"['patients with acute or chronic otoneurological disorders', 'patients presenting or having experienced dizziness and / or balance disorders']"
NCT02163083,Detection of Lymphnodes Using ICG During RARP,Detection of Lymph Nodes by Means of Intraoperative Fluorescence Lymphography Using Indocyanine Green (ICG) During the Radical Robot-assisted Prostatectomy,COMPLETED,INTERVENTIONAL,MALE,Inclusion Criteria: * Histologically confirmed locally limited prostate cancer; * Intermediate or high risk tumor * Recommended and planned prostatectomy; * Completed and signed written consent; * Voluntarily agreement to participate in this study * Age of the study participants ≥ 18 years. Exclusion Criteria: * Allergic reaction to active ingredient (indocyanine green); * Iodine allergy; * Hyperthyroidism; * High-grade renal impairment; * High-grade hepatic insufficiency; * Unwillingness to the storage and disclosure of pseudonymous disease and personal data * psychiatric pre-existing conditions or other circumstances that make a cooperation by the patient in question,18.0,75.0,['prostate cancer']
NCT02013583,The Glucose Transporter Type I Deficiency (G1D) Registry,The Glucose Transporter Type I Deficiency (G1D) Registry,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * Males and females * G1D diagnosis * Patients experiencing symptoms of G1D but who have not yet received a diagnosis Exclusion Criteria: * Patients who are not experiencing any symptoms of G1D,18.0,65.0,"['glut1 deficiency syndrome', 'glucose transporter type 1 deficiency syndrome', 'glucose transporter type1 (glut-1) deficiency', 'glut-1 deficiency syndrome']"
NCT00712283,Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers,"A Single Center, Randomized, Double-blind, Placebo-controlled, Parallel Group Design Study to Investigate the Effect of 12,5 mg, 25 mg, 50 mg and 75 mg Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * healthy volunteers, female and male * age 21 - 50 * BMI 18 - 30 kg/m2 * experienced drivers with a valid driver's license and at least 3 years of driving practice Exclusion Criteria: * any clinically relevant finding on physical examination affecting the study objectives * clinically relevant abnormalities in the ECG laboratory values * history or present evidence of clinically relevant metabolic, renal, hepatic, pulmonary or cardiovascular disease, CNS disorders, or disturbance of bleeding diagnosis of malignancy * females who are pregnant or breastfeeding",21.0,50.0,['healthy']
NCT02660983,A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: Patients who meet all of the following criteria will be eligible for inclusion in the study: 1. Male or female, age greater than or equal to (\>=) 40 years at the time of informed consent. 2. Possible or probable dementia associated with cerebrovascular disease as defined by National Institute of Neurological Disorders and Stroke (NINDS) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (AIREN) criteria (NINDS-AIREN Criteria) with dementia of greater than 3 months duration. 3. Radiological evidence of cerebrovascular disease. 4. Mini-Mental Status Examination (MMSE) score is ≥ 10 and ≤ 24. 5. Clinical Dementia Rating (CDR) ≥ 1. 6. Outpatients who are physically healthy, and ambulatory or ambulatory-aided (i.e., walker, cane or wheelchair). 7. Written informed consent (IC) is obtained from the patient (if possible) and from the patient's legal guardian prior to being exposed to any study-related procedures. The caregiver must separately provide IC for his/her own participation in the study. 8. Patients having caregivers who submit written consent to cooperate with this study, have regular contact with the patient (i.e., an average of ≥ 4 hours/day and ≥ 3 days/week), provide patients' information necessary for this study, ensure the regular administration of assigned donepezil, as well as all concomitant therapies, at the correct dose, and escort the patients on required visits to study institution. 9. Comorbid medical conditions are clinically stable prior to Baseline, unless otherwise specified. Exclusion Criteria Patients who meet any of the following criteria will be excluded: 1. Anti-dementia drug therapy (cholinesterase inhibitors or memantine) within 12 weeks prior to Screening. 2. Clinical and/or radiological evidence for other serious degenerative neurological disorders or neuropsychiatric disorders. 3. Known human immunodeficiency virus disease, neurosyphilis, or a history of significant head trauma followed by persistent neurological deficits or known structural brain abnormalities. 4. Hypothyroidism at Screening. 5. Vitamin B12 or folate deficiency at Screening. 6. Evidence of a new transient ischemic attack (TIA) or stroke that occurs within 12 weeks prior to Screening, even if the symptoms are minor and do not require hospitalization, are excluded. 7. Supine diastolic blood pressure ≥ 95 mmHg. 8. Complication of sick sinus syndrome, abnormal auricular and atrioventricular (AV) junction conductions (AV block, ≥ II ventricular block, etc.), or with a prolonged QT/QTc interval (\> 450 ms) as demonstrated by a repeated electrocardiogram (ECG). 9. A history of life-threatening arrhythmias. 10. A history of malignant neoplasms treated within 5 years prior to study entry, current evidence of malignant neoplasm, recurrent, or metastatic disease. 11. A known or suspected history of drug or alcohol dependency or abuse. 12. Abnormal clinical laboratory values which are judged clinically significant by the investigator. 13. Patients who cannot swallow or who have difficulty swallowing whole tablets, as tablets should not be broken or crushed. 14. Known plan for elective surgery that would require general anesthesia and administration of neuromuscular blocking agents. 15. Pregnant women, lactating women, or women of child-bearing potential who don't agree to practice effective contraception throughout the entire study period and for 30 days after donepezil discontinuation, or who don't have a negative serum â-Human chorionic gonadotropin (HCG) test result or a negative urine pregnancy test result.",40.0,65.0,['dementia associated with cerebrovascular disease']
NCT06481241,Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL,Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. De novo and primary Ph/BCR-ABL1 negative acute lymphoblastic leukemia diagnosed by the bone marrow cytomorphology, immunophenotyping, cytogenetics and molecular biology according to WHO classification 2. Male or female patients aged 18 years or older 3. CD19 expression on blasts 4. Expected survival time greater than 3 months 5. Adequate end organ function as defined by: Total bilirubin ≤ 1.5 x upper limit of normal（ULN）; serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) ≤ 2.5 x ULN or ≤5 x ULN if leukemic involvement of the liver is present; Creatinine ≤ 1.5 x ULN; Serum amylase and lipase ≤ 1.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related; normal electrolytes: Potassium ≥ LLN; Magnesium ≥ LLN; Phosphorus ≥ LLN; Cardiac color Doppler ultrasound ejection fraction ≥ 45% 6. Subject has provided written informed consent prior to any screening procedure Exclusion Criteria: 1. Burkitt lymphoma/leukemia 2. Acute Leukemia of Ambiguous Lineage 3. Clinical manifestations of active CNS or extramedullary involvement with ALL 4. Female patients who are pregnant or breast feeding 5. Uncontrolled active serious infections that could, in the investigator's opinion, potentially interfere with the completion of treatment 6. Known HIV seropositivity 7. Clinically significant ventricular arrhythmias, unexplained syncope (not vasovagal) or sinus block, history of chronic bradycardia with a high degree of atrioventricular (AV) conduction block (unless a permanent pacemaker is implanted) 8. Any serious psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment 9. Other conditions assessed by the investigators to be inappropriate for this study",18.0,65.0,"['philadelphia chromosome negative all', 'acute lymphoblastic leukemia, adult']"
NCT01881841,"Computer Adaptation of Screening, Brief MET Intervention to Reduce Teen Drinking","Computer Adaptation of Screening, Brief MET Intervention to Reduce Teen Drinking",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * 14- to 20- yr-olds * arriving for routine care to one of our participating pediatric practices (Lexington Pediatrics, Lexington, MA; East Boston Community Health Center, Longwood Pediatrics, Tufts Medical Center Adolescent Clinic, Boston, MA; Cambridge Health Alliance Dept. of Pediatrics, Cambridge, MA) * any alcohol use days in the past 90 days, * have an email address and internet access at home, school, or library * provide informed assent/consent. Exclusion Criteria: * unable to read or understand English, * living away at college at the time of the recruitment visit, * not available for computer/telephone follow-ups, * judged by the provider to be medically or emotionally unstable at the time of the visit.",14.0,20.0,"['alcohol abuse', 'tobacco use disorder', 'substance use']"
NCT02637141,A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Diagnosis of celiac disease by intestinal biopsy at least 12 months prior to screening * On a gluten-free diet for at least 12 months * Negative celiac serology * Avoidance of pregnancy Exclusion Criteria: * Severe complications of celiac disease, such as refractory celiac disease * Celiac symptoms * Other concomitant autoimmune disease * Chronic, active gastrointestinal disease * Infections, concomitant diseases * Prohibited medications",18.0,75.0,['celiac disease']
NCT05243641,Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test,Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria 1. Signed Informed Consent Form (ICF) and comply with the requirements of the study protocol 2. Age ≥ 18 years. 3. ECOG performance status 0-1 4. Confirmed diagnosis of metastatic breast cancer or inflammatory breast cancer according to international consensus criteria: * Onset: Rapid onset of breast erythema, edema, and/or peau d'orange, and/or warm breast, with or without an underlying breast mass * Duration: History of such findings no more than 6 months * Extent: Erythema occupying at least 1/3 of whole breast * Pathology: Pathologic confirmation of invasive carcinoma 5. Patients who have metastatic disease which is not amenable to curative treatment with available local and systemic therapy. Patients must have received at least 1 line or up to 6 lines of therapy in the metastatic setting with at least 2 weeks washout period before the initiation of study treatment. i. Unless a contraindication to therapy exists, patients with ER+ breast cancer must have received prior endocrine therapy combined with a CDK4/6 inhibitor, patients with BRCA1 or BRCA2 mutations must have received prior PARP inhibitor, and patients with PD-L1+ triple negative breast cancer must have received prior immunotherapy. ii. Patients with HER2-positive disease must have received at least 2 regimens of anti-HER2 therapy in metastatic setting. 6. For Phase Ib, any ER, PR, and HER2 status, For Phase 2, HER2-negative per ASCO/CAP guidelines and any ER and PR status. 7. For Phase II only, Patients with measurable disease according to the Response Evaluation Criteria in Solid Tumor (RECIST, v1.1) (local or distant) and at least one metastatic lesion amenable for biopsy (core or punch) NOTE: Measurable disease: Measurable lesions are defined as those that can be accurately measured in at least one-dimension (longest diameter to be recorded) as ≥ 20mm by chest X-ray, ≥ 10mm by computed tomography (CT) scan, ≥ 10mm with calipers by clinical exam. Measurable malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph node must be ≥ 15mm in short axis when assessed by CT scan. Non-measurable disease: All other lesions (or sites of disease), including small lesions, are considered non-measurable. Bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis, cutis/pulmonitis, inflammatory breast disease, and abdominal masses \[not followed by CT or magnetic resonance imaging (MRI)\] are considered non-measurable. 8. Left Ventricular Ejection Fraction ≥ 50% measured by MUGA scan or Echocardiogram. 9. Abnormal HER-family and c-Met signaling activity based on CELsignia MP Test results (for phase II patients only). 10. Participants must have adequate organ function including the following laboratory values at the screening visit. Screening must occur within 28 days prior to the first dose of study drug. Screening samples for hematology and serum chemistries must be drawn within 14 days prior to the first dose of study drug: * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L without growth factor support * Platelets (PLT) ≥ 75 x 10\^9/L * Hemoglobin (Hgb) ≥ 9 g/dL * Calculated creatinine clearance (using Cockcroft-Gault formula) ≥ 45 mL/min * Total bilirubin (TBIL) ≤ ULN (upper limit of normal) with the following exception: Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be enrolled. * Aspartate transaminase (AST) ≤ 3 x ULN, except for participants with liver metastasis, who may only be included if AST ≤ 5 x ULN * Alanine transaminase (ALT) ≤ 3 x ULN, except for participants with liver metastasis, who may only be included if ALT ≤ 5 x ULN * Alkaline phosphatase (ALP) ≤ 5.0 x ULN * Asymptomatic serum amylase ≤ grade 2. Participants with grade 1 or grade 2 serum amylase at the beginning of the study must be confirmed to have no signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.) * Serum lipase ≤ ULN 11. Willing and able to comply with scheduled visits, treatment plan and laboratory tests. Patients who are cognitively impaired who may not be able to comply with the oral study medication schedule are excluded. i) Patients with ER positive (defined at ER\>/=10%)breast cancer, must start (or continue) an aromatase inhibitor of physician choice during the study duration. In addition, pre-/peri-menopausal women with ER+ breast cancer will also require ovarian suppression therapy. 12. Non-English speaking subjects are eligible as long as a translator is available at the treating site. Exclusion Criteria: 1. Concurrent anticancer therapy within 2 weeks of initiation of study treatment; except: i. Endocrine therapy (SERM, aromatase inhibitor, fulvestrant, medical ovarian suppression therapy) ii. Palliative radiotherapy for bone metastases \< 1 week prior to study treatment 2. Unstable and symptomatic brain metastasis (Stable disease is defined as CNS radiographic study ≥ 4 weeks from completion of radiotherapy and ≥ 2 weeks from discontinuation of corticosteroids) 3. Non-hematologic adverse events from prior anticancer therapy that have not resolved to Grade ≤ 1 (CTCAE v 5.0), except for alopecia, vitiligo, pain, constipation if these symptoms existed during screening baseline. i. Grade 3 or above neuropathy induced from prior treatment, that is not resolved to grade 2 or below despite best supportive care 4. Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis 5. Acute exacerbations of underlying condition within the last 12 months (requiring psoralen plus ultraviolet A radiation \[PUVA\], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids) 6. Patients with known HIV infection. Testing for HIV is not required for study screening: 1) CD4+ count\<350 cells/uL; or 2) had AIDS-defining opportunistic infections \< 12 months 7. Known active hepatitis B (chronic or acute) or hepatitis C infection. Testing for hepatitis is not required for study screening: i) Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen \[HbsAg\] test and a NEGATIVE anti-HBc \[antibody to hepatitis B core antigen\] antibody test). Patient is eligible if anti-HBc is POSITIVE, but should sample for HBV DNA and referral to virologist to monitor for HBV reactivation ii) Patients with positive for hepatitis C virus (HCV) antibody and have positive polymerase chain reaction (PCR) for HCV RNA. 8. Severe infections within 4 weeks prior to study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia 9. Signs or symptoms of infection within 2 weeks prior to study treatment per treating physician and PI judgement. 10. Concurrent oral or IV antibiotics within 5 days prior to study treatment \* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are allowed and eligible so long as the antibiotic is not prohibited with the study medication (See Tables 8). 11. Major surgical procedure within 28 days prior to study treatment or anticipation of need for a major surgical procedure during the course of the study. 12. Presence or history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention). 13. Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome. 14. Clinically significant, uncontrolled heart diseases. * Unstable angina within 6 months prior to screening * Myocardial infarction within 6 months prior to screening * History of documented congestive heart failure (New York Heart Association functional classification III-IV) * Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) ≥ 160 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg, with or without antihypertensive medication. Initiation or adjustment of antihypertensive medication(s) is allowed prior to screening * Ventricular arrhythmias * Supraventricular and nodal arrhythmias not controlled with medication * Other cardiac arrhythmia not controlled with medication * QTcF (QT interval corrected by Fridericia's formula) ≥ 470 ms on the screening ECG (as mean of triplicate ECG) 15. Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting study therapy or who have not recovered from side effects of such procedure. 16. Unable to swallow or absorb study drugs due to impairment of GI function or GI disease e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome 17. Participants receiving treatment with any enzyme-inducing anticonvulsant that cannot be discontinued at least 1 week before first dose of capmatinib, and for the duration of the study. 18. Other severe, acute, or chronic medical or psychotic conditions, substance abuse or laboratory abnormalities that in the opinion of the investigator may increase the risk associated with study participation, or that may interfere with the interpretation of study results. 19. Pregnant or nursing (lactating) women 20. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for one month after stopping treatment. Highly effective contraception methods include: * Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception * Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment * Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject * Use of injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception. Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before study entry. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child-bearing potential. 21. Sexually active males will not be eligible unless they use a condom during intercourse while taking drug and for 3 months after stopping treatment and should not father a child in this period. A condom is required for all sexually active male to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to partner. In addition, male participants must not donate sperm for the time period specified above. 22. Participants receiving treatment with the following medications that cannot be discontinued at least 1 week prior to the start of treatment with study therapy and for the duration of the study: 1. strong inducers of CYP3A 2. moderate inducer of CYP3A4 3. strong CYP3A4 inhibitor 4. concomitant use of a moderate CYP3A4 and P-gp dual inhibitor (verapamil). 5. proton pump inhibitor. Neratinib may be taken at least 2 hours before or 10 hours after an H2-receptor antagonist, and 3 hours after antacids. 6. P-gp substrates (such as digoxin, dabigatran, fexofenadine) or strong P-gp inducers (such as carbamazepine, phenytoin, rifampicin, and St. John's wort). 7. Chronic immunosuppressive therapies including systemic corticosteroids. Steroids given for physiological replacement, as anti-emetics or inhaled as well as short course of oral/topical steroids given for allergic reactions or asthma flares are allowed. 23. No prior treatment with Capmatinib, Neratinib, or other HER2 directed tyrosine kinase inhibitor (for phase II patients only).",18.0,65.0,"['metastatic breast cancer', 'breast cancer']"
NCT00327041,Monitoring Response to Antiplatelet Therapy,Pilot Study Investigating the Use of a Variety of Assays to Detect Individual Response to Antiplatelet Therapy,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: Patients aged 18-80 undergoing intended PCI for conventional indications. Informed written consent. Exclusion Criteria: Administration of GPIIbIIIa therapy prior to PCI, Oral anticoagulation, ticlopidine, dipyridamole, NSAID therapy, Pregnancy, Troponin I \>0.2mcg/l on day of procedure, Chest pain in the 24 hrs prior to PCI. Anaemia (Hb\ 450 x10\^9/l, Personal or family history of bleeding disorder.",18.0,80.0,"['coronary stenosis', 'coronary thrombosis', 'angioplasty, balloon']"
NCT00951041,Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults,Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * A male or female aged 18 to 60 years at the time of the first vaccination. * Subjects who the investigator believes that they can and will comply with the requirements of the protocol * Written informed consent obtained from the subject. * Satisfactory baseline medical assessment by history and physical examination. Stable health status is defined as the absence of health event satisfying the definition of a serious adverse event, or a change in an ongoing drug therapy due to therapeutic failure or symptoms of drug toxicity, within one month prior to enrollment. * Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line or mobile, but NOT a pay phone or multiple-user device. * Female subjects of non-childbearing potential may be enrolled in the study. * Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause. * Female subjects of childbearing potential may be enrolled in the study, if the subject: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test on the day of vaccination, and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series. Exclusion Criteria: * Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of the study vaccine or planned use during the study period. * Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports. * Presence of an axillary temperature ≥ 37.5°C, or acute symptoms greater than ""mild"" severity on the scheduled date of first vaccination. NOTE: The subject may be vaccinated at a later date, provided symptoms have resolved, vaccination occurs within the window specified by the protocol, and all other eligibility criteria continue to be satisfied. * Diagnosed with cancer, or treatment for cancer, within the past 3 years. * Persons with a history of cancer who are disease-free without treatment for 3 years or more are eligible. * Persons with a history of histological-confirmed basal cell carcinoma of the skin successfully treated with local excisions only are excepted and may enroll within 3 years of diagnosis, but other histological types of skin cancer require a 3-year untreated and disease-free window as above. * Women who are disease free 3 years or more after the treatment for breast cancer and receiving long-term prophylactic are excepted and may enroll. * Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection. * Clinically or virologically confirmed influenza infection within 6 months preceding the study start. * Chronic administration of immunosuppressants or other immune modifying drugs within 6 months of study enrolment or planned administration during the study period. * Receipt of any immunoglobulins and/or any blood products within 3 months of study enrolment or planned administration of any of these products during the study period. * Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin outside of 24 hours prior to vaccination are eligible. Persons receiving prophylactic antiplatelet medications, e.g., low-dose aspirin, and without a clinically-apparent bleeding tendency, are eligible. * An acute evolving neurological disorder or history of Guillain-Barré syndrome. * Administration of any vaccines within 30 days before vaccination. * Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine. * Pregnant or lactating female * Female planning to become pregnant or planning to discontinue contraceptive precautions. * Any conditions which, in the opinion of the investigator, prevents the subjects from participating in the study.",18.0,60.0,['influenza']
NCT00217841,Aurograb and Vancomycin in MRSA Infection,"A Multi Centre, Double-Blind, Randomised, Placebo Controlled Prospective Study on the Safety and Efficacy of Aurograb in Patients With Severe, Deep-Seated Staphylococcal Infections Receiving Vancomycin",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: All patients will have to satisfy the following inclusion criteria to enter the study: * Hospitalised adult patients (18 years or over) with severe, deep-seated staphylococcal infection being treated with vancomycin, this diagnosis being based on clinical signs and symptoms appropriate to the site of infection (as detailed under subsets, Section 4.6) plus a positive culture or Gram stain showing Gram positive cocci in clusters (not chains) from one or more of the following clinically significant sites: i. a blood culture ii. a lower respiratory tract specimen eg sputum or BAL iii. pleural fluid iv. intra-abdominal fluid or tissue v. urine (in patients with renal sepsis or complicated urinary tract infections) * The study drug must be started while there is clinical evidence of active infection (usually within 24 hours of starting vancomycin, although longer delays are acceptable if the patient is still clinically septic and culture positive within 24 hours of starting study drug). * Recruitment may be initiated on the basis of a Gram stain but, for the patient to be eligible to continue in the study, staphylococcal sepsis must subsequently be confirmed by culture. * The positive specimen must be from a clinically significant specimen taken within 2 days of starting the study drug. * Patients must be on i.v. vancomycin as the sole systemic antibiotic for the first 3 days of the study. * Patients must have sufficient venous access to permit administration of study drug and monitoring of safety variables * Written informed consent must be obtained for participation in the study. Exclusion Criteria: Patients fulfilling the following criteria will not enter the study: * Prior Antibiotic Usage: Patients who have received (within 48 hours of study entry) a systemic anti-staphylococcal antibiotic other than vancomycin for longer than 24 hours, unless the patient was considered to have failed that regime ie a documented treatment failure (ie 3 days' treatment and not responding) or the Staphylococcus is resistant to the antibiotic in vitro (e.g. the patient is initially treated with flucloxacillin but the isolate subsequently identified as resistant) - in such cases the antibiotic must be changed to vancomycin to enter the study. * Concomitant Antibiotics: usage of concomitant antibiotic except as allowed by the protocol (see Section 5.3) * Patients with devices infected with S. aureus, including implants and catheters, which cannot be removed * Patients known to have AIDS, who have a CD4 cell count \< 200 cells/mm3 * Patients with staphylococcal endocarditis, mediastinitis, meningitis, osteomyelitis and/or joint infections. * Asymptomatic carriers of MRSA - such patients must be clinically septic due to the MRSA * Patients with methicillin-sensitive CNS (MSSE) * Patients with methicillin-resistant CNS (MRSE) unless they are clinically significant blood culture isolates, as indicated by two blood cultures (taken from two different sites) growing the same CNS in a clinically septic patient in whom there is no other significant pathogen responsible for the sepsis * Females who have a positive pregnancy test * Patients who have a known allergy to any constituent of Aurograb® (i.e. hypersensitivity to antibody, nickel, urea or arginine) * Patients who have received an unlicensed drug within three months prior to the study * Patients with a concomitant medical condition, in whom, in the opinion of the Investigator, participation may create an unacceptable risk for the patient * Patients considered inappropriate for enrolment in this study by the Investigator for any other reason.",18.0,80.0,['staphylococcal infections']
NCT00494741,MMF vs. AZA for Kidney Transplantation,"A Randomized, Prospective, Multicenter Trial to Compare the Effect on Chronic Allograft Nephropathy Prevention of Mycophenolate Mofetil Versus Azathioprine as the Sole Immunosuppressive Therapy for Kidney Transplant Recipients",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Males and females aged 18 years or more; * First single or double kidney transplant from deceased donors; * Written informed consent. Exclusion Criteria: * Specific contraindications to RATG therapy such as severe leucopenia (WBC\ 10%; * History of malignancy (except non metastatic basal or squamous cell carcinoma of the skin that has been treated successfully; * Evidence of active hepatitis C virus, hepatitis B virus or human acquired immunodeficiency virus infection; * Any chronic clinical conditions that may affect completion of the trial or confound data interpretation; * Pregnancy or lactating; * Women of childbearing potential without following a scientifically accepted form of contraception; * Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequence of the trial; * Evidence of an uncooperative attitude; * Any evidence that patient will not be able to complete the trial follow-up.",18.0,75.0,['kidney transplant']
NCT05940441,A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma,A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma,RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * 1\. Age between 18 and 65 years old. 2. Histologically confirmed hypopharyngeal carcinoma, staged as IV (T4N0-1M0，anyTN2-3M0) (as defined by the 8th AJCC edition), Complete the recommended standard treatment (curative chemoradiotherapy, or radical surgery + postoperative chemo/radiotherapy ). 3\. No clinical evidence of persistent locoregional disease or distant metastases after definitive chemoradiotherapy. 4\. Within 8 weeks after completion of the last radiation dose. 5. Performance status of ECOG grade 0 or 1. 6. Adequate hematologic (neutrophil count \> 1.5×10\^9/L, hemoglobin \> 90g/L and platelet count \> 100×10\^9 /L), hepatic (alanine aminotransferase, aspartate aminotransferase ≤ 1.5×ULN, bilirubin ≤ 1.5×ULN, alkaline phosphatase \ 50 ml/min). 7\. Patients must be appraised of the investigational nature of the study and provide written informed consent. Exclusion Criteria: * 1.Patients who were known to be intolerable or allergic to capecitabine. 2. Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer. 3\. Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control). 4\. With esophagus cancer. 5. Pregnancy or lactation. 6. Other conditions that are not eligible for enrollment.",18.0,65.0,['to explore whether the adjuvant therapy of metronomic capecitabine could improve the disease-free survival of locoregionally advanced hypopharyngeal carcinoma']
NCT07167641,Caring for the Carer,Caring for the Carer,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * The participants must be a parent, caregiver, or supporter of a young person who has been referred to a CSC program for First Episode Psychosis (FEP) in the past 3 years. A parent or supporter is considered eligible for the study if their young person was referred to the program but chose not or was unable to engage in CSC or is currently on the waitlist for FEP treatment. * Parent, caregiver, or supporter must be at least 18 years of age * Participants recruited from UNC CSC programs * Parent, caregiver, or supporter must be able to engage in research assessments and consent to audio recording sessions for fidelity ratings Exclusion Criteria: * Parent, caregiver, or supporter is currently engaged in legal action against the loved one receiving services/experiencing psychosis * Parent, caregiver, or supporter's loved one has never experienced psychosis * Parent, caregiver, or supporter does not speak English",18.0,99.0,"['care burden', 'care giving burden', 'caregiver burnout', 'caregiver wellbeing']"
NCT01679041,High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment,A Phase II Study of High Dose Chemotherapy With Autologous Hematopoietic Progenitor Cell Transplant for Multiple Sclerosis That Failed at Least Two Lines of Therapy,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: Age between 18-60, inclusive Patients carry a diagnosis of multiple sclerosis, according to the McDonald's criteria for diagnosis (Polman et al, 2011). Must have a neurologist providing the primary care for the MS and be willing to be evaluated for the multiple sclerosis by the two neurologists who are the co-investigators in the protocol. Must be documented to be HIV negative. An EDSS of 3.5 - 5.5 Patients must be able to give written consent. Inflammatory disease despite primary disease modifying therapy with at least 6 months of interferon and another disease modifying therapy, including fingolimod,glativamir, natalizumab, and mitoxantrone. Failure is defined as two or more clinical relapses with documented neurologic changes (excluding sensory changes) within the year prior to the study. (NOTE: Relapses must have required treatment with corticosteroids). Failure may also be defined as one relapse (excluding sensory changes) treated with methylprednisone and, on a separate occasion within the previous 12 months, evidence of active inflammation (i.e. gadolinium enhancement on MRI scan of the CNS). No previous history of allergic reaction to cyclophosphamide, G-CSF or mesna Patients must not be pregnant Failure to accept or comprehend irreversible sterility as a potential side effect of therapy. Life expectancy of more than 6 months No evidence of myelodysplastic syndrome on peripheral blood smear Not allergic to cyclophosphamide, mesna, fludarabine or alemtuzumab Baseline serum creatinine must be \ 55%, adequate pulmonary functions (oxygen saturation at room air of \>90%), and AST and ALT not \> 2x upper limits of normal, and no history of previous or active malignancy, except for localized cutaneous basal or squamous cell carcinoma in situ of the cervix. Exclusion Criteria: Diagnosis of primary progressive MS.",18.0,60.0,['multiple sclerosis']
NCT03151941,Respiratory Monitoring of Intrathecal Baclofen- a Feasibility Study,A Feasibility Study Monitoring the Respiratory Status of Participants Receiving or Scheduled to Receive Intrathecal Baclofen (ITB),COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * -Adults over the age of 18 * A person who is able to provide consent or a family member/ close friend who is able to assent on behalf of the participant * A person or a family member/ close friend who is able to understand English (understand written English and spoken instructions) * A person currently receiving Intrathecal Baclofen or is scheduled to receive Intrathecal Baclofen (awaiting fitting of pump) therapy to manage spasticity * A patient of the Solent/ University Hospitals Southampton NHS Foundation Trust Intrathecal baclofen service Exclusion Criteria: * -Pre-existing use of overnight non-invasive ventilation (NIV) and is compliant with NIV treatment * A person who is unable to consent to the study and does not have a family/ close person to assent * The study will exclude a person who is unable to independently remove the polysomnography and is also without supervision from another person (carer or partner) during the night. This ensures the participant is able to take off the polysomnography (or assisted by a carer) if it becomes uncomfortable and/or causes distress.,18.0,110.0,"['intrathecal baclofen', 'multiple sclerosis', 'respiratory system', 'cerebral palsy']"
NCT06907641,Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy,Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy,RECRUITING,INTERVENTIONAL,MALE,"Inclusion Criteria: * Male patients aged 18 or above * Ability to provide informed consent documentation indicating that they understand the purpose of, and procedures required for the study, and are willing to participate in the study. * Prior radical prostatectomy for confirmed adenocarcinoma on histopathology. * Rising PSA (0.20 - 0.75 ng/mL) following radical prostatectomy with no prior salvage radiotherapy. * 68Ga PSMA-11 PET/CT within the last 4 weeks for prostate cancer biochemical recurrence. Exclusion Criteria: * Prior, or contraindication to, salvage radiotherapy for biochemically recurrent prostate cancer. * History of current active malignancy as per investigator discretion other than prostate cancer. * Known or expected hypersensitivity to 64Cu-SAR-bisPSMA * Systemic therapy for metastatic prostate cancer including androgen deprivation therapy.",18.0,65.0,['prostate cancer (post prostatectomy)']
NCT03765541,Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia,"Dexamethasone Plus Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Patients With First Relapsed or Refractory Acute Myeloid Leukemia: a Randomized, Controlled, Open-label, Multicenter, Phase III Study",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. At least 18 years of age or older 2. Diagnosis of acute myeloid leukemia by World Health Organization classification First relapsed or refractory acute myeloid leukemia with at least 5% blasts by bone marrow biopsy or aspirate, or at least 1% blasts in peripheral blood, and meeting the following criteria: First relapsed acute myeloid leukemia : * First relapse occurred at least 90 days to 24 months after the first complete remission or complete remission with incomplete recovery * The first complete remission or complete remission with incomplete recovery had to result from no more than 2 cycles of cytotoxic chemotherapy. At least 1 induction cycle must have consisted of an anthracycline and cytarabine combination with a reasonable schedule/dose of anthracycline in the judgment of the investigator. * The re-emergence of at least 5% leukemic blasts in bone marrow is not attributable to other causes, regardless of new or recurrent dysplastic changes or extramedullary disease, or the re-emergence of at least 1% blasts in the peripheral blood is not attributable to other causes such as regenerating marrow. Refractory acute myeloid leukemia : * Persistent acute myeloid leukemia was documented by bone marrow biopsy or aspirate at least 28 days after day 1 of the first induction cycle of 1 or 2 cycles of cytotoxic chemotherapy. * Re-emergence of at least 5% leukemic blasts in bone marrow or at least 1% blasts in peripheral blood is not attributable to other causes such as regenerating marrow, and was less than 90 days after the first complete remission or complete remission with incomplete recovery. * Prior induction therapy had to include no more than 2 cycles of cytotoxic chemotherapy. At least 1 induction cycle must have consisted of an anthracycline and cytarabine combination with a reasonable schedule/dose of anthracycline in the judgment of the investigator. 3. Eastern Cooperative Oncology Group performance status ≤ 2. 4. Left ventricular ejection fraction ≥ 50% by echocardiogram or multi-gated acquisition scan ; only applicable for patients who will receive intensive chemotherapy. 5. Serum creatinine ≤ 150 µmol/L and/or total bilirubin ≤ 1.5 × the upper limit of normal and/or, aspartate aminotransferase ≤ 2.5 × the upper limit of normal, and/or alanine aminotransferase ≤ 2.5 × the upper limit of normal (unless related to acute myeloid leukemia) 6. Any clinically significant non-hematological toxicity after prior chemotherapy must be resolved or of grade 1 as per Common Terminology Criteria for Adverse Events version 4.03. 7. Women must be surgically or biologically sterile, or in post-menopause (amenorrheic for at least 12 months), or if of childbearing potential, must have a negative urine or serum pregnancy test within 14 days prior to the randomization and agree to use a highly effective method of contraception throughout the entire duration of the study treatment (including dose interruptions) and until 3 months after the last study treatment administration. Men must be surgically or biologically sterile, or agree to use a highly effective method of contraception throughout the entire duration of the study treatment (including dose interruptions) and until 6 months after the last study treatment administration. 8. Registered to, or beneficiary of, social security insurance or equivalent. 9. Signed written informed consent by both the patient and the investigator prior to perform any study-relayed procedure not part of normal medical care. Exclusion Criteria: 1. Acute promyelocytic leukemia (M3 subtype of acute myeloid leukemia). 2. More than 2 cycles of first line induction chemotherapy. 3. Acute myeloid leukemia with Philadelphia chromosome or BCR-ABL1 or blast crisis stage of chronic myeloid leukemia. 4. Known or suspected central nervous system leukemia. 5. Undergoing allogeneic hematopoietic stem cell transplantation within 90 days prior to randomization, or being on immunosuppressive therapy for prophylaxis of graft-versus-host disease, or experiencing graft-versus-host disease within 2 weeks prior to randomization. 6. Use of any experimental, cytotoxic, or targeted, anti-leukemic therapy within 14 days prior to randomization, with the exception of hydroxyurea. 7. Formal contraindication to glucocorticoids. 8. Non-acute myeloid leukemia-associated organic or psychiatric severe disease that contraindicates use of study treatment. 9. Patient who may not be followed regularly in consultation because of psychological, family, social, or geographical reasons. 10. History of uncontrolled other malignancy for at least two years, with the exception of basal cell carcinoma and in situ cervix carcinoma. 11. Severe uncontrolled infection at time of inclusion. 12. Positive serology for human immunodeficiency virus-1 or 2, and/or Human T-Cell lymphotropic viruses-1 or 2, and/or active viral infection with hepatitis B virus and/or hepatitis C virus. 13. Pregnant (beta gonadotropic chorionic hormon positive) or breastfeeding woman. 14. Incapable patient of age, under guardianship, under curators or safeguard of justice. 15. Patient under State Medical Assistance.",18.0,65.0,['relapsed or refractory acute myeloid leukemia']
NCT06440941,Chatbot-based Mindfulness Programme for Depressive University Students: Pilot Intervention Study,Chatbot-based Mindfulness-based Stress Reduction Programme for University Students With Depressive Symptoms: Intervention Development and Pilot Evaluation,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * University students aged over 18 years * University students pursuing a bachelor degree, associate degree, or higher diploma in Hong Kong * University students with self-reported depressive symptoms (The depressive symptoms are assessed pre-intervention using the 9-item Patient Health Questionnaire, with cumulative scores of 5 or higher indicating at least mild depressive symptoms.) * Be able to provide informed consent, read Chinese, listen to Cantonese * Ensure internet access during the study Exclusion Criteria: * University students who have been diagnosed with a clinical psychotic condition pre-intervention * University students who are currently involved in any mindfulness-based or other psychosocial interventions",18.0,65.0,['depression']
NCT03657641,Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer,A Phase I/II Study of Regorafenib and Pembrolizumab in Metastatic Colorectal Cancer Patients in 3rd and 4th Line Setting,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients who provided written informed consent to be subjects in this trial * Patients with histologically or cytologically confirmed advanced or metastatic colorectal cancer who had failed or are intolerant of oxaliplatin, irinotecan, and fluorouracil (5-FU) * Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 * Patients capable of taking oral medication * Patients with evaluable or measurable lesions as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 * Neutrophil count \>= 200/mm\^3 * Platelet count \>= 7.5 x 10\^4/mm\^3 (transfusion \> 2 weeks before testing permitted) * Aspartate transaminase (AST), alanine transaminase (ALT) =\ = 12 months * In the case of men, the patient must agree after consenting to the study to take contraception for at least 31 weeks after taking the final dose of the investigational drug (a period of 90 days \[the spermatogenesis cycle\] is added to five times the elimination half-time of immuno-oncology (I/O) agent Exclusion Criteria: * Patients who have undergone systemic chemotherapy, radiotherapy, surgery, hormone therapy, or immunotherapy \ = 150 mmHg and diastolic blood pressure \>= 90 mmHg) despite treatment with several hypotensive agents * Patients with acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrollment * Patients with a large amount of pleural effusion or ascites requiring more than weekly drainage * Patients with a \>= grade 3 active infection according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 * Patients with symptomatic brain metastasis * Patients with partial or complete gastrointestinal obstruction * Patients with interstitial lung disease with symptoms or signs of activity * Patients who test positive for either anti-human immunodeficiency virus (HIV)-1 antibodies, anti-HIV-2 antibodies, anti-human T-lymphotropic virus (HTLV)-1 antibodies, hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV) antibodies\* * Patients who test positive for either anti-hepatitis B surface antigen (HBs) or anti-hepatitis B core antigen (HBc) antibodies, and those who have hepatitis B virus (HBV)-deoxyribonucleic acid (DNA) measurements greater than the detection sensitivity will also be excluded * Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease * Patients who require systemic corticosteroids (excluding temporary usage for tests, prophylactic administration for allergic reactions, or to alleviate swelling associated with radiotherapy) or immunosuppressants, or who have received such a therapy \ = grade III congestive heart failure according to the New York Heart Association functional classification * Patients with a seizure disorder who require pharmacotherapy * Persistent proteinuria \> 3.5 g/24 hours measured by urine protein-creatinine ratio from a random urine sample (\>= grade 3, NCI-CTCAE version \[v\] 4.0) * Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation * Major surgical procedure or significant traumatic injury within 28 days before start of study medication * Non-healing wound, non-healing ulcer, or non-healing bone fracture * Patients with evidence or history of any bleeding diathesis, irrespective of severity * Any hemorrhage or bleeding event \>= CTCAE grade 3 within 4 weeks prior to the start of study medication * Women who are pregnant or breastfeeding, or with the potential for pregnancy * EXCLUDED THERAPIES AND MEDICATIONS, PREVIOUS AND CONCOMITANT * Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib and pembrolizumab) * Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 2 weeks of trial entry (signing of the informed consent form is OK in the washout period) * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication * Therapeutic anticoagulation with vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids. However, prophylactic anticoagulation as described below is allowed: * Low dose warfarin (1 mg orally, once daily) with PT-INR =\< 1.5 x ULN is permitted. Infrequent bleeding or elevations in PT-INR have been reported in some subjects taking warfarin while on regorafenib therapy. Therefore, subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes * Low dose aspirin (=\< 100 mg daily) * Prophylactic doses of heparin * During the study, strong CYP3A4 inhibitors (eg, clarithromycin, grapefruit juice, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John?s wort) are not permitted * Live vaccines administered \< 30 days before the initiation of treatment with the investigational drug and during the trial period. Examples of live vaccines are as follows (however, the list is not exhaustive): measles, mumps, rubella, chicken pox/herpes zoster, yellow fever, rabies, BCG for tuberculosis, and typhoid vaccines. Inoculation with inactive vaccines (e.g., seasonal influenza vaccines) is permitted; however, the intranasal administration of attenuated influenza vaccines (e.g., Flu-Mist) is prohibited * Systemic glucocorticoids for purposes other than treating symptoms caused by notable events with a suspected immunological etiology. Upon deliberation with the trial coordinating committee, the use of corticosteroids may be permitted according to the physiological dose required to alleviate symptoms (e.g., to control symptoms of acute asthma)",18.0,65.0,"['colorectal cancer', 'colorectal cancer metastatic']"
NCT07161141,Developing an Immersive Virtual Reality Platform,Developing an Immersive Virtual Reality Platform to Support Birth Preparedness and Mental Wellbeing in Pregnant Women,NOT_YET_RECRUITING,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * The pregnant women between the ages of 18-49 * Primiparous * At least 20 weeks of gestation * Single pregnancy * Without any visual and hearing problems andcan communicate verbally are included to this study. Exclusion Criteria: * Pregnant women with multiple pregnancies were multiparous * Risky pregnancy, and did not accept participation in the study will excluded from the study. * Individuals with a history of any psychiatric disorder (eg, mood disorder or anxiety disorder) will excluded from this study.",18.0,49.0,"['pregnancy', 'mental health (depression)', 'childbirth preparation program']"
NCT06300541,Prevalence and Impact of Sarcopenia in Patients With Inflammatory Bowel Disease,Prevalence and Impact of Sarcopenia in Patients With Inflammatory Bowel Disease and the Significance of Removing the Colon,RECRUITING,OBSERVATIONAL,ALL,Inclusion Criteria: * All adult patients experiencing an acute flare-up of their bowel disease (ulcerative colitis or Crohn's disease) admitted to a hospital in the Region Västra Götaland and Stockholm are invited to participate in the study. Exclusion Criteria: * Not wishing to participate in the study Inability to understand the language or study procedures,18.0,65.0,"['inflammatory bowel diseases', 'sarcopenia']"
NCT02758041,A Study to Evaluate Sebacia Microparticles in Patients With Inflammatory Acne Vulgaris,A Study to Evaluate Sebacia Microparticles in Patients With Inflammatory Acne Vulgaris,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Male or female, 16-45 years of age. 2. Moderate to moderately-severe facial inflammatory acne vulgaris 3. Fitzpatrick skin phototype I-III Exclusion Criteria: 1. Pregnant, lactating, nursing or planning to become pregnant 2. Tattoo in the treatment area 3. Active skin disease, excessive scarring or excess facial hair in the treatment area 4. Certain current or recent acne treatments 5. Recent light treatments including Intense Pulsed Light or other lasers, microdermabrasion or chemical peels in the treatment area 6. Contraindicated for laser treatment, or is unable or unwilling to avoid excessive sun exposure or tanning bed use 7. Known allergy to gold",16.0,45.0,['facial acne vulgaris']
NCT04682041,Evaluating the Impact of EnteraGam In People With COVID-19,"Randomized Open-Label Clinical Study Evaluating the Impact of EnteraGam, a Nutritional Intervention Containing Bovine Plasma-Derived Immunoglobulin CoNcentrate, on Clinical Outcomes In People With COVID-19",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Subject is ≥18 years of age. 2. Male or female. Females of childbearing (reproductive) potential must have a negative urine pregnancy test at screening. 3. Subject with diagnosis of COVID-19 based on + RNA or immunoglobulin M (IgM) test or compatible clinical presentation\* who: 1. is being discharged from the emergency department without hospitalization, or 2. is admitted to the hospital or was previously hospitalized and still in the hospital, does not require invasive mechanical ventilation and does not require management in the intensive care unit. Inpatients can be enrolled in the study at any time of their hospitalization, if they comply with the inclusion criteria. (\*)Compatible clinical presentation will consider compatible symptoms (cough, fever, myalgia, dyspnea, ageusia / anosmia) and examination of general condition, heart rate and respiratory rate, oxygen saturation, cardiopulmonary auscultation, compatible radiology. 4. Ability to consume EnteraGam. 5. Subject or surrogate decision maker is capable of understanding the requirements of the study, understands the language of the informed consent form, and is capable and willing to sign the informed consent form. Exclusion Criteria: 1. Female subjects who are pregnant or breast-feeding. 2. Subject is enrolled in another randomized clinical trial. 3. Subject is taking anti-IL-6 treatment (e.g. tocilizumab), anti-IL-1 treatment (e.g. canakinumab, anakinra), or other biologic immunomodulators or immunosuppressant drugs. Note: Topical/inhaled immunomodulators and corticosteroids are not restricted. 4. Subject has immediate need for GI surgery or intervention for active GI bleeding, pancreatitis, peritonitis, intestinal obstruction, or intra-abdominal abscess. 5. Subject has active inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease, or celiac disease), GI malignancy, GI obstruction, pancreatitis, gastroparesis, carcinoid syndrome, amyloidosis, ileus, or cholelithiasis. 6. Subject has active gastric ulcer, duodenal ulcer, diverticulitis, colitis, enteritis, infectious gastroenteritis, or GI neoplasm, other than benign polyps. 7. Subject has a history of allergy or intolerance to beef or to any ingredient in the product. 8. Subject has active drug or alcohol abuse that in the opinion of the investigator may interfere with the subject's ability to comply with this protocol. 9. History of uncontrolled psychiatric disorders (includes significant depression or suicidal ideation), that in the opinion of the investigator may interfere with the subject's ability to comply with this protocol. 10. In the opinion of the investigator, progression to death is imminent and highly likely within the next 24 hours.",18.0,65.0,['covid19']
NCT01985841,Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer,"Phase II, Open-label Non-randomized Trial to Investigate the Efficacy of Bevacizumab in Combination With Dose Dense Sequential Chemotherapy in the Neo-adjuvant Setting for HER2 Negative Breast Cancer Patients",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Female patients with histologic proven, corebiopsied, invasive ductal adenocarcinoma of the breast \>2 cm in size and of any N stage (clinical and/or radiological T-stage \> T1, including T4d), scheduled to receive preoperative chemotherapy. * Age 18-70 years * ECOG performance-status ≤1 * No prior or current neoplasm except for curatively treated non melanoma skin cancer, in situ carcinoma of the cervix * No distant disease/secondary carcinoma * Normal cardiac function * Results of the following assessments at the time of inclusion must be available: 1. bilateral Mammography (before enrolment) 2. histology 3. grading 4. hormone-receptor-status 5. HER2 status negative (is defined as FISH/CISH negative or IHC0 or IHC1+, or IHC2+ and FISH/CISH negative) * Laboratory requirements (within 1 week before enrolment): 1. Hematology: Neutrophils ≥ 1.5 x 109/l, Platelets ≥ 100 x 109/l, Hemoglobin\>11 g/dl 2. Hepatic function: Total bilirubin \ grade 2 by NCI-CTC AE * Preoperative local treatment for breast cancer (i.e. incomplete surgery, radiotherapy) * Prior or concurrent systemic antitumor therapy * Evidence of wound healing complications, bone fracture, ulcer or the presence of clinically significant peripheral vascular disease * Clinically significant cardiac disease e.g. congestive heart failure. * Other serious illness or medical condition-uncontrolled hypertension or high risk uncontrolled arrythmias -history of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent-active uncontrolled infection-unstable peptic ulcer, unstable diabetes mellitus or other contraindication for the use of corticosteroids * Known hypersensitivity reaction to the compounds or incorporated substances. * Evidence of bleeding diathesis or coagulopathy * The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR, or appropriate monitoring test is within therapeutic limits and the patient has been on a stable dose of anticoagulants for at least two weeks at the time of randomization. Patients not receiving anti coagulant medication must have an INR ≤ 1.5 an aPTT ≤ 1.5 x ULN within 7 days of randomization. * Ongoing treatment with aspirin (\> 325mg / day) or other medications known to predispose to gastrointestinal ulceration. * Major surgery (including open biopsy), significant traumatic injury within 28 days prior to enrolment. * Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion * Treatment with an investigational drug within 30 days prior to study entry. * Legally incapacitated and/or other circumstances which make it undesirable for the subject to understand the nature, meaning and consequences of the clinical study",18.0,70.0,['breast cancer']
NCT00424541,Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension,"A Multiple Center, Randomized, Double Blind, Parallel Group, Multiple Oral Doses Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profiles of 150 mg and 300 mg of SPP100 in Japanese Patients With Mild to Moderate Essential Hypertension",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Japanese patients with mild to moderate essential hypertension aged 20 to 80 years * Blood pressure: Mean (based on 3 recordings at 1-2 minute intervals) sitting diastolic blood pressure values on 14 days or 3 days before the treatment should meet the following criteria: * 14 days before treatment: ≥ 90 mmHg and \< 110 mmHg * 3 days before treatment: ≥ 95 mmHg and \< 110 mmHg * The difference in mean sitting diastolic blood pressure between 14 days and 3 days before the treatment is within 10 mmHg * Body weight no less than 50 kg Exclusion Criteria: * Patients with mean (based on 3 recordings at 1-2 minute intervals) systolic blood pressure ≥ 180 mmHg and/or mean diastolic blood pressure ≥ 110 mmHg at Day -28, Day -14 and Day -3. * Patients with or suspected of having secondary hypertension * Patients suspected of having malignant hypertension Other protocol-defined inclusion/exclusion criteria may apply",20.0,80.0,['hypertension']
NCT07367841,FIND HF Risk-guided Screening for Heart Failure - Pilot Study,FIND HF: Risk-guided Screening for Heart Failure,NOT_YET_RECRUITING,OBSERVATIONAL,ALL,Inclusion Criteria: Registered with a doctor practice that uses electronic health system to record patient medical notes Age at enrolment greater or equal to 40 Identified as at risk of developing Heart Failure Exclusion Criteria: Registered with a doctor practice that is participating in research studies relating to heart failure screening * Known diagnosis of HF * On the palliative care register * Unable to give written informed consent for participation in the study * Unable to adhere to the study requirements,40.0,65.0,['heart failure']
NCT02264041,Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine,"The Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine (an Open-label, Randomised, Single-dose, Two-way Crossover Study)",COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: 1. Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests 1.1 No finding deviating from normal and of clinical relevance 1.2 No evidence of a clinically relevant concomitant disease 2. Age ≥21 and Age ≤55 years 3. BMI ≥18.5 and BMI \ 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial 7. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial. 8. Participation in another trial with an investigational drug within two months prior to administration or during the trial 9. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes/day) 10. Inability to refrain from smoking on trial days 11. Alcohol abuse (more than 60 g/day) 12. Drug abuse 13. Blood donation (more than 100 mL within four weeks prior to administration or during the trial) 14. Excessive physical activities (within one week prior to administration or during the trial) 15. Any laboratory value outside the reference range that is of clinical relevance",21.0,55.0,['healthy']
NCT01841554,Cardioband With Transfemoral Delivery System,Cardioband Adjustable Annuloplasty System For Transcatheter Repair of Mitral Valve Regurgitation,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age \> 18 years * Moderate to severe functional Mitral Regurgitation (MR) * Symptomatic Patients (NYHA ClassII-IV) despite optimal medical therapy , including Cardiac Resynchronization (CRT) if indicated. * Left Ventricle Ejection Fraction (LVEF) ≥ 25%, LVEDD ≤ 65mm * Subject is high risk to undergo Mitral Valve (MV) surgery (as assessed by a surgeon and a cardiologist, at the site) * Transseptal catheterization and femoral vein access is determined to be feasible * Subject is able and willing to give informed consent and follow protocol procedures Exclusion Criteria: * Active bacterial endocarditis * Severe organic lesions with retracted chordae or congenital malformations with lack of valvular tissue * Heavily calcified annulus or leaflets * Subjects in whom transesophageal echocardiography is contraindicated * Untreated clinically significant Coronary Artery Disease (CAD) requiring revascularization * CRT implant within 3 months prior to procedure * Any percutaneous coronary, carotid, endovascular intervention or carotid surgery within 30 days or any coronary or endovascular surgery within 3 months * Cerebrovascular Accident (CVA) or Transient Ischemic Attack (TIA) within 6 months or severe carotid stenosis (\>70% by Ultra sound) * Renal insufficiency requiring dialysis * Life expectancy of less than twelve months * Subject is participating in concomitant research studies of investigational products * Mitral valve anatomy which may preclude proper device treatment * Right-sided congestive heart failure with echocardiographic evidence of severe right ventricular dysfunction and severe tricuspid regurgitation",18.0,65.0,['mitral regurgitation']
NCT05598554,The Effects of Telerehabilitation And Chair-based Yoga In The Elderly,The Effects of Chair-Based Yoga With Telerehabilitation on Function and Quality of Life in Elderly Individuals,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * 65 years and over, * Having a Standardized Mini Mental Test Score of 24 and above, * physically active (self-sustaining), Exclusion Criteria: * severe cardiopathy, * uncontrolled hypertension, * mental disorder, * Presence of any health condition that may prevent functional autonomy test such as hearing and vision, * have mental disorders and dementia, * people with any unstable medical condition",65.0,65.0,"['telerehabilitation', 'chair-based yoga', 'elderly people']"
NCT05966454,Complex And Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure - UCSF,Complex And Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure (CASA RELAX) Using Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR) -A Randomized Controlled Trial,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: Age ≥ 18 years * Age ≥ 18 years * Planned appendectomy (laparoscopic or open) * Working telephone number or reliable method to contact patient after hospital discharge Exclusion Criteria: * Unable to consent * Pregnant Women * Prisoners * Immunocompromised as determined by clinical team, or patients actively receiving steroids, chemotherapy, or immunosuppressing medications (for example tacrolimus), or patients with active hematologic malignancy affecting the immune system, leukopenia, or end-stage AIDS * Heart failure * Allergy to bupivacaine * Unlikely to comply with treatment or follow-up * Inpatient consultation for appendicitis * Clinically suspected of sepsis based on Sepsis-3 definition * Current use of antibiotics for other indications * Type 1 Diabetes or uncontrolled hyperglycemia * Surgeon preference * Patient preference * Research team unavailable",18.0,65.0,['appendicitis']
NCT01068054,Efficacy Study of FK-506 and Cyclosporine in Vernal Keratoconjunctivits (VKC),A Double-blind Comparison of 0.1% Tacrolimus Ophthalmic Ointment and 2% Cyclosporine Eye Drops in the Treatment of Vernal Keratoconjunctivits (VKC),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * patients with clinical diagnosis of vernal keratoconjunctivitis Exclusion Criteria: * coexisting ocular diseases such as glaucoma, other corneal disease, ocular infections, other coexisting systemic diseases",18.0,65.0,"['keratoconjunctivitis, vernal']"
NCT00135954,Treatment of Patients With Idiopathic Membranous Nephropathy,Treatment of Patients With Idiopathic Membranous Nephropathy at Risk for Renal Insufficiency: Comparison of Early Versus Late Start of Immunosuppressive Therapy,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Idiopathic membranous nephropathy * Serum creatinine \< 1.5 mg/dl * Nephrotic syndrome Exclusion Criteria: * Infection * Instable angina * Systemic disease * Pregnancy * Renal vein thrombosis * Prior therapy with immunosuppressant agents * Liver dysfunction * Use of nonsteroidal anti-inflammatory drugs (NSAIDs),18.0,75.0,"['glomerulonephritis, membranous']"
NCT06512454,A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems,Prospective Observational Study on the Natural History of Alpha-1 Antitrypsin Deficiency and Associated Liver Disease,RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: Participants who meet all the following criteria will be included in the study. Cohorts 1 and 2: 1. Willing to provide written informed consent or currently enrolled in an ongoing participating AATD patient registry that does not require reconsenting to participate in the study. 2. \>=18 years of age at enrollment in this study. 3. Participants with documented diagnosis of AATD, meeting the following criteria: 1. Cohort 1 (AATD-Pi\*ZZ genotype/phenotype). • Pi\*ZZ genotype as documented from rapid genetic assay, sequencing, or polymerase chain reaction (PCR), or Pi\*ZZ phenotype as documented from iso-electric focusing (IEF) electrophoresis. 2. Cohort 2 (AATD-Pi\*SZ genotype/phenotype with liver disease manifestation). * Pi\*SZ genotype as documented from rapid genetic assay, sequencing, or PCR, or Pi\*SZ phenotype as documented from IEF electrophoresis, and * Moderate-advanced or severe liver disease manifestation as defined by either liver biopsy or surrogate laboratory or imaging measures, as determined through: * Lab and imaging measures to define liver disease manifestation Exclusion Criteria: Participants who meet any following criteria will be excluded from the study. 1. Documented AATD genotype/phenotype other than Pi\*ZZ or Pi\*SZ. 2. History of liver transplant. 3. No results for either biopsies, magnetic resonance elastography (MRE), fibro scan (vibration controlled transient elastography \[VCTE\]), or Aspartate aminotransferase to platelet ratio index (APRI) in the 24 months prior to the index/enrollment date and has none of these tests ordered during the index period. 4. Participants who had previously been treated or in an active participation in an interventional trial studying liver or lung disease. 5. Treatment with liver directed AATD investigational therapy as part of a compassionate use request.",18.0,65.0,['alpha1-antitrypsin deficiency']
NCT02785354,Anticoagulants Comparative Benefit-risk Ratio in Real Life,Engel 2: REal-life aNticoaGulants Comparative bEnefit-risk in Nonvalvular Atrial fibrilLation (NVAF) in France,COMPLETED,OBSERVATIONAL,ALL,"Inclusion criteria: Patients with NVAF with a first reimbursed dispensation of Pradaxa®, Xarelto®, or VKA in 2013, with no other identified indication for anticoagulation; Without any VKA or NOAC (Pradaxa®, Xarelto®, or Eliquis®) reimbursed dispensation for the last 3 years before the first reimbursed dispensation of Pradaxa®, Xarelto®, or VKA Exclusion criteria: None",18.0,65.0,['atrial fibrillation']
NCT00867854,Treatment De-Intensification and Residual HIV-1 in Youth,Treatment De-Intensification and Residual HIV-1 in Adolescents and Young Adults: A Sub-Study of ATN 061 and ATN 071.,COMPLETED,OBSERVATIONAL,ALL,"081 participants must first be enrolled in either ATN 061 or ATN 071 and meet the eligibility criteria of those protocols in addition to those below. Inclusion Criteria: 061 Participants * Currently on treatment with an ATV/r-based HAART regimen (ATV/r, FTC, TDF is the preferred regimen); * HIV-1 viral load \ 350 cells/mm3 at week 24; and * Able to provide informed consent for the sub-study and adhere to the protocol. 071 Participants * Initiated HAART according to current DHHS guidelines (CD4+ T cells \ 350 cells/mm3 at week 24 on HAART; measurement to be collected from clinical care results contained in the medical record at the clinical site within +/- 30 days of week 24 on therapy; and * Able to provide informed consent for the sub-study and adhere to the protocol. General Exclusion Criteria: * Currently enrolled in the Standard Care Arm of ATN 061; * Pregnancy or breast feeding; * Severe (Grade ≥ 3) anemia or other conditions that would not allow adequate blood volume to be drawn; * Active treatment for systemic infections; * Treatment with immune modulators, including immunosuppressive or immune modulating therapy (IL-2, intravenous gammaglobulin, and therapeutic or other experimental vaccines including HIV-1 vaccine given for primary prevention at any time (short courses (\<14 days) of prednisone for reactive airway disease (RAD) are permitted); * Active hepatitis B infection as defined by Hepatitis B antigen (Ag) positive; * Disallowed Medications (see Section 5.3.2); * Active drug or alcohol use or dependence that, in the opinion of the site personnel, would interfere with adherence to the study; or * History of chronic renal insufficiency or Grade 3 or greater serum creatinine. 061-Specific Exclusion Criteria * History of an Acquired Immunodeficiency Syndrome (AIDS)-defining illness; * Meets any ATN 061 exclusion criteria for de-intensification; or * Meets any ATN 061 premature study discontinuation criteria. 071-Specific Exclusion Criteria: None",18.0,24.0,"['hiv-1', 'hiv infections']"
NCT01534754,Mesalazine and/or Lactobacillus Casei in the Diverticular Disease of the Colon,"Mesalazine and/or Lactobacillus Casei in Maintaining Remission of Symptomatic Uncomplicated Diverticular Disease of the Colon: a Double-blind, Double-dummy, Placebo-controlled Study",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * diagnosis of diverticular disease diagnosed for the first time or established by previous colonoscopy * symptomatic episode of uncomplicated diverticular disease no more than 4 weeks prior to study entry * patients who have given their free and informed consent. Exclusion Criteria: * acute diverticulitis (both complicated and uncomplicated) * diverticular colitis * active or recent peptic ulcer * chronic renal insufficiency * allergy to salicylates * patients with intended or ascertained pregnancy, lactation * women of childbearing age not using contraceptives * lactulose-lactitol use in the two weeks before the enrolment and during the study * presence of diverticulitis complications (fistulas, abscesses, and/or stenoses) * use of probiotic preparations either prescribed or over-the counter within two weeks prior to study entry * inability to give a valid informed consent or to properly follow the protocol * patients with active malignancy of any type, or history of a malignancy (patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years before study enrolment were also acceptable) * recent history or suspicion of alcohol abuse or drug addiction * any severe pathology that can interfere with the treatment or the clinical or instrumental tests of the trial * use of NSAIDS for one week before and throughout the study period (only paracetamol was permitted).",18.0,65.0,['diverticular disease of the colon']
NCT00683254,Analysis of Impact on Nasal Obstruction by Commercially Available Internal Nasal Stents,Analysis of Impact on Nasal Obstruction by Commercially Available Internal Nasal Stents,WITHDRAWN,OBSERVATIONAL,ALL,"Inclusion Criteria: * 18 years or older Exclusion Criteria: * history of nasal surgery, currently using topical nasal steroid spray, over the counter decongestant, history of recurrent epistaxis or history of nosebleed within 2 weeks prior to data collection, currently pregnant",18.0,80.0,['nasal obstruction']
NCT03213054,A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer,"A Phase 1 Study to Evaluate the Safety of OBP-301, Telomelysin in Combination With Radiation Therapy in Patients With Esophageal Cancer Not Applicable for Standard Therapy",UNKNOWN,INTERVENTIONAL,ALL,"Key Inclusion Criteria: 1. Patients who have primary tumor or metastatic lesion of histologically or cytologically diagnosed with esophageal carcinoma. 2. Patients are feasible for injection of OBP-301 into target legion 3. Patients aged in 20 to 89 years. 4. Patients with ECOG Performance Status Score ≤ 2. 5. Patient who have life expectancy longer than 12 weeks. 6. Patients who are not applicable to standard therapy. 7. Patients who have adequate organ function. Key Exclusion Criteria: 1. Patients who have an active, treatment-required concomitant malignancy. 2. Patients who had been enrolled within 4 weeks to other clinical trials of unapproved drugs. 3. Patients who have had chemotherapy within 4 weeks. 4. Patients who have treatment history of cancer immunotherapy. 5. Patients who had radiotherapy to treatment targeted lesion. 6. Patients who have active infection which required systemic treatment. 7. Patients who are scored III or IV by NYHA (New York Heart Association). 8. Patients who are judged as inappropriate to this trial by investigator(s).",20.0,89.0,['esophageal cancer']
NCT00055354,Acupuncture for the Treatment of Post-Traumatic Stress Disorder (PTSD),Acupuncture Diagnosis and Treatment of DSM-IV PTSD,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria * DSM-IV diagnosis of PTSD * Stage I PTSD symptoms * PTSD Symptom Scale-Self Report (PSS-SR) score \> 16 * Meets PSS-SR diagnostic criteria Exclusion Criteria * Stage I substance abuse and/or dependence in the past 6 months * Psychotic disorder * Inability to commit to treatment or wait-list conditions * Current treatment specifically for PTSD * Certain medical conditions, including thyroid disease, class IV heart failure, active cancer treatment, and uncontrolled diabetes * Pregnant * Use of benzodiazepines, narcotics, opiates, narcotic antagonists, sleep medication, muscle relaxants, analgesics, or sedatives.",18.0,65.0,"['stress disorders, post-traumatic']"
NCT07353554,Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma,Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Newly diagnosed or relapsed MM patients * Written informed consent obtained and capable of undergoing follow-up. Exclusion Criteria: * Severely abnormal liver and kidney function * Women who are planning pregnancy, are pregnant, or are breastfeeding, as well as those with childcare plans during the study period; subjects of childbearing potential must use effective contraceptive measures throughout the study. * Individuals unable to lie flat for 30 minutes. * Individuals who decline to participate in this clinical study. * Patients with claustrophobia or other psychiatric disorders, or poor compliance that may compromise their ability to cooperate with the study procedures. * Other circumstances deemed by the investigator as unsuitable for participation in this clinical trial.",18.0,85.0,['multiple myeloma (mm)']
NCT06214754,Efficacy and Safety of Intravascular High-pressure Cutting Balloon Catheters for PCI,"A Prospective, Multicenter, Randomized Controlled Clinical Trial of the Efficacy and Safety of Intravascular High-pressure Cutting Balloon Catheters for PCI",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Be between 18 and 80 years of age (including boundary values) and have a life expectancy of more than 12 months； 2. Be able to understand the purpose of the study, voluntarily participate in and sign the informed consent, and be able and willing to accept the follow-up established in this study; 3. Ischemic cardiomyopathy with single or multiple coronary artery lesions and diagnostic evidence \[e.g., stable angina, unstable angina, or occult ischemia (evidence of myocardial ischemia)； 4. Investigator is believed that the target atherosclerotic plaque needs to be incised and that predilation (if necessary) can enable the incised balloon to pass through the lesion； 5. The presence of coronary artery stenosis confirmed by imaging examination, suitable for percutaneous coronary intervention, coronary vessel stenosis ≥70%; Or ≥50% (visual) with evidence of ischemia, TIMI ≥ level 1； 6. The patient had autogenous coronary angiogenesis or restenosis, requiring stent treatment； 7. The reference vessel diameter of target lesion was 2.0mm-4.0mm, and the lesion length was ≤20mm； 8. When there are multiple lesions that need to be treated, only one in situ coronary lesion is selected as the target lesion, and the non-target lesion must be located on different vascular branches； Exclusion Criteria: 1. Patients with bleeding tendencies, contraindications to antiplatelet and anticoagulant therapy, who are unable to undergo anticoagulant therapy； 2. Have had any myocardial infarction within a week； 3. People who have an allergic reaction to contrast media or can't take medication 4. There was severe renal failure with or without dialysis, glomerular filtration rate (eGFR) \ 2.0 mg/ dl； 5. cardiogenic shock； 6. Patients who have received heart transplants； 7. Patients who are not eligible for coronary artery bypass surgery； 8. The patient had active peptic ulcer or active gastrointestinal bleeding within 1 month before surgery； 9. The patient had a stroke or transient ischemic attack within 2 months before surgery； 10. Patients in the pregnancy or lactation period； 11. Participants are currently participating in any other clinical trial within 1 month prior to the trial； 12. Patients deemed unsuitable for inclusion by other investigators； 13. Severe calcified lesions and twisted lesions or lesion sites \> 45 degrees angled； 14. Lesions with significant endometrial tears 15. Unprotected left main lesion； 16. The contrast showed a blood clot； 17. Scaffold fracture lesion； 18. Distal stent lesion after stent implantation；",18.0,80.0,['atherosclerotic plaque']
NCT03675854,"Defining the Optimal Duration of Treatment for ""Low-Risk"" Peritoneal Dialysis-Related Peritonitis","Defining the Optimal Duration of Treatment for ""Low-Risk"" Peritoneal Dialysis-Related Peritonitis",WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * peritonitis episodes caused by CNSS, Streptococcal species, or negative bacterial culture Exclusion Criteria: * relapsing peritonitis episodes * episodes that do not show a clinical response after 5 days of antibiotic therapy * patients who have difficulty in adhering to the antibiotic therapy",18.0,65.0,['peritoneal dialysis-associated peritonitis']
NCT02251054,Virtual Avatar Coaches for Behavioral Therapy of Patients With Overactive Bladder,Virtual Avatar Coaches for Behavioral Therapy of Patients With Overactive Bladder,COMPLETED,INTERVENTIONAL,FEMALE,Inclusion Criteria: * age 55 or older * women living in the community * who could read and speak English * urgency (≥3 episodes/24 hrs.) ± urge urinary incontinence * urinary frequency (≥8 times/24 hrs.) * nocturia (awakening ≥2 times at night) Exclusion Criteria: * hematuria * abdominal pain * fever * cognitive impairment (Mini-Cog \ 3) * hearing issues * uncorrected visual difficulties,55.0,65.0,['overactive bladder']
NCT05686954,Cottonseed Oil Dose Response,Nutritional Effects of Different Doses of Cottonseed Oil in Humans,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * 25-75-year-old men and women at increased risk for cardiovascular disease. Increased risk for cardiovascular disease will be defined by either elevated cholesterol profiles -or- overweight/obesity. * Elevated cholesterol profiles will be defined as: * ""Borderline High"" and/or ""at risk"" in two or more of the following variables (total cholesterol: 180-239 mg/dL, LDL cholesterol 110-159 mg/dL, triglycerides 130-199 mg/dL) --or--- * ""High"" in total cholesterol (240 mg/dL and higher), LDL (160 mg/dL or higher), or triglycerides (between 200 - 350 mg/dl). Overweight/obesity will be defined by body mass index (overweight 25-29.9 kg/m2 or obesity 30 kg/m2 or greater). Exclusion Criteria: * Probable familial hypercholesterolemia, defined by: total cholesterol greater than 290 mg/dL or LDL levels greater than 190 mg/dL plus a family history of myocardial infarction (MI) before 50 years of age in a 2nd-degree relative or below age 60 in a 1st-degree relative. * women on hormone replacement therapy for less than 2 years * women who are pregnant * individuals who regularly exercise more than 3 h/w * weight gain or loss of more than 5% of their body weight in the past 3 months * plans to begin a weight loss/exercise regimen during the trial * history of medical or surgical events that could affect digestion or swallowing * gastrointestinal surgeries, conditions or disorders, * any chronic diseases (including moderate to severe asthma, chronic lung disease, and kidney disease), * metabolic diseases * atherosclerosis * previous MI or stroke * cancer * fasting blood glucose levels greater than 126 mg/dL * blood pressure greater than 180/120 mmHg * medication use affecting digestion and absorption, metabolism (e.g., thyroid meds), lipid-lowering medications, medications for diabetes, steroid/hormone therapies, or current antibiotic cycles * medically prescribed or special diets * Food allergies (specific to the foods in the study, including wheat, dairy, and cottonseed oil) * fish oil supplements, * excessive alcohol use (greater than 3 drinks/d for men; greater than 2 drinks/d for women) * tobacco or nicotine use * underweight BMI (\<18.5 kg/m2)",25.0,75.0,"['dyslipidemias', 'overweight and obesity', 'nutrition, healthy']"
NCT03742154,Hollings Cancer Center Varenicline Sampling Study,A Pilot Translational Study of Varenicline Sampling to Promote Treatment Engagement and Smoking Cessation,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * age 18+ * daily smoker (25+ days/previous month) * smoking 5+ cigarettes/day; * smoking \> 1yr; * some interest in eventual quitting (\>2 on 10-point scale); * has a primary care doctor and has seen that doctor at least once in past year; and * own a smartphone or have regular (daily) access/use of email. Exclusion Criteria: * reports of history of seizures or seizure disorders; * suicidal ideation in past month; * any lifetime suicide attempt; * currently pregnant, breastfeeding, or planning to become pregnant; or * reports of hallucinations.",18.0,65.0,"['smoking', 'smoking cessation', 'smoking, tobacco', 'smoking, cigarette']"
NCT01302054,"A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.",A 14 Week Randomized Parallel Group Placebo-Controlled Double-Blind Multicentre Study Of Fesoterodine 8 Mg In Overactive Bladder Patients With Sub-Optimal Response To Tolterodine 4 Mg Extended Release (ER).,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Diagnosis of overactive bladder with symptoms for at least 6 months. * Moderate to severe incontinence episode frequency and subsequent sub-optimal response to tolterodine * Women of child-bearing potential must not intend to become pregnant, be pregnant or producing breast milk at the time of study entry, and must use contraception Exclusion Criteria: * Conditions or prior treatment that may also affect bladder function * Clinically significant urinary tract infection (UTI) * Ongoing treatment with overactive bladder medications (these can be stopped at the first visit to allow entry into the study).",18.0,65.0,"['urinary bladder, overactive']"
NCT00034554,Study of gp75 Vaccine in Patients With Stage III and IV Melanoma,Phase I Study of gp75 DNA Vaccine in Patients With AJCC Stage III and IV Melanoma,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. The patient has a diagnosis of American Joint Commission on Cancer (AJCC) stage 111 or IV malignant melanoma. A patient who is free of disease after surgical resection of stage 111 or IV disease, but at high risk (defined as a primary tumor \>4 rnm, satellite or in-transit lesions, one or more positive lymph nodes or distant metastases) for recurrence is also eligible. A patient with metastatic disease may have no more than five sites of disease. The skin represents one site regardless of the number of lesions. Stage 111 melanoma is defined as a pT4 primary tumor (\>4m in depth or Clark level 5) in-transit metastases, satellites lesions or regional lymph nodes involved with melanoma.Pathology slides must be reviewed by the investigational site's Department of Pathology. 2. The patient's Karnofsky performance status is 280 at study entry. 3. The patient has given signed informed consent. 4. The patient has had surgery for their melanoma at least 6 months prior to study entry, or has had prior interferon therapy, or developed unacceptable toxicities to interferon therapy, or has a pre-existing condition(s) that precludes the patient fkom receiving interferon treatment. 5. The patient is 21 8 years of age. 6. The patient must have completed any prior irradiation, chemotherapy, or systemic immunotherapy (interferon-alpha, or interleukin-2) at least 30 days prior to study entry. 7. The patient has adequate hematologic function as defined as a platelet count 2100,000/mm3 and white blood cell (WBC) level 23,000/mm3. 8. The patient has serum lactose dehydrogenase (LDH) within normal range and a serum creatinine level \<2.0 mg/dL. 9. The patient agrees to use effective contraception if procreative potential exists. Exclusion Criteria: 1. The patient has stage I11 disease otherwise eligible to receive standard of care melanoma therapy. 2. The patient has a medical condition or use of medication (eg, corticosteroids) that might make it difficult for the patient to complete the full course of treatments or to respond immunologically to them, in the opinion of the investigator. 3. The patient has received irradiation, chemotherapy, or systemic immunotherapy (interferon-alpha, or interleukin-2) within 30 days prior to study entry. 4. The patient is pregnant (confirmed by serum beta human chorionic gonadotropin \[PHCG\], if applicable) or is breast feeding. 5. The patient has received any investigational agents within 30 days of study entry. 6. The patient has received prior cancer vaccine therapy. 7. The patient has evidence of central nervous system (CNS) metastasis. 8. The patient has evidence of an ocular abnormality, as detected by a slit-lamp ophthalmologic examination, within 4 weeks prior to study entry.",18.0,65.0,['malignant melanoma']
NCT00954005,Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma,"Multicentric Phase I/II Study for the Efficacy of a Combination of Rituximab, Gemcitabine and Oxaliplatin in Relapsed/Refractory Indolent Lymphoma",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Need for therapy in patients with relapsed/refractory patients * Histological proven diagnosis of an indolent B-cell lymphoma according to the World Health Organization (WHO) classification belonging to one of the following entities: * follicular lymphoma * mantle cell lymphoma * lymphoplasmacytic lymphoma * nodal or splenic marginal zone lymphoma * measurable disease * lymphoma specific therapy in the last four weeks * WHO performance grade 0, 1 or 2 Exclusion Criteria * Patients suitable for high dose therapy * Transformation in high grade lymphoma * Leukocytes \< 1,5/nl or platelets \< 100/nl (except due to lymphoma)",18.0,65.0,['indolent lymphoma']
NCT04293705,Congenital Disability and Rehabilitation: the TOPS Program,Congenital Disability and Rehabilitation of Cognitive and Behavioral Difficulties by Using the Teen Online Problem-Solving (TOPS) Program.,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * diagnosis of congenital disability due to brain malformation/syndrome Exclusion Criteria: * history of abuse * familiarity for psychiatric hospitalization,11.0,19.0,['congenital disorders']
NCT03399305,Safety and Efficacy of Apixaban in Severe Renal Impairment,Safety and Efficacy of Apixaban in Severe Renal Impairment,WITHDRAWN,OBSERVATIONAL,ALL,Inclusion Criteria: * Patients with creatinine clearance \<15 mL/min who are on anticoagulation with apixaban or warfarin. Exclusion Criteria: * Patients without end stage renal disease who are not on anticoagulation with apixaban or warfarin.,18.0,65.0,"['renal disease, end stage', 'anticoagulant-induced bleeding']"
NCT00593905,Pharmacogenomics in Pulmonary Arterial Hypertension,Pharmacogenomics in Pulmonary Arterial Hypertension: A Multi-Center International Study to Determine Whether in PAH Patients Clinical Associations Exist Between the Efficacy and Toxicity of Endothelin Receptor Antagonists and Several Gene Polymorphisms in Several Key Disease-Specific and Therapy Specific Genes,WITHDRAWN,OBSERVATIONAL,ALL,"Inclusion Criteria: GROUP 1 * Patients have to be currently enrolled or previously enrolled in STRIDE FPH01, FPH01-XC FPH02, FPH02x, FPH03, FPH04 or FPH06. * WHO Group 1 Pulmonary Arterial Hypertension: Idiopathic, Familial, Associated with (APAH) Collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, Drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy) Associated with significant venous or capillary involvement, Pulmonary veno-occlusive disease, Pulmonary-capillary hemangiomatosis. GROUP 2 * Patients currently receiving bosentan or ambrisentan OR who have previously received bosentan or ambrisentan for greater than 4 (four) months. * WHO Group 1 Pulmonary Arterial Hypertension: Idiopathic, Familial, Associated with (APAH), collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, or splenectomy), associated with significant venous or capillary involvement, pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis. Exclusion Criteria: GROUP 1 * Not enrolled in the Encysive Pharmaceutical's STRIDE study(sitaxsentan). * Known infectious disease (HIV, Hepatitis). GROUP 2 * Never enrolled in the STRIDE study for sitaxsentan patients. * Not currently or previously on bosentan or ambrisentan. * Patients who were previously on bosentan or ambrisentan must have been on bosentan or ambrisentan for greater than 4 months. * Known infectious disease (HIV, Hepatitis).",18.0,65.0,"['pulmonary arterial hypertension', 'pulmonary hypertension', 'pah who group i']"
NCT05843305,A Study of BPI-452080 in Subjects With Solid Tumors,"A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-452080 in Subjects With Solid Tumors",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Histologically or cytologically confirmed locally advanced or metastatic solid tumor patients, who had disease progression after standard therapy, intolerable to standard therapy, refuse to standard therapy or for whom no standard therapy exists * Dose expansion phase: Arm1：has locally advanced or metastatic ccRCC and has progressed during treatment with at least one prior therapeutic regimen Arm2：Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma Arm3：Other solid tumors * Adequate organ function * Evaluable lesion required for dose escalation phase and at least 1 measurable lesion required for dose expansion phase Exclusion Criteria: * Has received prior treatment with another HIF-2α inhibitor * Inadequate wash-out of prior therapies described per protocol, which may include anti-tumor therapies, tumor adjuvant drugs, organ or stem cell transplantation, moderate or strong CYP3A inhibitor or inducer, etc * Patients with major surgery within 4 weeks, severe or unstable systemic disease, unstable/symptomatic CNS metastasis, other malignant tumors, ILD, clinical significant cardiac disease, bleeding or embolic disease, active infectious disease, or other medical or psychiatric condition that might interfere with participation in the trial or interfere with the interpretation of trial results, in the opinion of the investigator or medical monitor * Pregnancy or lactation",18.0,65.0,"['solid tumor', 'renal cell carcinoma', 'von hippel-lindau disease']"
NCT00723905,Remicade Infusion Management Program,Remicade Infusion Management Program,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * Subject is a good candidate to receive infliximab as per the Product Monograph * Subject is prescribed infliximab by an appropriate physician * Subject receives infusion in a community infusion centre. * Subject has signed the approved consent form. Exclusion Criteria: * Not specified in the protocol,18.0,65.0,"['crohn disease', 'arthritis, rheumatoid']"
NCT01242605,"ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer","ABC-04 a Phase 1B Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * A histopathological or cytological diagnosis of non-resectable, recurrent or metastatic biliary tract (intra- or extra-hepatic), gallbladder or ampullary carcinoma * ECOG performance status 0, 1, or 2 * Age ≥ 18 * Estimated life expectancy \> 3 months * Adequate haematological function: * Haemoglobin 9g/dL (prior transfusions for patients with low haemoglobin are allowed) * WBC \>/= 3.0 x 10\*9/L * Absolute neutrophil count (ANC) \>/= 1.5 x 10\*9/L * Platelet count \>/= 100 x 10\*9/L * Adequate liver function: * Total bilirubin ≤1.5 x upper limit of normal (ULN) OR ≤ 3.0 x upper limit of normal (ULN) if stable for a duration of two weeks * ALT and/or AST \& alkaline phosphatase ≤ 5 x ULN * Adequate renal function: * Serum urea and serum creatinine \ /= 45 mL/min. If the calculated GFR is below 45ml/min, isotope EDTA confirmation of adequate renal function is required * Capable of giving written informed consent * Prior therapy is allowed (provided there has been a full recovery): * Surgery (non-curative operation), must have evidence on nonresectable disaes progression prior to trial entry * Radiotherapy, must have clear evidence of disease progression prior to inclusion * Prior adjuvant chemotherapy is allowed provided neither gemcitabine nor cisplation were used and treatment was completed 28 days prior to trial entry. Exclusion Criteria: * Any prior exposure to MEK, Ras, or Raf inhibitors * Cardiac conditions as follows: * Uncontrolled hypertension (BP ≥150/95 despite optimal therapy) * Heart failure (NYHA Class II or above) * Prior or current cardiomyopathy * Baseline LVEF ≤50% * Atrial fibrillation with heart rate \>100 bpm * Unstable ischaemic heart disease (MI within 6 months prior to starting treatment, or angina requiring use of nitrates more than once weekly). * Incomplete recovery from previous surgery. * Patients undergoing current treatment with curative intent. * History of prior malignancy that could interfere with the response evaluation (exceptions include in-situ carcinoma of the cervix treated by cone-biopsy/resection, non-metastatic basal and/or squamous cell carcinomas of the skin, any early stage (stage I) malignancy adequately resected for cure greater than 5 years previously). * Any evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial. * Any psychiatric or other disorder (e.g brain metastases) likely to impact on informed consent. * Pregnancy or breast-feeding. Women of child-bearing potential should must have a negative pregnancy test prior to study entry AND be using an adequate contraception method, which must be continued for 3 months after completion of chemotherapy * NB. Whilst not excluded, patients with significant impaired hearing must be made aware of potential ototoxicity and may choose not to be included. If included, baseline audiograms are recommended and should be followed by repeat audiograms prior to cycle 2.",18.0,65.0,"['biliary tract neoplasms', 'cholangiocarcinoma', 'gallbladder neoplasms']"
NCT02454205,An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis,Evaluating a New Treatment Regimen for Patients With Multidrug-resistant TB (MDR-TB) - a Prospective Open-label Randomised Controlled Trial,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Newly diagnosed culture and/or GeneXpert positive pulmonary TB. * Rifampicin resistance detected using at least two susceptibility testing assays (GeneXpert, HainMTBDRplus or phenotypic) using a sputum sample during screening. * Provide written informed consent prior to all trial-related procedures including HIV testing. * Male or female aged 18 years and older. * Body weight between 40 and 90 kg, inclusive. * Women of non-childbearing potential or participants of either sex who are using or willing to use effective methods of birth control Exclusion Criteria: * A participant who in the opinion of the investigator is unlikely to cope with regular visits to the trial site either because of travel constraints, or because of drug or alcohol abuse, or other reason. * Known at screening to have XDR-TB or pre-XDR-TB (i.e. fluoroquinolone or second-line injectable drug (SLID) resistance i.e. to capreomycin, amikacin and kanamycin). * Previous history of treatment for MDR-TB or XDR-TB or previous treatment with bedaquiline. * Currently on MDR-TB treatment for more than 2 weeks. * Any participant with a Karnofsky score \ 1.4 times ULN) * Hemoglobin level grade 4 (HB \ 5 times ULN) * Total bilirubin grade 3 or worse (\>2.5 times ULN) * Specific prior or concurrent medication/treatments (see Restrictions section below, Table 3). * Rifampicin monoresistant TB. * Fluoroquinolone and/or SLID resistance. Although in South Africa, the standard of care does not single out MDR-TB with fluoroquinolone or aminoglycoside resistance at initiation of MDR-TB treatment, in this study the Hain MTBDRsl LPA will be used on the sputum sample to exclude any pre-XDR and XDR cases from participation in the study (results from the LPA and phenotypic DST testing on the isolate will be available 3-6 weeks later). All inclusion and no exclusion criteria must be met prior to enrolment and randomisation. Whenever the investigator has reason to suspect that there might be a health problem (other than TB) participation should only be considered after discussing the case with the medical monitor. Note: Participants who are currently on, or have previously been on drug-sensitive TB treatment are not excluded from participation. Post-randomisation exclusion criteria: • Fluoroquinolone and/or SLID resistance detected on DST using the isolate. Note: A woman who falls pregnant during the treatment phase of the trial will not be excluded but will be counselled regarding potential termination of pregnancy.",18.0,65.0,"['tuberculosis', 'multidrug resistant tuberculosis', 'extensively-drug resistant tuberculosis']"
NCT07292805,Bronchial Thermoplasty for Adults With Severe Asthma in the Biologic Era,Bronchial Thermoplasty (BT) for Severe Asthma in the Biologic Era: a Randomized Controlled Trial (BOOSTER Trial),RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * adult (\>18 years) * severe uncontrolled asthma (defined as ACQ above 1.5) despite optimal medical therapy (GINA treatment step 5; alternative diseases excluded, therapy compliance and adequate inhalation technique confirmed) * 1 or more trials of treatment with a biologic or ineligible for biologic treatment * 2 or more severe asthma exacerbations in the previous year (defined as the need for a course of OCS or doubling dose of maintenance OCS for at least 3 consecutive days) * FEV1 ≥ 50% predicted after 400μg inhaled salbutamol or equivalent Exclusion Criteria: * chronic OCS therapy at a dose \>20 mg/day prednisone equivalent * 1 or more ICU admission for mechanical or endotracheal intubation for * asthma in the previous year. * anti-coagulation therapy that cannot be stopped temporarily * pregnancy * body mass index ≥35 * current or ex-smokers with \>20 pack years * DLCOc \<70% * Subject has a known sensitivity to medications required to perform bronchoscopy * Subject is using immunosuppressant therapy other than oral steroid therapy that impact on BT * Subject has bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/mm2 or known coagulopathy * Comorbidities that are a contra-indication for BT such as severe heart failure and other respiratory diseases including bronchiectasis, interstitial lung disease, emphy-sema, cystic fibrosis, mechanical upper airway obstruction, Churg-Strauss syndrome, and allergic bronchopulmonary aspergillosis (ABPA) * Subject uses an internal or external pacemaker or cardiac defibrillator..",18.0,65.0,"['asthma exacerbations', 'severe asthma', 'bronchial thermoplasty']"
NCT01420705,Bacille Calmette-Guérin (BCG) Vaccine and Atopy,The Effect of Giving BCG Vaccine at Birth to Low Birth-weight Infants on Development of Allergy and Asthma in Childhood - Follow up of a Randomised Trial in Guinea-Bissau,COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * Previous enrolment in NCT00146302 * Living within Bandim Health Project study area Exclusion Criteria: * Children with known history of anaphylaxis * Children with skin infections or severe skin conditions for who SPT could not be reliably performed * Children currently taking anti-histamine medication,3.0,9.0,"['asthma', 'eczema', 'food hypersensitivity']"
NCT07160205,"Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)","A Phase 2-Phase 3, Double-blinded, Randomized, Dose-repeating, Cross-over Study to Assess the Safety and Efficacy of Allogeneic ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM)",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Participants will be ≥18 years old. 2. Diagnosis of idiopathic inflammatory myositis (IIM) based on 2017 EULAR/ACR Classification Criteria for adult IIM, corresponding to a score of ≥ 5.5 (≥ 6.7 with muscle biopsy). 3. Active disease as defined by any one of the following test results: 1. Elevated Creatine Kinase (CK) or Aldolase (more than 1.5 x the upper limit of normal) at screening, OR 2. MRI positive for active, muscle inflammation within 12 weeks prior to screening, OR 3. EMG read as active myositis within 12 weeks prior to screening, OR 4. muscle biopsy obtained within 12 weeks of the screening showing active inflammatory disease. 4. Muscle weakness or active cutaneous manifestations of dermatomyositis assessed at Screening and documented with either of the following scores: 1. Bilateral MMT-8 score of ≤142/150, OR 2. CDASI Total Activity score of ≥ 7. 5. Participants must be receiving standard of care treatment with one or more immunosuppressants or at least 5 mg prednisone (or corticosteroid equivalent). 1. Immunosuppressive doses should be stable for at least 12 weeks prior to enrollment. Participants must remain on stable immunosuppressive therapy for the duration of the trial unless discontinuation is warranted due to toxicity or another clinical reason. 2. Hydroxychloroquine (HCQ) doses should be stable for at least 12 weeks prior to enrollment. 3. Steroid doses should be stable for at least 4 weeks prior to enrollment. At screening and enrollment, maximum dose allowed is 25 mg/day prednisone (or corticosteroid equivalent). 4. Allowed immunosuppressants include: methotrexate, azathioprine, mycophenolate, cyclosporine, IVIG, and others to be evaluated at the discretion of the investigator. 6. Participants will either be: 1. positive for a myositis-associated antibody, OR 2. will have undergone evaluation to exclude mimics, as deemed appropriate by the Investigator. Note: The minimum workup to be performed on all prospective participants to exclude mimics is as standardly followed, which may include: * Medical history and physical exam to determine the clinical course and progression of symptoms, the distribution of weakness, and the absence of features of myelopathy, neuropathy, neuromuscular disease, myotonic dystrophy, and congenital myopathy; * Elevated Creatine Kinase (CK) or Aldolase levels in blood; * Electromyography (EMG) and/or MRI of clinically affected 99+proximal muscle group; * Myositis-specific and myositis-associated autoantibodies in blood; * Muscle biopsy with characteristic features of IIM and excluding features of muscular dystrophy, metabolic myopathies, drug-induce myopathy, inclusion body myopathy, and necrotizing myopathy; * Blood tests for exclusion of HIV, Hepatitis B (HBV), and Hepatitis C (HCV). \[Screening tests are done for HIV ELISA, HBs Ag, HBc Ab, and HCV Ab with reflex for HCV RNA (PCR) for exclusion criteria.\] 7. Adequate pulmonary function, defined as saturated oxygen (SpO2 ≥ 94%) on room air. 8. Left ventricular ejection fraction (LVEF) ≥ 30% as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed within 8 weeks prior to Screening. 9. Participants must have the ability to comply with the requirements of the study. 10. All participants of reproductive age/capacity will be required to use adequate contraception, defined as at least one form of a highly effective contraceptive (i.e., condoms, hormonal birth control, IUD), with any partners during the study period and for at least three months beyond the study period, for safety. 11. Participant will have the ability to understand and provide written informed consent. Exclusion Criteria: The presence of any of the following criteria excludes a participant from study enrollment: 1. A diagnosis of inclusion body myositis, juvenile DM or PM, myositis in the context of significant autoimmune rheumatologic disease. 2. Diagnosis of IIM as part of an overlap syndrome (except overlap with Sjogren's syndrome). 3. Initiation of Rituxan (rituximab) treatment within 12 weeks of randomization. If participant is already on Rituxan, they must remain on a stable dose throughout the trial. 4. Use of other biologic or investigational drug within 6 half-lives for the agent. 5. Diagnosis of myositis-associated interstitial lung disease or cardiac involvement sufficient to limit participation in the trial in the discretion of the PI. 6. End-stage IIM with irreversible muscle involvement seen on biopsy. 7. Patients with predominant muscle atrophy secondary to uncontrolled or chronic DM or PM, based on clinical, biochemical, and/or radiologic assessment, despite previous optimized treatment. 8. Non-immune myopathies. 9. Cancer associated with myositis. 10. Hypersensitivity to study product components including history of hypersensitivity to dimethyl sulfoxide (DMSO). 11. Pregnant or lactating participants. 12. Concomitant severe cardiac, pulmonary disease, active infection, or other conditions that preclude assessment of safety and efficacy of the study product. 13. Anticipated need for surgery during the trial period. 14. A history of prevalent noncompliance with medical therapy. 15. Recipient of an organ transplant. 16. Neutropenia \[absolute neutrophil count \<1,800/mm\^3 (or \<1,000/mm\^3 in African-American participants)\]. 17. Severe impairment in renal function (estimated glomerular filtration rate \<30 ml/kg\*min). 18. Recent or planned use of vaccination with live attenuated viruses. 19. Active cancer or prior diagnosis of cancer within the past 2 years, except non-melanoma skin cancer and carcinoma in situ of cervix Potential participants diagnosed with IIM \<3 years before screening will have mandatory evaluation for cancer. 20. Participants with current or prior hepatitis B infection that could be at risk for reactivation. \[For eligibility, screening test results must be HBsAg (DNA) negative and anti-HBc (core antibody total) negative).\] 21. Participant with HIV or active Hepatitis C. \[For eligibility, the following screening tests must have negative or non-reactive results: HIV ELISA, HCV Ab with reflex for HCV RNA (PCR); if HCV Ab test is positive, exclude if HCV RNA (PCR) is positive.\] 22. Condition that would impair an assessment of muscle strength, including neurological disorders such as Parkinson's disease or severe musculoskeletal condition. 23. Any other condition that, in the judgment of the Investigator or Sponsor, would be a contraindication to enrollment, study product administration, or follow-up.",18.0,65.0,"['idiopathic inflammatory myositis (iim)', 'dermatomyositis or polymyositis']"
NCT00580905,Role of Adenosine in the Release of VEGF and Cytokines,Role of Adenosine in the Release of VEGF and Cytokines,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age 18-60 yr. * All potential volunteers will have routine blood test to screen for hepatic, renal, and hematological abnormalities. * Body mass index \< 27 Kg/m2 . * Female volunteers of childbearing potential will undergo HCG pregnancy test at screening and again on the study day. Exclusion Criteria: * Pregnancy females * Subjects unable to give voluntary informed consent * Subjects on anticoagulant drugs or anemic * Subjects with a recent medical illness * Subjects with a history of coronary heart disease * Subjects with known kidney or liver disease * Subjects with history of asthma * Recent (past three days) use of phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil or vardenafil) * History of intolerance to adenosine or nitroprusside * History of methemoglobinemia * Use of theophylline products * Subjects with hematological abnormalities",18.0,60.0,['inflammation']
NCT02664805,"Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema","A Phase 2a, Proof of Concept Trial, Testing Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Clinical diagnosis of chronic hand eczema with or without atopic etiology/background with a history of not adequately controlled disease activity with cutaneously applied steroid * Physician's Global Assessment of disease severity graded as at least mild at Visit 1 * In overall good health including well controlled diseases Exclusion Criteria: * Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), retinoids (e.g. alitretinoin) or corticosteroids within 6 weeks prior to randomization (inhaled or intra-nasal steroids corresponding to up to 1 mg prednisone for asthma or rhinitis may be used). * PUVA (Psoralen Ultraviolet A) or UVB (Ultraviolet B) therapy on the hands within 4 weeks prior to randomization * Cutaneously applied treatment with immunomodulators (pimecrolimus, tacrolimus) or corticosteroids on the hands within 2 weeks prior to randomization. * Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 2 weeks prior to randomization * Concurrent skin diseases on the hands * Current diagnosis of exfoliative dermatitis * Significant clinical infection (impetiginized hand eczema) on the hands which requires antibiotic treatment * A marked abnormal ECG at baseline * Known hepatic dysfunction or hepatic dysfunction tested at Screening * Current participation in any other interventional clinical trial",18.0,65.0,['hand eczema']
NCT05740605,Implementation of a HABIT-ILE Intervention at Home for Children With Bilateral Cerebral Palsy,Implementation of a HABIT-ILE at Home Intervention for Children With Bilateral Cerebral Palsy: a Non-inferiority Randomized Controlled Trial,RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: * Children with confirmed diagnosis of bilateral Cerebral Palsy * Age 5 to 18 years old * Ability to interact and understand simple instructions in order to complete assessments and therapy * Availability of a caregiver for 6h30 per day during two weeks of therapy Exclusion Criteria: * Uncontrolled seizure * Botulinum toxin injection in the last 6 months before the first assessment or during the therapy * Intensive therapy in the last 6 months before the first assessment or during the therapy * Surgery that could affect the assessments or therapy in the last 6 months before the first assessment or during the therapy * Severe visual or cognitive impairments interfering with treatment and or assessments * Any typical contraindication for MRI,5.0,18.0,['cerebral palsy']
NCT03035994,Effect of Altered Mechanical Loading in ACLR,Effect of Altered Mechanical Loading on Lower Extremity Biomechanics and Biochemical Markers in Individuals With an Anterior Cruciate Ligament Reconstruction,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Have a history of a primary, unilateral ACLR using either a hamstring or patellar tendon autograft, cleared by a physical for full return to physical activity with no limitations, and participate in at least 30 minutes of physical activity 3 times per week Exclusion Criteria: * History of injury to either leg, other than ACLR (e.g. ankle sprain, muscle strain), within 6 months prior to participation in the study, history of lower extremity surgery other than ACLR, history of osteoarthritis or current symptoms related to knee osteoarthritis (e.g. pain, swelling, stiffness), currently pregnant, or planning to become pregnant while enrolled in the study, cardiovascular restrictions that limit the participant's ability to participate in physical activity.",18.0,35.0,['anterior cruciate ligament reconstruction']
NCT07101094,Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU),Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU),RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * Aged ≥18 years at index date. * Have a confirmed diagnosis of schizophrenia before index date. * Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy. * Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines. * Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish). * English or Spanish speaking. Exclusion Criteria: * Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening. * Evidence of use of XT prior to time of eligibility screening.",18.0,65.0,['schizophrenia']
NCT01347294,Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations,Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Clinical diagnosis of Venous malformation * Must be able to fill in questionary form * Must be able to sign informed consent form Exclusion Criteria: * Kidney disease * Lung disease * Pregnancy or not willing to safe contraception * Allergy to Bleomycin or Fibrovein,12.0,80.0,['venous malformation']
NCT01858194,REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation,REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * ≥ 18 years of age * Structural heart disease (post-MI, dilated cardiomyopathy, sarcoid myopathy, hypertrophic cardiomyopathy, chagas-related cardiomyopathy, etc.) * Planned for catheter-based ablation of VT * All patients will have an existing ICD * Accessibility of renal vasculature (determined by renal angiography) * Ability to understand the requirements of the study * Willingness to adhere to study restrictions and comply with all post- procedural follow-up requirements Exclusion Criteria: * MI or CVA within 30 days * Coronary Artery Bypass Graft (CABG) within 30 days of this procedure * Known renovascular abnormalities that would preclude RSDN (eg, renal artery stenosis) * GFR \<30 ml/min (unless receiving dialysis) * Life expectancy \<1 year for any medical condition * Any condition resulting in a contraindication to anticoagulation (e.g. GI bleeding) * Inability to give informed consent * Known pregnancy or positive -HCG within 7 days of procedure.",18.0,65.0,['ventricular tachycardia']
NCT01202994,Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET,Practice Effects and Amyloid Imaging Using 18F-PIB (18F-39-F-6-OH-BTA1) Known as [18FGE067]) or Flutemetamol PET and FDG-PET,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Subjects must be currently enrolled in an NIA-sponsored, community-based study of practice effects in non-demented adults age 65 and older living independently (NIA #5K23AG028417-05) Exclusion Criteria: * History of neurological disease known to affect cognition (e.g., stroke, head injury with loss of consciousness of \>30 minutes, seizure disorder, demyelinating disorder, mental retardation, etc.) * Dementia based on DSM-IV criteria * Current or past major psychiatric illness (e.g., schizophrenia, bipolar affective disorder) * 30-item Geriatric Depression Score \>14 * Evidence of stroke or mass lesion on CT or MRI scan * History of alcoholism or other substance abuse * Current use of cholinesterase inhibitors, other cognitive enhancers, antipsychotics, or anticonvulsant medications * History of radiation therapy to the brain * History of significant major medical illnesses, such as cancer or AIDS * Uncontrolled diabetes or blood glucose \>180 mg/dl on the day of the FDG-PET scan * Currently pregnant",65.0,65.0,"[""alzheimer's disease""]"
NCT06357494,Assessment of Thyroid Doppler Ultrasound in Followup of Pediatric Graves' Disease,Assessment of Thyroid Doppler Ultrasound in Relation to Clinical and Laboratory Parameters in Follow up of Pediatric Graves' Disease,NOT_YET_RECRUITING,OBSERVATIONAL,ALL,Inclusion Criteria: * All newly diagnosed children with clinical and laboratory hyperthyroidism (high T4 \& low TSH) with positive TRAbs. Exclusion Criteria: * Patients receiving radioiodine Patients underwent thyroid surgery History of neck radiation or neck surgery,1.0,18.0,"[""graves' disease""]"
NCT04979494,Association Between SMA Flow and AGI in Critically Ill Patients,Association Between Blood Flow of Super Mesenteric Artery (SMA) and Acute Gastrointestinal Injury (AGI) Using Point-of-care Ultrasound in Critical Care Unit,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: 1. 18 \~ 80 years old; 2. Under deep sedation (RASS score ≤ -3) with mechanical ventilation at the time of enrollment; 3. Acute Physiology and Chronic Health Evaluation II (APACHE-II) score ≥8. Exclusion Criteria: 1. Pregnancy; 2. Recent gastrointestinal surgery; 3. History of acute or chronic gastrointestinal dysfunction before ICU admission; 4. Primary or secondary vascular malformation of SMA; 5. Any contraindication to the use of ultrasound evaluation (e.g., abdominal incision).",18.0,80.0,"['gastrointestinal dysfunction', 'critical illness']"
NCT00493194,Fibrosis in Renal Allografts,"Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic)",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Recipients of a renal allograft, with a minimum age of 18 years. 2. Male or female recipients. Women of child-bearing age must practice adequate contraception 3. For renal allografts from living donors, at least one HLA-mismatch is required. 4. Written informed consent, compliant with local regulations. Exclusion Criteria: 1. Recipients of a second or third renal allograft, with a past history of graft failure due to rejection. 2. Recipients of a renal allograft from a haplotype-identical living donor or a non-heart beating donor. 3. Cold ischemia time \> 24 hours 4. Recipients of a kidney from donors ≥ 65 years of age 5. Recipients of multiple organs. 6. Pregnant women. 7. Immunological high-risk recipients, defined as current or historical PRA \> 50 % 8. Recipients with focal segmental sclerosis as primary renal disease. 9. Recipients with leucopenia (WBC \ 300 mg/dl or Triglycerides \> 300 mg/dl) 10. Previous history of malignancy, except completely excised basocellular skin tumor 11. Chronic active infection. 12. Inadequate compliance to treatment. 13. Use of specific drugs: Terfenadine, pimozide, astemizole, fluconazole, ketoconazole and cimetidine.",18.0,65.0,"['kidney failure, chronic', 'transplantation', 'immunosuppression', 'interstitial fibrosis']"
NCT06400394,Impact of Surgical Site Infection in Peritonitis After Peritoneal Lavage With Super-oxidixed Solution,"Impact of Surgical Site Infection in Peritonitis After Peritoneal Lavage With Super-oxidixed Solution: A Randomised Double-Blind, Placebo-controlled Trial",NOT_YET_RECRUITING,INTERVENTIONAL,ALL,Inclusion Criteria: 1. Patients age 13yrs and above 2. Diagnosed with perforated viscus intraoperatively 3. Undergo Midline Laparotomy 4. ASA 3 and below Exclusion Criteria: 1. Surgical technique: Laparoscopic washouts 2. Patients on steroid treatment and immunosuppressant therapy. 3. More than ASA 3 4. Inability to give/understand informed consent 5. Revision-surgery (previous abdominal surgery within the last 30 days) 6. Planned re-laparotomy within 30 days 7. Terminal kidney failure requiring dialysis 8. Concurrent abdominal wall infections,13.0,65.0,['surgical site infection']
NCT03269994,Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?,"A Phase III Multicenter, Open Label Randomized Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age \>/= 18 years * Patients undergoing elective pancreatoduodenectomy (PD) for any diagnosis/indication Exclusion Criteria: * Patients undergoing a minimally invasive PD, such as laparoscopic or robotic PD * Patients with known and documented allergies to any of the penicillins, cephalosporins, or β-lactamase inhibitors * Patients who are otherwise ineligible to receive the antibiotics in this study * Patients highly unlikely to undergo PD according to the surgeon's judgment, such as conditions amenable to pancreas enucleation, ampullectomy, etc. * Patients with long-term glucocorticosteroid use. The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular) * Patients unable to provide informed consent * Creatinine clearance (CrCl) \</= 40 mL/min * Patients receiving hemodialysis or peritoneal dialysis * Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test * Patients with a known bacterial infection present at the time of surgery or who received antimicrobial therapy within 7 days prior to surgery",18.0,65.0,"['pancreatic cancer', 'pancreas cancer', 'pancreatic diseases']"
NCT04248894,Impact of Interval Training on Sympathetic Hyperactivity and Vascular Function,The Impact of High-intensity Interval Training Versus Moderate Continuous Training on Neurovascular Control in Patients With Heart Failure,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Functional Class II to III of New York Heart Association * Left ventricular ejection fraction ≤40% * Peak oxygen uptake (V̇O2) \ 30 kg/m2 * History of smoking,30.0,65.0,['heart failure']
NCT03080194,The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia,"The Effect of a Community-based Long-acting Antipsychotic-treated Management Model on the Violence Risk of Patients With Schizophrenia: a 1-year, Open-label Randomized Controlled Study",UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Diagnosed as schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition (DSM-V) and rated under 70 in PANSS; * Had violent behavior such as smashing or breaking, threatening with a weapon, commiting arson or explosion in the past one year, whether the behavior can be stopped by persuading or not; * Living with a guardian or a caregiver; * Informed consent from the patients or their guardians; * Resulted negative in urine pregnancy test if female at their reproductive age; female subjects must take effective measures to prevent pregnancy during the whole study or have been postmenopausal. Exclusion Criteria: * Patients who have had suicidal ideation or suicidal attempts within 12 months before screening or in screening period; * Intravenous drug abuse or Opioid dependence within 3 months before screening; * Patients with treatment-resistant schizophrenia; * Large dose of Clozapine (≥200mg/day) or other long-acting injectable antipsychotics used within 3 months or within 2 drug half-life periods before screening; * Patients with any severe or unstable cardiovascular, respiratory, nervous system or other system diseases; clinically significant abnormality in laboratory examinations or ECG; * Communication difficulties caused by cognitive impairment or unable to complete the assessments in the study; * Patients assessed as unsuitable for the study in other reasons, such as allergic or intolerant to risperidone or paliperidone, resistant to risperidone or paliperidone (ineffective after adequate dosage and duration in medical history); unable to provide informed consent; historical treatments which might effect the results of the study; historical neuroleptic malignant syndrome or tardive dyskinesia.",18.0,60.0,['schizophrenia']
NCT00967694,Effect of Nitrous Oxide (N2O) on Intraocular Pressure in Healthy Volunteers,Effect of N2O on Intraocular Pressure in Healthy Volunteers,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Adults aged 18-40 * American Society of Anesthesiologists Physical Classification System (ASA) Status 1-2 * Nil per os (NPO) prior to study (2 hrs clear liquids, 4 hrs milk, 6 hrs light food, 8 hrs heavy/greasy food) Exclusion Criteria: * Lack of volunteer consent * Pregnancy * History of features suggestive of a difficult airway on pre-anesthetic evaluation and physical examination * Active gastroesophageal reflux disease * Active obstructive sleep apnea * History of recent trauma * History of pneumothorax or lung cyst * History of Vitamin B12 deficiency * History of recent middle ear surgery (\<3months) * Current or recent (\<3 weeks) respiratory tract infection * Any acute illness or exacerbation of chronic illness such as asthma, chronic lung disease etc. * Any history of cardiac ischemia (angina), myocardial infarction, or cardiac dysrhythmia. * Myopia greater than -3 spherical equivalents or hyperopia greater than +3 spherical equivalents * History of eye surgery of any sort, including refractive surgery, cataracts, and vitrectomy * History of any ocular disease or infection",18.0,40.0,"['glaucoma', 'sedation']"
NCT01460394,Normative Data of Brain Network Activation in Adolescents and Young Adults,Establishment of Normative Data of Brain Network Activation (BNA) Using Evoked Response Potentials in Adolescents and Young Adults,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Age 15-24 years. * Willingness to participate and able to give informed assent (child) and/or consent (parent for minors or adult 18+ years of age for self). Exclusion Criteria: * Currently participate in a contact sport (e.g., football, hockey, soccer, rugby, lacrosse, martial arts). * Currently with lice, open wounds on scalp. * Any chronic disease. * Any psychiatric disorder, e.g., depression, bipolar disorder, schizophrenic disorder, etc. * Any CNS neurologic disorder, e.g., epilepsy, seizures, etc. * Any neuropsychological disorders, e.g.: ADHD, Autistic Spectrum Disorder (ASD), etc. * History of Special education, e.g., reading disorder (dyslexia), writing disorder (dysgraphia), math disorder (dyscalculia), nonverbal learning disorder. * History of any medication affecting CNS within the last 3 months, e.g., antidepressants, anticonvulsants, psychostimulants, first generation antihistamines, etc. * Substance abuse in the last 3 months. * Significant sensory deficits, e.g., deafness or blindness. * History of any brain trauma.",15.0,24.0,['healthy controls']
NCT07097194,Be A Quitter: Illinois Small Business EX Program Dissemination,Be A Quitter: Illinois Small Business EX Program Dissemination,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Resident of Illinois * 18 years of age or older * Current tobacco user * Seeking to quit tobacco use and willing to participate in the EX program * Willing to answer surveys at 5 occasions over the course of a year * Employed at collaborating business in Illinois Exclusion Criteria: * Not employed at collaborating business in Illinois,18.0,120.0,['tobacco use']
NCT05161494,Gait in Rare Diseases,"Identification of Gait Disorders in Children, Adolescents and Young Adults With Rare Genetic Diseases",ACTIVE_NOT_RECRUITING,OBSERVATIONAL,ALL,Inclusion Criteria: * diagnosed with tuberous sclerosis complex according to the criteria of Northrup et al. (2012) * aged 6 years or older * being able to walk without aids for a minimum distance of 6 meters Exclusion Criteria: * severe epileptic seizure (status epilepticus or tonic-clonic insult over 3 min) within the 24 hours before the assessment * insufficient cooperation to perform 3D gait analysis,6.0,25.0,"['tuberous sclerosis', 'stxbp1 encephalopathy with epilepsy']"
NCT01747694,Respiratory Muscle Exercise Training in COPD Patients,The Effectiveness of Multi-respiratory Muscle Training on Respiratory Function in Patients With COPD,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Clinical diagnosis of Chronic Obstructive Pulmonary Disease * Must be stable * Never participate in respiratory muscle trainig program Exclusion Criteria: * Infection or acute excerbation condition * Abdominal surgical * Severe neuromuscular, cardiac disease or dementia",40.0,80.0,['copd']
NCT00096694,Effect of an Intrauterine Contraceptive Device (IUD) in HIV Infected Women,A Pilot Study Evaluating the Effect of the Levonorgestrel-Releasing Intrauterine Device on Genital HIV Shedding in HIV-1-Infected Women,COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * HIV infected * Willing and able to delay initiation or reinitiation of antiretroviral therapy until after Week 4 study visit * Unlikely to develop a clinical indication to start antiretroviral therapy within 4 weeks of study entry * CD4 count of 200 cells/mm3 or more * Viral load of 10,000 copies/ml or more within 90 days prior to study entry * Endocervical viral load of 2,500 copies/ml or more within 90 days prior to study entry * History of prior pregnancy lasting at least 20 weeks * Willing to continue any current use of hormonal contraceptives, except medroxyprogesterone acetate, until after Week 4 study visit * Start of last menstrual period within 7 days prior to study entry Exclusion Criteria: * Antiretroviral medications within 90 days prior to study entry * AIDS diagnosis, including CD4 count of less than 200 cells/mm3 * Cervicitis, bacterial vaginosis, trichomoniasis, or symptomatic vaginal candidiasis within 90 days prior to study entry. Participants with any of these infections within 90 days prior to study entry are not excluded if they have received appropriate treatment and have documented resolution of the infection. * Acute or history of pelvic inflammatory disease, chlamydia, or gonorrhea in the year prior to study entry * Abnormal Pap smear requiring treatment in the year prior to study entry * History of ectopic pregnancy or a condition that would predispose the participant to ectopic pregnancy * Known uterine anomaly, including fibroids * Known or suspected breast cancer * Acute liver disease or liver tumor * Have previously inserted IUD that has not been removed * Fungal infection in the genitals * Genital bleeding of unknown cause * Endometritis or infected abortion within 90 days of study entry * Known allergy or hypersensitivity to any component of the IUD used in this study * Current drug or alcohol abuse that, in the opinion of the investigator, may interfere with the study * Serious infection or other serious medical illness that is potentially life threatening and requires systemic therapy or hospitalization within 14 days of study entry * Use of etonogestrel and ethinyl estradiol vaginal ring (NuvaRing) within 30 days prior to study entry * Medroxyprogesterone acetate within 90 days prior to study entry * Pregnant or breastfeeding",18.0,65.0,['hiv infections']
NCT01524666,Nutritional Supplementation With Agmatine Sulfate During Small Fiber Neuropathy,Nutritional Supplementation With Agmatine Sulfate During Small Fiber Neuropathy,UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: * Men and Women Ages 18-75 with symptoms of small Fiber Neuropathy and have been diagnosed via autonomic function testing and or skin biopsy Exclusion Criteria: * Women who are pregnant or breast feeding, patients with history of substance abuse, and patients with myelopathy",18.0,75.0,['peripheral neuropathy']
NCT02110966,Mepivacaine-Tramadol on the Success of Inferior Alveolar Nerve Block in Symptomatic Irreversible Pulpitis,Efficacy of the Combination Mepivacaine-Tramadol on the Success of Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis: a Randomized Clinical Trial.,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Subjects diagnosed with symptomatic irreversible pulpitis in the first and second mandibular molars. Exclusion Criteria: * Pregnancy * Hypersensitivity to local anesthetics and Tramadol * Teeth with insufficient tooth structure for restoration, periodontal disease, root resorption, root fracture * Systemic diseases: diabetes, uncontrolled hypertension. * Patients taking drugs or narcotics. * Patients who have used analgesics in the last 8 hours. * Patients ingested IMAOS and tricyclic antidepressants 14 days before. * Patients ingested carbamazepine (anticonvulsants) * Patients in active treatment with ketoconazole and erythromycin.",18.0,50.0,['symptomatic irreversible pulpitis']
NCT05273866,The Effect of Virtual Reality Glasses on Pain on Intravenous Cannulatıon in Children,A Technological Intervention in Pain Control on Intravenous Cannulatıon in Children Virtual Reality Glasses: A Randomized Controlled Study,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * between the ages of 7-12, * Does not have a disease that causes chronic pain, * Not taking any analgesic medication in the last 8 hours before the procedure, * No mental or neurological disability, * Having no visual or auditory problems that prevent you from applying the scales or watching videos, * Does not have eye problems and/or does not use glasses to be able to wear VR glasses, * The first vascular access procedure was performed during this hospitalization at the clinic, * Vascular access opened on the first try, * Speaking and understanding Turkish, * Children whose parents and themselves agreed to participate in the study were included in the study. Exclusion Criteria: * Does not understand the Turkish language * the child is under 7 years old or 12 years older * having vision, hearing or speech problems * having a mental or neurological disability",7.0,12.0,"['pain, procedural']"
NCT06393166,Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer,"An Open-label, Single-arm, Multicenter, Phase II Clinical Study of the Efficacy and Safety of Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Patients With Untreated Advanced Pancreatic Cancer",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Voluntarily agree to participate in the study and sign the informed consent; 2. ≥18 years of age and ≤75 years of age on the day of signing the informed consent form, regardless of gender; 3. Pancreatic ductal adenocarcinoma confirmed by pathologic histology or cytology; 4. No prior systemic therapy for unresectable locally advanced or metastatic pancreatic cancer; 5. Measurable lesions at baseline according to RECIST 1.1 criteria; if the subject has only 1 measurable lesion at baseline, the area of the lesion must not have received radiotherapy in the past or there must be evidence of significant progression of the lesion after completion of radiotherapy treatment; 6. the ECOG physical status score was 0 or 1 and the Expected survival ≥12 weeks; 7. No serious organic diseases of the heart, lungs, brain and other organs; 8. Adequate organ function 1. Bone Marrow Function: (no transfusion within 14 days prior to screening, no use of granulocyte colony stimulating factor \[G-CSF\], no use of drug correction) : i. Hemoglobin ≥90g/L; ii. Leukocytes ≥ 4.0 x 109/L, Neutrophils ≥1.5×109/L; iii. Platelet ≥80×109/L; 2. Coagulation function: PT or APTT ≤ 1.5 x ULN in subjects not receiving anticoagulation; if subjects are receiving anticoagulation, as long as the PT is within the range of the anticoagulant drug formulation; 3. liver function: (no albumin infusion within 14 days prior to screening): Serum total bilirubin ≤ 1.5 x ULN (with biliary obstruction, allowing enrollment of subjects undergoing biliary drainage or in the midst of stenting therapy who have a total bilirubin ≤ 2.5 x ULN). In subjects without liver metastasis, Aspartate aminotransferase (AST), alanine aminotransferase (ALT)≤2.5×ULN; In subjects with liver metastasis, ALT and AST≤5×ULN, but without elevated bilirubin; 4. Renal function: serum creatinine ≤1.5 x ULN, creatinine clearance (CCr) ≥50 mL/min, urinary protein \ 10 mg/day prednisone or equivalent of other corticosteroid for ≥7 consecutive days) or immunosuppressive therapy within 14 days prior to enrollment in this study; with the exception of inhaled or locally applied hormones, or physiologic replacement doses of hormone therapy due to adrenal insufficiency; short-term (≤7 days) corticosteroids are allowed for prophylaxis (e.g., contrast allergy) or treatment of Non-autoimmune conditions (eg, delayed hypersensitivity reactions caused by exposure to allergens) ; 10. subjects with uncorrectable albumin decline (serum albumin \ 470 msec (women)/450 msec (men) \ , hypokalemia, long QT syndrome, atrial fibrillation with heart rate \>100 bpm at rest or severe cardiac valvular disease, history of medically significant arrhythmias); 19. unrecovered toxicity from prior antitumor therapy to CTCAE ≤ Grade 1 (NCI-CTCAE v5.0), except for baldness (any grade allowed) and peripheral neuropathy (recovery to ≤ Grade 2 required); 20. history of prior allogeneic bone marrow or organ transplantation; 21. prior history of allergic reaction, hypersensitivity reaction, intolerance to investigational drugs or similar medications; prior significant allergy to drugs or foods or other substances (e.g., severe allergic reaction, immune-mediated hepatotoxicity, immune-mediated thrombocytopenia, or anemia) 22. pregnant and/or lactating women; 23. other conditions that, in the opinion of the investigator, would affect the safety of or adherence to treatment with the study medication, including alcoholism, drug abuse, other serious illnesses (including psychiatric illnesses) that require comorbid treatment, the presence of serious laboratory test abnormalities, moderate to large amounts of plasmapheresis such as pleural fluid, pericardial effusion, ascites, and other concomitant familial or social factors, which would affect the safety of the patient;",18.0,75.0,['non-resectable pancreas carcinoma']
NCT05052866,Ryan Companion Robot for Assisting Elderly People With Alzheimer's Disease,Development of Ryan Companion Robot for Assisting Elderly People With Alzheimer's Disease,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * HAVING EARLY STAGE AD/ADRD AS ASSESSED BY THE SLUMS SCORE (BETWEEN 15-26), * VERBAL SKILL TO INTERACT, * BEING AVAILABLE FOR A PERIOD OF 8-10 WEEKS TO INTERACT WITH RYAN, * HEALTHY INDIVIDUALS WEIGHING AT LEAST 110 POUNDS (FOR SAFE COLLECTION OF BLOOD SAMPLES). Exclusion Criteria: * AGGRESSIVE BEHAVIOR * DIAGNOSTICS OF SEVERE DEMENTIA OR MEMORY LOSS * ACUTE PHYSICAL ILLNESS THAT IMPAIRS ABILITY TO PARTICIPATE * DURING THE STUDY IF A PARTICIPANT'S MID-STUDY SLUMS SCORE IS LESS THAN 15 (INDICATING MORE SEVERE DEMENTIA) AND/OR THE PHQ-9 IS EQUAL TO OR GREATER THAN 20, THE CUTOFF FOR SEVERE DEPRESSION, THE RESEARCHERS WILL REMOVE THE PARTICIPANT FROM THE STUDY * IF A PERSON IS UNCOMFORTABLE WITH BLOOD DRAW, HE/SHE IS EXCLUDED FROM THE STUDY.",65.0,65.0,"['alzheimer disease, early onset']"
NCT04363866,Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19),A Randomized-Control Pilot Study to Assess Hydroxychloroquine in Patients Infected With SARS-CoV-2 (COVID-19),WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Ability to understand and the willingness to sign a written informed consent document. 2. Individuals aged ≥ 18 years of all races and ethnic groups. 3. Must have documented positive test result for SARS-CoV-2 (COVID19), or high clinical suspicion for SARS-CoV-2 based on presence of typical clinical findings (e.g., fever, respiratory symptoms, pulmonary abnormalities on chest X-ray or CT scan), lack of alternative diagnosis, and history of exposure to a known case of SARS-CoV- 2 infection within the past 14 days 4. Not receiving institutional therapy for treatment of SARS-CoV-2, including (but not limited to) remdesivir, chloroquine, hydroxychloroquine, or any other investigational agent(s). 5. Must meet at least one of the following clinical stratifications: 1. Have at least 1 minor criterion per ATS criteria (refer to Appendix A), or 2. Have fever, respiratory symptoms, with pneumonia visible on chest imaging (e.g., X-ray or computed tomography \[CT\]), or 3. High risk for poor outcome, as defined by any one of the following: i. Age ≥ 60 years old ii. Underlying medical comorbidities, defined as: * Serious cardiovascular disease * Poorly controlled diabetes (i.e., A1c levels \>7%) * Chronic kidney disease requiring dialysis * Significant liver disease (Pugh-Child B or C) * Severe obesity (body mass index \[BMI\] ≥ 40) * Chronic respiratory disease (e.g., COPD) * Hypertension, defined as blood pressure ≥ 140 / 90 mmHg iii. Solid organ or stem cell transplant recipient iv. Diagnosis of solid or hematologic malignancy being treated with systemic chemotherapy v. Receipt of biologic agent or prednisone \> 0.5 mg/kg/day (or equivalent) 6. Patient must be within 5 days of symptom onset, as determined by clinical team. 7. Participants with preexisting auditory damage are allowed. 8. Participants with a history of epilepsy are allowed. 9. Female participants of childbearing potential (FOCBP) must have a negative serum or urine pregnancy test (per institutional standards) prior to the start of study drug. 10. FOCBP must agree to use highly-effective method(s) of contraception (Appendix B) during the study and for 1 months after the last dose of study drug. FOCBP are those who have not been surgically sterilized or have not been free from menses for \>1 year without an alternative medical cause. 11. Male participants must agree to use an adequate method of contraception (Appendix B) starting with the first dose of study therapy through at least 1 months after the last dose of study drug. 12. Participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment. Exclusion Criteria: 1. The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study. 2. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements. 3. Psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results, or substantially increase risk of incurring AEs, or compromise the ability of the patient to give written informed consent. 4. Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation \>500 ms, electrolyte disturbances, etc.), or participants with congenital long QT syndrome 5. Patients with Myesthenia Gravis or other neuromuscular disorders 6. Patients with history of psoriasis. a. May be waived at the discretion of the PI 7. Patients with history of porphyria a. May be waived at the discretion of the PI 8. Concomitant use of other antiviral agents for the study's duration, but may be waived at discretion of the Principal Investigator 9. Hypersensitivity to the study agent, or any of its excipients. 10. Females who are pregnant or lactating.",18.0,65.0,"['covid-19', 'sars-cov-2']"
NCT06746766,Registry Study on Rare Cancers in Korea,Registry Study on Rare Cancers in Korea,RECRUITING,OBSERVATIONAL,ALL,Inclusion Criteria: * Adults aged ≥19 years * Confirmed rare cancer * Life expectancy ≥3 months Exclusion Criteria: -Serious or unstable medical/psychiatric conditions,19.0,65.0,['rare cancer']
NCT06997666,"Effect of Prone Position on Oxygen, Blood Gas, and Respiratory Parameters in Intensive Care Patients With COVID-19-induced ARDS","The Effect of Prone Position on Oxygen Saturation, Blood Gas Parameters, and Respiratory Rate in Intensive Care Patients With COVID-19-induced ARDS",COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Age 40 years or older * Admission to an intensive care unit (ICU) * Confirmed diagnosis of COVID-19 * Developed Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 * Intubated at the time of enrollment * Provided informed verbal and written consent (or consent provided by legal representative) Exclusion Criteria: * Significant hearing or vision impairments affecting communication * Cognitive impairment or inability to understand instructions * Patient died during the course of the study * Early discharge from intensive care before completion of all measurements * Non-intubated patients whose level of consciousness could not be monitored,40.0,65.0,"['covid - 19', 'ards (acute respiratory distress syndrome)']"
NCT04769466,LifeBio Memory Digital Reminiscence Platform,Development of a Reminiscence Therapy Online Platform With Machine Learning to Increase Engagement With People Living With Dementia and Their Care Partners,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria (Staff): * Work within a residential care facility participating in the study * Speak and read English * Able to provide own transportation to and from interviews with residents Inclusion Criteria (Residents * Must reside within a participating residential care facility * Must be at least 55 years of Age * Must speak and read English * Have a Dementia diagnosis * Have a Score of at least 15 on the Mini Mental State Examination Exclusion Criteria (Residents) * Residents will be excluded from the study if they show signs of rapid cognitive decline or physical deterioration over the last 6 months, as evidence by information gained during screening.",18.0,112.0,"['dementia', 'cognitive impairment']"
NCT02273466,Pharmacokinetics of Oral Desipramine With and Without Concomitant Administration of Crobenetine Infusion in Healthy Male Subjects,"Pharmacokinetics of 50 mg Desipramine Daily, Given Orally Over 7 Days With and Without Concomitant Administration of 175 mg Crobenetine, Given as a 6 Hrs i.v. Infusion (One Hour Loading Dose Directly Followed by a Five Hours Maintenance Dose). A Randomized, Placebo Controlled, Single Blind (for Crobenetine), Two-way Cross Over Trial in Healthy Male Subjects",COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: All participants in the study should be healthy males, range from 21 to 50 years of age and their bodymass index (BMI) be within 18.5 to 29.9 kg/m2. In accordance with Good Clinical Practice and local legislation all volunteers will have given their written informed consent prior to admission to the study. Exclusion Criteria: * Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * History of relevant orthostatic hypotension, fainting spells or blackouts * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * Intake of drugs with a long half-life (\> 24 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study * Use of any drugs which might influence the results of the trial (within one week prior to administration or during the trial) * Participation in another trial with an investigational drug (within two months prior to administration or during the trial) * Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day) * Inability to refrain from smoking on trial days * Alcohol abuse (\> 60 g/day) * Drug abuse * Blood donation (\>= 100 mL within four weeks prior to administration or during the trial) * Excessive physical activities (within the last week before the study) * Any laboratory value outside the reference range of clinical relevance * Cytochrome P450 2D6 poor metaboliser (to be determined by phenotyping or genotyping)",21.0,50.0,['healthy']
NCT03778866,Comparing HEPES-buffered With Bicarbonate-buffered as Handling Media During the ICSI Procedure on Live Birth Rate,Whether the Use of HEPES-buffered Medium Would Affect Live Birth Rate After ICSI,COMPLETED,INTERVENTIONAL,FEMALE,Inclusion Criteria: * ICSI indicated cycles Exclusion Criteria: * severe medical illness,18.0,40.0,['infertility']
NCT07014566,Effectiveness of Digital Physiotherapy in the Short and Long-Term Management of Lower Extremity Lymphedema,Effectiveness of Digital Physiotherapy in the Short and Long-Term Management of Lower Extremity Lymphedema,COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Diagnosed with unilateral lower extremity lymphedema (either primary or secondary) * Patients aged 18 years or older Exclusion Criteria: * Presence of metastatic disease * History of coronary heart disease, pulmonary disease, or acute infection of any cause * Presence of peripheral neuropathy",18.0,65.0,['lower extremity lymphedema']
NCT02177266,Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation,Colchicine Versus Placebo in Post-Cardiac Surgery Patients to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * All consecutive adult patients (age \> 40) undergoing standard (non-minimally invasive) coronary artery bypass surgery and/or aortic valve surgery will be approached for enrollment. * All patients must be able to provide informed consent and comply with the 3 month follow-up. * For women of reproductive capability, contraception is necessary and required. Exclusion Criteria: * Epidermal growth factor receptor (eGFR) \ 2.5 mg/dL or requiring dialysis * Known permanent or current atrial fibrillation (history of paroxysmal atrial fibrillation allowed if in sinus rhythm at present) * Allergy to colchicine or already treated with colchicine. * Known blood dyscrasia (acute or chronic leukemia, pancytopenia, aplastic anemia, leukopenia) * Known serious gastrointestinal disease * Known severe liver disease (cirrhosis, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 2x the upper limit of normal, Model End Stage Liver Disease (MELD) score \> 20) * Women of childbearing potential not using contraception. * Patients with HIV or AIDS as the use of protease inhibitors can result in serious colchicine toxicity. * Patients who are treated with strong CYP3A4 inhibitors (clarithromycin/erythromycin, chloramphenicol, ketoconazole/itraconazole, and nefazodone). * There is a risk of rhabdomyolysis with the use of digoxin and colchicine, we will exclude patients who require ongoing treatment with digoxin. * Inability or unwillingness of the individual to give written informed consent.",40.0,65.0,"['atrial fibrillation', 'post-pericardiotomy syndrome', 'constriction']"
NCT01267656,Study to Evaluate a Contact Lens Lubricating and Rewetting Drop,Study to Evaluate the Product Feasibility of a Contact Lens Lubricating and Rewetting Drop,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings. * Adapted wearers of soft contact lenses, wear a lens in each eye, and each lens must be of the same manufacture and brand. * Use a lens care system on a regular basis. * Wear their habitual lenses (or be willing to wear lenses) a minimum of 8 hours per day. * Willing to use drops 4 times per day. Exclusion Criteria: * Participating in a conflicting study. * An active ocular disease, any corneal infiltrative response, or are using any ocular medications. * Any scar or neovascularization within the central 4mm of the cornea. * Any grade 2 or greater finding during the slit lamp examination * Using any systemic or topical medications that will affect ocular physiology or lens performance. * Aphakic. * Amblyopic. * Allergic to any component in the study care products. * Have had any corneal surgery.",18.0,65.0,['dry eye']
NCT00704756,An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN),"An Observational Multi-Center Study Exploring the Association of Safety, Patient Characteristics, Virological, and Histological Parameters With Patient Outcome (Relapse Rate, Achievement of Sustained Viral Response in Daily Clinical Practice in Belgium- PEGIMPACT",WITHDRAWN,OBSERVATIONAL,ALL,"Inclusion Criteria: * Male and female adult (18 years or older) subjects for whom the treating physician has decided to start treatment with PegIntron® and Rebetol® and reaching the End-of-Treatment time point. * For the prospective component, evidence of treatment response at EOT after a complete course of therapy as per SmPC. * Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent. * Subjects must be diagnosed with chronic hepatitis C (genotypes 1, 2, 3, 4, 5 or 6). * Subjects must be free of any clinically significant disease that would interfere with study participation. Exclusion Criteria: * For prospective component of the study: patients not achieving End-of-Treatment response after a complete course of therapy as per SmPC.",18.0,65.0,"['hepatitis c, chronic', 'hepatitis c']"
NCT02389556,"Serum ANGPTL3, ANGPTL8 and Glypican 4 Concentrations in Relation to the Development of Obesity in Korean Children","Serum ANGPTL3, ANGPTL8 and Glypican 4 Concentrations in Relation to the Development of Obesity in Korean Children: a Three Year Prospective Cohort Study",COMPLETED,OBSERVATIONAL,ALL,Inclusion Criteria: * Participants who were reexamined for the 3 year follow-up assessment Exclusion Criteria: * Participants who were not being available for the 3 year follow up assessment,9.0,12.0,['obesity']
NCT00498056,Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa,"A Phase IIB Test-of-Concept, Randomized, Double-Blind, Placebo-Controlled, International Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in HIV Uninfected Persons",WITHDRAWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * At risk for HIV-1 sexual exposure within 24 weeks prior to study entry. More information about this criterion is available in the protocol. * HIV uninfected within 6 weeks prior to study entry * Willing to undergo HIV testing and counseling * Willing to receive HIV test results * Willing to use highly reliable method for contraception for at least the first 6 months of study Exclusion Criteria: * Participation in a clinical trial of another investigational product within 12 weeks prior to study entry * Contraindication to intramuscular injections, history of bleeding disorder, or use of anticoagulant therapy in the 4 weeks prior to study entry * Previously received an investigational HIV vaccine * History of severe local or systemic reactogenicity to vaccines or severe allergic reactions or recurrent rash for unknown reasons in the 5 years prior to study entry * Received an inactivated vaccine within the 2 weeks prior to study entry or of live attenuated within 4 weeks of study entry * Received any blood products or any immunomodulatory agents within 12 weeks of study entry * History of cancer. Participants with a history of localized squamous cell or basal cell carcinoma of the skin are not excluded. * History of clinically significant autoimmune disease or immune deficiency syndrome * Use of immunosuppressive medications within 24 weeks of study entry. Participants who have completed a short course of steroids more than 2 weeks prior to study entry, or using inhaled or topical steroids are not excluded. * Seizure disorder. Participants who have had seizures with fever under the age of 2, seizures secondary to alcohol withdrawal more than 3 years prior to study entry, or a singular seizure more than 3 years ago that has not recurred or required treatment within the last 3 years are not excluded. * Any medical condition or acute medical illness that, in the opinion of the investigator, would interfere with the study * Pregnancy, plan to become pregnant, or breastfeeding",18.0,45.0,['hiv infections']
NCT06047756,Hippotherapy Versus Swiss Ball Training to Improve Trunk Control and Balance on Spastic Daiplegic Cerebral Palsy,Effects of Hippotherapy Versus Swiss Ball Training to Improve Trunk Control and Balance on Spastic Daiplegic Child,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria:• Children (male and female) * Age group 4 to 11 years * Subject diagnosed with CP * Mild Spastic Diaplegic of the lower limbs according to the modified ashworth scale grade 1 to 1+ * GMFM scale sitting balance score less than 20 * Medically stable and able to understand commands Exclusion Criteria:• Children with mental retardation, * Epilepsy, other associated neurological disorders, other type of cerebral palsy, * Attention deficit hyperactivity disorder and sensory issues(poor visual or hearing acuity)",4.0,12.0,['cerebral palsy spastic diplegia']
NCT07310056,The Construction and Clinical Application of an Integrated Perioperative Management System for Lung Cancer Based on Wearable Devices and Intelligent Platforms,The Construction and Clinical Application of an Integrated Perioperative Management System for Lung Cancer Based on Wearable Devices and Intelligent Platforms,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: Age ≥18 years and ≤85 years Pathologically confirmed primary non-small cell lung cancer (NSCLC) Scheduled to undergo elective curative-intent thoracoscopic lobectomy or segmentectomy Postoperative clinical condition is stable and judged by investigators to be suitable for discharge within 2-7 days after surgery Able to independently operate a smartphone and wearable device, or able to do so with caregiver assistance Willing to comply with study procedures and follow-up requirements Provided written informed consent prior to participation Exclusion Criteria: Preoperative long-term home oxygen therapy or severe resting respiratory failure Presence of severe or uncontrolled cardiopulmonary disease, cerebrovascular disease, hepatic insufficiency, or renal insufficiency Severe comorbid conditions that significantly limit physical activity or adherence to rehabilitation Known or suspected allergy to materials used in wearable devices or medical adhesives Severe postoperative complications requiring reoperation or prolonged mechanical ventilation Occurrence of serious adverse events during the six-minute walk test that prevent continuation of the study Any other condition that, in the judgment of the investigators, makes the participant unsuitable for study participation",18.0,85.0,"['non-small cell lung cancer (nsclc)', 'rehabilitation', 'thoracic surgery', 'perioperative management']"
NCT06557356,A Study of LY3532226 in Participants With Obesity,"A Dose-Escalation Phase 1, Investigator- and Participant-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3532226 in Participants With Obesity",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Have a body weight not exceeding 150 kilograms (kg) or 330 pounds (lb) and body mass index (BMI) within the range of 30 to 40 kilogram per square meter (kg/m²) * Have had a stable body weight that is less than or equal to 5% change in body weight for 3 months prior to screening and enrollment Exclusion Criteria: * Have a lifetime history of a suicide attempt * Have a history or presence of psychiatric disorders, including a history of major depressive disorder within the last 2 years * Have a baseline Patient Health Questionnaire-9 (PHQ-9) score of 15 or greater, and/or a score of 2 or greater for either of the first 2 questions on the PHQ-9 questionnaire * Have a known clinically significant gastric emptying abnormality, have undergone gastric bypass surgery or restrictive bariatric surgery * Have taken approved or investigational medication for weight loss, within the previous 3 months or 5 half-lives of study screening, whichever is earlier * Intend to use any weight-loss medications during study participation * Have obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity",18.0,65.0,['obesity']
NCT03974256,Preparation of Radiopharmaceuticals by Automaton: Operators Dosimetry,Evaluation of a New Strategy for the Preparation of Technetium Radioactive Medicaments Using an Innovative Automaton for Nuclear Medicine Examinations: Impact on the Dosimetry of Operators and on the Quality of Preparations,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Adult (age \> 18 years) * Operators: Technologist in Electro-Radiology Medical / Pharmacy Technician * Operators experienced and autonomous in labelling radiopharmaceuticals with technetium-99m, at least one year * Operators having agreed to participate in the study, having received complete information on the organization of the research and having signed a free and informed consent * Operators affiliated to a social security scheme or beneficiary of such a scheme Exclusion Criteria: * A woman of childbearing age who doesn't have effective contraception * Persons referred in Articles L. 1121-5, L 1121-8 of the French Public Health Code: * Pregnant woman, parturient or mother who is breastfeeding * Chil (not emancipated) * Adult subject to a measure of legal protection (guardianship, curators, safeguard of justice) * Adult unable to express consent * Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1",18.0,65.0,"['exposure, radiation']"
NCT00832156,Application of Cultured Autologous Keratinocytes for Burn Wound Healing,Application of Cultured Autologous Keratinocytes in Combination With a Meshed Split Skin Autograft for Burn Wound Healing,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Competent and temporarily incompetent patients 18 years of age or older with acute burn wounds that require widely meshed skin grafting, which do not need immediate excision * Minimal study wound area 100 cm2 * Maximal study wound area 300 cm2 * Maximal TBSA 30% full thickness wounds * Informed consent Exclusion Criteria: * Immunocompromised patients * Infected wounds * Use of high doses of (.20mg/pd) corticosteroids and/or cytostatica * Known penicillin allergy * Conditions where the patient is non compliant as judged by a medical specialist",18.0,65.0,['burns']
NCT05560256,Developing a Diabetes Mobile Health Application for and With Kenyan Adolescents,Building Capacity in Human-Centered Design: Developing a Diabetes Mobile Health Application for and With Kenyan Adolescents,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * T1D diagnosis 13-18 years old * Have an A1c \> 7 * Uses a phone * Fluent in Swahili Exclusion Criteria: * Being treated for significant medical condition other than T1D * Being treated for eating disorder,13.0,18.0,['type 1 diabetes']
NCT01387256,Comparing Two Regimens for Medical Abortion: Mifepristone + Misoprostol Versus Misoprostol Alone,Comparing Two Regimens for Medical Abortion: Mifepristone + Misoprostol Versus Misoprostol Alone-3 Hour Intervals,COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Gestational age \ 63 days LMP * Confirmed or suspected ectopic or molar pregnancy * Contraindications to medical abortion including intra-uterine device (IUD) in place (must be removed before procedure), chronic adrenal failure, concurrent long-term corticosteroid therapy, history of allergy to mifepristone, misoprostol or prostaglandin, hemorrhagic disorders or concurrent anticoagulant therapy, inherited porphyries.",18.0,65.0,['complete abortion']
NCT06869356,Expanded Indications of Endoscopic Submucosal Dissection for Early Gastric Cancer in China,"Expanded Indications of Endoscopic Submucosal Dissection for Early Gastric Cancer in China: a Multicenter, Ambispective, Observational, Open-cohort Study",COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: Patients aged 18-75 years (regardless of sex). Patients with tumor diameter \> 30 mm, ulceration (UL)(+), and differentiated mucosal carcinoma (T1a). Patients with tumor diameter \> 30 mm and differentiated, submucosal invasion depth \ 20 mm, UL(-), and undifferentiated (T1a). Patients with tumor diameter ≤ 30 mm, UL(+), and undifferentiated (T1a). Patients with tumor diameter \> 30 mm, UL(+), and undifferentiated (T1a). Exclusion Criteria: Patients with gastric stump cancer. Patients with recurrent gastric cancer. Patients with multiple primary malignant tumors.",18.0,75.0,['gastric cancer stage']
NCT02979756,Improve Detection and Management of Gestational Diabetes Through the Primary Health Care Level in Morocco,Améliorer la Detection et la Prise en Charge du diabète Gestationnel au Niveau Des établissements de Soins de santé Primaires au Maroc,COMPLETED,INTERVENTIONAL,FEMALE,Inclusion Criteria: * Pregnant women attending ANC (screening) * Women diagnosed with GDM (follow-up) * Informed consent Exclusion Criteria: * Pregnant women with pre-existing diabetes type 1 or 2 * No informed consent,18.0,65.0,['gestational diabetes mellitus in pregnancy']
NCT03846856,The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical Significance,The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical Significance,UNKNOWN,OBSERVATIONAL,FEMALE,Inclusion Criteria: * Women diagnosed with epithelium ovarian cancer who have undergone surgery Exclusion Criteria: * Pregnant women,18.0,65.0,['ovarian cancer']
NCT05062356,Pain Control Following Total Hip Arthroplasty,Prospective Randomized Study Comparing Suprainguinal Fascia Iliaca Block vs. Pericapsular Nerve Group Block vs. Local Anesthetic Infiltration vs. Spinal Anesthetic Without Adjuncts for Pain Control Following Total Hip Arthroplasty,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Adults (≥18 years old) who require an inpatient primary total hip arthroplasty under spinal anesthesia * Written consent * Any gender Exclusion Criteria: * Patients who require revision surgery * Anesthesia other than spinal (general, epidural, other) * Body mass index (BMI) \> 45 kg/m2 * Allergies to study medication * Previous fracture to affected area * Previous surgery to the affected hip * Diagnosis other than osteoarthritis (avascular necrosis, significant deformity such as post-Perthes, slipped capital femoral epiphysis, dysplasia classified as Crowe 3 or 4, or other diagnoses causing significant deformity of the femoral head or acetabulum) * THA for hip fractures * Patients taking daily opiod analgesics pre-operatively * Anesthetist on day of surgery who does not perform FICB and PENG and no alternate anesthetist available to perform the block * Patients who do not understand, read or communicate in either French or English",18.0,65.0,['chronic postoperative pain']
NCT02195622,Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures,Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures,COMPLETED,INTERVENTIONAL,MALE,Inclusion Criteria: * Patients scheduled to undergo HoLEP for bladder outlet obstruction due to the prostate. * Able to give informed consent. * Age 18 years or older Exclusion Criteria: * • Inability to give informed consent. * Age less than 18 years,18.0,65.0,['benign prostatic hypertrophy requiring surgical intervention']
NCT05619822,A Comprehensive Third-generation Intervention for People With Psychosis and Post-traumatic Stress Symptoms,"A Comprehensive Third-generation Intervention for People With Psychosis and Post-traumatic Stress Symptoms; Design, Implementation and Effectiveness",ENROLLING_BY_INVITATION,INTERVENTIONAL,ALL,"Inclusion Criteria: Those showing a high risk of PTSD (TSQ ≥6) will be further evaluated to determine whether they meet the inclusion criteria. Participants must: * Be between the ages of 18 and 65 fluent enough in Spanish language; * Meet the criteria for a diagnosis of a psychotic spectrum disorder or a mood disorder with psychotic symptoms according to MINI (Sheeman et al., 1997); * Meet PTSD diagnostic criteria according to the Clinician-Administered PTSD Scale (CAPS; Blake et al., 1995) Exclusion Criteria: * Those who have a diagnosis of substance or alcohol abuse or dependence in the 30 days prior to participation in the study * To have a severe neurocognitive problems or brain damage that interfere with the basic processing of information in psychotherapy.",18.0,65.0,"['trauma, psychological', 'psychosis']"
NCT04656522,Comic Intervention for Sexual Violence Prevention and Post-rape Care,A Participatory Comic Intervention for Sexual Violence Prevention and Post-rape Care With Refugee Adolescents and Youth in a Humanitarian Setting in Uganda,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria (Youth): * Resides in Bidi Bidi Refugee Settlement Zone 3 * Identify as a refugee/displaced person * Aged 16-24 years * Speak English, Bari or Arabic Exclusion Criteria (Youth): * Does not reside in Bidi Bidi Refugee Settlement Zone 3 * Does not identify as a refugee/displaced person * Is less than age 16 years or older than age 24 years * Does not speak English, Bari or Arabic Inclusion Criteria (Healthcare Provider): * Provides healthcare services in Bidi Bidi Refugee Settlement and/or Yumbe, Uganda * Aged greater than or equal to 18 years * Speak English, Bari or Arabic Exclusion Criteria (Healthcare Provider): * Does not provide healthcare services in Bidi Bidi Refugee Settlement and/or Yumbe, Uganda * Less than age 18 years * Does not speak English, Bari or Arabic",16.0,65.0,"['knowledge, attitudes, practice', 'post-exposure prophylaxis']"
NCT03157622,Single-Case Study on Therapeutic Change in Chronic Low Back Pain,Comparing Therapeutic Change During Exposure and Cognitive-Behavioral Therapy in the Context Chronic Low Back Pain,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * \> 6 months chronic low back pain * Sufficient level on fear avoidance scores (PCS \> 35, PASS \>20, QBPDS \> 30, PDI \> 20 and Phoda harm ratings of 13 activities \> 50, including 8 \> 80) * German-speaking * Agreeing to participate, verified by completion of informed consent Exclusion Criteria: * Red flags * Pregnancy * Illiteracy * Psychoses * Alcohol addiction * Surgeries during the last 6 months or planed surgeries * Specific medical disorders or cardiovascular diseases preventing participation in physical exercise * Participating in another psychotherapy",18.0,65.0,['chronic low back pain']
NCT04631822,Comparing Dexamethasone With Dexmedetomidine as Additives to Bupivacaine in Adductor Canal Block for Knee Arthroscopy.,"Comparative Study Between Dexamethasone, and Dexmedetomidine as Additives to Bupivacaine in Ultrasound Guided Adductor Canal Block in Knee Arthroscopy",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: - * Adult patients of aged more than 18 years old ASA ""American Society of Anaesthesia"" * physical status I or II under-going any unilateral knee arthroscopy. Exclusion Criteria: - * patient refusal. * Pre-existing pain ; postoperative pain similar to preoperative pain * Known contraindications to peripheral nerve block, including local skin infections, bleeding diathesis, and coagulopathy. * Allergies to local anesthetics, dexmedetomidine, or any component of multimodal analgesia.",19.0,60.0,"['pain, postoperative']"
NCT06457022,Outcome Measures of Modified Constraint Induced Movement Therapy Versus Dual Task Training on Upper Extremity and Cognitive Functions in Patients With Hemiparesis,Outcome Measures of Modified Constraint Induced Movement Therapy Versus Dual Task Training on Upper Extremity and Cognitive Functions in Patients With Hemiparesis,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients with age range between 55 and 65 years old. * The patients were from both genders (males \&females). * Patients were of duration of illness between 6 and 12 months. * The patients were scoring 1 \&1+ on modified Ashworth scale (mild spasticity). * The patients were of good ability to see and hear. * Consent form was obtained from all participants to approve the study and follow the commands. * All patients were scoring more than 26 on MMSE. All patients were medically stable. Exclusion Criteria: * patients with moderate and sever spasticity. * patients with cognitive disorder due to other cause rather than spasticity. * patients with unstable medical conditions. * patients with previous or recurrent stroke. * patients with respiratory problems. * patients with shoulder dislocation or subluxation or frozen shoulder. * patients with uncontrolled hypertension, diabetes mellitus, unstable angina or heart failure.",55.0,65.0,['hemiparesis']
NCT03325322,Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease,"Frailty, Inflammation, and Stem Cell Functionality in Chronic Kidney Disease",SUSPENDED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age 40-80 years * Chronic kidney disease estimated glomerular filtration rate (eGFR) 15-60 ml/min/1.73m2 * For the diabetic kidney disease (DKD) subgroup: Diabetes mellitus (on medication) Exclusion Criteria: * Hemoglobin A1c\>11% at screening for the DKD subgroup * Body weight \>150 kg or body mass index\>50 * Pregnancy * Active glomerulonephritis treated with immunosuppressive therapy * Solid organ transplantation (eg. kidney, pancreas, liver, lung, heart) * Active immunosuppression therapy * History of active substance abuse (including alcohol) within the past 2 years, * Current alcohol abuse (\>3 alcoholic beverages/day or \>21 per week), * Human immunodeficiency virus infection * Active hepatitis B or C infection * Total bilirubin \>2x upper limit of normal * Uncontrolled psychiatric disorder * Uncontrolled systemic lupus erythematosus * Uncontrolled pleural/pericardial effusions or ascites * New invasive cancer except non-melanoma skin cancers * Invasive fungal or viral infection * Inability to tolerate oral medications * Known hypersensitivity or allergy to Fisetin * Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6CYP2C9, CYP2C19, CYP1A2, Other (OATP1B1) (Unless willing and able to stop or modify the dosing of the drug) or strong inhibitors or inducers of CYP3A4 (e.g. cyclosporine, tacrolimus or sirolimus). * Tyrosine kinase inhibitor therapy * Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.). * Subjects on full-dose 325 mg aspirin or other anti-platelet agents (eg. clopidogrel) daily who are unable or unwilling to reduce or hold therapy prior to and during the 2-day drug dosing. Subjects may continue their previous regimen on day 3. * Baby aspirin (81 mg), if necessary for cardioprotection, will be allowed but encouraged to hold. * Subjects taking proton pump inhibitors who are unable or unwilling to reduce or hold therapy 2 days prior to and during the 2-day drug dosing. Subjects taking H2-antagonists and unwilling to discontinue therapy for 2 weeks before and one week following enrollment. (See Appendix 4) * Subjects taking glimepiride or glyburide for diabetes therapy who are unable or unwilling to reduce or hold therapy prior to and during the 2-day drug dosing. * Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin, erythromycin), Antivirals (nelfinavir, indinavir, saquinavir, ritonavir, elbasvir/grazoprevir), Rifampin * Corrected QT interval (QTc) \>450 msec * Tobacco use (smoking or chewing; Unless subject willing to reduce use by 50% prior to and during the study) - see Behavioral Modification information below. * Inability to give informed consent * Presence of any condition that the Investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial",40.0,80.0,"['chronic kidney diseases', 'diabetes mellitus', 'diabetic nephropathies']"
NCT03979222,Observational Cohort Study of a National Extracorporeal Membrane Oxygenation Service for Adults With Respiratory Failure: the NHS ECMO Study.,Observational Cohort Study of a National Extracorporeal Membrane Oxygenation Service for Adults With Respiratory Failure: the NHS ECMO Study.,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * Ultimately at the discretion of the clinician at the relevant ECMO centre * Aged ≥16 years * Severe acute respiratory failure refractory to conventional management * No contra-indication to ongoing ECMO therapy Exclusion Criteria: * Any contra-indication to ongoing ECMO therapy * Need for ECMO due to other aetiology than acute respiratory failure (e.g. bridge to transplantation, extracorporeal CPR, isolated acute cardiac failure)",16.0,65.0,['acute respiratory failure']
NCT00640822,Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds,"A Phase 3 Study Comparing an Ointment Containing Calcipotriol 25 mcg/g Plus Hydrocortisone 10 mg g With Tacalcitol 4 mcg/g Ointment and the Ointment Vehicle Alone, All Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and on the Intertriginous Areas",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Clinical diagnosis of psoriasis vulgaris involving the face * Clinical signs of psoriasis vulgaris on the trunk and/or the limbs, or earlier diagnosed with psoriasis vulgaris on the trunk and/or the limbs * An extent of psoriatic involvement of the face of at least 10 cm2 (the sum of all facial lesions) * Treatment areas (the face and the intertriginous areas) amenable to topical treatment with a maximum of 10 g of ointment per day * Disease severity graded as mild, moderate, severe or very severe according to the investigator's global assessment of disease severity of the face Exclusion Criteria: * Systemic treatments with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues, retinoids, immunosuppressants) within the 4-week period prior to randomisation * Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on psoriasis vulgaris (e.g., alefacept, efalizumab, etanercept, infliximab, adalimumab) within 3 months prior to randomisation * PUVA therapy or Grenz ray therapy within the 4-week period prior to randomisation * UVB therapy within the 2-week period prior to randomisation * Topical treatment of the face and the intertriginous areas within the 2-week period prior to randomisation (use of emollients is allowed on treatment areas during this 2-week period, but not during the study) * Topical treatment with very potent WHO group IV corticosteroids within the 2-week period prior to randomisation * Initiation of or expected changes in concomitant medication that may affect psoriasis vulgaris (e.g., beta blockers, anti-malaria drugs, lithium and ACE inhibitors) during the study * Systemic treatment with vitamin D preparations above 500 IU per day * Current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis * Patients with any of the following conditions present on the treatment area: viral (e.g., herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds * Other inflammatory skin diseases (e.g., seborrhoeic dermatitis, contact dermatitis and cutaneous mycosis) that may confound the evaluation of psoriasis vulgaris on the face or on the intertriginous areas * Planned exposure to sun, UVA or UVB that may affect the psoriasis vulgaris during the study * Known or suspected severe renal insufficiency or severe hepatic disorders * Known or suspected disorders of calcium metabolism associated with hypercalcemia",18.0,65.0,['psoriasis vulgaris']
NCT02369822,Trial of Vitamin C as Add on Therapy for Children With Idiopathic Epilepsy,Trial of Vitamin C as Add on Therapy for Children With Idiopathic Epilepsy,UNKNOWN,INTERVENTIONAL,ALL,Inclusion Criteria: * Normal neuroimaging Exclusion Criteria: * Developmental delay. * Suspected metabolic problems.,2.0,16.0,['idiopathic epilepsy']
NCT01271322,Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG),Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG): The Heidelberg Imaging Program in Cancer of the Oesophago-gastric Junction During Neoadjuvant Treatment: HICON Trial,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Biopsy-proven adenocarcinoma of the distal oesophagus (AEG type I) or cardia (AEG type II) with or without metastases in local lymph nodes (tumor stage cT3/T4, cNX, and cM0 in the tumor-node-metastasis classification) * Staging procedures include endoscopy, endoscopic ultrasound and computed tomography (CT) of the chest and abdomen. * Eligible patients have to be fit for platin-containing chemotherapy * Tumors must be potentially R0 resectable tumors during consecutive operation. * Tumors must have demonstrated a minimal amount of FDG-uptake in the baseline PET-CT, defined as 18FDG-uptake in tumor at first examination \> 1,35 x hepatic-SUV + 2 x standard-deviation of hepatic-SUV, and must be a metabolic non-responder under EOX, defined as a decrease of the SUVmax of \ 1 * Previous or secondary malignancy * Life expectancy of less than 3 months * Uncontrolled bleeding from the tumor * Tumor infiltration of the airways * Pregnancy * Uncontrolled diabetes * Patients are also ineligible if they have undergone previous chemotherapy, radiotherapy, or endoscopic laser therapy.",18.0,75.0,['adenocarcinomas of the esophagogastric junction']
NCT04871022,Double-layer Versus Purse Uterine Closure Techniques : Impact on Residual Myometrial Thickness After Cesarean,Double-layer Versus Purse Uterine Closure Techniques : Impact on Residual Myometrial Thickness After Cesarean,COMPLETED,INTERVENTIONAL,FEMALE,Inclusion Criteria: * Planned cesarean * Primary cesarean * ≥ 38 gestational weeks Exclusion Criteria: * Previous cesarean * Women \ 35 kg/m2 * Placenta praevia * Chronic systemic disease * Covid-19 infection,18.0,48.0,['uterine scar defect']
NCT04850222,Fluoxetine Mitigation Mental Health Study for Patients With Musculoskeletal Trauma,Can Fluoxetine Mitigate the Mental Health Decline Seen in Patients With Musculoskeletal Trauma?,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * patients 18 and older under the care of the UF Orthopedic Trauma Division admitted to UF Health for trauma resulting in one or more extremity or pelvic fractures requiring surgery will be screened. Exclusion Criteria: * patients with Traumatic Brain Injury or a past medical history of bipolar or other mental health conditions on current medical management will be excluded * patients unlikely to follow up (live in at a distance from Gainesville, incarcerated etc.) will also be excluded.",18.0,65.0,['musculoskeletal injury']
NCT04618822,Play-based Motor-Cognitive Training for Improved Reading,Motor-enriched Learning for Improving Pre-reading and Word Recognition Skills in Preschool Children Aged 5-6 Years,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Children five to six years old who have just started school Exclusion Criteria: * Children who do not speak any Danish * Children with cognitive or physical disabilities hindering participation in the project activities,5.0,7.0,['reading']
NCT02122822,Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96,Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Able to read and understand the informed consent document; must sign the informed consent. 2. Aged 18 to 75 years old , sex is not limited 3. Newly Diagnosed supratentoria glioma, Must have undergone a at least a 80% resection 4. Availability of at least 1 g tumor sample. 5. Karnofsky functional status rating \> or equal to 70. 6. Adequate bone marrow function including the absence of lymphopenia (ANC \> 1,500/ mm3; Hemoglobin \> 10g/dL ; platelet count \>100,000/mm3), adequate liver function (serum glutamic oxaloacetic transaminase/ aspartate aminotransferase \[AST\], alanine amino transferase \[ALT\] \<2.5 times institutional upper limit of normals \[IULNs\] ), and adequate renal function (BUN and creatinine \<1.5 times IULNs) 7. Agree to Surgical indications of Heart \& lung and without the coagulation system disease 8. Negative pregnancy test for female patients of childbearing potential 9. Agree to use contraception or abstain from sexual activity from the time of consent through 3 month after the end of study drug administration Exclusion Criteria: 1. Inability to comply with study-related procedures 2. patient not suitable for Neurosurgery. 3. Unavailability of at least 6 doses of vaccine 4. Progression prior to vaccination as determined by the Principal Investigator 5. Patient with allergic constitution 6. Unstable or severe intercurrent medical conditions 7. Current diagnosis of Human Immunodeficiency Virus and Patients with active uncontrolled infection. 8. patients with any systemic disease needed to be treated with immunosuppressant or Corticosteroids. 9. any other clinical trials within 30 days pre-vaccination. 10. Female patients who are pregnant or breastfeeding",18.0,75.0,['glioma']
NCT05892822,Amyotrophic Lateral Sclerosis Registry,Amyotrophic Lateral Sclerosis Registry,UNKNOWN,OBSERVATIONAL,ALL,Inclusion Criteria: * 18 years old ≤ age ≤ 80 years old; * Patients are diagnosed definite or probable ALS according to the Awaji diagnostic criteria; * Sign an informed consent form. Exclusion Criteria: * Unable to cooperate with research or complete follow-up due to geographical or other reasons.,18.0,80.0,['amyotrophic lateral sclerosis']
NCT06360822,Increasing Equity in Lung Cancer Screening,Increasing Equity in Lung Cancer Screening,RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * • Eligible for LCS (50-80 years old, smoked in past 15 years, and smoked at least 20 pack years) Exclusion Criteria: * • Non-English/Spanish speaking * Decompensated psychiatric illness (suicidal, homicidal, psychosis). Will confirm with attending physicians at time of enrollment * Intoxicated with alcohol or drugs * Cannot provide reliable follow up contact information (cell phone) * Presenting to the ED with a life-threatening condition * Have received chest CT scan in past 12 months * Already enrolled in LCS * Hospice enrolled",50.0,80.0,['lung cancer']
NCT00454922,Effect of Glaucoma Educators on Adherence to Prescribed Therapeutic Regimens in Glaucoma Patients,Effect of Glaucoma Educators on Adherence to Prescribed Therapeutic Regimens in Glaucoma Patients,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Diagnosis of primary or secondary open angle glaucoma. * Currently on monotherapy drop treatment for glaucoma. * Age \> 18 years. * Patient has presented for care at the Rocky Mountain Lions Eye Institute Glaucoma Center. Exclusion Criteria: * Inability to independently administer eye drops due to physical disability as reported by the patient. * Cognitive impairment that would interfere with the ability to self-administer medications as evidenced by a TICS score \ 80% adherence to glaucoma treatment during the 30 day run-in period. * It is anticipated that the patient will require glaucoma surgery within the next six months.,18.0,65.0,['glaucoma']
NCT00913822,To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride Tablets,Bioavailability of Desipramine Hydrochloride Tablets,COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.",18.0,40.0,['depression']
NCT00933322,Trial to Assess the Effects of Different Trans-fatty Acids on Endothelial Function in Humans,Randomized-controlled Trial to Assess the Effects of Different Trans-fatty Acids on Endothelial Function in Humans,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * age 45-69 * body mass index 20-30 kg/m2 * willingness to hold physical activity constant over study duration * written informed consent Exclusion Criteria * smoking * hypertension (\> 140/90 mm Hg) * hypotension (men \ 30 kg/m2) * vegan * infections in the last 6 weeks * allergy for food (e.g., milk) * pregnancy * diabetes (elevated fasting blood glucose level) * clinical known coronary diseases * acute and/or chronical medication (incl. contraceptive) * abnormal kidney function * abnormal liver function * known cardiac arrhythmia (e.g., atrial fibrillation) * blood parameters (ALAT, Creatinin, Hb, potassium, CRP) in range",45.0,69.0,['healthy']
NCT05108922,A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4),"A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Gradual and progressive change in memory function reported by the participant or informant for ≥6 months. * Meet florbetapir F18 PET scan criteria. * A Clinical Dementia Rating (CDR)-Global Score of 0.5 or 1. * Must consent to apolipoprotein E (ApoE) genotyping * Must have a mini mental state examination (MMSE) score between 20 and 30 * Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will accompany the participant to study visits or be available by telephone at designated times. * Have adequate literacy, vision, and hearing for neuropsychological testing in the opinion of the investigator at the time of screening. * Women not of childbearing potential may participate Exclusion Criteria: * Significant neurological disease affecting the central nervous system (other than AD), that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, history of transient ischemic attack or stroke, or epilepsy or recurrent seizures (except febrile childhood seizures). * Current serious or unstable medical illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, psychiatric (including actively suicidal or deemed at risk of suicide, or current alcohol or substance abuse), immunologic, infectious, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of approximately ≤24 months. * History of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis). * History of bleeding disorder or use of medications with platelet anti-aggregant or anti-coagulant properties (unless aspirin at ≤325 milligram (mg). * Have had prior or current treatment with donanemab or aducanumab * Have known allergies to donanemab or aducanumab, related compounds, or any components of the formulation * Prior or current participation in any immunotherapy study targeting Amyloid beta",50.0,85.0,"['mild cognitive impairment (mci)', 'alzheimer disease']"
NCT04923022,Therapeutic Exercise and Vegan Diet on Pain and Quality of Life,The Effect of Therapeutic Exercise and Vegan Diet on Pain and Quality of Life in Young Women With Chronic Idiopathic Neck Pain.,COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Individuals aged 18-25, * neck pain for at least 3 months, * VAS score greater than 5 Exclusion Criteria: * using regular analgesic, * having had neck surgery, * the presence of neurological or specific problems in the neck (vertebral fracture, inflammation, infection, etc.), * cortisone use, * pregnancy, * serious chronic diseases, * those with serious psychiatric disorders * Individuals who received physical therapy within 3 months * Antidepressant use",18.0,25.0,['chronic idiopathic neck pain']
NCT04200222,Vanadium in Late-onset Preeclampsia,"Analyses of Maternal Plasma Cadmium, Lead and Vanadium Levels in the Diagnosis and Severity of Late-onset Preeclampsia; A Prospective and Comparative Study From Turkey",COMPLETED,OBSERVATIONAL,FEMALE,"Inclusion Criteria: * preeclampsia * healthy pregnancy Exclusion Criteria: 1. pregnant women with any systemic condition (such as chronic hypertension, renal disease and ) 2. using any kind of medication/supplement intake throughout pregnancy (such as heparin) 3. history of medication for PE treatment at the time of first admission 4. smoking 5. drug user 6. patients who had fetal congenital abnormalities or genetic syndromes 7. multiple-gestation pregnancies 8. pregnancies resulting from in vitro fertilization 9. intrauterine fetal death 10. having family history of preeclampsia",18.0,40.0,['preeclampsia']
NCT05704322,The Effectiveness of the Wim Hof Method in People with Spinal Cord Injury,The Effectiveness of the Wim Hof Method on Physical and Mental Health of People with a Spinal Cord Injury,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Individuals (Male/Female) with either a complete or incomplete chronic SCI. In this study, a chronic SCI is defined as a time since injury ≥ 1 year. * Participants have to be between 18 and 75 years old. Exclusion Criteria: * Cardiac arrhythmias or cardiac disease; * A history of severe autonomic dysreflexia assessed with the 'Autonomic standards assessment'; * Severe pulmonary disease (such as COPD) based on a pulmonary history; * Insufficient mastery of the Dutch language (speaking and reading); * Severe cognitive or communicative disorders; * Progressive disease; * Being or becoming pregnant during the study period; * Severe psychiatric illness or disorders (at the discretion of the treating rehabilitation physician); * Involved in another intervention study which may have an effect on the outcome measures of the present study; * Experience with (parts of) the Wim Hof Method. * Negative advice from physician to participate in the Wim Hof Method intervention based on the medical screening.",18.0,75.0,['spinal cord injuries']
NCT04852822,Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL,TERMINATED,OBSERVATIONAL,ALL,Inclusion Criteria: * Age \>= 18 years * A diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) * Willing and able to participate in all required evaluations and procedures in this study Exclusion Criteria: * Any evidence of prior SARS-CoV-2/COVID19 infection,18.0,65.0,"['chronic lymphocytic leukemia', 'small lymphocytic lymphoma']"
NCT05645822,Screen and Treat Implementation for HAT Control,Screen and Treat Implementation in Insecure Areas With Limited Capacities for HAT Control,WITHDRAWN,OBSERVATIONAL,ALL,"Inclusion Criteria: * Show any suggestive symptoms of gHAT, such as headache (\>14 days), long-term fever unless other obvious cause(s), malaise, weakness, arthralgia, facial edema, pruritus, lymphadenopathy, weight loss, mental confussion, abnormal behavior, logorrhea, speech impairment, anxiety, tremor, motor weakness, ataxia, abnormal gait, abnormal movements or seizures; * Being older than 6 years old and weighing at least 20 kg; * Willing and able to provide written informed consent (assent for minors); * Minors (6 to 17 years old) willing and able to provide a written assent, after obtaining written informed consent from their parents. Exclusion Criteria: * Being younger than 6 years old or weighing less than 20 kg; * Refusal to provide informed consent; * Previously treated for HAT (questionnaire to patients and/or family members); * Pregnant women.",6.0,65.0,"['sleeping sickness', 'trypanosomiasis, african']"
NCT07030322,Health and Financial Impact on the Use of a Personal Exoskeleton in the Home and Community: a Case Study,Health and Financial Impact on the Use of a Personal Exoskeleton in the Home and Community: a Case Study,ENROLLING_BY_INVITATION,OBSERVATIONAL,ALL,"Inclusion Criteria: * Femur lengths from 14.5"" to 19"" (35.5cm to 47 cm) * Healthy bone density * Height from 5'1"" to 6'3"" (1.5 to 1.9 m) * Seated hip width ≤ 16.6"" (42.2 cm) * Sufficient upper extremity strength to manage approved stability aids * Weight 250 lbs or less * Availability of a support person able to complete training and be present during all Indego sessions Exclusion Criteria: * Cognitive impairments resulting in inability to follow directions * Colostomy bag * Diminished standing tolerance caused by orthostatic hypotension * Heterotopic ossification * Hip or knee contractures greater than 10° or ankle contractures greater than 5° * History of severe neurological injuries other than SCI (multiple sclerosis, --cerebral palsy, amyotrophic lateral sclerosis, traumatic brain injury, etc). * Lower limb prothesis * Poor skin integrity in areas in contact with the device * Pregnancy * Psychiatric conditions that may interfere with proper operation of the device * Severe concurrent medical diseases: infections, circulatory, heart or lung, pressure sores * Severe or uncontrolled spasticity (Modified Ashworth 4) * Spinal instability or spinal orthotics * Uncontrolled autonomic dysreflexia * Uncontrolled hypertension or hypotension * Unhealed limb or pelvic fractures * Unresolved deep vein thrombosis * Any condition which in the opinion of a medical doctor prevents the user from using the device",18.0,65.0,['spinal cord injury']
NCT07175922,Research Into the Expression of the csgA-gene and How it Changes in Patients With Parkinson's Disease,"Evaluation of csgA Prevalence, Gene Expression and Week-to-Week Variability in Participants With Parkinson's Disease and a History of Gastrointestinal Dysfunction",RECRUITING,OBSERVATIONAL,ALL,"Inclusion Criteria: * A diagnosis of PD within 10 years from the time of ICF signing * A history of gastrointestinal (GI) dysfunction or constipation prior to PD diagnosis at the discretion of the investigator based on screening assessment * All participants must understand and provide written informed consent prior to any study specific procedures * Able to speak, read, and understand study procedures in Dutch sufficiently to allow completion of all study assessments Exclusion Criteria: * Any known GI disorder if deemed clinically significant by the investigator. GI disorders may include, but are not limited to: Crohn's disease, ulcerative colitis, celiac disease, irritable bowel syndrome, or lactose intolerance * Recent GI infection in the past 3 months if deemed clinically significant by the investigator. * Major GI surgery (excluding appendectomy/cholecystectomy), such as bariatric surgery, gastrectomy, esophagectomy, vagotomy, small intestine surgeries, any type of colectomy, colostomy and anorectal surgeries if deemed clinically significant by the investigator",18.0,80.0,['parkinsons disease (pd)']
NCT01553422,Relation Between Intrabdominal Pressure and Collapsibility Index of Inferior Vena Cava Before and After Fluid Therapy,Assessment of Relation Between Intrabdominal Pressure and Collapsibility Index of Inferior Vena Cava by Emergency Ultrasonography Before and After Fluid Therapy,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Body Mass index less than 30 * Written agree of the patient to participate in the study Exclusion Criteria: * neurogenic bladder or any documented previous surgery on bladder, spastic or contractile bladder * large abdominal hernia * patients who received neuromuscular blocking agents * Patients with abdominal respiration due to chest pain",18.0,65.0,['abdominal compartment syndrome']
NCT01544322,Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors,Phase 1 Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Provision of informed consent * Male or female ≥ 18 years of age * Histologic or cytologic confirmed locally advanced or metastatic cancer that has no standard therapeutic alternatives. * ECOG Performance status 0-1 (Appendix A) * A minimum life expectancy of 12 weeks * Adequate bone marrow, hepatic and renal function as evidenced by: * Absolute neutrophil count (ANC) \> 1.5 x 109/L * Platelet count \> 100 x 109/L * Hemoglobin \> 9.0 g/dL * Serum bilirubin \ 470 msec at screening, the screening ECG may be repeated twice (at least 24 hours apart). * LV Ejection Fraction \> lower limit of institutional normal level * All potentially fertile patients will agree to use an effective form of contraception during the study and for 30 days following the last dose of ME-344 (an effective form of contraception is defined as an oral contraceptive or a double barrier method). * At least 4 weeks must have elapsed prior to Day 1 Cycle 1 since prior chemotherapy (6 weeks for nitrosourea or mitomycin C), investigational drug or biologic therapy and any toxicity associated with these treatments has recovered to ≤ NCI-CTCAE Grade 1. * At least 21 days must have elapsed prior to Day 1 Cycle 1, radiotherapy, immunotherapy or following major surgery and any surgical incision should be completely healed. At least 14 days must have elapsed prior to Day 1 Cycle 1 for ""limited palliative radiotherapy"", defined as a course of therapy encompassing \<25% total bone marrow volume and not exceeding 30 Gy. Exclusion Criteria: * Patients who are pregnant or breastfeeding * Tumor involvement of the Central Nervous System (CNS): * Patients with treated and stable CNS metastases may be eligible to participate after discussion and approval from the Medical Monitor * Uncontrolled infection or systemic disease. * Clinically significant cardiac disease not well controlled with medication (e.g., congestive heart failure, symptomatic coronary artery disease e.g. angina, and cardiac arrhythmias) or myocardial infarction within the last 12 months. * Any major surgery, radiotherapy, or immunotherapy within the last 21 days. Limited palliative radiation, defined as encompassing \<25% of total bone marrow volume and not exceeding a total dose of 30 Gy, within the last 14 days. * Chemotherapy regimens with delayed toxicity within the last 4 weeks (or within 6 weeks for prior nitrosourea or mitomycin C). Chemotherapy regimens given continuously or on a weekly basis with limited potential or delayed toxicity within the last 2 weeks. * No concurrent systemic chemotherapy or biologic therapy is allowed. * Known hypersensitivity to any components of ME-344 study drug product. * Known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both). * History of solid organ transplantation. * Psychiatric disorder or social or geographic situation that would preclude study participation.",18.0,65.0,['solid tumors']
NCT01934322,Case Management for Frequent Users of the Emergency Department,Case Management for Frequent Users of the Emergency Department: A Randomized Controlled Trial,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * 5 or more attendances during the previous 12 months at the Emergency Department of the University Hospital of Lausanne * Be capable of communicating in any of the languages spoken by the team (i.e. French, English, German, Italian and Spanish) or through a community interpreter Exclusion Criteria: * Patients who cannot give informed consent or are ineligible to receive Case Managers services (e.g. acutely confused, acutely psychotic, intoxicated) * Patients who are in prison * Patients with a diagnose of cognitive disorders (delirium, dementia, and other cognitive disorders) * Patients who are not expected to survive at least 18 months after enrollment * Patients who will not remain in Switzerland for 12 to 18 months after enrollment * Family members of a participant already included",18.0,65.0,"['frequent users of the emergency department', 'vulnerable populations']"
NCT01876251,A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer,Phase 1b Study Of Docetaxel + Pf 03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer,TERMINATED,INTERVENTIONAL,FEMALE,Inclusion Criteria: * Diagnosis of breast cancer with evidence of a) metastatic or b) locally recurrent/advanced disease. Exclusion Criteria: * Prior treatment with a gamma secretase inhibitors or other Notch signaling inhibitors.,18.0,65.0,['breast cancer metastatic']
NCT02810951,A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB),A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB),TERMINATED,INTERVENTIONAL,ALL,"Key Inclusion Criteria: 1. Age 1. Phase I: Eighteen (18) years or older. 2. Phase II: Seven (7) years or older. 2. Diagnosis of recessive dystrophic epidermolysis bullosa (RDEB) Key Exclusion Criteria: 1. Medical instability limiting ability to travel to the investigative center. 2. Active infection with HIV, hepatitis B or hepatitis C or evidence of other systemic infection 3. Current evidence of metastatic squamous cell carcinoma at the site to be injected 4. Clinically significant abnormal laboratory result or other significant clinical abnormalities 5. Receipt of a chemical or biological study product for the specific treatment of RDEB in the past six months",7.0,65.0,"['epidermolysis bullosa dystrophica, recessive']"
NCT00498251,Prevention of Lung Edema After Thoracic Surgery,Does Inhaled Salbutamol Prevent Lung Edema After Thoracic Surgery? A Randomized Controlled Study,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: Patients with at least 3 risk factors for postoperative lung edema * age \> 60 yrs * history of chronic alcohol consumption (\>60g/day) * prior radiation or chemotherapy * cardiac insufficiency (left ventricular ejection fraction \< 40%, or a history of past acute heart failure) * coronary artery disease (history of myocardial infarct, Q wave on the ECG, positive stress test or coronary angiogram) * recent pneumonia (within 6 weeks of hospital admission) * reduced diffusion capacity for carbon monoxide (DLCO \< 60% of predicted values) * predicted postoperative lung perfusion of \< 55% of total lung perfusion Exclusion Criteria: * pneumonectomy * intracardiac shunts * valvular diseases * aortic abdominal aneurysm * chronic treatment with inhaled bronchodilators * a history of any adverse reaction to bronchodilators * liver or kidney insufficiencies",18.0,65.0,"['lung injury, acute', 'thoracotomy', 'anesthesia', 'intensive care, surgical', 'extravascular lung water']"
NCT05108051,Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir,"A Phase 1, Open-Label, Three-Period, Single-center Study to Assess the Pharmacokinetic Interactions Between ZSP1273 and Oseltamivir in Healthy Subjects",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Males and female subjects between 18-45 years (Both inclusive); * Body weight is no less than 50kg in males and no less than 45kg in females.Body mass index (BMI) 18\~26 kg/m2 (Both inclusive); BMI is determined by the following equation: BMI = weight/height2 (kg/m2); * Subjects (including partners) are willing to voluntarily use effective contraception from screening to 3 months after the last study drug administration. Exclusion Criteria: * Known history of allergic constitution (multiple drugs especially with ZSP1273 or oseltamivir and its preparation of the main ingredient allergy, food allergy); * Subjects who donated blood or bleeding profusely(\> 450 mL)in the 3 months preceding study screening; * History or presence of any disease or condition known to increase the risk of bleeding, eg.hemorrhoids, acute gastritis or gastric and duodenal ulcer, etc; * Use of any prescription or over-the-counter (OTC) medications, vitamins and herbal within 14 days prior to screening; * Concomitant therapy with any drugs with known hepatic enzyme-inducing or inhibiting agents that may change the activity of drug metabolic enzymes ，is intended to be taken in combination 28 days prior to screening or during the study period； * Participated in another clinical research study or received any investigational products within 3 months prior to dosing; * Presence of clinically significant abnormalities in ECG , QTcB\>450ms in males,or QTcB\>470ms in females; * Any of the following diseases (including but not limited to gastrointestinal, renal, liver, neurological, hematological, endocrine, tumor, pulmonary, immune, psychiatric or cardiovascular and cerebrovascular diseases) that are clinically significant in clinical laboratory examination or other clinical findings within 6 months prior to screening; * Breast-feeding women or those with positive pregnancy test results; * Subjects who should not be included in the study in the opinion of the Investigator.",18.0,45.0,['drug-drug interaction']
NCT02344251,Assessing the Effectiveness and Safety of the ID-Cap System for Medication Monitoring and Adherence,A Phase II Randomized Trial to Assess the Effectiveness and Safety of the ID-Cap System for Medication Ingestion Monitoring and Enhancing Adherence,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Must be between the ages of 18 and 65 years * If female and of childbearing potential, must agree to use acceptable methods of birth control for the duration of the trial * Must consent to random assignment, and be willing to commit to medication ingestion * Must be able to read and provide informed consent * Must function at an intellectual level sufficient to allow accurate completion of assessments * Must have a Body Mass Index (BMI) below 35 Exclusion Criteria: * Women who are pregnant, nursing, or plan to become pregnant during the course of the study * Must not have evidence of a significant medical condition which may affect capsule passage through the gastrointestinal tract (including, but not limited to, Crohn's disease, small bowel tumors, intestinal adhesions, ulcerations, and radiation enteritis) * Must not have a current major psychiatric disorder as these may interfere with assessment measures * Must not be currently dependent on other substances, with the exception of nicotine or caffeine, within the past 60 days * Hypersensitivity to riboflavin or any capsule component; * Individuals with embedded electronic devices * Patients who, in the investigator's opinion, would be unable to comply with study procedures or assessments, or would be unacceptable study candidates (e.g., poses threat to staff)",18.0,65.0,['medication adherence']
NCT01322451,Oral Bioavailability of Two Solid Formulations of GLPG0259.,"A Randomized, Open Label, 2-way Crossover Study to Compare the Oral Bioavailability of 2 Solid Dose Formulations of GLPG0259 After Single-dose Intake in Healthy Subjects",COMPLETED,INTERVENTIONAL,MALE,"Inclusion Criteria: * healthy male, age 18-50 years * BMI between 18-30 kg/m², inclusive. Exclusion Criteria: * significantly abnormal platelet function or coagulopathy * smoking * drug or alcohol abuse",18.0,50.0,['healthy']
NCT06989151,Cognitive Remediation for Autistic Adolescents,A Pilot Study of Cognitive Remediation Therapy for Autistic Adolescents,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * 12-16 years of age with a confirmed clinical diagnosis of autism (based on verified diagnostic report). * Verbal/intellectual ability in average range * Sufficient spoken English to access the intervention. * Young person must be under the care of a local mental health service who can respond to any changes in routine clinical care / risk issues that arise. Exclusion Criteria: * Not currently receiving alternative psychological intervention * Not actively self-harming or deemed at risk to themselves or others,12.0,16.0,['autism spectrum disorder']
NCT01014351,Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma,A Phase II Study of Everolimus in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Histologically confirmed metastatic melanoma. 2. Stage III or IV disease that is not amenable to resection. 3. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. If the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation. 4. ECOG Performance Status of 0 or 1. 5. Life expectancy ≥12 weeks. 6. No prior cytotoxic chemotherapy or targeted therapy. Immunotherapy is allowed (i.e., interleukin-2 or interferon). 7. Adequate hematological function: * absolute neutrophil count (ANC) ≥1500/µL and * platelets ≥100,000/µL and * hemoglobin \>9 g/dL 8. Adequate renal function: serum creatinine ≤2.0 mg/dL or calculated (measured) GFR ≥50 mL/min. 9. Adequate hepatic function: * serum bilirubin ≤1.5 x institutional upper limit of normal (ULN); * aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN, or ≤5 × ULN in patients with documented liver metastases. 10. Normal PT, INR. Patients on coumadin anticoagulation are eligible if they are on a stable dose, with an INR in the therapeutic range. 11. Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can be included after initiation of appropriate lipid lowering medication. 12. Age ≥18 years. 13. Ability to swallow whole pills. 14. Patient must be accessible for treatment and follow-up. 15. Patients must be able to understand the investigational nature of this study and give written informed consent prior to study entry. Exclusion Criteria: 1. Previous treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus), paclitaxel, or carboplatin. 2. Treatment with any investigational agent ≤4 weeks of protocol treatment. 3. Patients currently receiving anticancer therapies or who have received anticancer therapies ≤3 weeks of the start of the study drug (including radiation therapy, immunotherapy). 4. Patients, who have had a major surgery or significant traumatic injury ≤4 weeks of start of study drug or patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia). 5. Patients receiving chronic, systemic treatment with corticosteroids (dose \>10 mg daily of methylprednisolone or equivalent) or other immunosuppressive agents. Topical or inhaled steroids are allowed. 6. Immunization with attenuated live vaccine ≤1 week of study or anytime during study treatment period. 7. Patients with active brain metastases are ineligible. Patients with treated brain metastases are eligible if (1) radiation therapy was completed ≥4 weeks prior to study entry; (2) surgery was completed ≥4 weeks prior to study entry; (3) follow-up scan shows no disease progression; and (4) patient does not require steroids. 8. Any severe and/or uncontrolled medical conditions or other conditions that could affect participation in the study such as: * severely impaired lung function defined as a DLCO ≤50% of the normal predicted value and/or O2 saturation ≤88% at rest on room air. * symptomatic congestive heart failure of New York Heart Association Class III or IV. * unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant disease. * uncontrolled diabetes as defined by fasting serum glucose \>1.5 x ULN. * active (acute or chronic) uncontrolled severe infections. * liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis. 9. Active, bleeding diathesis. 10. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection). 11. A known history of human immunodeficiency virus (HIV) seropositivity. 12. Known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients. 13. Use of St. John's Wort is prohibited. Drugs or substances (e.g., grapefruits, star fruits, seville oranges, and their juices and products), known to be inhibitors or inducers of the isoenzyme CYP3A4 should be avoided. Co-administration with substrates, inducers, or inhibitors of P glycoprotein should also be avoided. 14. Female patients who are pregnant or breastfeeding or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Hormonal contraceptives are not acceptable as a sole method of contraception. (Women of childbearing potential \[WOCBP\] must have a negative urine or serum pregnancy test within 7 days prior to administration of everolimus.) WOCBP should continue to use effective contraception for 8 weeks after ending everolimus treatment. 15. Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin. 16. History of noncompliance to medical regimens. Patients unwilling to, or unable to, comply with the protocol. 17. History of any other disease, physical examination finding, or clinical laboratory finding that gives reasonable suspicion of a disease or a condition that may render the patient at high risk for treatment complications using these agents.",18.0,65.0,['metastatic melanoma']
NCT01222351,Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172,"BAY 94-9172 PET/CT in Cognitively Normal Older Adults, Older Adults With Mild Cognitive Impairment, and Older Adults With Alzheimer's Disease",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Current Washington Heights-Inwood Community Aging Project (WHICAP) participant Age 65 or older Residing in the community of Washington-Heights/Inwood/Hamilton Heights * Is able to provide informed consent, understand the information provided on the purpose and conduct of the trial and exhibits adequate visual, auditory and communication capabilities to enable compliance with study procedures. This includes performing the psychometric testing and being able to lie down flat in the Positron Emission Tomography (PET) scanner * Possesses a general health that permits adequate compliance with all study procedures. * Informed consent has been signed and dated (with time) by the subject and/or the subject's caregiver (for probable Alzheimer's Disease (AD) patients) Exclusion Criteria: * Has any contraindication to PET, such as claustrophobia, or inability to lie flat for half an hour as determined by the onsite radiologist performing the scan * Current, past, or anticipated exposure to radiation, which may include being badged for radiation exposure in the workplace or participation in nuclear medicine procedures, including research protocols in the last year * Significant active physical illness particularly those that may affect the brain including blood dyscrasias, lymphomas, hypersplenism, endocrinopathies, renal failure or chronic obstructive lung disease, autonomic neuropathies, peripheral vascular disease, low hemoglobin and malignancy * Scheduled for surgery and/or another invasive procedure within the time period of up to 24 hours following scan * Allergic to the tracer or any of its constituents and/or has a history of severe allergic reactions to drugs or allergens (e.g. patients with allergic asthma) * Critically ill and/or medically unstable and whose clinical course within the observation period is unpredictable, e.g. participants with 14 days of myocardial infarction or stroke, unstable participants with previous surgery (within 7 days), participants with advanced heart insufficiency (New York Heart Association (NYHA) stage IV), or participants with acute renal failure. * Has received any contrast material (X-ray, Magnetic Resonance Imaging (MRI)), or radiopharmaceuticals within 48 hours prior to the application of the Investigational Medicinal Product (IMP) or for whom application of such a substance is planned for 24 hours following IMP administration",65.0,65.0,['late onset alzheimer disease']
NCT02405351,Telerehabilitation for Attention and Memory in Stroke,Telerehabilitation for Attention and Memory in Stroke (TEAMS): Development and Initial Evaluation of an Internet-Based Training Program,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * at least 3 months post first stroke documented clinically or by imaging * subjective concerns or objective assessment data regarding deficits in attention and working memory ability * normal or corrected-to-normal vision * have access to a computer at home Exclusion Criteria: * severe aphasia or dementia * other neurological diagnosis such as epilepsy, multiple sclerosis, Parkinson's disease * current diagnosis of a severe psychiatric disorder such as major depressive disorder or psychosis",18.0,65.0,['stroke']
NCT05832151,A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Diabetic Gastroparesis",COMPLETED,INTERVENTIONAL,ALL,"Key Inclusion Criteria: * Is a male or female ≥18 years of age; * Has a diagnosis of Type 1 or Type 2 diabetes, according to the American Diabetes Association criteria; * Has a current diagnosis of diabetic gastroparesis defined by the following: 1. Persistent gastrointestinal symptoms that in the opinion of the Investigator are consistent with gastroparesis within 6 months prior to Screening; AND 2. Documented delayed gastric emptying as determined by gastric emptying breath test (GEBT), scintigraphy, or manometry. * Body mass index (BMI) between 18 and 49 kg/m2, inclusive; * Glycosylated hemoglobin (HbA1c) level \<10% at Screening; * If receiving treatment with GLP-1RA, may be considered for the study if all of the following criteria are satisfied: 1. The GLP-1 RA has been prescribed for the management of diabetes and not specifically for weight loss/weight management; 2. Has been on a stable dose of GLP-1RA for a minimum of 3 months before Screening and is anticipated to sustain the same dose during GEBT and throughout the study; 3. Is tolerating the GLP-1RA well based on Investigator's judgment; 4. None of the study-qualifying signs/symptoms of gastroparesis are solely attributable to the use of GLP-1RA; and 5. The symptoms of gastroparesis preceded the initiation of GLP-1RA therapy. * Willing to washout from ongoing treatment for gastroparesis. Key Exclusion Criteria: * Has known cause of gastroparesis other than diabetes (eg, idiopathic gastroparesis and/or gastroparesis attributed to surgery, viral illness, cancer, scleroderma, or other neurologic disorder); * Has been hospitalized within 3 months prior to Visit 1 for diabetic gastroparesis and/or diabetic ketoacidosis and/or malnutrition; * History or evidence of clinically significant arrhythmia; * History of pyloroplasty, pyloromyotomy, or gastric peroral endoscopic myotomy, fundoplication, gastrectomy, vagotomy, or bariatric surgery; * Currently receiving parenteral feeding or presence of a nasogastric or other enteral tube for feeding or decompression; * Pyloric injection of botulinum toxin within 6 months of Screening; * Positive test for drugs of abuse; * Has a known allergy to eggs or spirulina; * Females who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.",18.0,65.0,['diabetic gastroparesis']
NCT03953651,Clinical Presentation and Outcomes in Patients at Risk of Type II Myocardial InfarctioN in the emerGency Department.,Clinical Presentation and Outcomes in Patients at Risk of Type II Myocardial InfarctioN in the emerGency Department.,COMPLETED,OBSERVATIONAL,ALL,"Inclusion Criteria: * age 18 years old or older ; * At least one condition of myocardial oxygenation imbalance : * Oxygen saturation below 90% ; * Haemoglobin level below 130 grams/Liter (g/L) for men, 120 g/L for women ; * Persistent heart rate over 110 beats per minute, for more than 20 minutes ; * Persistent systolic blood pressure below 90 millimeters of mercury (mmHg) for more than 20 minutes despite fluid resuscitation ; * Persistent systolic blood pressure over 180 mmHg for more than 20 minutes. Exclusion Criteria: * Patient admitted with type 1 myocardial infarction ; * Patient presenting a condition for Non Ischemic Myocardial Infarction (pulmonary embolism, acute stroke, acute kidney failure, etc…) * Patient who declines to participate; * Pregnant or breastfeeding women ; * Patient deprived of liberty (inmate, administrative protection)",18.0,65.0,"['myocardial oxygenation imbalance', 'myocardial infarction']"
NCT07163351,Prefabricated CAD CAM Allogeneic Ring Blocks in the Anterior Maxilla With Immediate Implantation,Prefabricated CAD CAM Allogeneic Ring Blocks in the Anterior Maxilla With Immediate Implantation a Prospective Single-Arm Clinical Study,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Aged between 18 and 65 years. * Both sexes. * Patients presenting with anterior maxillary alveolar bone defects resulting from previous implant failure. * Systemically healthy individuals, classified as American Society of Anesthesiologists (ASA) physical status I or II. * Participants were either non-smokers or light smokers consuming fewer than 10 cigarettes per day. Exclusion Criteria: * Uncontrolled systemic conditions such as diabetes mellitus or osteoporosis. * Pregnant or breastfeeding at the time of recruitment. * Individuals with a history of head or neck radiation therapy. * Cases in which insufficient bone volume for implant placement persisted following augmentation.",18.0,65.0,"['prefabricated', 'cad', 'cam', 'allogeneic ring blocks', 'anterior maxilla', 'immediate implantation']"
NCT05637151,Different Effects of Delayed Clamping on Neonatal Bilirubin Levels Between Pregnant Women With Intrahepatic Cholestasis of Pregnancy and Normal Pregnant Women,Different Effects of Delayed Cord Clamping on Neonatal Bilirubin Levels Between Pregnant Women With Intrahepatic Cholestasis of Pregnancy and Normal Pregnant Women,UNKNOWN,INTERVENTIONAL,FEMALE,"Inclusion Criteria: 1. The pregnant woman is born at a gestational age of 37-40 weeks; 2. The pregnant woman has a single child; 3. Regular obstetric examination durinv pregnancy with complete obstetric examination data was diagnosed as intrahepatic cholestasis of pregnancy(ICP). Exclusion Criteria: 1. Pregnancy complicated with medical and surgical diseases, such as thyroiddysfunction and chronic hypertension; 2. Insufficiency of vital organ function or complicated tumor; 3. Pregnant women with other pregnancy complications besides ICP, such as preeclampsia, etc.",18.0,40.0,['intrahepatic cholestasis of pregnancy']
NCT04174651,Stress-induced Scratching in Healthy and AD,The Cerebral Mechanism of Stress-Induced Spontaneous Scratching in Healthy Volunteers and Patients With Atopic Dermatitis (AD),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Healthy subjects and AD patients between 18 and 59 years of age. 2. Healthy subjects: In general, good health without history of neurological and psychiatric diseases. 3. AD patients: An average itch rating of 3 out of 10 or greater in the past two weeks using a Numerical Rating Scale (NRS). 4. All patients will be required to cease use of oral antihistamines from the night before each study visit until the end of the experiment. The purpose is to avoid that participants fall asleep during MRI measurement due to side effect oral antihistamine (i.e., sedation). 5. Women of child bearing potential will be administered a pregnancy test to verify that they are not pregnant. 6. MRI Compatibility, criteria include having no major contraindication for MRI (pacemaker, vascular stents, metallic ear tubes, and absence of metal implants or braces) as assessed by MRI technologist using site approved screening form. 7. Participants have to be able to speak and read English fluently. 8. Participants must have signed a written informed consent before being enrolled in the study Exclusion Criteria: 1. Individuals under 18 or over 59 years of age. 2. Inability to complete the required measures. 3. Suffering from any disease state or physical condition, which would increase their health risk by study participation. 4. Currently enrolled in any investigational study in which the subject is receiving any type of drug, biological, or non-drug therapy. 5. Recent initiation (within last 3 months) of centrally acting agents such as antidepressants, neuroleptics or neuropathic medications. 6. Patients who use centrally acting agents only when they need. The purpose is to avoid a risk of acute effect of these agents on brain activity and perceived stress due to the stress task. 7. Current treatment with opioid analgesics. 8. Uncontrolled thyroid disease. 9. Use of illicit drugs or history of opiate addiction. 10. Diagnosis of a major psychiatric disorder such as schizophrenia, major depression or bipolar disorder that is active right now. 11. Any known diseases or disorders that may affect conducting the experiments (e.g., intracranial pathology, claustrophobia, severe respiratory or cardiovascular problems, active fibromyalgia) or diseases that have potential risks of infections (e.g., HIV, Hepatitis C, etc). 12. Inability to speak and read English. 13. Being pregnant. 14. Incarcerated.",18.0,59.0,"['healthy', 'atopic dermatitis']"
NCT04850651,Effect of Fluconazole on the Pharmacokinetics of Pyrotinib in Healthy Subjects,"A Single-centre, Open, Single-dose, Self-control Study to Investigate the Effect of Fluconazole on the Pharmacokinetics of Pyrotinib in Healthy Chinese Adult Subjects.",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Participants has given written informed consent with full understanding of the trial content, process and possible adverse reactions; 2. Ability to complete the study as required by the protocol; 3. Healthy male or female subjects aged 18 to 45 (including 18 and 45) at the date of signing the informed consent; 4. Male body weight ≥ 50 kg, female body weight ≥ 45 kg, and body mass index (BMI) within the range of 19 \~ 26 kg /m2 (including 19 and 26); 5. Willing to take contraception or male subjects who can guarantee not to donate sperm during the trial and within 6 months after the last dose; female subjects with fertility who did not use contraception for at least 2 weeks before dosing; Exclusion Criteria: 1. Allergic constitution or Allergic to a drug ingredient or component; 2. History of drug use, or drug abuse screening positive; 3. Alcoholic or often drinkers; 4. Left ventricular ejection fraction (LVEF) \<50% by echocardiography; 5. A clear medical history of important primary organ diseases such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolism and musculoskeletal system; 6. Abnormal clinical laboratory tests and clinical significance judged by the investigator or other clinical findings showing the following diseases, including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardiovascular and cerebrovascular diseases; 7. Participated in a clinical trial and has received an investigational product within 3 months prior to the first dosing day in the current study; 8. Positive value of HBsAg、HCV-Ab、HIV-Ab、TPPA at screening； 9. Blood loss ≥400mL within 3 months before first dosing; 10. Patients who had a positive blood pregnancy test and were breastfeeding at the time of screening. 11. The investigators determined that other conditions were inappropriate for participation in this clinical trial .",18.0,45.0,['healthy subjects']
NCT00671151,Effects of Low-Dose Theophylline During Chronic Obstructive Pulmonary Disease (COPD) Exacerbations,Molecular Mechanisms of COPD Exacerbations. Effect of Low-Dose Theophylline,COMPLETED,INTERVENTIONAL,MALE,Inclusion Criteria: * Severe COPD according to GOLD guidelines * Age between 40 and 75 * Admission to hospital due to COPD exacerbation Exclusion Criteria: * History of asthma * Pulmonary embolism * Pneumonia * Other chronic inflammatory disease * Patient on theophylline at the time of admission * Patient on oral steroids at the time of admission,40.0,75.0,['copd']
NCT05673551,VR-PAT During Home Burn Dressings - Multisite,A Randomized Clinical Trial of Smartphone Virtual Reality for Pain Management During Burn Care Transition,ENROLLING_BY_INVITATION,INTERVENTIONAL,ALL,"Inclusion Criteria: * Being treated for acute burn injury * Age 6-17 years, inclusive * Receiving their first outpatient clinic dressing change or being discharged from the ED or inpatient burn unit * Have a dressing that requires daily changes at home for at least 7 days after their first outpatient appointment or discharge from the hospital (ED or inpatient) * Patient and family caregivers can communicate (read and write) using English or Spanish * Reported at least moderate or worse NRS pain score of ≥3 (NRS 0-10 with 10 being worst pain) from the most recent dressing change. Exclusion Criteria: * Any wounds that may interfere with study procedures * Vision, hearing, or cognitive/motor impairments preventing valid administration of study measures * History of motion sickness, seizure disorder, dizziness, or migraine headaches precipitated by visual auras * Minors in foster care, prisoners, or currently pregnant * Suspected child abuse * Families who do not have access to a VR compatible smartphone.",6.0,17.0,"['burns', 'acute pain', 'procedural pain', 'injuries', 'pediatric all']"
NCT05219851,The Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors,"The Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors.in Real-world Clinical Practice: a Multicenter, Prospective, Open, Non-interventional Study",RECRUITING,OBSERVATIONAL,ALL,Inclusion Criteria: 1. Pathologically or cytologically confirmed malignant tumor 2. Cancer patients with previously received ICIs underwent thoracic intensity-modulated radiotherapy Exclusion Criteria: 1. Cancer patients did not receive immunotherapy before thoracic intensity-modulated radiotherapy 2. Non-thoracic radiotherapy patients,18.0,65.0,['cancer patients']
NCT03819751,MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection,MRI-targeted Biopsy of the Prostate: a Prospective Comparison of Software-based Fusion Versus Visual (Cognitive) Registration in the Accuracy of Clinically Significant Prostate Cancer Detection,RECRUITING,INTERVENTIONAL,MALE,"Inclusion Criteria: * willing to participate in the study by giving written informed consent. * male subjects aged between 50 to 75 years. * with a clinical suspicion of PCa: elevated prostate specific antigen (PSA) levels in blood and/or abnormal digital rectal examination (DRE). * good health condition based on medical history, physical examination and vital sign measurements. * with target lesion on dedicated MRI of the prostate (PI-RADS 3 to 5). Exclusion Criteria: * has a prior history of prostate cancer. * had prior prostate biopsy. * has a contra-indication for MRI (claustrophobia, non-compatible metallic implants). * has evidence of lymph nodes involvement on prostate MRI or abdominal CT * has evidence of bone metastasis on bone scan. * has a prior history of hip prosthesis, pelvic radiation therapy or androgen deprivation therapy * unable to perform transrectal ultrasound due to prior rectal surgery or active rectal diseases (rectitis, …) * has any condition, physical, mental, familial or sociological, that could impede compliance with the study protocol and further follow-up. This is not an absolute contra-indication, but should be discussed with patient prior to registration in the trial.",50.0,75.0,"['prostate cancer', 'prostate neoplasm']"
NCT06445751,Step Up for STEM and Health Careers,Step up for STEM and Health Careers: An Interactive Digital Resource to Reduce STEM-related Biases and Improve High School STEM Learning Environments,TERMINATED,INTERVENTIONAL,ALL,Inclusion Criteria: * English-speaking * Access to a computer and internet connection * Live in Chicago Metropolitan Area * Current high school student (enrolled in grade 9-12); or in 12th grade in 2023-2024 school year Exclusion Criteria: \-,13.0,19.0,['adolescent behavior']
NCT05477251,Comparative Study on the Efficacy and Safety of Microwave Ablation and Lobectomy in the Treatment of Ground Glass Nodules Located in the Pulmonary Hilar Region,Comparative Study on the Efficacy and Safety of Microwave Ablation and Lobectomy in the Treatment of Ground Glass Nodules Located in the Pulmonary Hilar Region,NOT_YET_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. The age ranged from 18 to 75 years old, male or female; 2. GGO lesions in the hilar region were diagnosed by imaging examination (CT / PET-CT). During the follow-up of 6-12 months, the lesions increased by more than 2mm, the solid components increased, or there were obvious solid components, or the GGOs were judged to be highly malignant by imaging. 3. The size of GGO lesions was 8mm-3cm, and the number of nodules was ≤ 3. 4. There was no lymph node metastasis, intrapulmonary metastasis or distant organ metastasis; 5. After multidisciplinary evaluation, the patients were feasible for lobectomy and CT guided microwave treatment; 6. No bleeding tendency, normal coagulation function or coagulation dysfunction can be corrected after treatment; 7. Patients and /or family members agreed to join the clinical trial and signed informed consent. Exclusion Criteria: 1. The general condition of the patient is very poor, ECOG physical fitness score \> 2, unable to tolerate lobectomy and MWA treatment, or has relevant contraindications; 2. The lesions had received other treatments before; patients with regional lymph node metastasis or distant metastasis or with pleural fluid and ascites; 3. Patients with poor compliance; 4. Severe heart, lung, kidney, brain and other important organ diseases; 5. The researcher believes that it is not suitable for inclusion",18.0,75.0,"['pulmonary nodule, multiple', 'pulmonary nodule, solitary']"
NCT04876651,"The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only","A Multinational, Multicenter, Prospective, Randomized, Controlled, Open Label Phase 3 Study With Best Standard of Care With and Without 177Lu-DOTA-rosopatamab for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug",RECRUITING,INTERVENTIONAL,MALE,"Inclusion Criteria: 1. Be a male, at least 18 years old, with metastatic adenocarcinoma of the prostate defined by histological / pathological confirmation of PC. 2. Be of ECOG Performance Status 0, 1, or 2 and have an estimated life expectancy of ≥6 months. 3. Have metastatic disease (≥1 metastatic lesions present on baseline CT, MRI, or bone scan imaging). 4. Have castration-resistant PC (defined as disease progressing despite castration by orchiectomy or ongoing use of luteinizing hormone-releasing hormone \[LHRH\]) and must have a castrate level of serum/plasma testosterone (\ 1.5×109/L. iii. Hemoglobin ≥10g/dL (no red blood cell transfusion in the previous 4 weeks). b. Liver function: i. Total bilirubin \< 1.5×the upper limit of normal (ULN). For patients with known Gilbert's Syndrome \<3×ULN is permitted. ii. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \<3×ULN OR \<5×ULN for patients with liver metastases. c. Renal function: i. Serum/plasma creatinine \<1.5×ULN or creatinine clearance ≥50 mL/min determined using the Cockcroft \& Gault formula. 12. Have the capacity to understand the study and be able and willing to comply with all protocol requirements. 13. Patients must comply with the radiation protection rules (including hospital admissions and isolation) that are used by the treating institution in order to protect their contacts and the general public, especially if a female partner of the patient is or could be pregnant. 14. Must agree to practice adequate precautions to prevent pregnancy in a partner and to avoid potential problems associated with radiation exposure to the unborn child (Refer to Clinical Trials Facilitation Group, 2020: Recommendations related to contraception and pregnancy testing in clinical trials Version 1.1, CTFG, 2020). Exclusion Criteria: 1. Are unable to understand or are unwilling to sign a written informed consent document or to follow investigational procedures in the opinion of the Investigator. 2. Have PC associated with pathological findings consistent with small cell or any histology other than adenocarcinoma of the prostate. If there are minor elements of neuroendocrine histology, this is acceptable. 3. Uncontrolled pain. 4. Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, patients with a prior history of malignancy that has been adequately treated and who have been disease-free for more than 3 years are eligible, as are patients with adequately treated non-melanoma skin cancer, and superficial bladder cancer. 5. Are at increased risk of hemorrhage or bleeding, or with a recent history of a thrombolytic event (e.g., deep vein thrombosis \[DVT\]/ pulmonary embolism \[PE\]) and have been administered long-term anti-coagulant or anti-platelet agents. 6. Have received prior treatment with monoclonal antibody (mAb) J591 or HuJ591 or any other PSMA targeted therapy. 7. Have known allergies, hypersensitivity, or intolerance to the investigational drug or its excipients. 8. Have received prior systemic anti-cancer therapy (e.g., chemotherapy, immunotherapy, or biological therapy) and/or radiation therapy within 4 weeks of randomization OR if any significant AEs have not resolved to National Cancer Institute (NCI) AE Criteria ≤2; OR are receiving other concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, or investigational therapy. 9. Have received prior treatment with radioisotopes, including but not limited to: 89Strontium, 153Samarium, 186Rhenium, 188Rhenium, 223Radium, or hemi-body irradiation within 6 months prior to randomization. 10. Have received other investigational therapy within 4 weeks of randomization. 11. Have known brain metastases or hepatic metastases. 12. Have a history of seizure and/or stroke within past 6 months. 13. Have clinical or radiologic findings indicative of impending cord compression or experience symptomatic cord compression. 14. Have a serious active or sub-clinical infection or angina pectoris (New York Heart Association \[NYHA\] Class III or IV), significantly prolonged QT interval or other serious illness(es) involving the cardiac, respiratory, central nervous system, renal, hepatic or hematological organ systems, which might impair the ability to complete this study or could interfere with determination of causality of any adverse effects experienced in this study, or which require treatment that could interact with study treatment, particularly with enzalutamide. 15. Have received treatment with any PARP inhibitors (i.e., Olaparib) or with any platinum based anti-neoplastic drugs. 16. Have a known alteration in breast cancer genes (BRCA) BRCA1, BRCA2, or Ataxia Telangiectasia Mutated Gene (ATM) gene and are eligible to receive Olaparib therapy according to their institution's SoC",18.0,65.0,['metastatic prostate cancer']
NCT00741351,Anesthesiological Strategies in Elective Craniotomy,"Anesthesiological Strategies in Elective Craniotomy: Randomized, Equivalence, Open Trial",COMPLETED,INTERVENTIONAL,ALL,"Inclusion criteria: * Patient scheduled for elective intracranial surgery under general anesthesia for a supratentorial mass lesion in the next 24 hours; * Physical state, evaluated with the ASA (American Society of Anesthesiologists ) classification I (normal healthy patient), II (patient with mild systemic disease), or III (patient with severe systemic disease); * Age 18-75 years; * Normal preoperative level of consciousness, i.e. Glasgow Coma Scale (GCS) = 15; * No signs of intracranial hypertension. Exclusion criteria: * Severe cardiovascular pathology, as uncontrolled arterial hypertension, documented reduced coronary reserve. * Renal or liver disease precluding the use of either anesthetic technique. * Pregnancy . * Known allergies to any anesthetic agent. * Reduced preoperative level of consciousness, i.e. * Glasgow Coma Scale (GCS) \< 15. * Body weight greater than 120 kg. * History of drug abuse or psychiatric conditions. * Documented disturbance of the hypothalamic region.Refusal to sign consent form. * Participation in other clinical trials. * Delayed awakening, because, due to the location or size of the lesion, postoperative sedation and mechanical ventilation are planned.",18.0,75.0,"['anesthesia', 'craniotomy', 'neurosurgery']"
NCT05868551,"Onchocerciasis-Associated Epilepsy, an Explorative Case-control Study","Onchocerciasis-Associated Epilepsy, an Explorative Case-control Study With Viral Metagenomic Analysis of Onchocerca Volvulus.",UNKNOWN,OBSERVATIONAL,ALL,"Inclusion Criteria: * Onchocerciasis nodules * Age 12-35 years old * informed consent signed * Living in Maridi County, Western Equatorial State, South Sudan Exclusion Criteria: * below the age of 12",12.0,35.0,"['onchocercal subcutaneous nodule', 'epilepsy', 'virus']"
NCT05156151,Stromal Lenticule Implantation for Management of Herpetic Stromal Keratitis,Stromal Lenticule Implantation for Management of Herpetic Stromal Keratitis,ENROLLING_BY_INVITATION,INTERVENTIONAL,ALL,Inclusion Criteria: * low transparenc of cornea * low visual acuity * recurrence of herpetic stromal keratitis Exclusion Criteria: * previous corneal or anterior segment surgery * any infection,21.0,46.0,['stromal keratitis']
NCT00801151,Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer,A Phase I Clinical Trial of Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer.,TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patient must have a histologically-confirmed metastatic or locally advanced cancer. * Patient is ≥ 18 years of age on day of signing informed consent. * Patient must have performance status \ 2.5 X ULN, then liver fraction should be ≤ 2.5 X ULN * Coagulation : prothrombin time (PT) ≤1.2 X ULN ; partial thromboplastin time (PTT) ≤1.2 X ULN 1. Patients should have adequate bone marrow function without the current use of colony stimulating factors 2. Creatinine clearance should be calculated according to Cockcroft-Gault formula * For female patients of childbearing potential: must have a negative serum pregnancy test within 72 h before drug administration * Male and Female patients of childbearing potential must agree to use an adequate method of contraception throughout the study starting with Visit 1 and for at least 30 days after the last dose of study medication. * Patient has voluntarily agreed to participate by giving written informed consent. * Patient must be available for periodic blood sampling, study related assessments, and management at the treating institution of the duration of the study. Exclusion Criteria: * Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent. * Patient pre-treated with one of the two investigational compounds (ie; vinorelbine or vorinostat) * Patients with active CNS metastases and/or carcinomatous meningitis and uncontrolled brain metastases are excluded. However, patients with CNS metastases who have completed a course of therapy would be eligible for the study provided they are clinically stable for 3 months prior to entry as defined as: (1) no evidence of new or enlarging CNS metastasis (2) off steroids or on a stable dose of steroids. * Patient has known hypersensitivity to the components of study drug or its analogs. * Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate * Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Patient is, at the time of signing informed consent, a regular user (including ""recreational use"") of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse. * Patient is pregnant or nursing, * Patient is known to be Human Immunodeficiency Virus (HIV)-positive. * Patient has known history of Hepatitis B or C. * Patient with a history of a prior malignancy with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated localized prostate carcinoma with PSA \<1.0; or who has undergone potentially curative therapy with no evidence of that disease for five years, and who is deemed at low risk for recurrence by his/her treating physician * Patient has preexisting grade 2 or higher neuropathy * Patients who had received radiotherapy to more than 30% of the bone marrow surface (i.e whole pelvis) * Patients under law protection",18.0,65.0,['malignant solid tumour']
NCT05449951,Effect of Dry Needling on Spasticity in Stroke Survivors.,Effect of Dry Needling on Spasticity in Stroke Survivors,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: \- 1: Ischemic or hemorrhagic stroke and includes any of the artery 2: Hemiplegia 3: Chronic stroke (stroke at least 6 months before the trial) 4: Present a level of spasticity equal or greater than between 1 to 3 according to Modified Ashworth Scale. 5: Preserve cognitive capacity according to 6 cognitive items test (6CIT), Montreal cognitive assessment (MoCA) and Mini mental state examination (MMSE) Exclusion Criteria: 1: Insurmountable fear of needles. 2: Wrist fracture. 3: Have received previous treatment with dry needling. 4: Have progressive or severe neurological disease. \-",35.0,65.0,['spastic hemiplegia']
NCT00542451,Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer,A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer,COMPLETED,INTERVENTIONAL,FEMALE,"Inclusion Criteria: * Histologically confirmed invasive carcinoma of the breast * Tumors must be less than or equal to 3cm in greatest dimension * Must have node-negative breast cancer according to teh AJCC 7th edition * ER/PR determination is required. ER- and PR-assays should be performed by immunohistochemical methods * HER-2 positive: IHC 3+ or FISH \>2 * Bilateral breast cancers that individually meet eligibility criteria are allowed * Patients should have tumor tissue available, and a tissue block of sufficient size to make 15 slides must be sent to DFCI for testing * Less than or equal to 84 days from mastectomy or from axillary dissection or sentinel node biopsy if the patient's most extensive breast surgery was a breast-sparing procedure * All tumor should be removed by either a modified radical mastectomy or a segmental mastectomy (lumpectomy), with either a sentinel node biopsy or axillary dissection * 18 years of age or older * ECOG Performance Status of 0 or 1 * Adequate bone marrow function, hepatic function, and renal function as outlined in protocol * Left ventricular ejection fraction of greater than or equal to 50% * Willingness to discontinue any hormonal agent prior to registration and while on study * Willingness to discontinue sex hormonal therapy, e.g. birth control pills, prior to registration and while on study * Patients with a history of ipsilateral DCIS are eligible if they were treated with wide-excision alone, without radiation therapy * Patients undergoing breast conservation therapy must not have any contraindications to radiation therapy Exclusion Criteria: * Pregnant or nursing women * Locally advanced tumors at diagnosis, including tumors fixed to the chest wall, peau d'orange, skin ulcerations/nodules, or clinical inflammatory changes * History of prior chemotherapy in past 5 years * History of prior trastuzumab therapy * Active, unresolved infection * Prior history of any other malignancy in the past 5 years, except for early stage tumors of the skin or cervix treated with curative intent * Sensitivity to benzyl alcohol * Grade 2 or greater neuropathy per NCI's CTCAv3.0. (Exception: Any chronic neurologic disorder will be looked at on a case-by-case basis by the study chair). * Active cardiac disease as outlined in protocol.",18.0,65.0,"['breast cancer', 'carcinoma of the breast']"
NCT02275429,Metabolic Disorders in Ultramarathon Runners During and After the Reunion Island Madmen's Diagonal,"Etude Des Troubles métaboliques Induits Par Une Course à Pied très Longue Distance, "" La Diagonale Des Fous "" de La Réunion / Metabolic Disorders in Ultramarathon Runners of the Madmen's Diagonal Race on Reunion Island",COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Ultramarathon runner in the Madmen's Diagonal on Reunion Island (October 2014 ) * Aged 18 years or older * Lives on Reunion Island * Gave informed consent * Medical certificate allowing the participation in an ultramarathon Exclusion Criteria: * Aged less than 18 years Ultramarathon runner in the Bourbon Trail or Mascarenes races (which take place at the same time as the Madmen's Diagonal),18.0,65.0,['metabolic diseases']
NCT02423629,Agili-C™ Implant Performance Evaluation in the Repair of Cartilage and Osteochondral Defects,Agili-C™ Implant Performance Evaluation in the Repair of Cartilage and Osteochondral Defects (OCD),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. 18 years or older 2. Up to 3 treatable cartilage lesions, ICRS IIIa - IVb on the femoral condyles or the trochlea, 3. Symptomatic total treatable area 1-7 cm2. Asymptomatic lesions will not be included in the calculation 4. KOOS Pain score at baseline is not less than 30 and not more than 65 5. Must be physically and mentally willing and able to comply with post- operative rehabilitation protocol and scheduled clinical and radiographic visits. 6. Informed consent signing Exclusion Criteria: 1. Bony defect depth deeper than 8mm, according to imaging Articular cartilage lesions in the tibia or the patella, ICRS grades IVa and IVb 2. Any previous ligamentous repair or malalignment correction in the index knee within the last 3 months 3. Significant instability of the index knee according to IKDC Knee Examination Form 2000, Grade C (abnormal) or D (severely abnormal) 4. Lack of functional remaining meniscus 5. Meniscal transplantation in the past 6 months 6. Malalignment more than 5 degrees varus OR 5 degrees valgus according to standing X-ray 7. Any known tumor of the index knee 8. Any know history of infection of the index knee 9. Any known history of inflammatory arthropathy or crystal-deposition arthropathy 10. Any known systemic cartilage and/or bone disorder such as but not limited to chondrodysplasia or osteogenesis imperfecta 11. Body mass index \>35 12. Osteoarthritis of the index knee graded as 4 according to the Kellgren- Lawrence scale 13. Chemotherapy treatment in the past 12 months 14. Any previous surgical cartilage treatment in the index knee within the last 6 months 15. History of allergic reaction or intolerance of materials containing calcium carbonate or hyaluronate 16. Patient who is pregnant or intends to become pregnant during the study 17. History of any significant systemic disease, such as but not limited to, HIV infection, hepatitis infection or HTLV infection; known coagulopathies, that might compromise the subject's welfare 18. Known substance abuse or alcohol abuse 19. Participation in other clinical trials within 30 days prior to the study or concurrent with the study 20. Known insulin dependent diabetes mellitus 21. Unable to undergo MRI or X-ray",18.0,65.0,['cartilage or osteochondral defects in the knee']
NCT01950429,Evaluation of Sickle Cell Liver Disease,Evaluation of Sickle Cell Liver Disease,COMPLETED,OBSERVATIONAL,ALL,"* INCLUSION CRITERIA 1. All age greater than 18 able to consent, male or female 2. Capacity to provide written informed consent 3. All ethnicities 4. Sickle cell genotypes; Homozygous Hemoglobin S Disease, Heterozygous Hemoglobin SC and S beta thalassemia including SB+ and SB0 5. Evidence of SCD liver dysfunction by abnormal liver laboratory parameters in at least 2 of the following; alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), direct and total serum bilirubin \> 1 times ULN) EXCLUSION CRITERIA: 1. If not taking measures to prevent pregnancy during the period of study 2. Incapacity to provide informed consent",18.0,99.0,['sickle cell disease']
NCT02093429,Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS),"A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)",TERMINATED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Subjects 18 years of age or older. * Subjects must be diagnosed with MDS according to the World Health Organization (WHO) classification for de novo or primary MDS (Vardiman et al 2009). * Subjects who require RBC transfusions or are either refractory to or unlikely to respond to ESA therapy should meet one of the following criteria: * ESA failure as defined by no improvement in Hgb of at least 1.5 g/dL after 8 weeks of at least 40,000 IU per week of EPO (or equivalent). * Have a serum erythropoietin (EPO) of ≥ 500 IU and Hgb level \ 10%. * Subjects with severely compromised bone marrow function as evidenced by trilineage cytopenias with anemia (Hgb \< 10 g/L, platelets \< 100 × 109/L, and absolute neutrophil count (ANC) \< 1.8 × 109/L). * Subjects who harbor the 5q deletion chromosomal aberration. * Subjects with chronic myelomonocytic leukemia (CMML). * Women who are pregnant or breastfeeding, and men and women who cannot comply with requirements to avoid fathering a child or becoming pregnant, respectively. * Subjects with impaired liver function, end stage renal disease on dialysis, or clinically significant concurrent infections requiring therapy. * Subjects with unstable cardiac function. * Invasive malignancies over the previous 2 years except treated basal or squamous carcinomas of the skin, completely resected intraepithelial carcinoma of the cervix, Stage 1 or 2 treated prostate",18.0,65.0,['mds (myelodysplastic syndrome)']
NCT02031029,Character Traits and Stress in Suspected Prostate Cancer,"A Questionnaire Study by Elevated Prostate Specific Antigen (PSA): Do Men Where Subsequent Assessment Shows Prostate Cancer, Higher Levels of Neuroticism and Stress Compared to Those Who do Not Get the Diagnosis?",TERMINATED,OBSERVATIONAL,MALE,"Inclusion Criteria: 1. Men who be referred a new urological outpatient and satisfy the following: * Wanted examined because of elevated PSA * Not strong family history of prostate cancer * It is taken biopsy as part of routine investigation. 2. Control group: Men referred to urological outpatient clinic, and who satisfy the following * urination complaints * Normal PSA * examination shows prostate size\> 40cc 3. Control group: Men first time referred urological / gastroenterological outpatient clinic, and which satisfy the following \-- symptoms that might indicate cancer suspicion in colorectum 4. Age\> 40 years and \<75 years Exclusion criteria: 1. known prostate cancer 2. Reduced consent 4 Familial occurrence of prostate cancer (one or more 1st degree relatives with CaP)",18.0,75.0,['prostatic diseases']
NCT02311829,Evaluation of a Telephone Follow-up Procedure on the Quality of Life in Psychogenic Non-epileptic Seizures,Evaluation d'un Dispositif de Suivi téléphonique Sur la Qualité de Vie Dans Les Crises Psychogènes Non Epileptiques.,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patient above 18 years old * Affiliation to social security * Evolution disorders for over three months with at least 3 psychogenic non-epileptic seizures spaced over 24 hours and less than two years * Diagnosis of PNES (associated or not with epilepsy) or laid confirmed following a video-EEG examination * Standardized announcement of the disease made by a neurologist participant / PHRC training * Good understanding of the French language * Patient consented to participate in the study Exclusion Criteria: * Acute psychiatric pathology at the time of inclusion warranting urgent hospitalization (acute suicidal risk, Table delusional ...) * Progressive neurological pathology intercurrent susceptible to aggravation for the duration of the study (glioma, multiple sclerosis, dementia ...) * A patient who can not physically comply with the six-monthly review at the discretion of the investigator (planned move ...) * Simultaneous participation to another therapeutic intervention study during the first 12 months",18.0,65.0,['psychogenic non epileptic seizure']
NCT03620929,Estrogen in the Prevention of Adhesion Reformation,The Effect of Estrogen in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis,UNKNOWN,INTERVENTIONAL,FEMALE,"Inclusion Criteria: patients with suspected Asherman syndrome Exclusion Criteria: * 1 has received estrogen therapy within 3 month of enrolment. 2 suffers from leiomyoma, endometrial polyps, cancer, or polycystic ovarian syndrome (PCOS). 3.History of genital tuberculosis; and 4. contraindications for estrogen therapy.",18.0,40.0,['asherman syndrome']
NCT06558929,Evaluating the Effectiveness of Intervention Based on the Model of Occupational Harmony in Patients With Sleep Disorders,Evaluating the Effectiveness of Intervention Based on the Model of Occupational Harmony in Patients With Sleep Disorders,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * ≥18 years of age * self-reported difficulties with sleep quality * active sleep disturbance as indicated by a PSQI \> 5 or an ISI ≥ 8 at screening * able to participate in research independently or with the assistance of a caregiver * participate voluntarily in the study and sign an informed consent form Exclusion Criteria: * unable to cooperate with the study process due to cognitive, sensory, and motor dysfunction * unable to skillfully use wearable monitoring devices or smartphones * diagnosed with severe cardiac, liver, and kidney dysfunction and nervous system diseases * have cardiac pacemakers * being pregnant * participating in other clinical trials",18.0,80.0,['circadian rhythm sleep-wake disorder']
NCT03544229,A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine Receptor D2/D3 Antagonist, TAK-906 for the Treatment of Adult Subjects With Symptomatic Idiopathic or Diabetic Gastroparesis",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: 1. Should have experienced symptoms of gastroparesis (e.g., postprandial fullness, nausea, vomiting, upper abdominal pain, and early satiety for at least 3 months before screening as assessed by a physician. 2. Must have confirmed delayed gastric emptying by meeting 1 of the following criteria: 1. Confirmed by an accepted diagnostic testing method (Gastric Emptying Breath Test \[GEBT\], scintigraphy, or wireless motility capsule) that is documented in the participant's medical records prior to screening; OR 2. Participants without previous confirmation of delayed gastric emptying prior to screening will undergo a GEBT after they have stopped taking prohibited medications. 3. Must have an average composite ANMS GCSI-DD symptom score ≥2 during the 7 days before randomization. The predominant symptom experienced by participants must not be abdominal pain. 4. Must experience nausea: nausea subscale (of ANMS GCSI-DD) symptom score ≥2 at least 4 of 7 days or an average nausea subscale symptom score ≥2 during the 7 days before randomization. Nausea symptoms must not be attributable to a central disorder (e.g. motion sickness, glaucoma, menstrual cycles, migraine headache). 5. Has a body mass index (BMI) of ≥18 to ≤40 kg/m\^2 inclusive. 6. Participant with diabetes mellitus must have glycosylated hemoglobin (HbA1c) ≤11% at screening and before randomization. 7. Absence of gastric outlet obstruction confirmed by upper GI, computed tomography or endoscopy. Exclusion Criteria: 1. Known secondary causes of gastroparesis including but not limited to Parkinson disease, cancer, viral illness, or connective tissue diseases. 2. Predominant gastroparetic symptom is epigastric pain, diffuse abdominal pain, or pain associated with bowel movement. 3. Is taking medications that affect gastric emptying including opioids, glucagon-like peptide-1 analogs (e.g., exenatide, liraglutide), amylin analogs (e.g., pramlintide), and cannabinoids. 4. Prior history of gastric surgery, including but not limited to gastrectomy, gastric bypass, gastric banding, bariatric surgery, pyloroplasty, vagotomy, or fundoplication, which has manipulated the natural anatomy of the stomach. 5. History of intra-pyloric botulinum toxin injection within 3 months of Screening or currently has functioning implantable electric stimulator. 6. Nasogastric, percutaneous endoscopic gastrostomy, or percutaneous endoscopic jejunostomy feeding tube or inpatient hospitalization for gastroparesis within 2 weeks before the Screening Visit. 7. Required parenteral nutrition for treatment of gastroparesis within 2 months before the Screening Visit. 8. Previous diagnosis of gastric bezoar (the presence of retained liquid, bile, or small amounts of poorly organized food residue is permitted). 9. Poor control of diabetes within 30 days prior to randomization, including diabetic ketoacidosis, hypoglycemia requiring medical intervention, admission for control of diabetes or diabetic complications. 10. Elevated serum prolactin (\>upper limit of normal \[ULN\]) at Screening. 11. Has concurrent hypogonadism, current clinically significant menstrual abnormalities, such as amenorrhea or oligomenorrhea, or other clinical features of hyperprolactinemia such as galactorrhea or gynecomastia. 12. Has acute or chronic liver disease meeting any of the criteria described below: * Has an alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total bilirubin \>2.0 times the ULN. * Has pre-existing liver cirrhosis that meets Child-Pugh Class B (moderate; total score 7 to 9 points) or C (severe; total score 10 to 15 points) (see Appendix B). * Has acute or chronic hepatitis B or C virus infection, manifesting as one of the following at screening: * Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). NOTE: if a participants tests negative for HBsAg, but positive for HBcAb, the participant would be eligible if the Investigator has documentation of other test results showing that the participant does not have active hepatitis B infection. * Participants with positive hepatitis C antibody (HCV IgG) and quantitative HCV polymerase chain reaction (PCR). HCV PCR is performed only if HCV IgG is positive. 13. Has renal impairment, defined as a lower limit of (estimated glomerular filtration rate \[eGFR\]) \<30 mL/min at screening visit. 14. Has active neoplastic disease or history of neoplastic disease within 5 years of screening visit (except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the uterine cervix that has been definitively treated with standard of care approaches). 15. Uncontrolled or poorly controlled medical or psychiatric comorbidities which might affect their ability to participate in the study. 16. Has known COVID-19 infection, or suspected COVID-19 infection (as assessed by the investigator). 17. Signs/symptoms or history of extrapyramidal system disease and other clinically relevant CNS or neuropsychiatric disease including but not limited to tardive dyskinesia, neuroleptic malignant syndrome, acute dystonia, parkinsonian like symptoms, severe mental depression, and history of suicide attempt.",18.0,85.0,"['diabetic gastroparesis', 'idiopathic gastroparesis']"
NCT01973829,The Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN),The Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN),COMPLETED,INTERVENTIONAL,ALL,"Inclusion: All adult (≥ 18 years) patients admitted for the first time to the participating ICUs will be included. Exclusion: Not critically Ill, admitted for low risk monitoring, planned ICU admissions for routine postoperative surveillance for less than 24 hours after uncomplicated surgery, readmission and transferred from outside ICU.",18.0,65.0,"['critical illness', 'sepsis', 'respiratory failure', 'shock', 'coma', 'bleeding', 'trauma']"
NCT07364929,"Altered Non-Visual Photoreception in Patients With Glaucoma: Impacts on Sleep, Alertness, Mood, and Cognition","Altered Non-Visual Photoreception in Patients With Glaucoma: Impacts on Sleep, Alertness, Mood, and Cognition",RECRUITING,INTERVENTIONAL,ALL,"Inclusion Criteria: * Patients with glaucoma must meet all of the inclusion criteria to participate in this study. * Patients diagnosed with primary open-angle glaucoma (POAG), as indicated by Humphrey Visual Field (HVF) mean deviation (VFMD) scores better than -12 dB in at least one eye during their most recent clinic visit. * Patients having spared central vision. * Patients aged 45 to 75 years old. * Patients with a best-corrected visual acuity better than 6/12 * English-speaking patients Healthy controls must meet all of the inclusion criteria to participate in this study: * Participants aged 50 to 70 years old. * Participants with a best-corrected visual acuity better than 6/12 * Normal ophthalmic examination * English-speaking participants Exclusion Criteria: * All subjects (patients and controls) meeting any of the exclusion criteria at baseline will be excluded from participation: * Participants with myopia exhibiting a refractive error exceeding -8.00 diopters (D) * Participants with a history of complicated previous intraocular surgery * Participants taking alpha-adrenergic agonist eye drops or other systemic medications or drugs that could affect the pupillary response * Participants with any past or current ocular condition (i.e., age-related retinal diseases (e.g., age-related macular degeneration), retinal pigment epithelium diseases (e.g., Best's disease), diabetic retinopathy, or other optic or generalized neuropathies, significant ocular trauma, or any eye condition affecting fixation (eg. Nystagmus)). * Participants diagnosed with cataracts at NS3+ (Nuclear Sclerosis) and above, as well as those with Posterior Subcapsular (PSC) cataracts * Participants with clinically diagnosed psychiatric or neurologic disorders, including cognitive impairment or dementia * Participants with diagnosed mood disorders * Participants engaged in night shift work within the past three months, are currently using sleeping pills, or have recently travelled across timezones within a month prior to the study * Participants with obstructive sleep apnea * Participants with abnormal auditory function * Participants with impaired color vision * Pre-menopausal women (last menstrual period \< 1 year) (If applicable) * Patients having unilateral glaucoma, congenital glaucoma, non-glaucomatous optic neuropathy, abnormal central vision * Diabetics on treatment",45.0,75.0,['glaucoma']
NCT02709629,CCT for Older Diabetic Adults,"The Effects of Computerized Cognitive Training on Diabetic Elderly, Who Are at High Risk for Dementia",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Age 65 and over * diagnosis of type 2 diabetes * Health cover provided by Maccabi Health Services (MHS) * Access to a home computer and internet connection * Availability of a close relative/informant with regular and frequent contact with the participant (at least 10 hours per week), willing to respond to questionnaires at all time points. * Fluency in Hebrew or English * Living in the Tel-Aviv metropolitan area and surrounds Exclusion Criteria: * An existing diagnosis of dementia * Prescription of dementia-related medication. * Participation in a previous cognitive intervention study in the preceding year. * Significant hearing/vision impairment likely to interfere with assessment and/or training * Significant psychiatric/neurological or medical issues that may affect cognitive function.",65.0,65.0,"['diabetes', 'older diabetic persons without dementia']"
NCT03901729,A Trial to Study BAY1753011 in Patients With Congestive Heart Failure,"A Multicenter, Randomized, Parallel Group, Double Blind, Active and Placebo Controlled Study of BAY1753011, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients With Congestive Heart Failure: AVANTI Study",COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * History of CHF on individually optimized treatment with HF medications unless contraindicated or not tolerated, for at least 12 weeks prior to index hospitalization and in accordance with international guidelines. * Subjects admitted to the hospital with a primary diagnosis of decompensated HF including symptoms and signs of fluid overload requiring IV diuretic therapy in the Emergency room (ER) or any time between day 1-3 of hospital admission (index hospitalization). * Subjects on an average/usual total daily dose of loop diuretic ≥ 40 mg of furosemide or equivalent, within 4 weeks prior to index hospitalization. * At least one of the following 5 parameters any day between 3-7 of index hospitalization (screening period) * Natriuretic peptides Brain natriuretic peptide/N-terminal prohormone of brain natriuretic peptide (BNP/NT-proBNP): * Drop in BNP or NT-proBNP ≤ 30% from admission values (if measured during index hospitalization) or * BNP ≥ 500 pg/ml or NT-proBNP ≥ 1800 pg/ml at screening (day 3 to 7 of index hospitalization) * Body weight (BW) loss \ 21 mm * IVC collapse with sniff \< 50% * At least 2+ peripheral edema or pulmonary edema or pleural effusion on chest X-ray or clinical exam Exclusion Criteria * Active or history of acute inflammatory heart disease, within 3 months prior to screening, e.g., acute myocarditis * Acute coronary syndrome, including unstable angina, Non-ST segment elevation myocardial infarction (NSTEMI) or ST segment elevation myocardial infarction (STEMI), or major Cardiovascular (CV) surgery including coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI) within 3 months prior to screening * Any primary cause of HF scheduled for surgery or interventional therapy (e.g., TAVI), e.g., valve disease such as severe aortic stenosis or mitral valve regurgitation * Requirement of mechanical support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device) or ultrafiltration/hemodialysis * Estimated glomerular filtration rate of \< 30 ml/min/1.73 m\*2 determined by the Modified Diet and Renal Disease equation at screening; reassessments allowed as clinically needed * Serum potassium ≥ 5.5 mmol/L or ≤ 3.3 mmol/L at screening; reassessments allowed as clinically needed * Serum sodium ≥ 146 mmol/L or ≤ 130 mmol/L at screening; reassessments allowed as clinically needed * Concomitant treatment with potassium-sparing diuretic (with the exception of mineralocorticoid- receptor antagonist (MRA) that cannot be stopped prior to randomization and for the duration of the treatment period.",18.0,85.0,['heart failure (hf)']
NCT03294031,Pilates as an Adjuvant Therapy in Parkinson Disease.,Pilates as an Adjuvant Physical Exercise Therapy in Patients With Parkinson Disease.,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: * Stages 1 through 3 on the Hoehn and Yahr Staging Scale; * Stable reaction to anti-Parkinson medication; * Not having taken part in any physical exercise program during the month prior to the study. Exclusion Criteria: * People with PD who were not able to ambulate independently or presented any comorbidities other than PD or any acute illness that would make training inappropriate.,60.0,85.0,['parkinson disease']
NCT01315431,A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors,A Phase I Study of Tesetaxel Administered in Combination With Capecitabine to Subjects With Solid Tumors,UNKNOWN,INTERVENTIONAL,ALL,"Inclusion Criteria: * At least 18 years of age * Confirmed diagnosis of a solid tumor malignancy, excluding lymphoma * Chemotherapy-naïve or previously treated with not more than 1 non-taxane-containing chemotherapy (Enrollment of patients with a history of prior taxane therapy in the adjuvant setting is allowed provided at least 6 months have passed since the conclusion of that therapy.) * ECOG performance status of 0 or 1 * Adequate bone marrow, hepatic, and renal function * At least 3 weeks and recovery from effects of prior surgery and anticancer therapy, with resolution of any toxicity to not more than Grade 1 Exclusion Criteria: * Brain metastasis or leptomeningeal disease * Second cancer (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which patient has been disease-free for 5 or more years) * Known history of human immunodeficiency virus infection or hepatitis B or hepatitis C infection * Recurrent diarrhea, defined as more than 3 episodes than is usual in any 24-hour period within the 30 days prior to enrollment in this study * Significant medical disease other than cancer * Neuropathy at least Grade 2 * Difficulty swallowing * Malabsorptive disorder * Need for other anticancer treatment while receiving study medication * Need to continue any regularly-taken medication that is a potent inhibitor or inducer of the CYP3A pathway or P-glycoprotein activity. A washout period of at least 2 weeks is required prior to the first dose of study medication. * Pregnancy or lactation * History of hypersensitivity to tesetaxel, capecitabine, 5-fluorouracil, or any of their components",18.0,65.0,['solid tumor']
NCT02919631,Triheptanoin in Mc Ardle,The Effect of Triheptanoin in Adults With Mc Ardle Disease (Glycogen Storage Disease Type V),COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * Male or female between 18 and 65 years of age, * Genetically and/or biochemically verified diagnosis of McArdle disease * Body Mass Index of 18-32 * Women in child-bearing age on contraceptive treatment with: Birth control pills, coil, ring, transdermal hormone patch injection of gestagen or subdermal implant. * French national health insurance * Signed informed consent * Available for phone calls Exclusion Criteria: * Minor * Significant cardiac or pulmonary disease * Pregnancy (confirmed by urinary-HCG) or breastfeeding. Pregnancy not planned and to be avoided during the study by use of effective contraceptive methods. * Persons deprived of their liberty by judicial or administrative decision * Adult subject under legal protection or unable to consent * Treatment with beta-blockers * Inability to perform cycling exercise * Any other significant disorder that may confound the interpretation of the findings * Person subject to an exclusion period for a previous clinical trial",18.0,65.0,['glycogen storage disease type v']
NCT05146531,Comparison of McCoy Laryngoscope and C-MAC D-blade Video Laryngoscope in Obese Patients,Comparison of McCoy Laryngoscope and C-MAC D-blade Video Laryngoscope in Obese Patients,COMPLETED,INTERVENTIONAL,ALL,"Inclusion Criteria: * American society of anesthesiologists physical status of I-II patients with BMI ≥ 35 kg/m² scheduled for general anesthesia Exclusion Criteria: * patients with tracheal diseases, sore throat, neck pain and loose tooth.",20.0,70.0,['obesity']
NCT00064831,Black Cohosh Extract in Postmenopausal Breast Health,The Effect of Black Cohosh Extract on the Human Breast,COMPLETED,INTERVENTIONAL,FEMALE,"* Postmenopausal females * 20 months since any breastfeeding * Active postmenopausal symptoms, i.e., hot flashes * At least 6 months since last menstrual period or have had a hysterectomy with both ovaries removed * Able to make 4 visits during the trial to the study clinic in Columbia, Missouri",18.0,65.0,"['menopause', 'hot flashes']"
NCT06398431,Validating Wireless Gait Sensor for Elderly Fall Risk Classification,A Study on Validation of Gait Analysis Wireless Small Inertial Sensor and Diagnostic Machine Learning Model for Classification of Elderly Fall Risk Group,COMPLETED,INTERVENTIONAL,ALL,Inclusion Criteria: 1. a person over the age of 55 2. Persons who can walk independently for at least one minute 3. Those who do not take drugs that affect their ability to maintain balance 4. A person who does not have an orthopedic problem such as a fracture of the lower extremities within six months Exclusion Criteria: 1. Those who have difficulty understanding the gait analysis program or difficulty expressing symptoms 2. A person deemed unfit for this study by a rehabilitation specialist due to other conditions 3. A person who is unable to apply this walking analysis program due to serious cardiovascular diseases,55.0,65.0,['elderly person']
